{"id":"109","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"46\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"142\", \"id_relation_type\": \"is source of\", \"id_resource_type_general\": \"Dataset\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"Santos-HoevenerC@rki.de\", \"role_phone\": \"+49 (0)30 187543198\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Robert Koch Institute (RKI)\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0001-5994-7715\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Nordufer 20, 13353, Berlin, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"https://www.rki.de/DE/Home/homepage_node.html\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01k5qnb77\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.13652.33\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Claudia\", \"role_name_personal_family_name\": \"Santos-H\\u00f6vener\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"PDF\", \"resource_titles\": [{\"title\": \"CORONA-MONITORING lokal - Short Questionnaire\", \"title_language\": \"EN (English)\"}, {\"title\": \"CORONA-MONITORING lokal - Kurzfragebogen\", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"CoMoLo Questionnaire \", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Questionnaire\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T000997092\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"\", \"resource_descriptions\": [{\"description\": \"A self-administered questionnaire on paper (SAQ-P) was provided at the study centre or during home visits. Participants filled out the questionnaire before the collection of blood specimens and oropharyngeal swab, but only if a consent form has been signed.\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Text\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Please contact the authors/contact persons to get permission to reuse the questionnaire in whole or parts of it.\", \"resource_id\": \"109\", \"resource_type\": \"Questionnaire\"}"}
{"id":"119","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"101\", \"id_relation_type\": \"is derived from\", \"id_resource_type_general\": \"Text\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"33\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"kristien.michielsen@ugent.be\", \"role_phone\": \"+32 (0)933 25290\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, University of Ghent\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-4119-6770\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Heymanslaan str. 10, 9000, Gent, Belgium\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.ugent.be/ge/phpc/en\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00cv9y106\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5342.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Kristien\", \"role_name_personal_family_name\": \"Michielsen\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"Data Dictionary of the I-SHARE Survey\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\"], \"resource_web_page\": \"https://mica.covid19.studyhub.nfdi4health.de/dataset/i-share\", \"resource_descriptions\": [{\"description\": \"This is a data dictionary for the \\\"Questionnaire of the I-SHARE Survey\\\".\\r\\nThis data dictionary is prepared for upload into OPAL/MICA applications of the OBiBa (Open Source Software for BioBanks) software suite. The variables are annotated with metadata using the variable classification taxonomy developed by Maelstrom Research. Further information about format and applications can be found in Doiron et al. (2017; https://doi.org/10.1093/ije/dyx180).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Please contact the authors/contact persons to get permission to reuse the data dictionary in whole or parts of it.\", \"resource_id\": \"119\", \"resource_type\": \"Data dictionary\"}"}
{"id":"121","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"93\", \"id_relation_type\": \"is derived from\", \"id_resource_type_general\": \"Text\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"alspac-secretaries@bristol.ac.uk\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"University of Bristol\", \"role_affiliation_address\": \"Bristol, United Kingdom\", \"role_name_organisational\": \"ALSPAC Secretariat\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0524sp257\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5337.2\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"Data Dictionary for the UK Covid-19 Questionnaire (The Wellcome Covid-19 Questionnaire)\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\"], \"resource_web_page\": \"https://mica.covid19.studyhub.nfdi4health.de/dataset/ukcov19\", \"resource_descriptions\": [{\"description\": \"This is a data dictionary for the \\\"UK Covid-19 Questionnaire (The Wellcome Covid-19 Questionnaire)\\\".\\r\\nThis data dictionary is prepared for upload into OPAL/MICA applications of the OBiBa (Open Source Software for BioBanks) software suite. The variables are annotated with metadata using the variable classification taxonomy developed by Maelstrom Research. Further information about format and applications can be found in Doiron et al. (2017; https://doi.org/10.1093/ije/dyx180).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Please contact the authors/contact persons to get permission to reuse the data dictionary in whole or parts of it.\", \"resource_id\": \"121\", \"resource_type\": \"Data dictionary\"}"}
{"id":"123","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"90\", \"id_relation_type\": \"is derived from\", \"id_resource_type_general\": \"Text\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \" habersaatk@who.int\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"WHO Regional Office for Europe\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"UN City, Marmorvej 51, DK-2100, Copenhagen, Denmark\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"https://www.euro.who.int/en\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01rz37c55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.420226.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Katrine\", \"role_name_personal_family_name\": \"Bach Habersaat\"}, {\"role_type\": \"Contact person\", \"role_email\": \"scherzerm@who.int\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"WHO Regional Office for Europe\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"UN City, Marmorvej 51, DK-2100, Copenhagen, Denmark\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"https://www.euro.who.int/en\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01rz37c55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.420226.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Martha\", \"role_name_personal_family_name\": \"Scherzer\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"World Health Organization. Regional Office for Europe\", \"role_affiliation_address\": \"UN City, Marmorvej 51, DK-2100, Copenhagen, Denmark\", \"role_name_organisational\": \"World Health Organization. Regional Office for Europe\", \"role_affiliation_web_page\": \"https://www.euro.who.int/en\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01rz37c55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.420226.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"Data Dictionary for the WHO Europe's Questionnaire on COVID-19 Behaviour\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\"], \"resource_web_page\": \"https://mica.covid19.studyhub.nfdi4health.de/dataset/who_europe-1\", \"resource_descriptions\": [{\"description\": \"This is a data dictionary based on the questionnaire included in the WHO Europe's \\\"Survey tool and guidance: rapid, simple, flexible behavioural insights on COVID-19\\\".\\r\\nThis data dictionary is prepared for upload into OPAL/MICA applications of the OBiBa (Open Source Software for BioBanks) software suite. The variables are annotated with metadata using the variable classification taxonomy developed by Maelstrom Research. Further information about format and applications can be found in Doiron et al. (2017; https://doi.org/10.1093/ije/dyx180).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"All rights reserved\", \"resource_use_rights_description\": \"All rights reserved by World Health Organization (WHO). Please contact the authors/contact persons to get permission to reuse the data dictionary in whole or parts of it.\", \"resource_id\": \"123\", \"resource_type\": \"Data dictionary\"}"}
{"id":"129","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"35\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"130\", \"id_relation_type\": \"is source of\", \"id_resource_type_general\": \"Dataset\"}, {\"id_date\": \"21.01.2021\", \"id_type\": \"DOI\", \"id_identifier\": \"10.1038/s41398-020-01150-4\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"matthias.zerban@unimedizin-mainz.de\", \"role_phone\": \"+49 (0)003 1178075\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Neuroimaging Center (NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"http://www.ftn.nic.uni-mainz.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q1fsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.410607.4\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Matthias\", \"role_name_personal_family_name\": \"Zerban\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Research Division of Mind and Brain, Department of Psychiatry and Psychotherapy CCM, Charit\\u00e9\\u2013Universit\\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\\u00e4t Berlin, Humboldt-Universit\\u00e4t zu Berlin, and Berlin Institute of Health\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Berlin, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Ilya M.\", \"role_name_personal_family_name\": \"Veer\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Research Division of Mind and Brain, Department of Psychiatry and Psychotherapy CCM, Charit\\u00e9\\u2013Universit\\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\\u00e4t Berlin, Humboldt-Universit\\u00e4t zu Berlin, and Berlin Institute of Health\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Berlin, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Antje\", \"role_name_personal_family_name\": \"Riepenhausen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Neuroimaging Center(NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q1fsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Matthias\", \"role_name_personal_family_name\": \"Zerban\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Research Division of Mind and Brain, Department of Psychiatry and Psychotherapy CCM, Charit\\u00e9\\u2013Universit\\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\\u00e4t Berlin, Humboldt-Universit\\u00e4t zu Berlin, and Berlin Institute of Health\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Berlin, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Carolin\", \"role_name_personal_family_name\": \"Wackerhagen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for ResilienceResearch (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Lara M. C.\", \"role_name_personal_family_name\": \"Puhlmann\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Neuroimaging Center(NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q1fsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Haakon\", \"role_name_personal_family_name\": \"Engen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Freiburg\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Freiburg, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0245cg223\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"G\\u00f6ran\", \"role_name_personal_family_name\": \"K\\u00f6ber\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nijmegen, The Netherlands\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05wg1m734\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Sophie A.\", \"role_name_personal_family_name\": \"B\\u00f6gemann\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Jeroen\", \"role_name_personal_family_name\": \"Weermeijer\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Psychology, University of Warsaw\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"039bjqg32\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Aleksandra\", \"role_name_personal_family_name\": \"U\\u015bci\\u0142ko\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Tel Aviv Sourasky Medical Center, Sagol Brain Institute Tel Aviv\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Tel Aviv, Israel\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04nd58p63\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Netali\", \"role_name_personal_family_name\": \"Mor\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Zurich\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Zurich, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02crff812\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Marta A.\", \"role_name_personal_family_name\": \"Marciniak\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychology, University of Oslo\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Oslo, Norway\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01xtthb56\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Adrian\", \"role_name_personal_family_name\": \"Dahl Askelund\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Bergamo\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Bergamo, Italy\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02mbd5571\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Abbas\", \"role_name_personal_family_name\": \"Al-Kamel\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Resilience Research (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Sarah\", \"role_name_personal_family_name\": \"Ayash\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"MRC Cognition and Brain Sciences Unit, University of Cambridge\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Cambridge, UK\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"055bpw879\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Giulia\", \"role_name_personal_family_name\": \"Barsuola\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Business and Technologies at Utena University of Applied Sciences\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Utena, Lithuania\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05q4md098\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Vaida\", \"role_name_personal_family_name\": \"Bartkute-Norkuniene\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Studies and Research in Cognitive Neuroscience, Department of Psychology, University of Bologna\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Bologna, Italy\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01111rn36\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Simone\", \"role_name_personal_family_name\": \"Battaglia\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Psychology, University of Economics and Human Sciences\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Yaryna\", \"role_name_personal_family_name\": \"Bobko\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Psychiatry Research, Department of Women\\u2019s and Children\\u2019s Health, Karolinska Institutet Center of Neurodevelopmental Disorders (KIND), Karolinska Institutet and Stockholm Health Care Services, Region Stockholm\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Stockholm, Sweden\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Sven\", \"role_name_personal_family_name\": \"B\\u00f6lte\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Resilience Research (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Paolo\", \"role_name_personal_family_name\": \"Cardone\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychological Methods, University of Amsterdam\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Amsterdam, The Netherlands\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04dkp9463\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Edita\", \"role_name_personal_family_name\": \"Chvojkov\\u00e1\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Laboratory for Experimental Psychology, Department of Psychology, University of Belgrade\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Belgrade, Serbia\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02qsmb048\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Kaja\", \"role_name_personal_family_name\": \"Damnjanovi\\u0107\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Joana\", \"role_name_personal_family_name\": \"De Calheiros Velozo\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Lena\", \"role_name_personal_family_name\": \"de Thurah\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Geneva\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Geneva, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01swzsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Yacila I.\", \"role_name_personal_family_name\": \"Deza-Araujo\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Research Division of Mind and Brain, Department of Psychiatry and Psychotherapy CCM, Charit\\u00e9\\u2013Universit\\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\\u00e4t Berlin, Humboldt-Universit\\u00e4t zu Berlin, and Berlin Institute of Health\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Berlin, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Annika\", \"role_name_personal_family_name\": \"Dimitrov\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychiatry and Psychotherapy, Semmelweis University\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Budapest, Hungary\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01g9ty582\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Kinga\", \"role_name_personal_family_name\": \"Farkas\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Geneva, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01swzsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Cl\\u00e9mence\", \"role_name_personal_family_name\": \"Feller\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Concentris Research Management GmbH\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"F\\u00fcrstenfeldbruck, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0571eed91\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Mary\", \"role_name_personal_family_name\": \"Gazea\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Resilience Research (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Donya\", \"role_name_personal_family_name\": \"Gilan\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Humanities and Social Sciences, University of Zagreb\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Zagreb, Croatia\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00mv6sv71\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Vedrana\", \"role_name_personal_family_name\": \"Gnjidi\\u0107\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychology, Faculty of Arts, Comenius University in Bratislava\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Bratislava, Slovak Republic\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Michal\", \"role_name_personal_family_name\": \"Hajduk\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Anu P.\", \"role_name_personal_family_name\": \"Hiekkaranta\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"PROMENTA Research Centre, Department of Psychology, University of Oslo\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Oslo, Norway\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01xtthb56\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Live S.\", \"role_name_personal_family_name\": \"Hofgaard\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Geneva, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01swzsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Laura\", \"role_name_personal_family_name\": \"Ilen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leuven Research and Development, Spin-off and Innovation Unit, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Zuzana\", \"role_name_personal_family_name\": \"Kasanova\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Tehran\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Tehran, Iran\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05vf56z40\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Mohsen\", \"role_name_personal_family_name\": \"Khanpour\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Counselling and Psychology, Hong Kong Shue Yan University\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Hong Kong\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"023t8mt09\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Bobo\", \"role_name_personal_family_name\": \"Hi Po Lau\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nijmegen, The Netherlands\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05wg1m734\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Dionne B.\", \"role_name_personal_family_name\": \"Lenferink\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center of Functionally Integrative Neuroscience (CFIN) and MINDLab, Department of Clinical Medicine, \\u00c5rhus University\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"\\u00c5rhus, Denmark\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Thomas B.\", \"role_name_personal_family_name\": \"Lindhardt\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Cognitive Science, Budapest University of Technology and Economics\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Budapest, Hungary\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02w42ss30\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"D\\u00e1vid \\u00c1.\", \"role_name_personal_family_name\": \"Magas\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Psychology, University of Warsaw\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"039bjqg32\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Julian\", \"role_name_personal_family_name\": \"Mituniewicz\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychiatry, University of Cambridge\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Cambridge, UK\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"013meh722\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Laura\", \"role_name_personal_family_name\": \"Moreno-L\\u00f3pez\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Psychology, University of Economics and Human Sciences\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Sofiia\", \"role_name_personal_family_name\": \"Muzychka\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Sleep Research Unit, First Department of Psychiatry, National and Kapodistrian University of Athens\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Athens, Greece\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04gnjpq42\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Maria\", \"role_name_personal_family_name\": \"Ntafouli\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Frankfurt am Main, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03f6n9m15\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Aet\", \"role_name_personal_family_name\": \"O\\u2019Leary\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institut des Sciences Cognitives Marc Jeannerod\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Lyon, France\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"058hz8544\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Ilenia\", \"role_name_personal_family_name\": \"Paparella\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute of Psychology, University of Tartu\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Tartu, Estonia\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03z77qz90\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Nele\", \"role_name_personal_family_name\": \"P\\u00f5ldver\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Aki\", \"role_name_personal_family_name\": \"Rintala\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"College of Inter-faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"039bjqg32\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Natalia\", \"role_name_personal_family_name\": \"Robak\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Social Studies, Department of Psychology, Masaryk University\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Brno, Czech Republic\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02j46qs45\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Anna M.\", \"role_name_personal_family_name\": \"Rosick\\u00e1\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"PROMENTA Research Centre, Department of Psychology, University of Oslo\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Oslo, Norway\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01xtthb56\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Espen\", \"role_name_personal_family_name\": \"R\\u00f8ysamb\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Johannes Gutenberg University Mainz\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"023b0x485\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Siavash\", \"role_name_personal_family_name\": \"Sadeghi\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Clinical Psychology Unit for Intellectual and Developmental Disabilities, Faculty of Psychology and Educational Sciences, University of Geneva\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Geneva, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"01swzsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Maude\", \"role_name_personal_family_name\": \"Schneider\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"MRC Cognition and Brain Sciences Unit, University of Cambridge\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Cambridge, UK\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"055bpw879\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Roma\", \"role_name_personal_family_name\": \"Siugzdaite\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Experimental Psychology, University of Oxford\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Oxford, UK\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"052gg0110\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Mirta\", \"role_name_personal_family_name\": \"Stanti\\u0107\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Ana\", \"role_name_personal_family_name\": \"Teixeira\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of Experimental Psychology, University of Oxford\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Oxford, UK\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"052gg0110\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Ana\", \"role_name_personal_family_name\": \"Todorovic\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Department of International Business, Tunghai University\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Taichung City, Taiwan\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00zhvdn11\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Wendy W. N.\", \"role_name_personal_family_name\": \"Wan\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute of Psychology, Goethe University Frankfurt\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Frankfurt am Main, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04cvxnb49\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Rolf\", \"role_name_personal_family_name\": \"van Dick\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Resilience Research (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Klaus\", \"role_name_personal_family_name\": \"Lieb\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Zurich\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Zurich, Switzerland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02crff812\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Birgit\", \"role_name_personal_family_name\": \"Kleim\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nijmegen, The Netherlands\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05wg1m734\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Erno J.\", \"role_name_personal_family_name\": \"Hermans\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Faculty of Psychology, University of Warsaw\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Warsaw, Poland\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"039bjqg32\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Dorota\", \"role_name_personal_family_name\": \"Kobyli\\u0144ska\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Tel Aviv Sourasky Medical Center, Sagol Brain Institute Tel Aviv\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Tel Aviv, Israel\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04nd58p63\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Talma\", \"role_name_personal_family_name\": \"Hendler\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"University of Freiburg\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Freiburg, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0245cg223\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Harald\", \"role_name_personal_family_name\": \"Binder\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Leuven, Belgium\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05f950310\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Inez\", \"role_name_personal_family_name\": \"Myin-Germeys\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nijmegen, The Netherlands\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05wg1m734\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Judith M. C.\", \"role_name_personal_family_name\": \"van Leeuwen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Resilience Research (LIR)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q5t0010\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Oliver\", \"role_name_personal_family_name\": \"T\\u00fcscher\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Neuroimaging Center(NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q1fsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Kenneth S. L.\", \"role_name_personal_family_name\": \"Yuen\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Research Division of Mind and Brain, Department of Psychiatry and Psychotherapy CCM, Charit\\u00e9\\u2013Universit\\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\\u00e4t Berlin, Humboldt-Universit\\u00e4t zu Berlin, and Berlin Institute of Health\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Berlin, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \"Henrik\", \"role_name_personal_family_name\": \"Walter\"}, {\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Neuroimaging Center(NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg University Medical Center\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Mainz, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00q1fsf04\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Raffael\", \"role_name_personal_family_name\": \"Kalisch\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"Questionnaire (Data Dictionary) of the DynaMORE cross-sectional survey study on psychological resilience to the mental health consequences of the Corona crisis (DynaCORE)\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"DynaCORE-C Questionnaire (Data Dictionary)\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"\", \"resource_descriptions\": [{\"description\": \"Questionnaire (data dictionary) of the DynaCORE study. The instrument is assembled of various existing questionnaires as well as new items about potential resilience factors relevent during the COVID-19 pandemic. Further a list of stressors and an instrument capturing mental health are used to calculate the stressor reactivity score (see Kalisch et al., 2020 for further information). See Veer et al., 2021 for a first publication.\\r\\n\\r\\nDynaCORE instruments:\\r\\nGHQ-12 (Goldberg et al., 1997),\\r\\nFSozU (Dunkel et al., 2005),\\r\\nASKU (Beierlein et al., 2012),\\r\\nBRS (Smith et al., 2008),\\r\\nBFI-10: Neuroticism (Rammstedt & John, 2007),\\r\\nBrief COPE(Carver, 1997),\\r\\nCERQ subscales (Garnefski,Kraaij, & Spinhoven, 2001),\\r\\nStressors based on MIMIS (Chmitorz et al., 2020) plus Corona-related stressors.\\r\\n\\r\\nReferences:\\r\\n- Beierlein, C., Kovaleva, A., Kemper, C. J., & Rammstedt, B. (2012). Ein Messinstrument zur Erfassung subjektiver Kompetenzerwartungen: Allgemeine Selbstwirksamkeit Kurzskala (ASKU).\\r\\n- Carver, C. S. (1997). You want to measure coping but your protocol\\u2019too long: Consider the brief cope. International journal of behavioral medicine, 4(1), 92-100.\\r\\n- Chmitorz, A., Kurth, K., Mey, L. K., Wenzel, M., Lieb, K., T\\u00fcscher, O., ... & Kalisch, R. (2020). Assessment of microstressors in adults: Questionnaire development and ecological validation of the mainz inventory of microstressors. JMIR mental health, 7(2), e14566.\\r\\n- Dunkel, D., Antretter, E., Fr\\u00f6hlich-Walser, S., & Haring, C. (2005). Evaluation der Kurzform des Fragebogens zur Sozialen Unterst\\u00fctzung (SOZU-K-22) in klinischen und nichtklinischen Stichproben. PPmP-Psychotherapie\\u00b7 Psychosomatik\\u00b7 Medizinische Psychologie, 55(05), 266-277.\\r\\n- Goldberg, D. P., Gater, R., Sartorius, N., Ustun, T. B., Piccinelli, M., Gureje, O., & Rutter, C. (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological medicine, 27(1), 191-197.\\r\\n- Kalisch, R., K\\u00f6ber, G., Binder, H., Ahrens, K. F., Basten, U., Chmitorz, A., ... & Engen, H. (2020). A generic solution for the operationalization and measurement of resilience and resilience processes in longitudinal observations: rationale and basic design of the MARP and LORA studies.\\r\\n- Rammstedt, B., Kemper, C., Klein, M. C., Beierlein, C., & Kovaleva, A. (2013). Eine kurze skala zur messung der f\\u00fcnf dimensionen der pers\\u00f6nlichkeit: big-five-inventory-10 (BFI-10). Methoden, Daten, Analysen (mda), 7(2), 233-249.\\r\\n- Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience scale: assessing the ability to bounce back. International journal of behavioral medicine, 15(3), 194-200.\\r\\n- Veer, I. M., Riepenhausen, A., Zerban, M., Wackerhagen, C., Puhlmann, L. M., Engen, H., ... & Kalisch, R. (2021). Psycho-social factors associated with mental resilience in the Corona lockdown. Translational psychiatry, 11(1), 1-11.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Fragebogen der DynaCORE-Studie. Das Instrument setzt sich aus verschiedenen bestehenden Frageb\\u00f6gen sowie neuen Items zu m\\u00f6glichen Resilienzfaktoren w\\u00e4hrend der COVID-19-Pandemie zusammen. Dar\\u00fcber hinaus werden eine Liste von Stressoren und ein Instrument zur Erfassung der psychischen Gesundheit verwendet, um den Stressor-Reaktivit\\u00e4ts-Score zu berechnen (siehe Kalisch et al., 2020 f\\u00fcr weitere Informationen). Siehe Veer et al., 2021 f\\u00fcr eine erste Ver\\u00f6ffentlichung.\\r\\n\\r\\nDynaCORE Instrumente:\\r\\nGHQ-12 (Goldberg et al., 1997),\\r\\nFSozU (Dunkel et al., 2005),\\r\\nASKU (Beierlein et al., 2012),\\r\\nBRS (Smith et al., 2008),\\r\\nBFI-10: Neuroticism (Rammstedt & John, 2007),\\r\\nBrief COPE(Carver, 1997),\\r\\nCERQ subscales (Garnefski,Kraaij, & Spinhoven, 2001),\\r\\nStressors based on MIMIS (Chmitorz et al., 2020) plus Corona-related stressors.\\r\\n\\r\\nQuellenangaben:\\r\\n- Beierlein, C., Kovaleva, A., Kemper, C. J., & Rammstedt, B. (2012). Ein Messinstrument zur Erfassung subjektiver Kompetenzerwartungen: Allgemeine Selbstwirksamkeit Kurzskala (ASKU).\\r\\n- Carver, C. S. (1997). You want to measure coping but your protocol\\u2019too long: Consider the brief cope. International journal of behavioral medicine, 4(1), 92-100.\\r\\n- Chmitorz, A., Kurth, K., Mey, L. K., Wenzel, M., Lieb, K., T\\u00fcscher, O., ... & Kalisch, R. (2020). Assessment of microstressors in adults: Questionnaire development and ecological validation of the mainz inventory of microstressors. JMIR mental health, 7(2), e14566.\\r\\n- Dunkel, D., Antretter, E., Fr\\u00f6hlich-Walser, S., & Haring, C. (2005). Evaluation der Kurzform des Fragebogens zur Sozialen Unterst\\u00fctzung (SOZU-K-22) in klinischen und nichtklinischen Stichproben. PPmP-Psychotherapie\\u00b7 Psychosomatik\\u00b7 Medizinische Psychologie, 55(05), 266-277.\\r\\n- Goldberg, D. P., Gater, R., Sartorius, N., Ustun, T. B., Piccinelli, M., Gureje, O., & Rutter, C. (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological medicine, 27(1), 191-197.\\r\\n- Kalisch, R., K\\u00f6ber, G., Binder, H., Ahrens, K. F., Basten, U., Chmitorz, A., ... & Engen, H. (2020). A generic solution for the operationalization and measurement of resilience and resilience processes in longitudinal observations: rationale and basic design of the MARP and LORA studies.\\r\\n- Rammstedt, B., Kemper, C., Klein, M. C., Beierlein, C., & Kovaleva, A. (2013). Eine kurze skala zur messung der f\\u00fcnf dimensionen der pers\\u00f6nlichkeit: big-five-inventory-10 (BFI-10). Methoden, Daten, Analysen (mda), 7(2), 233-249.\\r\\n- Smith, B. W., Dalen, J., Wiggins, K., Tooley, E., Christopher, P., & Bernard, J. (2008). The brief resilience scale: assessing the ability to bounce back. International journal of behavioral medicine, 15(3), 194-200.\\r\\n- Veer, I. M., Riepenhausen, A., Zerban, M., Wackerhagen, C., Puhlmann, L. M., Engen, H., ... & Kalisch, R. (2021). Psycho-social factors associated with mental resilience in the Corona lockdown. Translational psychiatry, 11(1), 1-11.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Parts of the questionnaire are subject to copyright. Using the instruments is not permitted without consent of the copyright holders. Please contact the authors/contact persons to get permission to reuse the questionnaire in whole or parts of it.\", \"resource_id\": \"129\", \"resource_type\": \"Data dictionary\"}"}
{"id":"137","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"105\", \"id_relation_type\": \"is derived from\", \"id_resource_type_general\": \"Text\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"17\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"eva-maria.skoda@lvr.de\", \"role_phone\": \"+49 (0)201 438755226\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychosomatische Medizin und Psychotherapie, LVR-Klinikum Essen, Universit\\u00e4t Duisburg-Essen\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-4667-5877\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"45147, Essen, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \" https://www.uni-due.de/rke-pp/forschung.php\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"04mz5ra38\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5718.b\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Eva-Maria\", \"role_name_personal_family_name\": \"Skoda\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"Data Dictionary of the CoPE with Corona Study\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"DE (German)\", \"EN (English)\"], \"resource_web_page\": \"https://mica.covid19.studyhub.nfdi4health.de/dataset/cope-with-corona\", \"resource_descriptions\": [{\"description\": \"This is a data dictionary for the \\\"Questionnaire of the CoPE with Corona Study\\\".\\r\\nThis data dictionary is prepared for upload into OPAL/MICA applications of the OBiBa (Open Source Software for BioBanks) software suite. The variables are annotated with metadata using the variable classification taxonomy developed by Maelstrom Research. Further information about format and applications can be found in Doiron et al. (2017; https://doi.org/10.1093/ije/dyx180).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Please contact the authors/contact persons to get permission to reuse the data dictionary in whole or parts of it.\", \"resource_id\": \"137\", \"resource_type\": \"Data dictionary\"}"}
{"id":"145","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"127\", \"id_relation_type\": \"is derived from\", \"id_resource_type_general\": \"Dataset\"}], \"roles\": [{\"role_type\": \"Creator/Author\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany\", \"role_name_organisational\": \"BIH at Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin\", \"role_affiliation_web_page\": \"https://www.bihealth.org/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0493xsw21\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.484013.a\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}, {\"role_type\": \"Contact person\", \"role_email\": \"julian.sass@charite.de\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-2068-7765\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"https://www.bihealth.org/de/forschung/wissenschaftliche-infrastruktur/core-facilities/interoperabilitaet/home\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0493xsw21\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.484013.a\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Julian\", \"role_name_personal_family_name\": \"Sass\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"XLSX\", \"resource_titles\": [{\"title\": \"German Corona Consensus Dataset (GECCO) - Data Dictionary\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Dictionary\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049210\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://mica.covid19.studyhub.nfdi4health.de/dataset/gecco-covid-19\", \"resource_descriptions\": [{\"description\": \"This is a data dictionary based on the \\\"German Corona Consensus Data Set\\r\\n(GECCO)\\\".\\r\\nThis data dictionary is prepared for upload into OPAL/MICA applications of the OBiBa (Open Source Software for BioBanks) software suite. The variables are annotated with metadata using the variable classification taxonomy developed by Maelstrom Research. Further information about format and applications can be found in Doiron et al. (2017; https://doi.org/10.1093/ije/dyx180).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Dataset\", \"resource_use_rights_label\": \"Other\", \"resource_use_rights_description\": \"Copyright \\u00a9 2021: Berlin Institute of Health, Anna-Louisa-Karsch-Str. 2, 10178 Berlin. The content of this specification is public. Reuse or publication claims are not limited. For the rights of use of the underlying FHIR technology see the FHIR Base Specification. Some code systems in use are issued and maintained by other organizations. The copyright of the respective publishers listed there is applicable.\", \"resource_id\": \"145\", \"resource_type\": \"Data dictionary\"}"}
{"id":"157","content":"{\"ids\": [{\"id_date\": \"11.03.2021\", \"id_type\": \"DOI\", \"id_identifier\": \"10.1136/bmjopen-2020-046127\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": \"\", \"id_type\": \"URL\", \"id_identifier\": \"https://tools.niehs.nih.gov/dr2/index.cfm/resource/21680\", \"id_relation_type\": \"is supplemented by\", \"id_resource_type_general\": \"Text\"}, {\"id_date\": \"\", \"id_type\": \"DOI\", \"id_identifier\": \"10.17605/OSF.IO/NSWCM\", \"id_relation_type\": \"is supplemented by\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"H\\u00f4pital Sacr\\u00e9-C\\u0153ur de Montr\\u00e9al 5400, boul Gouin O, Montreal, Qu\\u00e9bec H4J 1C5, Canada\", \"role_name_organisational\": \"Montreal Behavioural Medicine Centre (MBMC)\", \"role_affiliation_web_page\": \"https://mbmc-cmcm.ca/\", \"role_affiliation_identifiers\": []}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Other\", \"study_region\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_centers\": \"\", \"study_country\": [\"Canada\", \"United Arab Emirates\", \"Argentina\", \"Australia\", \"Austria\", \"Bangladesh\", \"Brazil\", \"Chile\", \"Colombia\", \"Cyprus\", \"Denmark\", \"France\", \"Germany\", \"Ghana\", \"Greece\", \"India\", \"Indonesia\", \"Ireland\", \"Israel\", \"Italy\", \"Jordan\", \"Kenya\", \"Malawi\", \"Malaysia\", \"New Zealand\", \"Nigeria\", \"Pakistan\", \"Peru\", \"Portugal\", \"Rwanda\", \"Saudi Arabia\", \"Serbia\", \"Slovakia\", \"South Africa\", \"Korea\", \"Sweden\", \"Switzerland\", \"Taiwan\", \"Turkey\", \"Uganda\", \"United Kingdom\", \"United States\"], \"study_subject\": \"Person\", \"study_end_date\": \"11.01.2022\", \"study_outcomes\": [], \"study_sampling\": \"Other\", \"study_conditions\": [{\"study_conditions\": \"International assessment of the link between COVID-19 related attitudes, concerns and behaviours in relation to public health policies\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"General Population\", \"study_start_date\": \"27.03.2020\", \"study_data_source\": [\"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"Survey data are captured using two data capture methods: convenience and representative sampling.\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": 120, \"study_age_min_examined\": 8, \"study_type_description\": \"The iCARE study uses different survey methodologies to gather information from people across the globe. These include:\\r\\n- Convenience cross-sectional surveys (distributed globally through a variety of methods);\\r\\n- Representative web-panel surveys (distributed in targeted countries to obtain representative samples);\\r\\n- Longitudinal survey (distributed in Canada).\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": null, \"study_eligibility_age_max\": -1, \"study_eligibility_age_min\": -1, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 25000, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"https://mbmc-cmcm.ca/covid19/apl/\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"The iCARE research materials are only available to formal study collaborators. The iCARE team encourages global collaboration and invites you to become a collaborator of the iCARE study by contacting the team directly: covid19study@mbmc-cmcm.ca.\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"International COVID-19 Awareness and Responses Evaluation Study\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"iCARE\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Quality of Life\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D011788\"}, {\"resource_keywords_label\": \"Life Style\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T023921\"}, {\"resource_keywords_label\": \"Mental Health\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T025592\"}, {\"resource_keywords_label\": \"Health Policies\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T001093842\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\", \"FR (French)\", \"ES (Spanish)\", \"Other\"], \"resource_web_page\": \"http://mbmc-cmcm.ca/covid19/\", \"resource_descriptions\": [{\"description\": \"The iCARE Study is a multi-wave international study of public awareness, attitudes, concerns and behavioural responses to public health policies implemented to reduce the spread of COVID-19, as well as the multidimensional impacts of the pandemic on people around the world. The goal is to link behavioural survey data with policy, mobility and case data to provide behavioural science, data-driven recommendations to governments on how to optimize current policy strategies to reduce the impact of the COVID-19 pandemic in Canada and around the world.\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"157\", \"resource_type\": \"Study\"}"}
{"id":"172","content":"{\"ids\": [{\"id_date\": \"01.03.2021\", \"id_type\": \"DOI\", \"id_identifier\": \"10.1007/s00787-021-01739-0\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_email\": \"elternschaft-in-coronazeiten@charite.de\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters\", \"role_affiliation_address\": \"Augustenburger Platz 1, 13353, Berlin, Germany\", \"role_name_organisational\": \"Charit\\u00e9 \\u2013 Universit\\u00e4tsmedizin Berlin\", \"role_affiliation_web_page\": \"https://kinder-und-jugendpsychiatrie.charite.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"001w7jn25\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}, {\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"Klinische Psychologie und Psychotherapie\", \"role_affiliation_address\": \"Habelschwerdter Allee 45, 14195, Berlin, Germany\", \"role_name_organisational\": \"Freie Universit\\u00e4t (FU) Berlin\", \"role_affiliation_web_page\": \"https://www.ewi-psy.fu-berlin.de/einrichtungen/arbeitsbereiche/klinische_psychotherapie/index.html\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"046ak2485\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.14095.39\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cross-section\", \"study_region\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_centers\": \"\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"11.08.2020\", \"study_outcomes\": [], \"study_sampling\": \"Non-probability (Quota)\", \"study_conditions\": [{\"study_conditions\": \"Parental stress and subjective and mental health during the corona pandemic\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Risk factors for an increase in occurrence of adverse childhood experiences\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Parents\\u2019 negative and positive experiences during the pandemic\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"Parents with underaged children\", \"study_start_date\": \"03.08.2020\", \"study_data_source\": [\"Questionnaire\", \"Interview\"], \"study_centers_number\": null, \"study_design_comment\": \"In parallel, a non-representative survey of nearly 5000 parents via social media took place in August 2020 and was repeated in October and December.\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": -1, \"study_eligibility_age_max\": null, \"study_eligibility_age_min\": null, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 1024, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"The study used a mixed mode design that combined computer-assisted telephone interviews (CATI) with a computerassisted web survey (CAWI).\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"Individual participant data that underlie the results reported in the article (doi:10.1007/s00787-021-01739-0), after deidentifcation, will be made available to researchers who provide a methodologically sound proposal. To gain access, data requestors will need to sign a data access agreement.\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Elternschaft in Corona-Zeiten\", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Parenting\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T049315\"}, {\"resource_keywords_label\": \"Parents\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T030398\"}, {\"resource_keywords_label\": \"Family\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T015896\"}, {\"resource_keywords_label\": \"Mental Health\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T025592\"}, {\"resource_keywords_label\": \"Stress, Psychological\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T039102\"}, {\"resource_keywords_label\": \"Adverse Childhood Experiences\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T000908692\"}, {\"resource_keywords_label\": \"Domestic Violence\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T052710\"}, {\"resource_keywords_label\": \"Child Abuse\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T007688\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://kinder-und-jugendpsychiatrie.charite.de/forschung/covid_19/bua_pandemie_call/\", \"resource_descriptions\": [{\"description\": \"The aim of the study is to assess parental health and stress during the corona pandemic and the connection with parenting behavior as well as with the occurrence of physical violence between parents and the occurrence of physical, sexual or emotional violence or neglect of parents towards their children.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Das Ziel der Untersuchung ist die Erfassung der elterlichen Gesundheit und Belastung w\\u00e4hrend der Corona-Pandemie sowie der Zusammenhang mit dem Erziehungsverhalten sowie mit dem Auftreten von k\\u00f6rperlicher Gewalt zwischen den Eltern sowie dem Auftreten von k\\u00f6rperlicher, sexualisierter oder emotionaler Gewalt oder Vernachl\\u00e4ssigung der Eltern gegen\\u00fcber ihren Kindern.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"172\", \"resource_type\": \"Study\"}"}
{"id":"175","content":"{\"ids\": [], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"78701, Austin, Texas, US\", \"role_name_organisational\": \"The University of Texas at Austin\", \"role_affiliation_web_page\": \"https://www.utexas.edu/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00hj54h04\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.89336.37\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cross-section\", \"study_region\": \"\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"\", \"study_country\": [\"United States\", \"Italy\", \"United Kingdom\", \"Japan\", \"Germany\", \"Switzerland\", \"Spain\", \"Turkey\", \"Portugal\", \"Brazil\", \"Poland\", \"Taiwan\"], \"study_subject\": \"Person\", \"study_end_date\": \"\", \"study_outcomes\": [], \"study_sampling\": \"Non-probability\", \"study_conditions\": [{\"study_conditions\": \"Effects of pandemic on people's daily lives, mental health, and connections with others\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"General Population\", \"study_start_date\": \"17.03.2020\", \"study_data_source\": [\"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": -1, \"study_eligibility_age_max\": -1, \"study_eligibility_age_min\": -1, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 20000, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"Online questionnaire\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"The Pandemic Project: The COVID Social Psychological Survey\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Life Style\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T023921\"}, {\"resource_keywords_label\": \"Mental Health\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T025592\"}], \"resource_language\": [\"EN (English)\", \"ES (Spanish)\", \"DE (German)\", \"Other\"], \"resource_web_page\": \"http://utpsyc.org/covid19/index.html\", \"resource_descriptions\": [{\"description\": \"This survey is attempting to track how the coronavirus is affecting the lives of people in the weeks and months after the outbreak. A series of questions are included that ask about the ways people are thinking about and responding to the current coronavirus outbreak. Individuals who complete the survey will get specific feedback about their coping strategies along with information that might help them deal with the current uncertainties.\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"175\", \"resource_type\": \"Study\"}"}
{"id":"191","content":"{\"ids\": [{\"id_date\": \"04.10.2021\", \"id_type\": \"DOI\", \"id_identifier\": \"10.3389/fped.2021.678937\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": \"\", \"id_type\": \"Other\", \"id_identifier\": \"TiKoCo19\", \"id_relation_type\": \"has grant number\", \"id_resource_type_general\": \"Other\"}, {\"id_date\": \"12.12.2020\", \"id_type\": \"DOI\", \"id_identifier\": \"10.22541/au.160776187.78854537/v1\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Preprint\"}], \"roles\": [{\"role_type\": \"Funder(public)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Salvatorplatz 2, 80 333, M\\u00fcnchen, Germany\", \"role_name_organisational\": \"Bavarian States Ministry of Science and Arts\", \"role_affiliation_web_page\": \"https://www.stmwk.bayern.de/englisch.html\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"grid.467835.b\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000121495207\", \"role_affiliation_identifier_scheme\": \"ISNI\"}, {\"role_affiliation_identifier\": \"01a44gd51\", \"role_affiliation_identifier_scheme\": \"ROR\"}]}, {\"role_type\": \"Funder(public)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Forrenstrasse 2, 6343, Rotkreuz, Switzerland\", \"role_name_organisational\": \"Roche Diagnostics\", \"role_affiliation_web_page\": \"https://diagnostics.roche.com/global/en/home.html\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"grid.417570.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000403741269\", \"role_affiliation_identifier_scheme\": \"ISNI\"}, {\"role_affiliation_identifier\": \"00by1q217\", \"role_affiliation_identifier_scheme\": \"ROR\"}]}, {\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"Klinik und Poliklinik f\\u00fcr Kinder- und Jugendmedizin der Universit\\u00e4t Regensburg (KUNO), Klinik St. Hedwig, Krankenhaus Barmherzige Br\\u00fcder\", \"role_affiliation_address\": \"Steinmetzstra\\u00dfe 1-3, 93049, Regensburg, Germany\", \"role_name_organisational\": \"WECARE Wissenschafts- und Entwicklungscampus Regensburg\", \"role_affiliation_web_page\": \"https://we-care.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"grid.469954.3\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000093210488\", \"role_affiliation_identifier_scheme\": \"ISNI\"}, {\"role_affiliation_identifier\": \"02pdsdw78\", \"role_affiliation_identifier_scheme\": \"ROR\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cross-section\", \"study_region\": \"W\\u00fcrzburg, Bamberg, Bayreuth, N\\u00fcrnberg, Weiden, Regensburg, Passau, Neuburg/Donau, Augsburg, M\\u00fcnchen, Memmingen, Passau, Starnberg, Rosenheim\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_centers\": \"Multicentric\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"22.07.2020\", \"study_outcomes\": [], \"study_sampling\": \"Non-probability (Availability)\", \"study_conditions\": [{\"study_conditions\": \"Antibodies (SARS-CoV-2)\", \"study_conditions_classification\": \"SNOMED CT\", \"study_conditions_classification_code\": \"http://snomed.info/id/68498002\"}, {\"study_conditions\": \"Neutralizing antibody (SARS-CoV-2)\", \"study_conditions_classification\": \"SNOMED CT\", \"study_conditions_classification_code\": \"http://snomed.info/id/260212000\"}], \"study_hypothesis\": \"\", \"study_population\": \"Children and adolescents who attended routine checkups in pediatric offices and children and adolescents with possible COVID-19.\", \"study_start_date\": \"22.05.2020\", \"study_data_source\": [\"Questionnaire\", \"Blood\", \"Serum\"], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": 17, \"study_age_min_examined\": 0, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": null, \"study_eligibility_age_max\": 14, \"study_eligibility_age_min\": 1, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 2934, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Cross-sectiona\"], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"The raw data supporting the conclusions of the article (doi:10.3389/fped.2021.678937) will be made available by the authors, without undue reservation.\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"- All children of age group 1 - 14 years who were scheduled for a prevention program visit in 2020 with the respective pediatrician; \\r\\n- All children aged 1 - 14 of families who actively wanted to participate and also siblings older than 14 years;  \", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Follow CoKiBa - Corona Virus in Children from Bavaria\", \"title_language\": \"EN (English)\"}, {\"title\": \"Follow CoKiBa - Corona-Virus bei Kindern in Bayern\", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"CoKiBa\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \" http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Paediatric\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D010372\"}, {\"resource_keywords_label\": \"Antibodies\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T002667\"}, {\"resource_keywords_label\": \"Childern\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T007685\"}, {\"resource_keywords_label\": \"Adolescents\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T000976)\"}, {\"resource_keywords_label\": \"Seroepidemiological Study\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T047631\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://we-care.de/focokiba\", \"resource_descriptions\": [{\"description\": \"Children and youth are affected rather mildly in the acute phase of COVID-19 and thus, SARS-CoV-2 infection infection may easily be overlooked. In the light of current discussions on the vaccinations of children it seems necessary to better identify children who are immune against SARS-CoV-2 due to a previous infection and to better understand COVID-19 related immune reactions in children.\\r\\nResults suggest that symptoms of SARS-CoV-2 infections are unspecific in children and antibody responses show a dichotomous structure with strong responses in many and no detectable antibodies in PCR positive children and missing neutralization activity in a relevant proportion of the young population.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Kinder und Jugendliche sind in der akuten Phase von COVID-19 eher leicht betroffen und daher kann eine SARS-CoV-2-Infektionsinfektion leicht \\u00fcbersehen werden. Angesichts der aktuellen Diskussionen \\u00fcber die Impfungen von Kindern erscheint es notwendig, Kinder, die aufgrund einer fr\\u00fcheren Infektion gegen SARS-CoV-2 immun sind, besser zu identifizieren und COVID-19-bedingte Immunreaktionen bei Kindern besser zu verstehen.\\r\\nDie Ergebnisse deuten darauf hin, dass die Symptome von SARS-CoV-2-Infektionen bei Kindern unspezifisch sind und Antik\\u00f6rperreaktionen eine dichotome Struktur mit starken Reaktionen bei vielen und keinen nachweisbaren Antik\\u00f6rpern bei PCR-positiven Kindern und fehlender Neutralisationsaktivit\\u00e4t bei einem relevanten Teil der jungen Bev\\u00f6lkerung zeigen.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"191\", \"resource_type\": \"Study\"}"}
{"id":"21","content":"{\"ids\": [], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"heutling.anja@mh-hannover.de\", \"role_phone\": \"+49 (0)511 53219347\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Comprehensive Cancer Center Hannover, Medizinische Hochschule Hannover\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Carl-Neuberg-Str. 1, 30625, Hannover, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00f2yqf98\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"Anja\", \"role_name_personal_family_name\": \"Heutling\"}, {\"role_type\": \"Principal investigator\", \"role_email\": \"haier.joerg@mh-hannover.de\", \"role_phone\": \"+49 (0)511 53219307\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Comprehensive Cancer Center Hannover, Medizinische Hochschule Hannover\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-1278-9438\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Carl-Neuberg-Str. 1, 30625, Hannover, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00f2yqf99\", \"role_affiliation_identifier_scheme\": \"ROR\"}], \"role_name_personal_given_name\": \"J\\u00f6rg\", \"role_name_personal_family_name\": \"Haier\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cohort\", \"study_region\": \"Lower Saxony\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"31.12.2021\", \"study_outcomes\": [], \"study_sampling\": \"Mixed probability and non-probability\", \"study_conditions\": [], \"study_hypothesis\": \"\", \"study_population\": \"Oncology nurses and doctors\", \"study_start_date\": \"01.07.2020\", \"study_data_source\": [\"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": 200, \"study_eligibility_age_max\": -1, \"study_eligibility_age_min\": 18, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 212, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"Data sharing conditions: upon request by email.\", \"study_eligibility_exclusion_criteria\": \"No exclusion criteria\", \"study_eligibility_inclusion_criteria\": \"No inclusion criteria\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Management in oncology during COVID-19 pandemic \\u2013 ethical, legal and health-economic implications\", \"title_language\": \"EN (English)\"}, {\"title\": \"Management in der Onkologie w\\u00e4hrend der COVID-19 Pandemie - ethische, rechtliche und gesundheits\\u00f6konomische Implikationen\", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"OnCoVID\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Oncology Service, Hospital\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D016522\"}, {\"resource_keywords_label\": \"Management Service Organizations\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D021661\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"\", \"resource_descriptions\": [{\"description\": \"Decision making on cancer care during the COVID-19 pandemic is characterized not only by limited resources and prioritizations of acute treatments, but also by multidimensional implications for treatment algorithms, long-term outcomes and clinical process management. This has to be considered during all phases of the pandemic progression: 0) regular treatment before the pandemic; 1) prevention of the spread and preparation for infected individuals; 2) resource scarcity, and 3) re-establishment of regular treatment routines. The complexity of cancer care requires specific considerations of ethical and medico-legal aspects, but currently such guidelines are only available for intensive/ emergency care. This project aims to develop data-based decisional guidelines for oncology care under the context of pandemics. Stakeholder perspectives will be assessed by specific questionnaires. Clinical data, data regarding oncology-specific critical resource availability and selected economic data will be used for modelling consequences in terms of morbidity development and disease-related outcome.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Die Entscheidungsfindung zur Krebsbehandlung w\\u00e4hrend der COVID-19-Pandemie ist nicht nur durch begrenzte Ressourcen und Priorisierung von Akutbehandlungen gekennzeichnet, sondern auch durch mehrdimensionale Auswirkungen auf Behandlungsalgorithmen, Langzeitergebnisse und klinisches Prozessmanagement. Dies muss in allen Phasen des Fortschreitens der Pandemie ber\\u00fccksichtigt werden: 0) regul\\u00e4re Behandlung vor der Pandemie; 1) Verhinderung der Ausbreitung und Vorbereitung auf infizierte Patienten; 2) Ressourcenknappheit und 3) Wiederherstellung regul\\u00e4rer Behandlungsroutinen. Die Komplexit\\u00e4t der Krebsbehandlung erfordert spezifische \\u00dcberlegungen zu ethischen und medizinisch-rechtlichen Aspekten.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"21\", \"resource_type\": \"Study\"}"}
{"id":"39","content":"{\"ids\": [{\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"107\", \"id_relation_type\": \"has part\", \"id_resource_type_general\": \"Text\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"108\", \"id_relation_type\": \"has part\", \"id_resource_type_general\": \"Text\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"124\", \"id_relation_type\": \"has part\", \"id_resource_type_general\": \"Dataset\"}, {\"id_date\": \"\", \"id_type\": \"NFDI4Health\", \"id_identifier\": \"125\", \"id_relation_type\": \"has part\", \"id_resource_type_general\": \"Dataset\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_email\": \"voelzke@uni-greifswald.de\", \"role_phone\": \"+49 (0)383 4867541\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute for Community Medicine, University of Greifswald\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0001-7003-399X\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Ellernholzstra\\u00dfe 1-2, 17487, Greifswald, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www2.medizin.uni-greifswald.de/icm/index.php?id=334\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00r1edq15\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5603.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Henry\", \"role_name_personal_family_name\": \"V\\u00f6lzke\"}, {\"role_type\": \"Contact person\", \"role_email\": \"carsten.schmidt@uni-greifswald.de\", \"role_phone\": \"+49 (0)383 4867713\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute for Community Medicine, University of Greifswald\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0001-5266-9396\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Ellernholzstra\\u00dfe 1-2, 17487, Greifswald, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www2.medizin.uni-greifswald.de/icm/index.php?id=334\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"00r1edq15\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5603.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Carsten Oliver\", \"role_name_personal_family_name\": \"Schmidt\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cohort\", \"study_region\": \"Western Pomerania region in the state of Mecklenburg-Western Pomerania\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"\", \"study_outcomes\": [], \"study_sampling\": \"Unknown\", \"study_conditions\": [], \"study_hypothesis\": \"\", \"study_population\": \"General population\", \"study_start_date\": \"01.10.2020\", \"study_data_source\": [\"Blood\", \"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"SHIP-COVID was implemented as part of an existing cohort. Therefore no formal inclusion criteria apply in addition to being participant in SHIP-4.\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": 1000, \"study_eligibility_age_max\": 79, \"study_eligibility_age_min\": 20, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": -1, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Unknown\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"Residents of the target region, aged 20-79 at the time of sampling\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"The Study of Health in Pomerania-COVID\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"SHIP-COVID\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"\", \"resource_descriptions\": [{\"description\": \"The sub-study is based on the established SHIP study. Volunteers from the SHIP-4 cohort are included starting September 2020. Two subgroups are to be distinguished: Subgroup 1 consists of test persons (n=500), for whom the SHIP study is still pending and for subgroup 2, the SHIP study has already been conducted. \\r\\nSubgroup 1 will be tested by PCR for a possible, currently existing SARS-CoV-2 infection and by antibody testing for SARS-CoV-2 infections. In addition, they are asked by means of a questionnaire about their symptoms, behavior, expectations regarding the further course and effects of the pandemic, the assessment of their own risk and their agreement with preventive measures. This survey will be repeated monthly and is combined with a new antibody test (follow-up examinations) to detect possible infections with SARS-CoV-2 over the course of two years. For this purpose, the \\\"Dried Blood Spot\\\" (DBS) test is used. It enables the participants to collect the sample material themselves at home and send it to the study center by mail. In subgroup 2, a total of 500 subjects are included using a questionnaire and a DBS antibody test. The survey is repeated every four months over the same duration.\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"39\", \"resource_type\": \"Study\"}"}
{"id":"49","content":"{\"ids\": [], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_name_personal_given_name\": \" Irene\", \"role_name_personal_family_name\": \"Higginson\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Other\", \"study_region\": \"\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"\", \"study_country\": [\"United Kingdom\", \"Germany\", \"Ireland\", \"Italy\", \"Poland\"], \"study_subject\": \"Person\", \"study_end_date\": null, \"study_outcomes\": [], \"study_sampling\": \"\", \"study_conditions\": [], \"study_hypothesis\": \"\", \"study_population\": \"\", \"study_start_date\": null, \"study_data_source\": [], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [], \"study_target_sample_size\": null, \"study_eligibility_age_max\": null, \"study_eligibility_age_min\": null, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": null, \"study_status_halted_reason\": \"\", \"interventional_study_design\": {\"study_phase\": \"\", \"study_masking\": null, \"study_allocation\": \"\", \"study_masking_roles\": [], \"study_off_label_use\": \"\", \"study_primary_purpose\": \"\", \"study_masking_description\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": []}, \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"\", \"study_status_when_intervention\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [], \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_descriptions\": [{\"description\": \"Background and study aims: \\r\\nBreathlessness which affects people with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) even when they are receiving treatment is called refractory breathlessness. It can be frightening and cause: distress, disability, anxiety and social isolation.\\r\\nWe don\\u2019t know which treatment is best for refractory breathlessness and this study aims to test whether a widely used drug called Mirtazapine can help to reduce the symptoms of refractory breathlessness when compared to a dummy drug or \\u2018placebo\\u2019.\\r\\n\\r\\nCaregiver part of the study:\\r\\nWe are also finding out how refractory breathlessness affects caregivers such as close family members. Through questionnaires, we are collecting information about the caregiver\\u2019s views of the refractory breathlessness that is affecting the person that they are caring for\\r\\n\\r\\nWhat does the study involve?\\r\\nMain study:\\r\\nThe study team want to recruit 324 participants from 5 countries. The participants taking part are put into 1 of 2 groups at random. Neither you nor your doctor will be able to decide or know which group you are in.\\r\\nOne group will receive the drug mirtazapine which is being tested as a treatment and the other group will receive a dummy drug called the placebo. The drugs will be given as tablets which will be swallowed as one tablet per day for 56 days. Several study visits will take place, some will be face to face at hospital and some will be over the telephone. If your breathlessness does not get better after 14 days, you can take two tablets per day. If your breathlessness still does not get better after 28 days, you can take up to three tablets per day. During your study visits, you will also be asked to complete questionnaires about your personal experience of breathlessness and how it affects your quality of life.\\r\\n\\r\\nCaregiver part of the study\\r\\nCaregivers taking part in the caregiver part of the study will be asked to complete quality of life questionnaire booklets about their view of how breathlessness is affecting the person that they are caring for. This study will take place over several meetings, some will be face to face and some will be over the telephone.\\r\\nSource: https://covid19.studyhub.nfdi4health.de/resource/666916\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"49\", \"resource_type\": \"Study\"}"}
{"id":"50","content":"{\"ids\": [{\"id_date\": \"21.10.2021\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_identifier\": \"NCT04747366\", \"id_relation_type\": \"has alternate ID\", \"id_resource_type_general\": \"Other\"}, {\"id_date\": null, \"id_type\": \"Other\", \"id_identifier\": \"NAPKON-HAP\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"martin.witzenrath@charite.de\", \"role_phone\": \"+49 (0)30 450553892\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Charit\\u00e9 - University Medicine Berlin\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-9787-5633\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Berlin, Germany, 13353\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.charite.de/en/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"001w7jn25\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000122184662\", \"role_affiliation_identifier_scheme\": \"ISNI\"}], \"role_name_personal_given_name\": \"Martin\", \"role_name_personal_family_name\": \"Witzenrath\"}, {\"role_type\": \"Contact person\", \"role_email\": \"florian.kurth@charite.de\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Charit\\u00e9 - University Medicine Berlin\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-3807-473X\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Berlin, Germany, 13353\", \"role_name_personal_title\": \"Other\", \"role_affiliation_web_page\": \"https://www.charite.de/en/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"001w7jn25\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000122184662\", \"role_affiliation_identifier_scheme\": \"ISNI\"}], \"role_name_personal_given_name\": \"Florian\", \"role_name_personal_family_name\": \"Kurth\"}, {\"role_type\": \"Principal investigator\", \"role_email\": \"martin.witzenrath@charite.de\", \"role_phone\": \"+49 (0)30 450553892\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Charit\\u00e9 University Hospital\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-9787-5633\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Berlin, Germany, 13353\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.charite.de/en/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"001w7jn25\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000122184662\", \"role_affiliation_identifier_scheme\": \"ISNI\"}], \"role_name_personal_given_name\": \"Martin\", \"role_name_personal_family_name\": \"Witzenrath\"}, {\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Berlin, Germany, 13353\", \"role_name_organisational\": \"Charit\\u00e9 - University Medicine Berlin\", \"role_affiliation_web_page\": \"https://www.charite.de/en/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.6363.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}, {\"role_affiliation_identifier\": \"0000000122184662\", \"role_affiliation_identifier_scheme\": \"ISNI\"}]}, {\"role_type\": \"Other\", \"role_email\": \"forschungsnetzwerk-unimedizin@charite.de\", \"role_phone\": \"+49 (0)30 450570292\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_name_organisational\": \"Network University Medicine (NUM)\", \"role_affiliation_web_page\": \"https://www.netzwerk-universitaetsmedizin.de/\", \"role_affiliation_identifiers\": []}, {\"role_type\": \"Other\", \"role_email\": \"info@bih-charite.de\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"10178, Berlin, Germany\", \"role_name_organisational\": \"Berlin Institute of Health at Charit\\u00e9\", \"role_affiliation_web_page\": \"https://www.bihealth.org/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0493xsw21\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.484013.a\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cohort\", \"study_region\": \"Freiburg, Heidelberg, Munich, Frankfurt, Giessen, Hannover, Cologne, Kiel, L\\u00fcbeck, Jena, Berlin\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"Multicentric\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"01.11.2025\", \"study_outcomes\": [{\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset.\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l)\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the Short Form Health 36\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire Short Form Health 36 (Sf36)\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the Patient-Reported Outcomes Measurement Information System (PROMIS Profile)\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire Patient-Reported Outcomes Measurement Information System (PROMIS Profile)\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the Neuropathy Questionnaire (Mnsi)\", \"study_outcome_time_frame\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire Neuropathy Questionnaire (Mnsi)\", \"study_outcome_description\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the Trauma Patient Health Questionnaire\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire Trauma Patient Health Questionnaire.\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in body temperature\", \"study_outcome_time_frame\": \"Every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks\", \"study_outcome_description\": \"Assessment of the patient\\u00b4s body temperature will be performed at all visits during the acute phase.\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in blood pressure\", \"study_outcome_time_frame\": \"Every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks\", \"study_outcome_description\": \"Assessment of the patient\\u00b4s blood pressure will be performed at all visits during the acute phase.\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5)\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5). The PTSD Checklist for DSM-5 is a 20-questions self-report measure that assesses the presence and severity of PTSD symptoms.\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset\", \"study_outcome_description\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire National Eye Institute Visual Function Questionnaire (NEI-VFQ).\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in Patient-reported Quality of life recorded with the help of the St. George's Respiratory Questionnaire (SGRQ)\", \"study_outcome_time_frame\": \"Health related quality of life after hospital discharge will be assessed with the questionnaire St. George's Respiratory Questionnaire (SGRQ)\", \"study_outcome_description\": \"Day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset.\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in neruocognitive testing with Cambridge Neuropsychological Test Automated Battery (CANTAB)\", \"study_outcome_time_frame\": \"CANTAB tests can detect changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.\", \"study_outcome_description\": \"At follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in neruocognitive testing with Montreal Cognitive Assessment Test (MOCA) [ Time Frame: at follow-up visits\", \"study_outcome_time_frame\": \"3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results).\", \"study_outcome_description\": \"This test is a screening procedure to determine cognitive deficits. Central cognitive functions are examined using 11 task complexes. This includes time and spatial orientation, learning and memory, attention, language and language skills, reading, writing, drawing and calculating (test duration approx. 10 minutes).\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in blood pressure measured during spiroergometry testing\", \"study_outcome_time_frame\": \"Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Using spiroergometry blood pressure is measured during the test and compared with normative values.\", \"study_outcome_description\": \"At follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"Changes in sensomotory testing with the questionnaire for peripheral neuropathy (Michigan Neuropathy Screening Instrument, MNSI)\", \"study_outcome_time_frame\": \"The MNSI will be used to screen patients for peripheral neuropathy.\", \"study_outcome_description\": \"At follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in heart rate\", \"study_outcome_time_frame\": \"Every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks\", \"study_outcome_description\": \"Assessment of the patient\\u00b4s heart rate will be performed at all visits during the acute phase.\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in breath frequency (respiratory rate) \", \"study_outcome_time_frame\": \"Every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks\", \"study_outcome_description\": \"Assessment of the patient\\u00b4s breath frequency (respiratory rate) will be performed at all visits during the acute phase.\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in peripheral oxygen saturation\", \"study_outcome_time_frame\": \"Every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks.\", \"study_outcome_description\": \"Assessment of the patient\\u00b4s peripheral oxygen saturation will be performed at all visits during the acute phase.\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the clinical score SOFA (sequential organ failure assessment)\", \"study_outcome_time_frame\": \"At primary admission to hospital, upon admission to ICU ward, every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks\", \"study_outcome_description\": \"At each study visit on the ICU ward, the SOFA score will be assessed (if provided in the clinical information system).\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the clinical score Berlin ARDS (acute respiratory distress syndrome) severity score (if provided)\", \"study_outcome_time_frame\": \"Every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks\", \"study_outcome_description\": \"At each study visit on the ICU ward, the Berlin ARDS (acute respiratory distress syndrome) severity score will be assessed (if provided in the clinical information system).\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the clinical score APACHE (Acute Physiology and Chronic Health Evaluation) Score\", \"study_outcome_time_frame\": \"Upon admission to ICU\", \"study_outcome_description\": \"At each study visit on the ICU ward, the APACHE (Acute Physiology and Chronic Health Evaluation) score will be assessed (if provided in the clinical information system).\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the clinical score NEWS (National Early Warning Score)\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study (day of hospitalization), if available.\", \"study_outcome_description\": \"At primary admission to hospital NEWS (National Early Warning Score) will be assessed (if provided in the clinical information system).\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the clinical score qSOFA Score (quick sequential organ failure assessment)\", \"study_outcome_time_frame\": \"At primary admission to hospital qSOFA Score will be assessed (if provided in the clinical information system).\", \"study_outcome_description\": \"Day 1 of enrollment in the study (day of hospitalization), if available\"}, {\"study_outcome_type\": \" Secondary\", \"study_outcome_title\": \"Changes in the Barthel Index\", \"study_outcome_time_frame\": \"Day 1 of enrollment in the study, every Monday, Wednesday and Friday during hospitalisation, (assessed up to 100 weeks?), immediately before discharge, at follow up visits 3, 12, 24 and 36 months after symptom onset.\", \"study_outcome_description\": \"The changes in the Barthel Index score will be recorded and evaluated, if provided.\"}], \"study_sampling\": \"Non-probability\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"MeSH\", \"study_conditions_classification_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}], \"study_hypothesis\": \"Information is not provided.\", \"study_population\": \"COVID-19 patients, hospitalised at any of the participating hospitals (see study sites) over the age of 18 years, who are willing and deemed able to participate in the study.\", \"study_start_date\": \"06.11.2020\", \"study_data_source\": [\"Questionnaire\", \"Urine\", \"Saliva\", \"Blood\", \"Other\"], \"study_centers_number\": 11, \"study_design_comment\": \"Study type: Non-interventional/Observational [Patient Registry]\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"No additional information is provided.\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": 750, \"study_eligibility_age_max\": -1, \"study_eligibility_age_min\": 18, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": -1, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"Additional information about questionnaires and other instruments and data sources used in the study can be found in the description of the outcomes.\", \"study_ethics_commitee_approval\": \"Unknown\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_biospecimen_retention\": [\"Samples with DNA\"], \"study_biospecomen_description\": \"Saliva, Urin, Oropharyngeal / Nasopharyngeal swab / Bronchoalveolar lavage (BAL) / Endotracheal aspirate (ENTA), whole blood\", \"study_target_follow-up_duration\": 3}, \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_age_max_examined_description\": \"No additional information is provided.\", \"study_age_min_examined_description\": \"No additional information is provided.\", \"study_data_sharing_plan_time_frame\": \"Information is not provided.\", \"study_data_sharing_plan_description\": \"Given a concrete inquiry and prior consent by the study participants in question, IPD (individual participant data) can be made available on a case by case basis.\", \"study_eligibility_exclusion_criteria\": \"- Refusal to participate by patient, or appropriate legal representative\\r\\n- Any condition that prohibits supplemental blood-sampling beyond routine blood drawing\", \"study_eligibility_inclusion_criteria\": \"- Age \\u2265 18 years\\r\\n- Willingness to participate in the study (consent to participate by patient or appropriate legal representative) or inclusion via deferred consent\\r\\n- Hospitalization at time of enrollment\\r\\n- Positive evidence for SARS-CoV-2 infection with PCR (polymerase chain reaction) or initial positive rapid diagnostic test in conjunction with typical clinical symptoms, confirmed by a later positive PCR test.\", \"study_status_enrolling_by_invitation\": \"Not applicable\", \"study_eligibility_age_max_description\": \"No additional information is provided.\", \"study_eligibility_age_min_description\": \"No additional information is provided.\", \"study_data_sharing_plan_access_criteria\": \"Information is not provided.\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"National Pandemic Cohort Network - High-resolution Platform (HAP) Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"Not existing\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"coronavirus\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"cohort\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"observational\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"phenotyping\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"NAPKON-HAP\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"NAPKON\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"chronic morbidity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"pa-covid\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Coronavirus Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D018352\"}, {\"resource_keywords_label\": \"Respiratory Tract Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D012141\"}, {\"resource_keywords_label\": \"Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D007239\"}, {\"resource_keywords_label\": \"Pneumonia, Viral\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D011024\"}, {\"resource_keywords_label\": \"Pneumonia\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D011014\"}, {\"resource_keywords_label\": \"Virus Diseases\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D014777\"}, {\"resource_keywords_label\": \"Coronaviridae Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D003333\"}, {\"resource_keywords_label\": \"Nidovirales Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D030341\"}, {\"resource_keywords_label\": \"RNA Virus Infections\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D012327\"}, {\"resource_keywords_label\": \"Lung Diseases\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D008171\"}, {\"resource_keywords_label\": \"Respiratory Tract Diseases\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D012140\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://napkon.de/\", \"resource_descriptions\": [{\"description\": \"NAPKON-HAP is the deep phenotyping platform of the National Pandemic Cohort Network (NAPKON) in Germany. NAPKON is a data and biospecimen collection of patients with COVID-19 and is part of the University Medicine Network (NUM) in Germany. The primary objective of the study is to provide a comprehensive collection of data and biosamples for researchers from national consortia and for participation in international research collaborations for studying COVID-19 and future pandemics.\\r\\n\\r\\nData is collected from patients with COVID-19 three times per week during their hospitalization and at follow-up visits after hospital discharge 3, 6, 12, 24, and 36 months after symptom onset. Data include epidemiological and demographic parameters, medical history and potential risk factors, documentation of routine medical procedures, and clinical course, including different patterns of organ involvement, quality of care, morbidity, and quality of life. Moreover, extensive serial high-quality bio sampling consisting of various sample types is performed to allow deep molecular, immunological, and virological phenotyping.\\r\\n\\r\\nPatients not requiring Intensive Care Unit (ICU)/ Intermediate Care (IMC) treatment will receive 7 and patients requiring ICU/IMC treatment will receive 16 full-phenotyping visits including sampling for biobanking. During hospitalisation the planned blood sampling rate in total is 35 ml at each visit. The total amounts and/or sampling dates may differ according to the ethics committee's regulations for different study centers.\\r\\n\\r\\nAt follow-up visits, the clinical assessment includes an update of the medical history and recent medical events from which additional clinical data is collected (i.e. outpatient CT-scans, echocardiography, external laboratory data). Clinical symptoms are recorded and a physical examination will be performed. Vital signs are recorded and routine blood testing and biosampling is continued. Quality of life is measured with patient-reported outcome questionnaires.\\r\\n\\r\\nFollow-up visits at months 3 and 12 are \\\"deep phenotyping\\\" visits with a comprehensive and detailed set of examinations. In the following visits at months 24 and 36, only examinations with pathologic results from the last deep phenotyping visit at month 12 will be performed.\\r\\n\\r\\nA shorter follow-up visit to record quality of life, recent medical events and with a reduced number of examinations focusing on cardiorespiratory performance will take place at month 6.\\r\\n\\r\\nIn case of relevant medical events, new medical information or changes in the participant\\u00b4s health status, an unscheduled visit can take place anytime within the entire study period.\\r\\n\\r\\nData collection during follow up includes standardized quality of life assessment including PROMIS\\u00ae (Patient-Reported Outcomes Measurement Information System). The pulmonary characterization will include body plethysmography, diffusion capacity, respiratory muscles strength measurement, spiroergometry, capillary blood gas analysis and lung imaging studies (low-dose Computed Tomography (CT), Magnetic Resonance Imaging (MRI) of the lung). Cardiological phenotyping includes echocardiography, electrocardiogram (ECG), 24h-ECG, 24h-blood pressure monitoring, stress cardiac MRI and pulse wave analysis. Neurocognitive testing includes brain MRI, electroencephalogram (EEG), somatosensory testing, refractometry (Visit 3 and 12 months), physical activity test, neurocognitive tests, somatosensory phenotyping, taste- and smell-test. Endocrinological phenotyping will incorporate Advanced Glycation Endproducts (AGE) reader, continuous glucose monitoring for 14 days, Air Displacement Plethysmography (ADP) or bioelectrical impedance analysis (BIA).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"No additional information is provided.\", \"resource_id\": \"50\", \"resource_type\": \"Study\"}"}
{"id":"57","content":"{\"ids\": [{\"id_date\": \"15.05.2020\", \"id_type\": \"Other\", \"id_identifier\": \"451265285\", \"id_relation_type\": \"has grant number\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Funder(public)\", \"role_email\": \"info@volkswagenstiftung.de\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kastanienallee 35, 30519, Hannover, Germany\", \"role_name_organisational\": \"VolkswagenStiftung\", \"role_affiliation_web_page\": \"https://www.volkswagenstiftung.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03bsmfz85\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.452969.6\", \"role_affiliation_identifier_scheme\": \"GRID\"}]}, {\"role_type\": \"Principal investigator\", \"role_email\": \"alexy@uni-bonn.de\", \"role_phone\": \"+49 (0)231 79221016\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute of Nutritional and Food Sciences - Nutritional Epidemiology, University of Bonn, DONALD study\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-1488-5175\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Heinst\\u00fcck 11, 44225, Dortmund, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"https://www.ernaehrungsepidemiologie.uni-bonn.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"041nas322\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.10388.32\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Ute\", \"role_name_personal_family_name\": \"Alexy\"}, {\"role_type\": \"Principal investigator\", \"role_email\": \"nicole.jankovic@uni-bonn.de\", \"role_phone\": \"+49 (0)231 79221034\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute of Nutritional and Food Sciences - Nutritional Epidemiology, University of Bonn, DONALD study\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-9235-5356\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Heinst\\u00fcck 11, 44225, Dortmund, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"https://www.ernaehrungsepidemiologie.uni-bonn.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"041nas322\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.10388.32\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Nicole\", \"role_name_personal_family_name\": \"Jankovic\"}, {\"role_type\": \"Contact person\", \"role_email\": \"nicole.jankovic@uni-bonn.de\", \"role_phone\": \"+49 (0)231 79221034\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Institute of Nutritional and Food Sciences - Nutritional Epidemiology, University of Bonn, DONALD study\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-9235-5356\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Heinst\\u00fcck 11, 44225, Dortmund, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"https://www.ernaehrungsepidemiologie.uni-bonn.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"041nas322\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.10388.32\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Nicole\", \"role_name_personal_family_name\": \"Jankovic\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cohort\", \"study_region\": \"City of Dortmund\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_centers\": \"Monocentric\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"01.09.2022\", \"study_outcomes\": [{\"study_outcome_type\": \"Other\", \"study_outcome_title\": \"Lifestyle changes during the lockdown in 2020\", \"study_outcome_time_frame\": \"\", \"study_outcome_description\": \"Lifestyle changes (diet, chronobiology and physical activity) during the lockdown in 2020 (from 15th of March till 11th of August 2020) among children and adolescence compared to the pre-COVID-19 pandemic period.\"}], \"study_sampling\": \"Non-probability\", \"study_conditions\": [], \"study_hypothesis\": \"\", \"study_population\": \"DONALD Study Population\", \"study_start_date\": \"01.03.2021\", \"study_data_source\": [\"Questionnaire\", \"Other\"], \"study_centers_number\": null, \"study_design_comment\": \"This study is a part of the DONALD study which is an ongoing, open cohort study. Therefore, no maximum age can be stated. In addition, no single hypothesis of the DONALD study exists. Main objectives are given on the website. However, our study grows over time due to new research questions and current research topics.\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": -1, \"study_eligibility_age_max\": 18, \"study_eligibility_age_min\": 2, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 100, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"Other data sources for this substudy include a) 3 day weighted dietary records; b) items from the Munich Chronotype Questionnaire (MCTQ) to access chronotype; c) items from the Adolescent Physical Activity Recall Questionnaires (APARQ) to assess physical activity.\", \"study_ethics_commitee_approval\": \"\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"Cooperations possible upon request\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"Participants of the DONALD study\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Dietary, physical and chronobiological changes during the corona crisis among children and adolescents in Germany, The DONALD Study\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"DONALD-COVID\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Life Style\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T023921\"}, {\"resource_keywords_label\": \"Diet, Food, and Nutrition\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T000864255\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\"], \"resource_web_page\": \"https://www.ernaehrungsepidemiologie.uni-bonn.de/forschung/donald-1/\", \"resource_descriptions\": [{\"description\": \"This research project investigates the impact of the corona crisis on lifestyle changes among DONALD (Dortmund Nutritional and Anthropometric Longitudinally Designed) Study participants. The results will show changes in dietary intake, physical activity and chronobiology among children and adolescence in Germany during the corona crisis in comparison to the behavior prior the lockdown. This project offers a unique opportunity to assess changes of well-known risk factors for chronic disease development helping to formulate targeted public health actions for the current and future pandemic crises.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Dieses Forschungsprojekt untersucht die Auswirkungen der Corona-Krise auf Ver\\u00e4nderungen des Lebensstils bei Probanden der DONALD (Dortmund Nutritional and Anthropometric Longitudinally Designed) Studie. Die Ergebnisse werden Ver\\u00e4nderungen in der Nahrungsaufnahme, der k\\u00f6rperlichen Aktivit\\u00e4t und der Chronobiologie bei Kindern und Jugendlichen in Deutschland w\\u00e4hrend der Corona-Krise im Vergleich zum Verhalten vor dem Lockdown zeigen. Dieses Projekt bietet die einmalige Gelegenheit, Ver\\u00e4nderungen bekannter Risikofaktoren f\\u00fcr die Entwicklung chronischer Krankheiten zu bewerten, was dazu beitr\\u00e4gt, gezielte Ma\\u00dfnahmen des \\u00f6ffentlichen Gesundheitswesens f\\u00fcr die aktuelle sowie zuk\\u00fcnftige Pandemiekrisen zu formulieren.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"57\", \"resource_type\": \"Study\"}"}
{"id":"62","content":"{\"ids\": [{\"id_date\": \"22.10.2020\", \"id_type\": \"DOI\", \"id_identifier\": \"10.1080/14616696.2020.1833229\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": \"02.06.2020\", \"id_type\": \"DOI\", \"id_identifier\": \"10.18148/srm/2020.v14i2.7741\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.3224/gwp.v69i3.14\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": null, \"id_type\": \"Handle\", \"id_identifier\": \"10419/216101\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Report\"}, {\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.7802/2042 \", \"id_relation_type\": \"is supplemented by\", \"id_resource_type_general\": \"Dataset\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_email\": \"mareike.buenning@wzb.eu\", \"role_phone\": \"+49 (0)302 5491297\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Wissenschaftszentrum Berlin f\\u00fcr Sozialforschung (WZB)\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0001-9419-5723\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Reichpietschufer 50, 10785, Berlin, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"https://www.wzb.eu/de\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03k0z2z93\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.13388.31\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Mareike\", \"role_name_personal_family_name\": \"B\\u00fcnning\"}, {\"role_type\": \"Principal investigator\", \"role_email\": \"lena.hipp@wzb.eu\", \"role_phone\": \"+49 (0)302 5491232\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Wissenschaftszentrum Berlin f\\u00fcr Sozialforschung (WZB)\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-1535-8748\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Reichpietschufer 50, 10785, Berlin, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.wzb.eu/de\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03k0z2z93\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.13388.31\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Lena \", \"role_name_personal_family_name\": \"Hipp\"}, {\"role_type\": \"Contact person\", \"role_email\": \"lena.hipp@wzb.eu\", \"role_phone\": \"+49 (0)302 5491232\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Wissenschaftszentrum Berlin f\\u00fcr Sozialforschung (WZB)\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0002-1535-8748\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Reichpietschufer 50, 10785, Berlin, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.wzb.eu/de\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03k0z2z93\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.13388.31\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Lena\", \"role_name_personal_family_name\": \"Hipp\"}, {\"role_type\": \"Researcher\", \"role_email\": \"stefan.munnes@wzb.eu\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Wissenschaftszentrum Berlin f\\u00fcr Sozialforschung (WZB)\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Reichpietschufer 50, 10785, Berlin, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"https://www.wzb.eu/de\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03k0z2z93\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.13388.31\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Stefan\", \"role_name_personal_family_name\": \"Munnes\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Panel\", \"study_region\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_centers\": \"\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"02.08.2020\", \"study_outcomes\": [], \"study_sampling\": \"Non-probability\", \"study_conditions\": [{\"study_conditions\": \" Individuals\\u2019 everyday experiences during the Covid-19 lockdown in Germany\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"General population\", \"study_start_date\": \"23.03.2020\", \"study_data_source\": [\"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": 10000, \"study_eligibility_age_max\": 98, \"study_eligibility_age_min\": 14, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": 14754, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"https://www.wzb.eu/de/node/67069/subpage/67227\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Unknown\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": [\"Code book\", \"Analytic code\"]}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Everyday life during the COVID-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"Corona-Alltag\", \"acronym_language\": \"DE (German)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Life Style\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T023921\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://www.wzb.eu/de/forschung/dynamiken-sozialer-ungleichheiten/arbeit-und-fuersorge/corona-alltag\", \"resource_descriptions\": [{\"description\": \"The everyday life of people has changed seriously in a short time due to the Corona virus. With online survey on Corona everyday life (www.corona-alltag.de), we investigate what concrete impact the measures to contain the pandemic have had on the work situation and family life of people in Germany: How do business closures, production shutdowns, and daycare and school closures affect people of different ages, genders, and backgrounds? How are families faring? How are work situations and incomes changing? What are people most concerned about, and how do these concerns vary across population groups?\", \"description_language\": \"EN (English)\"}, {\"description\": \"Der Alltag der Menschen hat sich durch das Corona-Virus in kurzer Zeit gravierend ver\\u00e4ndert. Mit Online-Umfrage zum Corona Alltag (www.corona-alltag.de), untersuchen Sie, welche konkreten Auswirkungen die Ma\\u00dfnahmen zur Eind\\u00e4mmung der Pandemie auf die Arbeitssituation und das Familienleben der Menschen in Deutschland hat: Wie wirken sich Gesch\\u00e4ftsschlie\\u00dfungen, die Stilllegung von Produktion und das Schlie\\u00dfen von Kitas und Schulen auf Menschen unterschiedlichen Alters, Geschlechts und Herkunft aus? Wie geht es den Familien? Wie ver\\u00e4ndern sich Arbeitssituation und Einkommen? Wor\\u00fcber machen sich Menschen am meisten Sorgen, und wie variieren diese Sorgen zwischen den Bev\\u00f6lkerungsgruppen?\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"62\", \"resource_type\": \"Study\"}"}
{"id":"63","content":"{\"ids\": [], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_email\": \"frank.padberg@med.uni-muenchen.de\", \"role_phone\": \"+49 (0)894 40053358\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universit\\u00e4t (LMU) M\\u00fcnchen\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0001-7638-8310\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Nu\\u00dfbaumstra\\u00dfe 7, 80336, M\\u00fcnchen, Germany\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.lmu-klinikum.de/psychiatrie-und-psychotherapie\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05591te55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5252.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \" Frank\", \"role_name_personal_family_name\": \"Padberg\"}, {\"role_type\": \"Contact person\", \"role_email\": \"S.Rek@med.uni-muenchen.de\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universit\\u00e4t (LMU) M\\u00fcnchen\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nu\\u00dfbaumstra\\u00dfe 7, 80336, M\\u00fcnchen, Germany\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"https://www.lmu-klinikum.de/psychiatrie-und-psychotherapie\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05591te55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5252.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Stephanie\", \"role_name_personal_family_name\": \"Rek\"}, {\"role_type\": \"Researcher\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universit\\u00e4t (LMU) M\\u00fcnchen\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"Nu\\u00dfbaumstra\\u00dfe 7, 80336, M\\u00fcnchen, Germany\", \"role_name_personal_title\": \"Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"05591te55\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.5252.0\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Matthias\", \"role_name_personal_family_name\": \"Reinhard\"}, {\"role_type\": \"Sponsor (primary)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"M\\u00fcnchen, Germany\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen (LMU Klinikum)\", \"role_affiliation_web_page\": \"https://www.lmu-klinikum.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"02jet3w32\", \"role_affiliation_identifier_scheme\": \"ROR\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Longitudinal\", \"study_region\": \"\", \"study_status\": \"Ongoing (II): Recruitment and data collection ongoing\", \"study_centers\": \"\", \"study_country\": [\"Germany\"], \"study_subject\": \"Person\", \"study_end_date\": \"31.12.2021\", \"study_outcomes\": [], \"study_sampling\": \"Unknown\", \"study_conditions\": [{\"study_conditions\": \"Psychosocial impact of the corona pandemic\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"Psychiatric inpatients and individuals from the general population.\", \"study_start_date\": \"26.04.2020\", \"study_data_source\": [\"Questionnaire\"], \"study_centers_number\": null, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": 500, \"study_eligibility_age_max\": 75, \"study_eligibility_age_min\": 18, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": -1, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": null}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"NEAR-Corona-Study: My network, the others and resilience\", \"title_language\": \"EN (English)\"}, {\"title\": \"Mein Netzwerk, die Anderen und Resilienz\\u202f(NEAR)-Umfrage zu Corona Zeiten \", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"NEAR-Corona-Study\", \"acronym_language\": \"EN (English)\"}, {\"acronym\": \"NEAR-Corona-Umfrage\", \"acronym_language\": \"DE (German)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Mental Health\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T025592\"}], \"resource_language\": [\"DE (German)\"], \"resource_web_page\": \"https://www.lmu-klinikum.de/psychiatrie-und-psychotherapie/aktuelles/near-corona-umfrage/caa35611562c27f1\", \"resource_descriptions\": [{\"description\": \"Study to better understand the psychosocial impact of the current corona pandemic in psychiatric inpatients and individuals from the general population. The study examines how the corona crisis influences the way we deal with social networks and how it affects mental health.\", \"description_language\": \"EN (English)\"}, {\"description\": \"Studie zum besseren Verst\\u00e4ndnis der psychosozialen Auswirkungen der aktuellen Corona-Pandemie bei station\\u00e4ren Psychiatriepatienten und Personen aus der Allgemeinbev\\u00f6lkerung. Die Studie untersucht, wie die Coronakrise die Art und Weise beeinflusst, wie wir mit sozialen Netzwerken umgehen, und wie sie sich auf die psychische Gesundheit auswirkt.\", \"description_language\": \"DE (German)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"63\", \"resource_type\": \"Study\"}"}
{"id":"83","content":"{\"ids\": [{\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.1038/ijo.2011.30\", \"id_relation_type\": \"describes\", \"id_resource_type_general\": \"Journal article\"}, {\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.1007/978-3-319-98857-3\", \"id_relation_type\": \"describes\", \"id_resource_type_general\": \"Book\"}, {\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.1093/ije/dyw317\", \"id_relation_type\": \"describes\", \"id_resource_type_general\": \"Journal article\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_email\": \"ahrens@leibniz-bips.de\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Prevention Research and Epidemiology - BIPS\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0003-3777-570X\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_affiliation_web_page\": \"https://www.bips-institut.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0000000097503253\", \"role_affiliation_identifier_scheme\": \"ISNI\"}], \"role_name_personal_given_name\": \"Wolfgang\", \"role_name_personal_family_name\": \"Ahrens\"}, {\"role_type\": \"Contact person\", \"role_email\": \"alvarez@leibniz-bips.de\", \"role_phone\": \"\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"Leibniz Institute for Prevention Research and Epidemiology - BIPS\", \"role_name_identifiers\": [], \"role_affiliation_address\": \"\", \"role_name_personal_title\": \"Ms.\", \"role_affiliation_web_page\": \"https://www.bips-institut.de/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0000000097503253\", \"role_affiliation_identifier_scheme\": \"ISNI\"}], \"role_name_personal_given_name\": \"Ina\", \"role_name_personal_family_name\": \"Alvarez\"}, {\"role_type\": \"Hosting institution\", \"role_email\": \"\", \"role_phone\": \"\", \"role_name_type\": \"Organisational\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_name_organisational\": \"Leibniz Institute for Prevention Research and Epidemiology - BIPS\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"0000000097503253\", \"role_affiliation_identifier_scheme\": \"ISNI\"}]}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"study_design\": {\"study_type\": \"Cohort\", \"study_region\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_centers\": \"Multicentric\", \"study_country\": [\"Italy\", \"Cyprus\", \"Belgium\", \"Hungary\", \"Sweden\", \"Germany\", \"Spain\", \"Estonia\"], \"study_subject\": \"Person\", \"study_end_date\": \"28.02.2012\", \"study_outcomes\": [{\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"obesity\", \"study_outcome_time_frame\": \"\", \"study_outcome_description\": \"\"}, {\"study_outcome_type\": \"Primary\", \"study_outcome_title\": \"overweight\", \"study_outcome_time_frame\": \"\", \"study_outcome_description\": \"\"}, {\"study_outcome_type\": \"\", \"study_outcome_title\": \"insulin resistance\", \"study_outcome_time_frame\": \"\", \"study_outcome_description\": \"\"}, {\"study_outcome_type\": \"\", \"study_outcome_title\": \"metabolic syndrome\", \"study_outcome_time_frame\": \"\", \"study_outcome_description\": \"\"}], \"study_sampling\": \"Other\", \"study_conditions\": [{\"study_conditions\": \"overweight\", \"study_conditions_classification\": \"Other vocabulary\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"metabolic syndrome\", \"study_conditions_classification\": \"Other vocabulary\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"insulin resistance\", \"study_conditions_classification\": \"Other vocabulary\", \"study_conditions_classification_code\": \"\"}], \"study_hypothesis\": \"\", \"study_population\": \"A cohort of 16 229 children aged 2\\u20139 years from eight European countries (Sweden, Germany, Hungary, Italy, Cyprus, Spain, Belgium and Estonia) participated at the first population-based survey of the IDEFICS study.\", \"study_start_date\": \"01.09.2006\", \"study_data_source\": [\"Blood\", \"Saliva\", \"Administrative databases\", \"Medical records\", \"Interview\", \"Questionnaire\", \"Physiological/Biochemical measurements\", \"Urine\"], \"study_centers_number\": 8, \"study_design_comment\": \"\", \"study_primary_design\": \"Non-interventional\", \"study_age_max_examined\": null, \"study_age_min_examined\": null, \"study_type_description\": \"A cohort of 16 229 children aged 2\\u20139 years from eight European countries (Sweden, Germany, Hungary, Italy, Cyprus, Spain, Belgium and Estonia) participated at the first population-based survey of the IDEFICS study. This first survey, defined as T0, was the baseline of the prospective cohort study with the largest European children\\u2019s cohort established to date and also represents the baseline measure for the IDEFICS intervention.\\r\\n\\r\\nA second survey (the follow-up, T1,) reassessed the children 2 years later to determine the associations between possible factors influencing health status observed at baseline and selected follow-up outcomes, and also for assessing short-term effects of the intervention, comparing children from control and intervention areas. By the end of T1 around 70% of the children who participated at T0 had participated, plus more than 2 000 new children who entered the corresponding schools or classes between T0 and T1.\\r\\n\\r\\nA selection of morbidities observed at baseline (T0) was used for three retrospective case-control analyses in relation to overweight, insulin resistance (homeostasis model assessment (HOMA) and bone health. Finally, a mailed questionnaire was completed by parents at the third survey (T2) to assess the sustainability of the intervention.\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_target_sample_size\": null, \"study_eligibility_age_max\": 9, \"study_eligibility_age_min\": 2, \"study_status_halted_stage\": \"\", \"study_obtained_sample_size\": null, \"study_status_halted_reason\": \"\", \"study_data_sharing_plan_url\": \"\", \"study_data_source_description\": \"\", \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status_when_intervention\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_biospecimen_retention\": [\"Samples with DNA\"], \"study_biospecomen_description\": \"\", \"study_target_follow-up_duration\": 6}, \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_age_max_examined_description\": \"\", \"study_age_min_examined_description\": \"\", \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_description\": \"Use of data requires a mutual agreement between the study consortium and interested third parties on a case-by-case basis.\", \"study_eligibility_exclusion_criteria\": \"\", \"study_eligibility_inclusion_criteria\": \"\", \"study_status_enrolling_by_invitation\": \"Yes\", \"study_eligibility_age_max_description\": \"\", \"study_eligibility_age_min_description\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_supporting_information\": []}, \"resource_format\": \"\", \"resource_titles\": [{\"title\": \"Identification and prevention of Dietary- and lifestyle-induced health EFfects In Children and infantS\", \"title_language\": \"EN (English)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"IDEFICS\", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"childhood obesity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"diet-related diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"diet-related disorders\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"lifestyle-related diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"lifestyle-related disorders\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"childhood morbidity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"children\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"European\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"prospective cohort study\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"risk factor\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [\"EN (English)\", \"DE (German)\", \"ES (Spanish)\", \"Other\"], \"resource_web_page\": \"https://www.ideficsstudy.eu/\", \"resource_descriptions\": [{\"description\": \"The IDEFICS study started in September 2006 and ended in February 2012 after a prolongation of 6 months. The study was funded by the European Commission under the 6th Framework Programme, grant No. 016181.\\r\\n\\r\\nThe study delivers reliable data to make an international assessment of the problem of obesity in children possible. The focus of the IDEFICS Study lies in exploring the risks for overweight and obesity in children as well as associated long-term consequences. Beyond pure research, IDEFICS offered activities for health promotion and prevention in kindergartens and schools. These prevention programmes were developed, implemented and evaluated within the IDEFICS Study.\\r\\n\\r\\nThe multi-centre IDEFICS project consisted of two elements:\\r\\n\\r\\nA prospective cohort study in a large diverse sample of children. This investigated the causes of of diet- and lifestyle-related diseases and disorders with a strong focus on overweight and obesity. It assessed the prevalence of overweight and obesity, related simultaneous conditions and major risk factors, according to a highly standardised protocol. IDEFICS analysed the complex interplay of factors acting at different levels to disentangle the causal pathways leading to obesity and other health outcomes.\\r\\n\\r\\nThe development, implementation and evaluation of a community-oriented intervention programme for primary prevention of obesity in a controlled study design. This intervention part of the IDEFICS study examined feasibility, effectiveness and sustainability of a coherent set of intervention modules addressing diet, physical activity and coping with stress.\\r\\n\\r\\nThe IDEFICS children cohort was followed up in the phase between childhood and teenage years by the I.Family study funded by the European Commission under the 7th Framework Programme.\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Other\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"resource_id\": \"83\", \"resource_type\": \"Study\"}"}
{"id":"91","content":"{\"ids\": [{\"id_date\": null, \"id_type\": \"DOI\", \"id_identifier\": \"10.6103/SHARE.w8cabeta.001\", \"id_relation_type\": \"is described by\", \"id_resource_type_general\": \"Dataset\"}, {\"id_date\": null, \"id_type\": \"NFDI4Health\", \"id_identifier\": \"120\", \"id_relation_type\": \"is source of\", \"id_resource_type_general\": \"Dataset\"}, {\"id_date\": null, \"id_type\": \"NFDI4Health\", \"id_identifier\": \"34\", \"id_relation_type\": \"is part of\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Contact person\", \"role_email\": \"boersch-supan@mea.mpisoc.mpg.de\", \"role_phone\": \"+49 (0)893 8602355\", \"role_name_type\": \"Personal\", \"role_affiliation_name\": \"SHARE-ERIC, Munich Center for the Economics of Aging, Max Planck Institute for Social Law and Social Policy\", \"role_name_identifiers\": [{\"role_name_identifier\": \"0000-0003-0470-8850\", \"role_name_identifier_scheme\": \"ORCID\"}], \"role_affiliation_address\": \"Amalienstr. 33, 80799, Muenchen, Germany\", \"role_name_personal_title\": \"Mr.\", \"role_affiliation_web_page\": \"https://www.mpisoc.mpg.de/sozialpolitik-mea/forschung/share/\", \"role_affiliation_identifiers\": [{\"role_affiliation_identifier\": \"03vp67w60\", \"role_affiliation_identifier_scheme\": \"ROR\"}, {\"role_affiliation_identifier\": \"grid.462523.4\", \"role_affiliation_identifier_scheme\": \"GRID\"}], \"role_name_personal_given_name\": \"Axel\", \"role_name_personal_family_name\": \"B\\u00f6rsch-Supan\"}], \"provenance\": {\"data_source\": \"Manually collected\"}, \"resource_format\": \"PDF\", \"resource_titles\": [{\"title\": \"SHARE COVID-19 Questionnaire for telephone interviews\", \"title_language\": \"EN (English)\"}, {\"title\": \"SHARE COVID-19 Fragebogen f\\u00fcr Telefoninterviews\", \"title_language\": \"DE (German)\"}], \"resource_version\": \"\", \"resource_acronyms\": [{\"acronym\": \"SHARE COVID-19 Questionnaire \", \"acronym_language\": \"EN (English)\"}], \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/D000086382\"}, {\"resource_keywords_label\": \"Questionnaire\", \"resource_keywords_label_code\": \"http://id.nlm.nih.gov/mesh/T000997092\"}], \"resource_language\": [\"EN (English)\"], \"resource_web_page\": \"http://www.share-project.org/fileadmin/pdf_questionnaire_COVID-19/SHAREw8_COVID19_qnn_20200602_routing.pdf\", \"resource_descriptions\": [{\"description\": \"As a reaction to the seriousness of the COVID-19 outbreak and the prolonged lockdowns, a special SHARE COVID-19 questionnaire was developed. \\r\\nThis new questionnaire covers the most important life domains for the target population and asks specific questions about infections and changes in life during the lockdown: \\r\\n- Health and health behaviour such as general health before and after the COVID-19 outbreak, practice of safety measures (e.g. social distancing, wearing a mask); \\r\\n- Mental health (anxiety, depression, sleeping problems, and loneliness before and after the COVID-19 outbreak); \\r\\n- Infections and healthcare (COVID-19 related symptoms, SARS-CoV-2 testing and hospitalization, forgone medical treatment, satisfaction with treatments); \\r\\n- Changes in work and economic situation (unemployment, business closures, working from home, changes in working hours and income, financial support);\\r\\n- Social networks (changes in personal contacts with family and friends, help given and received, personal care given and received).\", \"description_language\": \"EN (English)\"}], \"resource_type_general\": \"Text\", \"resource_use_rights_label\": \"All rights reserved\", \"resource_use_rights_description\": \"Please contact the authors/contact persons to get permission to reuse the document or parts of it.\", \"resource_id\": \"91\", \"resource_type\": \"Questionnaire\"}"}
{"id":"ACTRN12620000421932","content":"{\"resource_id\": \"ACTRN12620000421932\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://anzctr.org.au/ACTRN12620000421932.aspx\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19 Critical Care Consortium Observational Study Incorporating the Extracorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease (ECMOCARD)\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"ACTRN12620000421932\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Extracorporeal Life Support Organisation\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \" <br>2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19) <br>Respiratory Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Respiratory Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Infection - Studies of infection and infectious agents\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Respiratory - Other respiratory disorders / diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: 1.\\tClinical suspicion or laboratory-confirmed COVID-19 infection by real-time PCR and/or next-generation sequencing\\n\\n2.\\tAdmission to an intensive care unit\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1.\\tPatients treated with mechanical ventilation for other concomitant causes.\\n\\n2.\\tPatients treated with ECMO for other concomitant causes\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 10000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Mortality\\n[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Both;\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"CTRI/2020/06/026228","content":"{\"resource_id\": \"CTRI/2020/06/026228\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44554\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Study in Hospitalized COVID-19 patients with Acalabrutinib along with the Best Supportive Care versus Best Supportive Care\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"CTRI/2020/06/026228\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Acerta Pharma BV\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Health Condition 1: J960- Acute respiratory failure\\nHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"29.06.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Not applicable\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: 1.\\tAbility to understand the purpose and risks of the study and provide signed and dated informed consent.  <br/ >\\n2.\\tMen and women \\u00e2?\\u00a518 years of age  <br/ >\\n3.\\tSARS-CoV-2 confirmed per World Health Organization (WHO) criteria within 4 days of randomization.  <br/ >\\n4.\\tCOVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation  <94% on room air or requires supplemental oxygen.  <br/ >\\n5.\\tAble to swallow pills.  <br/ >\\n6.\\tWilling to follow contraception guidelines  <br/ >\\n <br/ >\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: COVID-19 Related Medical Conditions  <br/ >\\n1. Respiratory failure at the time of screening due to COVID-19 pneumonia. <br/ >\\n2. Known medical resuscitation within 14 days of randomization.  <br/ >\\n3. Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigators judgment, precludes the subjects safe participation in and completion of the study <br/ >\\n4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARSCoV2).  <br/ >\\n5. In the opinion of the Investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments <br/ >\\n <br/ >\\nMedical Conditions  <br/ >\\n6. Not expected to survive 28 days given their pre-existing, uncorrectable medical condition.  <br/ >\\n7. Pregnant or breast feeding.  <br/ >\\n8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin \\u00e2?\\u00a5 3x upper limit of normal (ULN) and/or severe hepatic impairment (Child-Pugh class C).   <br/ >\\n9. Absolute neutrophil count (ANC)  < 500/\\u00ce\\u00bcL at screening (per local laboratory).  <br/ >\\n10. Platelet count  < 50,000/\\u00ce\\u00bcL at screening (per local laboratory).  <br/ >\\n11. Estimated creatinine clearance of  <30 mL/min calculated using the Cockcroft-Gault formula [(140age) \\u00c3? mass (kg)/(72 \\u00c3? creatinine mg/dL) multiply by 0.85 if female]. <br/ >\\n12.Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). <br/ >\\nException: Subjects with controlled, asymptomatic atrial fibrillation during screening area allowed to enrol on study. <br/ >\\n13.History of chronic hypercarbia, respiratory failure in past 6 months, or use of home oxygen in the setting of severe chronic respiratory disease. <br/ >\\n14.Quadriplegia. <br/ >\\n15.History of primary immunodeficiency, tuberculosis, progressive multifocal leukoencephalopathy (PML), aspergillus or other invasive mold/fungal infection, or received organ or bone marrow transplantation within 6 months of randomization. <br/ >\\n16.Known active hepatitis B or C infection requiring therapy. <br/ >\\n <br/ >\\nPrior/Concomitant Therapy: <br/ >\\n <br/ >\\n17.Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 14 days before first dose of study drug) or inducer (within 7 days before first dose of study drug). <br/ >\\n18.Requires treatment with proton-pump inhibitors. <br/ >\\n19.Received oral antirejection or immunomodulatory drugs.  <br/ >\\n20.Active participation in other drug clinical trials or received treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization/enrolment. <br/ >\\n21.Subjects at randomization who require inhaled corticosteroids or maintenance doses of more than 7.5 mg of prednisone or equivalent per day. <br/ >\\n22.Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of acalabrutinib. <br/ >\\n23.History of hypersensitivity (ie, allergic response) to active or inactive excipients of acalabrutinib or other Btk inhibitors. <br/ >\\n24.Known cytoreductive chemotherapy treatment within 14 days of randomization. <br/ >\\n25.Major surgery (as defined by the Investigator) within 4 weeks prior to randomization or still recovering from prior surgery.\", \"study_population\": \"\", \"study_target_sample_size\": 140, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"The overall objective of the study is to evaluate the efficacy of adding acalabrutinib to BSC for the treatment of COVID-19. <br/ >\\nFor the purpose of this study, respiratory failure, is defined based on resource utilization of any of the following modalities:  <br/ >\\n\\t(a) Endotracheal intubation and mechanical ventilation  <br/ >\\n\\t(b) Oxygen delivered by high-flow nasal cannula  <br/ >\\n\\t(c) Non-invasive positive pressure ventilation or continuous positive airway pressure  <br/ >\\n\\t(d) Extracorporeal membrane oxygenation  <br/ >\\nTimepoint: Proportion of subjects alive and free of respiratory failure at Day 14\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Centralized  Blinding and masking:Open Label\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"Intervention1: Acalabrutininb (ACP-196): 1:1Assignment\\nRoute of Administration: Oral. \\nDuration of therapy: 10 days \\nFrequency:Twice daily (BID)\\nControl Intervention1: Best Supportive Care: 1:1 Assignment\\nDuration of therapy: 10 days\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"CTRI/2020/08/027466","content":"{\"resource_id\": \"CTRI/2020/08/027466\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46198\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Outcomes of liver and pancreatic caner surgery during the COVID-19 pandemic\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"CTRI/2020/08/027466\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Tata Memorial Hospital\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"31.08.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Not applicable\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: 1) Adults age more than equal to 18 years with a confirmed diagnosis requiring HPB surgery, both benign and malignant <br/ >\\n <br/ >\\n2) Cholecystectomy will be included as \\u00e2??basic\\u00e2?? HPB surgery with very low morbidity and almost null mortality.\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1) HPB Surgery performed in the trauma setting.  <br/ >\\n <br/ >\\n2) HPB Surgery performed as a synchronous case with another specialty \\u00e2?? e.g. synchronous colonic and liver resections.  <br/ >\\n <br/ >\\n3) Liver transplantation  <br/ >\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"To evaluate the outcomes in all patients undergoing hepatobiliary and pancreatic HPB surgery outside liver or pancreas transplantations during the COVID-19 pandemic.Timepoint: 6 month\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Other<br>  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"CTRI/2020/12/029582","content":"{\"resource_id\": \"CTRI/2020/12/029582\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48958\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Baricitinib in Patients with COVID-19 Infection\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"CTRI/2020/12/029582\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Eli Lilly and Company India Pvt Ltd\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"18.12.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Not applicable\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: 1. Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain reaction (PCR) test or other commercial or public health assay in any specimen, as documented by either of the following: <br/ >\\n <br/ >\\n(a) PCR positive in sample collected  <72 hours prior to randomization; OR <br/ >\\n(b) PCR positive in sample collected \\u00e2?\\u00a572 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking  >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection. <br/ >\\n <br/ >\\n2. Have evidence of pneumonia (SpO2  <94 or PaO2/FiO2 [or SpO2/FiO2] ratio  <300 mmHg or chest imaging findings consistent with pneumonia), OR have evidence of active COVID infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate  >24 breaths/minute). <br/ >\\n <br/ >\\n3. Have indicators of risk of progression: at least 1 inflammatory markers  >upper limit of normal (ULN) (C reactive protein [CRP], D dimer, lactate dehydrogenase [LDH], ferritin) with at least 1 instance of elevation  >ULN within 2 days before study entry.\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1. Are receiving cytotoxic or biologic treatments (such as tumor necrosis factor [TNF] inhibitors, anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], T-cell or B-cell targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors for any indication at study entry. Note: A washout period 4 weeks (or 5 half-lives, whichever is longer) is required prior to screening. <br/ >\\n2. Have ever received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19. <br/ >\\n3. Have received high dose corticosteroids at doses  >20 mg per day (or prednisone equivalent) administered for \\u00e2?\\u00a514 consecutive days in the month prior to study entry. <br/ >\\n4. Strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study entry. <br/ >\\n5. Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required). <br/ >\\n6. Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product. <br/ >\\n7. Have received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of nonlive (inactivated) vaccinations is allowed for all participants. <br/ >\\n8. Require invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry. <br/ >\\n9. Current diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product. <br/ >\\n10. Have a history of venous thromboembolism (VTE) (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) within 12 weeks prior to randomization or have a history of recurrent ( >1) VTE (DVT/PE). <br/ >\\n11. Anticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry. <br/ >\\n12. Have neutropenia (absolute neutrophil count  <1000 cells/microliters). <br/ >\\n13. Have lymphopenia (absolute lymphocyte count  <200 cells/microliters). <br/ >\\n14. Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  >5 times ULN. <br/ >\\n15. Estimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease [MDRD])  <30 milliliter/minute/1.73 meters squared. <br/ >\\n16. Have a known hypersensitivity to baricitinib or any of its excipients. <br/ >\\n17. Are currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (start) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28. <br/ >\\n18. Are pregnant, or intend to become pregnant or breastfeed during the study. <br/ >\\n19. Are using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb\\u00c2\\u00ae. <br/ >\\n20. Are, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.\", \"study_population\": \"\", \"study_target_sample_size\": 1000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (including extracorporeal membrane oxygenation [ECMO])Timepoint: Time Frame: Day 1 to Day 28\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Stratified randomization  Method of allocation concealment:Centralized  Blinding and masking:Double Blind Double Dummy\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"Intervention1: Baricitinib: 4 milligrams (mg) of baricitinib given orally with background therapy.\\nTime Frame upto 14 days\\nControl Intervention1: Placebo: Placebo given orally with background therapy.\\nTime Frame upto 14 days\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"CTRI/2021/05/033836","content":"{\"resource_id\": \"CTRI/2021/05/033836\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=55147\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Safety and Efficacy of ATR-002 for Hospitalized Patients with COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"CTRI/2021/05/033836\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Atriva Therapeutics GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Not applicable\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: Informed Consent <br/ >\\n1. Capable of giving signed informed consent as described in Section 10.1.3, which includes <br/ >\\ncompliance with the requirements and restrictions listed in the informed consent form (ICF) <br/ >\\nand in this protocol. <br/ >\\nAge <br/ >\\n2. Study participant must be at least 18 years of age at the time of signing the ICF. <br/ >\\nType of Participant and Disease Characteristics <br/ >\\n3.1 Study participants in India with a laboratory confirmed diagnosis of SARS-CoV-2 infection <br/ >\\npresenting as moderate COVID-19 requiring hospitalization for COVID-19 and for medical <br/ >\\nreasons (see Section 8 and CLINICAL MANAGEMENT PROTOCOL: COVID-19, <br/ >\\nGovernment of India, Version 5, 03.07.20). <br/ >\\n3.2 At least one of the following clinical features need to be present: <br/ >\\nDyspnea <br/ >\\nHypoxia <br/ >\\nFever <br/ >\\nCough <br/ >\\nAND <br/ >\\n3.3 SpO2 between 90% and 93% on room air <br/ >\\nAND <br/ >\\n3.4 Respiratory Rate more or equal to 24 and less than 30 breaths per minute <br/ >\\nPatients presenting to the hospital without a laboratory confirmed SARS-CoV-2 infection will be <br/ >\\ntested locally for SARS-CoV-2 during the screening period. <br/ >\\nFor sites in the EU: A CE certified SARS-CoV-2 PCR test kit is required to confirm infection. <br/ >\\nFor sites outside the EU: SARS-CoV-2 PCR test kits certified according to local regulations are <br/ >\\nrequired to confirm infection. <br/ >\\nWeight <br/ >\\n4. Body weight at least 50 kg and have a body mass index (BMI) \\u00e2?\\u00a5 18.0 kg/m2 and  < 40.0 kg/m2. <br/ >\\n5. Male or female. <br/ >\\nPregnancy and Contraception <br/ >\\nContraceptive use by women and men should be consistent with local regulations regarding the <br/ >\\nmethods of contraception for those participating in clinical studies. <br/ >\\n6. A female study participant is eligible to participate if she is not pregnant or breastfeeding, <br/ >\\nand one of the following conditions applies: <br/ >\\na. She is not a WOCBP as defined in Section 10.3.1. <br/ >\\nb. Is a WOCBP and is using a contraceptive method that is highly effective, with a <br/ >\\nfailure rate of  <1%, as described in Section 10.3.2 during the IMP period and for at <br/ >\\nleast 4 weeks after the last dose of IMP. The investigator should evaluate the <br/ >\\npotential for contraceptive method failure (e.g., noncompliance, recently initiated) in <br/ >\\nrelationship to the first dose of IMP. <br/ >\\n7. A WOCBP must have a negative urine pregnancy test within 24 hours before the first dose of <br/ >\\nIMP, see Section 8.3.5. <br/ >\\na. If a urine pregnancy test cannot be confirmed as negative (e.g., an ambiguous result), <br/ >\\na serum pregnancy test is required locally. In such cases, the participant must not be <br/ >\\nrandomized if the serum pregnancy result is positive. <br/ >\\nb. If a serum pregnancy test is required as per local regulations, a serum pregnancy test <br/ >\\nis required locally. In such cases, the participant must not be randomized if the serum <br/ >\\npregnancy result is positive. <br/ >\\nc. The investigator is responsible for review of medical history, menstrual history, and <br/ >\\nrecent sexual activity to decrease the risk for inclusion of a woman with an early <br/ >\\nundetectable pregnancy. <br/ >\\n8. A male study participant is eligible to participate if: <br/ >\\na. He is azoospermic <br/ >\\nb. The partner is not a WOCBP as defined in Section 10.3.1. <br/ >\\nc. The partner is a WOCBP and is using a contraceptive method that is highly effective, <br/ >\\nwit\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1. Patient\\u00e2??s clinical condition is worsening rapidly. <br/ >\\n2. Requiring ICU admission or ventilator support at screening or at randomization. <br/ >\\nSuspected bacterial, fungal, viral, or other infection (besides COVID-19). <br/ >\\n4. History of any of the following: malignant disease, autoimmune disease, or severe liver, <br/ >\\nkidney, blood, cardiac, pulmonary, neurological, or endocrine disease as judged by the <br/ >\\ninvestigator. The medical monitor should be contacted by the investigator. <br/ >\\n5.1 Patients with uncontrolled hypertension (BP \\u00e2?\\u00a5 140/90 mmHg). <br/ >\\n6. Clinically significant cardiac conduction abnormalities, including QTc prolongation of  > <br/ >\\n450 milliseconds. <br/ >\\n7. Family history of Long QT Syndrome. <br/ >\\n8. Heart failure class 3, or 4, as defined by the New York Heart Association (NYHA). <br/ >\\n9.1 History of acute coronary syndrome (including myocardial infarction), coronary angioplasty, <br/ >\\nstenting, or thromboembolic event within 24 weeks prior to screening. <br/ >\\n10. Patients with implanted defibrillators or permanent pacemakers. <br/ >\\n11. Poorly controlled diabetes mellitus with an HbA1c  > 7.5 %. <br/ >\\n12. Renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome, or <br/ >\\nrenal tubular acidosis. <br/ >\\n13. Renal failure requiring renal replacement therapy or moderate renal impairment as defined <br/ >\\nby having an estimated glomerular filtration rate (eGFR, CKD-EPI)  < 45 ml/min/1.73m2. <br/ >\\n14. Chronic Obstructive Pulmonary Disease (COPD) GOLD C, or D, or hospitalization for <br/ >\\nexacerbation of COPD within 24 weeks prior to screening. <br/ >\\n15. Other chronic lung diseases including cystic fibrosis, neuromuscular diseases, severe chest <br/ >\\nwall deformities, interstitial lung diseases, outpatient chronic non-invasive ventilation due to <br/ >\\nchronic respiratory failure. <br/ >\\n16. Asthma with a symptom control level of \\\"uncontrolled\\\", according to current GINA <br/ >\\nguidelines. <br/ >\\n17. Currently suffering from diseases that seriously affect the immune system, such as: human <br/ >\\nimmunodeficiency virus (HIV) infection, or the blood system, or splenectomy, or organ/ <br/ >\\nstem cell transplantation. <br/ >\\n18. Known Hepatitis B or C infection. <br/ >\\n19. Any medical condition, physical examination finding or laboratory abnormality that, in the <br/ >\\nopinion of the investigator, might confound the results of the study or pose an additional risk <br/ >\\nto the patient. <br/ >\\n20. Alanine transaminase (ALT) or aspartate transaminase (AST)  >3.0 x ULN. <br/ >\\n21. Total bilirubin  >1.0 x ULN (\\u00e2?\\u00a51.5 x ULN total bilirubin if known Gilbert\\u00e2??s syndrome). <br/ >\\nPrior/Concomitant Therapy <br/ >\\n22. Taking concomitant medication metabolized by CYP2C8 and/ or CYP2C9 and listed as <br/ >\\n\\u00e2??prohibited\\u00e2?? in Section 10.5. <br/ >\\n23. Taking concomitant medication of any experimental treatment or use of marketed <br/ >\\nmedications including off-label use, that are intended as specific treatment for COVID19. <br/ >\\nAny such treatments must be washed out for 30 days or at least 5 half-lives prior to <br/ >\\nrandomization, whichever is longer, unless a formal written standard of care policy document requires otherwise. Inclusion needs to be approved by the investigator and <br/ >\\nmedical monitor. <br/ >\\nTaking medication that may seriously affect the immune system, e.g., chemotherapy, unless <br/ >\\nconsidered and documented as standard of care (e.g., corticosteroids\", \"study_population\": \"\", \"study_target_sample_size\": 220, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Clinical severity status on a 7 point ordinal scale at Day 15 <br/ >\\nTime from randomization to discharge from hospital <br/ >\\nTime to discharge from hospital or to score of \\u00e2?\\u00a42 maintained for 24 hours in NEWS2 whichever occurs first  <br/ >\\nTime to resolution of fever defined as \\u00e2?\\u00a436.6\\u00b0C (axilla) \\u00e2?\\u00a437.2\\u00b0C (oral) or \\u00e2?\\u00a437.8\\u00b0C (rectal or tympanic) for at least 24 hours without antipyretics for 24 hours.  <br/ >\\nTime to SpO2 94% on room air maintained for 24 hours  <br/ >\\nTimepoint: Day 15\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant and Investigator Blinded\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"Intervention1: ATR-002: 900 mg (6 tablets) once daily on Day 1\\n600 mg (4 tablets) once daily on Days 2 to 6\\nIntervention2: Placebo: 6 matching placebo tablets\\non Day 1\\n4 matching placebo tablets\\non Days 2 to 6\\nControl Intervention1: Matching Placebo: 6 tablets once daily on Day 1 and 4 tablets once daily on Days 2 to 6\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"DRKS00017294","content":"{\"resource_id\": \"DRKS00017294\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"PROSPECTIVE OBSERVATIONAL STUDY ON THE UTILISATION AND TREATMENT RESULTS OF PATIENTS NEWLY TREATED WITH DROPIZOL\\u00ae (OPIUM TINCTURE) UNDER CONDITIONS OF EVERYDAY PRACTICE\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Non-interventional study on utilisation, effectiveness, tolerability, and quality of life in patients with severe diarrhea who are newly treated with Dropizol within the indication of this finished product. The study was designed to be interdisciplinary, and patients with various underlying conditions associated with severe diarrhea can be documented.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CLARIFY DROPIZOL\\u00ae\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00017294\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"13.05.2019\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://awbdb.bfarm.de/ords/f?p=101:20:::NO:::\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"InnoCur Pharma GmbH\", \"role_email\": \"\", \"role_phone\": \"+49 (0) 69 400 55 36 00\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hanauer Landstr. 146, 60314 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"https://www.innocur.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Romy\", \"role_name_personal_family_name\": \"Wagner\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"romy.wagner@g-wt.de\", \"role_phone\": \"0351 259 33186\", \"role_affiliation_name\": \"GWT-TUD GmbH, Medizin\", \"role_affiliation_address\": \"Freiberger Str. 33, 01067 Dresden, Germany\", \"role_affiliation_web_page\": \"http://gwtonline.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"David\", \"role_name_personal_family_name\": \"Pittrow\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"david.pittrow@mailbox.tu-dresden.de\", \"role_phone\": \"0351 25933182\", \"role_affiliation_name\": \"GWT-TUD GmbH\", \"role_affiliation_address\": \"Freiberger Str. 33, 01067 Dresden, Germany\", \"role_affiliation_web_page\": \"http://gwtonline.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Romy\", \"role_name_personal_family_name\": \"Wagner\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"romy.wagner@g-wt.de\", \"role_phone\": \"0351 259 33186\", \"role_affiliation_name\": \"GWT-TUD GmbH, Medizin\", \"role_affiliation_address\": \"Freiberger Str. 33, 01067 Dresden, Germany\", \"role_affiliation_web_page\": \"http://gwtonline.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Severe diarrhea\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Other noninfective gastroenteritis and colitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K52\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"06.09.2019\", \"study_end_date\": \"30.04.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 3, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u2022 Severe diarrhoea, e.g. diarrhoea caused by cytostatic drugs, radiation or neuroendocrine tumours, if the application of other antidiarrheal drugs has not produced a sufficient effect.\\n\\u2022 Written consent before the first documentation.\\n\\u2022 Newly treated with Dropizol\\u00ae within the provisions of the Summary of Product Characteristics (SPC)\", \"study_eligibility_exclusion_criteria\": \"\\u2022 Contraindications as described in the Summary of Product Characteristics\\n\\u2022 Lack of cognitive and linguistic ability to participate in the study\\n\\u2022 Patient (probably) not available for follow-up period (up to 6 months)\\n\\u2022 Pregnancy\", \"study_population\": \"\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\\u2022 Change in number of stools per day at approximately 10 days compared to baseline (treatment initiation)\\n\\u2022 Ileostomy patients: change in excretion quantity (ml) in bag at approximately 10days compared to baseline (treatment initiation)\\n\\u2022 Dropizol\\u00ae dosage at approximately 10-14 days compared to baseline\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Change in number of stools per day at 6 months (or end of observation) compared to baseline (treatment initiation)\\n\\u2022 In ileostomy patients: change in excretion quantity (ml) in bag at end of observation compared to baseline\\no at reversal of ileostoma\\no at introduction of new line of chemotherapy (adjuvant therapy)\\no in any case no later than 6 months\\n\\u2022 Dropizol\\u00ae dosage at 6 months (or end of observation) compared to baseline (treatment initiation)\\n\\u2022 Time to effect (= days of Dropizol\\u00ae treatment leading to normalized frequency of stools per day)\\n\\u2022 Dosing pattern (number of Dropizol\\u00ae doses per day)\\n\\u2022 In oncological patients only: STIDAT total score at 6 months (or end of observation) compared to baseline (treatment initiation)\\n\\u2022 QoL (by EQ-5D VAS) at 6 months (or end of observation) compared to baseline (treatment initiation)\\n\\u2022 QLQ-C30 at 6 months (or end of observation) compared to baseline (treatment initiation)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients with servere diarrhea who are newly treated with Dropizol(R)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00018853","content":"{\"resource_id\": \"DRKS00018853\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Functional outcomes in children and adolescents with congenital heart disease\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Children with congenital heart defects show developmental deficits regarding conditional, sport motor and neurological factors. Lack of movement experience due to frequent hospital stays and the associated convalescence as well as overprotection of these children by their parents can lead to additional stagnation or even regression in the child's sports motor development.  \\nIn addition, there is a generally increasing lack of exercise in children and adolescents, which is why it is important to keep an early eye on cardiovascular comorbidities. Cardiovascular changes already begin subclinically in childhood and then develop progressively before arteriosclerosis manifests itself clinically. Smaller studies have already shown that adult patients with congenital heart defects have increased vascular stiffness and an increased cardiovascular risk profile. Therefore, prospective screening in a younger group is of particular importance and necessity. This should be multifactorial and include cardiovascular risk, motor skills, lifestyle and daily activity.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"FOOTLOOSE\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00018853\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.09.2019\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Kinderherzen F\\u00f6rdergemeinschaft Deutsche Kinderherzzentren e.V.\", \"role_email\": \"info@kinderherzen.de\", \"role_phone\": \"+49 228 422 800\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Elsa-Br\\u00e4ndstr\\u00f6m-Str. 21, 53225 Bonn, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Renate\", \"role_name_personal_family_name\": \"Oberhoffer\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"renate.oberhoffer@tum.de\", \"role_phone\": \"+49.89.289.24571\", \"role_affiliation_name\": \"Lehrstuhl f\\u00fcr Pr\\u00e4ventive P\\u00e4diatrie der Technischen Universit\\u00e4t M\\u00fcnchen\", \"role_affiliation_address\": \"Georg-Brauchle-Ring 60/62, 80992 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"M\\u00fcller\", \"role_name_personal_title\": \"Mr. PD Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"j.mueller@tum.de\", \"role_phone\": \"+49.89.289.24575\", \"role_affiliation_name\": \"Lehrstuhl f\\u00fcr Pr\\u00e4ventive P\\u00e4diatrie der Technischen Universit\\u00e4t M\\u00fcnchen\", \"role_affiliation_address\": \"Georg-Brauchle-Ring 60/62 , 80992 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"M\\u00fcller\", \"role_name_personal_title\": \"Mr. PD Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"j.mueller@tum.de\", \"role_phone\": \"+49.89.289.24575\", \"role_affiliation_name\": \"Lehrstuhl f\\u00fcr Pr\\u00e4ventive P\\u00e4diatrie der Technischen Universit\\u00e4t M\\u00fcnchen\", \"role_affiliation_address\": \"Georg-Brauchle-Ring 60/62, 80992 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Congenital malformations of cardiac chambers and connections\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q20\"}, {\"study_conditions\": \"Congenital malformations of cardiac septa\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q21\"}, {\"study_conditions\": \"Congenital malformations of pulmonary and tricuspid valves\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q22\"}, {\"study_conditions\": \"Congenital malformations of aortic and mitral valves\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q23\"}, {\"study_conditions\": \"Other congenital malformations of heart\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q24\"}, {\"study_conditions\": \"Congenital malformations of great arteries\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q25\"}, {\"study_conditions\": \"Congenital malformations of great veins\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q26\"}, {\"study_conditions\": \"Other congenital malformations of peripheral vascular system\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q27\"}, {\"study_conditions\": \"Other congenital malformations of circulatory system\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Q28\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.10.2014\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 6, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 17, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients with congenital heart defects who are recruited in the Clinic for Congenital Heart Defects and Pediatric Cardiology of the German Heart Center Munich.\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 2000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Do children and adolescents with a congenital heart defect already have an increased cardiovascular risk (high blood pressure, increased vascular stiffness, increased visceral fat) as well as motoric deficits compared to cardiac healthy of the same age?\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Are there gender differences?\\nAre there differences in the type of heart defect and the severity of the heart defect?\\nAre there correlations between cardiovascular risk, sports motor skills and quality of life?\\nHow does the COVID-19 pandemic affect the health-related quality of life of children and young people with congenital heart defects?\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Meassured longitudinally at each oupatient clinical appointment:\\n-Anamnesis (medication, heart defect, surgeries, cardiac catheter interventions, findings of cardio pulmonary exercise test) \\n-anthropometry (height, weight, waist circumference, hip circumference)\\nHealt related physical fitness screening (Fitnessgram\\u00ae: sit-ups (abdominal muscles), trunk lift (back extension), push-ups (upper limb), sit and reach (hamstring flexibility) and shoulder stretch (shoulder mobility) to quantify the main motor forms.\\n-Activity\\nobjective wearable-based meassurement  \\n- Cardiovascular screening (sonographic measurement of intima-media thickness (IMT) of the common carotid artery, determination of peripheral and central blood pressure  as well as oscillometric measured pulse wave velocity (Mobil-O-Graph\\u00ae).\\n-Health-related Quality of life\\nKINDL Questionnaire - children\\nKINDL Questionnaire \\u2013 parents\\n-Resilience:\\nResilience Scale RS-25\\n-Anxiety:\\nBecks Youth Inventory (BYI-2)\\nState-Trait-Angstinventar (STAI)\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00019207","content":"{\"resource_id\": \"DRKS00019207\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"influenza\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"EPICS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"emergency department\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Point of care (POC)\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ED\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"EPICS-14: Point of Care Influenzascreening and SARS-CoV-2 (COVID-19) testing in the Emergency Department\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In the flu season from November 2019 to April 2020, the rapid (&lt;30 min) and early (&lt; 2 hours after admission) flu testing with the Cobas Liat\\u00ae Influenza A+B Test will be evaluated in two independent emergency departments of the Charit\\u00e9 Universit\\u00e4tsmedizin Berlin (CVK, CCM) as part of a crossover study in all patients with fever and other flu symptoms.\\n\\nIt is an approved clinical routine multiplex real-time polymerase chain reaction (RT-PCR) test from nasopharyngeal swabs. The test result is available within 20 minutes. The \\\"Point-of-Care\\\" test (POCT) will be compared with routine testing in the central laboratory.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"EPICS-14\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00019207\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"23.12.2019\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Ethikvotum_EPICS14_Point of Care.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Roche Molecular Systems, Inc.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"4300 Hacienda Drive, 94588 Pleasanton, United States\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Charit\\u00e9 Universit\\u00e4tsmedizin BerlinNotfall- und Akutmedizin (CVK, CCM)\", \"role_email\": \"martin.moeckel@charite.de\", \"role_phone\": \"004930450553203\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"http://notfallmedizin.charite.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Martin\", \"role_name_personal_family_name\": \"M\\u00f6ckel\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"martin.moeckel@charite.de\", \"role_phone\": \"004930450553203\", \"role_affiliation_name\": \"Charit\\u00e9 Universit\\u00e4tsmedizin Berlin; Notfall- und Akutmedizin (CVK, CCM)\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"http://notfallmedizin.charite.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Martin\", \"role_name_personal_family_name\": \"M\\u00f6ckel\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"martin.moeckel@charite.de\", \"role_phone\": \"004930450553203\", \"role_affiliation_name\": \"Charit\\u00e9 Universit\\u00e4tsmedizin BerlinNotfall- und Akutmedizin (CVK, CCM)\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"http://notfallmedizin.charite.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Crossover\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"influenza due to identified seasonal influenza virus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J10\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"17.12.2019\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"All patients attending the Emergency Departments during the study period with any influenza symptom and fever (\\u226538.0\\u00b0C) will be eligible to participate in the study. \\nNo exclusion criteria will be applied.\\n\", \"study_eligibility_exclusion_criteria\": \"&lt; 18 years of age\", \"study_population\": \"\", \"study_target_sample_size\": 3000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"1. sick days of personnel\\n2. Proportion of patients treated with antibiotic and antiviral therapy\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"length of hospital stay, in-hospital mortality, proportion of patients tested, ICU admission, proportion of patients with a final diagnosis of influenza or pneumonia, proportion of secondary infections, Aspergillus infections, pneumococci infections,  between presentation to the ED and antiviral/antibiotic treatment, time to disposition, admission/discharge rate, medical procedures, laboratory tests performed, transmission rate on other patients.\\nturn-around-time until test result is available.\\nPhysician decision making (disposition, medical procedures, antiviral/antibiotic therapy, laboratory parameters).\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"data sharing ist not possible due to data protection requirements \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"conventional influenza testing in the central laboratory\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"rapid (&lt;30 Min) and early (&lt; 2 hours after admission) influenza testing \\u00b4directly in the emergency department\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021161","content":"{\"resource_id\": \"DRKS00021161\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Our study illustrates epidemiological and demographic data (e.g. urban vs country areas), clinical symptoms (e.g. fever, cough, muscle ache, rhinorrhea, diarrhea and others), comorbidities, ways of transmitting the infection, laboratory and radiological findings, and treatment strategies. Patients were enrolled in this study if they were diagnosed having a laboratory-confirmed Covid-19. The primary endpoints are composed of admission to an intensive care unit (ICU), tracheal intubation or death.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021161\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"07.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Department Innovation &amp; Research Support\", \"role_email\": \"petra.thuermann@helios-gesundheit.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Heusnerstra\\u00dfe 40, 42283 Wuppertal, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Irit\", \"role_name_personal_family_name\": \"Nachtigall\", \"role_name_personal_title\": \"Ms. PD Dr.med.\", \"role_name_identifiers\": [], \"role_email\": \"irit.nachtigall@helios-gesundheit.de\", \"role_phone\": \"+49 33631 7-3221\", \"role_affiliation_name\": \"Abteilung f\\u00fcr Krankenhaushygiene\", \"role_affiliation_address\": \"Pieskower Strasse 33, 15526 Bad Saarow, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Julius\", \"role_name_personal_family_name\": \"Dengler\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"julius.dengler@helios-gesundheit.de\", \"role_phone\": \"+49 33631 7-3840\", \"role_affiliation_name\": \"Klinik f\\u00fcr Neurochirurgie\", \"role_affiliation_address\": \"Pieskower Strasse 33, 15526 Bad Saarow, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Hauptmann\", \"role_name_personal_title\": \"Mr. Professor  Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"michael.hauptmann@mhb-fontane.de\", \"role_phone\": \"+493391 39-14580\", \"role_affiliation_name\": \"Institut f\\u00fcr Biometrie und Registerforschung, Medizinische Hochschule Brandenburg, Neu-ruppin\", \"role_affiliation_address\": \"Fehrbelliner Stra\\u00dfe 38, 16816 Neuruppin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Covid-19 disease\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"15.02.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"all patients who were diagnosed with SARS-CoV-2 after laboratory confirmation and who had been admitted to hospital since 15.02.20\", \"study_eligibility_exclusion_criteria\": \"Covid-19 negative Patients\", \"study_population\": \"\", \"study_target_sample_size\": 1000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary endpoints are composed of admission to an intensive care unit (ICU), tracheal intubation or death. \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The secondary endpoints are : length of stay at the ICU and utilization of ICU capacity\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"study protocol and statistical Analysis\\nThe Analysis will be on going for the next 2 years and there are going to be updates according to the data.  \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"All clinical and radiological data were extracted from an electronic database, named iNOK, which is collecting medical records of all patients admitted to the Helios Hospitals since February, 15 2020 . For this study medical records such as epidemiological, demographic, clinical, laboratory, management and outcome data \\nare collected by using a CRF. These data are merged in real time\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021208","content":"{\"resource_id\": \"DRKS00021208\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19 related obstetric and neonatal outcome study (CRONOS)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Summary of project\\nA novel coronavirus, termed SARS-CoV-2 (or COVID-19), has rapidly spread across the globe creating a massive public health problem. It causes potentially a life-threatening respiratory distress disease. Previous epidemics of many emerging viral infections have typically resulted in poor obstetrical outcomes including maternal morbidity and mortality, maternal-fetal transmission of the virus, and perinatal infections and death. The available literature describes only 38 pregnant women with SARS-CoV-2 with no maternal death and no evidence for intrauterine or transplacental transmission of the virus to their fetuses. \\nThe planned study is non-interventional prospective cohort study in order to overcome the lack of knowledge about epidemiology and clinical course of SARS-COV-2 in pregnant women to further develop evidence-based diagnostic and therapeutic recommendations. Data collection will be performed retrospectively after a pregnant patient case has been completed (treatment is finished or patient\\u2019s death). Recruitment will be bidirectional, including past patients, and prospective identification of patients with confirmed SARS-CoV-2 diagnosis. Only data from standard of care treatment will be collected (secondary data use). All data will be pseudonymised for anonymity from initial collection and entered to the online database https://castoredc.com.\\n\\nAt our study sites, we aim to recruit women admitted to hospital with confirmed SARS-CoV-2 in pregnancy. \\nThis will allow for \\n1. the recognition of outcomes of COVID-19 infection in pregnancy for both mother and infant\\n2. the identification of characteristics of women who are hospitalised due to COVID-19/have a concomitant COVID-19 infection, and to determine whether these characteristics influence pregnancy and/or disease outcome\\n\\nAmendment 24.02.2021 - data about\\n3. Vaccination history in or before pregnancy\\n4. Infection before pregnancy is also collected\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CRONOS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021208\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"31.03.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"im Auftrag der Deutschen Gesellschaft f\\u00fcr Perinatale Medizin e.V.c/o Conventus Congressmanagement &amp; Marketing GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Carl-Pulfrich-Str. 1, 07745 Jena, Germany\", \"role_affiliation_web_page\": \"https://www.dgpm-online.org\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Ulrich\", \"role_name_personal_family_name\": \"Pecks\", \"role_name_personal_title\": \"Mr. Professor Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"ulrich.pecks@uksh.de\", \"role_phone\": \"036413116475\", \"role_affiliation_name\": \"Vorstand der Deutschen Gesellschaft f\\u00fcr Perinatale Medizin (DGPM) e.V.c/o Conventus Congressmanagement &amp; Marketing GmbH\", \"role_affiliation_address\": \"Carl-Pulvrich-Str. 1, 07745 Jena, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Ulrich\", \"role_name_personal_family_name\": \"Pecks\", \"role_name_personal_title\": \"Mr. Professor Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"ulrich.pecks@uksh.de\", \"role_phone\": \"043150021241\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Schleswig-Holstein Campus Kiel Klinik f\\u00fcr Gyn\\u00e4kologie und Geburtshilfe\", \"role_affiliation_address\": \"Arnold-Heller-Str. 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Ulrich\", \"role_name_personal_family_name\": \"Pecks\", \"role_name_personal_title\": \"Mr. Professor Dr.\", \"role_name_identifiers\": [], \"role_email\": \"gs@dgpm-online.org\", \"role_phone\": \"036413116475\", \"role_affiliation_name\": \"Deutsche Gesellschaft f\\u00fcr Perinatale Medizinc/o Conventus Congressmanagement &amp; Marketing GmbH\", \"role_affiliation_address\": \"Carl-Pulvrich-Str. 1, 07745 Jena, Germany\", \"role_affiliation_web_page\": \"https://www.dgpm-online.org\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"03.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Proven Covid-19 infection before/ during pregnancy and childbed and relation to vaccination history\", \"study_eligibility_exclusion_criteria\": \"deny of informed consent, withdrawal of informed consent\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Trying to identify the risk/risk factors for bad outcome of Covid-19 infection during pregnancy for mother and baby until the end of the puerperium (6 weeks postpartum).\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Time of infection/vaccination in relation to critical illness of patient, risk factors, teratogenity, embryo toxicity, course of delivery, critical ill newborn, need for intensive care of mother/child, transmission of virus to baby, bonding and breastfeeding habits\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Protocol, ethical approval, Database will be provided for all additional study centres. Statistical analysis is \\\"work in progress\\\" and will be provided via URL of DGPM-online.org once established\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Medical history, clinical data of Covid-19 positive pregnant women will be collected during pregnancy, delivery, of the neonate and during childbed.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021214","content":"{\"resource_id\": \"DRKS00021214\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2;\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Tryptophan\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Nicotinamide;\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Vitamin B3;\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19;\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Improvement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The availability of tryptophan and its metabolites, especially nicotinamide (a form of vitamin B3) as a building block of NAD and NADP, are important factors in the immune system. Dysregulation can lead to immune deficiency, but also to chronic inflammation (Nikolaus et al. 2017, Gastroenterology 153:1504; Agus et al. 2018, Cell Host Microbe 23:716; Sorgdrager et al. 2019, Front. Immunol. 10:2565; Taleb 2019, Front. Immunol. 10:2113; Pongratz et al. 2019, Clin. Exp. Rheumatol. 37:450). Particularly in the context of pneumonia, certain metabolites of tryptophan are important and can strengthen lung immune functions and counteract chronic changes caused by inflammatory reactions in the lungs (Heseler et al. 2008, FEMS Immunol. Med. Microbiol. 52:273; Suzuki et al. 2011, J. Infect. 63:215; Meier et al. 2017, Clin. Chem. Lab. Med. 55:1060; Tsay et al. 2019, J. Transl. Med. 17:304; Michaudel et al. 2020, Front. Immunol. 11:144; Takei et al. 2020, Arthritis Res. Ther. 22:20; Zhou et al. 2020, Sci. Rep. 10:4436).\\n\\nSupplementation with nicotinamide has a strong anti-inflammatory effect in both tryptophan-deficient and normally fed animals (Hashimoto et al. 2012, Nature 487:477; Waetzig &amp; Seegert 2013, WO2013/186355; Bettenworth et al. 2014, Mol. Nutr. Food Res. 58:1474; Waetzig &amp; Seegert 2015, WO2015/086838). Reduced levels of nicotinamide and thus NAD(P) also impede immune defence against coronaviruses (Heer et al. 2020, J. Biol. Chem. 295:17986) and cell metabolism, especially also of macrophages and epithelial cells. The latter in particular are subject to a critically high turnover rate in the gut and lungs. Another link to SARS-CoV-2 beyond inflammation and the immune system could also be the SARS-CoV-2 entry receptor ACE2, as the presence of ACE2 on the cell surface enables the uptake of tryptophan via the transporter B0AT1 (Hashimoto et al. 2012, Nature 487:477). In severe courses of influenza, as in chronic inflammation, increased tryptophan degradation and thus increased kynurenine levels are observed, and inhibition of tryptophan degradation has beneficial effects in animal models (Boergeling &amp; Ludwig 2017, FEBS J. 284:218; Pizzini et al. 2019, Influenza Other Respir Viruses 13:603).\\n\\nIn turn, there is evidence in a wide variety of virus types that nicotinamide can reduce viral replication and support the body's defence mechanisms, e.g. in vaccinia (Child et al. 1988, Virus Res. 9:119), HIV (Murray 2003, Clin. Infect. Dis. 36:453), enteroviruses (Moell et al. 2009, J. Med. Virol. 81:1082) or hepatitis B (Li et al. 2016, Arch. Virol. 161:621). Adequate supply of B vitamins and explicitly nicotinamide to strengthen the immune system is also recommended to combat SARS-CoV-2 infection (Zhang &amp; Liu 2020, J. Med. Virol. 92:479; Gharote 2020, Ind. J. Med. Sci. 72:25; Shi et al. 2020, Cell Death Differ. 27:1451; Shakoor et al. 2021, Maturitas 144:108). Here, the improvement of the defence against secondary bacterial infections in disease models is particularly emphasised (Zhang &amp; Liu 2020, J. Med. Virol. 92:479). In the COVit trial, 1,000 mg of nicotinamide are administered, which is far below potentially harmful doses of several grams per day and very close to the acceptable daily intake of 900 mg/day (OECD-SIDS 2002, SIDS Initial Assessment Report for SIAM 15, Boston, MA, 22-25 October 2002; EFSA 2014, EFSA J. 12:3759). Meanwhile, several publications suggest the use of nicotinamide in COVID-19, but there are no trial data in this regard (Heer et al. 2020, J. Biol. Chem. 295:17986; Gharote 2020, Ind. J. Med. Sci. 72:25; Shi et al. 2020, Cell Death Differ. 27:1451; Shakoor et al. 2021, Maturitas 144:108; Mehmel et al. 2020, Nutrients 12:1616).\\n\\nIn the pilot phase of the COVit trial, patients received 1,000 mg of conventional nicotinamide or 245 mg of silica as a placebo-like dietary supplement. During a quality control of the data collection, it was surprisingly observed that considerably more patients in the nicotinamide arm were completely symptom-free already after two weeks of administration compared to the silica group. From the literature, depending on the patient population, very long convalescences can also be expected, e.g. 43 % symptom-free 14-21 days after positive SARS-CoV-2 test (Tenforde et al. 2020, MMWR Morb. Mortal. Wkly Rep. 69:993), &lt;30 % without respiratory symptoms after one month (Marshall 2020, Nature 585:339), 32% symptom-free at 30 days and still only 34% at 60 days after SARS-CoV-2 diagnosis (Carvalho-Schneider et al. 2020, Clin. Microbiol. infect. 10.1016/j.cmi.2020.09.052), or only 12.6% symptom-free after a mean of 60 days (Carfi et al. 2020, JAMA 324:603).\\n\\nIn addition, COVID-19 has been shown to be a systemic disease with an unexpectedly high gastrointestinal symptom frequency (Mitsuyama et al. 2020, J. Clin. Med. 9:3630). Recently, it has been published that the gut microbiome is also significantly and sometimes negatively affected by COVID-19 (Yeoh et al. 2021, Gut 70:698). The link between the gut microbiome and the metabolism of tryptophan and nicotinamide plays an important role in gut inflammation (Hashimoto et al. 2012, Nature 487:477; Waetzig &amp; Seegert 2013, WO2013/186355; Bettenworth et al. 2014, Mol. Nutr. Food Res. 58:1474; Waetzig &amp; Seegert 2015, WO2015/086838). Therefore, two different tablets, each containing 500 mg nicotinamide, will now be used as investigational preparations in the main phase of the COVit trial: the conventional immediate-release nicotinamide tablets from the pilot phase and the newly developed CICR-NAM (controlled-ileocolonic-release nicotinamide) tablets, which release the nicotinamide in a delayed and continuous fashion starting in the lower small intestine. This should increase the gastrointestinal beneficial effect of nicotinamide, specifically also on the microbiome and its interaction with the gut, as conventional nicotinamide is absorbed very quickly into the circulation (Fangmann et al. 2018, Diabetes Care 41:398). A trial with a CICR-NAM prototype have shown that systemic exposure resulting from this new dosage form will be lower than in the pilot phase of the study (Fangmann et al. 2018, Diabetes Care 41:398), in which exposure was already close to the acceptable daily intake anyway (see above). This will further reduce the already minimal risk of side effects.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVit\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021214\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"01.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Innere Medizin I (UKSH, Campus Kiel)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Arnold-Heller-Str 3; Haus C, Haus K3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Dekanat der Medizinischen Fakult\\u00e4t Christian-Albrechts-Universit\\u00e4t zu Kiel\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Arnold-Heller-Str. 3 - Haus 807, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Exzellenzcluster \\\"Precision Medicine in Chronic Inflammation\\\" (DFG EXC 2167)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Christian-Albrechts-Platz 4, 24118 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinik f\\u00fcr Innere Medizin I (UKSH Campus Kiel)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Arnold-Heller-Str. 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stefan\", \"role_name_personal_family_name\": \"Schreiber\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"s.schreiber@mucosa.de\", \"role_phone\": \"0431 500-22201\", \"role_affiliation_name\": \"Klinik f\\u00fcr Innere Medizin I, UKSH Campus Kiel\", \"role_affiliation_address\": \"Arnold-Heller-Str 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"ICD: U07.1: SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"04.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"SARS-CoV-2 infection confirmed by laboratory findings; the positive test must not date back more than 7 days.\\nRelevant infection symptoms, e.g. in the respiratory or gastrointestinal tract.\\nThe patient has been able to give written consent via a website before any trial procedure is performed and can comply with the trial-dependent prerequisites and requirements.\\n\", \"study_eligibility_exclusion_criteria\": \"Current participation in another trial.\\nPregnancy or breastfeeding.\\nVaccination against SARS-CoV-2.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 900, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Frequencies of individual COVID-19 symptoms at week 0, week 2 (primary time of analysis), week 4 and week 6 as well as after 6 months.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1.\\tSeverity of individual COVID-19 symptoms at week 0, week 2 (primary time of analysis), week 4 and week 6 as well as after 6 months.\\n2.\\tOccurrence and severity of symptoms that are characteristic for PCS (at month 6).\\n3.\\tLevels of antibodies directed against the N protein or S protein of SARS-CoV-2 after at least 6 months (anti-S protein stratified for presence and type of booster vaccination).\\n4.\\tComplete resolution of symptoms after 2 weeks.\\n5.\\tComplete resolution of symptoms after 4 weeks.\\n6.\\tComplete resolution of symptoms after 6 weeks.\\n7.\\tTime from diagnosis to resolution of individual symptoms (in days, up to 6 weeks).\\n8.\\tTime from diagnosis to complete resolution of symptoms (in days, up to 6 weeks).\\n\\nExploratory endpoints include the WHO COVID-19 Ordinal Scale for Clinical Improvement, the frequency of severe COVID-19, comparisons between findings from the pilot phase and the second part of the trial, changes in fatigue and quality of life and, in selected patients, changes in blood levels of tryptophan and its metabolites, changes in inflammatory markers, changes in blood cell counts and standard blood profiles, changes in the blood metabolome, the SARS-CoV-2 strain, changes in stool microbiome, metagenome and metabolome as well as the pharmacokinetics.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The medical data including routine clinical findings are not pseudonymised. However, the patients and biospecimens of the trial are pseudonymised with a study patient ID as soon as the data are released for analysis. The assignment of the patient data to the study patient ID is kept within the recruitment centre. The recruitment centre is operated by the University Hospital Schleswig-Holstein (UKSH) and the Competence Network for Intestinal Diseases e.V. in Kiel. Outside the recruitment centre, only study patient IDs are handled. Since the project is under medical supervision, all staff members are subject to medical confidentiality. Disclosure of data to unauthorised third parties (especially employers or insurance companies) is excluded. Samples and information are passed on to scientific cooperation partners exclusively in pseudonymised form, i.e. without personal details. At the end of the research activities (after 15 years at the earliest), the samples and the associated data are destroyed.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Nicotinamide, 1,000 mg/day p.o. (one each of 500-mg conventional and delayed-release nicotinamide tablets), for 4 weeks\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Placebo, p.o. (2 tablets), for 4 weeks\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021229","content":"{\"resource_id\": \"DRKS00021229\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"CoronaKids - Epidemiological data acquisition SARS-CoV2/Covid-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In December 2019, a new coronavirus infection (SARS-CoV-2, Covid-19) broke out in the city of Wuhan in China. SARS-CoV-2 primarily causes respiratory symptoms and can be transmitted from person to person [Chan et al., 2020 and Li et al., 2020]. In January 2020, the spread of SARS-CoV-2 reached an alarming number and since February, Italy and Germany, among others, have been more and more fighting against the daily increase in new infections. The Robert Koch Institute has classified the risk of SARS-CoV-2 as high. Since 8 March 2020, a total of 111 countries have been affected by SARS-CoV-2 and 111,817 cases have been confirmed worldwide, including 3,893 deaths [ECDC. Communicable Disease Threats Report. 2020]. In a recent report, the World Health Organization (WHO) summarizes information on the outbreak, transmission dynamics and clinical symptoms and declares the need for more in-depth research [WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID19)]. There are enormous gaps in knowledge about the best possible clinical care for infected patients and about the prognosis. In addition, there is almost no data on children that summarize the clinical course of the disease. Some papers discuss rather mild courses in children. In this context, we at the Center for Child and Adolescent Medicine would like to collect epidemiological facts about children and adolescents who present in our clinic as outpatients and inpatients. Nasopharyngeal swabs are taken from all outpatient children and adolescents. These are first frozen and then retrospectively tested for SARS-CoV-2. Furthermore, nasopharyngeal swabs as well as stool and urine samples are collected from all suspected cases, i.e. children and adolescents with fever and respiratory symptoms, and these are tested for SARS-CoV-2. Here the focus is on finding the infection localisation, especially in those who show a negative test result in the nasopharyngeal swabs. In addition, the viral genome will be examined in more detail for follow-up projects and potential individual mutations will be correlated, taking epidemiological factors into account.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoronaKids\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021229\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.07.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Zentrum f\\u00fcr Kinder- und Jugendmedizin, HELIOS Universit\\u00e4tsklinikum Wuppertal, Universit\\u00e4t Witten Herdecke\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \", 42283 Wuppertal, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Zentrum f\\u00fcr Kinder- und Jugendmedizin, HELIOS Universit\\u00e4tsklinikum Wuppertal, Universit\\u00e4t Witten Herdecke\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \", 42283 Wuppertal, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stefan\", \"role_name_personal_family_name\": \"Wirth\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"stefan.wirth@helios-gesundheit.de\", \"role_phone\": \"0202 896 3833\", \"role_affiliation_name\": \"Zentrum f\\u00fcr Kinder- und Jugendmedizin HELIOS Universit\\u00e4tsklinikum Wuppertal Universit\\u00e4t Witten Herdecke\", \"role_affiliation_address\": \"Heusnerstrasse 40, 42283 Wuppertal, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"27.03.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 18, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"All children and adolescents aged from &gt;1 day of life to &lt; 18 years who present themselves to the paediatric clinic on an outpatient basis or are admitted as inpatients.\", \"study_eligibility_exclusion_criteria\": \"Lack of informed consent.\", \"study_population\": \"\", \"study_target_sample_size\": 900, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Detection of SARS-CoV2 in nasopharyngeal swabs, urine and stool samples.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Analysis of the virus genome and single nucleotide polymorphisms (SNP) to detect regional differences.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Children and adolescents with respiratory symptoms - Immediate test for SARS-Cov2, storage of stool and urine samples.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Children and adolescents without respiratory symptoms - Later test for SARS-Cov2, no reservation of stool and urine samples.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021238","content":"{\"resource_id\": \"DRKS00021238\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"tocilizumab\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Evaluation of efficacy and safety of a tocilizumab treatment in patients with severe COVID-19 pneumonia.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"TOC-COVID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021238\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"22.04.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-001408-41\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04447-3\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tobias\", \"role_name_personal_family_name\": \"Wengenmayer\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"tobias.wengenmayer@uniklinik-freiburg.de\", \"role_phone\": \"0761-27034010\", \"role_affiliation_name\": \"Medizinische Klinik IIIAlbert-Ludwigs-Universit\\u00e4t Freiburg\", \"role_affiliation_address\": \"Hugstetter Str. 55, 79106 Freiburg i. Br., Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"COVID-19, SARS-CoV2, Corona-Virus\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Terminated: Recruitment, data collection, data and quality management halted prematurely and will not resume\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": \"One of the Ongoing\", \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Terminated\", \"study_start_date\": \"03.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 99, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Proof of SARS-CoV2 \\nSevere respiratory failure\\n- ambient air SpO2 \\u2264 92% or\\n- Need of \\u2265 6l O2/min or\\n- NIV or IMV\", \"study_eligibility_exclusion_criteria\": \"1. Invasvie or non-invasive mechanical ventilation \\u2265 48 hours\\n2. pregnancy or lactation period\\n3. Liver injury or failure (AST/ALT \\u2265 5x above normal)\\n4. Leucocytes &lt; 2 \\u00d7 10^3/\\u00b5l\\n5. Thrombocytes &lt; 50 \\u00d7 10^3/\\u03bcl\\n6. severe bacterial infection (PCT &gt; 3ng/ml)\\n7. rheumatoid arthritis\\n8. Immunosuppressive therapy\\n9. Known tuberculosis\\n10. Known active or chronic viral hepatitis\\n11. Allergic reactions to Tocilizumab or its ingredients\\n12. Life expaction of less then 1 year (independent of Covid-19)\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"ventilator free days (in the first 28 days)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Mortality\\n- 28-day mortality (%)\\n- hospital mortality (%)\\nAdmission to ICU (%)\\nDays on ICU (d)\\nVentilator freee days (without NIV) (d)\\nRenal failure and dialysis (%)\\nChange of ventilation mode and invasivity\\n- Horrowitz Index (PaO2/FiO2)\\n- fiO2 on NIV/IMV\\n- fiO2 on O2-Maske/Highflow-Therapie\\n- PEEP und Compliance on NIV/IMV\\nSOFA-Score\\nSeven-Scale Category\\nTreatment safety \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Other\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Intervention: \\nTocilizumab - Application of 8mg/kg body weight (BW) Tocilizumab i.v. once immediately after randomisation (12 mg/kg for patients with &lt;30kg BW; total dose should not exceed 800 mg) + Conventional treatment\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control: Placebo i.v. once immediately after randomisation + Conventional treatment \"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021254","content":"{\"resource_id\": \"DRKS00021254\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Investigation of the influence of the new coronavirus pandemic (COVID-19) on pain, mood and everyday life of patients with painful polyneuropathy\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"With the help of various questionnaires about pain, quality of life and general well-bein, changes will be observed prospectively during corona pandemic.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COSOPA\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021254\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"03.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Leiter der Sektion Neurologische Schmerzforschung und -Therapie Universit\\u00e4tsklinikum Schleswig-Holstein, Campus Kiel\", \"role_email\": \"r.baron@neurologie.uni-kiel.de\", \"role_phone\": \"043150023911\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Arnold-Heller-Stra\\u00dfe 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Gr\\u00fcnenthal GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \", 52078 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Ralf\", \"role_name_personal_family_name\": \"Baron\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"r.baron@neurologie.uni-kiel.de\", \"role_phone\": \"043150023911\", \"role_affiliation_name\": \"Leiter der Sektion Neurologische Schmerzforschung und -Therapie Universit\\u00e4tsklinikum Schleswig-Holstein, Campus Kiel\", \"role_affiliation_address\": \"Arnold-Heller-Stra\\u00dfe 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Dilara\", \"role_name_personal_family_name\": \"Kersebaum\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"dilara.kersebaum@uksh.de\", \"role_phone\": \"043150023911\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Schleswig-Holstein, Campus KielKlinik f\\u00fcr Neurologie Sektion Neurologische Schmerzforschung und -therapie\", \"role_affiliation_address\": \"Arnold-Heller-Stra\\u00dfe 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"painful polyneuropathy\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Polyneuropathies and other disorders of the peripheral nervous system\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"G60-G64\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"05.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"diagnosis of painful polyneuropathy\", \"study_eligibility_exclusion_criteria\": \"not able to give independent consent\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Pain development during the corona crisis.\\nEnd: as soon as the measures are cancelled and daily life can take place again as before\\nwith which: the assessment is carried out using the questionnaires mentioned\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Change of parameters that are evaluated using all mentioned questionnaires - general health, functionality, depression, anxiety.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"patients with painful polyneuropathy\\nEvaluation of questionnaires (DN4, BPI, PainDETECT, PROMIS, EuroQol 5D, Pain catastrophizing scale, IPAQ, PGIC)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021295","content":"{\"resource_id\": \"DRKS00021295\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"infection\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"dialysis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"chronic kidney disease\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Clinical characteristics of renal patients with COVID-19 infection\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Renal patients with COVID-19 are a risk Population with diverse clinical course of disease. Aim of the present Project is to get a better understanding of COVID-19 clinical courses, to identify biomarkers and immunological Parameters for severe diseases and to evaluate pathogenesis of COVID-19. Patients on risk might be detected in future and therapeutic options might be individualized.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021295\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"04.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Nierenzentrum e.V.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 162, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Nierenzentrum Heidelberg e.V.\", \"role_email\": \"\", \"role_phone\": \"06221 91120\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 162, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Claudia\", \"role_name_personal_family_name\": \"Sommerer\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"claudia.sommerer@med.uni-heidelberg.de\", \"role_phone\": \"06221 91120\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 672, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Claudia\", \"role_name_personal_family_name\": \"Sommerer\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"info@nierenzentrum-heidelberg.com\", \"role_phone\": \"06221 91120\", \"role_affiliation_name\": \"Sektion NephrologieMedizinische Universit\\u00e4tsklinik Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 162, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"06.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1. possility to consent\\n2. written informed consent\\n3. male and female aged \\u226518 years\\n4. SARS-CoV-2 infection.\\n5. renal disease\\n\", \"study_eligibility_exclusion_criteria\": \"refusal of consent\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"It is an explorative study to get better understanding of the disease in order to provide preventive and therapeutic Options in future.\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"incidence of acute renal failure\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Basic data will be collected in a national and European COVID-19 registry.\\n\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"patients with chronic renal failure\\n\\nProspective cohort study, non-interventional\\n\\nDemographic and clinical data will be collected in supposed and verified SARS-CoV-2 infection. Follow-up regarding the clinical course, complications, therapeutic interventions and recovery will be documented.\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021432","content":"{\"resource_id\": \"DRKS00021432\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"mental strain\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"detraining\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"deconditioning\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"older people\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Limitations of social life in the context of the COVID-19 pandemic - Effects on physical performance and health-related quality of life of older people\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The project aims to assess the physical and psychological effects of the restrictions in social life caused by the COVID-19 pandemic. \\nFor this purpose, patients from the risk group of the elderly (&gt; 60 years) who train in the so-called Milon circuit, will be included. The training data collected via the software of the Milon-circuit enables an objective comparison of the physical performance before the restrictions came into force from mid-March with the data one week after the training is resumed. The participants are asked about their physical activity before the pandemic-related restrictions began and how the existing situation with the restriction of social contacts, as well as the limited opportunities for exercise, affect quality of life, physical activity and mobility in everyday life.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoNFINE\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021432\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"04.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Carl von Ossietzky Universit\\u00e4t OldenburgFakult\\u00e4t VI Medizin und GesundheitswissenschaftenDepartment f\\u00fcr VersorgungsforschungAbteilung f\\u00fcr Geriatrie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Carl von Ossietzky Universit\\u00e4t OldenburgFakult\\u00e4t VI Medizin und GesundheitswissenschaftenDepartment f\\u00fcr VersorgungsforschungAbteilung f\\u00fcr Geriatrie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tania\", \"role_name_personal_family_name\": \"Zieschang\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"tania.zieschang@uol.de\", \"role_phone\": \"+49 441 7984644\", \"role_affiliation_name\": \"Carl von Ossietzky Universit\\u00e4t Oldenburg, Fakult\\u00e4t VI Medizin und Gesundheitswissenschaften, Department f\\u00fcr Versorgungsforschung, Abteilung f\\u00fcr Geriatrie\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"https://www.uni-oldenburg.de/geriatrie\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jessica\", \"role_name_personal_family_name\": \"Koschate\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"jessica.koschate@uol.de\", \"role_phone\": \"+494417984760\", \"role_affiliation_name\": \"Carl von Ossietzky Universit\\u00e4t Oldenburg, Fakult\\u00e4t VI Medizin und Gesundheitswissenschaften, Department f\\u00fcr Versorgungsforschung, Abteilung f\\u00fcr Geriatrie\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"https://www.uni-oldenburg.de/geriatrie\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"deconditioning\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"20.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 60, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Training in the Milon strength endurance circuit 1\", \"study_eligibility_exclusion_criteria\": \"No training session in the last month before the start of the restrictions\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary outcome of the study is the difference in the product of training weight and number of repetitions at the Milon-circuit leg extension machine. The product is measured at the last week of training before and the first week of training after the restrictions due to the COVID-19 pandemic.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1. Training weight and number/speed of repetitions and sets on the strength training equipment of the Milon Circle\\n2. Heart rate and output on the endurance training equipment\\n3. Age, sex, height, body weight, current diagnoses, aids, medication, falls, degree of care, daily habits\\n4. Health-related quality of life\\n5. Participation\\n6. Fear of falling\\n7. Handling technology\\n8. Acceptance of technology\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"For Patients \\u226560 years of age with regular training in the milon-training circuit,milon training data is collected one week before the restriction, one week after resuming training and 6 months after resuming training. In addition they are interviewed before, during an after the COVID-19 restrictions about their physical performance and health-related quality of life.  \\nDue to the occurrence of a second wave, as of 2.11.2020\\nonce again closed all structured sports. Therefore, we will, on the one hand\\nthe third survey time point of the study by one month and 6 months after the resumption of training after the renewed\\nAdding to the closure of the sports offerings.\\nBecause the constraints on social life in the context of the COVID\\n19 pandemic are very dynamic, we would like to see further government action,\\nwe would like to conduct further surveys along the same lines.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021439","content":"{\"resource_id\": \"DRKS00021439\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"neurotropy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"cerebral involvement\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID 19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID 19, SARS-CoV2, neurotropy, cerebral involvement\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent?\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Since December 2019, the new SARS-CoV2 coronavirus has spread from the city of Wuhan in China to the entire globe. Infection leads to the disease called COVID-19, which is mainly characterized by fever and respiratory symptoms (especially cough) (Guan et al., 2020; Huang et al., 2020). In extreme cases, COVID-19 can lead to severe pneumonia and ultimately cause a lung failure (ARDS, \\\"Acute respiratory distress syndrome\\\"). There is an increasing body of evidence that a neurological pathomechanism could contribute to this fatal course of teh disease: many Covid 19 patients develop neurological symptoms, including Ageusia, anosmia, cephalgia, nausea, fatigue and even strokes. The occurrence of neurological symptoms is associated with a severe course (Mao et al., 2020). The neuroinvasive potential of coronaviruses was also described in the SARS-CoV outbreak in 2002/2003: Coronaviruses were only found in brain cells, not in the surrounding blood or lymphatic vessels, which suggests a spread of the disease via neurons and not blood or lymphatic vessels (Ding et al., 2004). The neural route of infection has already been demonstrated in animal experiments; it runs from the mucous membrane of the nasal and oropharyngeal space to free nerve endings and ultimately the brain. The viruses are probably passed on via the synapses via endocytosis / exocytosis (Li et al., 2020, 2012). This can lead to a viral infection, particularly of the brain stem - this has been convincingly demonstrated in an animal model with similar viruses (see review: Li et al., 2020). Nuclei in the formatio reticularis of the medulla oblongata such as the nucleus tractus solitarii and the dorsal vagus nucleus are particularly affected. These nuclei are also part of the vital respiratory and circulatory centers of the brain stem (Dampney, 2016). It can therefore be assumed that ageusia and anosmia in particular are precursors of a viral invasion of SARS-CoV-2 into the nuclei of the medullary respiratory and circulatory group, which in extreme cases can lead to life-threatening brain stem encephalitis (Li et al., 2020). In the current SARS-CoV2 pandemic, too, it is widely reported that patients suffer from respiratory failure unusually quickly and sometimes even die without first developing respiratory symptoms (Guan et al., 2020; Huang et al., 2020). In addition, qualitative and quantitative disturbances of consciousness are reported in COVID-19 patients (Mao et al., 2020) - these occur in the context of brainstem encephalitis too, but could also be attributed to an affection of limbic structures in the vicinity of the primary olfactory cortex (area piriformis).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021439\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"20.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Neurologie und Neurophysiologie Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"cornelius.weiller@uniklinik-freiburg.de\", \"role_phone\": \"0761-270-50010\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Breisacher Str. 64, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Cornelius\", \"role_name_personal_family_name\": \"Weiller\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Cornelius.Weiller@uniklinik-freiburg.de\", \"role_phone\": \"0761-270-50010\", \"role_affiliation_name\": \"Klinik f\\u00fcr Neurologie und Neurophysiologie Universit\\u00e4tsklinikum Freiburg\", \"role_affiliation_address\": \"Breisacher Str. 64, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jonas\", \"role_name_personal_family_name\": \"Hosp\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"jonas.hosp@uniklinik-freiburg.de\", \"role_phone\": \"0761-270-50010\", \"role_affiliation_name\": \"Klinik f\\u00fcr Neurologie Universit\\u00e4tsklinikum Freiburg\", \"role_affiliation_address\": \"Breisacherstr. 64, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"20.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Age &gt; 18 Years\\nProof of SARS-CoV-2 Infection\\nAnamnestic Anosmia/Ageusia \\nClinical or radiological indication of encephalitis in COVID-19 disease\", \"study_eligibility_exclusion_criteria\": \"Lack of possibility for oral and written patient information\", \"study_population\": \"\", \"study_target_sample_size\": 70, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Predictive value of the clinical symptoms ageusia and anosmia for a negative outcome of COVID-19 disease and for the detection of changes in the brain, meninges and cerebrospinal fluid in the instrumental diagnostics. \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022 Correlation between the results of different diagnostic procedures and the clinical course\\n\\u2022 Correlation between the results of various diagnostic procedures and vital parameters and, if applicable, ventilation parameters and clinical findings\\n\\u2022 Death from COVID-19 disease\\n\\u2022 Further research questions are derived in the course of the project\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Local Registry Study\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Observation group:\\nAll patients with a focal-neurological deficit and positive SARS-CoV-2 PCR who are in the Freiburg University Hospital for Treatment or are presented on an outpatient basis \\n\\nAll findings of routine clinical diagnostics including findings from laboratory chemistry, instrumental and especially imaging procedures are recorded in a registry. No examinations are performed outside of clinical routine.\\n\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021440","content":"{\"resource_id\": \"DRKS00021440\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"hereditary angioedema\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"C1 inhibitor protein\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the disease\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"On March 11th of 2020 the outbreak of the novel coronavirus SARS-CoV-2 was declared as a pandemic by the World Health Organization. Beside the severe infectivity and primary affection of the upper airways, a severe course of coronavirus disease 2019 (COVID-19) is characteristic in about 5% of the patients. The amount of critically ill COVID-19 patients is increasing in Giessen. Actually, no blood test is available for the prediction of the course of COVID-19. Unfortunately, a specific therapy is lacking. Ongoing clinical trials have revealed no clearly result. Beside duration of exposure and number of aerosols, cardiovascular or immunosuppressive diseases, other risk factors for an aggravating course are ambiguous. Recent studies have demonstrated, that SARS-CoV-2 enters the cells through angiotensin-converting-enzyme 2 (ACE2) and suppresses the expression of ACE2. While bradykinin is depleted by ACE2, it could be increased during SARS-CoV-2 infection. In the case of C1-esterase-inhibitor deficiency bradykinin is increased. Bradykinin is responsible for vasodilatation and increased vascular permeability. Therefore, bradykinin can lead to oedema in lungs or intestine, which causes cough and diarrhea. During an infection with SARS-CoV-2, bradykinin could be considerably augmented. This could explain the fact, that only a few patients develop a severe course. Therefore, we want to analyze the blood of 25 intensive care and ambulant patients, respectively, to measure the concentration and activity of C1-esterase inhibitor.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021440\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"28.01.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Gie\\u00dfen und Marburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Rudolf-Buchheim-Str. 8, 35392 Giessen, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-giessen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Gie\\u00dfen und Marburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Rudolf-Buchheim-Str. 8, 35392 Giessen, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-giessen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Sander\", \"role_name_personal_title\": \"Mr. Professor\", \"role_name_identifiers\": [], \"role_email\": \"michael.sander@chiru.med.uni-giessen.de\", \"role_phone\": \"0641-98544401\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologie und operative Intensivmedizin\", \"role_affiliation_address\": \"Rudolf-Buchheim-Stra\\u00dfe 7, 35392 Gie\\u00dfen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"17.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"positive PCR SARS-CoV-2; treatment on intensive care unit or home quarantine\", \"study_eligibility_exclusion_criteria\": \"age &lt; 18 years\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Concentration and activity of C1-Esterase-Inhibitor.\\n\\nBlood withdrawal is performed singular after informed consent with the morning routine.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Concentration of des-Arg9-Bradykin\\nConcentration of Angiotensin II\\nMurray Score for ARDS\\nAcute Kidney Injurie\\nDialysis\\nArrhythmia\\nTroponin\\nCRP\\nPCT\\nLymphocytes\\nGOT\\nGPT\\nLDH\\nD-Dimere\\nFibrinogen\\nThe above-mentioned parameters are registered at the timepoint of blood withdrawal.\\nThe following parameters are captured after hospital discharge.\\n\\n28 days lethality\\nduration of stay on intensive care \\nduration of stay at hospital\\nduration of ventilation\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"positive PCR SARS-CoV-2 and treatment on intensive care unit:\\nBlood withdrawal is performed singular after informed consent with the morning routine to measure the primary and secondary endpoints.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"positive PCR SARS-CoV-2 and home quarantine:\\nBlood withdrawal is performed singular after informed consent to measure the primary and secondary endpoints. Lethality after 28 days is determined by telephon interview.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021443","content":"{\"resource_id\": \"DRKS00021443\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Physical therapy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Videotherapy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"older people\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"tablet\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19,\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Physical therapy,\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Videotherapy,\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"tablet\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"older people,\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Feasibility and usability of video-based physical therapy for older people in the context of the COVID-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of this monocentric feasibility study is to evaluate how the technical support of physical therapists and their patients affects the frequency of use of video treatments for people aged 60 and over. In addition, we will ask how the new form of therapy is subjectively perceived by physical therapists and patients.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ConVideo\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021443\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"28.04.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://doi.org/10.1007/s00391-021-01899-3\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Carl von Ossietzky Universit\\u00e4t Oldenburg, Fakult\\u00e4t VI Medizin und Gesundheitswissenschaften\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Andreas\", \"role_name_personal_family_name\": \"Hein\", \"role_name_personal_title\": \"Mr. Prof. Dr.-Ing.\", \"role_name_identifiers\": [], \"role_email\": \"andreas.hein@uol.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4t Oldenburg, Department f\\u00fcr Versorgungsforschung, Abteilung f\\u00fcr Assistenzsysteme und Medizintechnik\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rebecca\", \"role_name_personal_family_name\": \"Diekmann\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"rebecca.diekmann@uol.de\", \"role_phone\": \"04417984359 \", \"role_affiliation_name\": \"Universit\\u00e4t Oldenburg, Department f\\u00fcr Versorgungsforschung\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstra\\u00dfe 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rebecca \", \"role_name_personal_family_name\": \"Diekmann\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"rebecca.diekmann@uol.de\", \"role_phone\": \"04417984334\", \"role_affiliation_name\": \"Universit\\u00e4t Oldenburg, Department f\\u00fcr Versorgungsforschung, Abteilung f\\u00fcr Assistenzsysteme und Medizintechnik\", \"role_affiliation_address\": \"Ammerl\\u00e4nder Heerstr. 140, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"older people (\\u2265 60 years) with an indication for physiotherapeutic treatment\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"23.04.2020\", \"study_end_date\": \"15.01.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 60, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Patient lives in Oldenburg, district of Oldenburg, district of Ammerland and practice is located in Oldenburg, district of Oldenburg, district of Ammerland \\n- valid prescription for a treatment with which videotherapy is possible according to the decision of the GKV-Spitzenverband, twice a week\\n- treating pysical therapist makes indication for video treatment\\n- Patient agrees to participate in video treatment\\n\\n\", \"study_eligibility_exclusion_criteria\": \"- Lack of ability to give consent\\n- Insufficient ability to understand the contents of the course of study and the German language\\n- Lack of mobility (bedriddenness)\\n- Participation in other studies\\n- Patients without telephone connection\", \"study_population\": \"\", \"study_target_sample_size\": 30, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Feasibility: The feasibility of videotherapy during the COVID-19 pandemic in elderly people measured by the number and type of treatments provided.\\n\\nsubjective perception: subjective evaluation of the feasibility of videotherapy and identification of barriers and supportive factors using a self-developed telephone questionnaire\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessment of activity, participation and health-related quality of life before, during and after the corona crisis and/or the associated restrictions.\\n1] Physical activity, measured with the Taylor questionnaire on calorie consumption in leisure activities\\n2] Health-related quality of life, measured with the SF-12\\n3] Participation, measured with the Lucas Index\\n4] Fear of falling, measured with the FES-I\\n5] Acceptance of technology, measured with items 1- 4 short scale for recording the motivation to use technology according to Neyer \\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"No request for disclosure of IPD data sharing was submitted to the responsible ethics committee.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Physical therapists and their patients over 60 years of age are enabled to perform video-based physiotherapy. Appropriate technology is provided and support is offered for its application. \\n\\nAfter the end of participation in the study, both patients and therapists are retrospectively interviewed by telephone about the frequency of use and the perceived barriers and opportunities in the implementation of video therapy for patients over 60 years of age.\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021516","content":"{\"resource_id\": \"DRKS00021516\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Anosmia\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Olfactory disorder\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Olfactory loss\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Loss of taste\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Dysosmia\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Taste disorder\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Dysgeusia\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Dysosmia and Dysgeusia in COVID-19 patients\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"SARS-CoV-2 is a novel coronavirus, which was first identified in China in 2019 and triggers the disease COVID-19. There is currently a COVID-19 pandemic affecting daily life and health of people worldwide.\\nThere are currently first signs of new symptoms in COVID-19 patients: the smell and taste disorder. However, there is still too little scientific data available. In our research project, we would like to analyze and objectify the symptoms of dysosmia and dysgeusia in detail as part of COVID-19 as a basis for further studies. On the one hand, a patient collective is interviewed using validated questionnaires, on the other hand, a second group is interviewed using a questionnaire and examined using a smell and taste test.\\nThe aim of the study is to evaluate the incidence and the extent of the olfactory and taste disorders as well as their correlation to known previous illnesses and medication.\\nAny COVID-19 positive patient who has not had any sinus surgery or radio / chemotherapy can participate.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021516\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"22.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Kantonsspital Aarau\", \"role_email\": \"\", \"role_phone\": \"+418385103\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Tellstrasse 25, 5001 Aarau, Switzerland\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Steffi Johanna\", \"role_name_personal_family_name\": \"Brockmeier\", \"role_name_personal_title\": \"Ms. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"hanna.brockmeier@ksa.ch\", \"role_phone\": \"+41628385103\", \"role_affiliation_name\": \"Kantonsspital Aarau\", \"role_affiliation_address\": \"Tellstrasse 25, 5001 Aarau, Switzerland\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thirza\", \"role_name_personal_family_name\": \"Singer-Cornelius\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"thirza.singer@ksa.ch\", \"role_phone\": \"+41628385784\", \"role_affiliation_name\": \"Kantonsspital Aarau\", \"role_affiliation_address\": \"Tellstrasse 25, 5001 Aarau, Switzerland\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"22.04.2020\", \"study_end_date\": \"01.12.2020\", \"study_country\": [], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"COVID-19 positiv tested\", \"study_eligibility_exclusion_criteria\": \"sinus surgery, radio-/chemotherapy\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The aim of the study is to include 100 patients with fully completed questionnaires, 50 patients with fully completed questionnaires and completely completed odor and taste tests in order to be able to make a valid statement about the incidence of smell and taste disorders\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"/\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"100 patients: questionnaires, 50 patients questionnaires and smell and taste test\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021523","content":"{\"resource_id\": \"DRKS00021523\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"ARDS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"proton pump inhibitor\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"bacterial superinfection\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"The influence of proton pump inhibitor therapy on the clinical course of COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Patients with confirmed SARS-CoV2 infection (COVID-19) will be included in this observational study. Most of the patients with COVID-19 show a mild course of disease with typical symptoms such as fever and coughing. However, some patients develop severe respiratory symptoms with development of acute respiratory distress syndrome (ARDS). To date, it is not well characterized which patient will develop ARDS. Many different predictive factors including the patients' medication are currently evaluated. Importantly, previous studies have shown that treatment with proton pump inhibitors (PPI) are associated with the development of infectious complications, especially with pneumonia. This may be due to an increase in the gastric ph resulting in an increasing bacterial load. Further, due to microaspiration there is an increased risk of conlonisation of the lung with consecutive development of pneumonia. Moreover, there are preliminary data pointing towards an aggravted pro-inflammatory status in patients treated with PPIs. These two mechanims may increase the risk of  ARDS development in PPI treated patients who are infected with SARS-CoV2.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVID.PPI\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021523\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg, Klinik f\\u00fcr Innere Medizin II\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Dominik\", \"role_name_personal_family_name\": \"Bettinger\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"dominik.bettinger@uniklinik-freiburg.de\", \"role_phone\": \"0761/270-34010\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg Department Innere Medizin Klinik f\\u00fcr Innere Medizin II\", \"role_affiliation_address\": \"Hugstetter Str. 55, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other viral pneumonia\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J12.8\"}, {\"study_conditions\": \"[generalization J80: Adult respiratory distress syndrome]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J80.0\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"28.04.2020\", \"study_end_date\": \"31.07.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Confirmed SARS-CoV2- infection, hospitalized patients\", \"study_eligibility_exclusion_criteria\": \"SARS-CoV2 infection excluded, outpatient treatment\", \"study_population\": \"\", \"study_target_sample_size\": 152, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"1. Prevalence of bacterial superinfection in patienst with and without proton pump inhibitor (PPI) treatment. \\n2. Development of ARDS in patients with and without PPI treatment.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1. Index mortality\\n2. Prevalence of intensive care treatment in patients with and without PPI treatment\\n3. Cours eof inflammatory markers in patients with and without PPI treatment and its impact on the development of disease associated complications\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"N/A\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients who are hospitalized due to confirmed SARS-CoV2 infection since January 2020 will be included in this data analysis. Baseline and laboratory data as well as complications during the course of disease (ARDS) will be assessed. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021574","content":"{\"resource_id\": \"DRKS00021574\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"co-morbidity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"d-dimer\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"coagulation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"coagulation factors\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"severity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hypercoagulability\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Investigation of the predictive value of coagulation parameters for the course of disease in COVID-19 patients\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The majority of COVID-19 infected patients show only weak symptoms, but for a group of patients we have to expect severe symptoms like ARDS, sepsis or death (Zhou et al., 2020). Especially older patients, men and patients with pre-existing medical conditions at risk of complications. Zhou et al. (2020) found at hospitalization start of critically ill COVID-19 patients increased D-dimers and coagulopathies. Increased d-dimers and a prolonged prothrombin time at inpatient admission combined with age and Sequential Organ Failure Assessment (SOFA)-score were significantly associated with mortality. Therefore it is  recommended to use low-molecular heparine as prophylactic anti-coagulation already at hospital admission to prevent thrombotic events and organ damages. Study aim is to identify patients early who benefit from a closer monitoring and coagulation management. Additionally to the prognostic value of thrombophilic parameters the role of preexisting conditions for the course of infection should be evaluated. The study will be conducted non-interventionelly in the university hospital Frankfurt for one year. Up to 1000 patients with COVID-19 diagnosis or suspect will be included at inpatient admission. Coagulation parameters will be determined at day 1 and day 7 of hospitalization. Additionally data about infection symptoms, course of disease, outcome, therapy and pre-existing conditions will be collected.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVID_coagulation\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021574\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"H\\u00e4mophiliezentrum, Institut f\\u00fcr Transfusionsmedizin, Medizinische Klinik III, Goethe Universit\\u00e4tsklinikum\", \"role_email\": \"wolfgang.miesbach@kgu.de\", \"role_phone\": \"06963015051\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany\", \"role_affiliation_web_page\": \"http://www.blutspende.de/medizinische-fachkreise/haemophiliezentrum-frankfurt/haemophiliezentrum-frankfurt.php\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Johann Wolfgang Goethe-Universit\\u00e4t Frankfurt am Main\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"https://www.kgu.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Wolfgang\", \"role_name_personal_family_name\": \"Miesbach\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"wolfgang.miesbach@kgu.de\", \"role_phone\": \"06963015051\", \"role_affiliation_name\": \"H\\u00e4mophiliezentrum, Institut f\\u00fcr Transfusionsmedizin, Medizinische Klinik III, Goethe Universit\\u00e4tsklinikum\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany\", \"role_affiliation_web_page\": \"http://www.blutspende.de/medizinische-fachkreise/haemophiliezentrum-frankfurt/haemophiliezentrum-frankfurt.php\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"08.04.2020\", \"study_end_date\": \"02.02.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"-at least 18 years old\\n- hospitalisation with suspected  or confirmed COVID-19 diagnosis\", \"study_eligibility_exclusion_criteria\": \"-younger than 18 years\", \"study_population\": \"\", \"study_target_sample_size\": 1000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Blood sampling (6 ml Plasma) at day 1 and 7 of hospitalization: determination of Quick, PTT, fibrinogen, D-dimer, antithrombin, hs-troponin, coagulation factors und VWF-antigen, Protein C und Protein S, thrombin generation, plasminogen-activator inhibitor-Type 1 \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"-clinical symptoms\\n-type and duration of antikoagulation\\n-Therapy (medication, heparin, oxygen, NIV/IV, ECLS)\\n-duration of hospitalization\\n-Outcome (morbidity, mortality)\\n-Co-morbidities and medication\\nAdditional data will be documented in CRF about:\\nsex, age, secondary infections (viral, bacterial), SOFA Score, small blood count, CRP \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The study protocol can be provided. Data will be collected in a CAPNETZ-subregistry. Data can be made available to researchers, who provide request with sound methodology. At the earliest data will be provided at end of project, but not before successful publication in a scientific journal. \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Determination of coagulation status in patients with COVID-19 at day 1 and 7 of hospitalization\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021582","content":"{\"resource_id\": \"DRKS00021582\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"list experiment\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"randomized control trial\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"knowledge\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hygiene\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"behavioral intent\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"A short, animated video to improve COVID-19 hygiene uptake: an online randomized experiment with 20,000 participants\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"A large amount of knowledge and information about novel coronavirus (COVID-19) hygiene has been disseminated by the traditional mass media since the outbreak of the pandemic. However, it is unclear if this dissemination has improved the uptake of COVID-19 hygiene, possibly because mass-media channels have missed key target populations (i.e., the youth) or have been perceived as politicized or culturally localized. In response to these limitations, we have designed a short, animated video without speech, text, or cultural signifiers (a CoVideo) that can be rapidly distributed through social media channels to a global audience. To evaluate the effect of the CoVideo on COVID-19 hygiene uptake, we will recuit 20,000 online participants (aged 18\\u201359 years) from the United States, United Kingdom, Germany, Mexico, and France.  Participants will be assigned to one of three trial arms:  1) the CoVideo and then COVID-19 questions, 2) a placebo attention control and then COVID-19 questions, or 3) COVID-19 questions and then the CoVideo. Results will be used to scientifically support the CoVideo\\u2019s ongoing dissemination as well as optimize the design of videos for future COVID-like outbreaks.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoVideo\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021582\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"12.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Heidelberg Institute of Global Health\", \"role_email\": \"till.baernighausen@uni-heidelberg.de\", \"role_phone\": \"06221560\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"130.3 Im Neuenheimer Feld, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Till\", \"role_name_personal_family_name\": \"Baernighausen\", \"role_name_personal_title\": \"Mr. Prof Dr\", \"role_name_identifiers\": [], \"role_email\": \"till.baernighausen@uni-heidelberg.de\", \"role_phone\": \"06221560\", \"role_affiliation_name\": \"Heidelberg Institute of Global Health, University of Heidelberg, Germany\", \"role_affiliation_address\": \"130.3 Im Neuenheimer Feld, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Alain\", \"role_name_personal_family_name\": \"Vandormael\", \"role_name_personal_title\": \"Mr. Dr\", \"role_name_identifiers\": [], \"role_email\": \"alain.vandormael@uni-heidelberg.de\", \"role_phone\": \"06221560\", \"role_affiliation_name\": \"Heidelberg Institute of Global Health, University of Heidelberg\", \"role_affiliation_address\": \"130.3 Im Neuenheimer Feld, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Alain\", \"role_name_personal_family_name\": \"Vandormael\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"alain.vandormael@uni-heidelberg.de\", \"role_phone\": \"06221560\", \"role_affiliation_name\": \"Heidelberg Institute of Global Health\", \"role_affiliation_address\": \"130.3 Im Neuenheimer Feld, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Behavioral intent toward COVID-19 hygiene uptake\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Knowledge of COVID-19 \", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"31.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"International\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 59, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Must be a registered account holder with the online recruitment platform Prolific.co. Must currently reside in the United States, United Kingdom, Germany, Spain, Mexico. \", \"study_eligibility_exclusion_criteria\": \"Do not meet the inclusion criteria.\", \"study_population\": \"\", \"study_target_sample_size\": 20000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary outcome Behavioral intent to uptake COVID-19 hygiene in the \\\"next week\\\". Behavioral intent will be measured using a list experiment in each of the three arms.\\n\\nWe will analyze the binary endpoints of the list experiments using modified Poisson regression.\\n\\nAnother primary outcome is knowledge of COVID-19 hygiene. We will measure knowledge using True/False items in the questionnaire. \\n\\nWe will analyze the binary endpoints of the knowledge items using modified Poisson regression. \\n\\nAs secondary analysis, we will repeat all of the analyses described above, controlling for baseline covariates (i.e., age, sex, and educational attainment). \\n\\nWe will also measure bias between the intervention items that appear in the list experiments and as standalone items. \\n\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\n\\n As secondary analysis, we will repeat all of the analyses described above, controlling for baseline covariates (i.e., age, sex, and educational attainment). \\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"An Applicant must complete and submit a letter of intent (LOI) to access the data. The LOI may be rejected and access to the data refused. If access to the data is granted, all data will be anonymized. \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Participants first receive a 2.30 minute video about the COVID-19 outbreak (CoVideo). The CoVideo is animated with sound effects, but has no words, speech, or text. It shows how the virus is spread (airborne, physical contact) and recommends best hygiene practices to prevent onward transmission (staying at home, not congregating in public spaces, and sanitizing hands/surfaces). It also covers the mass media coverage of the outbreak and the public\\u2019s response to this media coverage, which includes a subplot on the stockpiling of essential goods, and the impact thereof on health-care services (e.g., doctors being unable to access protective equipment). After the video, participants answer COVID-19 related questions. \\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The participants first receive the COVID-19 questions, and then receive the CoVideo.\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The participants first receive an attention placebo control (PAC) video, which is animated, has the same duration as the CoVideo, and deals with the impact of daily life choices and health outcomes. After the PAC, participants will receive the COVID-19 questions. \"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021585","content":"{\"resource_id\": \"DRKS00021585\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Lung Ultrasound in Covid-19 Pneumonia\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Prospective evaluation of the agreement between Lung-Ultrasound according to the Basic Lung Ultrasound in Emergency (BLUE)-protocol and computed tomography of the lungs in diagnosis of viral pneumonia.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"LUCID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021585\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"29.04.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Vivantes Humboldt Klinikum - Zentrale Notaufnahme\", \"role_email\": \"andreas.umgelter@vivantes.de\", \"role_phone\": \"030130121682\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Am Nordgraben 2, 13509 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Andreas\", \"role_name_personal_family_name\": \"Umgelter\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"andreas.umgelter@vivantes.de\", \"role_phone\": \"030130121682\", \"role_affiliation_name\": \"Vivantes Humboldt Klinikum - Zentrale Notaufnahme\", \"role_affiliation_address\": \"Am Nordgraben 2, 13509 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Andreas\", \"role_name_personal_family_name\": \"Umgelter\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"andreas.umgelter@vivantes.de\", \"role_phone\": \"030130121682\", \"role_affiliation_name\": \"Vivantes Humboldt Klinikum - Zentrale Notaufnahme\", \"role_affiliation_address\": \"Am Nordgraben 2, 13509 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other viral pneumonia\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J12.8\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"24.04.2020\", \"study_end_date\": \"21.04.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"acute respiratory symptoms (cough, sore throat) and one of three: dyspnea, age &gt; 60, relevant comorbidity (Diabetes, cardiovascular or chronic pulmonary) and Temperature &gt; 37.3\\u00b0C or lymphopenia &lt; 1.1 G/L\", \"study_eligibility_exclusion_criteria\": \"not able to consent, lack of informed consent, unstable Patient, age &lt; 18yrs\", \"study_population\": \"\", \"study_target_sample_size\": 220, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Cohen`s kappa regarding the binary outcome pulmonary opacities/infiltrations yes/no by both Methods.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"sensitivity and specificity of lung ultrasound for pulmonary infiltrates\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Lung Ultrasound\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"CT thorax\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021588","content":"{\"resource_id\": \"DRKS00021588\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Internet\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Sars-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Stress\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Naturalistic evaluation of an Internet-based psychological training program for mental strain associated with the coronavirus / COVID-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In a pragmatic study, data of max. N=1000 persons who partake in a free Internet-based intervention format as part of the initiative \\\"Stark durch die Krise\\\" (www.starkdurchdiekrise.de) are examined. The intervention is based on the Internet-based format \\\"GET.ON Fit im Stress\\\". The intervention concept examined in the study project was adapted in part to take current stressors caused by the COVID-19 pandemic into account. In accordance with scalable universal prevention concepts, the Intervention is implemented without direct personal feedback. However, it is possible to use a support address and a free, companion \\\"corona hotline\\\" to establish personal contact with trained psychologists. Due to the universal, low-threshold intervention approach, only \\\"treatment starters\\\", who have completed at least the first session of the training, will be considered for the primary effectiveness evaluation.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"HelloBetter Corona\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021588\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"04.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Lehrstuhl f\\u00fcr Klinische Psychologie, Institut f\\u00fcr Psychologie\", \"role_email\": \"matthias.berking@fau.de\", \"role_phone\": \"09131-85 67575\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"N\\u00e4gelsbachstra\\u00dfe 25a, 91052 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Matthias\", \"role_name_personal_family_name\": \"Berking\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"matthias.berking@fau.de\", \"role_phone\": \"09131 85 67575\", \"role_affiliation_name\": \"Universit\\u00e4t Erlangen-N\\u00fcrnberg, Institut f\\u00fcr Psychologie, Lehrstuhl f\\u00fcr Klinische Psychologie und Psychotherapie\", \"role_affiliation_address\": \"N\\u00e4gelsbachstra\\u00dfe 25a, 91052 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Mathias\", \"role_name_personal_family_name\": \"Harrer\", \"role_name_personal_title\": \"Mr. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"mathias.harrer@fau.de\", \"role_phone\": \"09131 85 67575\", \"role_affiliation_name\": \"Universit\\u00e4t Erlangen-N\\u00fcrnberg, Institut f\\u00fcr Psychologie, Lehrstuhl f\\u00fcr Klinische Psychologie und Psychotherapie\", \"role_affiliation_address\": \"N\\u00e4gelsbachstra\\u00dfe 25a, 91052 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Mathias\", \"role_name_personal_family_name\": \"Harrer\", \"role_name_personal_title\": \"Mr. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"mathias.harrer@fau.de\", \"role_phone\": \"09131 85 67575\", \"role_affiliation_name\": \"Lehrstuhl f\\u00fcr Klinische Psychologie und Psychotherapie, Friedrich-Alexander-Universit\\u00e4t Erlangen-N\\u00fcrnberg\", \"role_affiliation_address\": \"N\\u00e4gelsbachstr. 25a, 91052 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Mild depressive episode\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F32.0\"}, {\"study_conditions\": \"Adjustment disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F43.2\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"08.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Internet Access, E-Mail Address\", \"study_eligibility_exclusion_criteria\": \"Dissociative symptoms currently or in the past, suicidality, no informed consent\", \"study_population\": \"\", \"study_target_sample_size\": 1000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Depressive Symptoms, Patient Health Questionnaire 8-item version (PHQ-8; Kroenke, Spitzer, Williams, 2001), Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks (Post-assessment)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"- Anxiety, Generalized Anxiety Disorder 7 (GAD-7; Spitzer et al., 2006), Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks (Post-assessment)\\n- Perceived Stress, Perceived Stress Scale (PSS-4; Cohen, 1983), Baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks (Post-assessment)\\n- Mood Rating (Visual Analog Scale 0-10), daily, optional\\n- Stress Rating (Visual Analog Scale 0-10), daily, optional\\n- Demographic Assessments (Age, Sex)\\n- Intervention Satisfaction (Usefulness, Complexity, Recommendation), after each session, optional\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data on depressive symptoms, anxiety symptoms and perceived stress (baseline, 2-weekly interim assessments, post) examined in the effectiveness analysis can be passed on anonymously on request after completion of the primary data analysis.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Online training \\\"HelloBetter Corona\\\", consisting of 8 weekly sessions. Each session will be completed in approximately 45-60 minutes. Contents of the online training refer to problem- and emotion-focused coping for potentially solvable or unsolvable stressors. Concepts and contents are based on the intervention \\\"Get.On Fit im Stress\\\". Contents were adapted to the special conditions and stressors in the context of the \\\"Corona crisis\\\".\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021591","content":"{\"resource_id\": \"DRKS00021591\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Identification of predictive biomarkers for severe progression of COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In this study, we aim to identify biomarkers in a cohort of hospitalized immunocompetent patients which can predict the severity of a SARS-CoV-2 infection.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"PreBiSe-COV\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021591\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.04.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"VotumEthik-Komission,\\u00c4rztekammerBerlin_COVID-19_Serumstudie_gescannt_200416.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Sanit\\u00e4tsakademie der Bundeswehr, Direktor Wehrmedizinische Wissenschaft und F\\u00e4higkeitsentwicklung Sanit\\u00e4tsdienst\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ingolst\\u00e4dter Stra\\u00dfe 240, 80939 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Maximilian\", \"role_name_personal_family_name\": \"Schreiner\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"MaximilianSchreiner@bundeswehr.org\", \"role_phone\": \"+493028412850\", \"role_affiliation_name\": \"Bundeswehrkrankenhaus Berlin, Klinik I (Innere Medizin)\", \"role_affiliation_address\": \"Scharnhorststra\\u00dfe 13, 10115 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Maximilian\", \"role_name_personal_family_name\": \"Schreiner\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"MaximilianSchreiner@bundeswehr.org\", \"role_phone\": \"+493028412850\", \"role_affiliation_name\": \"Bundeswehrkrankenhaus Berlin, Klinik I (Innere Medizin)\", \"role_affiliation_address\": \"Scharnhorstra\\u00dfe 13, 10115 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christian\", \"role_name_personal_family_name\": \"Zobel\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"ChristianZobel@bundeswehr.org\", \"role_phone\": \"+493028412806\", \"role_affiliation_name\": \"Bundeswehrkrankenhaus Berlin, Klinik I (Innere Medizin)\", \"role_affiliation_address\": \"Scharnhorststra\\u00dfe 13, 10115 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"29.04.2020\", \"study_end_date\": \"28.01.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 4, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Hospitalized patient due to clinical suspicion of COVID-19\", \"study_eligibility_exclusion_criteria\": \"Patients under 18 years of age, immunosuppression, 2 x negative SARS-CoV-2 PCR during clinical course AND no typical signs of COVID-19 on chest CT\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Invasive or non-invasive ventilation within 30 days of onset of COVID-19 related symptoms\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Death of all causes within 1 year after onset of COVID-19 related symptoms\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Serum is taken from hospitalized patients with COVID-19 at the following time points: within 24 hours of hospital admission, as well as on days 7, 10, 14, and 21 after onset of symptoms of COVID-19. In these samples, the following cytokines/chemokines are measured by ELISA: IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, TGF-beta1, TNF-alpha, Interferon-alpha, Interferon-beta, Interferon-gamma, TIMP-1, MMP-9, bFGF, CTGF, CXCL2, CCL2, CCL5, CXCL5. Additionally, SARS-CoV-2 antibodies are measured.\\nFurthermore, the following vital signs are recorded on these time points: O2-saturation, blood pressure, heart rate, respiratory rate, and (on ventilated patients) parameters of mechanical ventilation.\\nBronchial fluids will be collected for measurement of these cytokines/chemokines from patients who need to undergo bronchoscopy for medical reasons.\\nPatients who are discharged from hospital before reaching some of these time points will not be measured as outpatients: the respective time points will be omitted (the same applies for patients who present to hospital later than day 7 within onset of symptoms).\\nAfter 30 days from onset of symptoms, the need for invasive or non-invasive ventilation will be recorded.\\nAfter 1 year from onset of symptoms, the patient's family will be contacted and possible death will be recorded. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021604","content":"{\"resource_id\": \"DRKS00021604\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The goal of the study is to investigate the incidence of pulmonary embolism and/or deep vein thrombosis in patients with COVID-19 infection. 100 in-patients with SARS-CoV2 positive naso-pharyngeal swab or clinical high suspicion of COVID-19 and an age-adjusted elevation of the D-Dimer concentration will be included in the study. Diagnostic will be done using computed tomography of the pulmonary arteries as well as compression, doppler ultrasound of the deep pelvic and femoral veins and echocardiography. Furthermore, patients undergoing physical examination, laboratory work-up as well as blood-gas analysis and EKG. The individual Wells score will be calculated and the predictive value of the Wells score in COVID-19 patients will be compared to the predictive value in (historic) patients without COVID-19.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Thrombembolic compications in COVID-19 patients\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021604\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"01.07.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Zollernalb Klinikum Balingen\", \"role_email\": \"erwin.biecker@zollernalb-klinikum.de\", \"role_phone\": \"0743390922600\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"T\\u00fcbingerstr. 30, 72336 Balingen, Germany\", \"role_affiliation_web_page\": \"https://www.zollernalb-klinikum.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Erwin\", \"role_name_personal_family_name\": \"Biecker\", \"role_name_personal_title\": \"Mr. PD Dr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"erwin.biecker@zollernalb-klinikum.de\", \"role_phone\": \"0743390922600\", \"role_affiliation_name\": \"Zollernalb Klinikum Balingen\", \"role_affiliation_address\": \"T\\u00fcbingerstr. 30, 72336 Balingen, Germany\", \"role_affiliation_web_page\": \"https://www.zollernalb-klinikum.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Erwin\", \"role_name_personal_family_name\": \"Biecker\", \"role_name_personal_title\": \"Mr. PD Dr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"erwin.biecker@zollernalb-klinikum.de\", \"role_phone\": \"0743390922600\", \"role_affiliation_name\": \"Zollernalb Klinikum Balingen\", \"role_affiliation_address\": \"T\\u00fcbingerstr. 30, 72336 Balingen, Germany\", \"role_affiliation_web_page\": \"https://www.zollernalb-klinikum.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Deep vein Thrombosis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"Pulmonary embolism without mention of acute cor pulmonale\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"I26.9\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"18.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u2022written informed consent\\n\\u2022naso-pharyngeal swap SARS-CoV-2 PCR positiv or clinical high suspicion of COVID-19 infection \\n\\u2022Elevated D-Dimer concentration of &gt; 10\\u00b5g/l*age (starting at 50 years, in younger patients the cut-off is 500 \\u00b5g/l) and dyspnoea and/or a O2-saturation &lt;92%\\n\\u2022indication for in-patient treatment\", \"study_eligibility_exclusion_criteria\": \"\\u2022\\tAge &lt; 18 years\\n\\u2022\\tAllergy to contrast agent\\n\\u2022\\tRenal insufficiency with a GFR &lt; 40 (ml/min/1,73 m2)\\n\\u2022\\tPregnancy\\n\\u2022\\tPulmonary embolism and/or deep vein thrombosis in the last six months \\n\\u2022\\tHyperthyreosis\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022\\t60 days in-hospital mortality due to thromboembolism\\n\\u2022\\t60 days all-cause mortality\\n\\u2022\\tNeed for treatment in the ICU\\n\\u2022\\tNeed for ventilation therapy\\n\\u2022\\tDuration of hospitalisation\\n\\u2022\\tPositiv predictive value of Wells Score in COVID-19 patients \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients with COVID-19 infection undergo diagnosis for pulmonary embolism and/or deep vein thrombosis.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021605","content":"{\"resource_id\": \"DRKS00021605\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"CT\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"https://www.studienzentrum-bodensee.de\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19 in an academic teaching hospital in Konstanz/Germany - evaluation of the \\\"double rule out - single rule in\\\" concept (DURO-SIN)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The new corona-virus disease (COVID-19) may induce a rapid progressive pulmonary disease with potential intensive care treatment and mechanical ventilation. This study aims at early detecting potentially severe courses of COVID-19 by a combination of naso-pharyngeal swabs detecting SARS-CoV-2 RNA and - according to disease severity - radiological examinations (i.e. computed tomography, CT) according to (inter-)national recommendations. Patients with severe hypoxic respiratory failure may be diagnosed with thoracic CT earlier.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"DURO-SIN\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021605\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"28.04.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1251-0310\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinikum Konstanz II. Medizin\", \"role_email\": \"stephan.walterspacher@glkn.de\", \"role_phone\": \"075318011451\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Mainaustr. 35, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"https://www.lungenzentrum-bodensee.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Stephan\", \"role_name_personal_family_name\": \"Walterspacher\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"stephan.walterspacher@glkn.de\", \"role_phone\": \"075318011451\", \"role_affiliation_name\": \"Klinikum Konstanz II. Medizin\", \"role_affiliation_address\": \"Mainaustr. 35, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"https://www.lungenzentrum-bodensee.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stephan\", \"role_name_personal_family_name\": \"Walterspacher\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"stephan.walterspacher@glkn.de\", \"role_phone\": \"075318011451\", \"role_affiliation_name\": \"Klinikum Konstanz II. Medizin\", \"role_affiliation_address\": \"Mainaustr. 35, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"https://www.lungenzentrum-bodensee.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"27.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Suspected COVID-19\", \"study_eligibility_exclusion_criteria\": \"Missing clinical or radiological features of COVID-19\\nPregnancy\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Descriptive evaluation of the DURO-SIN concept regarding SARS-CoV-2 detection in naso-pharyngeal swabs and positive radiological features\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Clinical course of positively screened patients (RNA, CT) regarding disease severity (evaluated with regard to respiratory support), treatment duration and treatment course.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Radiological features of COVID-19 in the thoracic CT following a negative PCR test result regarding SARS-CoV-2 in clinically highly suspected cases\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021611","content":"{\"resource_id\": \"DRKS00021611\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"hyperchloremia\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"sars-cov-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hypernatremia\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Hypernatremia in critically ill patients with Covid-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Covid-19, the disease caused by SARS-CoV-2, is a systemic disease, which can lead to acute respiratory distress syndrome, acute kidney failure and an impairment of the gastrointestinal system. When treating critically ill patients with covid-19 infections on our ICU we detected severe hypernatremias in multiple patients. The extent of the elevation seems to correlate with the severity of the disease. This study retrospectively captures the courses of disease of 12 critically ill patients with covid-19 treated on the ICU and compares their course of disease to covid-19 patients treated on a general ward as well as a group of patients that suffered from ARDS due to other causes. The study focuses on the course of sodium levels in serum, the amounts of fluids administered, as well as the potential correlation between sodium levels and severity of disease. The collection of data will include measurements that have been taken during the course of treatment, such as lab parameters, administered medication and fluids, fluid balances as well as urine analysis. The aim of the study is to be able to classify the observed hypernatremia in the setting of a covid-19 infection and to obtain indications to the potential pathogenesis. Should a correlation of sodium levels and course of disease prove to be accurate, sodium levels could be used as one easy and cheap to obtain parameter to help interpret the course of disease in individual patients.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021611\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"12.05.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"273-20_Votum.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Studienprotokoll.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Ortenauklinikum, Betriebsstelle Lahr\", \"role_email\": \"\", \"role_phone\": \"07821930\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Klostenstr.19, 77933 Lahr, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Ortenauklinikum, Betriebsstelle Lahr\", \"role_email\": \"\", \"role_phone\": \"07821930\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Klostenstr.19, 77933 Lahr, Germany\", \"role_affiliation_web_page\": \"https://www.ortenau-klinikum.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Milena\", \"role_name_personal_family_name\": \"Zimmer\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"milena.zimmer@ortenau-klinikum.de\", \"role_phone\": \"07821931113\", \"role_affiliation_name\": \"Ortenauklinikum, Betriebsstelle Lahr\", \"role_affiliation_address\": \"Klostenstr. 19, 77933 Lahr, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other disorders of fluid, electrolyte and acid-base balance\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E87\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"15.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"group 1: patients with positive PCR for SARS-CoV-19 and treatment on ICU, respiratory symptoms with acute onset; bilateral diffuse infiltrates in imaging; interstitial edema, not explained by cardiac causes; paO2/FiO2 &lt; 300 mmHg\\ngroup 2: patients with positive PCR for SARS-CoV-19 and treatment on general ward, no ventilation\\n\", \"study_eligibility_exclusion_criteria\": \"group 1&amp;2: PCR for SARS-Cov-2 repeatedly negative\\nall groups: preexisting end stage renal failure with dialysis\", \"study_population\": \"\", \"study_target_sample_size\": 33, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"absolute numbers and dynamic of sodium levels\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"classification of hypernatremia\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"patients with covid-19 treated on the icu. no new exams are being conducted. This study only looks retrospectively at the data collected while treating the patients. These include lab results of sodium, chloride, potassium, creatinin concentrations. Urine diagnostics: sodium, potassium, creatinin, urea, glucose.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"patients with covid-19 treated on the normal ward. no new exams are being conducted. This study only looks retrospectively at the data collected while treating the patients. These include lab results of sodium, chloride, potassium, creatinin concentrations. Urine diagnostics: sodium, potassium, creatinin, urea, glucose.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021653","content":"{\"resource_id\": \"DRKS00021653\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Crohn's disease\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Sars-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ulcerative Colitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"https://www.gisg.eu\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Retrospective examination of the course of a Covid-19 infection\\nin patients with inflammatory bowel disease\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The COVID-19 pandemic is an outbreak of the novel respiratory disease COVID-19 (for Corona virus disease 2019). It first became apparent at the end of December 2019 in the city of Wuhan in the Chinese province of Hubei, developed into an epidemic in January 2020 in the People's Republic of China and spread worldwide. (Source: Wikipedia)\\n\\nPatients with IBD are currently often concerned that their illness and / or the immunosuppressive medication required as a result have a negative effect on the course of a Covid-19 infection. Medical advice is difficult because as of March 15, 2020 there is no literature on this question (www.ncbi.nlm.nih.gov/pubmed).\\n\\nIt is therefore necessary to examine this question for the first time in an exploratory study. The data is recorded in a compressed form - taking into account the currently high workload.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021653\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"05.06.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Gesellschaft f\\u00fcr Klinische Studien\", \"role_email\": \"teich@igvs.de\", \"role_phone\": \"++49-341-6003650\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Nordstra\\u00dfe 21, 04105 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.igvs.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Niels\", \"role_name_personal_family_name\": \"Teich\", \"role_name_personal_title\": \"Mr. Prof.Dr.med.\", \"role_name_identifiers\": [], \"role_email\": \"teich@igvs.de\", \"role_phone\": \"++49-341-6003650\", \"role_affiliation_name\": \"Gesellschaft f\\u00fcr Klinische Studien\", \"role_affiliation_address\": \"Nordstra\\u00dfe 21, 04105 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.igvs.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Niels\", \"role_name_personal_family_name\": \"Teich\", \"role_name_personal_title\": \"Mr. Prof.Dr.med.\", \"role_name_identifiers\": [], \"role_email\": \"teich@igvs.de\", \"role_phone\": \"++49-341-6003650\", \"role_affiliation_name\": \"Gesellschaft f\\u00fcr Klinische Studien\", \"role_affiliation_address\": \"Nordstra\\u00dfe 21, 04105 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.igvs.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"21.04.2020\", \"study_end_date\": \"31.01.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 130, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"inflammatory bowel disease, Covid-19 disease\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Retrospective observation of the course of a Covid-19 infection in patients with inflammatory bowel diseases\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Doctors who treat patients with inflammatory bowel diseases document their Covid-19 course retrospectively on a questionnaire. There is no control group.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021658","content":"{\"resource_id\": \"DRKS00021658\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"risk factors\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"acute kidney injury\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Incidence and risk factors for acute kidney injury in COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"We plan a retrospective evaluation of patients with COVID-19 at the University Hospital Freiburg with regard to the development of acute kidney failure. In particular, risk factors for acute kidney failure shall be identified. For this reason, previous illnesses, clinical parameters such as blood pressure, fever, oxygen demand, predisposing symptoms such as diarrhea and the current medication shall be analyzed. In order to enable an assessment of the severity of the disease, laboratory values such as the C-reactive protein, interleukin-6 and procalcitonin should be evaluated. In order to determine the reason for kidney failure in the context of multi-organ failure, the transaminases should also be evaluated, and to detect rhabdomyolysis, the creatine kinase should be evaluated. Furthermore, characteristics of kidney failure should be examined. These include baseline and maximum creatinine as well as urine characteristics such as hematuria, proteinuria and leukocyturia, fractional uric acid and urea excretion as well as the quantification of proteinuria in the protein-creatinine quotient and urine sediment diagnostics. In addition, outcome parameters such as mortality, intensive care and intubation as well as the need for dialysis should be examined.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021658\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"05.05.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"276-20_Votum.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Studienprotokoll.docx\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Johanna\", \"role_name_personal_family_name\": \"Schneider\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"johanna.schneider@uniklinik-freiburg.de\", \"role_phone\": \"0761-270 32842\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg - Medizin IV\", \"role_affiliation_address\": \"Hugstetterstra\\u00dfe 55, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Johanna\", \"role_name_personal_family_name\": \"Schneider\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"johanna.schneider@uniklinik-freiburg.de\", \"role_phone\": \"0761-270 32842\", \"role_affiliation_name\": \"Uniklinik Freiburg - Medizin IV\", \"role_affiliation_address\": \"Hugstetterstra\\u00dfe 55, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"Acute renal failure, unspecified\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"N17.9\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"01.03.2020\", \"study_end_date\": \"30.04.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"COVID-19, hospitalized at the Universitiy Hospital of Freiburg from March 1st 2020 - April 30th 2020\", \"study_eligibility_exclusion_criteria\": \"asymptomatic for COVID-19\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Acute kidney injury\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"i. Assessment of the outcome after acute kidney failure (recovery of kidney function, renal replacement therapy, transfer to the intensive care unit, intubation, ECMO, mortality)\\nii. Influence of accompanying factors on the development of kidney failure such as the severity of illness, preexisting disorders, current medication, further organ failure\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Hospitalized COVID-19 patients with acute kidney injury; \\nnon-interventional study\\n--&gt; retrospective evaluation regarding risk factors like severity of illness, preexisting disorders, current medication, further organ failure and outcome parameters like recovery of kidney function, renal replacement therapy, transfer to the intensive care unit, intubation, ECMO, mortality\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Hospitalized COVID-19 patients WITHOUT kidney injury\\nnon-interventional study\\n--&gt; retrospective evaluation in comparisn to group #1 regarding risk factors like severity of illness, preexisting disorders, current medication, further organ failure and outcome parameters like recovery of kidney function, renal replacement therapy, transfer to the intensive care unit, intubation, ECMO, mortality\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021671","content":"{\"resource_id\": \"DRKS00021671\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Social Support\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Oxytocin\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Lonelines\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Cortisol\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Neuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Research by our own and international working groups shows that social contact, close social relationships, physical touches, but also felt closeness, can buffer stress on a psychological and physical level. The health-protective effect of social inclusion was described in overview papers and meta-analyses as even exceeding health-protective behavior (sports, weight reduction, alcohol reduction). The positive effects of social relationships are currently reduced by the necessary requirements of contact restriction and social distancing for the Covid-19 prevention. At the same time, threat directly by the disease, as well as social and economic consequences, has increased significantly.\\nAt the psychobiological level, the effect of social support is mediated through the physical stress systems, including the neuropeptide oxytocin, the steroid hormone cortisol (as an effector hormone of the stress-sensitive hypothalamus-pituitary cortex axis, HHNA) and catecholamines of the sympathetic nervous system (an indirect indicator ia the saliva enzyme alpha amylase). These substances can be measured non-invasively in everyday life via repeated saliva samples, at the same time the study participants report their current stressors and social contacts (= psychobiological ecological momentary assessment, EMA) via an application on their smartphones online in real time. During the current crisis, we would like to assess the effects of a) the subjective threat of the virus on individuals, couples and families and b) the simultaneous restrictions on social contact by collecting saliva samples in participants' daily lives.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SoDi Study\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021671\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"06.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut f\\u00fcr Medizinische Psychologie am Uniklinikum Heidelberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \", 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Institut f\\u00fcr Medizinische Psychologie des Universit\\u00e4tsklinikums Heidelberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Bergheimer Stra\\u00dfe 20, 79115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Monika\", \"role_name_personal_family_name\": \"Eckstein\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"monika.eckstein at med.uni-heidelberg.de\", \"role_phone\": \"06221567871\", \"role_affiliation_name\": \"Institut f\\u00fcr Medizinische Psychologie des Universit\\u00e4tsklinikums Heidelberg\", \"role_affiliation_address\": \"Bergheimer Stra\\u00dfe 20, 79115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Ekaterina\", \"role_name_personal_family_name\": \"Schneider\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"sodi.studi@med.uni-heidelberg.de\", \"role_phone\": \"06221567871\", \"role_affiliation_name\": \"Institut f\\u00fcr Medizinische Psychologie des Universit\\u00e4tsklinikums Heidelberg\", \"role_affiliation_address\": \"Bergheimer Str. 20, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Persons in quarantine or social isolation\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"03.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"min. 18 years old,\\ninformed consent\", \"study_eligibility_exclusion_criteria\": \"underage\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Subjective well-being, psychological and physical symptoms (SCL-K9, CTQ, UCLA Loneliness) perceived stress (PSS-10), anxiety and depressiveness (HADS), social relationships (PFB, SCORE-15, F-SozU, SNI), trust.\\nOnce during the current pandemic and one after the pandemic.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Psychobiological characteristics of social Isolation. Cortisol and oxytocin levels over 2 days during the pandemic and over 2 days after the end of the pandemic.\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"After final completion of the study and after the publication of all planned results, the data will be available anonymously via HeiData (platform of Heidelberg University).\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Cross-section of the population during the Covid-19 pandemic with heterogenous levels of isolation.\\n\\nThe subjects are participate over two days in their everyday life using EMA about their current stress levels and their social contacts, in parallel saliva samples for cortisol and oxytocin analyses are collected. Another 2-day measurement will be carried out after the end of the pandemic.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021706","content":"{\"resource_id\": \"DRKS00021706\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Evaluation of online support during the coronavirus (COVID-19) pandemic: Online cognitive behavioral therapy for obsessive-compulsive disorder (OCD NET program)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This study is conducted in the psychiatric outpatient clinic of the Leipzig University Hospital. Patients with obsessive-compulsive disorder will be offered to participate in a therapist-guided online intervention based on cognitive behavioral therapy (OCD NET program). When using the program, patients will be supported by a therapist and will receive written feedback. The program consists of 10 modules. The main focus of the program is on conducting exercises on exposure and ritual prevention. Further, the program includes psychoeducation, techniques for cognitive restructuring, and relapse prevention strategies. OCD NET was originally developed at the Karolinska Institute in Stockholm, Sweden, and its efficacy has been shown in several clinical trials. The aim of this study is to examine the feasibility and acceptance of the OCD NET program and evaluate its effect on the patients\\u2019 symptoms of obsessive-compulsive disorder and their quality of life. Online questionnaires will be completed at the beginning of the intervention, after completing each module, and at the end of the intervention (after completing the program).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021706\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Leipzig\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 18, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-leipzig.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Christine\", \"role_name_personal_family_name\": \"Rummel-Kluge\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"pia_ocd@medizin.uni-leipzig.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Leipzig, Klinik und Poliklinik f\\u00fcr Psychiatrie und Psychotherapie\", \"role_affiliation_address\": \"Semmelweisstra\\u00dfe 10, Haus 13, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christine\", \"role_name_personal_family_name\": \"Rummel-Kluge\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"pia_ocd@medizin.uni-leipzig.de\", \"role_phone\": \"03419724681\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Leipzig, Klinik und Poliklinik f\\u00fcr Psychiatrie und Psychotherapie\", \"role_affiliation_address\": \"Semmelweisstra\\u00dfe 10, Haus 13, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Obsessive-compulsive disorder\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F42\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"Yes\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Enrolling by invitation\", \"study_start_date\": \"09.06.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Male and female patients (age 18 or over) meeting diagnostic criteria for obsessive-compulsive disorder; Sufficient knowledge of the German language; Adequate eyesight and ability to read; Internet connection\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Feasibility and acceptance of the program, assessed via log-in data of the participants and questionnaires: Questionnaire on Patient Satisfaction, adapted (ZUF-8) and Credibility/Expectancy Questionnaire (CEQ) at end of intervention\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy of the program on the patients\\u2019 symptoms of obsessive-compulsive disorder and quality of life, assessed at end of intervention via Obsessive-Compulsive Inventory-Revised (OCI-R) and WHO Quality of Life-BREF (WHOQOL-BREF)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be available upon request after the end of the study.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Study participants (patients with obsessive-compulsive disorder, age 18 or over, N = 40) will be offered to participate in the therapist-guided online program OCD NET over the course of 10 weeks. The aim of this study is to examine the feasibility and acceptance of the OCD NET program and evaluate its effect on the patients\\u2019 symptoms of obsessive-compulsive disorder and their quality of life. Online questionnaires will be completed at the beginning of the intervention, after completing each module, and at the end of the intervention (after completing the program).\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00021727","content":"{\"resource_id\": \"DRKS00021727\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Covid 19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"long term course\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Incidence and long-term course of subclinical and clinical myocardial damage as well as pulmonary vascular and structural changes in patients with COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Recording of the incidence, predictors and long-term course of newly occurring subclinical and clinical myocardial damage as well as pulmonary vascular and structural changes in patients with proven COVID-19 using multiple parameters including echocardiography and MRI.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021727\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"12.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsherzzentrum Freiburg Bad Krozingen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"S\\u00fcdring 15, 79189 Bad Krozingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Nikolaus\", \"role_name_personal_family_name\": \"L\\u00f6ffelhardt\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"nikolaus.loeffelhardt@universitaets-herzzentrum.de\", \"role_phone\": \"07633 4020\", \"role_affiliation_name\": \"Universit\\u00e4tsherzzentrum Freiburg Bad Krozingen\", \"role_affiliation_address\": \"S\\u00fcdring 15, 79189 Bad Krozingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Nikolaus\", \"role_name_personal_family_name\": \"L\\u00f6ffelhardt\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"nikolaus.loeffelhardt@universitaets-herzzentrum.de\", \"role_phone\": \"07633 4020\", \"role_affiliation_name\": \"Universit\\u00e4tsherzzentrum Freiburg Bad Krozingen\", \"role_affiliation_address\": \"S\\u00fcdring 15, 79189 Bad Krozingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"12.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- PCR-secured SARS-CoV-2 infection\\n- Clinically manifest signs of SARS-CoV-2 infection\\n- Ability / willingness to come to the 6-month follow-up\\n\", \"study_eligibility_exclusion_criteria\": \"- Missing written informed consent\\n- Contraindication for MRI examination according to the current guidelines (e.g. metal implants, severe allergy to MRI contrast media)\\n- severe renal failure (creatinine clearance &lt;30ml / min / 1.73m2)\\n- People who are in a dependency or employment relationship with the clinic or examiner stand\\n- Placement in an institution based on a judicial or official order \\n- Demential development or other illness (e.g. substance abuse) that a Understanding of the clarification in the study and / or a legally effective clarification makes unlikely.\\n- pregnancy\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Left and right ventricular ejection fraction (echo and MRI) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022 Markers for myocardial damage that are not detected by a decrease in the ejection fraction (including blood: highly sensitive troponin T, NT-proBNP / ECG: QRS fragmentation / echo: myocardial strain, pulmonary arterial pressure / MRI: late enhancement ) at the time of inpatient treatment for Sars-CoV2 infection and after 6 months\\n\\u2022 Cardiovascular event rate within 12 months (death, myocardial infarction, hospitalization for heart failure)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients with PCR-secured Sars-Cov2 infection and inpatient treatment are included.\\nDuring the initial inpatient stay, data of examinations indicated in clinical routine is collected, which can provide information on myocardial damage and pulmonary vascular and structural changes.\\nThese examinations are repeated as part of an outpatient examination after 6 months. At 12 months there is a telephone contact to record clinical events.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021740","content":"{\"resource_id\": \"DRKS00021740\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"CoViD-19 imaging register study Aachen\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Development of diagnostic criteria of CoViD-19 disease at different stages of infection or disease for early detection of the disease or detection of complications.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoBRA\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021740\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Diagnostische und Interventionelle Radiologie, Uniklinik RWTH Aachen\", \"role_email\": \"ckuhl@ukaachen.de\", \"role_phone\": \"+49 241 80 88522\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Pauwelsstra\\u00dfe 30, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Christiane\", \"role_name_personal_family_name\": \"Kuhl\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"ckuhl@ukaachen.de\", \"role_phone\": \"+49 241 80 88522\", \"role_affiliation_name\": \"Klinik f\\u00fcr Diagnostische und Interventionelle Radiologie, Uniklinik RWTH Aachen\", \"role_affiliation_address\": \"Pauwelsstra\\u00dfe 30, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christiane\", \"role_name_personal_family_name\": \"Kuhl\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"ckuhl@ukaachen.de\", \"role_phone\": \"+49 241 80 88522\", \"role_affiliation_name\": \"Klinik f\\u00fcr Diagnostische und Interventionelle Radiologie, Uniklinik RWTH Aachen\", \"role_affiliation_address\": \"Pauwelsstra\\u00dfe 30, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"05.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Completed study data \\n- defined SARS-CoV-2 status or CoViD-19 disease confirmed by RT-PCR\", \"study_eligibility_exclusion_criteria\": \"No exclusion criteria\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Analysis of the presentation form of the SARS-CoV-2 infection and the different stages and manifestations or organ manifestations of the COVID-19 disease in imaging procedures (X-ray diagnostics, CT, ultrasound, MRT).\\nAs this is a register, this endpoint will be examined regularly and at regular intervals.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"- Analysis of the predictive values of individual findings and their constellations in different stages of the disease\\n- Determination of the diagnostic accuracy with which the diagnosis of an existing SARS-CoV-2 infection or CoViD-19 disease and its thoracic, abdominal and cerebral complications can be established using imaging techniques\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"In order to analyze the manifestation of SARS-CoV-2 infection or CoViD-19 disease in the different imaging modalities and to determine the accuracy with which we can detect CoViD-19 induced or associated changes of the internal organs (lung, myocardium, kidney, intestine) using imaging, we want to record the imaging findings for different stages of disease and evaluate them with regard to their diagnostic and differential diagnostic performance. \\n\\nThe results will be systematically analysed, grouped according to clinical situation and severity/stage of disease, and finally criteria will be developed to differentiate between other diseases with a similar clinical picture or diseases with a similar constellation of radiological findings. \\n\\nFor this purpose, we will draw on already available data of completed treatment cases, which were collected from persons or patients with defined SARS-CoV-2 status or CoViD-19 disease confirmed by RT-PCR. The image data or correlative clinical data (see below) will be integrated into a CoViD-19 image database in anonymised form.\\n\\nIn order to make rapid progress here, we will network with the radiological institutions of the Aachen/D\\u00fcren/Heinsberg region and create a joint database containing not only image data but also clinical data for a rough categorization of the disease and the patients' outcome as follows\\n\\nAs a result we will present diagnostic imaging criteria including the respective predictive values, i.e. data on the diagnostic accuracy with which different stages of SARS-CoV-2 infection or CoViD-19 disease can be diagnosed in imaging.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021756","content":"{\"resource_id\": \"DRKS00021756\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.drks.de/DRKS00021756\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Psychological coping with the COVID-19-pandemic\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021756\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf,Institut f\\u00fcr diagnostische und interventionelle Radiologie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_identifiers\": [], \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Jonas\", \"role_name_personal_family_name\": \"Jansen\", \"role_name_personal_title\": \"Other\", \"role_email\": \"jonas.jansen@med.uni-duesseldorf.de\", \"role_phone\": \"02131888-1679\", \"role_affiliation_name\": \"Rheinlandklinikum Neuss GmbH, Lukas Krankenhaus Neuss, Medizinische Klinik II\", \"role_affiliation_address\": \"Preuenstr. 84\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"F43 - Reaction to severe stress, and adjustment disorders\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: German citizen\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: Non German citizen\", \"study_population\": \"\", \"study_target_sample_size\": 9000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": 18.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Our goal is to conduct novel research into how people cope psychologically with the current coronavirus crisis (e.g., confinement, feelings of stress and depression). \\n\\nWith this knowledge we will be able to identify the characteristics of the most resilient and also the most vulnerable people with the long-term objective of generating interventions that can help in times of crisis like this.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Prevention;\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00021763","content":"{\"resource_id\": \"DRKS00021763\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"employee health\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"clinic staff\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"health behavior\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"quarantine\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Influence of the Corona regulation on the physical activity of hospital staff - COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"According to a survey from 2015, almost 43% of women and 48% of men in Germany reach the recommended 150 min. activity per week. If strength training is added, the number reduced to approx. 20% of those surveyed. The term \\\"physical activity\\\" defines any form of physical movement that is produced by the skeletal muscles and increases energy consumption above the basal metabolic rate. Physical activity combines both organized sports activities in clubs and activities of daily living (e.g. cycling, walking). Studies show a positive influence of physical activity to avoid cardiovascular diseases, metabolic diseases and diseases of the musculoskeletal system. People who are physically active are less likely to be overweight, have a lower risk of high blood pressure or diabetes and show a better lipid profile. Physical activity offers are also an important tool for health promotion in the workplace. These can be divided into offers at the workplace, during lunch breaks and in employees' free time. The impact of restrictions on leisure activities (e.g. quarantine, curfews) in the context of a pandemic on both physical and psychological resilience is unclear. It is conceivable that there will be a sharp decrease in physical activity due to the direct restriction of people's freedom of movement as well as indirect influence due to the loss of the offer (e.g. closure of gyms, swimming pools etc.). Even inactivity for a few weeks, with sustained reduced fitness, can cause a significant loss of physical performance even in young healthy people. A deterioration in young or middle age can lead to reduced metabolic fitness or increased mortality after just a few years.\\nOn the other hand, there is also an increase in activity by eliminating / reducing the workload, for example through reduced work orders or short-time work. This in turn can have a positive effect on metabolic risk, quality of life and life expectancy. We assume an influence on the physical activity of clinic staff through the restrictions within the corona prescription. Therefore, we would like to ask the employees about their activity behavior in minutes per week before and during the currently applicable restrictions.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CovAK-study\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00021763\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"29.05.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut f\\u00fcr Bewegungs- und Arbeitsmedizin Department Innere Medizin Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"peter.deibert@uniklinik-freiburg.de\", \"role_phone\": \"+49 761 270-74540\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 47, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Peter\", \"role_name_personal_family_name\": \"Deibert\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"peter.deibert@uniklinik-freiburg.de\", \"role_phone\": \"+49 761 270-74540\", \"role_affiliation_name\": \"Institut f\\u00fcr Bewegungs- und Arbeitsmedizin Department Innere Medizin Universit\\u00e4tsklinikum Freiburg\", \"role_affiliation_address\": \"Hugstetter Strasse 47, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Philipp\", \"role_name_personal_family_name\": \"Maier\", \"role_name_personal_title\": \"Mr. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"philipp.maier.ibam@uniklinik-freiburg.de\", \"role_phone\": \"+49 761 270 74930\", \"role_affiliation_name\": \"Institut f\\u00fcr Bewegungs- und Arbeitsmedizin Department Innere Medizin Universit\\u00e4tsklinikum Freiburg\", \"role_affiliation_address\": \"Hugstetter Strasse, 47, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"physical activity\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"02.06.2020\", \"study_end_date\": \"19.06.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"clinic staff members, minimun age: 18 years\", \"study_eligibility_exclusion_criteria\": \"/\", \"study_population\": \"\", \"study_target_sample_size\": 175, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Physical activity questionnaire in minutes per week.\\nMeasurement with an online version of the Freiburg physical activity questionnaire. During the survey period, the questionnaire can be called up at any time via a link. The survey period is 2 weeks.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Perceived sitting time in different situations of daily life using an online questionnaire. It should be recorded whether the employees sit more, less or unchanged in the respective situations compared to the time before the Corona regulation.\\nRecord of average daily cigarette consumption before and during the current Corona regulation. During the survey period, the questionnaire can be accessed at any time via a link. The survey period is 2 weeks.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Observational study\\nClinical staff are asked once about their physical activity behavior within two periods of time with a questionnaire \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022032","content":"{\"resource_id\": \"DRKS00022032\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Pupils\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Corona\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Saxony\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Children\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Teachers\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Scools\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Sars-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Students\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Study on the Evaluation of the Infectious Process of SARS-CoV-2 in Teachers and Students in Saxony (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of the study is to estimate the prevalence and sero-prevalence among teachers and students of Saxon general education schools to support decision makers in the gradual opening of general education schools (possibly stratified by age groups) and to determine the effect of infection control measures or their relaxation on the incidence rates in the target population. The target population are teachers and pupils of Saxon schools. The Dresdner/Zwickauer/Leipziger general education schools are suitable as sampling frames for the study population stratified by school type; the regions of Dresden, Zwickau and Leipzig as well as Werdau were chosen as rural areas because they represent areas with relatively low or high prevalence.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SchuCo\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022032\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.06.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"260-20-ek-18052020(1).pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"studienprotokoll-schuco-neueinsendung-ethik.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"S\\u00e4chsisches Staatsministerium f\\u00fcr Kultus\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Carolaplatz 1, 01097 Dresden, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Beate\", \"role_name_personal_family_name\": \"Sch\\u00fccking\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"rektorin@uni-leipzig.de\", \"role_phone\": \"+47-341-9730000\", \"role_affiliation_name\": \"Universit\\u00e4t Leipzig\", \"role_affiliation_address\": \"Ritterstra\\u00dfe 26, 04109 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Wieland\", \"role_name_personal_family_name\": \"Kiess\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"wieland.kiess@medizin.uni-leipzig.de\", \"role_phone\": \"+498-341-9726000\", \"role_affiliation_name\": \"Universit\\u00e4t Leipzig\", \"role_affiliation_address\": \"Liebigstra\\u00dfe 27, Haus E, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Anne\", \"role_name_personal_family_name\": \"Jurkutat\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"child-info@life.uni-leipzig.de\", \"role_phone\": \"+49-341-9726538\", \"role_affiliation_name\": \"Universit\\u00e4t Leipzig\", \"role_affiliation_address\": \"Philipp-Rosenthal-Str. 27, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"infection and antibody status for Sars-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"Yes\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Enrolling by invitation\", \"study_start_date\": \"27.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 18, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Teacher or student at one of the selected saxon schools / class levels.\", \"study_eligibility_exclusion_criteria\": \"unable to attend school\", \"study_population\": \"\", \"study_target_sample_size\": 4000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Infection with Sars-CoV-2 (RT-PCR tasts of throat swab), presence of antibodies (IgG) in the blood sample\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"/\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"The study results are the aggregated numbers of the prevalence of Sars-CoV-2 infections or antibodies, which are published in coordination with the sponsor of the study. A provision of the data on individual level is not planned as no additional clinical data will be collected.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"A throat-swab and a blood sample are taken, and tests for antibodies (IgG) and an acute infection are performed.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022110","content":"{\"resource_id\": \"DRKS00022110\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Hygiene measures\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"chronic pain\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19 pandemic\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"http://forschdb.verwaltung.uni-freiburg.de/servuni/forschdbuni.recherche0?xmldokumentart=Projekt&amp;lfdnr=11889&amp;sprache=D&amp;Layout=uni&amp;Ausgabeart=bs&amp;Rahmen=1&amp;CSS=https://forschdb.verwaltung.uni-freiburg.de/uni2002/content.css&amp;Variante=3\\n\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Patients with chronic pain prefer maintenance of pain treatment despite COVID-19 pandemic restrictions\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of this prospective study is to clarify whether chronic pain patients are impaired in treatment by the hygiene measures caused by the pandemic.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022110\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"21.12.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1262-4221\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Patients with chronic pain....2021.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg, Medizinische Fakult\\u00e4t, Albert-Ludwigs-Universit\\u00e4t Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Breisacherstrasse 117, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg, Medizinische Fakult\\u00e4t, Albert-Ludwigs-Universit\\u00e4t Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Breisacherstrasse 117, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Barbara\", \"role_name_personal_family_name\": \"Kleinmann\", \"role_name_personal_title\": \"Ms. Dr. med., MSc.\", \"role_name_identifiers\": [], \"role_email\": \"barbara.kleinmann@uniklinik-freiburg.de\", \"role_phone\": \"0761 270 50200\", \"role_affiliation_name\": \"Interdisziplin\\u00e4res SchmerzzentrumUniversit\\u00e4tsklinikum Freiburg, Medizinische Fakult\\u00e4t, Albert-Ludwigs-Universit\\u00e4t Freiburg\", \"role_affiliation_address\": \"Breisacherstrasse 117, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Barbara\", \"role_name_personal_family_name\": \"Kleinmann\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"barbara.kleinmann@uniklinik-freiburg.de\", \"role_phone\": \"0761 270 50020\", \"role_affiliation_name\": \"Interdisziplin\\u00e4res SchmerzzentrumUniversit\\u00e4tsklinikum FreiburgMedizinische Fakult\\u00e4t\", \"role_affiliation_address\": \"Breisacherstrasse 117, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinik-freiburg.de/schmerzzentrum.html\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"[generalization F45.4: Persistent somatoform pain disorder]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F45.41\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"15.06.2020\", \"study_end_date\": \"30.10.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 99, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"patients with chronic pain and treatment in the pain clinic during the COVID-19 pandemic\", \"study_eligibility_exclusion_criteria\": \"younger than 18 years, inadequate German language skills\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Survey by means of a questionnaire and telephone interview\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"There is none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The anonymised study data will be published as supplementary data.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Supportive care\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients are interviewed using a questionnaire and telephone interview.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022155","content":"{\"resource_id\": \"DRKS00022155\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Survey\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Koco19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Morbus Crohn\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"clincial care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Ulcerative Colitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"IBD\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Clinical care situation, health problems and psychosocial burden during the COVID-19-pandemic in patients with chronic inflammatory bowel disease (IBD) - Part 1: Baseline survey and seroprevalence of SARS-CoV-2 antibodies compared to Munich population cohort (KoCo19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The corona pandemic has led to extensive changes in many areas of life. Many of our patients with IBD have been particularly affected by concerns and limitations in recent months. Outpatient appointments and endoscopies had to be cancelled in some cases. There is uncertainty regarding certain drugs, which are used to treat IBD have an affect on the immune system, increasing the risk of COVID-19 disease or for a particularly severe course of it. Time and time again, we received questions from patients whether medication should be reduced or paused, and in which case one is classified as a risk patient and how one should behave at work or in training after the initial restrictions have been lifted. \\n\\nAs doctors at the hospital, we were instructed on 16.3.2020 to treat only \\\"emergency cases\\\". Doctors from the IBD outpatient clinics were assigned to other areas and were therefore temporarily not available for regular care. This was also an exceptional situation for us.\\n\\nAs you may have read in the press, there is a large population study (KoCo19 study) being carried out in Munich in which more than 3000 representatively selected households are visited at various intervals over several months to investigate the infection status of the participants and collect further health-related information. At the LMU Clinic, we are conducting a sub-study of this large study, which includes only IBD patients (KoCo19-CED Study). \\n\\nTo better understand how our patients have been doing in the last three months, we conducted the KoCo19-CED study which includes a detailed questionnaire and a blood test. This study aims to involve all IBD patients receiving outpatient care of the University Hospital of Munich including all ages from children, adolescents to adults with IBD. The questionnaire covers the course of chronic bowel disease, vaccinations, living and housing situation, medical care and worries during the lockdown period and thereafter. This information should help us to systematically capture the situation of IBD patients and allow us to understand the concerns of our IBD patients, and aiming to improve patient care in case of a second wave of infection. We also offered all participants in this study a blood test (serology) to determine whether they have already had the disease (COVID-19) or not.\\n\\nThe first part of this study consists of questionnaires and the blood test. The questions relate to the IBD course of the child and general questions regarding the living and housing situation during the contact restriction period. These questions are identical to the study of randomly selected Munich citizens who will be monitored for the next 18 months or until a vaccination is available. This KoCo19 study is led by Prof. Dr. med. H\\u00f6lscher, Head of the Institute for Infections and Tropical Medicine at the LMU, and is financially supported by the Bavarian Ministry of Science and Culture. The KoCo19-IBD study in IBD patients is a sub-study of this major project. It allows the comparison of IBD patients with the general population of Munich.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"KoCo19-CED-1\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022155\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"24.08.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"DRKS00021698\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Sibylle\", \"role_name_personal_family_name\": \"Koletzko\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"Dr. von Haunersches Kinderspital Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie Klinikum der Universitaet Muenchen (A\\u00f6R)\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/de/ambulanzen/gastroenterologie/index.html\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thu Giang\", \"role_name_personal_family_name\": \"Le Thi\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"Dr. von Haunersches Kinderspital Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie Klinikum der Universitaet Muenchen (A\\u00f6R)\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Leandra\", \"role_name_personal_family_name\": \"Koletzko\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kococedmed2@med.uni-muenchen.de\", \"role_phone\": \"089 4400 76014\", \"role_affiliation_name\": \"LMU Klinikum, Medizinische Klinik und Poliklinik II, CED-Ambulanz\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Simone\", \"role_name_personal_family_name\": \"Breiteneicher\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"kococedmed2@med.uni-muenchen.de\", \"role_phone\": \"089440076014\", \"role_affiliation_name\": \"LMU Klinikum, Medizinische Klinik und Poliklinik II, CED-Ambulanz\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tobias\", \"role_name_personal_family_name\": \"Schwerd\", \"role_name_personal_title\": \"Ms. PD Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"Dr. von Haunersches KinderspitalAbt. P\\u00e4diatrische Gastroenterologie &amp; HepatologieKlinikum der Universitaet Muenchen (A\\u00f6R)\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Elisabeth\", \"role_name_personal_family_name\": \"Klucker\", \"role_name_personal_title\": \"Ms. Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"Dr. von Haunersches KinderspitalAbt. P\\u00e4diatrische Gastroenterologie &amp; HepatologieKlinikum der Universitaet Muenchen (A\\u00f6R)\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Crohn disease [regional enteritis]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K50\"}, {\"study_conditions\": \"Ulcerative colitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K51\"}, {\"study_conditions\": \"Other noninfective gastroenteritis and colitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K52\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"04.07.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"(a) Patients (male, female) with diagnosed IBD (Crohn's disease, ulcerative colitis, unclassified IBD) with or without comorbidity, with or without therapy at the time of inclusion\\n(b) Age &gt;12 months\\n(c) Patients and parents (care givers) have adequate knowledge of German language\\n(d) Consent to participate in the study if the person of legal age or guardian has given written and oral consent by the study staff \\n(e) have been visiting the outpatient clinic for chronic inflammatory bowel diseases at the University Hospital of Munich (LMU Klinikum) within the last 2 years\\n\", \"study_eligibility_exclusion_criteria\": \"(a) Inclusion criteria not met\\n(b) Patients with monogenetic immunodeficiency disease confirmed as a cause of IBD\\n\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The study aims to establish a cohort of &gt;400 IBD patients of all age groups for further studies of SARS-CoV-2 infections at the LMU hospital (KoCo19-CED) parallel to the Munich KoCo19-cohort (representative sample of the general population in Munich) with a phenotype of the underlying disease and a survey of treatments and comorbidities.\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Secondary outcomes include:\\na) to record of previous diagnosis and symptoms of the COVID-19 infection.\\nb) to investigate the seroprevalence of SARS-CoV-2 antibodies in IBD patients compared to KoCo19\\nc) to record self-reported vaccination status (varicella zoster virus, measles, mumps and rubella, pneumococcus, influenza), immune response (varicella zoster virus, measles virus) if applicable.\\nd) to assess the impact of the pandemic to date on medication, use of outpatient and inpatient health services and the course of the IBD.\\ne) to observe the impact of the pandemic on mental health, disease-related quality of life and social contacts at work and in private life, as well as on attendance at nursery, kindergarten, school and at work compared to the KoCo-19 cohort.\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"no plan for IPD sharing\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"All IBD patients who are registered in the outpatient clinic of the University Hospital of Munich have received from 04.07.2020 to 11.07.2020 a postal invitation to participate in the study with a secure online link to the questionnaire.\\n\\nAll participants in this study will be offered a blood test (serology) to determine whether they have already experience COVID-19. The blood test is in the framework of routine clinical care. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022157","content":"{\"resource_id\": \"DRKS00022157\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"isolation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Corona Pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"general practitioner\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"physician-patient contact.\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Physical and Psychological Impact of the COVID-19 Pandemic in Germany - a Survey of General Practitioners\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The dangers of isolation and quarantine as a result of the Corona pandemic are obvious: chronic diseases, such as diabetes, arterial hypertension as well as heart and lung disease have reduced patient-physician contacts in outpatient care. After termination of restrictive measure, it must be feared that patients will report with clinical deteriorations, also because they may have ignored red flags, such as weight gain or increase in dyspnea. It may be assumed that patients did this in fear of getting infected during their visit to the general practitioner's office. By creating a questionnaire to assess the development of physical and psychological symptoms, we want to analyse the development of symptoms during the crisis (increase of angina, dyspnea, symptoms of depression as  endpoints) as well as a potential increase in drug abuse (alcohol, sedatives..) and reduction of physical activity. Additionally, we also want to elucidate factors, which influence the probability of the primary endpoint, such as isolation and co-morbidities with logistic regression analysis. Patients older than 18 years, who are treated in our office can take part. We aim to include at least 500 patients to achieve enough statistical power. Data analysis will be done in a pseudonymized way.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022157\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"03.08.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://pubmed.ncbi.nlm.nih.gov/34631041/\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Sauerlandpraxis Medebach, Hallenberg, Winterberg\", \"role_email\": \"foertim@googlemail.com\", \"role_phone\": \"+49/2982 92120\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Niederstrasse 2, 59964 Medebach, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Tim Henning\", \"role_name_personal_family_name\": \"F\\u00f6rster\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"foertim@googlemail.com\", \"role_phone\": \"+49/2982 92120\", \"role_affiliation_name\": \"Sauerlandpraxis Medebach, Hallenberg, Winterberg\", \"role_affiliation_address\": \"Niederstrasse 2, 59964 Medebach, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Simon\", \"role_name_personal_family_name\": \"Wernhart\", \"role_name_personal_title\": \"Mr. Dr.med. Dr.rer.nat.\", \"role_name_identifiers\": [], \"role_email\": \"simon.wernhart@gmx.de\", \"role_phone\": \"+491751830099\", \"role_affiliation_name\": \"Sauerlandpraxis F\\u00f6rster, Kraushaar, B\\u00f6ttcher.\", \"role_affiliation_address\": \"Niederstrasse 2, 59964 Medebach, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Deterioration of chronic diseases during the COVID-19 restrictions.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Increase of drug abuse and reduced physical activity during the Corona restrictions.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Terminated: Recruitment, data collection, data and quality management halted prematurely and will not resume\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": \"One of the Ongoing\", \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Terminated\", \"study_start_date\": \"10.08.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"patients of our general practitioner's office, legal capacity and willingness to take part, age&gt;18 years.\", \"study_eligibility_exclusion_criteria\": \"lack of legal capacity or willingness to take part, age&lt;18 years.\", \"study_population\": \"\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Detection of the point prevalence of a newly developed depressive episode (defined as presence of at least 2 out of 4 symptoms: loss of energy, tendency to brood, insomnia, listlessness) during the Corona crisis.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Detection of a change in symptoms during the Corona crisis, such as: increase of dyspnea (changes of NYHA stage), increase of angina pectoris (according to the CCS classification), change of intake of sedatives and pain medication, change of physical activity.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Observational study, there is no control group. All patients receive a questionnaire.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022244","content":"{\"resource_id\": \"DRKS00022244\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Telemedicine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"remote patient management\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"http://telemed5000.de\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Telemedicine follow-up of hospitalized patients with coronavirus disease-2019 (COVID-19).\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The primary study objective is to follow up patients suffering from COVID-19 after hospitalization for a period of 1 year by the daily recording of vital signs (ECG, blood pressure, oxygen saturation, self-assessment, weight) weekly voice recording and monthly measurement of physical activity.\\n\\nThe aim is to find out whether daily measurements can detect worsening of existing chronic diseases, secondary diseases and emergencies. It will also explore whether voice or a 6-minute activity test can be used to detect deterioration in health at an early stage.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Telemed5000-Covid-19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022244\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"25.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Wirtschaft und Energie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \", 11019 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Friedrich\", \"role_name_personal_family_name\": \"K\\u00f6hler\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"friedrich.koehler@charite.de\", \"role_phone\": \"+49 30 450 514184\", \"role_affiliation_name\": \"Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin Charit\\u00e9Centrum 11 f\\u00fcr Herz-Kreislauf-Medizin Arbeitsbereich Kardiovaskul\\u00e4re Telemedizin\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"http://telemedizin.charite.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Friedrich\", \"role_name_personal_family_name\": \"K\\u00f6hler\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"friedrich.koehler@charite.de\", \"role_phone\": \"030/450514184\", \"role_affiliation_name\": \"Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin Charit\\u00e9Centrum 11 f\\u00fcr Herz-, Kreislauf- und Gef\\u00e4\\u00dfmedizin Arbeitsbereich Kardiovaskul\\u00e4re Telemedizin\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"http://telemedizin.charite.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Contact person\", \"role_name_organisational\": \"Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin Charit\\u00e9Centrum 11 f\\u00fcr Herz-, Kreislauf- und Gef\\u00e4\\u00dfmedizin Arbeitsbereich Kardiovaskul\\u00e4re Telemedizin\", \"role_email\": \"telemed5000@charite.de\", \"role_phone\": \"030/450514440\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Charit\\u00e9platz 1, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"18.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1.Hospitalization with detection of SARS-CoV-2 RNA (PCR) in naso-/oropharyngeal swab (hospital discharge letter available).\\n2.age of majority \\n3.written informed consent of the patient\", \"study_eligibility_exclusion_criteria\": \"1.inability or unwillingness to measure daily vital signs (e.g., dementia, blindness, deafness, wheelchair use, inadequate German language skills, speech or voice disorders that interfere with voice analysis, limited informal self-determination)\\n2.participation in therapy studies (observational studies and registries are possible).\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Number of unplanned clinical events (emergency telemedicine interventions, emergency department presentations, unplanned hospitalizations, death from any cause) as a composite endpoint during 1 year of telemedicine follow-up of hospitalized COVID-19- patients.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1.Days lost due to unplanned hospitalizations and death from any cause during one-year follow-up.\\n2.total mortality\\n3.number of unplanned hospitalizations\\n4.number of emergency department presentations\\n5.Number of telemedicine interventions for emergencies\\n6.changes in quality of life during follow-up \\n7.number of TMZ-contacts to the patient due to abnormal telemonitoring findings. \\n8.number of TMZ contacts to primary care physicians due to abnormal telemonitoring findings\\n9.adherence to telemonitoring\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Possible upon request and depending of the research question.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Telemedical follow-up: \\nFrom the day of training at home by nurses, the patient measures their body weight, blood pressure, oxygen saturation, an ECG and enters their condition on the tablet 1x each day. 1x a week, each patient records an approx. 2-minute voice sample via an app on the tablet. For this purpose, the patient is guided through 4 short voice tasks.\\nOn the day of device training and at device pick-up, a TMZ specialist nurse conducts a 6-minute walk test with each patient outside the patient's home and measures the distance the patient can walk in 6 minutes using a measuring wheel and the received tablet. In the course of the one-year follow-up, each patient is asked to perform a 6-minute activity test with the tablet on his/her own 1x/month if he/she feels healthy enough to do so. Patients will be called and reminded 1x/month for this.\\n\\nAll data are transmitted via Bluetooth (except ECG, which is directly transmitted) from the measuring devices to the tablet and sent to a server of the TMZ in the Charit\\u00e9 via mobile network in an encrypted manner.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022259","content":"{\"resource_id\": \"DRKS00022259\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Antibodies\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Hospital\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Healthcare provider\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Prevalence of SARS-CoV-2 Infections in the employees of the Pius-Hospital Oldenburg, confirmed through virus antibody testing - COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Monocentric, longtitudinal cohort study determining the prevalence of (past) SARS-CoV-2 Infections in the employees of the Pius-Hosptial in Oldenburg through testing for Virus antibodies in serum and establishing correlation to certain possible risk factors.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Co-Kl-Ak\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022259\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"10.07.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Pius-Hospital Oldenburg\", \"role_email\": \"dirk.weyhe@pius-hospital.de\", \"role_phone\": \"04412291472\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Georgstr. 20, 26121 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Dirk\", \"role_name_personal_family_name\": \"Weyhe\", \"role_name_personal_title\": \"Mr. Professor Dr.\", \"role_name_identifiers\": [], \"role_email\": \"dirk.weyhe@pius-hospital.de\", \"role_phone\": \"04412291472\", \"role_affiliation_name\": \"Pius-Hospital Oldenburg\", \"role_affiliation_address\": \"Georgstr. 20, 26121 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Haitham\", \"role_name_personal_family_name\": \"Mansour\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"haitham-mansour@hotmail.com\", \"role_phone\": \"01738316196\", \"role_affiliation_name\": \"Pius-Hospital Oldenburg\", \"role_affiliation_address\": \"Georgstra\\u00dfe 12, 26129 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Uslar\", \"role_name_personal_family_name\": \"Verena\", \"role_name_personal_title\": \"Ms. Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"verena.ulsar@pius-hospital.de\", \"role_phone\": \"04412290\", \"role_affiliation_name\": \"Pius-Hospital Oldenburg\", \"role_affiliation_address\": \"Georgstrasse 20, 26121 Oldenburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07.1 COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"22.06.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Employees of the Pius-Hospital with physical presence in the hospital perimeters in the time period between 01/2020 till 12/2020.\", \"study_eligibility_exclusion_criteria\": \"- Home-Office workers\\n- Termination of work during the study\\n- Failure to provide consent\\n- Illiteracy\\n- Incompliance\\n- Withdrawal of Consent\", \"study_population\": \"\", \"study_target_sample_size\": 1250, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Percentage of antibody-positive workers in Pius-Hospital.\\n\\nQuestionnaire to document the possible risk factors by each participant plus a blood test for presence of  SARS-CoV-2 antibodies, these 2 to be repeated in 3 time intervals in June, September and December 2020 and the results to be statistically analyzed in January 2021.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"n/a\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Prevalence values in 3 different chronological points\\nCorrelation percentage for the tested risk factors\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Employees of the Pius-Hospital Oldenburg will have to fill out a questionnaire detailing their potential risk factors and a blood test for Serum Antibodies will be done at 3 different stages in July, September and January.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022292","content":"{\"resource_id\": \"DRKS00022292\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Serological screening and metabolic analysis for evaluation of the immune response to SARS-CoV2 (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"SARS-CoV2 is a single-strand RNA virus that belongs to the Coronaviridae. This virus is pathogenic to humans and can lead to symptoms of an infection of the respiratory tract. Symptoms might include fever, pharyngitis and shortness of breath. In severe cases patients can develop a life-threatening pneumonia. SARS-CoV2 has caused a pandemia that poses significant challenges to the health care system, the economics and the society in many countries. There is still unsufficient data regarding the question how many people have actually been in contact with the virus and have developed an immune response. It is also not known why some patients develop severe symptoms, whereas others have only mild symptoms or are asymptomatic. In this project, we would like to develop an ELISA-based antibody test that allows a quantification of the antibody titer. Using this test, we would like to test our study population. We are going to include people who have had professional or private exposure to SARS-CoV2, even if they have not had a positive PCR test. With this test we can answer the question whether infections can have a subclinical course. Furthermore, we will study groups of people living in the same household to describe transmission rates within families. The antibody titers will be correlated with the clonical manifestation. After a first screening, we will include selected subjects for further analysis of immune cells and their metabolism. We would like to study whether there is a connection between immune cell metabolism, antibody titers and severity of symptoms.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022292\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.06.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Freiburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Strasse 49, 79095 Freiburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-freiburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Cornelius\", \"role_name_personal_family_name\": \"Waller\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"cornelius.waller@uniklinik-freiburg.de\", \"role_phone\": \"+49 (0)761 270 34220\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg Klinik f\\u00fcr Innere Medizin I\", \"role_affiliation_address\": \"Hugstetter Str. 55, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Cornelius\", \"role_name_personal_family_name\": \"Waller\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"cornelius.waller@uniklinik-freiburg.de\", \"role_phone\": \"+49 (0)761 270 34220\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg Klinik f\\u00fcr Innere Medizin I\", \"role_affiliation_address\": \"Hugstetter Str. 55, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.06.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 5, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Age at least 5 years, signed written informed consent form (for &lt;18 years old, signed by the parent)\", \"study_eligibility_exclusion_criteria\": \"acute symptoms of COVID-19 in the last two weeks (fever, cough, shortness of breath)\", \"study_population\": \"\", \"study_target_sample_size\": 250, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary outcome is the level of IgM- and IgG antibodies against SARS-CoV2. The titers will be measured up to 3x within one year. In one part of the experiments we will also study the virus-specific Tcells.\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The prevalence of antibodies in the population, a correlation between antibody titer, virus-specific T cells and symptoms; the correlation between metabolic parameters in immune cells, antibody titers and symptoms. \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Not approved by the responsible ethics committee\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Early-phase-1\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"subjects exposed to SARS-CoV2 (contact with SARS-CoV2-infected people)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"historic controls (biomaterial from 2019 or earlier available)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022337","content":"{\"resource_id\": \"DRKS00022337\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"resolution\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SPMs\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"inflammation\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Analytical study of the profile of pro-inflammatory and pro-resolution factors in non-obese males with pulmonary symptomatology resulting from SARS Covid-19 verified with PCR blood analysis.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Evaluation of the plasma and serum parameters of the inflammation and resolution factors of SARS Covid-19 positive males and measurement the ratio of these parameters\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Insolcov-19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022337\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"29.06.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Chemo Group\", \"role_email\": \"josemiguel.rizo@chemogroup.com\", \"role_phone\": \"+34 - 91 302 15 60\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Manuel Pombo Angulo, 28 \\u2013 4th floor, 28050 Madrid, Spain\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Jose Miguel\", \"role_name_personal_family_name\": \"Rizo\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"JoseMiguel.Rizo@chemogroup.com\", \"role_phone\": \"+34 - 91 302 15 60\", \"role_affiliation_name\": \"Chemo Group\", \"role_affiliation_address\": \"Manuel Pombo Angulo, 28 \\u2013 4th floor,, 28050 Madrid, Spain\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Pedro-Antonio\", \"role_name_personal_family_name\": \"Regidor\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"pedro-antonio.regidor@exeltis.com\", \"role_phone\": \"+491738938132\", \"role_affiliation_name\": \"Exeltis Healthcare\", \"role_affiliation_address\": \"Adalperostr. 84, 81927 Ismaning, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rafael\", \"role_name_personal_family_name\": \"Silva Orellana\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"rafaelsilvao@gmail.com\", \"role_phone\": \"+56712201933\", \"role_affiliation_name\": \"Hospital Regional Talca, Chile\", \"role_affiliation_address\": \"4 Norte, 1640 Talca, Chile\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.2\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.2\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"29.06.2020\", \"study_end_date\": null, \"study_country\": [], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 90, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Female\"], \"study_eligibility_inclusion_criteria\": \"1. Male patients, age 18 and 90 years old\\n2. Severe pneumonia caused by SARS Covid 19\\n3. No necessity of artificial respiration \\n4. Informed consent\\n\", \"study_eligibility_exclusion_criteria\": \"1. BMI &gt; 30 \\n2. Patients with assisted respiration\\n\", \"study_population\": \"\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Evaluation of the plasma and serum parameters of the inflammation and resolution factors of SARS Covi-19 positive males and measurement the ratio of these parameters \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Not applicable\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Open demonstration of the obtained laboratory results\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Non-interventional study for plasma and serum detection of inflammation and resolution factors in male patients with severe pneumonia and SARS Covid 19 positive status.\\nEvaluation of the plasma and serum parameters of the inflammation and resolution factors of SARS Covi-19 positive males and measurement the ratio of these parameters in 15 patients.\\nPer patient: 3 consecutive days of blood test for the evaluation of inflammation and resolution parameters.  \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"5 healthy probands as control group\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022473","content":"{\"resource_id\": \"DRKS00022473\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"pandemic management\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"palliative care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Corona pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Palliative care expertise as an integral part of pandemic management (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"With the beginning of the corona pandemic in Germany, the pandemic operations managment (KEL) of the University Medical Center Freiburg decided to establish a specific care ward for COVID-19 patients with a high palliative care need (Ecker-Covid ward). A multi-stage concept for the implementation was developed by the Department for Palliative Care and the Ecker-Covid care station was put into operation from 17.3.-20.4.2020. The team of the Ecker ward, the palliative care unit and other nursing staff from other wards of the University Hospital worked together there. \\nIn order to best monitor the further course of the pandemic and to be able to draw conclusions for future crisis situations, the Department for Palliative Care is evaluating this form of early involvement of palliative medical expertise as an integral part of pandemic management with an interview study and a written questionnaire survey. \\nAim: To evaluate the Ecker-Covid ward, guideline-based telephone interviews with staff members (e.g. nurses, doctors, psycho-social team) and employees on the operational level (medical mangement, heads of station, nursing service management) will be conducted in order to find out how they have experienced the care of patients in the context of the corona pandemic so far, how the Ecker-Covid ward has been set up, how the \\\"new team\\\" has worked together and how palliative COVID-19 patients have been cared for. \\u2028\\nIn addition, members of the pandemic operations managment (KEL) will be interviewed by means of guideline-based interviews on the motives for the early planning and integration of a palliative care unit for COVID-19 patients.\\nIn addition, all physicians who were integrated into the AvD system (physician on duty) for medical care outside of the regular working hours of palliative physicians will be interviewed with a short questionnaire about their experiences with this changed task.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022473\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.08.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinik FreiburgKlinik f\\u00fcr Palliativmedizin\", \"role_email\": \"gerhild.becker@uniklinik-freiburg.de\", \"role_phone\": \"+49 761 270-95412\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Robert-Koch-Str.3, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Gerhild\", \"role_name_personal_family_name\": \"Becker\", \"role_name_personal_title\": \"Ms. Prof. Dr. med. Dipl.-Theol. Dipl.-Caritaswiss MSc\", \"role_name_identifiers\": [], \"role_email\": \"gerhild.becker@uniklinik-freiburg.de\", \"role_phone\": \"+49 761/270-95412\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg, Klinik f\\u00fcr Palliativmedizin\", \"role_affiliation_address\": \"Robert-Koch-Str.3, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Katharina\", \"role_name_personal_family_name\": \"Seibel\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"katharina.seibel@uniklinik-freiburg.de\", \"role_phone\": \"+49 761 270-33 280\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Freiburg, Klinik f\\u00fcr Palliativmedizin, Klinische Forschung\", \"role_affiliation_address\": \"Robert-Koch-Str.3, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"Palliative care\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z51.5\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"29.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Employees who have worked at the Ecker-Covid ward in the period March-April 2020 and/or have contributed at its operational level (medical mangement, heads of station, nursing service management) as well as members of the pandemic operations managment (KEL) of the University Medical Center Freiburg who are physically and mentally able to conduct an interview of 1 hour and have voluntarily and informedly agreed to participate.\", \"study_eligibility_exclusion_criteria\": \"Employees who were not involved in the planning and/or implementation of the Ecker-Covid ward, are physically and mentally unable to conduct a 1-hour interview or have not agreed to participate.\", \"study_population\": \"\", \"study_target_sample_size\": 30, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Exploration of the experiences of a) staff working in a care unit for Covid-19 patients with high palliative care needs set up in the context of the corona pandemic as well as b) the operational management (medical management, nursing service management, ward management) and c) the pandemic operations managment (KEL) concerning this care unit.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The aim is to document and evaluate the experiences of all those involved in planning and implementation in order to evaluate the challenges and opportunities of such a support unit and to make deductions for future crisis modes. \\nIn addition, the following should be learned: the motivation for setting up the ward or the work on the ward; the experience of the work on the Ecker-Covid ward; the experience of cooperation in the new team; the evaluation of the teambuilding measures; the evaluation of the quality of care with regard to patients and relatives in the dying phase; the experience of social and physical distance\\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"To evaluate scientifically the specific care ward for COVID-19 patients with a high palliative care need (Ecker-Covid ward), guideline-based telephone interviews will be conducted between May and September 2020. Interviewees are staff members who had worked at the Ecker-Covid ward (e.g. nurses, doctors, psychosocial team) or at its operational level (medical management, heads of station, nursing service management) in order to find out how the different stakeholders have experienced a) the care of patients in the context of the corona pandemic so far, b) the establishment of the Ecker-Covid ward and c) the cooperation in the \\\"new team\\\". Furthermore, the study explores the perceived challenges and support of staff members and their suggestions for improvement.\\nIn addition, members of the pandemic operations management (KEL) of the University Medical Center Freiburg will be interviewed about their experiences with and the reasons for the early planning and integration of a palliative care unit for COVID-19 patients.\\nIn addition, all physicians who were integrated into the AvD system (physician on duty) for medical care outside of the regular working hours of palliative physicians will be interviewed with a short questionnaire about their experiences with this changed task.\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022484","content":"{\"resource_id\": \"DRKS00022484\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"viral load\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hydrogen peroxide\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"mouthrinse\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2 (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Several specialist societies have recommended to perform a hydrogen peroxide mouthrinse in SARS-CoV-2 positive patients in order to reduce the intraoral viral load of SARS-CoV-2. Until now, there are no clinical data justifying this recommendation. Therefore, the aim of this study was to investigate the effects of a hydrogen peroxide mouthrinse on reducing the intraoral viral load of SARS-CoV-2.\\nFirst, the current intraoral load is determined in SARS-CoV-2 positive patients by obtaining oropharyngeal specimens and RT-PCR analysis. Then, patients are asked to thoroughly gargle their mouth and throat with 20 mL 1% hydrogen peroxide for 30 seconds. Thirty minutes after this mouthrinse, another oropharyngeal specimen is obtained and SARS-CoV-2 viral load is determined by RT-PCR.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022484\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"17.07.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Regensburg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-regensburg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Fabian\", \"role_name_personal_family_name\": \"Cieplik\", \"role_name_personal_title\": \"Mr. Priv.-Doz. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"fabian.cieplik@ukr.de\", \"role_phone\": \"0941 944 6024\", \"role_affiliation_name\": \"Poliklinik f\\u00fcr Zahnerhaltung und ParodontologieUniversit\\u00e4tsklinikum Regensburg\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"https://www.ukr.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Fabian\", \"role_name_personal_family_name\": \"Cieplik\", \"role_name_personal_title\": \"Mr. Priv.-Doz. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"fabian.cieplik@ukr.de\", \"role_phone\": \"0941 944 6024\", \"role_affiliation_name\": \"Poliklinik f\\u00fcr Zahnerhaltung und ParodontologieUniversit\\u00e4tsklinikum Regensburg\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"https://www.ukr.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07 COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"09.04.2020\", \"study_end_date\": \"31.07.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- hospitalized patients (isolation ward of the University Hospital Regensburg)\\n- positive SARS-CoV-2 test within the last 72 h\", \"study_eligibility_exclusion_criteria\": \"- indication for intubation or mechanical ventilation\\n- severe stomatitis\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Reduction of the intraoral SARS-CoV-2 viral load (measurements immediately before gargling with hydrogen peroxide and 30 min after gargling with hydrogen peroxide by RT-PCR)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"First, the current intraoral load is determined in SARS-CoV-2 positive patients by obtaining oropharyngeal specimens and RT-PCR analysis. Then, patients are asked to thoroughly gargle their mouth and throat with 20 mL 1% hydrogen peroxide for 30 seconds. Thirty minutes after this mouthrinse, another oropharyngeal specimen is obtained and SARS-CoV-2 viral load is determined by RT-PCR.\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00022500","content":"{\"resource_id\": \"DRKS00022500\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"psychosocial stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"children and adolescents\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"inflammatory bowel disease (IBD)\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"clinical care\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Online survey on clinical care, health problems and psychosocial stress during the corona pandemic in children and adolescents with chronic inflammatory bowel disease (IBD) (COVID19-CED-P\\u00c4D)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In Germany, circa 450,000 people are living with inflammatory bowel disease (IBD). About 16% of IBD patients were diagnosed at young age than 18 years. An IBD can manifest for the first time at any age, from young infant into adulthood. The highest incidence was detected from the adolescent age until young adulthood. Inflammatory intestinal diseases can be influenced in the course of the disease but cannot be cured, and they are associated with high morbidity and increased mortality. \\n\\nMost patients require immunosuppressive or immunomodulation therapy to treat the inflammatory and to reduce the risk of intra- and extra intestinal complications. Medications used in clinical routine care for IBD patients have different starting points in the inflammation chain and immune response and cause a wide range of side effects. Depending on the therapy used, the risk of susceptibility to and/or immune response to viral infections may be changed. \\n\\nWith the declaration of the WHO on 11 March 2020 of an existing pandemic of Sars-CoV-2 infection and the onset of extensive initial and contact restrictions, medical care for IBD patients also changed rapidly. Even though the initial and contact restrictions in the different states did not always start or loose at the same time, so it was applied nationwide from mid-March, that outpatient visits, inpatient admissions, endoscopies and operations should be limited to very urgent cases. People should avoid doctor visits, surgeries or visiting the outpatient clinics due to the risk of infection. In the media, there was talk about shortage of not only protective clothing, but also reported on medication. All this led to a strong uncertainty among IBD patients and their families, induced fears of infection or insufficient medical care. \\n\\nThere are uncertainties regarding the possible effects of the individual drugs on the risk of infection or an inadequate immune response in case of SARS-CoV-2 infection and a possible increased risk of severe or lethal outcome. No results from prospective studies and thus no evidence-based data are available by the beginning of June. The recommendations for IBD patients that have meanwhile been issued by German or European medical societies (GPGE, ESPGHAN, DGVS and ECCO) or by the German self-help group (DCCV) are based on expert assessments, or on their own experience, case series and registry data or extrapolated from data for other viral diseases (Stallmach et al. 2020; Turner et al. 2020; Haberman et al. 2020; Rubin et al. 2020). \\n\\nWith the beginning of liftung and opening of schools, day-care centers and kindergartens, patients and/or their parents are concerned that their children will be infected or siblings will carry the infection into the family. Some parents of affected children apply for a special permit for their children to remain at home as risk persons.\\n\\nWe conduct an anonymous online survey to collect data on the impact of the corona pandemic on medical care, disease progression and psychosocial stress in pediatric patients with IBD in Germany. Almost questions are identical to the questions we asked in the KoCo19-CED-1 Study of Munich pediatric IBD patients.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVID19-CED-P\\u00c4D\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022500\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"21.08.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen (LMU Klinikum)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Sibylle\", \"role_name_personal_family_name\": \"Koletzko\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Sibylle.Koletzko@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"LMU Klinikum, Dr. von Haunersches Kinderspital, Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thu Giang\", \"role_name_personal_family_name\": \"Le Thi\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"LMU Klinikum, Dr. von Haunersches Kinderspital, Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Elisabeth\", \"role_name_personal_family_name\": \"Klucker\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"LMU Klinikum, Dr. von Haunersches Kinderspital, Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tobias\", \"role_name_personal_family_name\": \"Schwerd\", \"role_name_personal_title\": \"Mr. PD Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"kococedkk@med.uni-muenchen.de\", \"role_phone\": \"+4989440057854\", \"role_affiliation_name\": \"LMU Klinikum, Dr. von Haunersches Kinderspital, Abt. P\\u00e4diatrische Gastroenterologie &amp; Hepatologie\", \"role_affiliation_address\": \"Lindwurmstr. 4, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Leandra\", \"role_name_personal_family_name\": \"Koletzko\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kococedmed2@med.uni-muenchen.de\", \"role_phone\": \"089 4400 76014\", \"role_affiliation_name\": \"LMU Klinikum, Medizinische Klinik und Poliklinik II, CED-Ambulanz\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Crohn disease [regional enteritis]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K50\"}, {\"study_conditions\": \"Ulcerative colitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K51\"}, {\"study_conditions\": \"Other noninfective gastroenteritis and colitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K52\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"25.08.2020\", \"study_end_date\": \"31.03.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 20, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients (male, female, divers) with diagnosed IBD (Crohn's disease, ulcerative colitis, unclassified IBD) with or without comorbidity, with or without therapy at the time of inclusion, age \\u2264 20 years and living in Germany.\", \"study_eligibility_exclusion_criteria\": \"When inclusion criteria cannot be met. \", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The online survey has been taken place in 2020 from August 25 to December 10.\\n\\nThe following questions should be answered by conducting this survey-based study: \\n1) How did the pandemic and the lock-down impact medical care?  \\na) on planned but postponed or cancelled outpatient or inpatient visits or surgery appointments, \\nb) to the IBD associated medication (reduction, reorientation) by the physicians (general practitioners, at IBD outpatient clinic) or patients/parents (without consulting a physician) so far?  \\nc) How many patients have postponed a planned outpatient visit for infusion of biologicals due to symptoms / COVID-19 contact / return home from high-risk areas / occupational exposure as indicated in the telephone/ e-mail consultation?  \\nd) Did any IBD flare occur during a pandemic-related change in care/ medication?  \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"2) How have patients experienced \\\"tele-medicine\\\" practiced in the clinic setting so far? Did they consider that they received sufficient information and care? \\n3) How did the pandemic influence social factors and mental health of the IBD patients regarding medication and severity of the disease? Are there any variations compared to the KoCo-19 cohort?  \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"no plan for IPD sharing. The collected and protected data is collected, stored, evaluated and published in anonymised form exclusively for the described study purposes.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Supportive care\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"We kindly ask parents together with their child or their adolescent with IBD to fill out the online questionnaire. The survey takes about 30 minutes.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022533","content":"{\"resource_id\": \"DRKS00022533\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"universal remote control\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"gesture-based\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"buttonless\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SmartPointer\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Pilot study to investigate the SmartPointer system in the context of domestic life with older people in need of support\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The universal remote control (SmartPointer) that extends usual universal remote controls in function and handling, enables a simple and intuitive usage of basic functions of several devices. Using a SmartPointer several household devices such as televisions, lamps, heating and radio can be operated using intuitive hand gestures from any spatial position. Above all, this should facilitate everyday life for older people and enable a central operation of household devices. Thus, the Smartpointer can also be used by people who are restricted in their mobility and who rely on help when operating devices. There is a high transfer potential to other target groups besides elder people, e.g. bedridden people or people with ALS, but also short-term mobility-impaired people. In this study, the SmartPointer system will be examined for functionality, implementation and acceptance. For this purpose, the potential users should use the system in their own home (retirement home) for a period of several days. Hereafter, the attitude towards the system of the study subjects will be assessed. Also, the test subjects will rate the user-friendliness of the system and possible areas of application of the system. Furthermore, an only survey will provide information of current use frequencies of smart home technologies (including evaluations) in older people to gain an impression of the potential of smart home technologies.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SPP \\u2013 SmartPointer Pilot study\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022533\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.08.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1256-0263\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin - Forschungsgruppe Geriatrie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Reinikendorferstra\\u00dfe 61, 13347 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Susan\", \"role_name_personal_family_name\": \"Vorwerg\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"susan.vorwerg@charite.de\", \"role_phone\": \"+49 (0) 30 450 \\u2013 553 696\", \"role_affiliation_name\": \"Charit\\u00e9 Universit\\u00e4tsmedizin BerlinForschungsgruppe Geriatrie\", \"role_affiliation_address\": \"Reinikendorfer Stra\\u00dfe 61, 13347 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Healthy participants\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.12.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 60, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Seniors over 60 years\\n- Seniors without physical limitations\\n- Seniors with mobility restrictions (use of a walker, wheelchair, walking stick or similar)\\n- Signed subject information and informed consent \", \"study_eligibility_exclusion_criteria\": \"- Seniors under 60 years\\n- severe cognitive impairment MMSE &lt;24\\n- Seniors in legal care\\n- Recent surgery on the dominant hand, which would make the use of the remote control painful or impossible \\n- Seniors with severe visual impairment so that the light beam from the remote control cannot be perceived\\n- Seniors with red-green weakness \", \"study_population\": \"\", \"study_target_sample_size\": 117, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"A) Germany-wide online survey from the end of August 2020\\n\\nB) How do older people in need of support use and accept the SmartPointer system in their home environment? The study will start in January 2021. A Mixed Methods Design consisting of qualitative guideline-based interviews, task-based testing of the system and quantitative validated assessments will be applied.\\nThe following validated questionnaires will be used:\\n- Mini Mental State Examination (MMSE) (Folstein et al., 1975)\\n- (Telephone Interview for Cognitive Status (TICS) (Brandt et al., 1988)\\n- Questionnaire on technology readiness (Neyer et al., 2012)\\n- User experience Questionnaire (UEQ) (Laugwitz et al., 2009)\\n- Technology Usage Inventory (TUI) (Kotgassner et al., 2012)\\n- NASA TLX (Task Load Index) questionnaire (YM Xiao et al., 2005)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Secondary research questions:\\nA) Online survey from the end of August 2020: \\n- Which smart home technologies do older people use in their own home?\\n- Which categories can the smart home technologies used be assigned to?\\n- How does the use of smart home technologies in older people take place? \\n- How do older people rate the use of smart home technologies?\\n- What expectations do older people have when using smart home technologies?\\n\\nB) Testing the SP system in January 2021: \\n- Does the gesture recognition function well and is it reliable? \\n- How do external influences affect the gesture recognition? \\n- Lighting conditions \\n- Distance between remote control and gesture detector\\n- Angle of incidence / position to the detector\\n- positioning of the subject (sitting, standing)\\n- How do the participants rate the manageability and usability of the system in everyday life? \\n- Are there differences between user groups (people with and without previous experiences in the field of smart home)\\n- What further expectations do the test subjects have on the system? \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Will individual participant data be available (including data dictionaries)? No\\nWhat data in particular will be shared? Not available\\nWhat other documents will be available? Not available\\nWhen will data be available (start and end dates)? Not applicable\\nWhith whom? Not applicable\\nFor what typs of analyses? Not applicable\\nBy what mechanism will data be made available? Not applicable\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Supportive care\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"A) Online survey: \\nThe online survey should discover the use frequency of smart home technologies in older people. \\nPart 1: Basic data collection; Basic socio-demographic data, living situation, care situation and disease-related data. \\nPart 2: Use of SmartHome technologies; Are SmartHome technologies used at home, which SmartHome technologies are used, how often are SmartHome technologies used\\nPart 3: Evaluation of SmartHome technologies\\nAssessment of acceptance, suitability for use, effort (cost) / benefit ratio, expectations\\n\\nB) Testing the SP System: \\nVisit 0: screening by telephone. Before conducting the study, the suitability of potential subjects is clarified using a personal screening by telephone. The potential test subjects are checked using the inclusion and exclusion criteria mentioned below. Hereafter, the subject information is sent to the participants by post or e-mail and an appointment is made for study participation. \\n\\nVisit 1: survey. Case 1: personal interview. Before the examination begins, a written declaration of consent is signed by the participant. Subsequently, the participant carries out a test to assess basic cognitive functions (Mini Mental Status Examination - MMSE). The study participants are informed about the course and objectives of the study. After this, the participants fill out a questionnaire on their socio-demographic data and experiences in the field of smart home technologies. Furthermore, the questionnaire assesses use of technology and technology commitment. Case 2: telephone interview. If a personal survey cannot take play due to the current Covid-19 situation, the study documents will be sent to the study subject by post. In this case, the cognitive assessment is carried out via telephone using TICS (Telephone interview for cognitive status). The remaining questionnaires should be completed independently or with support of nursing staff or relatives before the second visit. Alternatively, the study staff can conduct the survey by telephone. \\n\\nVisit 2: technology implementation. First, the SP system is set up and tested by the technical project partners in the participants' homes while adhering all necessary hygiene regulations of the facility. The subjects are then instructed in the proper use of the system. The participants will have sufficient time to test the system together with the study staff. Additionally, every participant receives a written manual, as well as the contact details of the study staff, who will support them when they have any questions or face technical problems. The test subjects will use the system for a week. During this time, the subjects are asked to keep a protocol in which the frequency of use, the number of attempts until the desired outcome occurs, as well as operating errors and technical defects should be noted. The study staff will contact the test subjects twice a week via phone. During these telephone sessions the study staff will assist with any technical problems or difficulties and also record the usage status. \\n\\nVisit 3: final survey. The system will be dismantled by the technical project partners after one week. While dismantling the system all hygiene regulations in the facility will be complied. Any changes inflicted to the participants' rooms will be restored to their original state. Finally, the overall impression of the system perceived by the test subjects will be examined. Also, questionnaires are used to assess usability and use of technology. Depending on the current Covid-19 situation, the questionnaires can also be sent by post and the interview can be held by phone. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022729","content":"{\"resource_id\": \"DRKS00022729\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"SARS-CoV-2 Surveillance in Day Care Centers (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Due to their lack of hygiene awareness and questionable compliance with protective measures, infants represent a critical population in the transmission of respiratory infections. The re-opening of day-care centres according to a structured concept will have an influence on this, but will not be able to completely exclude infection events and transmission chains. A reliable surveillance of the COVID-19 epidemiology in this population is therefore necessary to evaluate the protective measures taken and to carry out appropriate interventions if necessary. However, for ethical reasons, regular blood sampling in this age group is not a feasible option for monitoring the prevalence of COVID-19. \\nSARS-CoV-2 is also excreted in childhood to a relevant extent via the stool. Excretion takes place 2-4 weeks after infection. Regular stool tests can therefore be used to map the SARS-CoV-2 epidemiology. Reliable data on the spread of SARS-CoV-2 in this population allow risk-adapted control of current isolation measures and are therefore of great relevance to health policy.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"KiTaCoviDD19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022729\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.07.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Carl Gustav Carus\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Fetscherstr. 74, 01307 Dresden, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-dresden.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Jakob\", \"role_name_personal_family_name\": \"Armann\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"jakob.armann@uniklinikum-dresden.de\", \"role_phone\": \"0351 458 18568\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Carl Gustav Carus\", \"role_affiliation_address\": \"Fetscherstr. 74, 01307 Dresden, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinikum-dresden.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jakob\", \"role_name_personal_family_name\": \"Armann\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"jakob.armann@uniklinikum-dresden.de\", \"role_phone\": \"0351 458 18568\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Carl Gustav Carus\", \"role_affiliation_address\": \"Fetscherstr. 74, 01307 Dresden, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinikum-dresden.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07.1 COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"15.07.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"children attending day care Centers in Dresden\\nat least one Guardian &gt;18 years of Age\\nchildren and Guardians live in the same household\\nteachers in participating day care Centers &gt;18 years of age\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 750, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Anti-SARS-CoV-2 antibody seroprevalence in parents and teachers of toddlers and preschoolers\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Transmission dynamics in day care centers\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"toddler, preschoolers, their parents and teachers in day care Centers in Dresden, Germany\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022868","content":"{\"resource_id\": \"DRKS00022868\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Impact of the COVID-19 pandemic and the political measures to contain its spread on children with disabilities and chronic illnesses and their families\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The Covid-19 pandemic and related measures to protect the population against infection have far-reaching effects on the life and well-being of children and adolescents worldwide. Children with chronic illnesses and disabilities and their families are particularly hard hit. Firstly, chronically ill children often belong to risk groups due to their illnesses in which a severe course of a Covid-19 infection is feared. Second, they are protected from the pandemic measures by the elimination or reduction of supporting systems, such as home care services, special schools, etc. particularly affected. Third, the economic risk is increased in families in which parents are caring for their children, e.g. a parent loses their job. In the planned research project, the well-being of children and adolescents with chronic diseases and disabilities and their families during the Covid-19 pandemic is to be examined from different perspectives. As part of a longitudinal online survey with 3 interview times within 15 months, the care and stress situation of children with and without chronic diseases is comparatively analyzed. The endpoints are changes in opportunities for participation, the quality of medical care, and stresses in family life. The socio-economic status and the state of health of the child are recorded as co-variables. The study is carried out in cooperation with the umbrella organization for self-help for children with chronic diseases and disabilities, Kindernetzwerk e.V. The children's network is involved in the design of the survey instruments, the administration of the survey and the interpretation and use of the results. The findings of the studies are intended to contribute to a comprehensive understanding of the medical and social effects of the pandemic. They should support the development of measures to counter the negative effects of the pandemic for children and young people with chronic diseases and disabilities at the political and care level.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022868\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"20.08.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinik Freiburg Klinik f\\u00fcr Allgemeine Kinder- und Jugendmedizin Klinik f\\u00fcr Neurop\\u00e4diatrie und Muskelerkrankungen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Mathildenstr. 1, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinik Freiburg Klinik f\\u00fcr Allgemeine Kinder- und Jugendmedizin Klinik f\\u00fcr Neurop\\u00e4diatrie und Muskelerkrankungen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Mathildenstr. 1, 79106 Freiburg , Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thorsten\", \"role_name_personal_family_name\": \"Langer\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"thorsten.langer@uniklinik-freiburg.de\", \"role_phone\": \"+4976127043442\", \"role_affiliation_name\": \"Universit\\u00e4tsklinik Freiburg  Klinik f\\u00fcr Neurop\\u00e4diatrie und Muskelerkrankungen\", \"role_affiliation_address\": \"Mathildenstr. 1, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Families with chronically ill or healthy children between 1 and 18 years\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"11.08.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 15, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 99, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Parents of children aged 1-18 are surveyed. There are three groups:\\n- Healthy children\\n- Children with chronic diseases\\n- Children with complex chronic diseases.\", \"study_eligibility_exclusion_criteria\": \"Not applicable\", \"study_population\": \"\", \"study_target_sample_size\": 1619, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Quality of medical care for the child (parents perspective)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Opportunities for participation &amp; burdens in the family\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"In the planned research project, the well-being of children and adolescents with chronic diseases and disabilities and their families during the Covid-19 pandemic will be examined from different perspectives. In a longitudinal online survey with 3 survey points within 15 months, the care and stress situation of children with and without chronic diseases will be analysed comparatively. \\n\\nParents of children between the ages of 1-18 years will be interviewed. A distinction is made between three groups:\\n- healthy children\\n- Children with chronic diseases\\n- Children with complex chronic diseases.\\n\\nThe participants of all three groups need 10-15 minutes to complete the questionnaire.\\n\\nTranslated with www.DeepL.com/Translator (free version)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"see arm 1\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"see arm 1\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022909","content":"{\"resource_id\": \"DRKS00022909\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Covid-19 pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"naturopathic health preventive strategies\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Health realted self-help strategies during the COVID-19 pandemic - an online-based cross-sectional study\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"exploratory cross-sectional online survey\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Selfhelp in Covid -19 Pandemic\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022909\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"31.08.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut f\\u00fcr Sozialmedizin, Epidemiologie und Gesundheits\\u00f6konomie, Charit\\u00e9 Universit\\u00e4tsmedizin Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Luisenstr. 57, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Institut f\\u00fcr Sozialmedizin, Epidemiologie und Gesundheits\\u00f6konomie, Charit\\u00e9 Universit\\u00e4tsmedizin Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Luisenstr. 57, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Miriam\", \"role_name_personal_family_name\": \"Ortiz\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"miriam.ortiz@charite.de\", \"role_phone\": \"004930450529069\", \"role_affiliation_name\": \"Institut f. Sozialmedizin, Epidemiologie u. Gesundheits\\u00f6konomie, Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin\", \"role_affiliation_address\": \"Luisenstr. 57, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Margit\", \"role_name_personal_family_name\": \"Cree\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"margit.cree@charite.de\", \"role_phone\": \"0049 30 529 262\", \"role_affiliation_name\": \"Institut f\\u00fcr Sozialmedizin, Epidemiologie und Gesundheits\\u00f6konomie\", \"role_affiliation_address\": \"Luisenstr. 57, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 INFECTION\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"15.09.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Persons of full age \\nwith reference to naturopathy/complementary medicine \", \"study_eligibility_exclusion_criteria\": \"under 18 years\", \"study_population\": \"\", \"study_target_sample_size\": 2000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"- Sociodemographic data (age, gender, school-leaving qualifications, occupation)\\n- Questions about chronic diseases\\n- Questions on risk factors\\n- Questions on prevention and health promotion\\n- Information on Covid-19 infection status\\n- Application of general and complementary medical preventive measures in self-help \\n- Application of therapeutic complementary medicine measures in self-help or on the basis of a prescription\\n- Questions about the subjective feeling during the pandemic\\nThe survey will start at the end of September 2020.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"we assess only anonymeous data\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"cross-sectional study, non-interventional\\nIn an online survey, people are questioned once on the use of prevention measures and self-help strategies during the Covid-19 pandemic.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00022964","content":"{\"resource_id\": \"DRKS00022964\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Acute Respiratory Distress Syndrome (ARDS)\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19 associated coagulopathy (CAC)\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Extracorporeal membrane oxygenation (ECMO)\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Investigation of clinical characteristics, management and outcome of ARDS patients: a Germany-wide register study \\nDIVI ECMO COVID-19 Register\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Currently, COVID-19 is one of the biggest challenges in intensive care. Intensive care units (ICU) worldwide are facing a large number of patients with an acute respiratory distress syndrome (ARDS). These patients require long and complex intensive care treatment and eventually extracorporeal membrane oxygenation (ECMO) is necessary to ensure oxygenation and decarboxylation. In this case, in order to avoid activation of the coagulation cascade with consecutive thrombus formation and consumption of coagulation factors therapeutic anticoagulation is necessary. Due to the high technical and personnel requirements, as well as risks (e.g. bleeding and thromboembolic events) associated with ECMO, ECMO is considered as an ultima ratio in ARDS. \\nIn international observational studies published so far with several hundred COVID-19 intensive care patients, only a limited number of ECMO patients were described. \\nBoth general and specific questions about ECMO use in COVID-19 intensive care patients with severe ARDS remain unanswered. In the current study, technical characteristics, anticoagulation and ventilation strategies, outcomes, complications and risk factors for bleeding and other complications will be analyzed in patients with COVID-19 induced ARDS\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"DIVI ECMO COVID Register\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00022964\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"07.09.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr An\\u00e4sthesiologie, Universit\\u00e4tsklinikum W\\u00fcrzburg (UKW)\", \"role_email\": \"an_direktion@ ukw.de\", \"role_phone\": \"+49 931 201-30001\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Oberd\\u00fcrrbacher Stra\\u00dfe 6/ Haus A2, 97080 W\\u00fcrzburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Patrick\", \"role_name_personal_family_name\": \"Meybohm\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Meybohm_P@ukw.de\", \"role_phone\": \"+49 931 201-30001\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologie, Universit\\u00e4tsklinikum W\\u00fcrzburg (UKW)\", \"role_affiliation_address\": \"Oberd\\u00fcrrbacher Stra\\u00dfe 6/ Haus A2, 97080 W\\u00fcrzburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Peter Ulrich\", \"role_name_personal_family_name\": \"Heuschmann\", \"role_name_personal_title\": \"Mr. Prof. Dr\", \"role_name_identifiers\": [], \"role_email\": \"peter.heuschmann@uni-wuerzburg.de\", \"role_phone\": \"+49 (0)931 / 201 47308\", \"role_affiliation_name\": \"Institut f\\u00fcr Klinische Epidemiologie und Biometrie (IKE-B) der Universit\\u00e4t W\\u00fcrzburg\", \"role_affiliation_address\": \"Josef-Schneider-Str. 2 / Haus D7, 97080 W\\u00fcrzburg, Germany\", \"role_affiliation_web_page\": \"http://www.epidemiologie.uni-wuerzburg.de/startseite/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Patrick\", \"role_name_personal_family_name\": \"Meybohm\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Meybohm_P@ukw.de\", \"role_phone\": \"+49 931 201-30001\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologie, Universit\\u00e4tsklinikum W\\u00fcrzburg (UKW)\", \"role_affiliation_address\": \"Oberd\\u00fcrrbacher Stra\\u00dfe 6/ Haus A2, 97080 W\\u00fcrzburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 induced ARDS\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Intensive care unit treatment (participation in DIVI ECMO COVID Register) \", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"ECMO therapy during intensive care\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Adult respiratory distress syndrome\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J80\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U99.0\"}, {\"study_conditions\": \"Other viral pneumonia\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J12.8\"}, {\"study_conditions\": \"Special screening examination for infectious and parasitic diseases\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z11\"}, {\"study_conditions\": \"Contact with and exposure to other communicable diseases\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z20.8\"}, {\"study_conditions\": \"Carrier of other infectious diseases\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z22.8\"}, {\"study_conditions\": \"Systemic Inflammatory Response Syndrome of non-infectious origin without organ failure\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"R65.2\"}, {\"study_conditions\": \"Acute respiratory failure\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J96.0\"}, {\"study_conditions\": \"[generalization J96.0: Acute respiratory failure]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J96.09\"}, {\"study_conditions\": \"Systemic Inflammatory Response Syndrome of infectious origin with organ failure\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"R65.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"16.07.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 10, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"COVID-19 induced ARDS\\nIntensive care unit treatment (participation in DIVI ECMO COVID Register) \\nECMO therapy during intensive care\\n\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Clinical characteristics, management and survival of ARDS patients with COVID-19 and ECMO in Germany.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"ECMO management, ventilation parameters, anticoagulation management, as well as frequency and influencing factors of co- and super-infections, thromboembolic events and bleeding of ARDS patients with COVID-19 and ECMO.\\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"This is a German multicenter study for the investigation of clinical characteristics, management and outcomes of Covid-19 ARDS patients in cooperation between the German ARDS network and the section Respiratory Failure of DIVI (Deutsche Interdisziplin\\u00e4re Vereinigung f\\u00fcr Intensiv- und Notfallmedizin; German Interdisciplinary Association for Intensive Care and Emergency Medicine).\\n\\nThe project aims to improve the understanding of short-term disease history of patients with COVID-19, to identify possible factors influencing disease course on intensive care as well as to report the current patient care and outcome in Germany. \\n\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023136","content":"{\"resource_id\": \"DRKS00023136\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"CBT\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"telemedicine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"children\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"RCT\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"families\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"intervention\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"prevention\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"adolescents\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"group\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"group intervention\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Depression\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"transgenerational\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"online\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"multi-family therapy\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Evaluation of a sub form of the CHIMPS multi-family therapy (CHIMPS-MFT-CBT): GuG-Auf-online - a cognitive-behavioural, family- and group-based online prevention programme for children of depressed parents\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Since the children of parents who have depression are at elevated risk of developing depression themselves, preventive interventions for this population are a major public health priority. A cognitive-behavioral intervention (\\u201cGuG-Auf\\u201d) has previously shown positive effects on child outcomes (Compas et al., 2015; Loechner et al., in preparation). In response to the the needs of burdened families and the Covid-19 pandemic, a shortened online version of GuG-Auf (GuG-Auf-online) has been developed. It is a subform of the CHIMPS multi-family therapy. \\nThe present study is a randomized controlled pilot study and part of a national, multi-site research project that evaluates the efficacy of group- and family-based, preventive interventions for children of mentally ill parents (Wiegand-Grefe et al., 2020; ClinicalTrials.gov registration: NCT04369625). \\nThe first aim of our substudy at the Munich site to explore the\\u00a0acceptance and feasibility of\\u00a0GuG-Auf-Online by measuring the socio-economic status and demographic characteristics of participating families, recording attendance at the sessions, analysing weekly evaluation forms, conducting brief semi-structured interviews with\\u00a0families,\\u00a0and recording any technical issues or hurdles which arise. \\nThe second aim is to explore the efficacy of the\\u00a0GuG-Auf-Online intervention compared to treatment as usual (TAU; no intervention). We will include families with i) at least one parent who suffers (or has suffered) from an episode of major depressive disorder and ii) at least one child aged eight to 17 years who has no current psychiatric diagnosis.\\nEligible families recruited in Munich will be randomly allocated to receive the 8-session GuG-Auf intervention online (EG, n = 30) or no intervention (CG; n = 30). The primary outcome of internalizing symptoms (youth self-report; YSR) will be assessed 6 (T2) and at 12 (T3) and 18 months (T4) after the randomisation. We hypothesize that children in the EG condition, compared with those in the CG, will show fewer symptoms of psychopathology at follow-up. Hypothesised mediators of the effect are changes in children\\u2019s coping with stress (RSQ) and schemes (DISC), and parents\\u2019 parenting skills (ESI) from T1 (baseline) to T2. \\nExploratively, we will assess the participants' mood changes via the study app by administering daily questionnaires.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CHIMPS-NET\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023136\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.04.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"MUCHH_studyprotocol_20210423.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Innovationsausschuss beim G-BA\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Postfach 12 06 06, 10596 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Gerd\", \"role_name_personal_family_name\": \"Schulte-K\\u00f6rne\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Gerd.Schulte-Koerne@med.uni-muenchen.de\", \"role_phone\": \"089440055901\", \"role_affiliation_name\": \"LMU Klinikum, Klinik und Poliklinik f\\u00fcr Kinder- und Jugendpsychiatrie\", \"role_affiliation_address\": \"Nu\\u00dfbaumstr. 5a, 80336 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Belinda\", \"role_name_personal_family_name\": \"Platt\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"belinda.platt@med.uni-muenchen.de\", \"role_phone\": \"089440056932\\u00a0\", \"role_affiliation_name\": \"LMU Klinikum, Klinik und Poliklinik f\\u00fcr Kinder und Jugendpsychiatrie\", \"role_affiliation_address\": \"Waltherstr. 23, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Vanessa\", \"role_name_personal_family_name\": \"Danzer\", \"role_name_personal_title\": \"Ms. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"kjp-prodo@med.uni-muenchen.de\", \"role_phone\": \"089440056933\\u00a0\", \"role_affiliation_name\": \"LMU Klinikum, Klinik und Poliklinik f\\u00fcr Kinder- und Jugendpsychiatrie\", \"role_affiliation_address\": \"Waltherstr. 23, 80337 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Depressive episode\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F32\"}, {\"study_conditions\": \"Recurrent depressive disorder\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F33\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"05.10.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 8, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 17, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"i) the participating parent(s) has a primary diagnosis of depression according to ICD-10 (F32 without F32.3, F33), ii) the participating child is aged eight to 17 and does not fulfil criteria for a recent clinical diagnosis of any psychiatric disorder, and iii) all study participants must have adequate German-language skills. \", \"study_eligibility_exclusion_criteria\": \"i) The family has very poor interpersonal functioning deemed to be contra-productive for group-based intervention (score &gt; 40 on the Global Assessment of Relational Functioning Scale; GARF; Sa\\u00df, Wittchen, Zaudig &amp; Houben, 2003) and/or ii) a participating family member suffers from acute symptoms which may hamper their ability to take part such as suicidal tendencies, severe depression, addictions, manic symptoms, severe personality disorder, acute psychotic symptoms and/or dissociative symptoms, and/or iii) the participating child fulfils ICD-10 criteria for a current episode of any psychiatric disorder, or is undergoing treatment, including medication, for depression, and/or iv) the family takes part in family therapy during the course of the study period, and/or v) the depressed parent is insured with a health-care provider that is not cooperating with the study\", \"study_population\": \"\", \"study_target_sample_size\": 60, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Internalizing symptoms of the children and adolescents: 1) From the perspective of the children by the Youth Self Report ( YSR; D\\u00f6pfner et al., 2014; T1-T4)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1) Psychiatric symptoms of the children: From the perspective of an external rater by the Kiddie-SADS (K-SADS-PL; Delmo, Weiffenbach, Gabriel, Stadler &amp; Poustka, 2001; T1-T4), and from the perspective of the parents by the Child-Behavior-Checklist (CBCL; Achenbach, &amp; Rescorla, 2000; T1-4)\\n\\n2) Wellbeing of the children: From the perspective of the children by the KIDSCREEN-27 (Ravens-Sieberer et al., 2005, T1-T4)\\n\\n3) Soziodemographic information: From the perspective of the parents by a sociodemographic questionnaire (T1)\\n\\n4) Mental health of the parents: i) For the healthy parent by the Symptom-Checklist-90 SCL-90-R; (Franke, 2002; (self-report; T1), ii) For depressed parent from the perspective of an external rater by the Mini International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al., 1998; T1) and by the self-reported Brief Symptom Inventory (BSI; Franke, 2000; T1)\\n\\n5) Family functioning will be assessed by a rdiagnostician by the Global Assessment of Relational Functioning (GARF; Sa\\u00df et al., 2003)\\n\\n6) Stressful life events will be measured using the German version of the Child and Adolescent Survey of Experiences (CASE-C/P; Allen et al., 2012; T4)\\n\\n7) Children's coping with stress: From the perspective of the parents by the Responses to Stress Questionnaire (RSQ; Connor-Smith et al., 2000; T1-4). \\n\\n8) Cognitive schemas of the children: From the perspective of the children by the Dusseldorf Illustrated Schema Questionnaire for Children (DISC; Loose, Meyer &amp; Pietrowsky, 2018; T1-4).\\n\\n9) Parenting style: From the perspective of the children by the Erziehungsstil-Inventar (ESI; Krohne &amp; Pulsack, 1995; T1-4)\\n\\n10) The participants' mood and its changes will be tracked daily administrations of the German version of the Positive and Negative Affect Schedule (PANAS; Breyer &amp; Bluemke, 2016). The measurement will begin one week before the first session and will end one week after the last session with three-week breaks between session 6 and 7, and 7 and 8 (measurement burst design)\\n\\n11) Possible harms arising from the intervention will be monitored by using the Negative Effects Questionnaire (NEQ; Rozental et al., 2019; T2-4)\\n\\nNote: All parent questionnaires about the child will only be completed about the oldest child to reduce workload for the parents.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Other\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"GuG-Auf-online intervention (CHIMPS-MFT-CBT, intervention group); Eight sessions two hours each (session 1-6: weekly; session 7&amp;8: monthly); total duration of the intervention: 3-4 months\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"No intervention/treatment as usual (control group)\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00023184","content":"{\"resource_id\": \"DRKS00023184\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Performance\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"NASA TLX\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19; CPR\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Stress\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Impact of personal protective equipment (PPE) during a simulated cardiac arrest in times of the COVID-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Comparison of simulated resuscitation, once with and once without PPE with regard to performance (\\\"hands-on\\\" times), stress (NASA Task Load Index) and communication (comprehensibility). Intervention is the group with PPE compared to historical data from a comparable collective without PPE.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Corona CPR\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023184\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"07.10.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut f\\u00fcr Notfallmedizin\", \"role_email\": \"schwager@aim-arnsberg.de\", \"role_phone\": \"+49 2932 700 105\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Apothekerstrasse 27, 59755 Arnsberg, Germany\", \"role_affiliation_web_page\": \"https://www.aim-arnsberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Dietmar\", \"role_name_personal_family_name\": \"Wetzchewald\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"wetzchewald@aim-arnsberg.de\", \"role_phone\": \"+49 2932 700 105\", \"role_affiliation_name\": \"Arbeitsgemeinschaft Intensivmedizin (AIM) Arnsberg\", \"role_affiliation_address\": \"Apothekerstrasse 27, 59755 Arnsberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stephan\", \"role_name_personal_family_name\": \"Marsch\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"stephan.marsch@usb.ch\", \"role_phone\": \"+41 61 265 25 25\", \"role_affiliation_name\": \"Universit\\u00e4tsspital Basel\", \"role_affiliation_address\": \"Spitalstrasse 21, 4031 Basel, Switzerland\", \"role_affiliation_web_page\": \"https://www.usb.ch\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Timur\", \"role_name_personal_family_name\": \"Sellmann\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"t.sellmann@bethesda.de\", \"role_phone\": \"+49 203 6008 3100\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologie und Intensivmedizin\", \"role_affiliation_address\": \"Heerstrasse 219, 47053 Duisburg, Germany\", \"role_affiliation_web_page\": \"https://www.bethesda.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"simulated cardiac arrest\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"20.09.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 70, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Voluntary participation in medical training courses (intensive care medicine course, emergency medicine course)\", \"study_eligibility_exclusion_criteria\": \"Verbal rejection of the video recording after prior clarification, lack of written consent.\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Overall \\\"hands-on-time\\\"\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Influence of leadership (designated or free), overall performance (adherence to guidelines); level of perceived stress \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Evaluations may generally be passed on (as it is anonymous) - if wanted, please consult the principal investigator \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Resuscitation teams of 3 to 4 people. Before starting the resuscitation measures, the teams must put on full PPE, consisting of an FFP2 protective mask, glasses/ visor, gown and non-sterile disposable gloves.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Historical collective from the same setting / course format, comparable test subjects, same level of training, but WITHOUT PPE.\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00023301","content":"{\"resource_id\": \"DRKS00023301\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Iron Metabolism in Response to Infection\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Sepsis is a dysregulated host response to an infection, resulting in life-threatening organ dysfunction. In the course of the disease there are changes in the iron homeostasis, their dynamics and relevance at systemic and cellular level are not yet understood. Parameters of the iron metabolism could provide novel indicators for the severity of the disease and used for the monitoring of the course of sepsis. The aim of our clinical observational study in septic patients is to first characterise the changes in iron metabolism and their interaction with the function of the immune system during sepsis in more detail. In particular, it is intended to investigate the time- and course-of-disease-specific iron distribution during sepsis, markers of iron status and the polarization and activity of the immune cells, also with regard to the effect of allogeneic blood transfusions. The results will be correlated with clinical outcome parameters in order to develop approaches for to identify future therapies or to name risk constellations. This is a Hypothesis-generating query, the evaluation will be descriptive and, additionally, possible correlations will be analysed. \\nFor this purpose, 25 patients will be recruited in an exploratory design. Blood samples will be taken daily, starting on the day of inclusion (day 1) and on the four subsequent days (days 2-5). Patient blood will be analysed using molecular biological and immunological methods. The above mentioned parameters will be analysed in order to increase our understanding of the pathophysiological processes and interactions of iron metabolism and immune system during sepsis. The repeated measurements are use dto estimate the temporal dynamics of parameters. The data are not made available to the treating physicians in order not to influence therapeutical decisions.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SIMRI\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023301\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"17.11.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklilnikum Heidelberg Klinik f\\u00fcr An\\u00e4sthesiologie\", \"role_email\": \"dania.fischer@med.uni-heidelberg.de\", \"role_phone\": \"+49 6221 56-36166\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 420, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 672, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Dania\", \"role_name_personal_family_name\": \"Fischer\", \"role_name_personal_title\": \"Ms. PD Dr. med. habil.\", \"role_name_identifiers\": [], \"role_email\": \"dania.fischer@med.uni-heidelberg.de\", \"role_phone\": \"+49 6221 56-36166\", \"role_affiliation_name\": \"Universit\\u00e4tsklilnikum HeidelbergKlinik f\\u00fcr An\\u00e4sthesiologie\", \"role_affiliation_address\": \"Im Neuenheimer Feld 420, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other sepsis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"A41\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"26.04.2021\", \"study_end_date\": \"15.02.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients: Consent by the legal representative, age \\u2265 18 years, diagnosis \\\"sepsis\\\" according to sepsis 3 definition (sepsis-associated organ dysfunction indicated by a change of the Sequential Organ Failure Assessment (SOFA) score by 2 or more points compared to the previous day)\\nHealthy controls: consent, age \\u2265 18 years\", \"study_eligibility_exclusion_criteria\": \"Pregnancy, inclusion in an interventional study, infectious viral diseases (HBV, HCV, HIV, COVID-19) or unknown COVID-19 status, iatrogenic immunosuppression, diagnosis of \\\"sepsis\\\" &gt; 24h\", \"study_population\": \"\", \"study_target_sample_size\": 45, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Using molecular biological and immunological methods, parameters of the iron metabolism on cellular and humoral level as well as the function of the immune cells are examined on each of the daily blood samples\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory markers, occurrence of secondary infections, 30-day survival, length of stay in intensive care, basic demographic, therapeutic and clinical data \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Anonymized sample remains can be used for research purposes by other researchers of the Department of Anaesthesiology or the AG Professor Muckenthaler for a period of 10 years for topics related to iron metabolism or the immune system. Upon request, anonymized data would also be provided to the researchers for correlation purposes. New questions will be reviewed in advance by an ethics committee. \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"In 25 patients with sepsis, 30 ml blood is collected daily for a total of 5 days (day of diagnosis of \\\"sepsis\\\" = day 1). \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 healthy controls\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023393","content":"{\"resource_id\": \"DRKS00023393\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"social support\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"anxiety\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"self-efficacy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"depression\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"stress management\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"online survey\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Handling and coping with the corona pandemic (Covid-19) and its physical and psychological effects\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The health emergency of international proportions declared by the WHO in January 2020 due to the corona pandemic has also led to far-reaching government measures in Germany, which are intended to slow down the spread of the SARS CoV-2 virus in order to protect people's health and not overload the capacities of the German health system. Representative surveys indicate an increase in fears and concerns among the population associated with the pandemic. So far there is hardly any systematic scientific evidence on this. In the past, it has been shown that epidemics lead to a significantly increased stress level in the population and that the coping capacities of society as a whole correlate negatively with the epidemic-associated event frequency. In a recent report, the International Red Cross lists numerous fear reactions to a pandemic. These can be repressed and mutually reinforcing when dealing with infectious diseases. It is to be feared that as a result of the pandemic mental illnesses will be reactivated, exacerbate and their incidence will increase. Experts have published a number of recommendations for primary and secondary prevention of anxiety and stress in the general population. These are based on publications by the WHO on the COVID 19 pandemic, the United Nations Inter-Agency Standing Committee (IASC) and the International Red Cross. Against this background, the study aims to evaluate the health and psychological impact of the measures taken in the context of the corona pandemic to limit the spread of the corona virus. To this end, adults are repeatedly asked online how they are coping with the current corona pandemic, how they cope with it and what their health burdens are, in order to gain insights into helpful courses of action and, if necessary, to derive recommendations for future similar exceptional situations.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoPa\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023393\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.10.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1275-3792\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4t zu L\\u00fcbeck Institut f\\u00fcr Sozialmedizin und Epidemiologie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ratzeburger Allee 160, 23562 L\\u00fcbeck, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4t zu L\\u00fcbeck\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ratzeburger Allee 160, 23562 L\\u00fcbeck, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Elke\", \"role_name_personal_family_name\": \"Peters\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"elke.peters@uni-luebeck.de\", \"role_phone\": \"+49 451 500 51215\", \"role_affiliation_name\": \"Universit\\u00e4t zu L\\u00fcbeckInstitut f\\u00fcr Sozialmedizin und Epidemiologie\", \"role_affiliation_address\": \"Ratzeburger Allee 160, 23562 L\\u00fcbeck, Germany\", \"role_affiliation_web_page\": \"https://www.sozmed.uni-luebeck.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"mental diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"05.04.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 16, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Persons aged 16 and over\\nInformed consent to study \\nGerman language skills sufficient\", \"study_eligibility_exclusion_criteria\": \"Persons under 16 years of age\", \"study_population\": \"\", \"study_target_sample_size\": 5000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"- EORTc-QLQ30 (Question 29 - General health status)\\n- EORTc-QLQ30 (Question 30 Quality of life) \\n- Comorbidities\\n- Patient Health Questionnaire for Depression and Anxiety (PHQ-4) \\n- Stress and Coping Inventory (SCI) \\n\\nInterview dates:\\n1st survey in April 2020, \\n2nd survey in November 2020, \\nif necessary, further surveys depending on the pandemic\\n\\n\\nSurvey methodology:\\n1. online survey according to link distribution via social media\\n2. survey to e-mail addresses provided during the initial survey\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"- activities  to maintaining the well-being\\n- personal experience with quarantine/isolation\\n- possible Covid-19 disease\\n- Satisfaction with social restrictions\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"An anonymised survey data set can be requested after the study via the study officer.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Population sample is surveyed online several times (1st survey in April 2020, 2nd survey in November 2020, possibly further surveys depending on the pandemic events) using the following survey instruments:\\n- General self-efficacy short scale (ASKU) to record subjective competence expectations \\n- EORTc-QLQ30 (Question 29 - General health status)\\n- EORTc-QLQ30 (Question 30 Quality of life)\\n- List of comorbidities\\n- Patient Health Questionnaire for Depression and Anxiety (PHQ-4)\\n- Stress and Coping Inventory (SCI)\\n- Oslo-3 Social Support Scale (Oslo-3)\\n- Big Five Inventory (BIG 5)\\n- Sociodemographic\\nIn addition, questions are used that were developed on the basis of the WHO's recommendations on activities to maintain well-being in isolation and on distance. They refer to specific behavioural patterns in connection with the corona pandemic, personal experiences with quarantine/isolation, a possible Covid-19 disease and satisfaction with societal constraints.\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023507","content":"{\"resource_id\": \"DRKS00023507\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"SARS-CoV-2 Surveillance in childcare facilities\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Primary goal: \\nAssessment of the feasibility of regular SARS-CoV-2 testing in childcare facilities\\n\\nSecondary goals:\\nMeasuring turnaround times, determination of the acceptance of the children's sampling, determination of the time and personnel expenditure for the parents and the childcare facility staff as well as for the laboratory carrying out the testing (collection of samples, pooling, testing, evaluation, transfer of findings) \\n\\nAttendees: \\nChildren and staff of the selected childcare facility after giving their consent (of the legal guardians). \\n\\nMeasure: \\n(Self) collection of a saliva sample using a swab \\n\\nInclusion criteria: \\nMember or staff of one of the selected institutions, declaration of consent (of the legal guardian). \\nPrimary target variable: Feasibility of cost-effective and work-effective regular SARS-CoV-2 testing in childcare facilities \\n\\nSecondary outcomes: \\nQuantification of the time and personnel requirement for SARS-CoV-2 surveillance for parents, staff and the laboratory \\n\\nMonocentric: \\nInstitute for Virology, University Hospital Cologne\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SSC\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023507\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.11.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut f\\u00fcr Virologie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"F\\u00fcrst-P\\u00fcckler-Stra\\u00dfe 56, 50935 k\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Rolf\", \"role_name_personal_family_name\": \"Kaiser\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"rolf.kaiser@uk-koeln.de\", \"role_phone\": \"0221 478 85808\", \"role_affiliation_name\": \"Institut f\\u00fcr Virologie\", \"role_affiliation_address\": \"F\\u00fcrst-P\\u00fcckler-Stra\\u00dfe 56, 50935 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"http://virologie.uk-koeln.de/?pk_vid=96cd53bc3b656bb91606380485f43697\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Felix\", \"role_name_personal_family_name\": \"Dewald\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"felix.dewald@uk-koeln.de\", \"role_phone\": \"017672184672\", \"role_affiliation_name\": \"Virologie, Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"F\\u00fcrst-P\\u00fcckler-Strasse 56, 50935 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Felix\", \"role_name_personal_family_name\": \"Dewald\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"felix.dewald@uk-koeln.de\", \"role_phone\": \"017672184672\", \"role_affiliation_name\": \"Institut f\\u00fcr Virologie\", \"role_affiliation_address\": \"F\\u00fcrst-P\\u00fcckler-Stra\\u00dfe 56, 50935 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"29.11.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Staff or child in one of the childcare facility\\n- Informed consent (of the legal guardians, with sole custody, the legal guardian)\\n- Consent of the underaged\", \"study_eligibility_exclusion_criteria\": \"rejection of participation (by the legal Guardian(s))\", \"study_population\": \"\", \"study_target_sample_size\": 120, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Assessment of the feasibility of a periodical SARS-CoV-2 surveillance in childcare facilities (2 weeks, two times in one week).\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of the turnaround times, determination of the acceptance of the children's sampling, determination of the time and personnel expenditure for the parents and the day-care center staff as well as for the laboratory carrying out the testing (collection of samples, pooling, testing, evaluation, communication of test results)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"SARS-CoV-2 surveillance is performed in two childcare facilities for 2 weeks (two times in one week). For this purpose, the parents of the children will collect a saliva samples of their children with a regular swab. The swabs will be collected in the day care center and will be transported from there to laboratory. The samples will be tested by pool testing. After validation of the test results, the childcare facilities will be informed. In the case of a positive pool, the children in the positive pool can be tested individually.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023525","content":"{\"resource_id\": \"DRKS00023525\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"TEMPO - Telemedical psychiatry and psychotherapy for children and adolescents during the Covid-19 pandemic: feasibility, acceptance, satisfaction and pandemic-specific mental stress\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Due to the Covid-19 pandemic, the outpatient psychiatric and psychotherapeutic care of children and adolescents was considerably impaired, so that only emergency care in compliance with special hygiene rules was possible. The study is intended to examine to what extent the use of telemedical possibilities can maintain outpatient child and adolescent psychiatric and child and adolescent psychotherapeutic care under epidemic/pandemic conditions. \\nSince April 1, 2019, psychotherapists are basically entitled to perform treatment via video as a service of the statutory health insurance. This service was introduced with the Nursing Staff Strengthening Act for psychotherapists. Since October 1, 2019, psychotherapists can also be billed for video treatment. The Federal Association of Statutory Health Insurance Physicians and the Central Association of Statutory Health Insurance Funds have now made the necessary adjustments to the Uniform Assessment Scale. This allows both treatments that are predominantly conducted by distance therapy and various models of interlinked psychotherapy (blended psychotherapy) to be implemented, whereby such models have been tested in a few studies with adult patients in Germany (Baumeister et al., 2018). With the Covid-19 pandemic, the possibilities for video-assisted diagnosis and therapy in child and adolescent psychiatry as well as in child and adolescent psychotherapy have been significantly eased in both legal and billing terms.\\nAlthough a number of studies on the effectiveness of tele-mental health interventions (distance psychotherapy) in children and adolescents with mental disorders are now available from English-speaking countries and have been summarized in several systematic reviews (Myers et al., 2017, Nelson &amp; Patton, 2016), the significance of these studies is limited and they cannot be transferred to the German health care system. These mostly small studies show that distance psychotherapy for children and adolescents with mental disorders can be successfully implemented in various organizational settings (e.g. Duncan, Velasquez &amp; Nelson, 2014), that psychiatric and psychodiagnostic examinations can be reliably performed through video conferencing with patients and their caregivers (e.g. Szefte et al., 2012) and that distance psychotherapy sessions are well accepted by patients and their caregivers (e.g. Szefte et al., 2012, Myers, Va-lentine &amp; Melzer, 2007 ). Studies with adult patients* also show (Goldstein &amp; Glueck, 2016) that, compared to personal therapy sessions, similarly good therapeutic relationships can be developed between adults and therapists*. However, no meaningful results are yet available internationally on therapeutic relationships in the treatment of children. However, individual studies from the Anglo-American language area show a high level of satisfaction with distance psychotherapy among children and adolescents (e.g. Comer et al., 2014, Myers et al., 2017, Myers, Valentine &amp; Melzer, 2008, Xie et al., 2013) and also among their caregivers (e.g. Myers, Valentine &amp; Melzer, 2008).\\nTo our knowledge, there are almost no studies available in the German-speaking countries - with the exception of the work of our own working groups - on the exclusive use of distance psychotherapy or interlinked psychotherapy, as shown by reviews of German-speaking authors (e.g. Domhardt, Steubl &amp; Baumeister, 2020). Several studies were conducted by our own working group that prove the effectiveness of telephone-assisted self-help for parents of children with ADHD (e.g. Dose et al., 2017, D\\u00f6pfner et al., 2018), which, however, does not represent distance therapy. In addition, the feasibility and effectiveness of video-supported online coaching as an interlocking psychotherapy for children and adolescents with chronic tic disorders and for children and adolescents with obsessive-compulsive disorders could be proven in individual case analyses (Viefhaus et al., 2020, Adam et al., 2020).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"TEMPO\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023525\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"10.11.2020\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1260-8886\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Charit\\u00e9 - Universit\\u00e4tsmedizin Berlin, Campus Virchow KlinikumKlinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Juge\", \"role_email\": \"christoph.correll@charite.de\", \"role_phone\": \"030 450 566 201 \", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Augustenburger Platz 1, 13353 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.charite.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Stephan\", \"role_name_personal_family_name\": \"Bender\", \"role_name_personal_title\": \"Mr. Univ.-Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"stephan.bender@uk-koeln.de\", \"role_phone\": \"02214784370\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Robert-Koch-Str. 10, 50931 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stephan\", \"role_name_personal_family_name\": \"Bender\", \"role_name_personal_title\": \"Mr. Univ.-Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"stephan.bender@uk-koeln.de\", \"role_phone\": \"02214784370\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Robert-Koch-Str. 10, 50931 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Carolina\", \"role_name_personal_family_name\": \"Habbel\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"carolina.habbel@uk-koeln.de\", \"role_phone\": \"022147876766\", \"role_affiliation_name\": \"Ausbildungsinstitut f\\u00fcr Kinder- und Jugendlichenpsychotherapie an der Uniklinik K\\u00f6ln (AKiP K\\u00f6ln)\", \"role_affiliation_address\": \"Pohligstr. 9, 50969 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Manfred\", \"role_name_personal_family_name\": \"D\\u00f6pfner\", \"role_name_personal_title\": \"Mr. Univ.-Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"manfred.doepfner@uk-koeln.de\", \"role_phone\": \"022147876823\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Robert-Koch-Str. 10, 50931 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Manfred\", \"role_name_personal_family_name\": \"D\\u00f6pfner\", \"role_name_personal_title\": \"Mr. Univ.-Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"manfred.doepfner@uk-koeln.de\", \"role_phone\": \"022147876823\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Robert-Koch-Str. 10, 50931 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F10-F98\"}, {\"study_conditions\": \"Depressive episode\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F32\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.12.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 4, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 18, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"A total sample of 300 children and young people aged 4 to 18 years is planned. Recruitment of the test subjects is to take place in the context of initial patient registrations and / or follow-up visits (or ongoing treatment) as part of routine care through the following outpatient clinics: Ausbildungsinstitut f\\u00fcr Kinder- und Jugendlichenpsycho-therapie an der Uniklinik K\\u00f6ln (AKiP K\\u00f6ln) (n = 75), Klinik und Poliklinik f\\u00fcr Psychiatrie, Psychosoma-tik und Psychotherapie des Kinder- und Jugendalters an der Uniklinik K\\u00f6ln (n = 75) and three further outpatient clinics with n = 50 each. Currently, the child and adolescent psychiatric clinics in Aachen, Essen, G\\u00f6ttingen and Berlin are being contacted. Patient recruitment is planned until approximately 50 patients per center are reached.\", \"study_eligibility_exclusion_criteria\": \"The indication for a telemedical offer is the subject of the study. Contraindications will include: acute emergency situation (e.g. acute self-/external danger, acute psychotic symptoms), mental retardation, lack of German language skills, acute physical symptoms that directly require somatic diagnostics or treatment.\\n\\nThe consent of the patients* and parents for participation in the study (possibly telemedical care) is also a subject of the study.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary objective is the degree to which objectives are achieved in relation to the individual care objectives in each session. This is assessed in a newly developed procedure, the Supply Target Achievement List (VeZiel)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In addition, the following should also be collected\\n\\n- Indication: Percentage of patients for whom an initial indication for a telemedical offer can be made according to the expert's assessment.\\n- Acceptance: Number of patients who accept a telemedical care offer.\\n- Satisfaction is judged on the basis a specific satisfaction questionnaire for the telemedical supply offer and/or the supply offer with direct contact of patient inside (starting from 11 J.), parents and servicers inside. \\n- Side effects: Undesirable effects of the accomplished telemedical intervention are judged and seized on the part of the outpatient care Provider.\\n- Extent of pandemic-specific burden: On the basis of a specific questionnaire on corona burden, the parental judgement and self judgement from the age of 11 years are used to determine the extent to which pandemic-specific burdens are present in the patient and his/her family. \\n- Emotional and behavioral problems of the patient are recorded by means of questionnaires in the parental judgment and self-judgment from 11 years of age.  \\n- The patient's psychosocial functional level is recorded in the clinical judgment, parent's judgment and self-judgment from the age of 11. \\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Data is shared only in aggregated form\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"In this multi-center study, consecutively enrolled patients and / or how-presented or further treated patients are evaluated by expert groups with regard to whether an online first contact or an online session is professionally / ethically justifiable (see documentation Contraindication video session). If there is no contraindication, patients and guardians are called and their consent for (at least) one online session is requested and obtained. If the patient's guardian refuses, the reasons for the refusal are documented (see the video session refusal documentation). Patients or guardians who consent to online sessions (group 1: acceptance of telemedicine) and also patients and guardians who do not consent (group 2: rejection of telemedicine) are informed about the study and their willingness to participate in the study is queried. The group assignment for study participation is accordingly dependent on acceptance or rejection of the video consultation hour. Group 2: Rejection of telemedicine should serve as a benchmarking. If the study consent is available, the first contact or the re-submission is carried out online or as a face-to-face appointment.  At the end the investigator, if indicated, agrees on the follow-up contact (in the acceptance group online if possible, if not possible as face-to-face direct contact). After each session, the investigator assesses whether the corresponding (previously defined) content goals have been achieved (see Supply Target Achievement List [VeZiel]) and, in the case of online contacts, how well the onli-ne consultation hour was technically feasible and possible undesirable effects (see Documentation of side effects). In addition, the investigator documents basic sociodemographic data of the patient (see summary of sociodemographic basic documentation (D\\u00f6pfner &amp; Steinhausen, 2012)) and assesses the patient's functional level (see global assessment of psychosocial adaptation). Additionally, the satisfaction of the examiner is coded (see satisfaction of the examiner). Guardians and patients aged 11 years and older also assess their satisfaction with the session (see Parent &amp; Patient Satisfaction) and other questionnaires on symptoms (see Child Behavior Checklist/6-18R [CBCL; D\\u00f6pfner et al., 2014] &amp; Youth Self-Report/11-18R [YSR; D\\u00f6pfner et al, 2014]), functional level (see Third-party and self-assessment questionnaire for screening of mental disorders [FBB-/SBB-SCREEN; D\\u00f6pfner &amp; G\\u00f6rtz-Dorten, 2017]) and pandemic-specific stress (see Corona stress questionnaire - parents [CBB-E; D\\u00f6pfner &amp; G\\u00f6rtz-Dorten, unpublished] &amp; Corona stress questionnaire - children and adolescents [CBB-KJ; D\\u00f6pfner &amp; G\\u00f6rtz-Dorten, unpublished]). Follow-up contacts within two months will be conducted and evaluated according to a comparable pattern. \\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Group 2: Rejection\\nGroup 2: Rejection Telemedicine is intended to serve as a benchmark. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023717","content":"{\"resource_id\": \"DRKS00023717\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Covid-19 in elite sports - a multicentre cohort study\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"An infection with SARS-CoV-2 often goes along even without or mild symptoms but also could have a serious outcome. Athletes, till now, do not belong to one of the risk groups. This in turns does not state, they could not be infected. Especially secondary diseases after an infection with SARS-CoV-2 with regard to sports performance in athletes could have a serious impact in terms of performance. Before return-to-sports, athletes should undergo medical interventions after an infection with the virus. As mentioned, the pandemic brings along several challenges for elite athletes and especially for the maintenance. To cope with the current situation and problems, a multicenter approach could lead in the right direction. Incidence and type of health risks but also immunity are major questions which should be addressed. To deal with the problems and questions of this pandemic, our project aims to answer these following questions:\\n\\n- Are there cardial oder pulmonary abnormalities within elite athletes with positive serostatus with regard to SARS-CoV-2?\\n- Are there any organic or functional secondary outcomes after SARS-CoV-2 infection especially with regard to performance?\\n- Are there long term effects resulting from Covid-19 secondary damage?\\n- Impacts of the Covid-19-Pandemic?\\n- What about the rate of infection?\\n- Estimation for the risk of a hard course\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023717\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesinstitut f\\u00fcr Sportwissenschaft\", \"role_email\": \"\", \"role_phone\": \"0228 996400\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Graurheindorfer Stra\\u00dfe, Haus 198/7, 53117 Bonn, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Bundesinstitut f\\u00fcr Sportwissenschaft BISp\", \"role_email\": \"\", \"role_phone\": \"0228 996400\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Graurheindorfer Stra\\u00dfe, Haus 198/7, 53117 Bonn, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Manuel\", \"role_name_personal_family_name\": \"Widmann\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"manuel.widmann@med.uni-tuebingen.de\", \"role_phone\": \"07071 - 29 - 88378\", \"role_affiliation_name\": \"Sportmedizin\", \"role_affiliation_address\": \"Hoppe-Seyler Str. 6, 72076 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Manuel\", \"role_name_personal_family_name\": \"Widmann\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"manuel.widmann@med.uni-tuebingen.de\", \"role_phone\": \"07071 29 88378\", \"role_affiliation_name\": \"Innere Medizin V Abteilung Sportmedizin T\\u00fcbingen\", \"role_affiliation_address\": \"Hoppe-Seyler Str. 6, 72076 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"06.10.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 12, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 14, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Cohort 1: \\n1: age \\u2265 18 years \\n2: underwent Covid-19 infection (positive PCR and/or positive IgG+typical clinics)\\n3: frequent physical activity with at least 3 sessions per week with a minimum of 20 METS\\n\\nKohort 2: \\nAge \\u2265 14 \\nElite athletes belonging to a national squad\\nEither check up for annual main investigation or other routine diagnostics in the department \\n\", \"study_eligibility_exclusion_criteria\": \"1)Acute infection with SARS-Cov-2 or positive PCR\\n2) German skills do not match to fill out the questionnaire \\n3) Rejection of blood draw during routine diagnostics\\n4) acute infection, which prevents an inclusion to the sutdy \", \"study_population\": \"\", \"study_target_sample_size\": 3560, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"-\\tAre there cardial oder pulmonary abnormalities within elite athletes with positive serostatus with regard to SARS-CoV-2?\\n-\\tAre there any organic or functional secondary outcomes after SARS-CoV-2 infection especially with regard to performance?\\n-\\tAre there long term effects resulting from Covid-19 secondary damage?\\n-\\tImpacts of the Covid-19-Pandemic?\\n-\\tWhat about the rate of infection?\\n-\\tEstimation for the risk of a hard course\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"-With regard to covid-19 associated secondary diseases: are there predictors like physical fitness, type of sports or training schedule? \\n\\n-Is it possible to evaluate the risk for a serious outcome after an infection with SARS-CoV-2 with preliminary data when one gets infected over time? \\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"national squad members once a year have to do medical sports test in order to get their sports approval. These investigations comprise several testings such as case history, anthropometry, rest as well as exercise ECG, blood pressure measurements, ergometry, spirometry.\\n\\nBlood sampling is done as well as a SARS-CoV-2 antibody testing. \\n\\n\\n\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"post-covid patients \\n\\n \\nFor participants belonging to cohort 1, a separate reamp test including a sprioergometry is don on top to the testings also performed in cohort 2. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023741","content":"{\"resource_id\": \"DRKS00023741\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"self-esteem\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"physical activity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"belonging\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"drug adherence\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Loneliness\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"coping\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"interpersonal trust\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"life satisfaction\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"quality of sleep\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Capturing the subjective feeling of loneliness in patients with one or more mental illnesses\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"With the help of this prospective systematic survey, the subjective feeling of loneliness in patients with one or more psychiatric illnesses, as well as extrinsic and intrinsic factors influencing them, should be recorded using a web-based questionnaire. Intrinsic influencing factors include self-esteem, satisfaction with life, a sense of belonging and interpersonal trust. The extrinsic influencing factors that are considered are sleep quality, physical activity and social support. 300 patients who are undergoing psychiatric treatment in the Clinic and Polyclinic for Psychiatry and Psychotherapy of the Leipzig University Hospital are to be included after detailed information and consent. In addition, it should be checked whether and to what extent drug adherence is present in the above-mentioned patient sample.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"EinsamKrank\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023741\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"06.04.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Leipzig\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 18, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-leipzig.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Leipzig\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 18, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-leipzig.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christine\", \"role_name_personal_family_name\": \"Rummel-Kluge\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Christine.Rummel-Kluge@medizin.uni-leipzig.de\", \"role_phone\": \"0341/9724500\", \"role_affiliation_name\": \"Klinik und Poliklinik f\\u00fcr Psychiatrie und Psychotherapie Universit\\u00e4tsklinikum Leipzig\", \"role_affiliation_address\": \"Semmelweisstra\\u00dfe 10, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"psychiatric illness\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"17.05.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 85, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Ability to give consent, diagnosis of one or more psychiatric illnesses, adequate knowledge of German, adequate vision and reading skills and no acute suicidality.\", \"study_eligibility_exclusion_criteria\": \"People under 18 years of age or over 85 years of age, acute suicidality and adults unable to give their consent\", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Recording the emotional experience of loneliness in patients with mental illness (HES Hamburger Einsamkeitsskala as an adaptation of the Rev. UCLA Loneliness Scale, De Jong Gierveld Loneliness Scale, UCLA 3-Item Loneliness Scale/Variante SOEP)\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Recording the emotional experience of loneliness in patients with mental illnesses under pandemic conditions, recording intrinsic and extrinsic influencing factors (SWLS, Need to belong-Scale, Rosenberg-Self-Esteem-Scale, KUSIV3, Big Five 2 \\u2013 scale \\u201ccompatibility\\u201d, PSQI, IPAQ, Perceived Stress Scale/PSS-4, Brief Resilience Scale/BRS), as well as recording drug adherence and deviations (MARS, DAI) from the therapeutic recommendation.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be made available on request after the project has been completed.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"With the help of this prospective systematic survey, the subjective feeling of loneliness in patients with one or more psychiatric illnesses, as well as extrinsic and intrinsic factors influencing them, should be recorded using a web-based questionnaire. 300 patients who are undergoing psychiatric treatment in the Clinic and Polyclinic for Psychiatry and Psychotherapy of the Leipzig University Hospital are to be included after detailed information and consent.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023877","content":"{\"resource_id\": \"DRKS00023877\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"healthy volunteers\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"blood drawing\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"recovered patients\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"healthy subjects\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Evaluation of SARS-CoV2-specific serum parameters in blood samples of SARS-CoV2-seronegative healthy volunteers, hospitalized SARS-CoV2-patients with acute disease and recovered SARS-CoV2-patients with asymptomatic/mild/severe disease.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place.\\nThe aim of this trial is to evaluate SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of SARS-CoV-2-seronegative subjects, patients with acute COVID-19 disease as well as of recovered SARS-CoV-2-patients with asymptomatic/mild/severe disease.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVIAS - SARS-CoV-2-Induced Alterations in Serum Parameters\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023877\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.12.2020\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_email\": \"michaela.arndt@hditx.de\", \"role_phone\": \"+49 6221 3919 11\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_email\": \"clinical_research@hditx.de\", \"role_phone\": \"06221 391911\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rudolf\", \"role_name_personal_family_name\": \"\\u00dcbelhart\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Rudolf.Uebelhart@hditx.de\", \"role_phone\": \"06221 3919307\", \"role_affiliation_name\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Contact person\", \"role_name_organisational\": \"Klinisch-Pharmakologisches Studienzentrum\", \"role_email\": \"Klips@med.uni-heidelberg.de\", \"role_phone\": \"+49 6221 56 38931\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"15.04.2021\", \"study_end_date\": \"21.12.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1. Signed informed consent.\\n2. At least one positive SARS-CoV-2 swab/PCR-test (groups b-e).\\n3. Availability of data (e.g. discharge letters) to assign the patient in one of the groups (asymptomatic/mild/severe) and to document the course of the COVID-19-disease.\\n4. Subject/patient is at least 18 years old and able to give informed consent.\", \"study_eligibility_exclusion_criteria\": \"1. Every disease or status that does not allow the blood drawing according to the assessment of the consenting physician.\", \"study_population\": \"\", \"study_target_sample_size\": 150, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place.\\nThe aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (SARS-CoV-2-seronegative subjects, patients with acute COVID-19 disease as well as of recovered SARS-CoV-2-patients with asymptomatic/mild/severe disease).\\nThis trial is designed to establish assays that can be used in the future to clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"n.a.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be stored in a database. Access can be granted or data can be exchanged for specific projects upon request.\\nThe patients will be informed in the ICF about this.\\n\\nFurthermore, one vial of serum and plasma will be handed over to the \\\"fightCOVID\\\" initiative of the university hospital in Heidelberg which is a colaboration of scientists of the university hospital Heidelberg and the German cancer research center (DKFZ) with the aim to improve/accelerate diagnosis and therapy of COVID-19.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Single blood drawing\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00023904","content":"{\"resource_id\": \"DRKS00023904\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Comparison of different source material for the detection of SARS-CoV-2 (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"A mild and self-prepared sample procurement for SARS-CoV-2 detection will be compared to professional naso-pharyngeal swabs with respect to the sensitivity and specificity of RT-PCR-based viral RNA detection from these parallel samples. Ideally the mild, self generated throat wash sample could provide a safe procedure that does not expose medical personal during sampling.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023904\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.01.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4t Konstanz Fachbereich Biologie\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Universit\\u00e4tsstr. 10, 78457 Konstanz , Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Labor Dr. Brunner\", \"role_email\": \"j.zander@labor-brunner.de\", \"role_phone\": \"07531-817326\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Luisenstr. 7e, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Christof\", \"role_name_personal_family_name\": \"Hauck\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"christof.hauck@uni-konstanz.de\", \"role_phone\": \"07531-882286\", \"role_affiliation_name\": \"Universit\\u00e4t Konstanz Fachbereich Biologie\", \"role_affiliation_address\": \"Universit\\u00e4tsstr. 10, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christof\", \"role_name_personal_family_name\": \"Hauck\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"christof.hauck@uni-konstanz.de\", \"role_phone\": \"07531-882286\", \"role_affiliation_name\": \"Universit\\u00e4t Konstanz Fachbereich Biologie\", \"role_affiliation_address\": \"Universit\\u00e4tsstra\\u00dfe 10, 78457 Konstanz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Johannes\", \"role_name_personal_family_name\": \"Zander\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"j.zander@labor-brunner.de\", \"role_phone\": \"07531-817326\", \"role_affiliation_name\": \"Labor Dr. Brunner\", \"role_affiliation_address\": \"Luisenstr. 7e, 78464 Konstanz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.10.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Medical indication for SARS-CoV-2 testing by naso-pharyngeal sampling\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Sensitivity and specificity of detection of SARS-CoV2 RNA in parallel samples (throat wash, self-prepared naso-pharyngeal swab, professional naso-pharyngeal swab).\\n\\nThe RT-PCR will be performed within max. 6h after sample procurement.\\n \\nThe comparison will be based on Cq values of the RT-PCR analysis\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Naso-pharyngeal swab and throat wash (taken by the person him/herself) and nasopharyngeal swab taken by a healthcare professional\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00023971","content":"{\"resource_id\": \"DRKS00023971\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"cholinergic anti-inflammatory pathway\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"breathing exercise\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"autonomic nervous system\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vagal stimulation\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Breath-assisted stimulation of the anti-inflammatory reflex of the vagus nerve in covid-19 disease: a randomized-controlled trial\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"A major problem in the context of the pandemic with SARS-CoV-2 continues to be severe courses of disease that result not only directly from the virus-induced cellular damage but also from the sometimes vigorous immune response (\\\"cytokine storm\\\"). An intervention option that mitigates the immune response without compromising the defense against the virus is urgently needed.\\nThe anti-inflammatory reflex mediated via the vagus nerve may provide such a pathway (Pavlov VA, Tracey KJ. Neural regulation of immunity: molecular mechanisms and clinical translation. Nat Neurosci 2017; 20: 156-166 &amp; Leitzke M, Stefanovic D, Meyer J-J, et al. Autonomic balance determines the severity of COVID-19 courses. Bioelectron Med 2020; 6). This can be stimulated by a simple breathing technique. Whether this actually results in a clinically relevant change in inflammatory levels in the context of acute viral infection has not yet been investigated. The aim of our study is to investigate this question:\\nCan a breathing technique that increases vagotone decrease inflammatory levels in patients with SARS-CoV-2 infection compared to a control group of patients who also have SARS-CoV-2 infection but do not perform the breathing technique?\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"BEAT-COVID (Breathing against COVID)\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00023971\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"02.02.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1263-8658\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://medrxiv.org/cgi/content/short/2021.12.03.21266946v1\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Psychosomatische Medizin und Psychotherapie, Universit\\u00e4tsklinikum Ulm\", \"role_email\": \"Harald.guendel@uniklinik-ulm.de\", \"role_phone\": \"0731/50061801\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Albert-Einstein-Allee 23, 89081 Ulm, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinik-ulm.de/struktur/kliniken/psychosomatische-medizin-und-psychotherapie.html\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Elisabeth\", \"role_name_personal_family_name\": \"Balint\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"elisabeth.balint@uniklinik-ulm.de\", \"role_phone\": \"0731/50061904\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychosomatische Medizin und Psychotherapie, Uniklinik Ulm\", \"role_affiliation_address\": \"Albert-Einstein-Allee 23, 89081 Ulm, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinik-ulm.de/struktur/kliniken/psychosomatische-medizin-und-psychotherapie.html\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Marc N.\", \"role_name_personal_family_name\": \"Jarczok\", \"role_name_personal_title\": \"Mr. Dr. sc. hum.\", \"role_name_identifiers\": [], \"role_email\": \"marc.jarczok@uni-ulm.de\", \"role_phone\": \"0731/50061810\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychosomatische Medizin und Psychotherapie, Uniklinik Ulm\", \"role_affiliation_address\": \"Albert-Einstein-Allee 23, 89081 Ulm, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinik-ulm.de/struktur/kliniken/psychosomatische-medizin-und-psychotherapie.html\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Elisabeth\", \"role_name_personal_family_name\": \"Balint\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"elisabeth.balint@uni-ulm.de\", \"role_phone\": \"+49 (0)731 500-61904\", \"role_affiliation_name\": \"Klinik f\\u00fcr Psychosomatische Medizin und Psychotherapie, Uniklinikum Ulm\", \"role_affiliation_address\": \"Albert-Einstein-Allee 23, 89081 Ulm, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"Inpatients, hospitalized due to infection with SARS-CoV-2  \", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"21.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- SARS-CoV-2-infected patients hospitalized in \\\"normal wards\\\" (Not ICU) with a maximum moderate degree of disease according to RKI/WHO definition (see first exclusion criterion)\\n- Age min. 18 years\\n- Able to give informed consent at the time of study inclusion \", \"study_eligibility_exclusion_criteria\": \"- severe covid pneumonia with fever and bilateral lung infiltrates and respiratory rate&gt;30/min or SpO2&lt;90% on room air (adapted from RKI/WHO)\\n- Condition after surgery/trauma/acute event (stroke, myocardial infarction, acute covid-independent infection) in the last 4 weeks\\n- Known pregnancy \\n- Patients with pre-existing pulmonary disease who were on oxygen prior to infection (e.g., due to pulmonary fibrosis, COPD)\\n- limited ability to give consent (e.g. due to dementia)\\n- limited ability to perform breathing maneuvers independently (e.g. high frailty)\\n- limited ability to provide self-care (care level 2 or 3)\\n- lack of language skills\\n- seizures in the medical history\", \"study_population\": \"\", \"study_target_sample_size\": 60, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Course of inflammatory parameter  IL-6 at admission (day 1) and bi-daily until discharge (average length of stay 10 days, i.e. 5 measurements on average)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"1.) Course of other inflammatory parameters leukocytes, CRP, TNF-alpha (Bi-daily)\\n2) subjective dyspnea on admission (day 1) and for two days until discharge (5 measurements), day 30 after discharge\\n3.) Onset of ventilator requirement and intensive care requirement within 30 days of first hospitalization and death by 30 days after discharge\\n4.) Length of stay in normal ward \\n5.) Course of SDNN (recorded on admission and then bi-daily)\\n6.) Outpatient course (query of Covid-19-associated symptoms such as fatigue 30 days after discharge)\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"At the end of the primary evaluation, the data will be anonymized via the OPARU service of the University of Ulm and/or attached to the primary publication.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Intervention:\\nBreathing exercise to stimulate vagal activity to stimulate the cholinergic anti-inflammatory reflex.\\nAim: 3x20min daily with 6 breaths per minute and an inhale to exhale ratio of 4:6.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control group: Treatment as Usual\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024028","content":"{\"resource_id\": \"DRKS00024028\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Mouthwash\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Gargle\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antiseptic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Antiseptic gargle in COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This prospective, randomised trial examines if antiseptic gargling reduces viral load, infectivity and/or illness duration/severity. Stratified by age (&lt; 60 years and \\u2265 60 years), randomization takes place to 2 arms (see below). Every two to three days oropharyngeal sample are taken and tested for SARS-CoV-2.  In those who gargle, the sample is taken at least 3 hours after gargling. Also oxygen saturation is measured by pulse oximetry in every visit. \\n\\nThe following data is collected systematically:\\nAge, sex, height, body weight, comorbidities, vaccination status, date of potential infection,  start of symptoms, duration of symptoms, type of symptomes, duration of isolation, number of infected individuals by subject.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024028\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"11.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin Rostock\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ernst-Heydemann-Str. 6, 18057 Rostock, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin Rostock\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ernst-Heydemann-Str. 6, 18057 Rostock, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Emil\", \"role_name_personal_family_name\": \"Reisinger\", \"role_name_personal_title\": \"Mr. Prof. Dr. med. univ.\", \"role_name_identifiers\": [], \"role_email\": \"tropen@med.uni-rostock.de\", \"role_phone\": \"0381-494 7514\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin Rostock\", \"role_affiliation_address\": \"Ernst-Heydemann-Str. 6, 18057 Rostock, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Carlos\", \"role_name_personal_family_name\": \"Fritzsche\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"carlos.fritzsche@med.uni-rostock.de\", \"role_phone\": \"0381-494 7514\", \"role_affiliation_name\": \"Abteilung f\\u00fcr Tropenmedizin und Infektionskrankheiten Zentrum f\\u00fcr Innere Medizin, Universit\\u00e4tsmedizin Rostock\", \"role_affiliation_address\": \"Ernst-Heydemann-Str. 6, 18057 Rostock, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"24.01.2021\", \"study_end_date\": \"09.04.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 110, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Hospital admission at University Hospital Rostock and positive SARS-CoV-2 PCR (specimen from oropharyngeal swab), consent to participate\", \"study_eligibility_exclusion_criteria\": \"Pregnancy, past or current alcohol dependence, intolerance of chlorhexidine\", \"study_population\": \"\", \"study_target_sample_size\": 60, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Time from initial positive SARS-CoV-2 PCR (from nasopharyngeal swab) until first of two negative specimen (specimens are taken every 2-3 days).\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Course of oxygen saturation (pulse oximetry), oxygen flow through nasal cannula, invasive or non-invasive ventilation, admission to intensive care unit, time until symptom-free, death, known secondary infections by study participant\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"No intervention (standard of care)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Gargling 3 times daily for 60 seconds each with chlorhexidine/ethanol solution\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024044","content":"{\"resource_id\": \"DRKS00024044\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19-Pandemic and Mandatory Face Masks - Acute Effects of Different Face Mask Types on Energy Metabolism, Oxygen- and Carbon Dioxide Kinetics\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Background: This project evaluates effects of face pieces/masks on metabolism and breathing. Background of this study is the ongoing need of mandatory face masks in public during the COVID-19 pandemic. Our design compares the influence of Community masks, surgical face masks, standardized Filtering Face Piece (FFP) 2 and 3 types. Healthy subjects will wear the masks under resting condition and during moderate physical work on a cycling ergometer. Blood gases, glucose, lactate and spiroergometric parameters will be assessed. Additionally we analyze subjective parameters for well-being and cognitive performance. The study produces evidence on potential detrimental effects of face mask wearing during occupational and leisure activities. \\nAim:The projects has two primary goals: 1) Establishing a testing procedure for the interaction of face piece wearing and aerobic energy metabolism and breathing. 2) Analyzing the impact of different face mask types (Community masks, surgical masks, FFP2, FFP3) on cardiorespiratory and metabolic adaptations during physical activity. Hereby information regarding the influence of face masks during leisure time and sporting activities and in occupational settings can be gathered. Procedures: Four different face mask types are compared to a control intervention without wearing a face mask in a randomized controlled crossover intervention study. During each intervention trial participants cycle on an ergometer for 20 minutes with moderate intensity. Thus all participants cycle five times, one time with no face mask and one time with each mask type. Pre and post exercise data collection includes blood gases (pO2 and pCO2), glucose and lactate out of 100-150ul capillary blood (2-3 drops). Furthermore cognitive performance (Stropp Test for Interference Control) and subjective well-being well be assessed. During interventions spiroergometric data will be assessed for half of the participants (randomized). Participants: Healthy persons of all sexes with an age between 18 and 65 years. Hypotheses: 1. Are there differences in spiroergometric data (O2 uptake, CO2 exhalation, breathing frequency) during exercise testing dependent on the face masks type?  2. Are there differences in blood gas parameters (pO2, pCO2, glucose, lactate, pH) after exercise dependent on the face mask type? 3. Are there differences in well being and cognitive performance dependent on the face mask type?\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024044\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"10.08.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Berufsgenossenschaft f\\u00fcr Gesundheitsdienst und Wohlfahrtspflege\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Pappelallee 33/35/37, 22089 Hamburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Goethe Universit\\u00e4t, Institut f\\u00fcr Arbeitsmedizin, Sozialmedizin und Umweltmedizin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor Stern Kai 7 / Haus 9b, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tobias\", \"role_name_personal_family_name\": \"Engeroff\", \"role_name_personal_title\": \"Mr. Dr. med. Dr. phil.\", \"role_name_identifiers\": [], \"role_email\": \"engeroff@sport.uni-frankfurt.de\", \"role_phone\": \"06963013895\", \"role_affiliation_name\": \"Goethe Universit\\u00e4t, Institut f\\u00fcr Arbeitsmedizin, Sozialmedizin und Umweltmedizin\", \"role_affiliation_address\": \"Theodor Stern Kai 7 / Haus 9b, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Crossover\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Negative effects of Face Pieces/Masks on energy-metabolism during physical activities\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"05.08.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 65, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"-Voluntary participation, informed consent\\n-Participants are legally responsible and understand details and consequences of the examination and intervention\", \"study_eligibility_exclusion_criteria\": \"- Medication or drug use with significant impact on physical or cognitive performance\\n- Acute or chronic illnesses which lead to significant limitations in life quality or physical and psychological performance (cardiopulmonary or renal dysfunction, neurologic or psychiatric diseases treated with medication, physical or psychological degenerative diseases)\", \"study_population\": \"\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Capillary blood sampling for blood gas (pO2, pCO2). Comparison of pre- to post intervention values between different face pieces/masks\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Capillary blood sampling for glucose and lactate. Comparison of pre- to post intervention values between different face pieces/masks and control. \\nSpiroergometric assessment for O2 uptake and CO2 exhalation. Comparison of mean values during interventions between different face pieces/masks and control.\\nAssessment of subjective wellbeing (Feeling Scale) and cognitive performance (Stropp Interference Test). Comparison of pre- to post intervention values between different face pieces/masks.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 minute moderate intensity cycle-ergometer training with no mask (control intervention)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 minute moderate intensity cycle-ergometer training with community/textile mask\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 minute moderate intensity cycle-ergometer training with surgical face mask\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 minute moderate intensity cycle-ergometer training with Filtering Face Piece/Mask FFP2\"}, {\"study_arm_group_label\": \"Arm 5\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"20 minute moderate intensity cycle-ergometer training with Filtering Face Piece/Mask FFP3\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024184","content":"{\"resource_id\": \"DRKS00024184\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"hyposmia during childhood\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hyposmia in case of sinunasal obstraction\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"development of a screening odor-identification-test\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"U-Sniff-Test\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hyposmia after Covid-19 infection\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Hyposmia during childhood - differences between Covid-19 infection, sinunasal obstraction and normosmia regarding olfactory performance; Development of a screening test for hyposmia in children.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Hyposmia and the sources of hyposmia during childhood is a barely examined symptom. According to the prevalence of odor disfuction in childhood, there can be found no sufficiant data (1,2).\\nDuring a Covid-19 infection, hyposmia and hypogeusia sometimes occure as the only symptom, especially in younger people (3). \\nThe examination of odor dysfunctions in children is a challenge. With the creation of the \\\"U-Sniff-Test\\\" in 2018 there has been developed a child-friendly and validated odor-test for children for the fist time (5,6). In this test, 12 odors like banana or apple are presented to the children in special \\\"Sniffin-Sticks\\\". The children are then asked to chose the correct source of odor out of a selection of four pictures. \\nHyposmia has been examined quite rarely in the former studies. In our study, we would like to investigate children with sinunasal hyposmia, healthy children and children after a Covid-19 infection and search for differences. Additionally, the current literatur states that in case of a hyposmia due to a Covid-19 infection, the trigeminal  olfaction is limited, too (3). To pay attention to this phenomenom, we have included a 70%-ethanol Sniffin-stick in our study to test the trigeminal stimulus transmission. We also added a \\\"Sniffin-Stick\\\" filled with bubblegum-odor, because even children younger than 4 years of age seem to easily identify this odor (7) to expand the range of the test for young children.\\nIn this study, we would like to examine the possible differences in performance between different sources of hyposmia in children. In addition, we are going to try to create a shorter screening-test for hyposmia in children by only including the most meaningful odors after evaluation of each single \\\"Sniffin-stick\\\" result.\\n\\n1 Temmel AF., Quint C.,Schickinger-Fischer B., Klimek L., Stoller E., Hummel T., Characteristics of olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg. 2002; 128:635-41\\n\\n2 Oozeer NB., Forbes K., Clement AW., Kubba H., Management of paediatric olfactory dysfunction: how we do it. Clin Otolaryngol. 2011; 36:494-9\\n\\n3 Qui C., Cui C., Hautefort C., Haehner A., Zhao J., Yao Q., Zeng H., Nisenbaum EJ.,Liu L., Zhao Y., Zhang D., Levine CG., Cejas I., Dai Q., Jourdaine C., de With K., Draf, J., Chen B., Jayaweera DT., Denneny JC., Casiano R., Yu H., Eshraghi AA., Hummel T., Liu X., Shu y., Lu H., Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study, Otolaryngology \\u2013 Head and Neck Surgery 2020, doi:10.1177/0194599820934376\\n\\n4 Cameron EL., Olfactory perception in children, World Journal of Otorhinolaryngology \\u2013 Head and Neck Surgery 2018; 4:57-66\\n\\n5 Schriever VA., Agosin E., Altundag A., Avni H., Van HC., Cornejo C., de los Santos G., Fishman G., Fragola C., Guarneros M., Gupta N., Hudson R., Kamel R., Knaapila A. et al., Development of an International Odor Identification Test for Children: The Universal Sniff Test, J Pediatr. 2018; 198:265-272\\n\\n6 Zou L., Dworschak A., Alizadeh R., Kamrava K., Alwashahi M., Bock MA., Boesveldt S., Singh B., Brusevold I., Voznessenskaya V., Hummel T, Schriever VA., \\u201eU-Sniff\\u201c \\u2013 the international odor identification test for children: an extension of ist normative database and study of global reliability, Rhinology 2020; doi:10.4193/Rhin19.355; online ahead of print\\n\\n7 Richman RA., Sheehe PR., Wallace K., Hyde JM., Coplan J., Olfactory performance during childhood. II. Developing a discrimination task for children., J. Pediatr. 1995; 127:421-426\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"BoRieTest-Study\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024184\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"24.03.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Hals-, Nasen-, Ohrenheilkunde und Kopf-Halschrurgie Ruhr Universit\\u00e4t Bochum im St. Elisabeth Hospital\", \"role_email\": \"konstantin.vanAckeren@ruhr-uni-bochum.de\", \"role_phone\": \"0234-509-80\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Bleichstra\\u00dfe 15, 44787 Bochum, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Hannah\", \"role_name_personal_family_name\": \"Klein\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"hannah.klein@ruhr-uni-bochum.de\", \"role_phone\": \"0234-509-80\", \"role_affiliation_name\": \"Klinik f\\u00fcr Hals-, Nasen-, Ohrenheilkunde und Kopf-Hals-Chirurgie Ruhr Universit\\u00e4t Bochum, Katholisches Klinikum St. Elisabeth Hospital\", \"role_affiliation_address\": \"Bleichstra\\u00dfe 15, 44787 Bochum, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Hannah\", \"role_name_personal_family_name\": \"Klein\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"hannah.klein@ruhr-uni-bochum.de\", \"role_phone\": \"0234-509-80\", \"role_affiliation_name\": \"Klinik f\\u00fcr Hals-, Nasen-, Ohrenheilkunde und Kopf-Hals-Chirurgie Ruhr Universit\\u00e4t Bochum, Katholisches Klinikum St. Elisabeth Hospital\", \"role_affiliation_address\": \"Bleichstra\\u00dfe 15, 44787 Bochum, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other and unspecified disturbances of smell and taste\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"R43.8\"}, {\"study_conditions\": \"Hypertrophy of adenoids\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J35.2\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"05.03.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 5, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 17, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"children aged between 5 and 18 years, status after Covid-19 disease, sinunasal obstracion (adenoid vegetation, hyperplasia of tonsills), expected normosmia\", \"study_eligibility_exclusion_criteria\": \"Diagnosed anosmia (e.g. Kallmann-Syndrom, ICA), cognitive disorder, insufficient knowledge of the german language, severe traumatic head or brain injury in the past, acute respiratory infect\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Comparison of the results in an odor-identification test of children with normosmia, after Covid-19 infection and with sinunasal obstraction\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Examination wheather there is the possibility to shorten the U-sniff-test for screening purposes based upon an evaluation of the single odor data.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Cooperation with department of pediatrics, St. Josef Hospital Bochum (CorKid-Studie); anonymus data-exchange via post/letter\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"group 1: children with hyperplasia of lymphatic tissue; an odor identification test consisting out of 14 \\\"sniffin sticks\\\" is performed before planed surgery and after receiving the negative result of a SARS-Cov-19 PCR at the center for ENT of the Ruhr Universit\\u00e4t Bochum at St. Elisabeth Hospital  \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"group 2: children without hyperplasia of lamphatic tissue with expected normosmia; an odor identification test consisting out of 14 \\\"sniffin sticks\\\" is performed before planed surgery and after receiving the negative result of a SARS-Cov-19 PCR at the center for ENT of the Ruhr Universit\\u00e4t Bochum at St. Elisabeth Hospital  \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024214","content":"{\"resource_id\": \"DRKS00024214\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"B cells\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Plasmacells\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"autoantibodies\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antibodies\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Analysis of  the effect of SARS-CoV-2 vaccination in patients with chronic inflammatory diseases\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In this study we investigate the effects of vaccination against SARS-CoV-2 in individuals with chronic inflammatory diseases (CID). One focus of this study are B- and plasmacells which are often altered in patients with chronic inflammatory diseases and which are affected by immunosuppressants. \\nThe aim of this study is to analyse the immune cell compartment of CID patients which received one of the new mRNA vaccines against SARS-CoV-2. Healthy controls will serve as a control. Most important will be the question, if immunosuppressants have an influence on the vaccination efficiency in patients or if patients show the same efficency as healthy controls. In this study, we analyse subpopulations of immune cells in the peripheral blood. By this apporach we can investigate SARS-CoV-2 specific B cells and plasma cells. In addition, we investigate several serum parameters like cytokines and antibodies against SARS-CoV-2\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SAVE-CID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024214\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"17.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"UKSH Kiel/1. medizinische Klinik/Rheumatologie\", \"role_email\": \"bfhoyer@rheuma.uni-kiel.de\", \"role_phone\": \"0431 500 22203\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Arnold-Heller-Str 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Bimba Franziska\", \"role_name_personal_family_name\": \"Hoyer\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"bfhoyer@rheuma.uni-kiel.de\", \"role_phone\": \"0431 500 22203\", \"role_affiliation_name\": \"UKSH Kiel/1. medizinische Klinik/Rheumatologie\", \"role_affiliation_address\": \"Arnold-Heller-Str 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Ulf\", \"role_name_personal_family_name\": \"Geisen\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"ugeisen@rheuma.uni-kiel.de\", \"role_phone\": \"0431 500 22253\", \"role_affiliation_name\": \"UKSH Kiel/1. medizinische Klinik/Rheumatologie\", \"role_affiliation_address\": \"Arnold-Heller-Str 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Bimba Franziska\", \"role_name_personal_family_name\": \"Hoyer\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"bfhoyer@rheuma.uni-kiel.de\", \"role_phone\": \"0431 500 22203\", \"role_affiliation_name\": \"UKSH Kiel/1. medizinische Klinik/Rheumatologie\", \"role_affiliation_address\": \"Arnold-Heller-Str 3, 24105 Kiel, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Healthy controls SARS-CoV-2 vaccinated\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"chronic inflammation\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"22.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"a SARS-CoV-2 vaccination is planned. In addition, one of the following diseases: standard criteria (ACR/EULAR) for diagnosed Rheumatoid arthritis, spondyloarthorpathy, vasculitis or collagenosis. Gastroenterological diagnosed chronic inflammatory bowel disease (Morbus Crohn or Colitis Ulcerosa), Dermatologically confirmed Psoriasis.\\nFor the control group, the mentioned diseases are exclusion criteria.\\nIn addition, written informed consent is needed.\", \"study_eligibility_exclusion_criteria\": \"maligne disease, other autoimmune diseases (with immunosuppressive therapy), Infections (e.g. HIV, Hep C, Hep B) Age under 18 years, lacking capacity to consent.\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Antibodies against SARS-CoV-2 can be measured 1 week after the second immunisation.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Antibodies against SARS-CoV-2 can be measured 6 months after the second immunisation.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients with chronic inflammatory diseases (CID) SARS-CoV-2 vaccinated: \\nBlood samples will be analysed before and at several timepoints after the vaccination. Cellular components like B cells and plasmacells will be analysed as well as cytokines and antibodies. The results will be compared to healthy controls to estimate if patients with chronic inflammatory diseases show the same reaction towards the SARS-CoV-2 vaccine like healthy controls.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Healthy controls SARS-CoV-2 vaccinated: The same analyses will be performed as described for the CID patients. Cellular components like B cells and plasmacells will be analysed as well as cytokines and antibodies.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024422","content":"{\"resource_id\": \"DRKS00024422\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Immunome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Prospective sample collection, data collection and analysis for the clinical applicability of immunome profiles in the discrimination and therapy monitoring of COVID-19 patients in different disease stages as well as for the identification and characterization of long-term consequences of a SARS-CoV-2 infection in comparison to patients with a respiratory non-COVID-19 viral infectious disease and healthy controls.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The COVID 19 disease caused by the currently pandemic spread SARS-CoV-2 virus can cause severe symptoms including pneumonia, myocarditis and sepsis and can be potentially fatal. Acute and chronic consequences resulting from the disease are currently being discussed intensively. Some patients, e.g. with severe infestation of the lung tissue, show early conversion reactions of the pulmonary parenchyma to pulmonary fibrosis, which in some cases is only partially reversible. In addition, there is also evidence that in patients with severe COVID 19 course myocarditis may occur as an acute organ involvement in the context of the infection. The effects on immune reconstitution are so far completely unknown. Due to the shortness of the COVID 19 observation period, it is currently only possible to speculate on the short-term and long-term effects on the inflammatory and immune system and the affected organs (the respiratory, cardiovascular, nerve or digestive system) depending on the severity of the course of the disease. It seems very likely that patients with a very severe or severe COVID-19 disease, similar to sepsis survivors, have an increased risk of contracting infections or developing another disease such as, for example, immune or oncological diseases as a result of a weakened, impaired immune system.\\nImmune response to viral infections\\nT cells as part of the adaptive immune response play a central role in controlling viral infections. Cytotoxic cluster of differentiation (CD)8+ T cells are considered to be particularly important, as they lyse infected host cells before these cells are able to produce infectious particles, too. In addition, CD4+ T cells also have an important function in induction and control of the immune response. Its main function is the secretion of pro-inflammatory molecules. These have both local and systemic effects and are partly used to fight the virus directly, but mainly to coordinate the immune response. The function of CD4+ and CD8+ T cells is preceded by a specific activation via the T cell receptor. This receptor detects specific antigens which are presented on the cell surface through matching major histocompatibility complexes (MHC). The formation of antigen-loaded MHC-I occurs through the degradation of endogenously synthesized proteins (e.g., viral antigens in infected host cells). Protein fragments are intracellularly loaded on the MHC-I and presented on the cell surface activating CD8+ T cells. In contrary, CD4+ T cells are activated by antigens presented on MHC-II. MHC-II are expressed only by professionally antigen-presenting cells such as dendritic cells, macrophages and B cells. MHC-II present exogenous antigens that means with peptides derived from proteins which were taken up by the professionally antigen-presenting cells in advance. After MHC-antigen presentation, naive T-cells start to divide into T effector cells that control viral infections. Furthermore, B cells play an important role in the fight against many viral infections, especially in primary infections. They produce antibodies against antigens that are detected by the B cell receptor. Antibodies mainly inactivate extracellular particles.\\nImmune system malfunctions as a result of viral infection can lead to follow-up diseases and syndromes such as sepsis with the sometimes lethal consequences of multi-organ failure or chronic organ damage. Misregulated immune responses due to viral infections are also known to influence the development of (auto)immune diseases. For example, it has been shown that herpes virus infections greatly increase the risk of multiple sclerosis.\\nThe immunome as a molecular image of the immune system and its function\\nThe immune system's ability to fight diseases is achieved through the early detection and elimination of threats, such as viruses and other pathogens. This ability is based on a broad and specific spectrum of genes, proteins and molecular structures called the human immunome.\\nA viral infection activates the immune system and triggers a primary immune response to eliminate the viral load. This response may be appropriate regarding the physiological situation, but under some circumstances it may overshoot. The subsequent immune reconstitution may be therefore either complete (restitutio ad integrum) or deficient. In all phases of the immune response, a variety of pro- and anti-inflammatory cytokines, chemokines, lipid mediators and metabolites play a decisive role. These are elementary components of the immunome. The determination of the qualitative and quantitative composition of this specific spectrum of molecular structure provides detailed information on the strength of the immune response and reconstitution as well as clues about its function.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CoVImmun\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024422\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Fraunhofer ITMP\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Fraunhofer ITMP\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Eduard\", \"role_name_personal_family_name\": \"Resch\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"eduard.resch@itmp.fraunhofer.de\", \"role_phone\": \"+49 69 870025067\", \"role_affiliation_name\": \"Fraunhofer ITMP\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.03.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria for COVID-19 patients:\\n\\u2022 positive testing for SARS-CoV-2 (PCR) or first presentation to the hospital if the test is known to be positive\\n\\u2022 Written consent to participate in the study by the patient or, in the case of patients unable to consent, by the legal representative\\n\\u2022 Moderate or severe COVID-19 illness according to the WHO classification scheme:\\no Patient group 1: Score 5-7 (severe - very severe)\\no Patient group 2: Score 3 or 4 (moderate - moderate-severe) \\nInclusion criteria for patients with respiratory non-COVID-19 viral infectious disease:\\n\\u2022 positive test for a respiratory non-SARS-CoV-2 virus infection or first presentation in hospital if the test is known to be positive\\n\\u2022 negative test for SARS-CoV-2 within the last 2 weeks\\n\\u2022 Willingness and ability to give consent to participate in the study and clinical examinations and to adhere to the requirements of the study plan\\n\\u2022 Moderate to moderately severe respiratory non-COVID-19 viral infectious disease according to the WHO classification scheme:\\no Control group A: Score 3 or 4 (moderate - moderate-severe) \", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria for COVID-19 patients:\\n\\u2022 Imprisoned or incapacitated patients\\n\\u2022 Severe anemia (Hb &lt;8mg / dl), which does not allow drawing blood regularly\\n\\nExclusion criteria for patients with a respiratory non-COVID-19 viral infectious disease:\\n\\u2022 Imprisoned or incapacitated patients\\n\\u2022 Severe anemia (Hb &lt;8mg / dl), which does not allow drawing blood regularly \", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The changes in the function of organ systems (breathing, cardiovascular or digestive system) form our predictable endpoints. In this specific case, these are the changes of immunome profile: 1. the lipidome, 2. the metabolome and 3. the proteome in the patients blood in relation to the clinical disease activity, clinical infestation pattern, concomitant diseases and length of disease as well as the comparison to immunome profiles of the control groups.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022 Generation of an immunome profile composed of additional analyses:\\no DNA and RNA sequencing and profiling of specific cell populations from the blood; epigenetic analyses\\no additional studies (flow cytometry) of various immune-relevant cell populations and markers in the blood and urine\\no microbiome analysis \\n\\u2022 Clinical disease activity and quality of life (EQ-5D-questionnaire)\\n\\u2022 Comparison of immunome profiles in individual patients with regard to measurement at different times points, for example:\\no at different degrees of activity of the disease \\no during constant therapy\\no in case of a therapy adjustment\\no regarding comorbidities\\n\\u2022 Comparison of immunome profiles between patient groups depending on the degree of disease activity, length and quality of life  as well as in relation to control groups\\n\\u2022 Detection of overlaps and transitions within immunome profiles\\n\\u2022 Recording of the course of the disease:\\no Change in severity according to WHO guidelines\\no patient groups classification\\no number of patients who exhibit changes in disease severity during the study\\no number of patients with consistent WHO scores \\no sequence and reversibility of symptoms\\no number of patients recovering\\no time to recovery\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"All of the individual participant data collected during the trial after deidentification. Also the study protocol, statistical analysis plan and analytical code. Beginning 9 months and ending 36 months following article publication. For analysis to achieve aims in the approved proposal. Proposals should be directed to eduard.resch@itmp.fraunhofer.de . To gain access, data requestors will need to sign a data access agreement. \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"COVID-19-patients (Group 1): WHO score 5-7 (severe - very severe)\\nDepending on the duration of the inpatient treatment (current average around 14 days),  maximum drawing of 7 samples every 2 days in the acute phase and in the long-term follow-up a maximum of 5 samples, examinations should take place. \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"COVID-19-patients (Group 2): WHO score 3 or 4 (moderate - moderate-severe)\\nDepending on the duration of the inpatient treatment (current average around 14 days),  maximum drawing of 7 samples every 2 days in the acute phase and in the long-term follow-up a maximum of 5 samples, examinations should take place. \"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Respiratory non-COVID-19 viral infectious disease (Control group A): WHO score 3 or 4 (moderate - moderate-severe)\\nDepending on the duration of the inpatient treatment a maximum drawing of 3 samples every 2 days in the acute phase and in the long-term follow-up a maximum of 2 samples, examinations should take place. \\n\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024455","content":"{\"resource_id\": \"DRKS00024455\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Force controlled coronavirus  (COVID-19) swab study\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Infection with the SARS CoV-2 virus and the resulting COVID- 19 pneumonia represents an enormous burden for patients and healthcare systems worldwide. A number of tests are now established to detect the viral infection. The test with the currently highest sensitivity and specificity is PCR (polymerase chain reaction) for the detection of the viral genome. Due to continuing widespread and viral mutation, test accuracy may prove to be a greater problem in the long term. But laboratory diagnostics is divided into different phases ranging from test ordering (pre-preanalytical phase), diagnostic sample collection (preanalytical phase), sample analysis (analytical phase), reporting (postanalytical phase), and interpretation (postpostanalytical phase). However, it is already known that most of the errors occur in the preanalytical phase and here especially in the collection of the diagnostic samples of inappropriate or inadequate material (for quality or volume) Attempts were made to counteract this circumstance by various means. Standardized sample extractions were issued in writing and as a video. Furthermore, there is the possibility to produce a 3D print for training purposes. However, no efforts were made to optimize and, above all, standardize sample collection. \\nThe purpose of this study is to evaluate the influence of force during a coronavirus test swab on the PCR result.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"FCCSS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024455\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"09.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr OUP, Universit\\u00e4tsklinik Leipzig\", \"role_email\": \"fccss@medizin.uni-leipzig.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 20, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Ralf\", \"role_name_personal_family_name\": \"Henkelmann\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"fccss@medizin.uni-leipzig.de\", \"role_phone\": \"03419719883 \", \"role_affiliation_name\": \"Universit\\u00e4tsklinik Leipzig\", \"role_affiliation_address\": \"Liebigstr. 20, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Peter\", \"role_name_personal_family_name\": \"Melcher\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"fccss@medizin.uni-leipzig.de\", \"role_phone\": \"03419723879\", \"role_affiliation_name\": \"Klinik f\\u00fcr OUP, Universit\\u00e4tsklinikum Leipzig\", \"role_affiliation_address\": \"Liebigstr. 20, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Contact person\", \"role_name_organisational\": \"Klinik f\\u00fcr OUP, Universit\\u00e4tsklinik Leipzig\", \"role_email\": \"fccss@medizin.uni-leipzig.de\", \"role_phone\": \"03419723879\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 20, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"28.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"positive SARS-CoV2 Test, agree to the ICF\", \"study_eligibility_exclusion_criteria\": \"Age&lt;18, pregnant, breastfeeding women, cancer or  malformation in nose or throat\", \"study_population\": \"\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The aim is to show that a higher force during a SARS CoV 2 Swab results in lower cycle threshold of a PCR.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The secondary outcome ist to show a possible reduction of false negative SARS CoV 2 PCR tests by using a higher force in a SARS CoV 2 swab.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Early-phase-1\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"swab by force 1\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"swab by force 2\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"swab by force 3\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"nasopharyngeal swab (NPS)\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024531","content":"{\"resource_id\": \"DRKS00024531\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"physical performance\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"face mask\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"corona\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"physical strain\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Impact of wearing face masks as part of Covid-19 infection prevention on physical strain - Part I Effects of different face masks on physical performance and physiological parameters during a standardized bicycle ergometer test.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"After onset of the Covid-19 virus pandemic, politicians and medical experts established rules to avoid the spreading of the virus in order to protect the population. In this context face masks have become an important measure. The masks should be worn to avoid transmission of the virus by droplet infection or depending on the characteristics of the mask even protect the wearer from infection with contaminated aerosols. Due to Covid-19 employees from different professions who are performing a variety of occupational tasks with different levels of physical activity now have to wear these masks. It is unclear whether wearing these masks has implications on employees\\u2019 health, workability, and performance. Therefore it is highly relevant to further explore whether wearing face masks during cardiovascular strain reflecting physical work leads to increased physical strain or decreased performance which should be taken into account by ergonomic work place design. The study consists of two parts: Part one investigates the effects of face masks on physical performance at different levels of cardio-vascular strain. Part two is an explorative investigation exploring the influence of wearing face masks during 130 minutes of light and medium physical work on changes in physical strain.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ATEM - part I\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024531\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"18.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Daimler AG\", \"role_email\": \"thomas.gutschalk@daimler.com\", \"role_phone\": \"+49 160 8639436\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Merzedesbenzstr. 120, 70372 Stuttgart, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Benjamin\", \"role_name_personal_family_name\": \"Steinhilber\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"benjamin.steinhilber@med.uni-tuebingen.de\", \"role_phone\": \"07071-29-86805\", \"role_affiliation_name\": \"Institut f\\u00fcr Arbeitsmedizin, Sozialmedizin und Versorgungsforschung\", \"role_affiliation_address\": \"Wilhelmstra\\u00dfe 27, 72074 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Benjamin\", \"role_name_personal_family_name\": \"Steinhilber\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"benjamin.steinhilber@med.uni-tuebingen.de\", \"role_phone\": \"07071-29-86805\", \"role_affiliation_name\": \"Institut f\\u00fcr Arbeitsmedizin, Sozialmedizin und Versorgungsforschung\", \"role_affiliation_address\": \"Wilhelmstra\\u00dfe 27, 72074 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Crossover\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Healthy subjects\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"14.01.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 67, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u2022 Age between 18 and 67 years\\n\\u2022 Being able to work full shift\\n\\u2022 no diseases of the metabolism, cardiovascular or respiratory system\\n\\u2022 written informed consent \\n\\u2022 medically unobtrusive physical maximum endurance test and pulmonary function test\\n\", \"study_eligibility_exclusion_criteria\": \"\\u2022 acute myocardial infarction (within the last 48 h)\\n\\u2022 unstable angina pectoris with a high risk of infection\\n\\u2022 Uncontrolled symptomatic and hemodynamically unstable arrhythmias\\n\\u2022 Severe symptomatic aortic stenosis\\n\\u2022 Uncontrolled symptomatic heart failure\\n\\u2022 Acute myo- or pericarditis\\n\\u2022 Acute pulmonary embolism or acute pulmonary infarction\\n\\u2022 Acute aortic dissection\\n\\u2022 Main stem stenosis\\n\\u2022 Slight aortic stenosis\\n\\u2022 Arrhythmias tachyarrythmia, bradyarrhythmia, frequent ventricular extra systoles\\n\\u2022 Higher atrioventricular block\\n\\u2022 Severe hypertrophic obstructive cardiomyopathy of an outflow tract\\n\\u2022 Severe arterial hypertension (systolic BD &gt; 200 mmHg and/or diastolic BD &gt; 110 mmHg)\\n\\u2022 Electrolyte disorders, especially hyperkalemia,\\n\\u2022 Physical or psychological impairments, due to which an optimal examination is not possible (e.g. febrile infection)\\nAccording to (Chatterjee 2017)\\n\\u2022 diabetes\\n\\u2022 Acute illness\\n\\u2022 Under- or overweight (adipositas degree 1) - BMI &lt; 18,5 kg/m\\u00b2; or &gt; 30 kg/m\\u00b2\\n\\u2022 indications of a disease or disorder of the cardiovascular system assessed by a physical performance test (until subjective exhaustion on a standard bicycle ergometer)\\n\\u2022 indications of a disease or disorder of the respiratory system assessed by a pulmonary function test \\n\\u2022 pregnancy\\n\", \"study_population\": \"\", \"study_target_sample_size\": 36, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"difference in physical performance (achieved level/power at the end of a Physical work capacity 130 cycling ergometer protocol) while wearing MNP vs. no mask\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"difference in CO2 partial pressure, O2 saturation, blood pressure, breathing frequency, perceived shortness of breath  at the end of the PWC130 cycling ergometer protocol while wearing MNP vs. no mask\\n\\ndifference in CO2 partial pressure, O2 saturation, blood pressure, breathing frequency, perceived shortness of breath  at the end of the PWC130 cycling ergometer protocol while wearing MNP vs. FFP2exhaul vs. Community mask vs. no mask\\n\\ncorrelations between the difference in physical performance (MNP vs. no mask) and subjects fitness level\\n\\nassociations between the difference in physical performance (MNP vs. no mask) and gender\\n\\npressure under the mask during normal and forced breathing \\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental condition without wearing a face mask (no mask). Participants complete a bicycle ergometer test protocol that begins with a resistance of 50 watts and is increased by 25 watts every 2 min. The protocol is performed until 70% of the individual's maximum power (in watts) is reached. Maximum power will be determined in an endurance test using the same ergometer protocol, which will be performed several days prior to the four experimental conditions.\\nThe duration of the bicycle ergometer test is approximately 8 to 30 min, depending on the physical capacity of the study participants. This experimental condition is performed on a separate day.\\n\\nThe following measurements will be taken continuously during the bicycle ergometer test: \\nResistance on the bicycle ergometer to record the physical performance [watts/kg]; heart rate measurement using 12-lead electrocardiography with adhesive electrodes [Hz]; transcutaneous oxygen and carbon dioxide measurement using a skin sensor (tcPO2/tcPcO2 partial pressure [mmHg]; respiratory rate measurement using a chest belt [N].\\n\\nThe following measurements will be performed at each load level of the step protocol: \\nBlood pressure measurement using blood pressure cuff [mmHg]; Oxygen level using pulse oximetry [%]; Assessment of possible limited breathing ability using Borg CR-10 scale [values 0 - 10].\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental condition Mouth-nose-cover without exhaling valve (Community mask). Participants complete a bicycle ergometer test protocol that begins with a resistance of 50 watts and is increased by 25 watts every 2 min. The protocol is performed until 70% of the individual's maximum power (in watts) is reached. Maximum power will be determined in an endurance test using the same ergometer protocol, which will be performed several days prior to the four experimental conditions.\\nThe duration of the bicycle ergometer test is approximately 8 to 30 min, depending on the physical capacity of the study participants. This experimental condition is performed on a separate day.\\n\\nThe following measurements will be taken continuously during the bicycle ergometer test: \\nResistance on the bicycle ergometer to record the physical performance [watts/kg]; heart rate measurement using 12-lead electrocardiography with adhesive electrodes [Hz]; transcutaneous oxygen and carbon dioxide measurement using a skin sensor (tcPO2/tcPcO2 partial pressure [mmHg]; respiratory rate measurement using a chest belt [N].\\n\\nThe following measurements will be performed at each load level of the step protocol: \\nBlood pressure measurement using blood pressure cuff [mmHg]; Oxygen level using pulse oximetry [%]; Assessment of possible limited breathing ability using Borg CR-10 scale [values 0 - 10].\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental condition Disposable medical mouth-nose-protection without exhaling valve (MNP, EN 14683). Participants complete a bicycle ergometer test protocol that begins with a resistance of 50 watts and is increased by 25 watts every 2 min. The protocol is performed until 70% of the individual's maximum power (in watts) is reached. Maximum power will be determined in an endurance test using the same ergometer protocol, which will be performed several days prior to the four experimental conditions.\\nThe duration of the bicycle ergometer test is approximately 8 to 30 min, depending on the physical capacity of the study participants. This experimental condition is performed on a separate day.\\n\\nThe following measurements will be taken continuously during the bicycle ergometer test: \\nResistance on the bicycle ergometer to record the physical performance [watts/kg]; heart rate measurement using 12-lead electrocardiography with adhesive electrodes [Hz]; transcutaneous oxygen and carbon dioxide measurement using a skin sensor (tcPO2/tcPcO2 partial pressure [mmHg]; respiratory rate measurement using a chest belt [N].\\n\\nThe following measurements will be performed at each load level of the step protocol: \\nBlood pressure measurement using blood pressure cuff [mmHg]; Oxygen level using pulse oximetry [%]; Assessment of possible limited breathing ability using Borg CR-10 scale [values 0 - 10].\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental condition Disposable filtering face mask with exhaling valve protection class 2 (FFP2exhaul, Din 149). Participants complete a bicycle ergometer test protocol that begins with a resistance of 50 watts and is increased by 25 watts every 2 min. The protocol is performed until 70% of the individual's maximum power (in watts) is reached. Maximum power will be determined in an endurance test using the same ergometer protocol, which will be performed several days prior to the four experimental conditions.\\nThe duration of the bicycle ergometer test is approximately 8 to 30 min, depending on the physical capacity of the study participants. This experimental condition is performed on a separate day.\\n\\nThe following measurements will be taken continuously during the bicycle ergometer test: \\nResistance on the bicycle ergometer to record the physical performance [watts/kg]; heart rate measurement using 12-lead electrocardiography with adhesive electrodes [Hz]; transcutaneous oxygen and carbon dioxide measurement using a skin sensor (tcPO2/tcPcO2 partial pressure [mmHg]; respiratory rate measurement using a chest belt [N].\\n\\nThe following measurements will be performed at each load level of the step protocol: \\nBlood pressure measurement using blood pressure cuff [mmHg]; Oxygen level using pulse oximetry [%]; Assessment of possible limited breathing ability using Borg CR-10 scale [values 0 - 10].\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024585","content":"{\"resource_id\": \"DRKS00024585\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"A clinical trial to assess the efficacy and safety of PB432 in COVID-19 positive inpatients with acute respiratory insufficiency (ARI)\\n- COVARI study -\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Patients are hospitalised due to COVID-19 and acute respiratory insufficiency (ARI) and admitted to a separate isolation ward. The clinical picture presents a stable patient with respiratory and/or systemic symptoms or signs at time of admission and a need for supplemental oxygen, but does initially not present any clinical features suggesting a complicated course of illness (non-ARDS), or need for immediate transfer to intermediate (IMC) or intensive care unit (ICU). The clinical trial comprises 29 days with daily trial specific assessments as long as the patient is hospitalised. If the patient was discharged from hospital before Day 29, he / she is requested to complete diary until Day 29. End of trial evaluations will be performed on Day 29 - either inpatient or outpatient, depending on what applies.\\nEligible and consenting patients are randomly assigned to a 14-days (i.e. 336 hours) treatment (including hospitalised and discharged patients) with investigational medicinal product (IMP), either PB432 capsules or matched placebo. Both interventions are applied as add-on to centre specific COVID-19 related care.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVARI study\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024585\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"25.02.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-003779-17\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"G. Pohl-Boskamp GmbH &amp; Co. KG\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kieler Stra\\u00dfe 11, 25551 Hohenlockstedt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"G. Pohl-Boskamp GmbH &amp; Co. KG\", \"role_email\": \"k.roeschmann-doose@pohl-boskamp.de\", \"role_phone\": \"04826-59-525\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kieler Stra\\u00dfe 11, 25551 Hohenlockstedt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thomas\", \"role_name_personal_family_name\": \"Wittig\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"t.wittig@pohl-boskamp.de\", \"role_phone\": \"04826-59240\", \"role_affiliation_name\": \"G. Pohl-Boskamp GmbH &amp; Co. KG\", \"role_affiliation_address\": \"Kieler Stra\\u00dfe 11, 25551 Hohenlockstedt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thomas\", \"role_name_personal_family_name\": \"Wittig\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"t.wittig@pohl-boskamp.de\", \"role_phone\": \"04826-59-240\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kieler Stra\\u00dfe 11, 25551 Hohenlockstedt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Terminated: Recruitment, data collection, data and quality management halted prematurely and will not resume\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": \"One of the Ongoing\", \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Terminated\", \"study_start_date\": \"19.01.2021\", \"study_end_date\": \"19.07.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1.\\tMale / female / diverse adult \\u226518 years of age at time of enrolment\\n2.\\tLaboratory-confirmed SARS-CoV-2 infection (COVID-19) as determined by PCR or antigen test in any defined specimen prior to trial inclusion; samples of the first positive test collected within 8 (for symptomatic patients at the time of test) respectively 14 (for asymptomatic patients at the time of test) calendar days prior to randomisation are accepted.\\n3.\\tInpatient admitted to an isolation ward with dyspnoea and / or tachypnoea (e.g. respiratory rate &gt;20/minute) in stable conditions (i.e. without immediate plans for intermediate (IMC) or intensive care unit (ICU) transfer) and a need for supplemental oxygen with low-flow (i.e. up to 5 L/min) nasal cannula acc. to investigators assessment.\\n4.\\tSigned informed consent and data protection declaration prior to initiation of any trial procedures\\n\", \"study_eligibility_exclusion_criteria\": \"1. Acute respiratory distress syndrome (ARDS) at time of inclusion\\n2. Relevant laboratory abnormality (serum liver enzymes (ASAT, ALAT, GGT) &gt;3x upper range of normality)\\n3. Known hypersensitivity to trial medication or excipients\\n4. Presence of inflammatory gastrointestinal disease (e.g. Crohn\\u00b4s Disease, or colitis ulcerosa, diverticulitis or non-infectious acute gastritis) at time of inclusion\\n5. Presence of acute or recurrent inflammatory disease of the gall bladder and / or biliary ducts at time of inclusion\\n6. Severe hepatic disease (e.g. liver cirrhosis Child Pugh B or C, ongoing viral hepatitis) at time of inclusion\\n7. Hereditary fructose intolerance\\n8. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt;30 mL/min)\\n9. Only for female patients of childbearing potential: Pregnancy, positive urine pregnancy test on Day 1, breast feeding or no use of effective contraception\\n10. Active malignancy (active = running or immediately planned treatment options like e.g. surgery, chemo- or radiation therapy) or condition after carcinoma not longer than 2 years without relapse, which would make it in the opinion of the investigator unsafe or unsuitable for the patient to participate in this clinical trial\\n11. Use of systemic immunosuppressants (except corticosteroids) within 4 weeks before inclusion into the clinical trial\\nOthers\\n12. Patient in another clinical trial with an investigational medicinal product within 30 days before inclusion into the present clinical trial\\n13. Known to be or suspected of being unable to comply with the clinical trial protocol (e.g. no permanent address, history of drug abuse, known to be non-compliant or presenting an unstable psychiatric history)\\n14. Legal incapacity and / or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the clinical trial\\n15. Patient in custody by juridical or official order evidence of an uncooperative attitude \\n16. Patient, who is a member of the staff of the study centre, staff of the sponsor or CRO, the investigator him- / herself or close relatives of the investigator\\n\", \"study_population\": \"\", \"study_target_sample_size\": 150, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\\u2022 The daily scores of Ordinal Status Score (OSS) evaluating the clinical status of the patients, will be summed-up from Day 2 to Day 15, defined as SOSS-14 (sum of OSS) and Day 1 value will be used as baseline. This primary endpoint is based on the 7-point score that was mentioned above.\\n\\u2022 The number of days from Day 1 (randomisation) until first increase (improvement) by at least two points in OSS compared to Day 1. \\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022 The Daily Scores of OSS will be summed-up from Day 2 to Day 29, defined as SOSS-28 and will be evaluated analogously to the first primary endpoint.\\n\\u2022 Time to patient satisfies categories 5, 6 or 7 on the above mentioned 7 category ordinal scale.\\n\\u2022 Time to discharge (duration of hospitalisation)\\n\\u2022 Time to OSS score \\u22642 (ICU admission / death)\\n\\u2022 Mortality\\n\\u2022 Percent of patient discharged till Day 8, 15, 22, 29\\n\\u2022 Proportion of patients with SARS-CoV-2 free nasopharyngeal / oropharyngeal swabs / sputum samples (virus-free) on Days 8, 15, 22, 29\\n\\u2022 Proportion of patients with interference of daily activities by dyspnoea at least once after discharge\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Other\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Verum, PB432\\nCapsule\\nOne capsule contains 300 mg distillate of a mixture of four rectified essential oils\\nOral administration\\n2 capsules four times a day (i.e. in the morning, at noon, in the evening, and at bedtime). Each capsule has to be intactly swallowed approximately 30 minutes before a meal or before bedtime\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Matching placebo capsules\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024604","content":"{\"resource_id\": \"DRKS00024604\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://egepan.de/ap-3-3-app-basiertes-telemedizinisches-home-monitoring/\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"App-based home-monitoring for Covid-19 patients\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The further development of outpatient treatment concepts for COVID-19 patients represents a central challenge in the context of pandemic management. Compared to the extensive database of hospital care, there are significant information deficits in the outpatient sector. The introduction of the digital health application SaniQ with the associated telemedical treatment software SaniQ Praxis is intended to digitally support intersectoral cooperation. With the Covid-19@Home study, we are investigating whether outpatients suffering from Covid-19 benefit from using the SaniQ smartphone app. The participating patients measure their health data (SpO2, blood pressure, body temperature, pulmonary function and activity data) every day and document them together with their symptoms in the app. The treating physicians can access the data telemedically, which means that routine treatment can be complemented. In the period from January to June 2021, up to 500 patients in various phases of the disease will take part - acute, post-acute and as part of rehabilitation. As part of the study, we conduct qualitative interviews with participants to collect experience with this digital health application and develop concepts for the implementation of digital health applications as part of outpatient health applications. The health data collected are evaluated quantitatively and provide information about the course of the disease (acute, post-acute and in the context of rehabilitation) of Covid-19.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Covid-19@Home\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024604\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.04.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"20-1023cVotum.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Gernot\", \"role_name_personal_family_name\": \"Rohde\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"gernot.rohde@kgu.de\", \"role_phone\": \"069 6301 6336\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Frankfurt, Medizinische Klinik 1\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Beate S.\", \"role_name_personal_family_name\": \"M\\u00fcller\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"b.mueller@allgemeinmedizin.uni-frankfurt.de\", \"role_phone\": \"069-6301-7267\", \"role_affiliation_name\": \"Institut f\\u00fcr Allgemeinmedizin, Goethe-Universit\\u00e4t Frankfurt am Main\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"http://www.allgemeinmedizin.uni-frankfurt.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07.1\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"29.01.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 5, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"positiv PCR Test SARS-CoV-2\", \"study_eligibility_exclusion_criteria\": \"No access to a smartphone; pregnancy (only Aachen)\", \"study_population\": \"\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The use of the digital health application improves the treatment management of Covid-19 patients by\\n1. regularly recording vital signs and symptoms \\n2. collection of patient reported outcomes\\n3. exchange of data and information patients and physicians.\\n\\nAssessment via questionnaires on usability / user acceptance (patients and physicians); qualitative interviews on usability / user acceptance (patients and physicians); EQ-5D-3L: Health-related quality of life; Psychological Screening (PHQ-4, PTTS-10); assessment of current symptoms, relevant previous illnesses, medication plan; vital signs (pulse, blood pressure, body temperature, oxygen saturation) in the acute phase; parameters of lung function (FVC, FEV1, peak flow) and activity data (number of steps) in the post-acute / rehabilitation phase\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The use of the digital health application increases patient sovereignty.\\n\\nThe use of the digital health application improves shared decision-making between doctor and patient.\\n\\nThe use of the digital health application increases patient safety.\\n\\nThe use of the digital health application improves the alignment of treatment with guidelines and recognized standards.\\n\\nEvaluation by the same parameters as the primary endpoint.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Phase of acute infection: patients document vital signs and symptoms \\u200b\\u200bdaily using electronic devices and symptom questionnaires for at least 28 days\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Phase of post-/Long-Covid: patients document vital signs and symptoms \\u200b\\u200bdaily using electronic devices and symptom questionnaires for at least 12 weeks\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024621","content":"{\"resource_id\": \"DRKS00024621\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Exploratory survey on the situation of caregivers during the COVID-19 pandemic\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The questionnaire was specially compiled for this purpose based on validated questionnaires. It includes questions about the demographics of the relative and the person in need of care, questions about the care situation outside of the COVID-19 pandemic and about the care situation during the COVID-19 pandemic. In addition, questions are asked about the stress, depression and resilience of the caring relatives.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024621\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"23.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Zentrum f\\u00fcr psychische Gesundheit im AlterLandeskrankenhaus (A\\u00f6R)\", \"role_email\": \"k.geschke@zpga.landeskrankenhaus.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Katharina\", \"role_name_personal_family_name\": \"Geschke\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"k.geschke@zpga.landeskrankenhaus.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Zentrum f\\u00fcr psychische Gesundheit im AlterLandeskrankenhaus (A\\u00f6R)\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Katharina\", \"role_name_personal_family_name\": \"Geschke\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"k.geschke@zpga.landeskrankenhaus.de\", \"role_phone\": \"015780696759\", \"role_affiliation_name\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter Landeskrankenhaus (A\\u00f6R)\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Teresa\", \"role_name_personal_family_name\": \"Weber\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"t.weber@zpga.landeskrankenhaus.de\", \"role_phone\": \"061313783101\", \"role_affiliation_name\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter (ZpGA)Landeskrankenhaus (A\\u00f6R)\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"burden of caregivers\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"30.09.2020\", \"study_end_date\": \"31.01.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"caregiver\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Exploration of the situation of caregivers during the corona pandemic with regard to stress, depression and resilience \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Formulation of ideas for the direction of further research projects on this topic and of recommendations for preparations for further comparable situations.\\nValidation of the FARBE questionnaire by means of factor analysis and convergent / discriminant validity.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"one-time exploratory questioning of caregivers without follow-up \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024622","content":"{\"resource_id\": \"DRKS00024622\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Bile acids\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Serum profile of bile acids in COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"In addition to their helping role in the absorption of dietary fats, bile acids also play a role as a messenger substance in the serum. The effects of the bile acids are mediated via membrane and intracellular receptors. Although the serum concentrations of bile acids are low, they can also be detected in healthy people. In addition to determining the total concentration of bile acids in the serum, it is now also possible to determine the individual primary and secondary bile acids and their conjugation products. In a recently summary of the current literature on this topic, it was possible to show that the diseases previously examined for the concentrations of the bile acids all showed an increase in their total concentration. In addition, it could also be shown that the diseases differed in their individual bile acid profile. Even pathophysiologically closely related disease states showed a sometimes very different profile. A shock pattern was also found.\\nThe difference in serum bile acid patterns between the various diseases speaks very strongly in favor of an adaptation mechanism in the body. So far, nothing is known about the concentrations of the individual bile acids in people seriously ill with COVID-19, so this will be the first description of the concentrations of individual bile acids, both qualitatively and quantitatively, and over a period of time in this disease. Scientific findings from this investigation will most likely provide deeper insights into the pathophysiology of the COVID-19 disease, in particular how it is differentiated from other critical diseases or non-sick patients. In addition, we expect findings on liver function, which so far has not received much attention in COVID-19 disease.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SeProBACov\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024622\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen Klinik f\\u00fcr An\\u00e4sthesiologie\", \"role_email\": \"lars-olav.harnisch@med.uni-goettingen.de\", \"role_phone\": \"05513963579\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Robert-Koch Str. 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"https://www.umg.eu\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Lars-Olav\", \"role_name_personal_family_name\": \"Harnisch\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"lars-olav.harnisch@med.uni-goettingen.de\", \"role_phone\": \"05513963579\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen Klinik f\\u00fcr An\\u00e4sthesiologie\", \"role_affiliation_address\": \"Robert-Koch Str. 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"https://www.umg.eu\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Lars-Olav\", \"role_name_personal_family_name\": \"Harnisch\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"lars-olav.harnisch@med.uni-goettingen.de\", \"role_phone\": \"05513963579\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen Klinik f\\u00fcr An\\u00e4sthesiologie\", \"role_affiliation_address\": \"Robert-Koch Str. 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"https://www.umg.eu\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"22.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u2022 Female, male and diverse patients\\n\\u2022 Age&gt; 18 years\\n\\u2022 (critical) COVID-19 disease (= need for ICU treatment)\\n\\u2022 Treatment in the COVID-19 intensive care units of the University Medical Center G\\u00f6ttingen\", \"study_eligibility_exclusion_criteria\": \"\\u2022 Age &lt;18 years\\n\\u2022 Lack of consent\\n\\u2022 Refusal to participate in the study\\n\\u2022 Positive SARS-CoV-2 test without COVID-19 disease\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Bile acids in the serum at different times in the course of the disease (observationell / descriptive)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"critically ill patients suffering from COVID-19\\nSerial blood samples at three points in time within 10 days during the course of the disease and determination of the concentration of 15 individual bile acids / conjugation products of bile acids.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024664","content":"{\"resource_id\": \"DRKS00024664\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.allgemeinmedizin.uni-frankfurt.de/forschung5/kompan.html\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Transsectoral communication in the regional management of the pandemic (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"KomPan is a proof-of-concept study including an implemention of a communication tool (instant-messaging app) between health care providers (general practitioners, public health workers, university hospital). Moreover we evaluate the usability and influencing factors in two model regions through surveys, app data and interviews.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"KomPan\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024664\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.02.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Johann Wolfgang Goethe-Universit\\u00e4t Frankfurt am Main\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany\", \"role_affiliation_web_page\": \"https://www.kgu.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Angelina\", \"role_name_personal_family_name\": \"M\\u00fcller\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"a.mueller@allgemeinmedizin.uni-frankfurt.de\", \"role_phone\": \"+496963016476\", \"role_affiliation_name\": \"Goethe-Universit\\u00e4t Frankfurt, Institut f\\u00fcr Allgemeinmedizin\", \"role_affiliation_address\": \"Uniklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Angelina\", \"role_name_personal_family_name\": \"M\\u00fcller\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"a.mueller@allgemeinmedizin.uni-frankfurt.de\", \"role_phone\": \"06963016476\", \"role_affiliation_name\": \"Institut f\\u00fcr Allgemeinmedizin der Goethe-Universit\\u00e4t Frankfurt\", \"role_affiliation_address\": \"Theodor-Stern-Kai 7, 60590 Frankfurt, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"14.10.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 70, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"We include general practitioners and other healthcare providers such as public health workers, nurses and doctors involved in COVID-19 treatment from local university hospital. Participants provide health care in Frankfurt or Main-Kinzig-area, Hesse, Germany.\", \"study_eligibility_exclusion_criteria\": \"None.\", \"study_population\": \"\", \"study_target_sample_size\": 30, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Explorative study design.\\nThe aim of the study is to explore the feasibility and usability of a transsectoral communication tool (app) for health care providers\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"All participants use an app for instant-messaging with health care providers. They participate in an online survey at the beginning, after at least two weeks of use and after at least six weeks of use. Participants can also participate in qualitative interviews after at least three weeks of use. App data is analysed.\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00024695","content":"{\"resource_id\": \"DRKS00024695\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"IMS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"VOC\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Breath Test\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"IMS, VOC, Breath Test\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Rapid diagnostics of an floride infection by SARS-CoV-19 (COVID-19) using Ion Mobility Spectrometry for exhaled breath\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Detection of significant VOC in exhaled breath for diagnostic help in airway infections.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"IMS_2020_2\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024695\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"06.04.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Helios Klinikum Aue\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Gartenstra\\u00dfe 6, 08280 Aue, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Helios Klinikum Aue\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Gartenstra\\u00dfe 6, 08280 Aue, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thomas\", \"role_name_personal_family_name\": \"Junghans\", \"role_name_personal_title\": \"Mr. Dipl-med.\", \"role_name_identifiers\": [], \"role_email\": \"thomas.junghans@helios-gesundheit.de\", \"role_phone\": \"03771583516\", \"role_affiliation_name\": \"Helios-Klinikum Aue\", \"role_affiliation_address\": \"Gartenstr. 6, 08280 Aue, Germany\", \"role_affiliation_web_page\": \"https://www.helios.gesundheit.de/aue\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thomas\", \"role_name_personal_family_name\": \"Junghans\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"thomas.junghans@helios-gesundheit.de\", \"role_phone\": \"03771583516\", \"role_affiliation_name\": \"Helios-Klinikum Aue\", \"role_affiliation_address\": \"Gartenstr. 6, 08280 Aue, Germany\", \"role_affiliation_web_page\": \"https://www.helios.gesundheit.de/aue\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"16.12.2020\", \"study_end_date\": \"30.09.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 90, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Indikation gem\\u00e4\\u00df Zielstellung\\n- Verdacht auf COVID-19\\n- Patient/Proband kommt in Abstrichstelle\\n- gesund bzw. frei von florider klinisch relevanter Infektion, aber m\\u00f6gliche Kontaktperson zu COVID-positiven Patienten (V.a. symptomlosen Tr\\u00e4ger) oder Einweisung mit Beschwerden\\n\\nindication due to aim o the study,\\nsuspicion of COVID-19\\npresentation in test unit\\nhealthy or free of signs of infection\\ncontact to COVID-19 cases\\nor typical symptoms for Covid\", \"study_eligibility_exclusion_criteria\": \"mechanical closure of both nasal sides\\n\", \"study_population\": \"\", \"study_target_sample_size\": 250, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Primary target of the study is to find and demonstrate rproducible cluster of volatile markers in IMS-spectra of exhaled breath and biological samples which are sufficient hints of a virale or bacterial infection.\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"surely  exclusion of clinical relevant infection or absence of infective disease, resp., using exhaled markers.\\n\\n\\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"anonym data should be shared with peers for scientific validation.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"From all patient in COVID-test station will be  taken a breath sample for analysis in IMS device  additional to smear test from mouth or nose cavity, after receiving the patients consent. \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"non-infected volunteers (Co-worker in Helios Klinikum)\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024765","content":"{\"resource_id\": \"DRKS00024765\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"hemodynamics\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"microcirculation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hyperspectral imaging\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"exosomes\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"aortic valve stenosis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"perioperative intensive care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Aortic valve replacement\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Effects of altered microcirculation on renal function in transfemoral, transapical, and open aortic valve replacement.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The most common valvular heart disease in adults is the aortic valve stenosis; it occurs in 2-7% of those over 65 years of age. The accompanying reduction in aortic valve opening area results in increased left ventricular strain, which can lead to cardiac hypertrophy and heart failure. While aortic valve stenosis is often asymptomatic for a long time, mortality is greatly increased after the onset of typical symptoms (dyspnea, angina pectoris, syncope). If the aortic valve needs to be replaced, there are three different options for implanting a new aortic valve: 1. interventional using a catheter via the inguinal artery (transfemoral transcatheter aortic valve implantation 2. minimally invasive using an intercostal incision via the apex of the heart and 3. open surgical transthoracic transaortic in cardiac arrest with cardiopulmonary bypass. \\nNumerous patients develop acute renal failure after these procedures.  However, in approximately 60% of patients after transfemoral aortic valve replacement, renal function improves after the intervention and glomerular filtration rate increases. This is probably due to altered renal blood flow, glomerular hemodynamics, and capillary perfusion in the kidney. Other potential mediators or messengers of altered microcirculation could be exosomes. These are extracellular vesicles approximately 30 to 90 nm in size that appear to be present in many body fluids. Exosomes have been shown to play a role in both renal physiology and the pathogenic mechanisms of various renal diseases/disorders, e.g. as immune regulators.\\nIn the present study, we will first investigate whether and how the above-mentioned interventions are reflected in altered macro- and microcirculation and whether these changes have prognostic significance with regard to the occurrence of altered renal function.  In this observational study, the change in cardiac output will be measured by ultrasound before and after the intervention. To evaluate the microcirculation, a hyperspectral imaging system (TIVITA\\u00ae Tissue System) approved under the Medical Devices Act will be used to visualize and quantify changes in skin microcirculation before and after the intervention. The results will be correlated with clinical \\\"outcome\\\" parameters of renal function in order to identify approaches for future therapies or to identify risk constellations. Furthermore, urine and blood tests will be performed using molecular biological and immunological methods. Exosomes will also be isolated from the serum of the test persons and characterized in order to investigate their influence on inflammation and apoptosis in cell culture models. For this purpose, urine and blood samples will be taken.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"MiNiAKE\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024765\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"31.03.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr An\\u00e4sthesiologieUniversit\\u00e4tsklinikum Heidelberg\", \"role_email\": \"Dania.fischer@med.uni-heidelberg.de\", \"role_phone\": \"+49 (0)6 221 56 36166\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 420, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Dania\", \"role_name_personal_family_name\": \"Fischer\", \"role_name_personal_title\": \"Ms. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Dania.fischer@med.uni-heidelberg.de\", \"role_phone\": \"+49 (0)6 221 56 36166\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologieUniversit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 420, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Dania\", \"role_name_personal_family_name\": \"Fischer\", \"role_name_personal_title\": \"Ms. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Dania.fischer@med.uni-heidelberg.de\", \"role_phone\": \"+49 (0)6 221 56 36166\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologieUniversit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 420, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Other aortic valve disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"I35.8\"}, {\"study_conditions\": \"Acute renal failure with medullary necrosis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"N17.2\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"12.04.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients with aortic valve replacement:\\n- Written informed consent by the study participant \\n- Age \\u2265 18 years\\n- Planned aortic valve replacement in the cardiology or cardiosurgery clinic of Heidelberg University Hospital\\n\\nHealthy subjects:\\n- Written informed consent by the study participant \\n- Age \\u2265 18 years\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria common to all study groups: \\n- Failure to meet inclusion criteria.\\n- Infectious viral diseases (HBV, HCV, HIV, COVID-19) or unknown COVID-19 status.\\n- Refusal to participate in the study\\n- Pre-existing severe renal insufficiency with a glomerular (GFR) &lt;15 ml/min/m2 or need for dialysis\", \"study_population\": \"\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Hyperspectral measurement of various microcirculatory parameters (tissue oxygenation, near-infrared perfusion index, tissue hemoglobin index, tissue water index) on the hand before and after aortic valve replacement\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"-Kidney function/regeneration/injury markers such as creatinine, stathmin and PCNA, albumin, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl glucosaminidase (NAG).\\n\\n- Isolation and profiling of exosomes from serum and urine (using lineage- or cell lineage-specific markers) including evaluation as a potential effector in co-culture with renal cells\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"publication of results will be performed once the study is finished\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"1. interventional aortic valve replacement via catheter through the inguinal artery (transfemoral transcatheter aortic valve implantation.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"2. Minimally invasive via intercostal incision through the apex of the heart.\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"3. open surgery transthoracic transaortic in cardiac arrest with cardiopulmonary bypass \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024896","content":"{\"resource_id\": \"DRKS00024896\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Effects of the Covid-19 lockdown in Germany on the modulation of immunological responses in early infancy\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"For several decades, an increased prevalence of atopic diseases in childhood has been described in industrialized nations. In Europe, the International Study of Asthma and Allergies in Childhood (ISAAC study) showed that every fourth child suffers from an allergy. In particular, the prenatal modulation of the immune system by environmental influences is the focus of interest. Such modulation can be detected at the earliest stage, i.e. from the cord blood. Thus, decreasing exposure to microbial stimuli is considered to be an important risk factor for the development of allergic diseases. During the lockdown declared since March 2020 and on November 2020 in Germany due to the Corona pandemic, pregnant women lived isolated from society. Since then, in order to contain the pandemic, entering the public is always performed with face masks, a distance of 1.5 meters from other people and increased hygienic standards. In addition, the fear of infection as well as being in quarantine may have tremendous psychiatric effects on the affected individuals, among others, the induction of symptoms of post-traumatic stress disorder, anxiety symptoms, and insomnia have been described. Similarly, stress is one of the prenatal factors assumed to have unfavorable effects on the pregnancy outcome and subsequently on the immature immune system of the neonate. In this exploratory pilot study, we aim to investigate differences in the ratios of different subpopulations of the human leukocyte repertoire and of immune mediators in the peripheral blood. In this project, we hope to improve our knowledge of the etiology and pathogenesis of chronic, immune-associated diseases such as allergies.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Pregnant women during Covid-19-Lockdown\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024896\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"18.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Zemlin\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"michael.zemlin@uks.eu\", \"role_phone\": \"+4917681237531\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum des Saarlandes, Klinik f\\u00fcr Allgemeine P\\u00e4diatrie und Neonatologie\", \"role_affiliation_address\": \"Kirrberger Stra\\u00dfe, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Sybelle\", \"role_name_personal_family_name\": \"Goedicke-Fritz\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"sybelle.goedicke-fritz@uks.eu\", \"role_phone\": \"017681237531\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum des Saarlandes Universit\\u00e4t des Saarlandes Klinik f\\u00fcr Allgemeine P\\u00e4diatrie und Neonatologie\", \"role_affiliation_address\": \"Kirrberger Stra\\u00dfe, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"We study the effects of lockdown on the children's white blood cell profile\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"23.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 42, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [], \"study_eligibility_inclusion_criteria\": \"Between January 2021 and January 2022, pregnant women in the third trimester upon presentation to the hospital will be recruited. When recruiting, a distinction is made between \\u201clockdown pregnant women\\u201d and \\u201ccontrol pregnant women\\u201d. \\\"Lockdown pregnant women\\\" are women who have spent the majority of their pregnancy during the lockdown due to SARS-CoV-2 in isolation or at a distance, with increased hygiene and an everyday mask. The \\\"lockdown\\\" samples will be collected from January 2021 until the increased hygiene measures, the distance rules and the mask requirement are lifted. From January 2022, the control samples will then be collected over an identical period of time. Using questionnaires, demographic data and personal, family and social anamnesis of the mothers are collected. Umbilical cord blood is taken when the child is born. The samples are analyzed in the laboratory of general pediatrics and neonatology at the Saarland University Hospital.\\nThe following patient groups are to be recruited (gender share evenly distributed):\\n1. Mothers with an upcoming caesarean section (n = 50)\\n2. Umbilical cord blood samples\\na. Premature babies (gestational age &lt;37 weeks) (n = 50)\\nb. Full-term children (gestational age 37 + 0 to 42 + 0 weeks of gestation) (n = 50)\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria are chronic diseases of the mother and infections or antibiotic therapy in the last trimester of pregnancy. Children who were born before the completion of the 28th week of pregnancy or who developed perinatal infections will also be excluded from participation in the study. Birth without caesarean section.\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Using questionnaires, the epidemiological data will be collected with a focus on microbial exposure and stress as well as the development of allergic diseases, socio-economic factors and family history at birth and at the age of 6 months, 2 and 5 years. \\nIn addition, umbilical cord samples from lockdown and non-lockdown newborns are processed. In the long term, the question should be answered whether the immune regulation in the umbilical cord blood is already suitable for predicting a later development of an allergic disease. It is also assumed that prenatal stress influences the course of pregnancy and immune adaptations during pregnancy. Therefore, this work aims to investigate the relationship between perceived maternal stress and the frequencies of the leukocyte repertoire and cytokines in the newborn. Acute psychosocial stress experienced by the mother during pregnancy was selected as stress, which is an increasing factor for pregnant women during lockdown and has negative effects on the maintenance of pregnancy and on fetal development. \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Between January 2021 and August 2022, pregnant women in the third trimester upon presentation to the hospital will be recruited. When recruiting, a distinction is made between \\u201clockdown pregnant women\\u201d and \\u201ccontrol pregnant women\\u201d. \\\"Lockdown pregnant women\\\" are women who have spent the majority of their pregnancy during the lockdown due to SARS-CoV-2 in isolation or at a distance, with increased hygiene and an everyday mask. The \\\"lockdown\\\" samples will be collected from January 2021 until the increased hygiene measures, the distance rules and the mask requirement are lifted.  Using questionnaires, demographic data and personal, family and social anamnesis of the mothers are collected. Umbilical cord blood is taken when the child is born. The samples are analyzed in the laboratory of general paediatrics and neonatology at the Saarland University Hospital.\\nThe following patient groups are to be recruited (gender share evenly distributed):\\n1.\\tMothers with an upcoming caesarian section (n = 150)\\n2.\\tMothers with an upcoming caesarian section which have already been infected with SARS-CoV-2 before pregnancy (n = 50)\\n3.\\tMothers with an upcoming caesarian section which have been infected with SARS-CoV-2 during pregnancy (n = 50)\\n4.\\tMothers with an upcoming caesarian section and performed vaccination against  SARS-CoV-2 (n = 50)\\n5.\\tMothers with an upcoming caesarian section and performed vaccination against  SARS-CoV-2 prior to pregnancy (n = 50) \\n6.\\tCord blood\\na.\\tPre-term infants (Gestational age &lt; 37 weeks)  (n = 50)\\nb.\\tFull-term infants (Gestational age  37+0 bis 42+0 SSW) (n = 150)\\nc.\\tFull-term infants from mothers which have already been infected with SARS-CoV-2 before pregnancy (n = 50)\\nd.\\tFull-term infants from mothers which have already been infected with SARS-CoV-2 during pregnancy (n = 50)\\ne.\\tFull-term infants from mothers with performed vaccination against SARS-CoV-2 during pregnancy (n = 50)\\nf.\\tFull-term infants from mothers with performed vaccination against SARS-CoV-2 prior to  pregnancy (n = 50)\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"As soon as the pandemic situation permits (initially envisaged: January 2022) the control samples will then be collected over an identical period of time. Using questionnaires, demographic data and personal, family and social anamnesis of the mothers are collected. Umbilical cord blood is taken when the child is born. The samples are analyzed in the laboratory of general paediatrics and neonatology at the Saarland University Hospital.\\nThe following patient groups are to be recruited (gender share evenly distributed):\\n1. Mothers with an upcoming caesarean section (n = 50)\\n2. Umbilical cord blood samples\\na. Premature babies (gestational age &lt;37 weeks) (n = 50)\\nb. Full-term children (gestational age 37 + 0 to 42 + 0 weeks of gestation) (n = 50)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024908","content":"{\"resource_id\": \"DRKS00024908\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Exploratory survey on the impact of the Corona measures on the course and extent of grief, as well as mourners' health, following the loss of a loved one during the Covid-19-pandemic.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The purpose of this exploratory survey is to assess the impact of Corona measures on grievers following a loss during the Corona pandemic. In doing so, we hope to obtain preliminary findings on the following research questions: \\n- Are Corona-related changes in bereavement circumstances cross-sectionally associated with an increase in risk factors for complicated bereavement?\\n- Are corona-related changes in environmental factors longitudinally associated with a higher risk of persistent grief disorders?\\n- Do corona-related changes in grief coping correlate with poorer health status among bereaved individuals?\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024908\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"24.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter (ZpGA) Landeskrankenhaus (A\\u00f6R)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter Landeskrankenhaus (A\\u00f6R)\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Alexandra\", \"role_name_personal_family_name\": \"Wuttke-Linnemann\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"a.wuttke-linnemann@zpga.landeskrankenhaus.de\", \"role_phone\": \"015117273322 \", \"role_affiliation_name\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter (ZpGA) Landeskrankenhaus (A\\u00f6R)\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Svenja\", \"role_name_personal_family_name\": \"Palm\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"s.palm@zpga.landeskrankenhaus.de\", \"role_phone\": \"061313783103 \", \"role_affiliation_name\": \"Zentrum f\\u00fcr psychische Gesundheit im Alter (ZpGA) Landeskrankenhaus (A\\u00f6R)\", \"role_affiliation_address\": \"Hartm\\u00fchlenweg 2-4, 55122 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Strain and severity of grief symptomatology of bereaved relatives of persons who died during the COVID-19 pandemic.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"01.07.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Loss of a close relative since March 2020\", \"study_eligibility_exclusion_criteria\": \"Respondents are asked to participate in the study only if they are comfortable answering questions about their experience of loss. \", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"- Sociodemographic data \\n- Questions about stress experience due to COVID-19 pandemic\\n- Questions about circumstances / experience of bereavement\\n- Questions about the expression of grief\\n- Bereavement-specific rumination \\n- Questions about corona-specific general conditions \\n- Questions about coping with grief\\n- Questionnaire on stress and resilience\\n- Questionnaire on mental well-being \\n- Questions on perceived social support and self-efficacy experience\\n- Questions about the experience of loneliness \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Formulating ideas for the direction of further research on this topic as well as making recommendations on preparations for other similar situations.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Exploratory survey conducted with bereaved family members with follow-up survey 6 months after the first measurement time point.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024979","content":"{\"resource_id\": \"DRKS00024979\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"mixed-methods-design\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"specialist inpatient palliative care services\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19: National Strategy for Palliative Care during Pandemic Crisis\\\" (PallPan) - sub project specialist inpatient palliative care services (AP 5 PallPan)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Our study is a sub-project (WP 5) in cooperation with 12 universities and examines specialised inpatient palliative care in the current COVID-19 pandemic situation. Interviews with experts in leading positions in the field of inpatient hospice and palliative care in hospitals (palliative care units and specialist inpatient palliative care services) and a Germany-wide online survey (cross-sectional study) among specialist inpatient palliative care services, palliative care units and inpatient hospices provide an insight into the experiences, challenges and diverse solutions in times of the COVID-19 pandemic. The analyses contribute to a development and consensus of a national strategy and recommendations for action.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"PallPan (AP 5)\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024979\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"08.04.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Lukas\", \"role_name_personal_family_name\": \"Radbruch\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"lukas.radbruch@ukbonn.de\", \"role_phone\": \"+49 (0)228-287 13495\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Bonn / Klinik f\\u00fcr Palliativmedizin\", \"role_affiliation_address\": \"Venusberg-Campus 1/ Geb\\u00e4ude 66, 53127 Bonn, Germany\", \"role_affiliation_web_page\": \"http://www.palliativbonn.de/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Birgit\", \"role_name_personal_family_name\": \"Jaspers\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"birgit.jaspers@ukbonn.de\", \"role_phone\": \"+49 (0)228-287 13495\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Bonn / Klinik f\\u00fcr Palliativmedizin\", \"role_affiliation_address\": \"Venusberg-Campus 1 / Geb\\u00e4ude 66, 53127 Bonn, Germany\", \"role_affiliation_web_page\": \"https://www.palliativbonn.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"G\\u00fclay\", \"role_name_personal_family_name\": \"Ates\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"guelay.ates@ukbonn.de\", \"role_phone\": \"+49 (0)228-287 13495\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Bonn / Klinik f\\u00fcr Palliativmedizin\", \"role_affiliation_address\": \"Venusberg Campus 1 / Geb\\u00e4ude 66, 53127 Bonn, Germany\", \"role_affiliation_web_page\": \"https://www.palliativbonn.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"patients in need of palliative care and with or without COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"23.11.2020\", \"study_end_date\": \"18.02.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 0, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Persons with management function\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 589, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"12 Expert interviews: To gain a first insight into the experiences, challenges and diverse solutions in times of the COVID-19 pandemic.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Germany-wide online survey (cross-sectional study; N=589; response n=228): To get a snapshot of how many of the specialist inpatient palliative care services, palliative care units and inpatient hospices share the same experiences and challenges.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"expert interviews; German-wide cross-sectional online survey among specialist inpatient palliative care services, palliative care units and inpatient hospices\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00024990","content":"{\"resource_id\": \"DRKS00024990\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"nursing homes;Integration assistance facilities\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"general practitioners; resident specialists (oncologists); outpatient care services;\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"experiences; Pandemics; Sars-Cov- 2\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"National Strategy for Palliative Care Provision in Pandemics\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Description of the experiences, challenges and approaches of\\n1) general practitioners,\\n2) resident specialists (oncologists),\\n3) outpatient care services\\n4) Retirement and nursing homes as well\\n5) Integration assistance facilities\\nin the current pandemic situation with regard to the care of seriously ill and dying patients (with / without COVID-19) and their relatives.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"PallPan (WP2)\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00024990\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"13.04.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"\", \"id_type\": \"EUDAMED\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://www.friedrich-verlag.de/pflegen-demenz-palliativ/qualifizierung/pallpan-9843\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://doi.org/10.1371/journal.pone.0254056\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"https://doi.org/10.1007/s00761-021-00974-z\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung Dienstsitz Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Friedrichstra\\u00dfe 130 B, 10117 Berlin, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stephanie\", \"role_name_personal_family_name\": \"Stiel\", \"role_name_personal_title\": \"Ms. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"stiel.stephanie@mh-hannover.de\", \"role_phone\": \"+495115324548\", \"role_affiliation_name\": \"Medizinische Hochschule HannoverInstitut f\\u00fcr AllgemeinmedizinArbeitsgruppe Palliativversorgung\", \"role_affiliation_address\": \"Carl-Neuberg-Str. 1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"seriously ill and dying patients (with / without COVID-19) and their relatives\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"26.08.2020\", \"study_end_date\": \"31.03.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 12, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 110, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"none\\n\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 115, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"subjective experiences, challenges, solutions through survey and semi structured interviews\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"No data transfer intended\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Supportive care\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"General practitioners\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"resident oncologists\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"outpatient nursing care teams\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Nursing homes\"}, {\"study_arm_group_label\": \"Arm 5\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"facilities of integration assistance\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025053","content":"{\"resource_id\": \"DRKS00025053\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Emotion processing; EEG; EMG; somatoform pain disorder\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"facial mimicry\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Facial mimicry and emotion processing in patients with somatoform pain disorder - an EEG / EMG study\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Patients with somatoform pain disorder show a decreased perception of facial affect expression and often show a higher degree of alexithymia and a lower ability to regulate emotions. The aim of this study is to compare patients with somatoform pain disorder with regard to their emotion regulation and facial mimicry when exposed to emotional stimulus material with healthy subjects as well as before and after therapy.\\n\\nThe aim of this naturalistic pilot study is to evaluate the psychotherapeutic interventions and to investigate the disorder model of somatoform pain disorders. Compared to a healthy control group, patients with somatoform pain disorder show different reaction patterns in the components of the EEG in response to facial affect expression and this should improve through the therapy (exploratory question). There are connections between Low facial mimicry (EMG) and abnormal brain activity (EEG) in the specific brain regions.\\n\\nFirst, various questionnaires are collected. Then dynamic affect-expressive stimulus material is presented to the participants. The faces alternately show the emotions of sadness, joy and anger.\\n\\nAdditional, information about processes involved in affective mimicry can be obtained through the simultaneous use of electroencephalography (EEG). The vertex-positive / occiput-negative N170 component plays a central role in the structural encoding of faces and allows a differentiation between positive (higher amplitude, shorter latency) and negative emotions (weaker amplitude, longer latency). The decoding of the specific emotional expression of faces is viewed as a higher-order cognitive process in which the structural representation of the face is paired with semantic information.\\n\\nTo record the facial mimicry, the activity of various mimic muscles is measured electromyographically. The zygomaticus major (smiling) and corrugator supercilii (frowning) muscles give the most reliable results. In addition, the amplitude of the N170 correlates negatively with the extent of the contraction of the M. zygomaticus major and M. corrugator supercilii.\\n\\nThe questionnaires should help to identify covariates that can influence the processing of emotions. The differences in the activity pattern should possibly facilitate the diagnosis and treatment of somatoform disorders. It is possible that the emotional deficits of patients with somatoform pain disorders are related to impaired empathic and emotional skills.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"MISOMPA\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025053\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"22.04.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"LVR-Klinikum D\\u00fcsseldorfKliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorfKlinik f\\u00fcr Psychosomatische Medizin und Psychotherapie\", \"role_email\": \"joerg.rademacher@lvr.de\", \"role_phone\": \"+49(0)211 922-4708\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \" J\\u00f6rg \", \"role_name_personal_family_name\": \"Rademacher\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"joerg.rademacher@lvr.de\", \"role_phone\": \"+49(0)211 922-4708 \", \"role_affiliation_name\": \"LVR-Klinikum D\\u00fcsseldorfKliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorfKlinik f\\u00fcr Psychosomatische Medizin und Psychotherapie\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"J\\u00f6rg\", \"role_name_personal_family_name\": \"Rademacher\", \"role_name_personal_title\": \"Mr. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"joerg.rademacher@lvr.de\", \"role_phone\": \"+49(0)211 922-4708\", \"role_affiliation_name\": \"LVR-Klinikum D\\u00fcsseldorfKliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorfKlinik f\\u00fcr Psychosomatische Medizin und Psychotherapie\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Mahboobeh\", \"role_name_personal_family_name\": \"Dehghan Nayyeri\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"Mahboobeh.Dehghan-Nayyeri@lvr.de\", \"role_phone\": \"49(211)922-4768\", \"role_affiliation_name\": \"LVR-Klinikum D\\u00fcsseldorfKliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorfKlinik f\\u00fcr Psychosomatische Medizin und Psychotherapie\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Persistent somatoform pain disorder\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F45.4\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.05.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 60, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"at least 18 years\\nConfirmed diagnosis of somatoform pain disorder according to ICD-10 \", \"study_eligibility_exclusion_criteria\": \"\\u2022 COVID-19 disease in the infectious phase or symptoms that indicate a COVID-19 disease\\n\\n\\u2022 Past or current serious psychiatric, neurological or neuro-degenerative illnesses\\n\\n\\u2022 Current use of psychotropic drugs during the study participation (the use of antidepressants of the type SSRI, SSNRI, SNRI, SARI, if a stable dose has existed for at least 14 days, is tolerated.)\\n \\n\\u2022 Substance or alcohol abuse\\n\\n\\u2022 severe metabolic disorder, inflammatory diseases or tumor diseases\\n\\n\\u2022 uncorrected visual impairment (visual impairment)\\n\\n\\u2022 Disorders of the facial muscles\\n\\n\\u2022 Treatment with botulinum toxin (Botox) in the head area\\n\\n\\u2022 Insufficient German language skills\\n\\n\\u2022 Age: younger than 18 or older than 60 years\", \"study_population\": \"\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"EEG differences related to the processing time and the reaction pattern \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"EMG differences related to the processing time and the reaction pattern \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"All data can be viewed after anonymization. An informal application by e-mail to the study staff (PD Dr. J\\u00f6rg Rademacher) is sufficient. The study protocol, declarations of consent and the evaluation plan can also be viewed.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"EEG / EMG measurement when looking at emotional faces and processing questionnaires (patients with somatoform pain disorder / sick people) \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"EEG / EMG measurement when looking at faces and processing questionnaires (healthy subjects / control group)\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"EEG / EMG measurement when looking at emotional faces and processing questionnaires (patients with somatoform pain disorder after therapy)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025091","content":"{\"resource_id\": \"DRKS00025091\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"remote-patient-monitoring\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Prospective study analyzing course of disease and outcome in patients with acute COVID-19 with remote Patient monitoring\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"COVID-19 patients in the Rhein-Neckar district are included in a remote-patient-monitoring program either by phone or with a remote app in home quarantine. Data on course of disease, symptoms and outcome will be prospectively collected. The medical monitoring takes place via a remote dashboard to which all data will be transmitted.\\nIf medically indicated, home visit by the staff of the corona taxi team are in addition done. Blood and urine sampling to determine disease-relevant parameters as well as collection of 15ml of study related blood and urine will be performed. The aim of the study is to use analyze the clinical course of COVID-19, to identify predictive Parameters for the Course of the disease and to evaluate the outcome of the patients monitored via RPM.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVID-App\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025091\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"19.04.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_email\": \"uta.merle@med.uni-heidelberg.de\", \"role_phone\": \"004962215638709\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 59120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Uta\", \"role_name_personal_family_name\": \"Merle\", \"role_name_personal_title\": \"Ms. Prof. (apl.) Dr.\", \"role_name_identifiers\": [], \"role_email\": \"uta.merle@med.uni-heidelberg.de\", \"role_phone\": \"004962215638709\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 59120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Uta\", \"role_name_personal_family_name\": \"Merle\", \"role_name_personal_title\": \"Ms. Prof. (apl.) Dr.\", \"role_name_identifiers\": [], \"role_email\": \"uta.merle@med.uni-heidelberg.de\", \"role_phone\": \"004962215638709\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 59120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Emergency use of U07.1\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U07.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"25.05.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"acute COVID-19, written informed consent\", \"study_eligibility_exclusion_criteria\": \"Lack of legal capacity, lack of written consent, imprisonment, patients &lt;18 years.\", \"study_population\": \"\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Prospective analysis of COVID-19 patients monitored in home quarantine with patient-remote-Monitoring with respect to outcome and predictive Parameters.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Prospective register including biomaterials for analysis of predictive Parameters.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Anonymized data will be shared upon request after publication.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Data collection by means of RPM 3 times per day during the acute phase of the illness as well as data collection of the data collected in the case of corona taxi visits, in Addition recording of long-term outcome via phone-calls and mail up to 2 years after acute COVID 19.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025316","content":"{\"resource_id\": \"DRKS00025316\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Immunogenicity according to reactogenicity of Covid-19 vaccines\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"On December 27th 2020 Covid-19 vaccination have started at University Hospital Regensburg. A wide range of vaccine reactions have been observed. There are no data whether there is an association between reactogenicity and immunogenicity of Covid-19 vaccines. \\n\\nParticipants of this study are to be recruited from University Hospital Regensburg health care workers fully vaccinated with BNT162b2. \\n\\n45 Participants with severe vaccine reactions - resulting in absence from work - and 45 participants with no/minimal on injection side vaccine reactions are included. \\n\\nWe want to find out whether participants with severe vaccine reactions have a better immune response than the other group. Therefore we want to compare antibody levels and T-cell response - measured with ELISpot technique - of the two groups.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025316\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"12.05.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Regensburg\", \"role_email\": \"stilla.bauernfeind@ukr.de\", \"role_phone\": \"0941-944-4250\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Institut f\\u00fcr Mikrobiologie und Hygiene Regensburg\", \"role_email\": \"josef.koestler@ukr.de\", \"role_phone\": \"0941-944-16473\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Stilla\", \"role_name_personal_family_name\": \"Bauernfeind\", \"role_name_personal_title\": \"Ms. Dr. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"stilla.bauernfeind@ukr.de\", \"role_phone\": \"0941-944-4250\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Regensburg\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stilla\", \"role_name_personal_family_name\": \"Bauernfeind\", \"role_name_personal_title\": \"Ms. Dr. M.Sc.\", \"role_name_identifiers\": [], \"role_email\": \"stilla.bauernfeind@ukr.de\", \"role_phone\": \"0941-944-4250\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Regensburg\", \"role_affiliation_address\": \"Franz-Josef-Strau\\u00df-Allee 11, 93053 Regensburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Vaccination against SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U11.9\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"17.05.2021\", \"study_end_date\": \"18.06.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"o minimum age 18 years\\no two doses of BNT 162b2 at intervals of 3-6 weeks o 2nd dose 4-10 weeks before enrolment\\no informed consent\", \"study_eligibility_exclusion_criteria\": \"o no informed consent\\no no willingness to complete the survey\\no no history of covid-19\", \"study_population\": \"\", \"study_target_sample_size\": 90, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SARS-CoV-2 antibody level and T-cell response measured with ELISpot 4-10 weeks after 2nd vaccination with BNT162b2.\\n\\n\\n\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"survey results (demographic information, vaccine reaction information etc.)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"45 participants with severe vaccine reactions resulting in absence of work.\\n\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"45 participants without vaccine reactions or only minimal on injection side\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025503","content":"{\"resource_id\": \"DRKS00025503\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Ventilation-perfusion\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"gas exchange\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"mechanical ventilation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ARDS\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Ventilation \\u2013 Perfusion mismatch in COVID-19 as a potential cause for hypoxemia - a pathyphysioloigcal study\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"COVID-19 is a relatively new disease and many of its pathophysiological features are still unknown. COVID-19 associated Acute Respiratory Distress Syndrome (ARDS) may present atypical features when compared to ARDS from other forms. In particular, we have shown a remarkable dissociation between the well-preserved respiratory system mechanics and the severe impairment of the gas ex- change. Early in March 2020, this has led us to attribute the hypoxemia in COVID-19 to a dysregulation of the lung perfusion. Indeed, in the following months, more and more literature has shown that microthrombosis and perfusion inhomogeneity is a key feature of COVID-19 pneumonia. A definite proof that links the gas exchange impairment with the perfusion maldistribution is still lacking. We designed this study to provide the final word the question: what is the root cause of hypoxemia in COVID-19? To clarify  this, 13 critically-ill, COVID-19 positive, adult, mechanically ventilated patients will be studied with the Multiple Inert Gas Elimination Technique (MIGET) and Dual Energy CT scan. MIGET will be repeated after 5 days.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"VentPerf\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025503\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"23.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Robert-Koch-Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Robert-Koch-Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Mattia\", \"role_name_personal_family_name\": \"Busana\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"mattia.busana@med.uni-goettingen.de\", \"role_phone\": \"+495513966172\", \"role_affiliation_name\": \"An\\u00e4sthesie\", \"role_affiliation_address\": \"Robert Koch Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Onnen\", \"role_name_personal_family_name\": \"M\\u00f6rer\", \"role_name_personal_title\": \"Mr. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"omoerer@gwdg.de\", \"role_phone\": \"+495513967744\", \"role_affiliation_name\": \"An\\u00e4sthesie\", \"role_affiliation_address\": \"Robert Koch Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"ARDS from COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"13.10.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 90, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- ARDS from COVID-19\\n- Within 1 week from the Intubation\", \"study_eligibility_exclusion_criteria\": \"- Allergy to the radiological contrast\\n- Hepatic Cirrhosis\\n- ECMO/ECCO2R\\n- Patent foramen ovale\", \"study_population\": \"\", \"study_target_sample_size\": 13, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"We want to show that the functional (as evaluated by MIGET) and anatomical (as evaluated by DECT) features of COVID-19 ARDS are dissociated. \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The evolution of the causes of hypoxemia with passing time.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Protocol\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"13 COVID-19 patients within the 1 week from the intubation will undergo:\\n\\n1) MIGET: 6 inert gases (SF6, Ethane, Cyclopropane, Isoflurane, Ether und Acetone) dissolved in normal saline will be infused for 30 minutes (2 ml/min). An arterial blood and expired air samples will be taken and analyzed with gas chromatography\\n2) Hemodynamics and lung mechanics measurements\\n3) DECT\\n\\nPoint 1 and 2 will be repeated after 5 days. \"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00025507","content":"{\"resource_id\": \"DRKS00025507\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"immune cells\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"obstructive sleep apnea\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"chronic intermitted hypoxie\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"breathing-related sleep disorder\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Investigation of immune cells in patients with obstructive sleep apnea\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Obstructive sleep apnea (OSA) is the most common breathing-related sleep disorder and, according to evaluations of various studies, has a prevalence of up to 60.1% in adults (in Germany). OSA is characterized by repetitive partial or complete obstruction of the upper airways during the sleep phase, which leads to a decline in oxygen partial pressure in the blood and thus to an insufficient supply of tissues and organs (chronic intermittent hypoxia: CIH). \\nThe severity of OSA is indicated by the apnea / hypopnea index (AHI) (mild OSA: 5\\u2264 AHI \\u2264 15 / h; moderate OSA: 15 / h &lt; AHI \\u2264 30 / h; severe OSA: AHI &gt; 30 / h ). As a result, an untreated OSA is a risk factor for extensive health effects, ranging from daytime sleepiness, reduced quality of life, mental illness, arteriosclerosis, heart attack, stroke and cancer, which can partly be attributed to the development of reactive oxygen species (ROS). As a result, CIH can be the cause of changes in metabolism and the immune system.\\nRecently, we have shown a correlation between the severity of OSA and the oncological outcome in patients with squamous cell carcinoma of the head and neck region.\\nThe overall objective of ImZellOSA is an improved understanding of immune dysregulation in OSA and the development of predictive markers to identify high-risk patients.\\nFor this explorative study, specific immune cell populations (regulatory T-cells, CD4 + / CD8 +, naive / memory T-cells, \\u03b3\\u03b4 T-cells, dendritic cells (cDC1, cDC2, pDC), natural killer cells and monocytes (classic, inflammatory, vascular)) are compared between patients with clinically relevant OSA (AHI \\u2265 15 / h) and patients with mild OSA (AHI &lt; 15 / h).\\nEncouraged by the prospect of the investigation of CIH not only in OSA patients, but also in patients with squamous cell carcinoma of the head and neck region with comorbid OSA (approx. 95% of head and neck squamous cell carcinoma patients), the PD-1 / PD-L1 balance should be examined.\\nAdditionally, we focus on the investigation of the norepinephrine receptor on T-cells, because we see a connection of the disturbance of the immune regulation not only in correlation to the CIH, but also to other stressors associated with the autonomic nervous system, e.g. to a nocturnal hyper-arousal (awakening, sleep fragmentation/arousal).\\nThe study is financed by intramural funding of the University medical center Mainz.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ImZellOSA\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025507\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"20.07.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"15799 Votum mit Hinweisen vom  03.06.2021.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Ethikantrag ImZellOSA Version 3.0 20210606.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsmedizin der Johannes Gutenberg-Universit\\u00e4t MainzHals-, Nasen-, Ohrenklinik und Poliklinik\", \"role_email\": \"Haralampos.Gouveris@unimedizin-mainz.de\", \"role_phone\": \"06131-172099\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Langenbeckstr. 1, 55131 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Haralampos\", \"role_name_personal_family_name\": \"Gouveris\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Haralampos.Gouveris@unimedizin-mainz.de\", \"role_phone\": \"06131-172099\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin der Johannes Gutenberg-Universit\\u00e4t Mainz; Hals-, Nasen-, Ohrenklinik und Poliklinik\", \"role_affiliation_address\": \"Langenbeckstr. 1, 55131 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Haralampos\", \"role_name_personal_family_name\": \"Gouveris\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Haralampos.Gouveris@unimedizin-mainz.de\", \"role_phone\": \"06131-172099\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin der Johannes Gutenberg-Universit\\u00e4t Mainz; Hals-, Nasen-, Ohrenklinik und Poliklinik\", \"role_affiliation_address\": \"Langenbeckstr. 1, 55131 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Katharina\", \"role_name_personal_family_name\": \"Ludwig\", \"role_name_personal_title\": \"Ms. Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"Katharina.Ludwig@unimedizin-mainz.de\", \"role_phone\": \"06131-172099\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin der Johannes Gutenberg-Universit\\u00e4t Mainz; Hals-, Nasen-, Ohrenklinik und Poliklinik\", \"role_affiliation_address\": \"Langenbeckstr. 1, 55131 Mainz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"[generalization G47.3: Sleep apnoea]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"G47.31\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"16.07.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patient in the Sleep Medicine Centre &amp; Sleep Research Lab, Dept. of Otorhinolaryngology Head &amp; Neck Surgery, University Medical Center Mainz;\\nWillingness to participate in the study;\\nSuspicion of Obstructive Sleep Apnea;\\nSnoring or daytime sleepiness or observed breathing interruptions during sleep or an AHI \\u2265 5 / h screened by an outpatient cardiorespiratory  polygraph;\\nCurrently no therapy for breathing-related sleep disorders (e.g. continuous positive airway pressure: CPAP);\\nNo prior surgical procedure for OSA;\\nAge of the participant: &gt; 18 years;\\nGerman and / or English language skills\", \"study_eligibility_exclusion_criteria\": \"Age of the participant: &lt;18 years;\\nExisting pregnancy;\\nobesity (BMI&gt; 35 kg / m\\u00b2);\\nCOPD (chronic obstructive pulmonary disease);\\nHeart failure;\\nActive malignant disease (5 years after finishing the corresponding therapy);\\nHematological diseases (e.g. myelodysplastic syndrome);\\ndiagnosed immune deficiency (e.g. AIDS);\\nClinically relevant atherosclerosis (status post myocardial infarction, unstable angina pectoris, status post stroke, status post stenting of the coronary or peripheral arteries, status post surgery for peripheral arterial occlusive disease);\\nChronic active inflammatory diseases (psoriasis, rheumatoid arthritis, Wegener's disease, sarcoidosis, syst. Lupus erythemadotes, other autoimmune diseases);\\nActive specific infections (e.g. tuberculosis);\\nChronic therapy with oral steroids, immunosuppressants (e.g. cyclophosphamide, azathioprine or antibodies (immunotherapy);\\nRecently (within the last 4 weeks) history of vaccinations (e.g. against Covid-19)\", \"study_population\": \"\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Concentration / activity of blood CD4 + / CD8 + T cells\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Concentration / activity of blood dendritic cells (cDC1, cDC2, pDC)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"It is an exploratory study.\\nSpecific immune cell populations (T-cells (regulatory T-cells, CD4 + / CD8 +, naive / memory T-cells, \\u03b3\\u03b4 T-cells), dendritic cells (cDC1, cDC2, pDC), natural killer cells and monocytes (classic, inflammatory, vascular)) and also the PD-1 / PD-L1 balance and the norepinephrine receptor on T-cells in the blood of patients with obstructive sleep apnea are analyzed.\\nThe study participants are assigned to two different groups: \\n1) Patients diagnosed with a clinically relevant OSA (i.e. AHI \\u2265 15 / h)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"2) Patients diagnosed with a mild or clinically irrelevant OSA (i.e. AHI &lt;15 / h).\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025536","content":"{\"resource_id\": \"DRKS00025536\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Risk Assessment\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Score\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Validation of IKKA Score to unificate the evaluation of individual risk by a SARS-CoV-2 infection\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The assessment of estimated individual risks for a severe progression of COVID-19 presents significant challenges for doctors. The Score System, which has been processed and is to be tested in the given study, should offer a helpful resource for the standardisation of risk assessment, which should be sufficiently comprehensive and efficient to enable everyday usage in medical practice.\\n\\nMethodology\\nThe validity of the IKKA score should be evaluated in a retrolective-prospective, blinded approach using pseudonymised data of COVID-19 patients as well as people infected with SARS-CoV-2 without (severe) symptoms of the disease. For this purpose, data collection and evaluation should take the following steps into account:\\n1. Development of a table as well as a questionnaire designed to collect appropriate data on the persons mentioned above for the calculation of the IKKA score\\n\\n2. Blinding: Separation of initial diagnosis (sociodemographic data and data on prior conditions) and later progression of the SARS-CoV-2 infection.\\n\\n3. Calculation of the IKKA score in blinded form on the basis of comprehensive, pseudonymised data sets without knowledge of the corresponding progression of the SARS-CoV-2 infection.\\n\\n4. Aggregation of the calculated IKKA score and the data on the progression of the SARS-CoV-2 infection of the corresponding case.\\n\\n5. Statistical evaluation and presentation of results on the validity of the IKKA score.\\n\\n6. Investigation and presentation of autonomous risk factors for a severe progression of a COVID-19 disease via multivariate analysis of the collected data.\\n\\nObjective\\nThe primary objective of the study is the validation of the developed IKKA Score System. The secondary objective is the investigation of autonomous risk factors for a severe progression of COVID-19 in the studied collective on the basis of a multivariate analysis.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025536\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Institut und Poliklinik f\\u00fcr Arbeits-, Sozial- und Umweltmedizin (IPASUM)\", \"role_email\": \"hans.drexler@fau.de\", \"role_phone\": \"09131/8526150\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Henkestrassse 9-11, 91054 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Hans\", \"role_name_personal_family_name\": \"Drexler\", \"role_name_personal_title\": \"Mr. Prof. Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"hans.drexler@fau.de\", \"role_phone\": \"09131/85-26150  \", \"role_affiliation_name\": \"Institut und Poliklinik f\\u00fcr Arbeits-, Sozial- und Umweltmedizin (IPASUM)\", \"role_affiliation_address\": \"Henkestrasse 9 -11, 91054 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Hans\", \"role_name_personal_family_name\": \"Drexler\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"hans.drexler@fau.de\", \"role_phone\": \"09131/85-26150  \", \"role_affiliation_name\": \"Institut und Poliklinik f\\u00fcr Arbeits-, Sozial- und Umweltmedizin (IPASUM)\", \"role_affiliation_address\": \"Henkestra\\u00dfe 9-11, 91054 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tina\", \"role_name_personal_family_name\": \"Tischer\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"tina.tischer@fau.de\", \"role_phone\": \"091318526114\", \"role_affiliation_name\": \"Institut und Poliklinik f\\u00fcr Arbeits-, Sozial- und Umweltmedizin (IPASUM)\", \"role_affiliation_address\": \"Henkestrasse 9-11, 91054 Erlangen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"INFEKTION\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"22.06.2021\", \"study_end_date\": \"02.12.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Persons with a confirmed SARS-CoV-2 infection with  hospitalisation in Klinikum Weiden/Tirschenreuth or employees of the aforementioned clinic with a confirmed SARS-CoV-2 infection between 01/2020 and 12/2020\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 1379, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Using the issued questionnaires, the progression of the SARS-CoV-2 infection as well as the prior conditions of the corresponding person is retrospectively collected. Furthermore, the IKKA score is calculated in order to clarify whether the computation of an IKKA score is sufficient to identify persons with a severe progression of COVID-19.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Using the issued questionnaires, the prior conditions of the corresponding persons is retrospectively collected. With the aid of the collected data, potential autonomous risk factors should be investigated for a severe progression of a COVID-19 disease.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Validation of the IKKA score on patients and clinic employees of Kliniken Nordoberpfalz AG (Weiden, Tirschenreuth) with confirmed SARS-CoV-2 infection\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025606","content":"{\"resource_id\": \"DRKS00025606\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"neurological\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"long-term outcome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"neurorehabilitation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"long-COVID\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"COVID-19: Predictors, clinical course and long-term outcome\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Severe COVID-19 diseases can lead to considerable symptoms, which lead to long term sequelaes. Research about this new disease is of high importance regarding the lacking knowledge about disease course, prognosis and therapy approaches. Especially the long term sequelaes with symptoms lasting several months after the acute phase are poorly investigated so far. This cohort study with patients after COVID-19 disease shall help to gather information about this highly relevant disease. Additionally, predictors will be evaluated which allow prognoses e.g. in terms of a good long-term recovery. These questions will be answered by collecting data regarding independence in everyday life, health-related quality of life, activity and participation, fatigue, cognition, mental health, walking ability, utilization of health services up to one year after discharge. The first two study visits will take place at study inclusion and at discharge from rehabilitation, study visits 3,4 and 5 will be conducted 3,6 and 12 months after discharge with the help of telephone interviews.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025606\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"21.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Sch\\u00f6n Klinik Bad Aibling Harthausen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kolbermoorer Stra\\u00dfe 72, 83043 Bad Aibling, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Sch\\u00f6n Klinik Bad Aibling Harthausen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kolbermoorer Str. 72, 83043 Bad Aibling, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Marion\", \"role_name_personal_family_name\": \"Egger\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"megger@schoen-klinik.de\", \"role_phone\": \"08061 / 903 1954\", \"role_affiliation_name\": \"Sch\\u00f6n Klinik Bad Aibling Harthausen\", \"role_affiliation_address\": \"Kolbermoorer Str. 72, 83043 Bad Aibling, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U08.9G\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"02.06.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"laboratory-confirmed COVID-19 disease, after the infectious stage (after two negative PCR-tests), being discharged from intensive care unit.\", \"study_eligibility_exclusion_criteria\": \"Insufficient communication skills which would interfere with the accomplishment of the questionnaires and assessments, patients in palliative care. \", \"study_population\": \"\", \"study_target_sample_size\": 120, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Description of the clinical course and of the long-term outcome regarding motor function, activity and participation, lasting symptoms, mental health. \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Definition of predictors for a favorable health state at clinical discharge and 3,6 and 12 months after discharge. \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Five study visits will be conducted per patient. Visits 1 (at study inclusion) and visits 2 (at discharge from rehabilitation) consist of questionnaires and assessments regarding fatigue (Fatigue-Severity-Scale 7), overall disability (modified Rankin Scale), frailty (clinical frailty scale), anxiety and depression (Hospital Anxiety and Depression Scale), walking ability (Functional Ambulation Categories, Timed-Up-and-Go), motor function (Functional Status Score on Intensive Care Unit), strength (digital measurement of grip strength), dyspnoea (visual analogue scale; mMRC dyspnoea scale), health-related quality of life (EQ-5D-5L), pain and sensory impairments (visual analogue scale, descriptive) and olfactory function (sniffin\\u00b4 sticks). Additionally, information about the preclinical health status and living circumstances as well as information from the clinical records is collected. In the frame of clinical routine, electrophysiological tests, lung function tests and neuropsychological tests are carried out. \\nVisits 3,4 and 5 (3,6, and 12 months after discharge) are conducted as telephone interviews. Hereby, the before mentioned questionnaires as well as questionnaires regarding the overall health state (WHODAS-12), participation (reintegration to normal living\\u2013Index), impairments of attentiveness (German: \\u201cFragebogen Erlebter Defizite der Aufmerksamkeit (FEDA)\\u201c) and health services (medical / therapeutical services / live circumstances) are being used. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025704","content":"{\"resource_id\": \"DRKS00025704\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"TREATMENT OF HAND INFECTIONS USING WALANT -WHEN THE ANESTHESIOLOGIST IS NOT AVAILABLE: A RETROSPECTIVE COHORT STUDY\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of this study was to determine, if Wide Awake Local Anesthesia No Tourniquet (WALANT) can be used as an alternative method of providing anesthesia in management of deep infections of the hand. Since the advent of WALANT in 2003, infections of the hand have been regarded as a contraindication to its use. Occasional shortage of anesthesiologic manpower, especially during busy call hours and the current COVID-19 pandemic can lead to delay of treatment where urgent surgery is needed, to prevent progress of an infection, that can result in severe morbidity.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"WALINF\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025704\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"23.06.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Medizinische Hochschule Hannover\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Carl-Neuberg-Str. 1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"https://www.mh-hannover.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Medizinische Hochschule Hannover\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Carl-Neuberg-Str. 1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"https://www.mh-hannover.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Anieto\", \"role_name_personal_family_name\": \"Enechukwu\", \"role_name_personal_title\": \"Mr. \", \"role_name_identifiers\": [], \"role_email\": \"enechukwu.anieto@mh-hannover.de\", \"role_phone\": \"0049-(0)511 \\u2013 532 8894\", \"role_affiliation_name\": \"Klinik f\\u00fcr Plastische, \\u00c4sthetische, Hand- und WiederherstellungschirurgieMedizinische Hochschule Hannover (MHH)\", \"role_affiliation_address\": \"Carl-Neuberg-Str.1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Cellulitis of finger and toe\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"L03.0\"}, {\"study_conditions\": \"Cellulitis of other parts of limb\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"L03.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"10.03.2021\", \"study_end_date\": \"22.06.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Treatment of Handinfektions using WALANT\", \"study_eligibility_exclusion_criteria\": \"Allergy to Adrenaline or Lidocaine\", \"study_population\": \"\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The purpose of this study was to determine, if WALANT can be used as an alternative method to provide anesthesia in the management of deep tissue infections.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Delay of initiation of treatment following the arrival at the hospital and time of presentation after initial symptoms.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Data protection and privacy protection\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"We performed a retrospective cohort analysis of these patients and their surgical reports with emphasis on location of the infection, time of presentation, time till surgery and duration of operative treatment as well as intraoperative incidents and complications. We particularly evaluated the need for revision surgery and necessity to convert to general anesthesia. In addition to demographics and the aforementioned data collected, we included cause of the injury, bacterial contamination, antibiotic treatment, radiological images, comorbidities, laboratory values and histopathologic findings. Inclusion criteria was WALANT-technique in the treatment of hand infections.  Exclusion criteria were the ab initio use of a tourniquet, regional or general anesthesia. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025738","content":"{\"resource_id\": \"DRKS00025738\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"platelet factor 4; thrombosis; thrombocytopenia; SARS CoV2 vaccination\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"VITT\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Changes in anti-PF 4 antibodies in patients with VITT including changes of the antibodies after vaccination against COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Blood samples of patients with confirmed vaccine-induced thrombotic thrombocytopenia (VITT) will be assessed every 4 weeks regularly for follow-up of platelet activating antibodies. \\nWe used the PF4/heparin enzyme immunoassay to detect anti-PF4 IgG antibodies. Platelet activation by the antibodies will be tested in the PF4 dependent washed platelet assay. The results will be compared to previous samples of the same patient.\\nPatients with persistent antibodies will be identified. \\nPatients will be advised in case of additional vaccination or other medical interventions including duration of anticoagulation\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025738\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"02.07.2021\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"BB 052_21a EV Verwend Restblut  von Pat mit seltenen NW nach Covid2 Imfung.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"FV Amendment Verlaufskontrolle VITT.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Abteilung TransfusionsmedizinUniversit\\u00e4tsmedizin Greifswald\", \"role_email\": \"greinach@uni-greifswald.de\", \"role_phone\": \"03834 865482\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Sauerbruchstr, 17475 Greifswald, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Andreas\", \"role_name_personal_family_name\": \"Greinacher\", \"role_name_personal_title\": \"Mr. Prof Dr\", \"role_name_identifiers\": [], \"role_email\": \"greinach@uni-greifswald.de\", \"role_phone\": \"03834 865482\", \"role_affiliation_name\": \"Abteilung TransfusionsmedizinUniversit\\u00e4tsmedizin Greifswald\", \"role_affiliation_address\": \"Sauerbruchstr, 17475 Greifswald, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Linda\", \"role_name_personal_family_name\": \"Sch\\u00f6nborn\", \"role_name_personal_title\": \"Ms. Dr\", \"role_name_identifiers\": [], \"role_email\": \"linda.schoenborn@med.uni-greifswald.de\", \"role_phone\": \"+49 3834 865496\", \"role_affiliation_name\": \"Abteilung Transfusionsmedizin Greifswald\", \"role_affiliation_address\": \"Sauerbruchstr, 17475 Greifswald, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Linda\", \"role_name_personal_family_name\": \"Sch\\u00f6nborn\", \"role_name_personal_title\": \"Ms. Dr\", \"role_name_identifiers\": [], \"role_email\": \"Linda.Schoenborn@med.uni-greifswald.de\", \"role_phone\": \"+49 3834 865496\", \"role_affiliation_name\": \"Abteilung Transfusionsmedizin Greifswald\", \"role_affiliation_address\": \"Sauerbruchstra\\u00dfe, 17475 Greifswald, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Vaccine or biological substance, unspecified\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Y59.9\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"03.06.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"VITT with confirmed platelet activating anti-PF4 antibodies\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Changes in antibody titers; endpoint = date of the last, received blood sample of the patient. Antibody titers will be detected with PF4/heparin immuno assay\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Occurrence of new thrombosis and/or thrombocytopenia\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Study patients = patients with confirmed VITT after vaccination against COVID-19 with confirmed platelet activating antibodies against PF4.\\nFor follow-up of platelet activating antibodies, patients and/or the treating physicians send blood samples (ca. 4ml sera) every 4 weeks to the platelet lab of the Transfusion Medicine Greifswald. A PF4/heparin enzyme immunoassay will be performed to detect anti-PF4 IgG antibodies. Platelet activation by the antibodies will be tested in the PF4 dependent washed platelet assay. The results will be compared to previous samples of the same patient.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025794","content":"{\"resource_id\": \"DRKS00025794\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Pentaglobin\\u00ae\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"infection\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"immunoglobulins\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hyperinflammation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19, SARS-CoV-2, infection, hyperinflammation, immunoglobulins, Pentaglobin\\u00ae\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Use of human intravenous immunoglobulins in the treatment of severe COVID-19 \\u2013 a multicentre, pseudonymised, retrospective scientific data collection\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Polyclonal human intravenous immunoglobulins have been described as adjuvant or immunomodulatory therapy for various infectious diseases, and they can lead to an improvement in the clinical course and possibly also to an improved outcome. This effect has been described in severe community-acquired pneumonia and other hyper- inflammatory diseases. Therefore, polyclonal IgM-enriched preparations such as Pentaglobin\\u00ae could also offer a potential treatment benefit in severe COVID-19. Although IgM-enriched immunoglobulins are already used on this basis in the clinical care of COVID-19 patients at some centres, so far no multicentre retrospective data are available on the question of whether polyclonal human intravenous immunoglobulins (i.e. Pentaglobin\\u00ae) may offer potential treatment benefit in severe COVID-19. Such much-needed data could improve the evidence base and have a relevant impact both on the currently inadequate treatment options in severe COVID-19 and on the conduct of planned randomised controlled trials. The purpose of the multicentre, pseudonymised retrospective scientific data collection described here is to address this urgent need; it is intended to support, as promptly as possible, the acquisition of scientific data on possible adjuvant therapies in this pandemic.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Human immunoglobulin in COVID-19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025794\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"06.07.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Knappschaftskrankenhaus Bochum Klinik f\\u00fcr An\\u00e4sthesiologie, Intensivmedizin und Schmerzmedizin\", \"role_email\": \"Tim.Rahmel@ruhr-uni-bochum.de\", \"role_phone\": \"00492342993001\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"In der Schornau 23-25, 44892 Bochum, Germany\", \"role_affiliation_web_page\": \"http://www.anaesthesie.ruhr-uni-bochum.de/index.php?id=1\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Biotest AG\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Landsteinerstra\\u00dfe 5, 63303 Dreieich, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Tim\", \"role_name_personal_family_name\": \"Rahmel\", \"role_name_personal_title\": \"Mr. Priv.-Doz. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Tim.Rahmel@ruhr-uni-bochum.de\", \"role_phone\": \"00492342993001\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Knappschaftskrankenhaus Bochum Klinik f\\u00fcr An\\u00e4sthesiologie, Intensivmedizin und Schmerzmedizin\", \"role_affiliation_address\": \"In der Schornau 23-25, 44892 Bochum, Germany\", \"role_affiliation_web_page\": \"http://www.anaesthesie.ruhr-uni-bochum.de/index.php?id=1\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Tim\", \"role_name_personal_family_name\": \"Rahmel\", \"role_name_personal_title\": \"Mr. Priv.-Doz. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Tim.Rahmel@ruhr-uni-bochum.de\", \"role_phone\": \"00492342993001\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Knappschaftskrankenhaus Bochum Klinik f\\u00fcr An\\u00e4sthesiologie, Intensivmedizin und Schmerzmedizin\", \"role_affiliation_address\": \"In der Schornau 23-25, 44892 Bochum, Germany\", \"role_affiliation_web_page\": \"http://www.anaesthesie.ruhr-uni-bochum.de/index.php?id=1\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Severe COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"[generalization J80: Adult respiratory distress syndrome]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J80.0\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"11.07.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"International\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 26, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u02d7  Age \\u226518 years\\n\\u02d7  Confirmed infection with SARS-CoV-2\\n\\u02d7  Intensive-care treatment in the period between March 2020 and April 2021\\n\\u02d7  A severe course of COVID-19 disease with confirmation of (at least) one of the following symptoms:\\no Shortness of breath, respiratory rate \\u226530 breaths/minute\\no Oxygen saturation \\u2264 93% at rest under ambient air or mandatory oxygen\\no Oxygenation index \\u2264 300 mmHg (1 mmHg = 0.133 kPa)\", \"study_eligibility_exclusion_criteria\": \"Age &lt; 18 years\", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"30-day mortality\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"- Duration of stay in the intensive-care unit\\n- Duration of stay in hospital\\n- Mortality in the intensive-care unit\\n- Organ support free days (ventilation and vasopressor)\\n- Dialysis-free days\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"All individual participant data collected during the study will be shared after deidentification (anonymised data). Furthermore, the study-protocol and statistical analysis plan will be made available. The above mentioned data will be available beginning 3 months after publication and ending 36 months following article publication. Data will be made available to researchers on reasonable request (e.g. methodologically sound proposal). The request should be directed to Tim.Rahmel@ruhr-uni-bochum.de.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Treatment with IgM-enriched immunoglobulins\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00025986","content":"{\"resource_id\": \"DRKS00025986\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"parental stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"parenting style\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Adversive Childhood Experiences (ACE); psychopathology\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Assessment of parental adverse childhood experiences in children with psychological symptoms\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This study aims to evaluate the frequency of adverse childhood events (ACEs) and their association to stress caused by the COVID-19 pandemic in parents of children with psychiatric disorders. Further, we want to examine the effect of parental ACEs on parenting style and parental stress.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"-\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00025986\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"29.07.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie\", \"role_email\": \"eva.moehler@uks.eu\", \"role_phone\": \"06841 16 24395\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kirrberger Strasse, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"https://www.uks.eu/kjp\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Eva\", \"role_name_personal_family_name\": \"M\\u00f6hler\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"eva.moehler@uks.eu\", \"role_phone\": \"06841 16 24395\", \"role_affiliation_name\": \"Klinik f\\u00fcr Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie\", \"role_affiliation_address\": \"Kirrberger Strasse, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"https://www.uks.eu/kjp\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Justine\", \"role_name_personal_family_name\": \"Hussong\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"justine.hussong@uks.eu\", \"role_phone\": \"06841 16 24385\", \"role_affiliation_name\": \"Klinik f\\u00fcr Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie\", \"role_affiliation_address\": \"Kirrberger Strasse, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"https://www.uks.eu/kjp\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Stephanie\", \"role_name_personal_family_name\": \"Lion\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"stephanie.lion@uks.eu\", \"role_phone\": \"06841 16 24395\", \"role_affiliation_name\": \"Klinik f\\u00fcr Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie\", \"role_affiliation_address\": \"Kirrberger Strasse, 66421 Homburg, Germany\", \"role_affiliation_web_page\": \"https://www.uks.eu/kjp\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Disturbance of activity and attention\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F90.0\"}, {\"study_conditions\": \"All common child and adolescent psychiatric disorders \", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Nonorganic enuresis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F98.0\"}, {\"study_conditions\": \"Nonorganic encopresis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F98.1\"}, {\"study_conditions\": \"Depressive episode\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F32\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.09.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 17, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Age 0-17 years, written consent for study participation, sufficient German language knowledge\", \"study_eligibility_exclusion_criteria\": \"Age =/&gt; 18 years, insufficient German language knowledge \", \"study_population\": \"\", \"study_target_sample_size\": 350, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Assessment of associations between parental adverse childhood experiences (ACEs) and symptom severity, developmental factors in children and parental stress caused by the COVID-19-pandemic.\\n\\nAssessment by the following parental questionnaires: ACE-D; Corona-Belastungsbogen (questionnaire regarding stress caused by the pandemic), Child Behavior Checklist (CBCL), demographic information.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Effect of parental ACEs on paental stress and parenting style compared between 3 groups of children with different psychiatric disorders (internalizing disorder - ADHD - functional incontinence).\\n\\nAssessment by the following parental questionnaires: ACE-D; Child Behavior Checklist (CBCL), demographic information, parental stress questionnaire ('Elternstressfragebogen' - ESF); 'Eltern-Erziehungsinventar (EEI)' (Questionnaire assessing parenting style)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Caregivers (mostly parents) of all patients presented in the recruitment centers are assessed by questionnaires. \"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Caregivers (mostly parents) of all patients diagnosed with ADHD are assessed by questionnaires. \"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Caregivers (mostly parents) of all patients diagnosed with an internalizing disorder (anxiety disorder or depression) are assessed by questionnaires. \"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Caregivers (mostly parents) of all patients diagnosed with functional incontinence (wetting, soiling) are assessed by questionnaires. \"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00026029","content":"{\"resource_id\": \"DRKS00026029\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Humoral and cellular immune response of the adaptive immune system after vaccination or natural COVID infection\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"A comparison of humoral and cellular immune function after natural infection and/or vaccination will be performed in a collective of subjects (employees of the University Medical Center G\\u00f6ttingen) over time by repeated blood sampling. Basic properties of the adaptive immune system will be derived from these data.  This is also crucial for other infectious diseases such as influenza.  \\n\\nRetrospectively, we will determine which factors influence the development of the cellular and humoral immune response and in which way. In particular, factors such as previous (not currently existing) severe or mild COVID-19 infection, type of vaccination and timing of a vaccination, and age at vaccination will be considered. Fundamental factors affecting the immune system, such as chronic diseases (e.g. diabetes mellitus) or immunosuppression, will also be recorded.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COV-ADAPT\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026029\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.08.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Deutsche Forschungsgemeinschaft\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kennedyallee 40, 53175 Bonn, Germany\", \"role_affiliation_web_page\": \"https://www.dfg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Moritz\", \"role_name_personal_family_name\": \"Schnelle\", \"role_name_personal_title\": \"Mr. PD Dr. med\", \"role_name_identifiers\": [], \"role_email\": \"Moritz.schnelle@med.uni-goettingen.de\", \"role_phone\": \"05513965510\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen\", \"role_affiliation_address\": \"Robert-Koch Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Moritz\", \"role_name_personal_family_name\": \"Schnelle\", \"role_name_personal_title\": \"Mr. PD Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"moritz.schnelle@med.uni-goettingen.de\", \"role_phone\": \"0551-3965510\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen\", \"role_affiliation_address\": \"Robert-Koch-Stra\\u00dfe 40, 37075 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"https://www.humanmedizin-goettingen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Moritz\", \"role_name_personal_family_name\": \"Hollstein\", \"role_name_personal_title\": \"Mr. Dr. med. \", \"role_name_identifiers\": [], \"role_email\": \"moritz.hollstein@med.uni-goettingen.de\", \"role_phone\": \"0551-39066401\", \"role_affiliation_name\": \"Universit\\u00e4tsmedizin G\\u00f6ttingen\", \"role_affiliation_address\": \"Robert-Koch-Stra\\u00dfe 40, 37099 G\\u00f6ttingen, Germany\", \"role_affiliation_web_page\": \"https://www.humanmedizin-goettingen.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"IMPFANTWORT\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"U09.9\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"23.05.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 75, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Age between 18 and 75 years\\n- Ability to give consent is given \\n- Basic willingness to be vaccinated\\n- Basic willingness to have blood drawn at 3 points in time\\n- Employed at the University Medical Center G\\u00f6ttingen\", \"study_eligibility_exclusion_criteria\": \"- Acute COVID-19 infection\\n- domestic quarantine\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Antibody titer and T-cell response 3-6 months after the 2nd vaccination and 4-6 months after the 3 vaccination.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Development of the AK titre and the T cell response over time and the correlation between the two values\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Early-phase-1\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Before and after boost in heterologous ChAdOx (Astra Zeneca) vaccination, a total of three blood draws are performed (1st blood draw between prime and boost vaccination, 2nd blood draw up to three months after boost vaccination, and 3rd blood draw 3-6 months after boost vaccination).\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Before and after second vaccination with BNT (Biontech/Pfizer) vaccine, a total of three blood draws are performed (1st blood draw between prime and boost vaccination, 2nd blood draw up to three months after boost vaccination, and 3rd blood draw 3-6 months after boost vaccination).\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"After natural infection, before and after booster with BNT (Biontech/Pfizer) vaccine, a total of three blood draws are performed (1st blood draw between prime vaccination or natural infection and boost vaccination, 2nd blood draw up to three months after boost vaccination, and 3rd blood draw 3-6 months after boost vaccination).\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Regardless of arms 1-3, time point T4 (4-6 months after third vaccination) will be examined in all subjects who agree to continue in the study\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00026043","content":"{\"resource_id\": \"DRKS00026043\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"priorisation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"cancer\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"guidance\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"CancerCOVID - Allocating resources for cancer care in times of the Sars-CoV-2 outbreak. Evidence and ethical implications\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Allocation of health resources in times of a pandemic has potential clinically and ethically relevant implications for non-COVID-19 patients. However, a systematic assessment of evidence and interdisciplinary analyses regarding ethical and social aspects related to care for non-COVID-19 patients during the pandemic are missing. The interdisciplinary CancerCOVID consortium will analyse possible implications of the outbreak of Sars-CoV-2 for the access, process and outcomes of care, with a focus on patients with cancer in Germany. For this purpose, we will analyse quantitative data derived from the registry of colon cancer centres and data from a statutory health insurance provider regarding the care of patients with colorectal and pancreatic cancer. The focus of the analyses of new diagnoses, mortality, and of interactions with healthcare providers (i.e., preventative, diagnostic, and therapeutic) is the comparison of the year 2020 with the prior years, especially 2019. Findings will be compared to findings from similar analyses on diabetes, coronary heart disease and multiple sclerosis patients. In addition, we will explore the ethical and psycho-social challenges perceived by patients and health professionals during the pandemic by means of semi structured interviews and questionnaires. Based on the findings and together with major decision makers in the German healthcare system we will develop guidance for clinical and health policy decisions about priority settings regarding cancer care in times of pandemics and comparable major events.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CancerCOVID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026043\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"02.11.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Bundesministerium f\\u00fcr Bildung und Forschung, DLR Projekttr\\u00e4ger\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Heinrich-Konen Stra\\u00dfe 1, 53227 Bonn, Germany\", \"role_affiliation_web_page\": \"https://www.bmbf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Institut f\\u00fcr Geschichte und Ethik der Medizin, Martin-Luther-Universit\\u00e4t Halle-Wittenberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Magdeburger Str. 8, 06112 Halle (Saale), Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"Schildmann\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"jan.schildmann@medizin.uni-halle.de\", \"role_phone\": \"+493455573550\", \"role_affiliation_name\": \"Institut f\\u00fcr Geschichte und Ethik der Medizin, Martin-Luther-Universit\\u00e4t Halle-Wittenberg\", \"role_affiliation_address\": \"Magdeburger Str. 8, 06112 Halle (Saale), Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"Schildmann\", \"role_name_personal_title\": \"Mr. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"geschichte.ethik@medizin.uni-halle.de\", \"role_phone\": \"+493455573550\", \"role_affiliation_name\": \"Institut f\\u00fcr Geschichte und Ethik der Medizin, Martin-Luther-Universit\\u00e4t Halle-Wittenberg\", \"role_affiliation_address\": \"Magdeburger Str. 8, 06112 Halle (Saale), Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Division of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr-University Bochum\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Gudrunstr. 56, 44791 Bochum, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Center for Evidence-based Healthcare, University Hospital Carl Gustav Carus, Technische Universit\\u00e4t Dresden\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Fetscherstr. 74, 01307 Dresden, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Colorectal cancer, pancreatic cancer\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"coronary heart disease, diabetes mellitus, multiple sclerosis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"12.02.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"patients: presence of gastrointestinal cancer\", \"study_eligibility_exclusion_criteria\": \"lack of knowledge of German language, lack of capacity to give consent, Patients: veto of the treatment team \", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Aim: Assessment of ethical and psychosocial challenges in cancer care via semi-structured interviews with stakeholders (oncologists, nurses, patients) between January and July 2021. Assessment of psychosocial burden of oncologists, nurses and patients between February and July 2021 via questionnaires.\\npatients: Mini-SCL, EORTC QLQ-C30, NCCN Distress Thermometer, FACT-19\\noncologists: PHQ-9, PHQ-15, GAD-7, Maslach Burnout Inventory, Moral Distress Thermometer, FACT-19, sociodemographic questionnaire\\nnurses: PHQ-9, PHQ-15, GAD-7, Maslach Burnout Inventory, Moral Distress Thermometer, FACT-19, BERNCA, sociodemographic questionnaire \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"does not apply\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Not applicable\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"A qualitative interview study as well as a cross-sectional questionnaire survey is conducted with patients, oncologists and nurses working in the field of oncology (subproject 1). This is complemented by retrospective analysis of quantitative data derived from the registry of colon cancer centres (subproject 2) and data from the statutory health insurance (subproject 3).\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00026091","content":"{\"resource_id\": \"DRKS00026091\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"medical briefing\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"adverse effects\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"nocebo\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vaccination\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"LI(chten)Fe(ls) trial on the intensity of the nocebo effect concerning potential adverse effects after covid-19 vaccination based on the elaborateness of the medical briefing\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The hypothesis of the trial conjectures that a concise doctoral medical briefing before the SARS-CoV-2-vaccination can reduce the adverse side effects associated with the vaccination. The aim of the trial is the investigation of the correlation between the elaborateness of the doctoral medical briefing before vaccination against SARS-CoV-2 and the adverse effects experienced by the vaccinee.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"LIFe trial\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026091\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"10.05.2022\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Studienprotokoll.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Landratsamt Lichtenfels\", \"role_email\": \"\", \"role_phone\": \"09571180\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Gabelsbergerstr. 22, 96215 Lichtenfels, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Nora\", \"role_name_personal_family_name\": \"Beller\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"norabeller@gmail.com\", \"role_phone\": \"01714986777\", \"role_affiliation_name\": \"Impfzentrum Lichtenfels\", \"role_affiliation_address\": \"Gabelsbergerstr. 22, 96215 Lichtenfels, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Nora\", \"role_name_personal_family_name\": \"Beller\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"norabeller@gmail.com\", \"role_phone\": \"01714986777\", \"role_affiliation_name\": \"Impfzentrum Lichtenfels\", \"role_affiliation_address\": \"Gabelsbergerstr. 22, 96215 Lichtenfels, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Nora\", \"role_name_personal_family_name\": \"Beller\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"nora.beller@landkreis-lichtenfels.de\", \"role_phone\": \"09571180\", \"role_affiliation_name\": \"Landratsamt Lichtenfels\", \"role_affiliation_address\": \"Kronacherstr. 30, 96215 Lichtenfels, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"The trial hypothesis says that a concise medical briefing before SARS-CoV-2 vaccination can reduce the occurence and intensity of vaccination associated adverse effects.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.07.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Only patients that were willing and able to give consent are included in this study.\", \"study_eligibility_exclusion_criteria\": \"Patients that were not willing or unable to give consent were not included in this study.\", \"study_population\": \"\", \"study_target_sample_size\": 1500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"General occurrence of adverse effects, that can be attributed to the vaccination. Specification of the adverse effects that possibly occurred and their intensity. \\nUse of painkillers to reduce the adverse effects and, if yes, specification of the painkiller.\\nRequirement of a doctoral sick note after the vaccination and, if yes, duration of sick leave. \\nThese points are queried using an online or offline questionnaire 5 days after the vaccination (multiple choice).\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Rating of the visit at the Lichtenfels Vaccination Center. Satisfaction with the medical briefing.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared. Furthermore the Study Protocol, Statistical Analysis Plan and Analytic Code will be available. The data will be available beginning three months and ending five years following the article publication. The data will be shared with researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals should be directed to norabeller@gmail.com. To gain access, data requestors will need to sign a data access agreement.\\n\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The medical briefing of the control group will be very in-depth. The doctor will precisely adhere to the leaflet (\\u201edetailed medical briefing\\u201c) that had been handed out beforehand with all possible adverse effects reported for the vaccination.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The medical briefing of the experimental group will be limited to the medically relevant facts. The doctor will precisely stick to the leaflet (\\u201econcise medical briefing\\u201c) that had been handed out beforehand.\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00026607","content":"{\"resource_id\": \"DRKS00026607\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Test of the CLUNGENE COVID-19 Antigen Rapid Test for laypersons compared with results of a Covid 19 PCR test\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Test of the CLUNGENE\\u00ae COVID-19 Antigen Rapid Test des Sponsors Hangzhou ClongeneBiotech Co., Ltd. for sensitiviity, specifity and the usability  for lay persons.  The CLUNGENE\\u00ae COVID-19 Antigen Rapid Test is a Lateral-Flow-Immunoassay for the qualitative detection of the SARS-CoV-2-Nukleokapsid-Antigens of  nasal swabs for lay persons from age of 7 to adults. The reference test will be a commercial PCR test by licensed clinical lab.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026607\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"10.09.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Hangzhou Clongene Biotech Co., Ltd.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"No. 1 Yichuang Road, Yuhang Sub-district, Yuhang District , 311121 Hangzhou, China\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Xuxia\", \"role_name_personal_family_name\": \"Ying\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"clongene@clongene.com\", \"role_phone\": \"\", \"role_affiliation_name\": \"Hangzhou Clongene Biotech Co., Ltd.No. 1 Yichuang Road, Yuhang Sub-district, Yuhang District 311121Hangzhou, China\", \"role_affiliation_address\": \"No. 1 Yichuang Road, Yuhang Sub-district, Yuhang District, 311121 Hangzhou, China\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Zieger\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \" Michael.Zieger@srh.de\", \"role_phone\": \"+49 365 828 7758\", \"role_affiliation_name\": \"SRH Wald-Klinikum Gera GmbHZentrum f\\u00fcr klinische Studien\", \"role_affiliation_address\": \"Strasse des Friedens 122, 07548 Gera, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Zieger\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \" Michael.Zieger@srh.de\", \"role_phone\": \"+49 365 828 7758\", \"role_affiliation_name\": \"SRH Wald-Klinikum Gera GmbHZentrum f\\u00fcr klinische Studien\", \"role_affiliation_address\": \"Strasse des Freidens 122, 07548 Gera 07548 Gera, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Test of a Covid-19 rapid test used by lay persons based on a lateral flow immuno assay compared with aPCR assay.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Detection of Covid 19 antigens\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"14.09.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 7, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 85, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Persons with the ages of 7 to 85 \\n- Persons with and without symtoms of Covid 19 and with or without confirmed Covid 19 infection\\n-Persons with confirmed Covid 19 only until the day 7 after the positiv PCR test or the onset of clinical symptoms\\n- written consens of the probands after elucidation, for underaged persons until age of 18 years the written consent of the parents\", \"study_eligibility_exclusion_criteria\": \"-Persons with the age of lower than 7 years or age hgher than 85 years\\n-Persons with a bias to noose bleeding\\n-Skilled medical staff familiar with lateral flow tests\\n- Dylexics persons\\n-Certifiably insane persons\\n-Persons that had participated at the test before\", \"study_population\": \"\", \"study_target_sample_size\": 150, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Is the CLUNGENE COVID-19 Antigen Rapid Test save and easy to handle by lay persons? \\nComparison of the results of the CLUNGENE COVID-19 Antigen Rapid Test with a PCR reference test. The test will be observed and recorded by skilled persons.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Is the CLUNGENE COVID-19 Antigen Rapid Test suitable for the usage by lay persons? Observed and recorded by a skilled person.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"one arm, non intervention\\n\\nThe probands will perform only one self test with the Clungene Rapid Test Covid 19 under observation. The reference test is a PCR test performed by a clinical laboratory.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00026711","content":"{\"resource_id\": \"DRKS00026711\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Eligibility and efficacy of a CPC- and CHX-based antiviral mouthwash for the eliminaion of SARS-CoV-2 (COVID-19) from the saliva.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Currently, 83% (24/30) of EU countries (including Switzerland, the United Kingdom and Scotland) recommend the use of mouth rinses to eliminate SARS-CoV-2 in saliva before dental procedures (Becker et al. 2021).  \\nA particularly promising antiviral effect could be demonstrated in vitro for mouth rinses containing cetylpyridinium chloride (CPC) and chlorhexidine (CHX) (Mu\\u00f1oz-Basagoiti et al. 2021, Koch-Heier et al. 2021). \\nNevertheless, to the best of the authors' knowledge, there are currently no data on how long the effect lasts. Since SARS-CoV-2 replicates in the excretory ducts of the salivary glands and in the oral epithelium, and saliva is continuously produced, there is a possibility that the antiviral effect of the rinsing solutions does not last for the entire duration of a dental procedure. Therefore, the study aims to answer the following questions: \\n \\nIs a CPC+CHX-based antiviral mouth rinse suitable for the elimination of SARS-CoV-2 in saliva and what is its effectiveness? \\n \\nHospitalised patients from COVID-19 wards of the University Hospital D\\u00fcsseldorf will be included.  \\n  \\nSubjects will be randomly assigned to one of the following groups \\nTest group: cetylpyridinium chloride and chlorhexidine, conc. 0.05% each \\nControl group: sterile water \\nby opening a sealed envelope containing the respective group assignment. The patients should not know which group they are assigned to. Subsequently, the patients are asked to dispense 4 ml of oral saliva into a collection vessel for the quantitative determination of the viral load. They are then asked to rinse for 60 seconds with the mouth rinse solution, which is presented in a single-coloured cup without naming the product. Subsequently, after 15, 30 and 60 minutes, a further 4 ml of saliva is to be given for quantitative determination of the current viral load in the saliva. The quantitative determination of the viral load is carried out via quantitative reverse transcription real-time PCR (RT-qPCR) as well as via an ELISA kit (SARS-CoV-2 Nucleocapsid Protein(NP) High-sensitivity Quantitative ELISA Kit), which can detect the amount of SARS-CoV-2 Nucleocapsid protein.\\nSubsequently, the data of each group will be anonymised by Dr. Giulia Brunello and statistically analysed by PD Dr. Kathrin Becker (double blinding). For the statistical analysis, the Kruskal-Wallis test and the Nemenyi posthoc test (with p-value correction) will be used for each time point, provided that the Kruskal Wallis test has a P-value &lt; 0.05. \\n \\nInclusion criteria: \\nCOVID-19 positive able to rinse with a mouth rinse for 60 seconds and deliver 4 ml of saliva at each of the four time points. \\n \\nExclusion criteria: \\nVentilation Use of an antiseptic mouth rinse in the 48 hours prior to study entry Hypersensitivities or allergies to components of any of the mouth rinses Low viral load &lt; 25 samples by RT-qPCR. \\nPregnancy / breastfeeding Immunocompromised patients Xerostomia Tooth extraction less than 2 weeks ago  \\n\\n---\\n \\nReferences\\n\\nBecker K, Gurzawska-Comis K, Brunello G, Klinge B. Summary of European guidelines on infection control and prevention during COVID-19 pandemic. Clin. Oral Impl. Res. 2021; 00:1\\u201329. doi: 10.1111/ clr.13784. \\nKomine A, Yamaguchi E, Okamoto N, Yamamoto K. Virucidal activity of oral care products against SARS-CoV-2 in vitro. J Oral Maxillofac Surg Med Pathol. 2021;10.1016/j.ajoms.2021.02.002. doi:10.1016/j.ajoms.2021.02.002 Mu\\u00f1oz-Basagoiti J, Perez-Zsolt D, Le\\u00f3n R, Blanc V, Ra\\u00efch-Regu\\u00e9 D, Cano-Sarabia M, Trinit\\u00e9 B, Pradenas E, Blanco J, Gispert J, Clotet B, Izquierdo-Useros N. Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro. bioRxiv 2020.12.21.423779; doi:10.1101/2020.12.21.423779\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVID CHX-CPC\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026711\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"07.10.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Poliklinik f\\u00fcr Zahn\\u00e4rztliche Chirurgie und Aufnahme\", \"role_email\": \"jbecker@uni-duesseldorf.de\", \"role_phone\": \"02118118140\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Moorenstr. 5, 40225 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"J\\u00fcrgen\", \"role_name_personal_family_name\": \"Becker\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"jbecker@uni-duesseldorf.de\", \"role_phone\": \"02118118140\", \"role_affiliation_name\": \"Poliklinik  f\\u00fcr Zahn\\u00e4rztliche Chirurgie und Aufnahme\", \"role_affiliation_address\": \"Moorenstr. 5, 40225 D\\u00fcsseldrof, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Kathrin\", \"role_name_personal_family_name\": \"Becker\", \"role_name_personal_title\": \"Ms. PD Dr.\", \"role_name_identifiers\": [], \"role_email\": \"kathrin.becker@med.uni-duesseldorf.de\", \"role_phone\": \"+49 211 811 8145\", \"role_affiliation_name\": \"Poliklinik f\\u00fcr Kieferorthop\\u00e4die\", \"role_affiliation_address\": \"Moorenstr. 5, 40225 Dusseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Reduction of the risk of infection from dental staff during aerosol-generating procedures\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"None\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"19.01.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 80, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"COVID-19 positive\\nCapable of rinsing with a mouth rinse for 60 seconds and delivering 4 ml of saliva at each of the four time points\", \"study_eligibility_exclusion_criteria\": \"Ventilation\\nUse of an antiseptic mouth rinse in the 48 hours prior to study entry\\nHypersensitivities or allergies to components of any of the mouth rinses\\nLow viral load &lt; 25 samples by RT-qPCR \\nPregnancy / breastfeeding\\nPatients with weakened immune systems\\nXerostomia\\nTooth extraction less than 2 weeks ago\", \"study_population\": \"\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Nucleocapside (ELISA) fraction and virus load (qPCR) at 15 minutes\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Nucleocapside (ELISA) fraction and virus load (qPCR) at 30 and 60 minutes\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Hospitalized patients from COVID-19 wards of the University Hospital D\\u00fcsseldorf will be included.  \\n  The subjects will be randomly assigned to one of the following groups \\nTest group: cetylpyridinium chloride and chlorhexidine, concentration 0.05% each, Control group: sterile water. \\nRandomization will be performed by opening a sealed envelope containing the respective group assignment. The patients will not be told which group they will have been assigned to. Subsequently, the patients will be asked to provide 4 ml of oral saliva into a collection vessel for quantitative determination of the viral load. They will be then asked to rinse for 60 seconds with the mouth rinse solution, which will be provided in a colored tube with no product name. Subsequently, after 15, 30 and 60 minutes, a further 4 ml of saliva will be collected for quantitative determination of the current viral load in the saliva. The quantitative determination of the viral load will be performed by quantitative reverse transcription real-time PCR (RT-qPCR) as well as by an ELISA kit (SARS-CoV-2 Nucleocapsid Protein(NP) High-sensitivity Quantitative ELISA Kit), which can detect the amount of SARS-CoV-2 Nucleocapsid protein.\\nSubsequently, the data of each group will be anonymized by Dr. Giulia Brunello and statistically analyzed by PD Dr. Kathrin Becker (double blinding). For the statistical analysis, the Kruskal-Wallis test and the Nemenyi posthoc test (with p-value correction) will be used for each time point, provided that the Kruskal Wallis test has a P-value &lt; 0.05. \\n Study data will be made available on reasonable request.\\n\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Other\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Test group: cetylpyridinium chloride 0.05% and chlorhexidine 0.05% mouth rinses for 60 sec\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control group: sterile water for 60 sec\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00026778","content":"{\"resource_id\": \"DRKS00026778\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Vulnerable Groups in science and clinical care\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"First, a narrative literature review will be conducted. The aim of the review will be to capture in the existing research literature how previous research projects have defined vulnerable groups.\\nIn a second step, an exploratory qualitative study will be conducted in which a total of N=4 individuals will be interviewed. The content of the interviews will be the subjective working definition of the term \\\"vulnerable groups\\\" (see attached interview guide). \\nIncluded will be n=2 physicians and nurses, respectively. Recruitment will be done through personal contacts of the participating researchers. The interviews will have a duration of about 20-30 min.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"VulFoVer\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00026778\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"08.10.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum FreiburgSektion Versorgungsforschung und Rehabilitationsforschung\", \"role_email\": \"martina.bischoff@uniklinik-freiburg.de\", \"role_phone\": \"076127072461\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hugstetter Str. 49, 79110 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Martina\", \"role_name_personal_family_name\": \"Bischoff\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"martina.bischoff@uniklinik-freiburg.de\", \"role_phone\": \"076127072461\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum FreiburgSektion Versorgungsforschung und Rehabilitationsforschung\", \"role_affiliation_address\": \"Hugstetter Str. 49, 79110 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rieka\", \"role_name_personal_family_name\": \"von der Warth\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"rieka.warth@uniklinik-freiburg.de\", \"role_phone\": \"0761 270 73550\", \"role_affiliation_name\": \"Sektion Versorgungsforschung und Rehabilitationsforschung\", \"role_affiliation_address\": \"Hugstetter Str. 49, 79106 Freiburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"vulnerable groups\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"15.10.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Doctors, nurses\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 4, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Definition of vulnerable groups\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"/\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"N=4 interviews with physicians and nurses assessing their definition of \\\"vulnerable groups\\\"\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027094","content":"{\"resource_id\": \"DRKS00027094\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"antibody testing\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"IgG antibodies\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Antibody survey\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antibody development\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vaccination strategy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"health workers\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hospital staff\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"SARS-CoV-2 seroepidemiological investigation among healthcare workers at BG Klinikum Unfallkrankenhaus Berlin gGmbH (COVID-19)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"As part of a descriptive hypothesis-generating prevalence survey, the SARS-CoV-2-IgG antibody titers of voluntarily participating employees of the ukb are measured and, using an accompanying questionnaire, data on gender, year of birth, type of service and department, positive PCR test in the past and received vaccinations against SARS-CoV-2 are collected. Antibody ratios and neutralization titers of employees who tested seropositive, which were measured during an examination at the ukb in May / June 2020 and December 2020, are to be related to the prospective values \\u200b\\u200bto be collected.\\n\\nWith the planned project, we would like to expand the current state of research to include knowledge of how quantitatively SARS-CoV-2 immunoglobulin G (IgG) antibody titers are represented in a large cohort of hospital staff about 5-9 months after the primary vaccination has taken place and to what extent the titre varies depending on vaccination strategy, time interval between the second vaccination, proven SARS-CoV-2 infection, age, gender and occupational group. This should contribute to better understand the development of the antibody level over time and to be able to determine the point in time at which a future vaccination is necessary.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027094\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"12.11.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"BG Klinikum Unfallkrankenhaus Berlin gGmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Warener Stra\\u00dfe 7, 12683 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Robert Koch-Institut\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Nordufer 20, 13353 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"BG Klinikum Unfallkrankenhaus Berlin gGmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Warener Stra\\u00dfe 7, 12683 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Kristina\", \"role_name_personal_family_name\": \"Zappel\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"kristina.zappel@ukb.de\", \"role_phone\": \"030-56814050\", \"role_affiliation_name\": \"Zentrum f\\u00fcr Klinische Forschung BG Klinikum Unfallkrankenhaus Berlin gGmbH\", \"role_affiliation_address\": \"Brebacher Weg 15, Haus 49, 12683 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Kristina\", \"role_name_personal_family_name\": \"Zappel\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"kristina.zappel@ukb.de\", \"role_phone\": \"030-5681-4050\", \"role_affiliation_name\": \"Zentrum f\\u00fcr Klinische Forschung BG Klinikum Unfallkrankenhaus Berlin gGmbH\", \"role_affiliation_address\": \"Brebacher Weg 15, Haus 49, 12683 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV-2-IgG antibodies\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"04.01.2022\", \"study_end_date\": \"27.01.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1. Employed at ukb / subsidiaries of ukb\\n2. Age&gt; = 18 years\\n3. Able to give consent\\n4. Signed informed consent\", \"study_eligibility_exclusion_criteria\": \"1. Not employed at ukb / subsidiaries of ukb\\n2. Age &lt;18 years\\n3. Incapable of consent\\n4. No signed informed consent available\", \"study_population\": \"\", \"study_target_sample_size\": 1500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"No primary endpoint in the traditional sense due to the design of the study.\\n\\nPrimary question: Determination of the relationship between the quantitative antibody response and the vaccination strategy.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"No secondary endpoint in the traditional sense due to the design of the study.\\n\\nSecondary question: Influence of the time interval after the second vaccination, age, gender, occupational group, previous infection and booster vaccination on the quantitative antibody response.\\n\\nTertiary question: Development of the antibody response of employees who have previously tested seropositive.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Blood is taken once from employees of the ukb to test the antibody response to a vaccination and to a possible SARS-CoV-2 infection. In a short accompanying questionnaire, the professional activity, prior evidence of infection with SARS-CoV-2, vaccinations against SARS-CoV-2 as well as age and gender are recorded.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027218","content":"{\"resource_id\": \"DRKS00027218\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Covid-19 in patients with inflammatory bowel diseases: rates and courses of infection, rates of vaccination, potential side effects and antibody titers - An evaluation at the outpatient clinic for IBD of the University Hospital Heidelberg\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Inflammatory bowel disease (IBD) are relapsing or continuous inflammatory diseases of the gastrointestinal tract, but especially of the intestine, the etiology and pathogenesis of which have not yet been adequately clarified, and which in the affected patients usually imply a considerable impairment of the quality of life. The IBD disease group mainly includes ulcerative colitis and Crohn's disease. In particular, the more severe forms of the diseases are treated almost exclusively with immunosuppressive drugs, such as steroids, thiopurines (azathioprine, 6-mercaptopurine), or biologics (TNF\\u03b1 inhibitors, integrin inhibitors, IL12 / 23 inhibitors). Patients with immune-mediated diseases such as chronic inflammatory bowel disease can be exposed to an increased risk of SARS-CoV2 infections with severe courses, on the one hand due to the disease-related changes themselves and on the other hand due to the necessary immunocompromising drugs. The data available on this is currently still limited. With regard to the vaccinations available against a SARS-CoV2 infection, patients often have concerns about side effects, for example about a feared triggering of a disease flare-up by the vaccinations, but also about their effectiveness against the background of the frequently used immunosuppressive therapies. For a well-founded education of our patients and thus for an optimization of their care, we feel it is important to know our own data with which the questions listed above can be addressed in our IBD cohort.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Covid19CED\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027218\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"15.11.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 672, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Im Neuenheimer Feld 672, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Annika\", \"role_name_personal_family_name\": \"Gauss\", \"role_name_personal_title\": \"Ms. Prof. (apl.)\", \"role_name_identifiers\": [], \"role_email\": \"annika.gauss@med.uni-heidelberg.de\", \"role_phone\": \"062215638865\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Inflammatory Bowel Diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"16.11.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"a) Patient with ulcerative colitis or Crohn's disease reliably diagnosed according to the criteria of the DGVS (German Society for Digestive and Metabolic Diseases)\\nb) Age from 18 years\\nd) Treatment in the Department of Internal Medicine IV of the Heidelberg University Hospital at the time of sample collection\\ne) The patient is able to give consent.\\nf) Signed declaration of consent\", \"study_eligibility_exclusion_criteria\": \"Failure to meet the inclusion criteria\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The main objectives of the project are:\\n1. to record the prevalence of SARS-CoV2 infection in our IBD cohort,\\n2. Describe the severity of any SARS-CoV2 infections you may have had (hospitalization, intensive care treatment),\\n3. to record the vaccination rates against SARS-CoV2 in our cohort,\\n4. Describe the serological response (S and N antibodies) to SARS-CoV2 infection and vaccinations at different times, and\\n5. To record possible side effects of the vaccinations, especially with regard to the course of IBD.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In a further step, possible connections between disease activity of IBD, immunosuppressive therapy and both the severity of a possible SARS-CoV2 infection and the serological vaccination response are to be established. (knowing that the informative value of a serological evaluation alone is limited).\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The study is an observational cohort study with only one group. All patients are asked to fill in a questionnaire on potential Covid-19 infections, theit courses and vaccinations against Covid-19 as well as potential side effects.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027298","content":"{\"resource_id\": \"DRKS00027298\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Fine-tuning and coordination of synergistic and antagonistic upper limb muscles in frail people - Biomechanics meets Frailty\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of this study is to systematically investigate the relationship between muscular coordination patterns and the degree of frailty. \\nPersons over 65 years of age, healthy active and frail subjects, are systematically measured for this purpose. The flexion and extension of the elbow can be controlled in a standardized manner using a pulley. The joint angle, the speed and the muscle activity of biceps brachii, brachioradialis and triceps brachioradialis are measured during specified movements at different speeds.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"FUSIFoRM\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027298\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"03.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinik f\\u00fcr Altersmedizin - Medizinische Klinik VIUniklinik RWTH Aachen am Franziskus\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Morillenhang 27, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinik f\\u00fcr Altersmedizin - Medizinische Klinik VIUniklinik RWTH Aachen am Franziskus\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Morillenhang 27, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Thea\", \"role_name_personal_family_name\": \"Laurentius\", \"role_name_personal_title\": \"Ms. Dr. med. Dipl.-Ing.\", \"role_name_identifiers\": [], \"role_email\": \"tlaurentius@ukaachen.de\", \"role_phone\": \" 0241 7501-625/525\", \"role_affiliation_name\": \"Klinik f\\u00fcr Altersmedizin - Medizinische Klinik VIUniklinik RWTH Aachen am Franziskus\", \"role_affiliation_address\": \"Morillenhang 27, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Yvonne\", \"role_name_personal_family_name\": \"Fait\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"ifait@ukaachen.de\", \"role_phone\": \" 0241 7501-625/525\", \"role_affiliation_name\": \"Klinik f\\u00fcr Altersmedizin - Medizinische Klinik VIUniklinik RWTH Aachen am Franziskus\", \"role_affiliation_address\": \"Morillenhang 27, 52074 Aachen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Frailty\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Suspended: Recruitment, data collection, or data quality management, halted, but potentially will resume\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Suspended\", \"study_start_date\": \"28.09.2020\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 65, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1. \\u2265 65 years of age.\\n2. written declaration of consent.\\n3. Individuals who are legally competent and mentally capable of following staff instructions.\\n\\nFor the control group:\\n4. persons who are classified as non-frail or pre-frail (score \\u2264 2) according to the diagnostics regarding physical frailty, according to Fried's phenotype model [Fried et al., 2001].\\n\\nFor the study group:\\n4. persons who are classified as frail (score \\u2265 3) according to the phenotype model of Fried (Fried et al. 2001).\", \"study_eligibility_exclusion_criteria\": \"1. persons who have been placed in an institution by order of the authorities or the courts\\n2. persons who are in a dependent or working relationship with the examiner\\n3. persons who can perform upper extremity movement only with pain (e.g., due to osteoarthritis or tendonitis)\\n4. persons who have comorbidities that affect movement (e.g. orthopedic disease, neurological disease such as stroke and Parkinson's syndrome, or other relevant (neuro) psychiatric disease such as psychosis or dementia)\\n5. persons with a severe visual impairment\\n6. 3-G rules apply to all subjects: Only subjects with full vaccination protection, recovery status, or a negative current Sars-Cov-2 test can participate. If symptoms of a possible Covid-19 infection (e.g. fever, flu-like symptoms, cough etc.) appear, if the participants have had unprotected contact with Sars-Cov-2 infected persons in the last 14 days or if they have been abroad, they will be excluded for the duration of a possible Sars-Cov-2 infection.\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Influence of external load and movement speed on muscular coordination patterns and the relationship between frailty (according to Frailty Score 0-5) and muscular activation (in %)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"General correlation between occurring muscular coordination patterns and degree of frailty (according to Fried), age, and sex.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Frailty, muscular Coordination, ellbow flexion and extension\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"muscular coordination pattern of older people with frailty (Score higher or same as 3 after Fried)\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"control group of healthy older people (Frailty Score after Fried smaller as or equal to 2)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027310","content":"{\"resource_id\": \"DRKS00027310\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Beck Depression Inventory-II\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2 pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"item distribution\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"lockdown\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Beck Depression Inventory-II item distribution under COVID-19 pandemic in a day clinic/on regular wards under inpatient treatment in the LVR clinic D\\u00fcsseldorf \\u2013 clinics of the Heinrich-Heine-University D\\u00fcsseldorf\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Background: SARS-CoV-2 pandemic led to worldwide restrictions in daily life. After Sunday March 22nd 2020 when the german government announced a prohibition of contact, patients from our clinic claimed feelings of uncertainty and depressive symptoms. Depression is a common mental disorder and leading cause of disability worldwide (WHO 2020). Evaluation of symptoms for diagnosis and therapy is important. Depressive symptoms under SARS-CoV-2 pandemic can be amplificated. The Beck Depression Inventory-II (BDI-II) is an established self-disclosure questionnaire, focussing on negative thoughts about the world, the future and the self and is used during therapy to evaluate the severity of symptoms of patients with depression.  \\n\\nObjective: Based on patient contacts in doctor\\u2019s round where patients reported feelings of uncertainty and depression, we hypothesize that these complaints lead to changes in the BDI-II. We further hypothesize that the BDI-II might be useful to evaluate symptoms of psychiatric patients under pandemic. Findings could help to evaluate and treat psychiatry patients more effective under pandemic and shed more light on the utility of the BDI-II under pandemic. \\n\\nMethod: In a retrospective analysis the weekly BDI-II before (e.g. March, June, November  2019) and after the german government announced a prohibition of contact on the 22nd of March 2020 (e.g. June, November 2020 and March, April 2021) will be analyzed.\\n\\nData will be pseudonymized for the collection in one table and next anonymized before entering statistical analyses. Main focus here are changes pre and post lockdown announcement (begin of prohibition of contact on the 22nd of March 2020) of BDI-II total score and item scores. Data of psychiatric patients from two regular wards and one day clinic will be included when they were aged between 18 and 65 years. Patients are included independent of psychiatric ICD-10 diagnosis and regarding feelings of uncertainty (pandemic specific symptoms). The changes in BDI-Il will be compared to usual changes from one BDI-II result to another of patients under same therapeutic conditions in periods before (March, June, November 2019) and other timepoints still under pandemic ((a) June 2020 (b) begin 2nd lockdown on 2nd of November 2020 (c) 23rd of March 2021- announcement \\u201ceaster lockdown\\u201d (d) 24th of April 2021 \\u2013 begin \\u201cemergency break\\u201d) using the students t-test and chi square test. \\n\\nFurther CGI and GAF scores from the beginning and end of the therapy will be analyzed. Additionally minor and major depressive symptoms from doctor\\u2019s rounds, pandemic specific symptoms from doctor\\u2019s rounds, age, sex, occupation, number of psychiatric medication, psychiatric ICD-10 diagnosis, number of somatic diseases, duration of psychiatric diagnosis, age of onset of psychiatric diagnosis, form of ward (regular/day clinic), regular discharge (yes/no), BDI total score and item score upon admission/discharge, therapy days at pandemic specific timepoint and form of psychotherapy will be included.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"BDI-2-ID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027310\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"01.12.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"LVR-Klinikum D\\u00fcsseldorf - Kliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorf\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"LVR-Klinikum D\\u00fcsseldorf - Kliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorf\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Timo Jendrik\", \"role_name_personal_family_name\": \"Faustmann\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"timo.faustmann@lvr.de\", \"role_phone\": \"02119223430\", \"role_affiliation_name\": \"LVR-Klinikum D\\u00fcsseldorf - Kliniken der Heinrich-Heine-Universit\\u00e4t D\\u00fcsseldorf\", \"role_affiliation_address\": \"Bergische Landstra\\u00dfe 2, 40629 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Depressive episode\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F32\"}, {\"study_conditions\": \"Bipolar affective disorder\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F31\"}, {\"study_conditions\": \"Specific personality disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F60\"}, {\"study_conditions\": \"Schizoaffective disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F25\"}, {\"study_conditions\": \"Schizophrenia\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F20\"}, {\"study_conditions\": \"Acute and transient psychotic disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F23\"}, {\"study_conditions\": \"Mental and behavioural disorders due to use of alcohol\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F10\"}, {\"study_conditions\": \"Mental and behavioural disorders due to use of cannabinoids\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F12\"}, {\"study_conditions\": \"Recurrent depressive disorder\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F33\"}, {\"study_conditions\": \"Phobic anxiety disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F40\"}, {\"study_conditions\": \"Eating disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F50\"}, {\"study_conditions\": \"Mild mental retardation\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F70\"}, {\"study_conditions\": \"Specific developmental disorders of speech and language\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F80\"}, {\"study_conditions\": \"Hyperkinetic disorders\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F90\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.01.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 65, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients with psychiatric diagnosis (F diagnosis) on two regular wards and one day clinic in the LVR clinic D\\u00fcsseldorf\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"How is the BDI-II item distribution under certain timepoints under SARS-CoV-2 pandemic\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"How specific is the BDI-II under SARS-CoV-2 pandemic\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be collected at the LVR clinic D\\u00fcsseldorf. Data won't bei transferred to further institutions.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients from the year 2020 and 2021.\\nIn a retrospective analysis the weekly BDI-II before (e.g. March, June, November  2019) and after the german government announced a prohibition of contact on the 22nd of March 2020 (e.g. June, November 2020 and March, April 2021) will be analyzed.\\n\\nData will be pseudonymized for the collection in one table and next anonymized before entering statistical analyses. Main focus here are changes pre and post lockdown announcement (begin of prohibition of contact on the 22nd of March 2020) of BDI-II total score and item scores. Data of psychiatric patients from two regular wards and one day clinic will be included when they were aged between 18 and 65 years. Patients are included independent of psychiatric ICD-10 diagnosis and regarding feelings of uncertainty (pandemic specific symptoms). The changes in BDI-Il will be compared to usual changes from one BDI-II result to another of patients under same therapeutic conditions in periods before (March, June, November 2019) and other timepoints still under pandemic ((a) June 2020 (b) begin 2nd lockdown on 2nd of November 2020 (c) 23rd of March 2021- announcement \\u201ceaster lockdown\\u201d (d) 24th of April 2021 \\u2013 begin \\u201cemergency break\\u201d) using the students t-test and chi square test. \\n\\nFurther CGI and GAF scores from the beginning and end of the therapy will be analyzed. Additionally minor and major depressive symptoms from doctor\\u2019s rounds, pandemic specific symptoms from doctor\\u2019s rounds, age, sex, occupation, number of psychiatric medication, psychiatric ICD-10 diagnosis, number of somatic diseases, duration of psychiatric diagnosis, age of onset of psychiatric diagnosis, form of ward (regular/day clinic), regular discharge (yes/no), BDI total score and item score upon admission/discharge, therapy days at pandemic specific timepoint and form of psychotherapy will be included.\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients (2019)\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027324","content":"{\"resource_id\": \"DRKS00027324\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"fever\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-COV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Microbiome\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Vaccination and the human intestinal microbiome\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The intestinal microbiota has a profound influence on host health, in particular through its influence on immunity and susceptibility to infectious disease1,2. In turn, the immune system shapes the microbiota and modulates its activity2. However, while immune-microbiota interactions have been extensively studied in animal models, human data is limited. Emerging evidence suggests that the microbiota also influences human immune responses3. A better understanding of interactions between the gut microbiota and the human immune system is necessary to understand the impact of gut microbes on infection, vaccination, and immune homeostasis.\\nVaccine responses are heterogeneous between individuals and populations. This is a matter of serious public health concern, particularly in low- and middle- income countries, where oral vaccines for poliovirus, norovirus and cholera are significantly less effective than in industrialized settings4,5. More broadly, variation in the strength of immune responses between individuals can influence their protection against disease6. Given the influence of the gut microbiota on immune development, it has been proposed that variation in microbiota composition might underlie variation in vaccine responses3,4,7. Increased bacterial diversity and abundance of immunogenic Proteobacteria has been associated with improved responses to rotavirus and flu vaccines8\\u201312, suggesting the microbiota may act as a \\u2018natural adjuvant\\u2019. However, other studies have reported conflicting results, indicating that microbiota diversity and pathogen loads correlate negatively with vaccine responsiveness13\\u201316. Human studies to date have often been small and cross-sectional, and most have been performed in pediatric populations with underlying malnutrition and infectious disease; thus, the impact of microbiota on vaccine responses in healthy adults remains unclear.\\nVaccine-induced immune responses may in turn influence microbiota composition or activity, yet little is known about the impact of these immune responses on the intestinal microbiome. Like infectious disease, many vaccines induce a strong innate immune response, including fever. The evolutionary benefit of fever is to restrict the growth and activity of pathogenic microbes; indeed, microbial activity is inherently temperature-sensitive17,18. Acute immune responses in mice activate heat shock response genes in the gut microbiome19, while fever-like body temperatures have been associated with changes in microbiota composition in a variety of animal species20. Immunological fevers thus have the potential to alter the gastrointestinal niche, influencing the growth and activity of the intestinal microbiota.\\nMass vaccination campaigns against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) provide an unprecedented opportunity to study interactions between the healthy human microbiota and a defined, sterile and predictable immune response. All leading SARS-CoV2 vaccines induce a strong innate immune response, including fever in one-quarter to one-half of younger recipients21\\u201324. Moreover, antibody titers against SARS-CoV2 vaccinations, while generally robust, show substantial heterogeneity between individuals22\\u201324. The strength of the antibody response is linked to functional protection against the virus and thus is highly relevant to disease protection25. Here, we propose to profile the gut microbiota and immune response in healthy volunteers before and after SARS-CoV-2 vaccination in order to understand (a) the influence of the microbiota on immune responsiveness to vaccination and (b) the impact of immune activation on the microbiota.\\nA better understanding of immune-microbiota interactions in humans is of both fundamental and clinical importance. Understanding the impact of immune activation on the microbiota is highly relevant to the study of inflammatory and infectious disease, and may provide insight into the etiology of microbiota perturbations in these populations. Furthermore, defining microbiota factors that contribute to vaccine responsiveness would allow for the design of improved vaccination strategies in under-responsive populations, an area of immense global health relevance.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\\u00b5HEAT\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027324\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"07.07.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Department of Microbiome ScienceMax Planck Institute for Developmental Biology\", \"role_email\": \"ruth.ley@tuebingen.mpg.de\", \"role_phone\": \"+49 7071601449\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Max-Planck-Ring 5, 72076 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Ruth\", \"role_name_personal_family_name\": \"Ley\", \"role_name_personal_title\": \"Ms. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"ruth.ley@tuebingen.mpg.de\", \"role_phone\": \"+49 7071601449\", \"role_affiliation_name\": \"Department of Microbiome ScienceMax Planck Institute for Developmental BiologyEberhards Karls University of Tubingen\", \"role_affiliation_address\": \"Max-Planck-Ring 5, 72076 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Alexandra\", \"role_name_personal_family_name\": \"Roth\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"alexandra.roth@medizin.uni-tuebingen.de\", \"role_phone\": \"+49 7071 2982187\", \"role_affiliation_name\": \"Eberhard Karls University of T\\u00fcbingenMedizinische Klinik Innere Medizin VII, Institut f\\u00fcr Tropenmedizin, Reisemedizin, Humanparasitologie, Kompetenzzentrum Tropenmedizin Baden-W\\u00fcrttemberg\", \"role_affiliation_address\": \"Wilhelmstr. 27, 72074 T\\u00fcbingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Meral\", \"role_name_personal_family_name\": \"Esen\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"meral.esen@uni-tuebingen.de\", \"role_phone\": \"+4970712980240\", \"role_affiliation_name\": \"Eberhard Karls University of T\\u00fcbingenMedizinische Klinik Innere Medizin VIIInstitut f\\u00fcr Tropenmedizin, Reisemedizin, Humanparasitologie, Kompetenzzentrum Tropenmedizin Baden-W\\u00fcrttemberg\", \"role_affiliation_address\": \"Wilhelmstr. 27, 72074 Tubingen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Covid-19\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"U07.1\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"17.11.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 40, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Participants must be adults 18-40 years of age, with no underlying health conditions, belonging to the Robert Koch priority group 4 (de-prioritized for vaccination). Participants must intend to be vaccinated against COVID-19 and be able to receive their vaccination during the study timeline (~Sept 2021-Dec 2022). Any of the COVID-19 vaccinations approved by the Robert Koch Institute at the time of study participation (e.g., BioNTech/Pfizer, Moderna, Johnson &amp; Johnson or other commercially available vaccines) will be permitted for inclusion in the study, including booster shots. Participants must be able to read and understand German or English to provide informed consent for themselves. \", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria include known gastrointestinal disorders (e.g., Inflammatory Bowel Disease or Celiac Disease), recent antibiotics use (any antibiotics taken in the three months prior to study participation), and pregnancy. Any health factor which places someone at higher risk of COVID-19 disease, and therefore in a higher vaccine priority group (1-3) according to the Robert Koch Institute will also be excluded. These exclusion risk factors, as listed by the Robert Koch Institute, include diabetes mellitus, obesity (BMI&gt;30), asthma, autoimmune diseases, neurological diseases, cancer, and diseases of the lung, heart, liver, or kidney. Immunocompromised and immunosuppressed people are also explicitly excluded. \\nHowever, healthy individuals who receive vaccine prioritization for occupational reasons (for example, researchers working at the hospital campus) are not excluded from the study.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 256, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"1.\\tProfile the intestinal microbiota and host immune response in healthy adults over the course of COVID-19 vaccination.\\na.\\tDetermine whether the baseline microbiota (average longitudinal composition prior to vaccination) is associated with the strength of the subsequent immune response to vaccination (fever response, transcription of inflammatory markers in feces if present, serum antibody levels).\\nb.\\tDetermine whether there are microbiota shifts associated with vaccination (i.e., consistent changes in abundance or transcriptional activity following the vaccine compared to baseline).\\nc.\\tDetermine whether there are microbiota shifts associated with fever (i.e., changes in abundance or transcriptional activity associated with increased body temperature).\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"This study will target healthy young adults in Germany, aged 18-40, who are going to be vaccinated with a licensed vaccine against COVID-19. \\nStool, blood samples and temperature measurements will be collected before and after vaccination against Coronavirus Disease 2019 (COVID-19).\\nMicrobiome community structure and activity (using metagenomics and metatranscriptomics), and the host immune response (body temperature, fecal transcriptional activity if present, and serum antibodies) for all participants  will be determined before and after vaccination.\\n\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027372","content":"{\"resource_id\": \"DRKS00027372\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"oncology\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"immune response\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hematology\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19 vaccination\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antibodies\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Immune response to COVID-19 vaccination in hemato-oncology patients\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"On December 21, 2020, the first vaccine BNT162b2 (Comirnaty\\u00ae) was approved by the European Medicines Agency (EMA). The German government's vaccination prioritization is based on the vaccination recommendation of the Robert Koch Institute (RKI). In the \\\"Increased Priority\\\" level (according to the Federal Ministry of Health), persons who have a hemato-oncological disease should be vaccinated, among others.\\nFor a vaccination recommendation of known conventional vaccines for standard indications such as diphtheria and tetanus in patients with hemato-oncological diseases, the data situation is very different and ranges from a \\\"strong recommendation\\\" to \\\"weak recommendation\\\" to \\\"contraindicated / not recommended\\\". This is also true for patients* who have received a stem cell transplant.\\nFor the new vaccines against COVID-19, there are understandably no data from which to infer tolerability and efficacy in terms of immune response for patients with hemato-oncologic disease. The problem is further complicated by the rapid developments in new anticancer drugs such as the kinase and checkpoint inhibitors and the complex treatment options such as stem cell transplantation. Kinase inhibitors, such as ruxolitinib and imatinib, have very different cellular targets. They can suppress, enhance, or have no significant impact on the immune response. Based on their mechanism of action, checkpoint inhibitors such as nivolumab, pembrolizumab, or even ipilimumab are expected to enhance rather than suppress the immune response.\\nThe recommendation for COVID-19 vaccination in patients with blood disorders and cancer was developed in a position paper of the German Society of Hematology and Medical Oncology in collaboration with other cancer societies on Jan. 28, 2021. \\\"Shared decision making\\\" between physician and patient is the basis in patient-individual decision making about the implementation of a protective vaccination.\\nThe implementation of targeted research projects regarding efficacy and safety in COVID-19 vaccines, some of which are based on new vaccine technologies, is of particularly high importance and urgency in patients* with hemato-oncological diseases.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ImV-HOng\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027372\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"11.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Deutsche Leuk\\u00e4mie und Lymphom Stiftung\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Adenauerallee 87, 53113 Bonn, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Krukenberg Krebszentrum Halle\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Ernst-Grube-Stra\\u00dfe 40, 06120 Halle (Saale), Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Haifa Kathrin\", \"role_name_personal_family_name\": \"Al-Ali\", \"role_name_personal_title\": \"Ms. Ass. Prof. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"haifa.al-ali@uk-halle.de\", \"role_phone\": \"0345 557 7712\", \"role_affiliation_name\": \"Krukenberg Krebszentrum HalleUniversit\\u00e4tsklinikum Halle (Saale)\", \"role_affiliation_address\": \"Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"hematooncological diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Follow-up ongoing\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Active, not recruiting\", \"study_start_date\": \"17.03.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 7, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"patients\\n\\u2022 age \\u2265 18 years\\n\\u2022 one of the following malignant diagnoses:\\n- myeloid disorders (AML, MPN, or MDS)\\n- lymphatic disorders (CLL, lymphoma, or MM)\\n- malignant diseases treated with checkpoint inhibitors\\n\\nhealthy subjects\\n\\u2022 age \\u2265 18 Jahre\\n\\u2022 willingness to or present appointment for covid-19 vaccination\", \"study_eligibility_exclusion_criteria\": \"patients\\n\\u2022 patients not willing to or unable to get vaccinated\\n\\u2022 patients with a duration of remission of \\u2265 5 years\\n\\u2022 patients unable to give consent\\n\\nhealthy subjects\\n\\u2022 subjects not willing to or unable to get vaccinated according to recommendations of the Robert-Koch-Institut\\n\\u2022 subjects with a malignant disease and a duration of remission of &lt; 5 years\\n\\u2022 subjects unable to give consent\", \"study_population\": \"\", \"study_target_sample_size\": 417, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"humoral immune response to the covid-19 vaccine of patients with hemato-oncological diseases  compared to healthy subjects on day 35 (+7) after initial vaccination\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\\u2022 humoral immune status:\\n- before covid-19 vaccination (day 0 to -21)\\n- day 120 (+14) after initial vaccination\\n\\u2022 cellular immune status before, on day 35 (+7) and day 120 (+14) after initial vaccination\\n\\u2022 immune response of hemato-oncological diseases:\\n- myeloid disorders [acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)]\\n- lymphatic disorders [chronic lymphocytic leukemia (CLL), lymphoma, multiple myeloma (MM)]\\n- patients currently treated with checkpoint inhibitors\\n\\u2022 immune response of therapy versus \\u201ewatch and wait\\u201c\\n\\u2022 impact of patient and disease related factors on immune response\\n\\u2022 CRP and lymphocyte count in peripheral blood\\n\\u2022 post-marketing surveillance for collection of safety and tolerability data of the covid-19 vaccine in patients with hemato-oncological diseases and healthy subjects\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"hemato-oncological patients\\n\\nBlood samples before and after vaccination (day 35 and day 120 after the first vaccination) of patients and healthy controls, who decided to be vaccinated close to home according to the recommendation of the Robert Koch Institute, will be examined for a corresponding immune reaction.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"healthy subjects\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00027377","content":"{\"resource_id\": \"DRKS00027377\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"chronic COVID syndrome (CCS)\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post-COVID-19 syndrome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Long COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post-acute sequelae of COVID-19 (PASC)\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Beyond COVID - characterization of health and psychosocial long-term effects after convalescence of a SARS-CoV-2 infection (COVID-19) in North Rhine-Westphalia\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Prospective multicenter cohort study with a planned observation period of four years (1 year recruitment, 3 years follow-up). The aim is to provide outpatient care to build up a patient cohort across sites to observe and extensively phenotype this cohort. In addition to a baseline examination and regular follow-up examinations, the retrospective chronology of the early disease phase is documented. By a systematic and structured recording and characterization of health disorders and psychosocial factors, possible late effects of the infection as well as predisposing factors and the psychosocial consequences will be investigated. In addition, the humoral and cellular immunity directed against SARS-CoV-2 will be recorded over the long term and the immunological factors possibly responsible for the observed long-term effects should be identified.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Beyond COVID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027377\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"08.12.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Ministeriums f\\u00fcr Kultur und Wissenschaft durch des Landes Nordrhein-Westafalen\", \"role_email\": \"poststelle@mkw.nrw.de\", \"role_phone\": \"0211 89604\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"V\\u00f6lklinger Str. 49, 40221 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Other\", \"role_name_organisational\": \"Eigenmittel der Universit\\u00e4tskliniken Aachen, Bonn, Essen, D\\u00fcsseldorf, K\\u00f6ln und M\\u00fcnster\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \",  , \", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Moorenstr. 5, 40225 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinik-duesseldorf.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Bj\\u00f6rn\", \"role_name_personal_family_name\": \"Jensen\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Bjoern-ErikOle.Jensen@med.uni-duesseldorf.de\", \"role_phone\": \"02118116631\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf Klinik f\\u00fcr Gastroenterologie, Hepatologie und Infektiologie\", \"role_affiliation_address\": \"Moorenstra\\u00dfe 5, 40225 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Alexander\", \"role_name_personal_family_name\": \"Mertens\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"alexander.mertens@med.uni-duesseldorf.de\", \"role_phone\": \"02118104142\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf\", \"role_affiliation_address\": \"Moorenstra\\u00dfe 5, 40225 D\\u00fcsseldorf, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U09.9\"}, {\"study_conditions\": \"\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"U08.9\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"12.12.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 75, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Main residence in North Rhine-Westphalia in the area of the cities of Aachen, Bonn, D\\u00fcsseldorf, Essen, Cologne or M\\u00fcnster\\n- 18 - 75 years old\\n- Proof of a survived SARS-CoV-2 infection (PCR-test)\\n- Infection in the period from March 1st, 2021 (1st recruitment round)\\n- the time of infection is at least 3 months back (inpatients: date of the COVID-19-related inpatient admission day; outpatients: date of the first positive PCR test)\\n- The person is able to take part in the survey and the examinations\\n- sufficient knowledge of the German language or support from an interpreter\", \"study_eligibility_exclusion_criteria\": \"- Active SARS-CoV-2 infection and / or time of infection is less than 3 months back (inpatients: Date of admission; outpatients: date of the first positive PCR-test). Inclusion possible at a later date.\\n- Lack of diagnostic evidence of SARS-CoV-2 infection using a PCR test\\n- Person is unable to give written informed consent\\n- Other reasons that study participants can not visit the study center, e.g. due to logistical reasons.\", \"study_population\": \"\", \"study_target_sample_size\": 2000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"-Evaluate long term cardial, lung and liver function (abdominal sonography, echocardiocraphy, pulmonary function examination, blood tests)\\n-Changes in Quality of Life, physically and mental health, functioning and activity an public health aspects (multiple validated questionnaires)\\n-medical resource use (questionnaire)\\n-cognitive/neurological impairment (neuropsychological assessment)\\nTime schedule: At 3, 6, 12, 18, 24, 30 and 36 month after SARS-CoV-2-Infection\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"-Patient characteristics and differences in those with/without Long-Covid complications (blood tests, genetic analysis, humoral and cellular immunity directed against SARS-CoV-2; immunological factors responsible for the observed long-term effects)\\n-Definition and characteristics of the early and late COVID-19 complications\\n-Evaluation of Long-Covid depending on the severity of the course of COVID-19 and comorbidities\\nTime schedule: At 3, 6, 12, 18, 24, 30 and 36 month after SARS-CoV-2-Infection\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The data protection concept and the data management protocol of this study specifically regulate the collection, storage and transfer of data and biosamples. The regulations and the handling of the data and biosamples are also specified in the study protocol and the declaration of consent.\\nAll information from the study is fundamentally subject to medical confidentiality and the provisions of data protection and the regulations of the European General Data Protection Regulation (EU GDPR, Article 13 ff.) and the revised Federal Data Protection Act (BDSG-new, \\u00a7\\u00a7 32 ff). This also applies to the regulations governing data transmission to a third country or an international organization.\\nSo far there are no cooperation partners in EU or non-EU countries. Opportunities for cooperation and data exchange for scientific purposes with the aim of researching COVID-19 or Long-Covid may arise, provided that the cooperation partners have established an appropriate level of legal data protection in these countries / institutions in accordance with the requirements of the EU Commission.\\nThe data collected during the study will be stored a maximum of 10 years after completion of the study, unless there are other legal retention obligations.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prognosis\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Cohort I: clinical collective of hospitalized patients\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Cohort II: outpatient collective\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Cohort III: controls, NAKO sample\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027472","content":"{\"resource_id\": \"DRKS00027472\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Laboratory study on the annoyance of UAS-noise \\n(Unmanned Aircraft System)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Laboratory study on the annoyance of UAS-noise \\n(Unmanned Aircraft System)\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"EASA-SC01\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027472\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"28.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Europ\\u00e4ische Agentur f\\u00fcr Flugsicherheit (EASA)\", \"role_email\": \"info@easa.europa.eu\", \"role_phone\": \"+49 221 8999 000\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Konrad-Adenauer-Ufer 3, 50668 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"http://easa.europa.eu\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Susanne\", \"role_name_personal_family_name\": \"Bartels\", \"role_name_personal_title\": \"Ms. Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"Susanne.Bartels@dlr.de\", \"role_phone\": \"02203 601 3844\", \"role_affiliation_name\": \"DLR Deutsches Zentrum f\\u00fcr Luft- und Raumfahrt\", \"role_affiliation_address\": \"Linder H\\u00f6he, 51147 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Susanne\", \"role_name_personal_family_name\": \"Bartels\", \"role_name_personal_title\": \"Ms. Dr. rer. nat.\", \"role_name_identifiers\": [], \"role_email\": \"Susanne.Bartels@dlr.de\", \"role_phone\": \"02203 601 3844\", \"role_affiliation_name\": \"DLR Deutsches Zentrum f\\u00fcr Luft- und Raumfahrt\", \"role_affiliation_address\": \"Linder H\\u00f6he, 51147 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Healthy test person\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.02.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- at least 18 years old\\n- male, female or diverse\\n- normal hearing according to age\\n- presence of the signed declaration of consent \\n- sufficient knowledge of the German language\\n- recovered from COVID-19 or fully vaccinated (2G rule)\\n- willingness to wear a FFP2 mask during the whole experiment\", \"study_eligibility_exclusion_criteria\": \"- Hearing loss in the audiogram: i.e., hearing thresholds in the better ear are higher than the 10th percentile of the gender- and age-specific hearing thresholds in ISO 7029 (2017).\\n- Wearing a hearing aid\\n- Hearing disorders (tinnitus, hearing loss within the last 10 years)\\n- any other condition which, in the opinion of the physicians performing the test, makes the subject unsuitable for the test \\n- any medication with influence on the test parameters or consumption of stimulants and drugs with influence on the examination parameters, e.g. drug consumption, increased alcohol consumption and nicotine consumption, which does not allow at least 10 hours of abstinence\\n- not legally competent, as well as limited legally competent persons \\n- not able to speak the German language\\n- persons not immunized against COVID-19 (i.e. not vaccinated or recovered) \\n- presence of a positive COVID-19 self-test\\n- intolerance of the FFP2 mask or unwillingness to wear a FFP2 mask during the entire trial to wear a FFP2 mask during the entire experiment.\\n\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 60, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The key outcome measure according to the primary hypothesis is the probability of being acutely highly annoyed (%HA) by LAeq from drones in hover.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Due to the different noise generation of a drone during overflight, the likelihood of being acutely highly annoyed by drone overflights is also investigated by the SEL. Since the acceptance and pleasantness of noise was recorded in most of the laboratory studies, these psychological target variables should also be recorded here in order to ensure comparability of the results. \\nbe recorded to ensure comparability of results. Therefore, the \\nProbability of acceptance and pleasantness due to increasing LAeq\\nof drones in hover phases and by the increasing SEL of drone overflights will be determined. In addition, the influence of drone type, operating altitude as well as speed (only for overflights) on the subjective perceptions (annoyance, acceptance and pleasantness) will be exploratively investigated.\\n\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Subjects are asked to assess the noise level of drones by means of computer-assisted questionnaires.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027476","content":"{\"resource_id\": \"DRKS00027476\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Open-label placebos and stress during the Corona pandemic. A randomized controlled trial.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Until recently, it was believed that placebos only help if they are administered covertly. However, new research shows that openly administered placebos (open-label placebos) can also work, for example in chronic pain or depression. The aim of this study is to investigate whether openly administered placebos may help healthy participants who feel stress and anxiety due to the corona pandemic. Effects of hidden as well as openly assigned placebos on stress have already been shown in laboratory studies. Here we want to investigate whether openly administered placebos also have an effect on stress and anxiety in the Corona pandemic.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CORST\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027476\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"27.12.2021\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Medical School Berlin\", \"role_email\": \"michael.schaefer@medicalschool-berlin.de\", \"role_phone\": \"0306117542\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"R\\u00fcdesheimer Str. 50, 14197 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Schaefer\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"michael.schaefer@medicalschool-berlin.de\", \"role_phone\": \"0306117542\", \"role_affiliation_name\": \"Medical School Berlin\", \"role_affiliation_address\": \"R\\u00fcdesheimer Str. 50, 14197 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Michael\", \"role_name_personal_family_name\": \"Schaefer\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"michael.schaefer@medicalschool-berlin.de\", \"role_phone\": \"0306117542\", \"role_affiliation_name\": \"Medical School Berlin\", \"role_affiliation_address\": \"R\\u00fcdesheimer Str. 50, 14197 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Crossover\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Stress, Anxiety\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"27.12.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 60, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Healthy participants, who claim to feel stress and anxiety due to the Corona pandemic\\n\", \"study_eligibility_exclusion_criteria\": \"known history of psychiatric or neurologic diseases; pregnancy\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Feelings of being stressed (VAS scores) at the beginning and after 3 weeks\\n\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Health-related quality of life (SF-12) at the beginning and after 3 weeks\\n\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Raw data will be made available for other researchers.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The treatment group receives a placebo for three weeks (two each day).\\n\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control group (no placebo)\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00027565","content":"{\"resource_id\": \"DRKS00027565\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"FAPI\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Post-COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Fibrosis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"PET CT\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"FAPI-Scan for detection of structural lung changes post COVID-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Patients with COVID-19 disease will be enrolled. Patients of legal age who voluntarily agree to participate in a matched-pair study will be included in the study.\\n\\nThe study will be conducted at the Department of Nuclear Medicine and the Institute of Diagnostic and Interventional Radiology and Neuroradiology, University of Essen-Duisburg, Germany, respectively.\\n\\nParticipation in the study is possible by matched-pair procedure. The data collected there will then be evaluated and compared with each other afterwards.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ARTFUL (fApi-scan foR deTection oF strUctural Lung changes)\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027565\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"11.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Essen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Hufelandstra\\u00dfe 55, 45147 Essen, Germany\", \"role_affiliation_web_page\": \"https://www.uniklinikum-essen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Christoph\", \"role_name_personal_family_name\": \"Rischpler\", \"role_name_personal_title\": \"Mr. Professor Dr.\", \"role_name_identifiers\": [], \"role_email\": \"nuklearmedizin@bethesda.de\", \"role_phone\": \"004920360081451\", \"role_affiliation_name\": \"Klinik f\\u00fcr Nuklearmedizin Ev. Krankenhaus BETHESDA zu Duisburg\", \"role_affiliation_address\": \"Heeerstr. 219, 47053 Duisburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Timur\", \"role_name_personal_family_name\": \"Sellmann\", \"role_name_personal_title\": \"Mr. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"t.sellmann@bethesda.de\", \"role_phone\": \"+49 203 6008 3100\", \"role_affiliation_name\": \"Klinik f\\u00fcr An\\u00e4sthesiologie und Intensivmedizin\", \"role_affiliation_address\": \"Heerstrasse 219, 47053 Duisburg, Germany\", \"role_affiliation_web_page\": \"https://www.bethesda.de\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Factorial\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07.1\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Other interstitial pulmonary diseases with fibrosis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J84.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"Yes\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Enrolling by invitation\", \"study_start_date\": \"07.01.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Post covid patient with an inpatient hospitalization. \", \"study_eligibility_exclusion_criteria\": \"Pregnancy\", \"study_population\": \"\", \"study_target_sample_size\": 24, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Detection and extent of potential lung damage post COVID (esp. pulmonary fibrosis).  \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"An ethics application will be submitted, which has already been approved. \\nThe data will be anonymized after the study. \", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Diagnostic\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Nonrandomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Post-COVID, formerly intensive care. \\n\\nPatients undergo FAPI PET-CT after detailed informed consent to assess fibroblastic tissue remodeling of the lung.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"POST-COVID, inpatient, but not requiring intensive care.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00027869","content":"{\"resource_id\": \"DRKS00027869\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Occupational E-Mental-Health\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"effectiveness\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Healthcare professionals\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"digital health\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Effectiveness of a holistic and partially digitized intervention portfolio for workplace health promotion in nursing (Care4Care) - a pragmatic cluster-randomized controlled trial.\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Nurses are facing a variety of strain, not at least due to COVID-19 pandemic. Studies show that on average strain in nurses and healthcare workers is higher than in other working sectors (DGB-Index Gute Arbeit, 2018). The combination of high emotional demands and physically stressful work is associated with relatively high absence and turnover rates (BAuA, 2012; Drupp &amp; Meyer, 2020). Within the project Care4Care, we developed a holistic, partially digitized, intervention portfolio for health promotion in nursing facilities. Care4Care aims to help nurses and their supervisors in hospitals and in- and outpatient nursing services to build healthy working conditions as well as to strengthen individual stress coping. \\n\\nThe Care4Care portfolio includes 6 web-based trainings for individual health promotion for the following health domains: coping with stress*, increasing resilience, recovery from work*, coping with sleep problems due to shift work, self-compassion, and gratitude promotion*. \\nIt further includes 8 web-based trainings that provide knowledge and tips on how to organize healthy working conditions for nurses. The trainings address the following subthemes: fundamentals of healthy work design, fundamentals of healthy leadership, designing work tasks and processes, organizational culture, balancing work and personal life, work environment, accepting digital help, and dealing professionally with death, dying, and violence. These trainings will be followed in on-site team workshops, moderated by an external occupational health consultants. In addition, supervisors and their team members can participate in an on-site health-oriented leadership training, moderated by external occupational health consultants.\\n\\nThe primary study objective is to evaluate Care4Care in terms of improvements in the psychosocial climate (assessed by the Psychosocial Climate Scale from Hall et al. 2010) in nursing facilities with access to the Care4Care compared to nursing facilities without access. Secondary objectives include improvements in irritation, work-related stress, and symptoms of depression in nurses. Tertiary objectives include improvements of working conditions and other mental health-related outcomes.\\n\\nCare4Care will be evaluated in a cluster-randomized control trial. Nursing facilities will get access to the Care4Care portfolio either immediately or after 6 months. During this waiting period, nursing facilities with delayed access receive various offers to promote healthy exercise and nutrition in everyday care work. These offers are carried out on-site in the nursing facilities, by consultants for occupational health consultants of the AOK insurance company. After 6 months, these nursing facilities also get access to the Care4Care portfolio.\\n\\n* four out of the six web-based trainings have been evaluated in previous RCTs, showing superior mental heallth effects (Heber et al. 2016, Thiart et al. 2015, Ebert et al., 2016a, Ebert et al. 2016b, Nixon et al. 2021, Heckendorf et al. 2019, Hannibal et al. in preparation)\\n\\nReferences: \\n- BAuA (Hrsg.). (2012). Factsheet 10. Arbeit in der Pflege \\u2013 Arbeit am Limit? Arbeitsbedingungen in der Pflege-branche. Dortmund: Bundesanstalt f\\u00fcr Arbeitsschutz und Arbeitsmedizin. Verf\\u00fcgbar unter https://www.baua.de/DE/Angebote/Publikationen/Fakten/BIBB-BAuA-10.pdf\\n- DGB- Index Gute Arbeit (2018): Arbeitsbedingungen in den Pflegeberufen. Ergebnisse einer Sonderauswertung der Repr\\u00e4sentativumfragen des DGB-Index Gute Arbeit. Institut DGB Index Gute Arbeit: Berlin. \\n- Drupp, M. &amp; Meyer, M. (2020). Belastungen und Arbeitsbedingungen bei Pflegeberufen \\u2013 Arbeitsunf\\u00e4higkeits-daten und ihre Nutzung im Rahmen eines Betrieblichen Gesundheitsmanagements. In K. Jacobs, A. Kuhl-mey, S. Gre\\u00df, J. Klauber &amp; A. Schwinger (Hrsg.), Pflege-Report 2019. Mehr Personal in der Langzeitpflege \\u2013 Aber woher? (S. 23-47). Berlin, Heidelberg: Springer.\\n- Ebert, D. D., Heber, E., Berking, M., Riper, H., Cuijpers, P., Funk, B., &amp; Lehr, D. (2016). Self-guided internet-based and mobile-based stress management for employees: results of a randomised controlled trial. Occupational and Environmental Medicine, 73(5), 315\\u2013323. https://doi.org/10.1136/oemed-2015-103269\\n- Ebert, D. D., Lehr, D., Heber, E., Riper, H., Cuijpers, P., &amp; Berking, M. (2016). Internet- and mobile-based stress management for employees with adherence-focused guidance: efficacy and mechanism of change. Scandinavian Journal of Work, Environment &amp; Health, 42(5), 382\\u2013394. https://doi.org/10.5271/sjweh.3573\\n- Heber, E., Lehr, D., Ebert, D. D., Berking, M., &amp; Riper, H. (2016). Web-Based and Mobile Stress Management Intervention for Employees: A Randomized Controlled Trial. Journal of Medical Internet Research, 18(1), e21. https://doi.org/10.2196/jmir.5112\\n- Heckendorf, H., Lehr, D., Ebert, D. D., &amp; Freund, H. (2019). Efficacy of an internet and app-based gratitude intervention in reducing repetitive negative thinking and mechanisms of change in the intervention\\u2019s effect on anxiety and depression: Results from a randomized controlled trial. Behaviour Research and Therapy, 119, 103415. https://doi.org/10.1016/j.brat.2019.103415\\n- Mohr, G., M\\u00fcller, A., Rigotti, T., Aycan, Z., &amp; Tschan, F. (2006). The assessment of psychological strain in work contexts: Concerning the structural equivalency of nine language adaptations of the irritation scale. European Journal of Psychological Assessment, 22, 198\\u2013206. https://doi.org/10.1027/1015-5759.22.3.198\\n- Nixon, P., Bo\\u00df, L., Heber, E., Ebert, D. D., &amp; Lehr, D. (2021). A three-armed randomised controlled trial investigating the comparative impact of guidance on the efficacy of a web-based stress management intervention and health impairing and promoting mechanisms of prevention. BMC Public Health, 21(1), 1511. https://doi.org/10.1186/s12889-021-11504-2\\n- Thiart, H., Lehr, D., Ebert, D. D., Berking, M., &amp; Riper, H. (2015). Log in and breathe out: internet-based recovery training for sleepless employees with work-related strain - results of a randomized controlled trial. Scandinavian Journal of Work, Environment &amp; Health, 41(2), 164\\u2013174. https://doi.org/10.5271/sjweh.3478\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Care4Care\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027869\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"23.02.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Abteilung Pr\\u00e4vention Gesch\\u00e4ftsf\\u00fchrungseinheit Versorgung AOK-Bundesverband\", \"role_email\": \"Thomas.Lennefer@bv.aok.de\", \"role_phone\": \"+49 30 34646-2285\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Rosenthaler Strasse 31, 10178 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Dirk\", \"role_name_personal_family_name\": \"Lehr\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"lehr@leuphana.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Leuphana Universit\\u00e4t L\\u00fcneburg, Abteilung Gesundheitspsychologie und Angewandte Biologische Psychologie\", \"role_affiliation_address\": \"Universit\\u00e4tsallee 1, 21335 L\\u00fcneburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Leif\", \"role_name_personal_family_name\": \"Bo\\u00df\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"boss@leuphana.de\", \"role_phone\": \"041316771710\", \"role_affiliation_name\": \"Leuphana Universit\\u00e4t L\\u00fcneburg, Abteilung Gesundheitspsychologie und Angewandte Biologische Psychologie\", \"role_affiliation_address\": \"Universit\\u00e4tsallee 1, 21335 L\\u00fcneburg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Psychosocial Safety Climate and stress-related symptoms\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Problems related to life-management difficulty\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z73\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.03.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 16, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Working as nurse\", \"study_eligibility_exclusion_criteria\": \"None\", \"study_population\": \"\", \"study_target_sample_size\": 560, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Psychosocial Safety Climate (Hall et al. 2010; German version by Otto et al. 2016; adapted to care organizations), 6 months after randomization (T2)\\n\\nReference: \\n- Hall, G. B., Dollard, M. F., &amp; Coward, J. (2010). Psychosocial safety climate: Development of the PSC-12. International Journal of Stress Management, 17(4), 353\\u2013383. https://doi.org/10.1037/a0021320\\n- Otto, W.; Neuert, C.; Meitinger, K. et. al. (2016): Psychosocial Safety Climate - Weiterentwicklung und Validierung eines Instrumentes f\\u00fcr die Erfassung der Handlungsbereitschaft zum Schutz der psychischen Gesundheit der Besch\\u00e4ftigten auf organisationaler Ebene. Kognitiver Pretest. GESIS Projektbericht.\\nVersion: 1.0. GESIS - Pretestlabor. Text. http://doi.org/10.17173/pretest38\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Secondary outcomes:\\nIrritation (Irritationsskala; Mohr et al. 2005), t1*, t2*\\nPerceived Stress (Perceived Stress Scale; Cohen, 1983), t1, t2\\nDepressive symptoms, Patient-Health-Questionnaire (PHQ-8; Kroenke et al. 2009), t1, t2\\n\\nTertiary outcomes:\\nWork engagement, Work Engagement Subscale Vigor (Schaufeli &amp; Bakker, 2003), t1, t2\\nWork-Family-Conflict, Work-Family-Interferences strainbaised (Carlsen, 2000), t1, t2\\nSelf-Care, Health-oriented Leadership Subscale Self-Care (Pundt &amp; Felfe, 2017), t1, t2\\nWork satisfaction, 1-Item-Skala zur Messung von Arbeitszufriedenheit (Baillod &amp; Semmer, 1994), t1, t2\\nPsychosocial Safety Climate \\u2013 Kurzskala (Berthelsen et al. 2020; Otto et al., 2016), t1, t2\\nEffort-Reward-Imbalance (ERI) Questionnaire \\u2013 Kurzskala (Siegrist et al., 2009), t1, t2\\nQuestionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P; Bouwmans et al., 2013), t1, t2\\nSelf-rated employability (Mittag &amp; Raspe, 2003), t1, t2\\nIntention to change the workplace (self-developed), t1, t2\\nIntention to change the profession (self-developed), t1, t2\\nUse of other general and occupational health programs (self-developed), t1, t2\\n\\nonly intervention group:\\nAdherence to the Care4Care program (self-developed), t2 \\nSelf-rated usefullness of the Care4Care program (adapted from Ma\\u00dfnahmen-Erfolgs-Inventar (MEI, Kauffeld et al., 2009), t2 \\n\\nmoderator variables:\\nsocio-economic variables, t1\\nAffinity for Technology Interaction (ATI; Franke et al., 2018), t1\\n\\n* t1: baseline, prior to randomization\\n* t2: 6-months follow-up\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"/\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Prevention\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Nurses in care facilities randomized in this arm will get immediate access to the Care4Care program, including the following modules:\\nA) nurses can choose 6 web-based trainings for the following health domains: coping with stress, increasing resilience, recovery from work, coping with sleep problems due to shift work, self-compassion, and gratitude promotion. Each of these trainings consists of four to seven weekly sessions. Nurses participating in one of these trainings will receive written feedback after the first and again after the last trainings session by an e-coach.\\nB) Nurses can choose 8 web-based trainings to increase their knowledge on how to organize healthy working conditions with the following subthemes: fundamentals of healthy work design, fundamentals of healthy leadership, designing work tasks and processes, organizational culture, balancing work and personal life, work environment, accepting digital help, and dealing professionally with death, dying, and violence.\\nIn addition, nursing teams can initiate on-site workshops, moderated by an external occupational health consultant, to further work on these themes in teams. \\nC) Supervisors and their team members can participate in an on-site health-oriented leadership training, moderated by external occupational health consultants.\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Nursing staff in the organization receive selected offers from the AOK insurance company to promote healthy exercise and nutrition in everyday care work. The measures that are implemented are determined in consultation with the team supervises. The measures will be introduced by occupational health promotion consultants from the AOK insurance company.\\n\\nAfter 6 months, the nursing staff of the organizations in this arm are given access to the Care4Care program (Arm 1).\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00027911","content":"{\"resource_id\": \"DRKS00027911\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Feasibility, acceptance, and user satisfaction of virtual reality as a supportive offer during the Corona pandemic in the Psychiatric Outpatient Department\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This study is conducted in the Psychiatric Outpatient Clinic of the University Hospital Leipzig.\\nWithin this study, patients of the psychiatric outpatient department of the University Hospital Leipzig, who are only able to participate in group activities of the outpatient department to a limited extent or not at all due to restrictions during the SARS-CoV-2 pandemic, will be offered therapy-accompanying support through the independent use of virtual reality in the home environment. During the four-week intervention, the patients were asked to watch relaxing videos at least twice a week using virtual reality glasses. Paper-based questionnaires on their well-being and satisfaction with the offer will be collected at the beginning of the intervention, after each week and at the end of the intervention. \\nThe aim of the study is to assess the feasibility, acceptance and user satisfaction of a virtual reality offer in the psychiatric outpatient clinic.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027911\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"25.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum Leipzig\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Liebigstr. 18, 04103 Leipizg, Germany\", \"role_affiliation_web_page\": \"http://www.uniklinikum-leipzig.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Christine\", \"role_name_personal_family_name\": \"Rummel-Kluge\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"christine.rummel-kluge@medizin.uni-leipzig.de\", \"role_phone\": \"03419724681\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Leipzig, Klinik und Poliklinik f\\u00fcr Psychiatrie und Psychotherapie\", \"role_affiliation_address\": \"Semmelweisstra\\u00dfe 10, Haus 13, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Christine\", \"role_name_personal_family_name\": \"Rummel-Kluge\", \"role_name_personal_title\": \"Ms. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"christine.rummel-kluge@medizin.uni-leipzig.de\", \"role_phone\": \"03419724681\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Leipzig, Klinik und Poliklinik f\\u00fcr Psychiatrie und Psychotherapie\", \"role_affiliation_address\": \"Semmelweisstra\\u00dfe 10, Haus 13, 04103 Leipzig, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Patients who are being treated at the Psychiatric Outpatient Department of Leipzig University Hospital and have one or more mental illnesses.\\nExcluded are the clinical pictures schizophrenia, schizoaffective disorder and bipolar affective disorder.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.02.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Male and female patients 18 years and older who are being treated at the Psychiatric Outpatient Department, adequate German language skills, sufficient vision and reading ability, Internet access\", \"study_eligibility_exclusion_criteria\": \"severe motion sickness, schizophrenia, schizoaffective disorder and bipolar affective disorder\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Feasibility, acceptance and user satisfaction recorded at the end of the intervention by questionnaires: Credibility/Expectancy Questionnaire (CEQ), item on expectations of the service, adapted questionnaire on patient satisfaction (ZUF-8)\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Effectiveness in terms of improvement in quality of life and mental health, assessed at the end of the intervention by questionnaires: WHO Quality of Life-BREF (WHOQOL-BREF)Patient Health Questionnaire-9 (PHQ-9)\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be made available upon request after project completion.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Supportive care\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Within this study, the participants (patients of the Psychiatric Outpatient Department aged 18 years and older, N = 50) take part in a four-week virtual reality intervention. The aim of the study is to assess feasibility, acceptance and user satisfaction of the virtual reality offer. Paper-based questionnaires will be collected at the beginning of the intervention, after each week and at the end of the intervention. \"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00027933","content":"{\"resource_id\": \"DRKS00027933\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Telemedically supported rehabilitation after Covid-19\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"The aim of this study is to show that a 3-month individually controlled training and education can improve the limited quality of life, exercise capacity and cardiopulmonary function in patients after Covid-19 infection. With the concept of telemonitoring and coaching, adherence to the agreed measures should be &gt;80%.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00027933\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.01.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Erwin-R\\u00f6ver-Stiftung\", \"role_email\": \"\", \"role_phone\": \"0511/288 930\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Adelheidstrasse 4/5, 30171 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Erwin-R\\u00f6ver-Stiftung\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Adelheidstrasse 4/5, 30171 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Arno\", \"role_name_personal_family_name\": \"Kerling\", \"role_name_personal_title\": \"Mr. Privatdozent Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kerling.arno@mh-hannover.de\", \"role_phone\": \"0511/5325499\", \"role_affiliation_name\": \"Institut f\\u00fcr Sportmedizin, MH Hannover\", \"role_affiliation_address\": \"Carl-Neuberg-Strasse 1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Arno\", \"role_name_personal_family_name\": \"Kerling\", \"role_name_personal_title\": \"Mr. Privatdozent Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"kerling.arno@mh-hannover.de\", \"role_phone\": \"0511/532-5499\", \"role_affiliation_name\": \"Institut f\\u00fcr Sportmedizin, MH Hannover\", \"role_affiliation_address\": \"Carl-Neuberg-Strasse 1, 30625 Hannover, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Postviral fatigue syndrome\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"G93.3\"}, {\"study_conditions\": \"U09.9\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"09.09.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Women and men after Covid-19 illness (positive SARS-CoV-2 PCR or proof of antibodies)\\nanamnestic existing limitations in performance, fatigue Assessment Scale (FAS) (\\u226522 points)\\n\\u2265 18 years\", \"study_eligibility_exclusion_criteria\": \"current participation in another intervention study\\n- Other clinically relevant acute or chronic infections\\n- pregnancy\\n- surgery less than 8 weeks ago\\n- Illnesses or functional impairments making a physical training Intervention impossible\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Peak oxygen uptake, measured by bicycle spiroergometry\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"6 minute walk test\\nRetina Analysis\\nFlow-mediated dilation\\npulse wave velocity\\nvital capacity\\nhand grip strength\\nSit to stand test\\n\\nQuestionnaires:\\nHADS\\nfatigue\\nSF-36\\nmedas\\nRBANS\\nself-efficacy expectation\\n\\n7-day nutrition log\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Intervention group: Structured, telemedically supported exercise training\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control Group (Usual Care)\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00028158","content":"{\"resource_id\": \"DRKS00028158\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"blood drawing\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"recovered asymptomatic patients\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"acute disease\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Evaluation of SARS-CoV2-specific serum parameters in blood samples of hospitalized COVID-19 patients with acute disease and recovered COVID-19 patients with asymptomatic disease (HTXCOV-01K)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to evaluate SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of patients with acute COVID-19 disease as well as of recovered SARS-CoV-2-patients with asymptomatic disease.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVIAS_K\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028158\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"21.02.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_email\": \"michaela.arndt@hditx.de\", \"role_phone\": \"+49 6221 3919 11\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_email\": \"clinical_research@hditx.de\", \"role_phone\": \"06221 391911\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Rudolf\", \"role_name_personal_family_name\": \"\\u00dcbelhart\", \"role_name_personal_title\": \"Mr. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"rudolf.uebelhart@hditx.de\", \"role_phone\": \"+49 6221 3919 307\", \"role_affiliation_name\": \"Heidelberg ImmunoTherapeutics GmbH\", \"role_affiliation_address\": \"Max-Jarecki-Str. 21, 69115 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Selina\", \"role_name_personal_family_name\": \"Hein\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"s.hein@kk-km.de\", \"role_phone\": \"+492614964075\", \"role_affiliation_name\": \"Katholisches Klinikum Koblenz-Montabaur\", \"role_affiliation_address\": \"Rudolf-Virchow-Stra\\u00dfe 7 - 9, 56073 Koblenz, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U07.1\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"08.11.2021\", \"study_end_date\": \"17.02.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"1. Existence of consent to participate in the study.\\n2. The patient is at least 18 years old and capable of giving consent. In the case of patients of legal age who are unable to give their consent, consent can be given by a legal guardian.\\n3. Detection of at least one-time positive SARS-CoV-2 swab PCR test or antibody test for COVID-19.\\n4. Acute hospitalized due to COVID-19 pneumonia OR recovered with an asymptomatic course.\\n5. After prior consultation with the sponsor, patients who have received at least one vaccination against the SARS-CoV-2 virus may also be included.\", \"study_eligibility_exclusion_criteria\": \"1. Any illness or condition that does not medically permit the blood sample in the opinion of the consenting physician.\", \"study_population\": \"\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (patients with acute COVID-19 disease as well as recovered SARS-CoV-2-patients with asymptomatic disease). This trial is designed to establish assays that can be used in the future to plan clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"n/a\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be stored in a database. Access can be granted or data can be exchanged for specific projects upon request. The patients will be informed in the ICF about this.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"single blood drawing\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00028176","content":"{\"resource_id\": \"DRKS00028176\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Periodontitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Zahngesundheit\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Gingivitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Lungenfunktion\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"The impact of gingivitis reduction on lung function. A randomized trial under intensified oral hygiene\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Background: Periodontal disease and lung function impairment was found to be associated with low-grade systemic or local inflammation and it might be that gingival/ periodontal inflammation trigger lung function due to systemic inflammation or the transfer from oral bacteria or its components to the lung. A recent observational study in non-smoking subjects showed that spirometric lung volumes and flow rates were significantly reduced by 71-185 ml in the highest categories of gingivitis regardless of the adjustment for potential confounders. This result supported the notion that the reported association between periodontitis and reduced lung function is unlikely confounded by smoking. Moreover, this study did not support the idea that the association between gingivitis and lower lung function is caused by systemic inflammation. The designed interventional trial primarily aims to test the hypothesis that gingivitis reduction by optimized daily oral hygiene, professional tooth cleaning and antibacterial chlorhexidine (CHX) containing mouth rinse improves lung function in terms of forced vital capacity (FVC) by at least 2%. As secondary objective will be tested the hypothesis that gingivitis reduction improves forced expiratory volume in one second (FEV1) and forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) by at least 2%. Further, the influence of the oral microbiome needs to be considered.\\nMethods: The study has to include 120 non-smoking subjects aged between 18 and 30 years with biofilm-induced gingivitis. The chosen \\u201cwaiting control group design\\u201d will compare the immediate intervention group with the delayed intervention group, which serves as control group. As clinical parameters will be recorded the dental and gingival status, lung function and oral microbiome. The intensified preventive intervention \\u2013 professional tooth cleaning, one-stage full-mouth disinfection with CHX and safeguarding an optimal daily oral hygiene by each subject \\u2013 cannot be blinded, but the outcome measurement in terms of lung function tests is able blind.\\nDiscussion: This proposed multidisciplinary study has several strengths as there is only one intervention study with patients of severe periodontitis, who were mainly smokers. It is novel to include non-smoking subjects with mild and potentially reversible oral inflammation which were not considered so far. Further, this research is innovative, because it includes evidence-based interventions for gingivitis reduction, standardized measures of the outcome on lung function and oral microbiome and combines expertise from dentistry, lung physiology, oral microbiology and epidemiology/ statistically modelling.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"/\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028176\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"18.02.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Deutsche Forschungsgemeinschaft\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Kennedyallee 40, 53175 Bonn, Germany\", \"role_affiliation_web_page\": \"https://www.dfg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"Kuehnisch\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"jkuehn@dent.med.uni-muenchen.de\", \"role_phone\": \"089440059341\", \"role_affiliation_name\": \"Poliklinik f\\u00fcr Zahnerhaltung und Parodontologie \", \"role_affiliation_address\": \"Goethestrasse 70, 80336 Muenchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Poliklinik-fuer-Zahnerhaltung-und-Parodontologie/de/\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Jan\", \"role_name_personal_family_name\": \"Kuehnisch\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"jkuehn@dent.med.uni-muenchen.de\", \"role_phone\": \"089440059341\", \"role_affiliation_name\": \"Poliklinik f\\u00fcr Zahnerhaltung und Parodontologie\", \"role_affiliation_address\": \"Goethestrasse 70, 80336 Muenchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/Poliklinik-fuer-Zahnerhaltung-und-Parodontologie/de/\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Chronic gingivitis\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"K05.1\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"01.09.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 30, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Non-smoking subjects with biofilm-induced gingivitis aged 18 to 30 years\\n- Participants must be vaccinated against Covid-19\", \"study_eligibility_exclusion_criteria\": \"- Active smokers with other gingival/ periodontal diseases (Caton et al. 2018)\\n- Subjects with at least one tooth with a periodontal pocket depth and attachment loss &gt;4mm \\n- Subjects with asthma, diabetes and subjects with other chronic diseases, and anti-inflammatory treatment for chronic diseases\\n- Pregnant women \\n- Subjects without a written consent\\n- Not available for the period of repeated examination \", \"study_population\": \"\", \"study_target_sample_size\": 120, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"- Forced vital capacity (FVC) \", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"- Forced expiratory volume in one second (FEV1) \\n- Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"It is planned to give access to the full protocol, participant-level dataset, and statistical code on basis of a reasonable request.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Immediate preventive intervention\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Delayed preventive intervention\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"DRKS00028196","content":"{\"resource_id\": \"DRKS00028196\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"long-term invasive ventilation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"interprofessional care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"weaning-center\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"cost-analysis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"healthcare professionals\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"mechanical ventilation\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"https://www.wieder-selbst-atmen.de\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Early detection and early intervention program in high-risk patients to avoid invasive long-term ventilation \\u2013 Prevention of invasive ventilation\\nPRiVENT \\u2013 Health economic evaluation and process evaluation\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Mechanical ventilation has been a standard therapy in intensive care and acquires greater importance in times of the Covid-19 pandemic. The number of patients requiring invasive mechanical ventilation beyond their initial medical treatment rises with age and multimorbidity if they are not weaned off the ventilator properly. This not only impairs patients\\u2019 quality of life and affects their relatives, at the same time this practice poses financial and personnel challenges to the healthcare system. \\nThe overall objective of the PRiVENT-study (registered at clinicaltrials.gov ID: NCT05260853) is to prevent invasive long-term ventilation and to reduce the number of those who would be classified unsuccessfully weaned according to category 3cI of Germany\\u2019s current guideline on prolonged weaning. To this end, the PRiVENT-study will, among others, develop a structured care concept that will be tested in the cooperating weaning centres and clinics. \\nHealth economic analyses will thereby clarify the direct costs associated with invasive long-term ventilation as well as the intervention itself. The aim of the process evaluation is to check the intervention for its effectiveness, sustainability and scalability in the participating facilities, the four weaning centres and 40 clinics.\\n\\nThe process evaluation follows a mixed-method design combining structured surveys and interviews.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"PRiVENT HEEva &amp; ProcEva\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028196\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"02.03.2022\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"01_PRiVENT_Studienprotokoll_Prozessevaluation_Version_1_1_20210421_\\u00c4a_DRKS_oU.pdf\", \"id_type\": \"Other\", \"id_relation_type\": \"is described by\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Innovationsausschuss des Gemeinsamen Bundesausschusses\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"12 06 06 , 10596 Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Michel\", \"role_name_personal_family_name\": \"Wensing\", \"role_name_personal_title\": \"Mr. Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"michel.wensing@med.uni-heidelberg.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 130.03, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Selina\", \"role_name_personal_family_name\": \"von Schumann\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"privent.amed@med.uni-heidelberg.de\", \"role_phone\": \"06221 56-39141\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 130.03, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-heidelberg.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Selina\", \"role_name_personal_family_name\": \"von Schumann\", \"role_name_personal_title\": \"Ms. \", \"role_name_identifiers\": [], \"role_email\": \"privent.amed@med.uni-heidelberg.de\", \"role_phone\": \"06221 56-39141\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg\", \"role_affiliation_address\": \"Im Neuenheimer Feld 130.03, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"prolonged weaning, prolonged invasive ventilation, weaning failure\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Other chronic obstructive pulmonary disease\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J44\"}, {\"study_conditions\": \"Other interstitial pulmonary diseases\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J84\"}, {\"study_conditions\": \"Delirium, not induced by alcohol and other psychoactive substances\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F05\"}, {\"study_conditions\": \"Mental and behavioural disorders due to use of alcohol; Withdrawal state with delirium\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F10.4\"}, {\"study_conditions\": \"Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances; Withdrawal state with delirium\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"F19.4\"}, {\"study_conditions\": \"[generalization G62.8: Other specified polyneuropathies]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"G62.80\"}, {\"study_conditions\": \"[generalization G72.8: Other specified myopathies]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"G72.80\"}, {\"study_conditions\": \"Acute renal failure\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"N17\"}, {\"study_conditions\": \"Chronic kidney disease\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"N18\"}, {\"study_conditions\": \"[generalization E66.0: Obesity due to excess calories]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E66.01\"}, {\"study_conditions\": \"[generalization E66.0: Obesity due to excess calories]\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E66.02\"}, {\"study_conditions\": \"Type 1 diabetes mellitus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E10\"}, {\"study_conditions\": \"Type 2 diabetes mellitus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E11\"}, {\"study_conditions\": \"Malnutrition-related diabetes mellitus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E12\"}, {\"study_conditions\": \"Other specified diabetes mellitus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E13\"}, {\"study_conditions\": \"Unspecified diabetes mellitus\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"E14\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"08.07.2021\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria for the health economic evaluation: \\n\\n- Age \\u2265 30 \\n- Invasively ventilated for \\u2265 96 h\\n- Alive 11 days after the day of intubation\\n- Insured with the statutory health insurance AOK Baden-W\\u00fcrttemberg \\n- No evidence for a degenerative disease that would justify the need for an invasive ventilation\\n\\nInclusion criteria for the process evaluation:\\nINTERVIEWS\\n\\n- Patients:\\nAll patients who take part in the PRiVENT-study with oral German language skills and who sign the interview consent form\\n\\n- Relatives:\\nAll relatives of patients who take part in the PRiVENT-study with oral German language skills, aged 18 years or older who give their consent to be interviewed \\n\\n- Healthcare professionals:\\nHealthcare professionals working in one of the participating weaning centres or intensive care units of the PRiVENT-study with oral German language skills are considered eligible if they are 18 years or older and agree to the interview \\n\\n- Stakeholders:\\nRepresentatives of health insurance companies, self-help groups and politicians committed to health policy, who have oral German language skills, are 18 years or older and consent to take part in an interview\\n\\n\\nQUANTITATIVE SURVEYS\\n\\n- Patients:\\nAll patients who have written or oral German language skills and have themselves given consent to participate in the PRiVENT-study\\n\\n- Healthcare staff:\\nAll those involved in the care of patients who take part in the PRiVENT-study, i.e. doctors, nurses, respiratory therapists, physiotherapists, etc. working in one of the participating weaning centres or intensive care units, aged 18 years or older, who have written or oral German language skills, and agree to take part in the survey\", \"study_eligibility_exclusion_criteria\": \"All those who do not meet the above inclusion criteria will be excluded. \", \"study_population\": \"\", \"study_target_sample_size\": 256, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Health economic evaluation: cost savings resulting from the successful PRiVENT-intervention; process evaluation: implementation of the PRiVENT-intervention as a whole and its individual components\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Health economic evaluation: The costs associated with the PRiVENT-intervention, direct health care costs of patients with long-term invasive ventilation, patients\\u2019 quality of life associated with invasive long-term ventilation as well as with a successful PRiVENT-intervention. Process evaluation: impact on healthcare professionals' job satisfaction and interprofessional collaboration, and PRiVENT patients' decision-making behavior, quality of life, activity levels, and hospital discharge experiences.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"undecided\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Patients - written survey:\\nat discharge: EQ-5D\\nafter three months: EQ-5D, PEACS\\nafter six months: EQ-5D, PAM, PHQ9, PEF\\nafter 12 months: EQ-5D\\n\\npatient interviews: after discharge\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"relatives - interviews following discharge of patients\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"healthcare professionals in the participating clinics - written survey:\\nWCW\\nISVS\\nAITCS\\nself-developed items\\n\\nhealthcare professionals in the participating clinics -  interviews: \\nduring the intervention\"}, {\"study_arm_group_label\": \"Arm 4\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"further stakeholders in healthcare  (representatives of support groups, politicians, and representatives of  statutory health insurance) - interviews during the intervention\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00028278","content":"{\"resource_id\": \"DRKS00028278\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://www.drks.de/DRKS00028278\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Remote Programming in Spinal Cord and Dorsal Root Ganglion Stimulation\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028278\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_identifiers\": [], \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Guilherme\", \"role_name_personal_family_name\": \"Santos Piedade\", \"role_name_personal_title\": \"Other\", \"role_email\": \"guilherme.santospiedade@med.uni-duesseldorf.de\", \"role_phone\": \"0211 81 16058\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum D\\u00fcsseldorf\", \"role_affiliation_address\": \"Moorenstr. 5\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"R52.1 - Chronic intractable pain\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: 1. Implantation of a definitive system for spinal cord stimulation or dorsal root ganglion stimulation.\\n2. Pain intensity of more than 5 on visual analog scale for more than 3 months.\\n3. The patient has the ability to read, understand and give information reliably as required by the protocol.\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1. Patients with another pain disorder, which could influence the study results\\n2. Adults unable to give consent\\n3. Children and adolescents\", \"study_population\": \"\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": null, \"study_age_min_examined\": 18.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Pain intensity in the visual analog scale (VAS) on days 30, 60 and 90 after implantation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Allocation: Non-randomized controlled trial;. Masking: Open (masking not used). Control: Historical. Assignment: Other. Study design purpose: Treatment;\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00028526","content":"{\"resource_id\": \"DRKS00028526\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Structured Reporting of HRCT Exams for Fungal Pneumonia (FUNG-RADS)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Imaging signs of fungal pneumonia can be very specific and early use of HRCT lowers mortality in risk populations. This is particularly explained by earlier use of antifungal therapy. Microbiologic confirmation is often too time-consuming and would delay effective treatment, whereas HRCT can provide a fast and efficient assessment. However, no standardized reporting items are established for HRCT interpretation, e.g. to allow weighing the grade of suspicion (1 no, 5 high). In other areas, Reporting and Data Systems (RADS) are clinical routine, e.g. in breast cancer or in COVID-19 pneumonia. The aim of this study is to develop a RADS for fungal pneumonia (FUNG-RADS).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"FUNG-RADS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028526\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"21.06.2022\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"LMU-RAD00860\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Wolfgang\", \"role_name_personal_family_name\": \"Kunz\", \"role_name_personal_title\": \"Mr. PD Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"wolfgang.kunz@med.uni-muenchen.de\", \"role_phone\": \"+49 89 4400-73620\", \"role_affiliation_name\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://www.klinikum.uni-muenchen.de/de/index.html\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Shiwa \", \"role_name_personal_family_name\": \"Mansournia \", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"Shiwa.Mansournia@med.uni-muenchen.de\", \"role_phone\": \"(089) 4400-73647\", \"role_affiliation_name\": \"Klinik und Poliklinik f\\u00fcr Radiologie Klinikum der Universit\\u00e4t M\\u00fcnchen Campus Gro\\u00dfhadern\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"http://intranet.klinikum.uni-muenchen.de/de/index.html\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Pneumonia due to other specified infectious organisms\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"J16.8\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"29.06.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Proven Fungal Pneumonia\\nHost factors per EORTC/MSGERC-Definition\", \"study_eligibility_exclusion_criteria\": \"Primarily extrapulmonalary fungal infection\\nLimitation of diagnostic interpretation by confounding diseases\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The association of the individual radiological criteria with a confirmed or probable fungal pneumonia vs. no fungal pneumonia.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Development of a Reporting and Data System (FUNG-RADS) for standardized and simplified reporting of HRCT examinations when questioning about fungal pneumonia using a five-point suspicion scale.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"It is a retrospective, monocentric study.\\nIndividual course of study:\\n1. Collection of clinical and microbiological data as well as imaging, anonymization\\n2. Qualitative and quantitative reporting: Quantitative and qualitative, randomized and blinded evaluation of imaging\\n3. Evaluation: determination of the qualitative and quantitative parameters\\nStatistical comparison of qualitative and quantitative parameters\\nCreation of a scoring system from the strongest individuals predictors\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Controls are other infections which solely explain the clinical status of the patient\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00028639","content":"{\"resource_id\": \"DRKS00028639\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"cognitive behavior therapy; psychotherapy; video treatment; teletherapy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"telemedicine; children; adolescents; mental health; treatment; acceptance; treatment satisfaction\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Cognitive-behavioral teletherapy for children and adolescents with mental disorders and their families during the COVID-19 pandemic: A survey on acceptance and satisfaction\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Delivering psychotherapeutic sessions via videoconference (teletherapy) offers the opportunity to conduct psychotherapeutic treatment during the COVID-19 pandemic and social distancing restrictions. In addition, teletherapy has the potential to reduce treatment barriers such as travel time / costs and stigma, and to improve the mental health care situation in underserved areas. This observational study aims to evaluate the implementation and especially the acceptance of and the satisfaction with teletherapy during the first wave of COVID-19 in 2020 in a large clinical sample of children and adolescents receiving outpatient psychotherapy at the School for Child and Adolescent Cognitive Behavior Therapy (AKiP) at the University Hospital Cologne, Germany. A self-developed questionnaire was completed by caregivers and therapists. A follow-up assessment was conducted 12 month later.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028639\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"24.03.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Ausbildungsinstitut f\\u00fcr Kinder- und Jugendlichenpsychotherapie (AKiP) an der Uniklinik K\\u00f6ln\", \"role_email\": \"manfred.doepfner@uk-koeln.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Pohligstrasse 9, 50969 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Manfred\", \"role_name_personal_family_name\": \"D\\u00f6pfner\", \"role_name_personal_title\": \"Mr. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"manfred.doepfner@uk-koeln.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Ausbildungsinstitut f\\u00fcr Kinder- und Jugendlichenpsychotherapie (AKiP) an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Pohligstrasse 9, 50969 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Manfred\", \"role_name_personal_family_name\": \"D\\u00f6pfner\", \"role_name_personal_title\": \"Mr. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"manfred.doepfner@uk-koeln.de\", \"role_phone\": \"0049 221 478 76770\", \"role_affiliation_name\": \"Ausbildungsinstitut f\\u00fcr Kinder- und Jugendlichenpsychotherapie (AKiP) an der Uniklinik K\\u00f6ln\", \"role_affiliation_address\": \"Pohligstrasse 9, 50969 K\\u00f6ln, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"One or more mental health disorders\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Completed\", \"study_start_date\": \"15.06.2020\", \"study_end_date\": \"12.07.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 3, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 20, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"All patients receiving outpatient psychotherapeutic treatment during the first quarter of 2020 at the School of Child and Adolescent Cognitive Behavior Therapy (AKiP) at the University Hospital Cologne, Germany, can participate in the study.\", \"study_eligibility_exclusion_criteria\": \"none\", \"study_population\": \"\", \"study_target_sample_size\": 878, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Accepatnce of and satisfaction with teletherapy is assessed with a self-developed questionnaire.\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Caregivers and therapists of children and adolescents with a mental health disorder receiving outpatient cognitive behavior therapy were asked to rate acceptance of and satisfaction with teletherapy (psychotherapeutic sessions delivered via videoconfering) during the first wave of COVID-19 pandemic in 2020.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00028869","content":"{\"resource_id\": \"DRKS00028869\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"continuing medical education\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post-COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"intersectoral\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"long-COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"interprofessional\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"http://www.longcovidnetz.de/?page_id=53\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Long-COVID basic medical training - evaluation of an intersectoral and interprofessional knowledge transfer with exploration of further needs\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Within the explorative, non-randomized and non-controlled cross-sectional study with quantitative and qualitative data generation (online-questionnaire) physicians, physiotherapists, occpuational therapists and further health care professions are invited to participate in the study after having the possibility to use the basic medical training units. The films are provided by a registration on longcovidnetz.de. The survey is performed online by a link and anonymous data entry using heisurvey. The results aim to contribute to the development of intersectoral and interprofessional offerings of medical education with regard to Long-/ Post-COVID.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028869\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"26.04.2022\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1277-5293\", \"id_type\": \"UTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Ministerium f\\u00fcr Wissenschaft, Forschung und Kunst Baden-W\\u00fcrttemberg\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"K\\u00f6nigstr. 46, 70173 Stuttgart, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Uta\", \"role_name_personal_family_name\": \"Merle\", \"role_name_personal_title\": \"Ms. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"uta.merle@med.uni-heidelberg.de\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg, Abteilung Innere Medizin IV/ Long-COVID-Ambulanz\", \"role_affiliation_address\": \"Im Neuenheimer Feld 410, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Sandra\", \"role_name_personal_family_name\": \"Stengel\", \"role_name_personal_title\": \"Ms. Dr. med.\", \"role_name_identifiers\": [], \"role_email\": \"sandra.stengel@med.uni-heidelberg.de\", \"role_phone\": \"+49 6221 56 32 606\", \"role_affiliation_name\": \"Universit\\u00e4tsklinikum Heidelberg, Abteilung Allgemeinmedizin und Versorgungsforschung\", \"role_affiliation_address\": \"Im Neuenheimer Feld 130.3, 69120 Heidelberg, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"U09.9\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"28.04.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"target population for the study are\\n- minimum age of 18 years\\n- professional group of physicians, physiotherapists, occupational therapists or other health care profession\\n- Germany-wide\", \"study_eligibility_exclusion_criteria\": \"age under 18 years\", \"study_population\": \"\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The evaluation of the basic medical training by the users (physicians, physiotherapists, occupational therapists, other health care professions) by non-validated questionnaires (questions to satisfaction, practical relevance, impact on safety in the medical care of Long-/Post-COVID and wish for follow-up offers, scope of use) - quantitative data\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"negative and positive aspects of the basic medical training as well as wishes and ideas for the further development from the users\\u00b4perspective in free text fields (qualitative data). \", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Health care system\", \"study_phase\": \"Not applicable\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"Not applicable\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"physicians, physiotherapists, occupational ergotherapists, other health care professions have the possibility to watch an online on demand medical training 6x90min long-/post-COVID\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00028901","content":"{\"resource_id\": \"DRKS00028901\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"myocardial damage\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"MRI\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Evaluation of imaging biomarkers and longitudinal assessment of global and regional cardiac function by cardiac MRI during recovery from COVID-19 infection in a multicenter normalized cohort\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"Myocardial damage in the context of COVID-19 infection is associated with more severe disease courses and can be detected relatively frequently in hospitalized COVID-19 patients. A systematic assessment of the cardiac involvement in the recovery phase, especially with regard to a long-term prognosis, is currently insufficiently documented. In this context, we plan a comprehensive evaluation of affected patients using cardiac MRI imaging as a gold standard for diagnosis and prognostic assessments of myocardial injury or myocarditis. \\nHowever, especially quantitative MRI parameters are dependent on various site-specific and system-specific variables. This currently limits the comparability of individual patient data depending on the research question, especially in multicenter approaches. Therefore, the predictive value of quantitative biomarkers with respect to the occurrence of so-called MACE (Major Adverse Cardiac Events) will be analyzed. This analysis should overcome the above mentioned limitations.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"NAHAP-KAM\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00028901\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.06.2022\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"LMU-RAD00673\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Organisational\", \"role_type\": \"Sponsor (primary)\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen, Campus Gro\\u00dfhadern\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Marchioninistra\\u00dfe 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"https://www.klinikum.uni-muenchen.de\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Clemens\", \"role_name_personal_family_name\": \"Cyran\", \"role_name_personal_title\": \"Mr. Prof.\", \"role_name_identifiers\": [], \"role_email\": \"Clemens.Cyran@med.uni-muenchen.de\", \"role_phone\": \"+49 89 4400-73620\", \"role_affiliation_name\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Julia\", \"role_name_personal_family_name\": \"Ruat\", \"role_name_personal_title\": \"Ms. Dr. \", \"role_name_identifiers\": [], \"role_email\": \"julia.ruat@med.uni-muenchen.de\", \"role_phone\": \"(089) 4400-73640\", \"role_affiliation_name\": \"Klinik und Poliklinik f\\u00fcr Radiologie Klinikum der Universit\\u00e4t M\\u00fcnchen Campus Gro\\u00dfhadern\", \"role_affiliation_address\": \"Marchioninistr. 15, 81377 M\\u00fcnchen, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Single Group\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Observation for other suspected diseases and conditions\", \"study_conditions_classification\": \"ICD-10\", \"study_conditions_classification_code\": \"Z03.8\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Not yet recruiting\", \"study_start_date\": \"30.06.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"All patients (age: &gt;18 years, no gender or ethnicity restrictions) who underwent one or more cardiac MRI examination(s) as a result of detected COVID-19 acquisition (PCR test) in the NAPKON HAP cohort will be included in the analysis. \", \"study_eligibility_exclusion_criteria\": \"- Patients without an existing cardio-MRI examination. \\n- Lack of evidence of COVID-19 disease.\\n- Contraindication to MR imaging (metal, renal insufficiency, lack of compliance)\", \"study_population\": \"\", \"study_target_sample_size\": 150, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"(i) Evaluation of T1 and T2 mapping with respect to the occurrence of MACE (Major Adverse Cardiac Events)\\n(ii) Differences in gcardiac function according to severity of myocardial injury\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Association of anamnestic data with the development of COVID-19-associated myocardial injury.\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Other\", \"study_phase\": \"Other\", \"study_masking\": false, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Not applicable (for single-arm trials)\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"The target population of our study includes previously collected data from patients in the National Pandemic Cohort Network (NAPKON) High Resolution Platform (HAP) cohort in the recovery phase of COVID-19 disease with a focus on cardio-MRI data at various time points. It is a retrospective analysis.\\nData are irreversibly anonymized and analyzed in anonymized form. An assignment of patient data to individual persons is not possible.\"}], \"interventional_study_design_interventions\": []}, \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"DRKS00029151","content":"{\"resource_id\": \"DRKS00029151\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: DRKS\"}, \"resource_titles\": [{\"title\": \"Effects of whole body vibration and exercise therapy in Covid-19 patients (Long Covid symptoms)\", \"title_language\": \"EN (English)\"}], \"resource_descriptions\": [{\"description\": \"RCT to test the effectiveness of WBV and sports therapy on motor performance, fatigue, depression, and quality of life in long-covid.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"DRKS00029151\", \"id_type\": \"DRKS\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"30.05.2022\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_name_type\": \"Organisational\", \"role_type\": \"Funder (public)\", \"role_name_organisational\": \"Sportwissenschaftliches Institut\", \"role_email\": \"andrea.dincher@uni-saarland.de\", \"role_phone\": \"+496813022534\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"Uni Campus B8.1, 66123 Saarbr\\u00fccken, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Sponsor (primary)\", \"role_name_personal_given_name\": \"Andrea\", \"role_name_personal_family_name\": \"Dincher\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"andrea.dincher@uni-saarland.de\", \"role_phone\": \"+496813022534\", \"role_affiliation_name\": \"Sportwissenschaftliches Institut\", \"role_affiliation_address\": \"Uni Campus B8.1, 66123 Saarbr\\u00fccken, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_type\": \"Personal\", \"role_type\": \"Contact person\", \"role_name_personal_given_name\": \"Andrea\", \"role_name_personal_family_name\": \"Dincher\", \"role_name_personal_title\": \"Ms. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"andrea.dincher@uni-saarland.de\", \"role_phone\": \"+496813022534\", \"role_affiliation_name\": \"Sportwissenschaftliches Institut\", \"role_affiliation_address\": \"Uni Campus B8.1, 66123 Saarbr\\u00fccken, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Parallel\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"LONGCOVID\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"Request submitted, approval granted\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": null, \"study_status_halted_stage\": null, \"study_status_halted_reason\": \"\\n\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"01.06.2022\", \"study_end_date\": null, \"study_country\": [\"Germany\"], \"study_region\": \"National\", \"study_centers\": \"\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"confirmed diagnosis by a physician, no age or gender limits\", \"study_eligibility_exclusion_criteria\": \"parallel participation in another interventional study\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary Outcome\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Motor abilities test (strength, endurance, coordination, speed, flexibility), questionnaires to assess fatigue, depression, quality of life\", \"study_outcome_time_frame\": \"\"}, {\"study_outcome_title\": \"Secondary Outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"none\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"\", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"Treatment\", \"study_phase\": \"Not applicable\", \"study_masking\": true, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"Randomized\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [{\"study_arm_group_label\": \"Arm 1\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental group Whole body vibration: 1 - 2x per week balance and strengthening exercises on vibration platform (Galileo Med Advanced), max. 30 minutes duration\"}, {\"study_arm_group_label\": \"Arm 2\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Experimental group exercise therapy, 1 - 2x per week exercise therapy program consisting of strengthening, endurance, coordination and flexibility exercises, max. 30 minutes duration as group trainings in presence or in online format\"}, {\"study_arm_group_label\": \"Arm 3\", \"study_arm_group_type\": \"\", \"study_arm_group_description\": \"Control group no intervention (waiting position)\"}], \"interventional_study_design_interventions\": []}}}"}
{"id":"EUCTR2016-002460-13-AT","content":"{\"resource_id\": \"EUCTR2016-002460-13-AT\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002460-13\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Effect of high-dose vitamin D on 28-day mortality in adult critically ill patients with severe vitamin D deficiency\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2016-002460-13-AT\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Medical University of Graz\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Adult critically ill patients with severe vitamin D deficiency\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n-\\t =18 years\\n\\n-\\tAnticipated ICU stay = 48 hours\\n\\n-\\tAdmission to ICU = 72 hours before screening\\n\\n-\\t Severe vitamin D deficiency (=12 ng/ml or undetectable) \\n\\n\\n\\n\\n\\n\\n\\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 1200\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 1200\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n-\\tSevere gastrointestinal dysfunction (> 400 ml residual volume)/unable to take study medication\\n\\n-\\tDNR order/imminent death \\n\\n-\\thypercalcemia\\n\\n-\\tknown recent nephrolithiasis, active tuberculosis or sarcoidosis ( within the last 12 month )\\n\\n-\\tpregnancy/lactation\\n\\n-\\tnot deemed appropriate by study team/physician\\n\\n-                   hypersensitivity to drug or excipient\\n\", \"study_population\": \"\", \"study_target_sample_size\": 2400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): 28-day mortality;Secondary Objective: 90-day mortality\\n1-year mortality\\nICU and hospital mortality\\nHospital and ICU length of stay\\nSOFA Score at day 5 (48 hours tolerance) and number of organ failures (> 2 SOFA points in each of the 6 categories)\\nKatz Activities of Daily Life (ADL) at day 90\\nSelf - reported infections requiring antibiotics until day 90\\nHospital and ICU readmission until day 90\\n\\nHypercalcemia on day 5 (48 hours tolerance)\\nSelf-reported falls, fractures until day 90\\nNew episodes of kidney stones\\n;Main Objective: To test if high-dose vitamin D3 is beneficial for the clinical outcome of critically ill adult patients with severe vitamin D deficiency\\n28-day mortality\\n\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: Oleovit\\nPharmaceutical Form: Oral liquid\\nINN or Proposed INN: Colecalciferol \\nOther descriptive name: COLECALCIFEROL CONCENTRATE (OILY FORM)\\nConcentration unit: ml millilitre(s)\\nConcentration type: equal\\nConcentration number: 14.400 I.E.-\\nPharmaceutical form of the placebo: Oral liquid\\nRoute of administration of the placebo: Oral use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-001270-29-GB","content":"{\"resource_id\": \"EUCTR2020-001270-29-GB\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-001270-29-GB\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"sanofi-aventis recherche & d\\u00e9veloppement\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Coronavirus infection <br>MedDRA version: 20.1\\nLevel: PT\\nClassification code 10053983\\nTerm: Corona virus infection\\nSystem Organ Class: 10021881 - Infections and infestations\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nParticipants must be hospitalized with illness consistent with COVID-19 pneumonia by chest imaging and/or clinical examination and with moderate to severe disease\\n\\nLaboratory-confirmed SARS-CoV-2 infection\\n\\nOnset of COVID-19 symptoms  within 2 weeks before randomization \\n\\nWomen of childbearing potential must have a negative highly sensitive\\n\\npregnancy test at screening and should agree to use an acceptable\\n\\ncontraceptive method\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 175\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 175\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nUnlikely to survive for >48 hours from screening\\n\\nParticipants  with critical disease or multi-organ failure \\n\\nAny contraindication to HCQ or intolerance to HCQ \\n\\nAny medical condition or concomitant therapy that may put the particpants at risk if they are treated with HCQ\\n\\nPregnant or breastfeeding women\\n\\nUse of antiarrhythmic medications and medications known to prolong\\n\\nQT interval or cause Torsades de Pointes (TdPs)\\n\\nParticipants with history of congenital or acquired long QT, arrhythmia,\\n\\nfamily history of long QT or sudden cardiac death, or any other cardiac\\n\\ncondition that, by the judgement of the Investigator, would put the\\n\\npatient at higher risk for QTc prolongation or sudden cardiac death\\n\\nParticipants with the following ECG findings at screening: QTcF >470\\n\\nmsec for women or >450 msec for men or heart rate <50 beats/minute\\n\\nParticipants with known glucose-6-phosphate dehydrogenase (G6PD)\\n\\ndeficiency\\n\", \"study_population\": \"\", \"study_target_sample_size\": 350, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary end point(s): 1. Phase 2: Change in SpO2/FiO2 ratio from baseline  to  Day 15.\\n2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15;Timepoint(s) of evaluation of this end point: 1, 2. Baseline to Day 15;Secondary Objective: Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19\\nEvaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19  \\nEvaluate the safety of HCQ + standard of care as compared to standard of care ;Main Objective: Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio  in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19) \", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes\\nRandomised: yes\\nOpen: yes\\nSingle blind: no\\nDouble blind: no\\nParallel group: yes\\nCross over: no\\nOther: no\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: no\\nOther: yes\\nOther specify the comparator: Standard of care\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: PLAQUENIL 200 mg, comprim\\u00c3\\u00a9 pellicul\\u00c3\\u00a9\\nProduct Code: SAR390530\\nPharmaceutical Form: Tablet\\nCAS Number: 747-36-4\\nCurrent Sponsor code: SAR321068\\nOther descriptive name: HYDROXYCHLOROQUINE SULFATE\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 200-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-001411-25-GB","content":"{\"resource_id\": \"EUCTR2020-001411-25-GB\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Low Dose Oral Selinexor in Patients with Severe COVID-19 Infection\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-001411-25-GB\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Karyopharm Therapeutics Inc.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Severe COVID-19 Infection <br>MedDRA version: 23.0\\nLevel: PT\\nClassification code 10051905\\nTerm: Coronavirus infection\\nSystem Organ Class: 10021881 - Infections and infestations\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"24.04.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nPatients are eligible to be included in the study only if they meet all the following criteria:\\n\\n1. Age =18 years\\n\\n2. Confirmed laboratory diagnosis of SARS-CoV2 by standard approved RT-PCR assay (local labs) within 7 days of enrollment.\\n\\n3. Currently hospitalized.\\n\\n4. Informed consent.\\n\\n5. Has symptoms of severe COVID-19 as demonstrated by:\\n\\na. At least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress.\\n\\nAND\\n\\nb. Clinical signs indicative of lower respiratory infection with COVID-19, with at least one of the following: SpO2 <92% on room air in last 12 hours or requires =4 LPM oxygen by nasal canula, non-rebreather/Ventimask (or similar device) or high flow nasal canula in order to maintain SpO2 =92%, PaO2/FiO2 <300 mm/hg. Patients with COPD or chronic lung disease must demonstrate evidence of increased oxygen needs above baseline.\\n\\n6. Elevated CRP > 2 x ULN.\\n\\n7. Concurrent anti-viral and/or anti-inflammatory agents (e.g., biologics) are permitted. If in the physician\\u2019s judgement, it is in the best interest of the patient to use anti-viral or anti-inflammatory treatments, these treatments are to be documented in the patient\\u2019s chart and entered in the electronic case report form. Note: Patients who may have received plasma convalescent therapy > 48 hours prior to enrollment with no clinical improvement and who still meet criteria for severe COVID-19 may enroll. On study plasma convalescent therapy is not permitted. Patients who receive plasma convalescent therapy within 48 hours may be permitted to enroll based on discussion with sponsor.\\n\\n8. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment. Highly effective methods of contraception are listed in Section 8.3.1. of the protocol.\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 60\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 240\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nPatients are excluded from the study if any of the following criteria apply:\\n\\n1. Evidence of critical COVID-19 based on:\\n\\na. Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations)\\n\\nb. Septic shock (defined by investigator assessment or requiring vasopressors)\\n\\nc. Multiple organ dysfunction/failure\\n\\n2. In the opinion of the investigator, unlikely to survive for at least 48 hours from screening.\\n\\n3. Inadequate hematologic parameters as indicated by the following labs:\\n\\na. Patients with severe neutropenia (ANC <1,000 x 109/L) or\\n\\nb. Thrombocytopenia (e.g., platelets <100,000 per microliter of blood)\\n\\n4. Inadequate renal function and liver function as indicated by the following labs:\\n\\na. creatinine clearance (CrCL) <20 mL/min using the formula of Cockcroft and Gault\\n\\nb. Aspartate transaminase (AST) or alanine transaminase (ALT) > 5x the upper limit of normal.\\n\\n5. Hyponatremia defined as sodium less than 130 mEq/L\\n\\n6. Unable to take oral medication when informed consent is obtained.\\n\\n7. Patients with a legal guardian or who are incarcerated.\\n\\n8. Pregnant and breastfeeding women\\n\", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Throughout the study;Primary end point(s): Proportion of patients with at least a 2 point improvement (increase) in the Ordinal Scale from baseline to Day 14.\\nThe Ordinal Scale is an assessment of the clinical status at the first assessment on each day of hospitalization. The scale is as follows:\\n1. Death;\\n2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);\\n3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;\\n4. Hospitalized, requiring supplemental oxygen;\\n5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);\\n6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;\\n7. Not hospitalized, limitation on activities and/or requiring home oxygen;\\n8. Not hospitalized, no limitations on activities.;Secondary Objective: Key Secondary Objectives:\\n- To evaluate improvement in clinical measures across the 2 treatment\\narms\\nAdditional Secondary Objectives:\\n- To evaluate improvement in additional\\nclinical measures across the 2 treatment\\narms\\n- To determine the anti-inflammatory and\\nimmune effect of selinexor\\n- To assess safety and tolerability of\\nselinexor [time frame: up to 28 days];Main Objective: Day 14 Ordinal Scale improvement\\n(OSI)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes\\nRandomised: yes\\nOpen: no\\nSingle blind: yes\\nDouble blind: no\\nParallel group: no\\nCross over: no\\nOther: yes\\nOther trial design description: enrollment stratified by: Use of concomitant therapies and High Risk Comorbidities\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: yes\\nOther: no\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: Selinexor\\nProduct Code: KPT-330, XPOVIO\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: Selinexor\\nCAS Number: 1393477-72-9\\nCurrent Sponsor code: KPT-330\\nOther descriptive name: SELINEXOR\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 20-\\nPharmaceutical form of the placebo: Film-coated tablet\\nRoute of administration of the placebo: Oral use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-001675-33-DE","content":"{\"resource_id\": \"EUCTR2020-001675-33-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001675-33\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A study to investigate whether vaccination with VPM1002 can reduce elderly people's days with severe respiratory infectious diseases at hospital and/or at home\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-001675-33-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Vakzine Projekt Management GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"infectious respiratory diseases (e.g. COVID-19) <br>MedDRA version: 20.0\\nLevel: HLGT\\nClassification code 10024970\\nTerm: Respiratory tract infections\\nSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"29.05.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Male or female adult (= 60 years)\\n2. Subject is contractually capable, able to understand information on study\\nand has signed informed consent sheet\\n3. Subject has access to an internet-enabled electronic device\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 500\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 1538\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. Known active or latent Mycobacterium tuberculosis infection\\n2. Fever (> 38 \\u00b0C) or respiratory tract infection within the past 24 hours\\n3. Current active viral or bacterial infection\\n4. Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with = 4 weeks between these vaccinations and the trial vaccination\\n5. Participation in another interventional study within 30 days before screening and during this study\\n6. Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Gu\\u00e9rin (BCG) administration\\n7. Severely immunocompromised subjects, including:\\n(a) subjects with known infection by the human immunodeficiency\\nvirus (HIV-1);\\n(b) subjects with solid organ transplantation;\\n(c) subjects with bone marrow transplantation;\\n(d) subjects under chemotherapy, immunotherapy, or radiotherapy;\\n(e) subjects with primary immunodeficiency;\\n(f) treatment with any anti-cytokine therapies;\\n(g) treatment with oral or intravenous steroids defined as daily doses\\nof 10 mg prednisone or equivalent for longer than 3 months, or\\nlikely use of oral or intravenous steroids in the next 4 weeks;\\n8. History of malignancies, unless the subject has been free of the disease for = 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial\\n9. Previous positive SARS-CoV-2 test result\\n10. Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator\\n\", \"study_population\": \"\", \"study_target_sample_size\": 2038, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Objective: To assess the reduction of days with severe respiratory infectious diseases at hospital and/or at home in elderly subjects during the pandemic of SARS-CoV-2;Secondary Objective: To assess the reduction of disease severity, the duration of hospital admission, intensive care unit (ICU) admission, or death in elderly subjects during the pandemic of SARS-CoV-2;Primary end point(s): Number of days with severe respiratory disease at hospital and/or at home;Timepoint(s) of evaluation of this end point: From day 0 to day 240\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: VPM1002\\nPharmaceutical Form: Lyophilisate for suspension for injection\\nINN or Proposed INN: VPM1002\\nCurrent Sponsor code: VPM1002\\nOther descriptive name: Recombinant Mycobacterium bovis rBCG?ureC::hly; VPM1002\\nConcentration unit: CFU/ml colony forming unit(s)/millilitre\\nConcentration type: range\\nConcentration number: 2000000-8000000\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intradermal use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-002282-33-DE","content":"{\"resource_id\": \"EUCTR2020-002282-33-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002282-33\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)\\n\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-002282-33-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Charit\\u00e9 - Universitaetsmedizin Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Patients with moderate to severe COVID-19 disease which may cause acute cardiac injury\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Subject must be willing, understanding and able to provide written informed consent\\n2. Subject must be a man or a woman with age > 18 years at screening \\n3. Subject must have an active moderate to severe COVID-19 confirmed by\\n    a. A positive SARS-CoV-2 PCR test in the last 14 days\\n4. At least one of the following features should be present \\n    a. D-Dimer elevation > 1.5 ULN (age adjusted cut-offs) AND/OR\\n    b. Cardiac injury reflected by an elevation in hs-cTnT > 2.0 ULN AND at least one of the following conditions:\\n         i. Known CAD\\n         ii. Known diabetes mellitus\\n         iii. Active smoking\\n5. A woman of childbearing potential must have a negative serum or urine pregnancy test before randomization occurs. Before randomization, a woman must be either:  \\n    a. Postmenopausal, defined as >45 years of age with amenorrhea for at least 18 months,  \\n    b. If menstruating:\\n         i. If heterosexually active, practicing a highly effective method of birth control with a failure rate less than 1% per year, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch or intrauterine device, or male partner sterilization, consistent with local regulations regarding use of birth control methods for subjects participating in clinical studies, for the duration of their participation in the study, or\\n         ii. Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or\\n        iii. Not heterosexually active \\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 130\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 270\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nAny potential subject who meets any of the following criteria will be excluded from participating in the study. \\n1. Subject has a very high bleeding risk: Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding, such as, but not limited to, the following:\\n     a. Any bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 1 months prior to randomization or occurring during index hospitalization. \\n     b. Major surgery, biopsy of a parenchymal organ, ophthalmic surgery (excluding cataract surgery), or serious trauma (including head trauma) within 4 weeks before randomization.\\n     c. A history of hemorrhagic stroke or any intracranial bleeding at any time in the past, evidence of primary intracranial hemorrhage on CT or magnetic resonance imaging scan of the brain, or clinical presentation consistent with intracranial hemorrhage. This applies as well to subjects hospitalized for ischemic stroke upon randomization.\\n     d. Subject has a history of or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (AV) malformation, or aneurysm.\\n     e. Active gastroduodenal ulcer, defined as diagnosed within 1 months or currently symptomatic or known AV malformations of the gastrointestinal tract.\\n     f. Platelet count <90,000/\\u00b5l at screening. \\n     g. Patients with the diagnosis of bronchiectasis, that due to the investigator judgement are at an increased bleeding risk.\\n2. Subject has any of the following diseases in the medical history: \\n      a. Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. Chronic hormonal therapy (e.g. tamoxifen, anastrozole, leuprolide acetate) for cancer in remission is allowed.\\n      b. Any medical condition (e.g. atrial fibrillation) that requires use of any therapeutic parenteral or oral anticoagulant(s) (e.g. warfarin sodium or other vitamin K antagonists, Factor IIa or FXa inhibitors, fibrinolytics) concomitantly with study medication. In case of \\u201coff label use of a NOAC, the patient can be included in the study if the NOAC was stopped for 24 hours or more.\\n      c. Subject has known allergies, hypersensitivity, or intolerance to rivaroxaban or any of its excipients. \\n      d. Baseline eGFR <30 mL/min/1.73m2 calculated using CKD-EPI formula provided in attachment 3\\n      e. Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) which is associated with coagulopathy or moderate or severe hepatic impairment.\\n      f. Known HIV infection.\\n3. Subject has undergone any of the following procedures or received any of the following drugs: \\n      a. Received fibrinolysis during index hospitalization.\\n      b. Use of antiplatelet therapy with prasugrel or ticagrelor up to 7 days prior to randomization. Other P2Y12 antagonists can be given. However, the use of concomitant antiplatelet therapy should be carefully considered. ASS > 100 mg/d and continuous NSAIDs should be avoided.\\n      c. Use of dual antiplatelet therapy, such as aspirin plus clopidogrel during the study.\\n4. Subjects with acute critical illness that leads to an altered mental status affecting the ability to consent (i.e. hemodynamically unstable, pa\", \"study_population\": \"\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Objective: The primary objective is to assess the effect of rivaroxaban compared with standard of care (SOC) with the use of prophylactic low molecular weight heparin (LMWH) or unfractionated heparin (UFH) (see Attachment 1) on D-dimer as a clinical marker for the clinical outcome  at day 7 post randomization adjusted for baseline measurement in patients with moderate to severe COVID-19.\\nThe co-primary objective is to evaluate the impact of rivaroxaban compared with standard of care (SOC) with the use of prophylactic low molecular weight heparin (LMWH) or unfractionated heparin (UFH) on a seven-category (Attachment 2) ordinal scale recommended by the WHO (23-25) as a measure of clinical benefit at day 7 post randomization adjusted for baseline score in patients with moderate to severe COVID-19.\\n;Secondary Objective: Secondary objectives:\\nThe secondary objective is to assess the efficacy and safety of rivaroxaban compared with standard of\\ncare (SOC) (if appropriate including the use of prophylactic low molecular weight heparin (LMWH) or\\nunfractionated heparin (UFH) (see Attachment 1)) in the prevention of the composite endpoint described\\nbelow up to day 35 in patients with moderate to severe COVID-19.\\n\\n\\nSafety objectives:\\nThe safety objectives are to compare rivaroxaban with SOC with prophylactic LMWH or UFH in bleeding outcomes up to day 35 in patients with moderate to severe COVID-19.\\n\\n;Primary end point(s): Primary Endpoint\\n\\tD-dimer at day 7 post randomization \\nCo-primary Endpoint\\n\\tSeven-category ordinal scale recommended by the WHO at day 7 post randomization \\n;Timepoint(s) of evaluation of this end point: up to day 35\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: Standard of Care with prophylactic LMWG or UFH<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: Xarelto \\nProduct Name: Xarelto\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: RIVAROXABAN\\nCAS Number: 366789-02-8\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 20-\\n\\nTrade Name: Xarelto\\nProduct Name: Xarelto\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: RIVAROXABAN\\nCAS Number: 366789-02-8\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 15-\\n\\nTrade Name: Xarelto\\nProduct Name: Xarelto\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: RIVAROXABAN\\nCAS Number: 366789-02-8\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 10-\\n\\nPharmaceutical Form: Solution for injection\\nOther descriptive name: HEPARIN-NATRIUM EX SCHWEINE-MUCOSA\\nConcentration unit: IU international unit(s)\\nConcentration type: equal\\nConcentration number: 25000-\\n\\nPharmaceutical Form: Solution for injection in pre-filled syringe\\nOther descriptive name: TINZAPARIN SODIUM\\nConcentration unit: IU/ml international unit(s)/millilitre\\nConcentration type: equal\\nConcentration number: 10000-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-002913-16-BE","content":"{\"resource_id\": \"EUCTR2020-002913-16-BE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002913-16\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"The TRISTARDS trial - ThRombolysIS Therapy for ARDS A study to test whether different doses of alteplase help people with severe breathing problems because of COVID 19.\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-002913-16-BE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"SCS Boehringer Ingelheim Comm. V\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Acute respiratory distress syndrome caused by Covid-19 <br>MedDRA version: 21.1\\nLevel: PT\\nClassification code 10001052\\nTerm: Acute respiratory distress syndrome\\nSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"26.11.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1.\\tAge = 18 years (or above legal age)\\n2.\\tARDS with PaO2*/FiO2 ratio >100 and =300 , either on non-invasive ventilator support, OR on mechanical ventilation (<48 hours since intubation), \\n\\u2022\\twith bilateral opacities in chest X-ray or CT scan (not fully explained by effusions, lobar/lung collapse, or nodules)\\n\\u2022\\twith respiratory failure (not fully explained by cardiac failure/fluid overload)\\n*or estimation of PaO2/FiO2 from pulse oximetry (SpO2/FiO2)\\n3.\\tSARS-CoV-2 positive (laboratory-confirmed RT-PCR test) \\n4.\\tFibrinogen level = lower limit of normal\\n5.\\tD-Dimer = upper limit of normal (ULN) according to local laboratory\\n6.\\tSigned and dated written informed consent in accordance with ICH Good Clinical Practice (GCP) and local legislation prior to admission to the trial.\\n\\n\\nAre the trial subjects under 18? yes\\nNumber of subjects for this age range: 8\\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 250\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 60\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1.\\tMassive confirmed PE with haemodynamic instability at trial entry, or any (suspected or confirmed) PE that is expected to require therapeutic dosages of anticoagulants during the treatment period\\n2.\\tIndication for therapeutic dosages of anticoagulants at trial entry\\n3.\\tMechanical ventilation for longer than 48 hours\\n4.\\tChronic pulmonary disease i.e. with known FEV1 <50%, requiring home oxygen, or oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator\\u2019s opinion, or primary pulmonary arterial hypertension\\n5.\\tHas a Do-Not-Intubate (DNI) or Do-Not-Resuscitate (DNR) order\\n6.\\tIn the opinion of the investigator not expected to survive for > 48 hours after screening.\\n7.\\tPlanned interventions during the first 5 days after randomization, such as surgery, insertion of central catheter or arterial line, drains, etc.\\n8.\\tKnown hypersensitivity to the active substance alteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients\\n9.\\tSignificant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesis\\n10.\\tPatients receiving effective oral anticoagulant treatment, e.g. vitamin K antagonists with INR >1.3, or any direct oral anticoagulant within the past 48 hours\\n11.\\tAny history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)\\n12.\\tHistory or evidence or suspicion of intracranial haemorrhage including sub-arachnoid haemorrhage\\n13.\\tSevere uncontrolled arterial hypertension (according to the investigator`s judgement)\\n14.\\tMajor surgery or significant trauma in the past 10 days, recent trauma to head or cranium\\n15.\\tCardiac arrest and/or cardiopulmonary resuscitation during the current hospital stay\\n16.\\tObstetrical delivery within the past 10 days\\n17.\\tSevere hepatic dysfunction i.e. Child-Pugh B and C, including biopsy confirmed hepatic cirrhosis, portal hypertension, hepatic encephalopathy, or active hepatitis\\n18.\\tBacterial endocarditis, pericarditis\\n19.\\tAcute pancreatitis\\n20.\\tDocumented ulcerative gastro-intestinal disease during the last 3 months\\n21.\\tSevere heart failure (New York Heart Association Class IV)\\n22.\\tArterial aneurysms, arterial/venous malformations\\n23.\\tMalignancy (Stage IV) with increased bleeding risk\\n\\nFurther criteria apply.\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 320, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: 1) up to day 28;Primary end point(s): 1) Time to clinical improvement or hospital discharge up to Day 28, defined as the time from randomization to either an improvement of two points on the 11-point WHO Clinical Progression Scale or discharge from the hospital, whichever comes first. ;Secondary Objective: Not applicable;Main Objective: To evaluate the efficacy and safety of intravenous alteplase in ARDS triggered by COVID-19.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: standard of care<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: Alteplase Powder and Solvent for Solution for Injection/Infusion (TPA-05, 50 mg/vial)\\nPharmaceutical Form: Powder and solvent for solution for injection/infusion\\nINN or Proposed INN: ALTEPLASE\\nCAS Number: 105857-23-6\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 1-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-003998-22-DE","content":"{\"resource_id\": \"EUCTR2020-003998-22-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003998-22\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-003998-22-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"CureVac AG\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Vaccination for prophylaxis of COVID-19 (healthy adults) <br>MedDRA version: 23.1\\nLevel: LLT\\nClassification code 10084464\\nTerm: COVID-19 immunization\\nSystem Organ Class: 100000004865\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nINCLUSION CRITERIA FOR ALL SUBJECTS:\\n1. Male or female subjects 18 years of age or older.\\n2. Be willing and able to provide written informed consent prior to initiation of any trial procedures.\\n3. Expected compliance with protocol procedures and availability for clinical follow-up through the last planned visit.\\n4. Females of non-childbearing potential defined as follows: surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or postmenopausal {defined as amenorrhea for = 12 consecutive months prior to screening (Day 1)} without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status. \\n5. Females of childbearing potential: negative pregnancy test {human chorionic gonadotropin (hCG)} within 24 hours prior to each trial vaccination on Day 1 and Day 29.  \\n\\nFull list of inclusion criteria is provided in the protocol.\\n\\nROLL-OVER CRITERIA FOR THE OPEN-LABEL PHASE:\\n1. Subjects must have received at least 1 dose of CVnCoV during the randomized observer blinded phase.\\n2. Subjects must provide additional written informed consent to be eligible for the open label phase.\\n\\u2022 Cohort A: CVnCoV-AV \\n3. Subjects of the CVnCoV treatment arm who received or will receive any AV as standard of care through their national vaccination program.\\n\\u2022 Cohort B: CVnCoV only\\n3. Subjects have not received any vaccination with any other investigational/authorized SARS CoV-2 vaccine or another coronavirus (SARS CoV, MERS-CoV) vaccine\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 30000\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 6500\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nEXCLUSION CRITERIA FOR ALL SUBJECTS:\\n1. History of virologically-confirmed COVID-19 illness. \\n2. For females: pregnancy or lactation. \\n3. Use of any investigational or non-registered product (vaccine or drug) within 28 days preceding the administration of the first trial vaccine or planned use during the trial.\\n4. Receipt of licensed vaccines within 28 days (for live vaccines) or 14 days (for inactivated or any other vaccines) prior to the administration of the first trial vaccine.\\n5. Prior administration of any investigational SARS-CoV-2 vaccine or another coronavirus (SARS-CoV, MERS-CoV) vaccine or planned use during the trial.\\n\\nFull list of exclusion criteria is provided in the protocol.\\n\\nROLL-OVER CRITERIA FOR THE OPEN-LABEL PHASE:\\n1. Subjects must have received at least 1 dose of CVnCoV during the randomized observer blinded phase.\\n2. Subjects must provide additional written informed consent to be eligible for the open label phase.\\n\\u2022 Cohort A: CVnCoV-AV \\n3. Subjects of the CVnCoV treatment arm who received or will receive any AV as standard of care through their national vaccination program.\\n\\u2022 Cohort B: CVnCoV only\\n3. Subjects have not received any vaccination with any other investigational/authorized SARS CoV-2 vaccine or another coronavirus (SARS CoV, MERS-CoV) vaccine\\n\", \"study_population\": \"\", \"study_target_sample_size\": 36500, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: as specified in the endpoints;Primary end point(s): END POINTS FOR THE RANDOMIZED OBSERVE-BLINDED PHASE:\\nPrimary Efficacy Endpoints\\n Occurrence of first episodes of virologically-confirmed {reverse transcription polymerase chain reaction (RT-PCR) positive} cases of COVID-19 of any severity meeting the case definition for the primary efficacy analysis.\\n\\nPrimary Safety Endpoints\\nAll safety endpoints will be analyzed in all subjects, in subjects seronegative at baseline, and in subjects seropositive at baseline.\\n Occurrence, intensity, and relationship of medically-attended AEs collected through 6 months after the second trial vaccination in all subjects.\\n Occurrence, intensity, and relationship of SAEs and AESIs collected throughout the trial in all subjects.\\n Occurrence of fatal SAEs throughout the trial in all subjects.\\n Occurrence, intensity, and duration of each solicited local AE within 7 days after each trial vaccination in Phase 2b subjects. \\n Occurrence, intensity, duration of each solicited systemic AE within 7 days after each trial vaccination in Phase 2b subjects.\\n Occurrence, intensity and relationship of unsolicited AEs occurring within 28 days after each trial vaccination in Phase 2b subjects.\\n Occurrence of AEs leading to vaccine withdrawal or trial discontinuation throughout the trial in all subjects.\\n\\nENDPOINTS FOR THE OPEN-LABEL PHASE:\\n Occurrence, intensity, and relationship to CVnCoV of SAEs and AESIs collected throughout the trial until the end of trial (EOT). \\n Occurrence of fatal SAEs throughout the trial until EOT.\\n Only for Cohort A: CVnCoV-AV: Occurrence of AEs leading to AV withdrawal or trial discontinuation after the first dose with an AV in the open-label phase until EOT\\n\\nOpen-label Exploratory Endpoint\\n Occurrence of first episodes of symptomatic virologically-confirmed (RT-PCR positive) cases of COVID-19 of any severity as assessed by the Investigator.  \\nAny further modifications to endpoints in the open-label phase will be described in the statistical analysis plan (SAP).;Secondary Objective: SECONDARY OBJECTIVES FOR THE RANDOMIZED OBSERVE-BLINDED PHASE:\\nKey Secondary Efficacy Objectives\\n To demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed moderate to severe cases of COVID-19 in SARS CoV-2 na\\u00efve subjects.\\n To demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed severe cases of COVID-19 in SARS-CoV-2 na\\u00efve subjects. \\n To demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity caused by wild type (i.e., WT/D614G lineages A.1/B.1 without the variant of concern [VOC] B.1.1.7 [Alpha], B.1.351 [Beta], B.1.429 [Epsilon]) and UK (B.1.1.7 [Alpha]) SARS CoV 2 strains in SARS CoV 2 na\\u00efve subjects.\\n\\nSECONDARY OBJECTIVES FOR THE OPEN-LABEL PHASE:\\nNone. \\n\\nFor full list see protocol.;Main Objective: OBJECTIVES FOR THE RANDOMIZED OBSERVE-BLINDED PHASE:\\nPrimary Efficacy Objectives\\n To demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 na\\u00efve subjects.  \\n\\nPrimary Safety Objectives\\n To evaluate the safety of CVnCoV administered as a 2-dose schedule to subjects 18 years of age and older.  \\n To evaluate the reactogenicity of CVnCoV administered as a 2-dose schedule to subjects 18 years of age and older participating in Phase 2b of the trial.\\n\\nOBJECTIVES FOR THE OPEN-LABEL PHASE:\\nPrimary Safety Objective:\\n\\tTo evaluate safety in all subjects = 18 years of age remaining in the trial after unblinding\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes\\nRandomised: yes\\nOpen: no\\nSingle blind: no\\nDouble blind: no\\nParallel group: no\\nCross over: no\\nOther: yes\\nOther trial design description: Randomized observer-blinded followed by an Open Label Phase\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: yes\\nOther: no\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: CVnCoV\\nProduct Code: CV07050101\\nPharmaceutical Form: Solution for injection\\nINN or Proposed INN: Zorecimeran\\nCurrent Sponsor code: R9515\\nConcentration unit: g/l gram(s)/litre\\nConcentration type: equal\\nConcentration number: 1-\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intramuscular use\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intramuscular use\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intramuscular use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-004695-18-DE","content":"{\"resource_id\": \"EUCTR2020-004695-18-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004695-18\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals - RES-Q HR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-004695-18-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Heinrich-Heine-University D\\u00fcsseldorf\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This trial focusses on SARS-CoV-2 positive patients with pre-existing risk factors for a moderate or severe COVID-19 disease course. <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10053983\\nTerm: Corona virus infection\\nSystem Organ Class: 100000004862\\n <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084272\\nTerm: SARS-CoV-2 infection\\nSystem Organ Class: 100000004862\\n <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084442\\nTerm: SARS-CoV-2 PCR test positive\\nSystem Organ Class: 100000004848\\n <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084270\\nTerm: SARS-CoV-2 acute respiratory disease\\nSystem Organ Class: 100000004862\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1.Individuals (female, male diverse) = 18 years with SARS-CoV-2 infection, confirmed by PCR before study enrollment\\n2.SARS-CoV-2 positive PCR = 3 days old (date of NP swab)\\n3.Ability to provide written informed consent\\n4.Potassium values between 3.5-4.9 mmol/l\\n5.Platelets on full blood count must be = 50.000/\\u00b5l\\n6.Presence of at least one of the following criteria:\\n- Patients = 55 years\\n- BMI = 35 kg/m2, \\n- coronary artery disease (CAD),\\n- chronic kidney disease (CKD) with GFR <60 ml/min but = 30 ml/min,\\n- diabetes mellitus, \\n- active tumor disease\\n-Patients with chronic pulmonary disease, e.g. obstructive pulmonary disease (COPD), pulmonary fibrosis\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 398\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 95\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1.Age <18 years \\n2.Unable to give informed consent\\n3.Pregnant women or breast-feeding mothers\\n4.Known hypersensitivity to camostat mesylate and/or severe pancreatitis\\n5.Life expectancy < 6 months\\n6.Duration SARS-CoV-2 typical symptoms > 3 days\\n7.SARS-CoV-2 PCR detection older than 3 days\\n8.SARS-CoV-2 associated clinical condition = WHO stage 3 (patients hospitalized for other reasons than mAB treatment, pAB-treatment, CP-treatment, \\n   social reasons and COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria)\\n9.Previously or currently hospitalized due to SARS-CoV-2\\n10.Previous antiviral therapy for SARS-CoV-2\\n11.ALT or AST > 5 x ULN at screening\\n12.Liver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial)\\n13.Chronic kidney disease with GFR < 30 ml/min\\n14.Concurrent or planned anticancer treatment during trial period\\n15.Accommodation in an institution due to legal orders (\\u00a740(4) AMG).\\n16.Any psycho-social condition hampering compliance with the study protocol. \\n17.Evidence of current drug or alcohol abuse.\\n18.Use of other investigational treatment within 5 half-lives of enrollment is prohibited\\n19.Concomitant proven influenza A infection\\n20.Patients with organ or bone marrow transplant in the three months prior to Screening Visit \\n\", \"study_population\": \"\", \"study_target_sample_size\": 497, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Cumulative number of persons in the SoC+treatment arm versus SoC+placebo in WHO category 3 by day 28;Primary end point(s): The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale = 4 up to and including day 28.;Secondary Objective: % of patients with at least 1 COVID-19-related medically visit (incl. telemedicine/phone) through day 28;\\nCumulative no. in the SoC+treatment arm vs. SoC+placebo in WHO categories 4-8 by day 8,14,56 & 90;\\nCumulative no. in the SoC+treatment arm vs. SoC+placebo in WHO categories 3 by day 8,14,28,56 & 90;\\n\\\"Event-free survival at day 90 & evaluation of all-cause mortality at day 90 using Kaplan-Meier;\\nThe proportion of patients with remdesivir therapy & WHO status at initiation of remdesivir;\\nThe proportion of patients on dexamethasone therapy & WHO status at baseline dexamethasone;\\n% of patients with novel COVID-19- associated symptoms,\\nTime to resolution of COVID-19 related symptoms;\\nTime to first negative SARS-CoV-2-PCR ;\\nDuration of oxygen therapy (days);\\n% of participants in each group with need for mechanical ventilation (& ventilation days);\\nDuration of hospital stay (days), duration in intensive care (days);\\nAll-cause mortality at day 28\\nSARS-CoV-2 genetic variants;Main Objective: The working hypothesis to be tested in the RES-Q HR study is that the early use of camostat mesylate reduces the likelihood of disease progression to modified WHO stages 4-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative number of individuals who progressed to or beyond category 4 on the modified WHO COVID-19 ordinal scale within 28 days after randomization.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: 2-arm, multicenter, randomized, double-blind, controlled trial<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: Camostat mesylate\\nProduct Name: Camostat mesylate\\nPharmaceutical Form: Film-coated tablet\\nPharmaceutical form of the placebo: Film-coated tablet\\nRoute of administration of the placebo: Oral use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-004715-27-DE","content":"{\"resource_id\": \"EUCTR2020-004715-27-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004715-27\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A study to investigate the effect of NOC-100 in terms of efficacy, safety, tolerability and drug levels in the blood in patients with acute and chronic cough.\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-004715-27-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Nocion Therapeutics, Inc.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Cough <br>MedDRA version: 20.0\\nLevel: PT\\nClassification code 10011224\\nTerm: Cough\\nSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nPart 1:\\n1. Male and female participants between the ages of 18 to 80 years, inclusive.\\n2. Has had CC for = 12 months and a diagnosis of refractory or unexplained CC (Per CHEST chronic cough diagnosis guidelines, Irwin et al, 2018).\\n3. Chest radiograph or CT thorax within the timeframe supporting the diagnosis of CC, and within the last 60 months, not demonstrating any abnormality considered to be significantly contributing to the CC.\\n4. If a female of childbearing potential, must be either sexually inactive (abstinent as a lifestyle*) for 28 days prior to the first dosing and throughout the study or using one of the following highly effective birth control methods: \\na. hormonal oral contraceptives, transdermal patch, or hormone-releasing intrauterine device for at least 3 months prior to the first dosing and with either a physical (e.g., condom, diaphragm, or other) or a chemical (e.g., spermicide) barrier method from the time of screening and throughout the study.\\nb. Depot/implantable hormone (e.g., Depo Provera\\u00ae, Implanon\\u00ae) for at least 3 months prior to the first dosing and throughout the study.\\nIn addition, female participants of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 14 days after the last dose of study drug. Females will also be advised not to donate ova during the trial for at least 30 days after the last dose.\\n*abstinence should only be used as a contraceptive method if it is in line with the participants\\u2019 usual and preferred lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception.\\n5. If a female of non-childbearing potential, must have undergone one of the following sterilisation procedures at least 6 months prior to the first dosing:\\na. hysteroscopic sterilisation;\\nb. bilateral salpingectomy;\\nc. hysterectomy;\\nd. bilateral oophorectomy or\\ne. or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.\\n6. A non-vasectomised, male participant must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.  (No restrictions are required for a vasectomised male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomised less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomised male).\\n7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.\\n8.\\tUnderstands the study procedures in the Informed Consent Form (ICF) and be willing and able to comply with the protocol. Participants must have signed and dated an IRB/IEC approved written ICF including all authorisations required by local law (e.g., collection and handling of personal data, especially health information). The ICF must be obtained before the performance of any protocol related procedures that are not part of the normal standard of care.\\n9. Aspartate transaminase (AST) and alanine aminotransferase (ALT) <2 x upper limit of normal (ULN); alkaline phosphatase (ALP) and bilirubin =1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).\\n10. Creatinine clearance =50 mL/min.\\n11. Awake-cough frequency of =10 per hour (average) at Screening.\\n12. Score of =40 \", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nPart 1:\\n1. Current smoker or individuals who have given up smoking within the past 6 months prior to screening, or those with >20 pack-year smoking history.\\n2. Current diagnosis of COPD, bronchiectasis, unexplained pulmonary fibrosis, or asthma.\\n3. History of concurrent malignancy or recurrence of malignancy in the 2 years prior to the screening visit, participants with adequately treated non-melanomatous skin carcinoma will be permitted.\\n4. History of recent respiratory tract infection (including SARS-CoV-2 infection) or recent significant change in pulmonary status within 4 weeks of the screening visit.\\n5. Is currently or has at any time had severe symptoms related to SARS-CoV-2 and required hospitalisation.\\n6. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.\\n7. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\\n8. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.\\n9. History of recent (within the past 6 months) acute myocardial infarction, acute thromboembolic event, myocarditis, hospitalization for unstable angina or heart failure; history or presence of a clinically important arrhythmia; Wolff-Parkinson-White syndrome or bundle branch block.\\n10. History or presence of alcohol or drug use disorder, per DSM-5, within the past 2 years prior to screening.\\n11. History or presence of hypersensitivity to the study drugs or related compounds.\\n12. Drink alcohol in excess of 21 glasses/units per week for males or 14 glasses/units per week for females, with one unit = 150 mL of wine or 360 mL of beer or 45 mL of 45% alcohol. \\n13. Current opiate/opioid use in the past 7 days prior to screening, or medical history of opiate/opioid use disorder (OUD).\\n14. Unable to refrain from the use of:\\na. Gabapentin, pregabalin, and/or amitryptline or other tricyclics within 4 weeks prior to screening and throughout the study.\\nb. Chronic, systemic corticosteroid use within 4 weeks prior to screening and throughout the study.\\nc. Inhalers including long-acting and short acting beta 2 agonists (LABA, SABA) and ICS within 12 weeks prior to screening and throughout the study.\\nd. Lidocaine or related compounds of any form within 14 days prior to screening and throughout the study.\\ne. Medication or remedies to aid sleeping 14 days prior to screening and throughout the study.\\nf. ACE-inhibitor within 12 weeks prior to screening and throughout the study.\\ng. Antitussives 7 days prior to screening and throughout the study.\\nh. Speech and language therapy for CC within 4 weeks prior to screening and throughout the study.\\ni. Food and beverages containing xanthines/caffeine for 12 hours prior to screening (small amounts of caffeine derived from normal foodstuffs e.g., 250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction).\\nj. Food and beverages containing alcohol for 24 h prior to screening.\\n15. Donation of blood or plasma within 90 days prior to the first dosing.\\n16. Participation in another clinical study involving an investigational drug within 60 days prior to the first dosing. The 60-day window will b\", \"study_population\": \"\", \"study_target_sample_size\": 130, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Please refer to protocol for timepoints.;Primary end point(s): Part 1:\\nIncidence of:\\n- TEAEs, \\n- SAEs, \\n- severe AEs, \\nAEs leading to study and/or treatment discontinuation.\\n\\n\\nPart 2:\\nRelative reduction in VAS score for cough severity \\nIncidence of: \\n- TEAEs, \\n- SAEs, \\n- severe AEs, \\n- AEs leading to study and/or treatment discontinuation\\n\\n;Secondary Objective: Part 1:\\nTo evaluate the treatment effect of escalating nebulised inhaled doses of NOC 100 (single and 2 consecutive QD doses) as determined by awake-coughs per hour in participants with CC.\\n\\nTo evaluate the treatment effect of escalating nebulised inhaled doses of NOC 100 (single and 2 consecutive QD doses) as determined by 24-hour coughs per hour in participants with CC.\\n\\nTo characterise the PK profile of NOC 100 following escalating nebulised inhaled doses (single and 2-consecutive QD doses) in participants with CC.\\n\\nTo identify the dose level and NOC 100 schedule for future development and administration in patients with CC. \\n\\nPart 2:\\nTo evaluate the treatment effect of nebulised inhaled doses of NOC 100 as determined by awake-coughs per hour and 24-hour coughs per hour in participants with AC.\\n\\nTo characterise the PK profile of NOC 100 following nebulised inhaled doses in participants with AC.;Main Objective: Part 1:\\nTo evaluate the safety and tolerability of escalating nebulised inhaled doses of NOC 100 (single and 2 consecutive QD doses) in participants with CC.\\n\\nPart 2:\\nTo evaluate the treatment effect of nebulised inhaled doses of NOC 100 as determined by VAS score for cough severity in participants with AC.\\n\\nTo evaluate the safety and tolerability of nebulised inhaled doses of NOC 100 in participants with AC. \", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: no<br>Cross over: yes<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 4<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: NOC-100\\nPharmaceutical Form: Nebuliser solution\\nINN or Proposed INN: NTX-1175\\nCurrent Sponsor code: NTX-1175\\nOther descriptive name: NTX-1175 chloride\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 1.5-\\nPharmaceutical form of the placebo: Nebuliser solution\\nRoute of administration of the placebo: Inhalation use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-005315-44-IT","content":"{\"resource_id\": \"EUCTR2020-005315-44-IT\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005315-44\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Phase 3, Double-blind, Placebo-controlled Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-005315-44-IT\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"ASTRAZENECA AB\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 (Coronavirus Disease 2019) <br>MedDRA version: 23.0\\nLevel: PT\\nClassification code 10051905\\nTerm: Coronavirus infection\\nSystem Organ Class: 10021881 - Infections and infestations\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"16.02.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Participant has a documented laboratory-confirmed SARS-CoV-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, NP, or nasal swab, or saliva) collected = 3 days prior to Day 1.\\n2. WHO Clinical Progression Scale score > 0 and < 4.\\n3. Participant must be dosed with IMP no more than 7 days from selfreported onset of COVID-19-related symptoms (mild to moderate COVID-19) or measured fever, defined as the self-reported date of first\\nreported sign/symptom.\\n4. One or more of the following signs/symptoms must be present within 24 hours prior to Day1: Cough, Sore throat, Shortness of breath or difficulty breathing at rest or with activity, Body pain or muscle pain/aches, Fatigue, Headache, Chills, Nasal obstruction or congestion, Nasal discharge, Nausea or vomiting, Diarrhea, New loss of taste or smell.\\n5. Oxygenation saturation of = 92% obtained at rest by study staff within 24 hours prior to Day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition).\\n6. Participant agrees not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest).\\n7. Participant must be = 18 years of age, provide informed consent and is able to comply with study requirements/procedures.\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 1700\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 1020\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. History or current hospitalization for COVID-19.\\n2. Need for hospitalization/immediate medical attention in a clinic/emergency room service\\n3. Previous adverse reaction to any monoclonal antibodies or known allergy to components of the IMP or placebo.\\n4. Receipt of any investigational or licensed vaccine for prevention of COVID-19 at any time prior to entry into this study.\\n5. Requirement or anticipated impending need for mechanical ventilation.\\n6. Any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study.\\n7. Received convalescent COVID-19 plasma treatment any time prior to entry into this study.\\n8. Pregnant or breastfeeding women.\\n9. Receipt of any IMP in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of IMP during the study follow-up period, or concurrent participation in another interventional study.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1700, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Objective: Efficacy of AZD7442 in the prevention of the composite endpoint of either severe COVID-19 or death from any cause through study Day 29.;Secondary Objective: Efficacy of AZD7442 in the prevention of the composite endpoint of either death or hospitalization for COVID-19 complications or sequelae through Day 169.;Primary end point(s): A composite of either severe COVID-19 or death from any cause through Day 29.;Timepoint(s) of evaluation of this end point: Day 29\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: na\\nProduct Code: [AZD8895]\\nPharmaceutical Form: Solution for injection/infusion\\nINN or Proposed INN: ACIDO ACETILSALICILICO\\nCAS Number: 2420564-02-7\\nCurrent Sponsor code: AZD8895\\nOther descriptive name: monoclonal antibody (mAb)\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 100-\\nPharmaceutical form of the placebo: Solution for injection/infusion\\nRoute of administration of the placebo: Intramuscular use\\n\\nProduct Name: na\\nProduct Code: [AZD1061]\\nPharmaceutical Form: Solution for injection/infusion\\nINN or Proposed INN: ACIDO ACETILSALICILICO\\nCAS Number: 2420563-99-9\\nCurrent Sponsor code: AZD1061\\nOther descriptive name: monoclonal antibody (mAb)\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 100-\\nPharmaceutical form of the placebo: Solution for injection/infusion\\nRoute of administration of the placebo: Intramuscular use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-005544-34-DE","content":"{\"resource_id\": \"EUCTR2020-005544-34-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005544-34\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Double-blind placebo-controlled proof-of-concept trial to demonstrate the anti-viral efficacy of different doses of azelastine in COVID-19 positive patients.\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-005544-34-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"URSAPHARM Arzneimittel GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Diagnosis of SARS-CoV-2 infection documented by a positive PCR test (patients do not need to suffer from COVID-19 symptoms) <br>MedDRA version: 23.1\\nLevel: PT\\nClassification code 10084460\\nTerm: COVID-19 treatment\\nSystem Organ Class: 10042613 - Surgical and medical procedures\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nPatients must meet all of the following inclusion criteria in order to participate in this study: \\n\\n\\n\\n- Legally competent patients who are personally capable of giving informed consent and to date the Consort Form prior to any trial related activity\\n\\n- Patients aged from 18 - 60 years \\n\\n- Having the diagnosis of SARS-CoV-2 infection documented by a positive PCR test (patients do not need to suffer from COVID-19 symptoms)\\n\\n- Enrolment only permitted on the day of availability of positive COVID-19 PCR test result, and on the subsequent day, however, not longer than 48 hours after the swab was taken \\n\\n- For females: non-pregnant, non-lactating with adequate contraception until D16, or females unable to bear children (i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period).\\n\\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 90\\nF.1.3 Elderly (>=65 years) no\\nF.1.3.1 Number of subjects for this age range \\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nPatients must not meet any of the following non-inclusion criteria in order to participate in this study:\\n\\n\\n\\n- Patients requiring hospitalization,\\n\\n- Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion,\\n\\n- No enrolment permitted if COVID-19 testing was performed more than 48 hours ago\\n\\n- Being in any relationship or dependence with the Sponsor, CRO and/or Investigator,\\n\\n- Patients being on risk for a serious course of the disease (e.g., insulin-dependent diabetic patients, patients treated with antihypertensive drugs),\\n\\n- Inability to understand instructions/study documents,\\n\\n- Inability to administer the nasal spray\\n\\n- Specific vulnerable patients: subjects who are detained or commited to institutions by law court or by legal authorities, such as psyhiatric wards, prisons or other state institutions\\n\\n- Any concurrent anti-histamine therapy (systemic as well)\\n\\n- Any concurrent nasal spray \\n\\n- Females who are pregnant, lactating, or of child-bearing potential and not using an adequate contraceptive method until D16,\\n\\n- Having any contraindication for the use of azelastine (incl. hypersensitivity to the active substance or other ingredients).\\n\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 90, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Any of the six timepoints (day 2, day 3, day 4, day 5, day 8 and day 11) after baseline (day 1);Primary end point(s): Primary Endpoint\\nFirst data on efficacy of the treatment with azelastine nasal spray will be assessed by the decrease in median virus load of SARS-CoV-2 between the treatment groups via regular quantitative PCR measurements from nasopharyngeal swabs.\\n\\nPrimary endpoint of the efficacy of azelastine nasal spray in COVID-positive patients is the baseline adjusted course of the median of virus load in nasopharyngeal swabs of the three treatment groups at any of the six timepoints (day 2, day 3, day 4, day 5, day 8 and day 11) after baseline (day 1). Comparisons will be made via regularly performed quantitative PCR measurements from nasopharyngeal swabs. ;Secondary Objective: Secondary objectives of the trial are: \\n- To assess the clinical impact of the treatment with azelastine nasal spray with regards to the SARS CoV-2 virus shedding. \\n- To assess the clinical impact of the treatment with azelastine nasal spray with regard to symptoms via a patient diary.\\n- To assess the clinical improvement of the patient state\\n- To assess the clinical impact of the treatment with azelastine nasal spray with regards to Quality of Life \\n\\n;Main Objective: The primary objective of this study is to assess the first data on efficacy of azelastine nasal spray in SARS-CoV-2 infected patients with regards to virus load in nasopharyngeal swabs. \", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 3<br>\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: Pollival\\u00c2\\u00ae 1 mg/ml Nasenspray, L\\u00c3\\u00b6sung\\nPharmaceutical Form: Nasal spray, solution\\nINN or Proposed INN: Azelastinhydrochlorid\\nOther descriptive name: AZELASTINE HYDROCHLORIDE\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 1-\\nPharmaceutical form of the placebo: Nasal spray, solution\\nRoute of administration of the placebo: Nasal use\\n\\nProduct Name: Azelastin 0.02 % nasal spray, solution\\nPharmaceutical Form: Nasal spray, solution\\nINN or Proposed INN: Azelastinhydrochlorid\\nOther descriptive name: AZELASTINE HYDROCHLORIDE\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 0.2-\\nPharmaceutical form of the placebo: Nasal spray, solution\\nRoute of administration of the placebo: Nasal use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-005752-38-DE","content":"{\"resource_id\": \"EUCTR2020-005752-38-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005752-38\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC)\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-005752-38-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Novartis Pharma GmbH\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"secondary progressive multiple sclerosis (SPMS)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Nervous System Diseases [C10]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"18.03.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Signed informed consent must be obtained prior to participation in the study.\\n2. One of the following MS treatments as part of clinical routine: \\na. Cohort 1: Siponimod treatment according to EU SmPC without interrupting daily dosing for the purpose of vaccination with SARS-CoV-2  modRNA \\nb. Cohort 2: Siponimod treatment according to EU SmPC interrupting daily dosing for the purpose of vaccination with SARS-CoV-2 modRNA \\nc. Cohort 3: Dimethylfumarate, glatirameracetate, interferon, teriflunomode as per respective EU SmPC or no current treatment with diagnosis of SPMS or with RRMS at risk to develop SPMS (at the discretion of the treating physician)\\n3. Planning to receive a SARS-CoV-2 modRNA vaccination as part of clinical routine\\n4.\\tNo change regarding DMT within 4 weeks prior to inclusion to AMA-VACC, i.e. stable on current DMT according to dosing within label, no interruption, start or withdrawal of DMT in this period of time and no planned switch of DMT within following 2 months\\n5.\\tPatients willing and eligible to receive a modRNA vaccine against COVID-19 as part of clinical routine\\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 50\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 10\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. History of COVID-19\\n2. SARS-CoV-2 antibodies at screening\\n3. Patients likely not being able or willing to complete the study\\n4. Use of other investigational drugs within 5 half-lives of enrollment/initiation of study treatment (e.g. small molecules) or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer\\n5. Patients with any medical or psychological condition that, in the investigators opinion, renders the patient unable to understand the nature, scope, and possible consequences of the study and who are therefore not able to comply with the requirements of the study and capable of giving informed consent\\n6. No person directly associated with the administration of the study is allowed to participate as a study subject \\n7. No family member of the investigational study staff is allowed to participate in this study\\n8. Known or suspected clinically relevant allergy, intolerance or hypersensitivity to peanuts, soya (only cohort 1 and 2) or to any of the study treatments designated for the individual subject (DMTs or mRNA vaccines) or drugs of similar chemical classes (active substance or excipients)\\n9. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 10 days of study treatment after stopping medication.\\n10. For cohort 3: patients with contraindications for their current MS medication according to the respective EU SmPC\\n\", \"study_population\": \"\", \"study_target_sample_size\": 60, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Objective: To estimate the proportion of those achieving seroconversion (i.e. having SARS-CoV-2 serum functional antibodies) after receiving a modRNA vaccine in participants treated concomitantly with siponimod and siponimod treatment break.;Timepoint(s) of evaluation of this end point: 1 week after second dose of vaccine in participants treated concomitantly with siponimod and siponimod treatment break;Primary end point(s): Proportion of participants achieving seroconversion as defined by detection of SARS-CoV-2 serum functional antibodies one week after second dose of vaccine in participants treated concomitantly with siponimod and siponimod treatment break (yes/no);Secondary Objective: \\tDescribing SARS-CoV-2 serum functional antibody levels in participants treated concomitantly with siponimod versus siponimod treatment break versus first-line DMTs and in patients currently not on a DMT \\n\\tDescribing the T cell response to modRNA vaccines in participants treated concomitantly with siponimod versus siponimod treatment break versus first-line DMTs and in patients currently not on a DMT \\n\\tDescribing safety, incl. AEs related to discontinuation and new onset of siponimod treatment and patients developing COVID-19\\n\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: max recommended dose at the discretion of the investigator (routinely used first line MS treatments)<br>Number of treatment arms in the trial: 3<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-4\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nTrade Name: Mayzent 2 mg Filmtabletten\\nProduct Name: Mayzent 2 mg Filmtabletten\\nProduct Code: BAF312A\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: SIPONIMOD\\nCAS Number: 1234627-85-0\\nCurrent Sponsor code: BAF312\\nOther descriptive name: Siponimod\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 2-\\n\\nTrade Name: Mayzent 0,25 mg Filmtabletten\\nProduct Name: Mayzent 0,25 mg Filmtabletten\\nProduct Code: BAF312A\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: SIPONIMOD\\nCAS Number: 1234627-85-0\\nCurrent Sponsor code: BAF312\\nOther descriptive name: Siponimod\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 0.25-\\n\\nTrade Name: Spikevax\\nPharmaceutical Form: Dispersion for injection\\nINN or Proposed INN: COVID-19 mRNA Vaccine (nucleoside modified)\\nOther descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414)\\nConcentration unit: \\u00c2\\u00b5g microgram(s)\\nConcentration type: equal\\nConcentration number: 100-\\n\\nPharmaceutical Form: Capsule, hard\\nINN or Proposed INN: DIMETHYL FUMARATE\\nCAS Number: 624-49-7\\nOther descriptive name: DIMETHYL FUMARATE\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 240-\\n\\nPharmaceutical Form: Film-coated tablet\\nINN or Proposed INN: TERIFLUNOMIDE\\nCAS Number: 108605-62-5\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 14-\\n\\nPharmaceutical Form: Solution for injection in pre-filled syringe\\nINN or Proposed INN: GLATIRAMER ACETATE\\nCAS Number: 147245-92-9\\nOther descriptive name: GLATIRAMER ACETATE\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 40-\\n\\nPharmaceutical Form: Powder and solvent for solution for injection\\nINN or Proposed INN: RECOMBINANT INTERFERON BE\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-005759-18-DK","content":"{\"resource_id\": \"EUCTR2020-005759-18-DK\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005759-18\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A study to evaluate the Efficacy, Safety, and Antiviral Activity of RO7496998 (AT-527) in Patients with Mild or Moderate COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-005759-18-DK\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"F. Hoffmann La Roche Ltd.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Mild to Moderate coronavirus disease 2019 (COVID-19) <br>MedDRA version: 23.1\\nLevel: LLT\\nClassification code 10084401\\nTerm: COVID-19 respiratory infection\\nSystem Organ Class: 100000004862\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"18.05.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nAge >=18 years (regardless of weight) at the time of signing informed consent or age >=12 to <18 years (weight >=40 kilogram) at the time of signing informed consent (and assent)\\nAbility to comply with all aspects of the study protocol, including providing samples for virology, in the opinion of the investigator\\nAt least three of the following symptoms of at least moderate (score >=2 as per COVID-19 Symptom Diary) intensity: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills or sweats, feeling hot or feverish, nausea, vomiting, or diarrhea\\nPositive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) diagnostic test (reverse-transcriptase polymerase chain reaction [RT-PCR] or validated rapid antigen test) <=72 hours prior to randomization\\nSymptoms consistent with mild or moderate COVID-19, as determined by the Investigator, with onset <=5 days before randomization\\nFor women of childbearing potential and girls at or beyond menarche (age >=12 to <18 years): agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for 30 days after the final dose of RO7496998 (AT-527)\\n\\n\\nAre the trial subjects under 18? yes\\nNumber of subjects for this age range: 150\\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 1236\\nF.1.3 Elderly (>=65 years) no\\nF.1.3.1 Number of subjects for this age range \\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nClinical signs indicative of COVID-19 illness requiring hospitalization\\nAdmitted to a hospital prior to randomization or is hospitalized (inpatient) at randomization due to COVID-19\\nIn the opinion of the investigator, is likely to experience imminent deterioration and require hospitalization\\nTreatment with an investigational drug within 5 half-lives or 3 months (whichever is longer) of randomization\\nTreatment with a COVID-19 therapeutic agent against SARS-CoV-2 including, but not limited to, other direct or indirect acting antivirals against SARS CoV 2 (such as remdesivir or favipiravir), systemic or inhaled steroids (such as dexamethasone or inhaled budesonide), colchicine, ivermectin, interferons, convalescent plasma, monoclonal antibodies against SARS CoV-2 or Interleukin 6 (IL-2) intravenous immunoglobulin or other emergency use authorization (EUA)-approved treatments within 3 months or less than 5 drug elimination half-lives (whichever is longer) prior to the screening visit\\nConcomitant use of P-glycoprotein (P-gp) inhibitors or inducers\\nKnown allergy or hypersensitivity to components of study drug\\nPregnant or breastfeeding, or intending to become pregnant during the study or within 30 days after the final dose of RO7496998 (AT-527)\\nAbnormal laboratory test results at screening\\nRequirement of any prohibited medications during the study\\nOther known active viral or bacterial infection at the time of screening, such as influenza. This exclusion does not apply to patients with stable chronic viral infections, such as chronic HCV or HIV providing other eligibility criteria are met\\nAny clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, could jeopardize the safety of the patient or affect patient compliance or safety/efficacy observations during the study\\nCOVID 19 vaccination within <=40 days prior to enrollment (second dose if applicable)\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1386, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Objective: To evaluate the efficacy of RO7496998 (AT-527) compared with placebo based on the time to alleviation or improvement of COVID-19 symptoms;Timepoint(s) of evaluation of this end point: 1. Day 1 to day 29;Primary end point(s): 1.Time to alleviation or improvement of COVID-19 symptoms (Items 1-12 of the COVID-19 symptom diary) maintained for a duration of 21.5 hours\\ndefined as follows:\\nFor new symptoms:  time from randomization to the alleviation of COVID 19 symptoms (i.e., a score of 0 [none] or 1 [mild] on the COVID 19 Symptom Diary) \\nFor preexisting symptoms:  time from randomization to when a patients symptoms have been maintained or improved (Note:  Improved requires at least a single category improvement from baseline on the COVID-19 Symptom Diary Likert scale)\\n;Secondary Objective: -To evaluate the efficacy of RO7496998 (AT-527) compared with placebo (defined as the time from randomization to the point at which the following criterion is met and maintained for at least 21.5 hours) based on:\\nTime to alleviation or improvement of COVID-19 symptoms  \\nTime to alleviation of symptoms\\nTime to one-category improvement of baseline presenting COVID-19 symptoms \\nTime to alleviation of individual symptoms \\nProportion of patients requiring hospitalization for COVID-19\\nProportion of patients with >=1 COVID-19 related medically attended visit through to study end\\nDuration of fever \\nFrequency of COVID-19 related complications,\\nProportion of patients with any post-treatment infection \\nProportion of patients with all-cause mortality\\n-To evaluate the antiviral activity of RO7496998 (AT-527) compared with placebo\\n-To evaluate the safety of RO7496998 (AT-527) compared with placebo\\n-To characterize the pharmacokinetic (PK) profile of AT-511 and major metabolites in plasma\\n\\n\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes\\nRandomised: yes\\nOpen: no\\nSingle blind: no\\nDouble blind: yes\\nParallel group: no\\nCross over: no\\nOther: no\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: yes\\nOther: no\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: RO7496998 hemisulfate (AT-527)\\nProduct Code: RO7496998\\nPharmaceutical Form: Tablet\\nINN or Proposed INN: Not available yet\\nCAS Number: 2241337-84-6\\nCurrent Sponsor code: RO7496998\\nOther descriptive name: AT-527\\nConcentration unit: mg milligram(s)\\nConcentration type: equal\\nConcentration number: 275-\\nPharmaceutical form of the placebo: Tablet\\nRoute of administration of the placebo: Oral use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-005801-14-DE","content":"{\"resource_id\": \"EUCTR2020-005801-14-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-005801-14\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-005801-14-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Janssen Vaccines & Prevention B.V.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Healthy Volunteers (Prevention of SARS-CoV-2-mediated COVID-19) <br>MedDRA version: 23.1\\nLevel: LLT\\nClassification code 10084465\\nTerm: COVID-19 vaccination\\nSystem Organ Class: 100000004865\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"15.02.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1.Participant is 18 to 55 years of age, inclusive, on the day of signing the ICF.\\n\\n2.Participant must have a BMI <35.0 kg/m2.\\n\\n3.Participant must be healthy, in the investigator\\u2019s clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled and not considered to be comorbidities related to an increased risk of severe COVID-19 , except for smoking, which is allowed. If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participant will be included on the basis of physical examination, medical history, and vital signs.\\n\\n4.Contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.\\n\\n5.Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine.\\n\\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 1590\\nF.1.3 Elderly (>=65 years) no\\nF.1.3.1 Number of subjects for this age range \\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n 1.Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature =38.0\\u00baC (100.4\\u00b0F) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor.\\n\\n2.Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence).\\n\\n3.Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine).\\n\\n4.Participant has abnormal function of the immune system resulting from:\\n\\na.Clinical conditions (eg, autoimmune disease, potential immune mediated disease or known or suspected immunodeficiency, chronic kidney disease [with dialysis]) expected to have an impact on the immune response of the study vaccine. Participants with clinical conditions stable under non-immunomodulator treatment eg, autoimmune thyroiditis, autoimmune inflammatory rheumatic disease such as rheumatoid arthritis) may be enrolled at the discretion of the investigator. Non-immunomodulator treatment is allowed as well as steroids at a non-immunosuppressive dose or route of administration.\\n\\nb.Chronic or recurrent use of systemic corticosteroids within 6 months before administration of study vaccine and during the study.     \\n\\nNote: Ocular, topical or inhaled steroids are allowed.\\n\\nc.Administration of antineoplastic and immunomodulating agents or radiotherapy within 6 months before administration of study vaccine and during the study.\\n\\n5.Participant has a history of any neurological disorders or seizures including Guillain-Barr\\u00e9 syndrome, with the exception of febrile seizures during childhood.\\n\\n6.Participant has a history of chronic urticaria (recurrent hives), eczema or adult atopic dermatitis.\\n\\n7.Participant received treatment with immunoglobulins in the 3 months or exogenous blood products (autologous blood transfusions are not exclusionary) in the 4 months before the planned administration of the first dose of study vaccine or has any plans to receive such treatment during the study.\\n\\n8.Participant received or plans to receive:\\n\\na.Licensed live attenuated vaccines \\u2013 within 28 days before or after planned administration of the first or subsequent study vaccinations\\n\\nb.Other licensed (not live) vaccines \\u2013 within 14 days before or after planned administration of the first or subsequent study vaccinations.\\n\\n9.Participant received an investigational drug (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational Ig or monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study.\\n\\n10.Participant is a woman who is pregnant or planning to become pregnant within 3 months after the last dose of study vaccine.\\n\\n11.Participant has a history of an underlying clinically significant acute \", \"study_population\": \"\", \"study_target_sample_size\": 1590, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: 28 days after vaccination;Primary end point(s): Main study:\\nBinding antibody concentrations to SARS CoV-2 S protein as measured by ELISA 28 days after vaccination\\nNI will be demonstrated in terms of humoral immune response expressed by the GMCs of S-ELISA, 28 days post-dose 1, using a NI margin of 2/3 for the GMC ratio (GMC 9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp/GMC 5x10^10 vp) \\nBinding antibody concentrations to SARS CoV-2 S protein as measured by ELISA 14 days after vaccination 2\\nNI will be demonstrated in terms of humoral immune response expressed by the GMCs of S-ELISA, 14 days post-dose 2 (9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp) and 28 days post-dose 1 or 14 days post-dose 2 (5x10^10 vp), using a NI margin of 2/3 for the GMC ratio (GMC 9x10^10 vp, 7x10^10 vp, 3.5x10^10 vp, 2.5x10^10 vp, or 1.25x10^10 vp/GMC 5x10^10 vp)\\n;Secondary Objective: For the main study:\\n1.To assess the humoral immune response and durability to Ad26.COV2.S across all groups, at all blood collection timepoints.\\n2.To assess the seroconversion rate to 1 dose or 2 doses of Ad26.COV2.S across all groups, at all blood collection timepoints.\\n3.To assess the safety and reactogenicity of Ad26.COV2.S administered at several dose levels.\\n\\nFor the sub-study:\\n1. To assess the humoral immune response and durability to Ad26.COV2.S across all groups in the sub study, at all blood collection timepoints.\\n2. To assess the safety and reactogenicity of Ad26.COV2.S administered at several dose levels.;Main Objective: For the main study:\\nTo demonstrate non-inferiority (NI) in sequential order:\\n 1-dose 9x10^10 vp vs 1-dose 5x10^10 vp (release titer)\\n 1-dose 7x10^10 vp vs 1-dose 5x10^10 vp \\n 1-dose 3.5x10^10 vp vs 1-dose 5x10^10 vp \\n 1-dose 2.5x10^10 vp vs 1-dose 5x10^10 vp \\n 1 dose 1.25x10^10 vp vs 1-dose 5x10^10 vp  \\n\\nTo demonstrate NI in sequential order:\\n 2-doses 9x10^10 vp vs 1-dose 5x10^10 vp\\n 2-doses 9x10^10 vp vs 2-doses 5x10^10 vp\\n 2-doses 7x10^10 vp vs 1-dose 5x10^10 vp\\n 2-doses 7x10^10 vp vs 2-doses 5x10^10 vp\\n 2-doses 3.5x10^10 vp vs 1-dose 5x10^10 vp\\n 2-doses 3.5x10^10 vp vs 2-doses 5x10^10 vp \\n 2-doses 2.5x10^10 vp vs 1-dose 5x10^10 vp\\n 2-doses 2.5x10^10 vp vs 2-doses 5x10^10 vp\\n 2-doses 1.25x10^10 vp vs 1-dose 5x10^10 vp\\n 2-doses 1.25x10^10 vp vs 2-doses 5x10^10 vp\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: Different doses of Ad26.COV2.S<br>Number of treatment arms in the trial: 6<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: Ad26.COV2.S\\nProduct Code: VAC31518\\nPharmaceutical Form: Suspension for injection\\nINN or Proposed INN: Not available\\nCurrent Sponsor code: VAC31518\\nOther descriptive name: Ad26.COV2.S\\nConcentration unit: billion organisms/ml billion organisms/millilitre\\nConcentration type: equal\\nConcentration number: 200-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-006082-11-DE","content":"{\"resource_id\": \"EUCTR2020-006082-11-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006082-11\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-006082-11-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Adagio Therapeutics Inc.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084382\\nTerm: Coronavirus disease 2019\\nSystem Organ Class: 100000004862\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"23.07.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Age:\\na. Ph 2: Is an adult aged 18 years and above\\nb. Ph 3: Is an adult aged 18 years and above or is an adolescent aged 12-17 years (inclusive) and weighing =40 kg at the time of screening \\n2. Has had SARS-CoV-2 positive antigen, RT-PCR, or other locally approved molecular diagnostic assay obtained within 5 days prior to randomization\\n3. Has had initial onset of one or more of the following self-reported COVID-19-related signs or symptoms within 5 days prior to randomization: \\n(temperature =38\\u00b0C, subjective fever, chills, cough, sore throat, congestion, shortness of breath or difficulty breathing with exertion worse than usual, muscle or body aches, fatigue, headache, loss of taste or smell, nausea or vomiting, diarrhea)\\n4. Has one or more of the following COVID-19-related signs or symptoms on the day of randomization\\n(temperature =38\\u00b0C, subjective fever, chills, cough, sore throat, congestion, shortness of breath or difficulty breathing with exertion worse than usual, muscle or body aches, fatigue, headache, loss of taste or smell, nausea or vomiting, diarrhea)\\n5. Is at high risk of disease progression defined as:\\na. Age >55 years\\nb. Age 18 to =55 years with one or more stable preexisting medical conditions as follows \\ni. Obesity [BMI = 30 kg/m2]\\nii. Diabetes (Type 1 or Type 2)\\niii. Chronic kidney disease\\niv. Chronic lung disease \\nv. Cardiac disease\\nvi. Sickle cell disease or thalassemia \\nvii. Solid organ or blood stem cell transplant recipients\\nviii. Other immunodeficiency due to underlying illness or immunosuppressant medication\\nix. Down Syndrome\\nx. Stroke or cerebrovascular disease, which affects blood flow to the brain\\nxi. Substance use disorder\\nxii. Pregnant (Phase 3 only; after review Ph2 data by iDMC)\\nc. Age 12 to 17 years (inclusive) with one or more preexisting medical conditions as follows\\ni. BMI >85th percentile for age and gender based on CDC growth charts\\nii. Diabetes (Type 1 or 2)\\niii. Chronic kidney disease\\niv. Sickle cell disease or thalassemia\\nv. Congenital or acquired heart disease\\nvi. Neurodevelopmental disorders\\nvii. A medically related technological dependence\\nviii. Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control\\nix. Solid organ or blood stem cell transplant recipients\\nx. Other immunodeficiency due to underlying illness or immunosuppressant medication\\nxi. Substance use disorder\\nxii Pregnant (Ph 3 only: enrollment only after Ph2 data reviewed by iDMC)\\n6. Has been assigned female sex at birth and is of nonchildbearing potential. A female participant who is not of reproductive potential is eligible without requiring the use of contraception and pregnancy testing is not required. This includes female participants who have not undergone menarche or who are documented to be surgically sterile or postmenopausal. Follicle stimulating hormone is not required in postmenopausal females with amenorrhea for >2 years.\\n7. Has been assigned female sex at birth and is of childbearing potential and fulfills all the following criteria: \\na. Has a negative urine or serum pregnancy test at Screening\\nb. Has practiced adequate contraception for or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1)\\nc. Has agreed to continue adequate contraception for sexual activity that could lead to pregnancy through 6 months following study drug administration\\nd. Is not currently breastfeeding\\nAdequate contraception for particip\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. Is currently hospitalized or in the opinion of the investigator requires urgent medical attention or is anticipated to require hospitalization within 48 hours of randomization\\n2. Has oxygen saturation (SpO2) =93% on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) <300 mmHg, respiratory rate =30 per minute, or heart rate =125 per minute.\\n3. Is on supplemental oxygen therapy at the time of randomization for any reason or in the opinion of the investigator anticipated impending need for mechanical ventilation.\\n4. Has a history of a positive SARS CoV 2 antibody serology test. Note: serology testing is not required for study eligibility, exclusion criterion is based on known history only. \\n5. Has participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.\\n6. Has known allergy/sensitivity or hypersensitivity to study drug, including excipients.\\n7. Has received a SARS CoV 2 vaccine, monoclonal antibody, or plasma from a person who recovered from COVID 19 any time prior to participation in the study. \\n8. Has a known active co infection (eg, influenza, urinary tract infection, etc).\\n9. Has any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study including but not limited to any co-morbidity requiring surgery or conditions considered life-threatening within 29 days.\\n10. Has a clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.\\n11. Is or has an immediate family member (eg, spouse, sibling, child, guardian/LAR, parent) who is an investigator or site or sponsor staff (or designee) directly involved with the study.\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1084, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: - day 29\\n-  day 4 and day 29;Primary end point(s): - COVID-19 related hospitalization or all-cause death through Day 29\\n- Assessment of safety through Day 29 based on:\\no The incidence of TEAEs\\no Incidence of solicited injection site reactions through Day 4\\no Changes from baseline in clinical laboratory tests (ie, CBC with differential, serum chemistry, coagulation) \\no Changes from baseline in vital signs (body temperature, heart rate, respiration rate, and systolic and diastolic blood pressure)\\n;Secondary Objective: - To evaluate the effect of ADG20 on the following clinical parameters in participants with mild or moderate COVID 19 and high risk of disease progression\\no Severity of COVID-19\\no COVID-19 related emergency room visits, COVID-19 related hospitalizations, or all cause death\\no COVID-19  related medically attended visits\\no Time to sustained recovery of COVID-19 symptoms\\no All cause mortality\\n- To evaluate the effect of ADG20 on SARS-CoV-2 viral load and clearance in participants with mild or moderate COVID-19 and high risk of disease progression\\n- To evaluate the safety and tolerability of ADG20 compared to placebo through Month 14 in participants with mild or moderate COVID-19 and high risk of disease progression\\n- To evaluate the PK of ADG20 following IM administration \\n- To evaluate the immunogenicity (ADAs) to ADG20\\n- To evaluate the emergence of resistance to ADG20\\n;Main Objective: - To evaluate the efficacy of ADG20 compared to placebo in the treatment of mild or moderate COVID 19 in participants at high risk of disease progression\\n- To evaluate the safety and tolerability of ADG20 compared to placebo through Day 29 in participants with mild and moderate COVID-19 and high risk of disease progression\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Code: ADG20\\nPharmaceutical Form: Solution for injection\\nCAS Number: 2516243-50-0\\nCurrent Sponsor code: ADG20\\nOther descriptive name: ADG20\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 100-\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intramuscular use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2020-006082-11-GR","content":"{\"resource_id\": \"EUCTR2020-006082-11-GR\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006082-11\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2020-006082-11-GR\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Adagio Therapeutics Inc.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084382\\nTerm: Coronavirus disease 2019\\nSystem Organ Class: 100000004862\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Age:\\na. Ph 2: Is an adult aged 18 years and above\\nb. Ph 3: Is an adult aged 18 years and above or is an adolescent aged 12-17 years (inclusive) and weighing =40 kg at the time of screening \\n2. Has had SARS-CoV-2 positive antigen, RT-PCR, or other locally approved molecular diagnostic assay obtained within 5 days prior to randomization\\n3. Has had initial onset of one or more of the following self-reported COVID-19-related signs or symptoms within 5 days prior to randomization: \\n(temperature =38\\u00b0C, subjective fever, chills, cough, sore throat, congestion, shortness of breath or difficulty breathing with exertion worse than usual, muscle or body aches, fatigue, headache, loss of taste or smell, nausea or vomiting, diarrhea)\\n4. Has one or more of the following COVID-19-related signs or symptoms on the day of randomization\\n(temperature =38\\u00b0C, subjective fever, chills, cough, sore throat, congestion, shortness of breath or difficulty breathing with exertion worse than usual, muscle or body aches, fatigue, headache, loss of taste or smell, nausea or vomiting, diarrhea)\\n5. Is at high risk of disease progression defined as:\\na. Age >55 years\\nb. Age 18 to =55 years with one or more stable preexisting medical conditions as follows \\ni. Obesity [BMI = 30 kg/m2]\\nii. Diabetes (Type 1 or Type 2)\\niii. Chronic kidney disease\\niv. Chronic lung disease \\nv. Cardiac disease\\nvi. Sickle cell disease or thalassemia \\nvii. Solid organ or blood stem cell transplant recipients\\nviii. Other immunodeficiency due to underlying illness or immunosuppressant medication\\nix. Down Syndrome\\nx. Stroke or cerebrovascular disease, which affects blood flow to the brain\\nxi. Substance use disorder\\nxii. Pregnant (Phase 3 only; after review Ph2 data by iDMC)\\nc. Age 12 to 17 years (inclusive) with one or more preexisting medical conditions as follows\\ni. BMI >85th percentile for age and gender based on CDC growth charts\\nii. Diabetes (Type 1 or 2)\\niii. Chronic kidney disease\\niv. Sickle cell disease or thalassemia\\nv. Congenital or acquired heart disease\\nvi. Neurodevelopmental disorders\\nvii. A medically related technological dependence\\nviii. Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control\\nix. Solid organ or blood stem cell transplant recipients\\nx. Other immunodeficiency due to underlying illness or immunosuppressant medication\\nxi. Substance use disorder\\nxii Pregnant (Ph 3 only: enrollment only after Ph2 data reviewed by iDMC)\\n6. Has been assigned female sex at birth and is of nonchildbearing potential. A female participant who is not of reproductive potential is eligible without requiring the use of contraception and pregnancy testing is not required. This includes female participants who have not undergone menarche or who are documented to be surgically sterile or postmenopausal. Follicle stimulating hormone is not required in postmenopausal females with amenorrhea for >2 years.\\n7. Has been assigned female sex at birth and is of childbearing potential and fulfills all the following criteria: \\na. Has a negative urine or serum pregnancy test at Screening\\nb. Has practiced adequate contraception for or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1)\\nc. Has agreed to continue adequate contraception for sexual activity that could lead to pregnancy through 6 months following study drug administration\\nd. Is not currently breastfeeding\\nAdequate contraception for particip\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. Is currently hospitalized or in the opinion of the investigator requires urgent medical attention or is anticipated to require hospitalization within 48 hours of randomization\\n2. Has oxygen saturation (SpO2) =93% on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) <300 mmHg, respiratory rate =30 per minute, or heart rate =125 per minute.\\n3. Is on supplemental oxygen therapy at the time of randomization for any reason or in the opinion of the investigator anticipated impending need for mechanical ventilation.\\n4. Has a history of a positive SARS CoV 2 antibody serology test. Note: serology testing is not required for study eligibility, exclusion criterion is based on known history only. \\n5. Has participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.\\n6. Has known allergy/sensitivity or hypersensitivity to study drug, including excipients.\\n7. Has received a SARS CoV 2 vaccine, monoclonal antibody, or plasma from a person who recovered from COVID 19 any time prior to participation in the study. \\n8. Has a known active co infection (eg, influenza, urinary tract infection, etc).\\n9. Has any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study including but not limited to any co-morbidity requiring surgery or conditions considered life-threatening within 29 days.\\n10. Has a clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.\\n11. Is or has an immediate family member (eg, spouse, sibling, child, guardian/LAR, parent) who is an investigator or site or sponsor staff (or designee) directly involved with the study.\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1084, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Primary end point(s): - COVID-19 related hospitalization or all-cause death through Day 29\\n- Assessment of safety through Day 29 based on:\\no The incidence of TEAEs\\no Incidence of solicited injection site reactions through Day 4\\no Changes from baseline in clinical laboratory tests (ie, CBC with differential, serum chemistry, coagulation) \\no Changes from baseline in vital signs (body temperature, heart rate, respiration rate, and systolic and diastolic blood pressure)\\n;Timepoint(s) of evaluation of this end point: - day 29\\n-  day 4 and day 29;Secondary Objective: - To evaluate the effect of ADG20 on the following clinical parameters in participants with mild or moderate COVID 19 and high risk of disease progression\\no Severity of COVID-19\\no COVID-19 related emergency room visits, COVID-19 related hospitalizations, or all cause death\\no COVID-19  related medically attended visits\\no Time to sustained recovery of COVID-19 symptoms\\no All cause mortality\\n- To evaluate the effect of ADG20 on SARS-CoV-2 viral load and clearance in participants with mild or moderate COVID-19 and high risk of disease progression\\n- To evaluate the safety and tolerability of ADG20 compared to placebo through Month 14 in participants with mild or moderate COVID-19 and high risk of disease progression\\n- To evaluate the PK of ADG20 following IM administration \\n- To evaluate the immunogenicity (ADAs) to ADG20\\n- To evaluate the emergence of resistance to ADG20\\n;Main Objective: - To evaluate the efficacy of ADG20 compared to placebo in the treatment of mild or moderate COVID 19 in participants at high risk of disease progression\\n- To evaluate the safety and tolerability of ADG20 compared to placebo through Day 29 in participants with mild and moderate COVID-19 and high risk of disease progression\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Code: ADG20\\nPharmaceutical Form: Solution for injection\\nCAS Number: 2516243-50-0\\nCurrent Sponsor code: ADG20\\nOther descriptive name: ADG20\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 100-\\nPharmaceutical form of the placebo: Solution for injection\\nRoute of administration of the placebo: Intramuscular use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-000408-39-BE","content":"{\"resource_id\": \"EUCTR2021-000408-39-BE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000408-39\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A study to test whether BI 767551 can prevent COVID-19 in people who might have been exposed to SARS-CoV-2\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-000408-39-BE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"SCS Boehringer Ingelheim Comm. V\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. = 18 years old, males and females.\\n2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.\\n3. Asymptomatic for COVID-19 at time of screening and at randomization.\\n4. Household contact with exposure to an individual with a diagnosis of SARS-CoV-2 infection (i.e. exposure to the index case).\\n5. Randomization within 96 hours of collection of the index cases' positive SARS-CoV-2 diagnostic test sample (nucleic acid or antigen-based) from any respiratory tract specimen (e.g. oropharyngeal, NP, or nasal swab, or saliva); based on test sample collection date not the result date.\\n6. From screening and randomization, the trial participant anticipates living in the same household with the index case until protocol Day 29.\\n7. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 1300\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 400\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. Body weight of less than 40 kg.\\n2. Residents of skilled nursing facilities. Definition of skilled nursing facility: assisted living facility that typically provides daily nursing care, 24-hour supervision, three meals a day, and assistance with everyday activities.\\n3. History of laboratory confirmed SARS-CoV-2 infection (e.g. antigen or nucleic acid\\ntest)at any time before screening.\\n4. Active respiratory or non-respiratory symptoms consistent with COVID-19, in the opinion of the investigator.\\n5. History of respiratory or non-respiratory symptoms consistent with COVID-19, within the prior 6 months to screening, in the opinion of the investigator.\\n6. Participant has lived with individuals who have had previous SARS-CoV-2 infection or currently lives with individuals who have SARS-CoV-2 infection, with the exception of the index case(s) who is defined as the first individual(s) known to be infected in the household.\\n7. Receipt of intraveneous immunoglobulin within 12 weeks prior to Visit 2.\\n8. Receipt of COVID-19 convalescent plasma treatment at any time prior to Visit 2.\\n9. Receipt of any SARS-CoV-2 monoclonal antibody treatment at any time prior to Visit 2.\\n10. Receipt of SARS-CoV-2 vaccine at any time prior to Visit 2.\\n11. Receipt of an investigational product for COVID-19 within 5 half-lives prior to Visit 2.\\n12. Receipt of systemic steroids (e.g. prednisone, dexamethasone) within 4 weeks prior to Visit 2 unless used for chronic condition.\\n13. Subjects who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.\\n14. Any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life threatening in the opinion of investigator within 30 days prior to randomization.\\n15. Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study.\\n16. Subjects not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator\\u2019s opinion, makes the subject an unreliable trial participant).\\n17. Currently enrolled in any other type of medical research judged not to be compatible with\\nthis study.\\n18. Known allergy/sensitivity or any hypersensitivity to any of the components used in the formulation of the interventions.\\n19. Previous enrolment in this trial.\\n20. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 1700, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Week 4 ;Primary end point(s): Symptomatic SARS-CoV-2 infection (RT-qPCR confirmed based on nasopharyngeal swabs, with a score of >=2 on the WHO Clinical Progression Scale) by Week 4 ;Secondary Objective: Additional objectives are to numerically compare the BI 767551 dose regimen to placebo for virological and other clinical outcomes. Safety and tolerability of BI 767551 for postexposure prevention of SARS-CoV-2 infection will be investigated.\\nFurther objectives are to explore further measures of efficacy and safety of the BI 767551 dose regimen in household contacts to a laboratory confirmed SARS-CoV-2 infected individual, as well as the assessment of the pharmacokinetics (PK), the evaluation of the development of anti-drug antibodies (ADA), and the investigation of SARS-CoV-2 viral load.;Main Objective: This is a confirmatory trial to evaluate the efficacy, safety and tolerability of BI 767551 for post-exposure prevention in individuals who are household contacts to a confirmed SARS-CoV-2 infected individual.\\n The primary trial objective is to demonstrate superiority of the BI 767551 dose regimen over placebo.\\nThe primary treatment comparison will be performed on all randomized subjects in Cohort A\\n(with negative SARS-CoV-2 RT-qPCR and serology test at baseline), including all data prior\\nto start of any other treatment with a similar mode of action as BI 767551 that has proven\\nefficacy (either preliminary via EUA by FDA or via approval by the FDA, EMA or PMDA).\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 3<br>\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Code: BI 767551\\nPharmaceutical Form: Concentrate for solution for infusion\\nINN or Proposed INN: None yet\\nCurrent Sponsor code: BI 767551\\nOther descriptive name: EX 14870\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 50-\\nPharmaceutical form of the placebo: Solvent for...\\nRoute of administration of the placebo: Intravenous use\\n\\nProduct Code: BI 767551\\nPharmaceutical Form: Nebuliser solution\\nINN or Proposed INN: None yet\\nCurrent Sponsor code: BI 767551\\nOther descriptive name: EX 14870\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 50-\\nPharmaceutical form of the placebo: Solvent for...\\nRoute of administration of the placebo: Inhalation use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-000417-16-DE","content":"{\"resource_id\": \"EUCTR2021-000417-16-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000417-16\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A trial to test the safety and efficacy of a new drug (human immune cells against COVID-19, administered intravenously) for patients with COVID-19 in need of treatment or at risk for severe COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-000417-16-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"University of Cologne\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease\\n-WHO ordinal scale 4 with at least one additional risk factor for disease progression \\nor \\n-WHO ordinal scale 5 <br>MedDRA version: 23.0\\nLevel: LLT\\nClassification code 10084272\\nTerm: SARS-CoV-2 infection\\nSystem Organ Class: 100000004862\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"20.10.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nFor phase I and II\\n1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent (participants = 18 years of age)\\n2. Willing to follow contraception guidelines\\n3. Tested positive for SARS-CoV-2 by PCR <72 hours prior to inclusion \\n4. A maximum of 14 days between onset of symptoms and\\nenrollment\\n5. WHO score 4 with at least one additional risk factor for disease progression\\nAcceptable risk factors are:\\na. Radiographically proven lung infiltrates\\nb. Immunosuppression either by malignant disease or its treatment, or other underlying diseases leading to immunodeficiency or underlying diseases that require treatment resulting in immunosuppression\\nc. Immunosuppressive drugs, including steroids at a prednisolone equivalent of <1 mg/kg BW. 6mg dexamethasone per os or intravenous 1x/d (SOC) are allowed, but are not considered as inclusion criterion in the sense of immunosuppressive treatment\\nd. Receipt of an autologous transplant within the last 5 years\\ne. Receipt of an allogeneic transplant within the last 5 years or ongoing immunosuppression OR\\n6. WHO score Score 5\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 34\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 17\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nFor phase I and II\\n1. Participation in any other clinical trial of an experimental agent treatment \\n2. Active or history of GvHD\\n3. History of CAR-T-Cell Therapy\\n4. COVID-19 WHO ordinal scale =6\\n5. Anticipated life-expectancy <72 hours\\n6. Expected duration of hospital stay <72 hours\\n7. Sepsis-induced leukopenia or thrombocytopenia (leukocytes <1000/\\u00b5l or platelets <50.000/\\u00b5l). If the cytopenias result from underlying hematologic disease or its treatment, this will not be\\nregarded as exclusion criterion.\\n8.  CT pneumonia score =13, if CT has been performed as SoC\\n9. Any other Steroids = 1mg/kg Prednisolon-equivalent/kg BW, besides 6mg Dexamethasone i.v. or p.o. 1x/d as SoC for COVID-19\\n10. Therapeutic donor lymphocyte infusion (DLI) less than 100 days prior to IMP infusion\\n11. Known hypersensitivity to iron dextran\\n12. Known pre-existing human anti-mouse antibodies (HAMAs)\\n13. Contraindication against mandatory protocol-inherent comedication(s): antihistamine and/or\\nacetaminophen\\n14. Pregnant or breast feeding\\n15.  Any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the subject\\u2019s safe participation in and completion of the study\\n\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 51, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Please see protocol section 4.8.;Primary end point(s): Phase I\\n Dose-limiting toxicities until day 28 after infusion of viable human SARS-CoV-2- specific T lymphocytes\\nPhase II\\n AUC of the course of disease measured by the WHO ordinal scale for COVID-19;Secondary Objective: Phase I part:\\n To gain first data on biological activity of viable human SARS-CoV2-specific T lymphocyte therapy \\n To assess the feasibility of production of viable human SARS-CoV-2-specific T lymphocytes from convalescent donors with a HLA match of = 2/6 loci and < 10/10\\nPhase II part:\\n Evaluation of safety and tolerability of a single administration of viable human SARS-CoV-2-specific \\nT lymphocytes\\n Overall survival (OS) of patients treated with viable human SARS-CoV-2-specific T lymphocytes (until day 100)\\n Effect of viable human SARS-CoV-2 specific T lymphocytes infusion on viral shedding in nasooropharyngeal swabs\\n Characterization of efficacy with respect to the course of disease\\n;Main Objective: Phase I part:\\n To determine the recommended phase II dose (RP2D) of viable human SARS-CoV-2-specific T lymphocytes by evaluation of safety and tolerability\\n\\nPhase II part:\\n To gain first data on efficacy of human SARS-CoV-2-specific T lymphocytes therapy\\n\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: Phase I: monocentric open label, Phase II: multi-centre, randomized,  IMP+SoC versus SoC<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: In Phase II: IMP+SoC versus SoC<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-1-phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: human SARS-CoV-2 specific T lymphocytes\\nProduct Code: SUB222337\\nPharmaceutical Form: Infusion\\nINN or Proposed INN: human SARS-CoV-2 specific T lymphocytes\\nCurrent Sponsor code: human SARS-CoV-2-specific T lymphocytes\\nOther descriptive name: Allogeneic SARS-CoV-2-specific CD4+ and CD8+ T lymphocytes\\nConcentration unit: Other\\nConcentration type: up to\\nConcentration number: 5000-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-000613-16-DE","content":"{\"resource_id\": \"EUCTR2021-000613-16-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000613-16\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"CCR1 antagonist treatment in patients hospitalized with COVID-19\\nA multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-000613-16-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Charit\\u00e9  Universit\\u00e4tsmedizin Berlin\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Patients with acute SARS-CoV-2 infection, proven by a positive SARS-CoV-2 PCR test. The health status of the patients at inclusion in the clinical trial is rated 5 - 6 according to the WHO scale (see protocol, CATCOVID_v1.2, 27.09.2021, page 13). Patients are at high risk of severe disease progression with ARDS and/or multiple organ failure, and at high risk of mortality.\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"26.11.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\nIn order to be eligible to participate in this study, a patient must meet all of the following inclusion \\ncriteria: \\n\\n1. Age = 18 years\\n2. Male or non-pregnant*/non-breast-feeding female\\n3. Subject understands the clinical trial and signed the informed consent form\\n4. Positive laboratory-confirmed SARS-CoV-2 PCR test\\nAllergy to dexamethasone\\n5. WHO clinical progression scale 5-6\\n6. Onset of COVID-19 symptoms < 10 days before randomization\\n\\n*negative pregnancy test\\n\\nSee protocol, CATCOVID_v1.2, 27.09.2021: Chapter 7 (Study Population); Subchapter 7.1, page 37f.\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 208\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 208\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\nExclusion Criteria:\\n\\n1. Patient has a chance of survival < 48 hours at time of randomization\\n2. Participation in another interventional clinical trial\\n3. Specific immunomodulatory treatment for COVID-19 according to the S3 living guideline for > 72 hours before randomization\\n4. Other indications for systemic or inhaled glucocorticoid treatment\\n5. Immunosuppressive medication within the last 30 days before randomization\\n6. Immunosuppressive disease\\n7. Chronic inflammatory airways disease (e.g., COPD)\\n8. Renal failure requiring dialysis\\n9. Acute (or acute on chronic) liver failure, Chronic liver failure (Child-Pugh class C)\\n10. Chronic heart failure NYHA III/IV\\n11. Acute right heart failure\\n12. Clear evidence of active tuberculosis, bacterial, fungal, viral, or other infection (besides SARS-CoV-2)\\n13. Current or regular treatment with Chloramphenicol*\\n14. Current or regular treatment with Nefazodone*\\n15. Current or regular treatment with Cimetidin*\\n16. Current or regular treatment with macrolide antibiotics*\\n17. Current or regular treatment with azole antimycotics*\\n18. Treatment with Phenytoin**\\n19. Person is placed in an institution based on an official or judicial order \\n20. Person who is dependent on the Sponsor, Principal Investigators, or the study site\\n\\n*Please note that only clinically relevant strong CYP3A4 inhibitors were considered, please note that \\nprotease inhibitors will not be relevant for this study as patients with an immunosuppressive disease \\nare excluded (see also section 8.1.4).\\n** Please note that only strong CYP3A4 inducers were considered (see also section 8.1.4)\\n\\nSee protocol, CATCOVID_v1.2, 27.09.2021: Chapter 7 (Study Population); Subchapter 7.1, page 37f.\\n\", \"study_population\": \"\", \"study_target_sample_size\": 208, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Ventilator-free days at day 28;Primary end point(s): The primary endpoint is the number of ventilator-free days during the study period of 28 days.\\n\\nVentilator-free days are defined as the number of days after the last extubation:\\n Each day after the discharge of a Subject will be counted as ventilator-free day. \\n In case of a tracheal cannula, the equivalent to extubation is 48 hours without respirator.\\n Death will be counted as zero ventilator-free days, regardless of whether the patient was \\nintubated at any point or not\\n\\nFor further definitions, see Protocol_CATCOVID_v1.2 (27.09.2021), Chapter 5.1 and Figure 1 (page 30).;Secondary Objective: We will monitor several clinical parameters as secondary outcomes and a detailed assessment \\nof the clinical course of the COVID-19 patients. Additionally, we will monitor the pharmacokinetics in a sub-cohort during the initial phase of the clinical trial. Besides the assessment of the efficacy, we will also evaluate the safety of BAY 86-5277.;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of the CCR1 antagonist BAY 86-5277 in comparison to the placebo control arm of the study in patients hospitalized with COVID-19.\\n\\nThe primary objective is the reduction of a critical disease progression in hospitalized COVID-19 patients with the need for oxygen supplementation. Mechanical ventilation is one of the key clinical \\nfeatures of severe COVID-19. The primary endpoint is the number of ventilator-free days during the study period of 28 days. The survey of ventilator-free days, i.e. the reduced need for mechanical ventilation, allows an assessment of whether BAY 86-5277 reduces progression to more severe courses of COVID-19.\\n\\nSee protocol, CATCOVID_v1.2, 27.09.2021: Chapter 5 (Objectives and Endpoints); Subchapter 5.1, page 30.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes\\nRandomised: yes\\nOpen: no\\nSingle blind: no\\nDouble blind: yes\\nParallel group: no\\nCross over: no\\nOther: no\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: yes\\nOther: no\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: BAY 86-5277\\nPharmaceutical Form: Oral solution\\nINN or Proposed INN: BAY 86-5277\\nOther descriptive name: [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-piperazin-1-yl]-2-oxo-ethoxy]phenyl]urea\\nConcentration unit: mg/ml milligram(s)/millilitre\\nConcentration type: equal\\nConcentration number: 60-\\nPharmaceutical form of the placebo: Oral liquid\\nRoute of administration of the placebo: Oral use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-001393-31-DE","content":"{\"resource_id\": \"EUCTR2021-001393-31-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001393-31\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects.\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-001393-31-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Bavarian Nordic A/S\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 disease <br>MedDRA version: 23.1\\nLevel: PT\\nClassification code 10084457\\nTerm: COVID-19 immunisation\\nSystem Organ Class: 10042613 - Surgical and medical procedures\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1.\\tSubjects =18 years of age at SCR.\\n2.\\tSeronegative (Group 1): negative qualitative test for SARS-CoV-2 antibodies at SCR. \\nSeropositive (Group2) and Group 3): Previous COVID-19 disease or previously completed vaccination regimen with an authorized SARS-CoV-2 vaccine at least 90 days before planned trial vaccination, and a positive qualitative test for SARS-CoV-2 antibodies at SCR.\\u201cAuthorized SARS-CoV-2 vaccine refers to authorization status at SCR, i.e.,subjects can be eligible if they previously received investigational vaccines that have since been authorized for emergency use or granted full market licensure. Receipt of a single dose of an authorized COVID-19 vaccine regimen in subjects with a previous diagnosis of COVID-19 or a mix/match series of 2 doses of any authorized COVID-19 vaccine will be considered as a completed vaccination.\\n3.\\tGeneral good health, without acute medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator.\\n4.\\tPrior to performance of any trial specific procedures, the subject has read, signed and dated an informed consent form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject. \\n5.\\tBody mass index (BMI) =18.5 and <40.\\n6.\\tFemale subjects of childbearing potential (WOCBP) and male subjects who are sexually active with a WOCBP must agree to the use of an effective method of birth control from at least 30 days prior to administration of the vaccine until 30 days after the vaccination. A woman is considered of childbearing potential unless post-menopausal (defined as =12 months without a menstrual period at SCR) or surgically sterilized (bilateral oophorectomy, bilateral tubal ligation, hysterectomy). Acceptable contraception methods are restricted to abstinence (abstinence only acceptable if refraining from heterosexual intercourse during the entire period of 30 days prior to administration of the vaccine until 30 days after the vaccination), double barrier contraceptives, vasectomy, intrauterine contraceptive devices or licensed hormonal products.\\n7.\\tWOCBP must have a negative serum pregnancy test at SCR.\\n8.\\tNegative human immunodeficiency virus antibody test (anti HIV), negative hepatitis B surface antigen (HBsAG) and negative antibody to hepatitis C virus (HCV).\\n\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 105\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 105\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1.\\tGroup 1 only: History of COVID-19 infection or previous vaccination with a licensed or candidate SARS-CoV-2 vaccine, or positive qualitative test for SARS-CoV-2 antibodies at SCR. Groups 2 and 3 only: History of COVID-19 infection and subsequent receipt of more than one licensed or candidate SARS-CoV-2 vaccine.\\n2.\\tPositive test for SARS-CoV-2 infection at SCR.\\n3.\\tPregnant or breastfeeding women.\\n4.\\tSubject has an acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses.\\n5.\\tHistory of or active autoimmune disease. History of Guillain-Barr\\u00e9 syndrome or Reye\\u2019s syndrome. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded. \\n6.\\tKnown or suspected impairment of immunologic functions including, but not limited to, known immunodeficiency syndrome.\\n7.\\tHistory of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to SCR that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site. \\n8.\\tLaboratory parameters (such as complete blood count, serum biochemistry including aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphokinase [AP], bilirubin, or creatinine values), pulse rate, blood pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically relevant by the investigator.\\n9.\\tClinically significant mental disorder not adequately controlled by medical treatment.\\n10.\\tActive or recent history (within 6 months before SCR) of chronic alcohol abuse, intravenous drug abuse, or nasal drug abuse.\\n11.\\tHistory of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\\n12.\\tHistory of anaphylaxis or severe allergic reaction to any vaccine.\\n13.\\tHaving received any vaccinations or planned vaccinations with a live vaccine within 30 days prior to or after trial vaccination.\\n14.\\tHaving received any vaccinations or planned vaccinations with an inactivated vaccine within 14 days prior to or after trial vaccination.\\n15.\\tRecent blood donation (including platelets, plasma and red blood cells) within 4 weeks prior to SCR, or planned blood donations any time during the trial.\\n16.\\tChronic systemic administration (defined as more than 14 days) of >5 mg prednisone (or equivalent)/day, or any other immune-modifying drugs during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. The use of topical, inhaled, ophthalmic and nasal glucocorticoids is allowed.\\n17.\\tPost organ transplant subjects, whether or not receiving chronic immunosuppressive therapy.\\n18.\\tAdministration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. Receipt of packed red blood cells given for an emergency indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells given in emergency during an elective surgery).\\n19.\\tUse of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the administration of trial vaccine, or planned administration of such a drug or vaccine throughout the trial.\\n20.\\tClinical trial si\", \"study_population\": \"\", \"study_target_sample_size\": 210, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: 2 weeks after the last vaccination;Primary end point(s): SARS-CoV-2 neutralizing antibody titers at 2 weeks after the last vaccination, i.e., after the second vaccination in initially seronegative subjects and after the single boost vaccination in initially seropositive subjects.\\n;Secondary Objective: To assess the safety and tolerability of the ABNCoV2 vaccine in adult seropositive and seronegative subjects.;Main Objective: To assess SARS-CoV-2 specific humoral immune responses of the ABNCoV2 vaccine in initially SARS-CoV-2 seronegative and seropositive subjects.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: no\\nRandomised: no\\nOpen: yes\\nSingle blind: no\\nDouble blind: no\\nParallel group: no\\nCross over: no\\nOther: no\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: no\\nOther: no\\nNumber of treatment arms in the trial: 3\\n\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Code: ABNCov2\\nPharmaceutical Form: Injection\\nINN or Proposed INN: COVID-19 cVLP vaccine\\nOther descriptive name: ABNCoV2\\nConcentration unit: \\u00c2\\u00b5g microgram(s)\\nConcentration type: equal\\nConcentration number: 50 or 100-\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-002387-50-DE","content":"{\"resource_id\": \"EUCTR2021-002387-50-DE\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002387-50\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A trial testing the safety and effects of two vaccines in healthy adults\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-002387-50-DE\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"BioNTech SE\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Protection against COVID-19 <br>MedDRA version: 23.0\\nLevel: PT\\nClassification code 10051905\\nTerm: Coronavirus infection\\nSystem Organ Class: 10021881 - Infections and infestations\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Therapeutic area: Diseases [C] - Virus Diseases [C02]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"22.07.2021\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1.\\tHave given informed consent by signing the informed consent form (ICF) before initiation of any trial-specific procedures.\\n2.\\tWilling and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (including those requested by the German and federal Governments, e.g., to follow good practices to reduce chances of spreading COVID 19), and other requirements of the trial.\\n3.\\tHave received BNT162 vaccine candidates in the BNT162-01 or BNT162-04 trials.\\n4.\\tRemain overall healthy (i.e., has not medically deteriorated significantly since participation in the parent trial, is not anticipated to die in the next 26 weeks, and is able to provide blood as specified by the trial without anticipated, deleterious medical consequences) in the clinical judgment of the investigator based on medical history and physical examination. Screening clinical laboratory tests are to assess the subjects \\u201cnew baseline unless required for eligibility (e.g., platelets).\\n5.\\tAgree not to enroll in another trial of an IMP, starting after Visit 0 and continuously until Visit 5 (Day 50).\\n6.\\tLess than 18 months have passed since their last IMP injection in their parent trial.\\n7.\\tIf they received 30 \\u00b5g Comirnaty twice in the BNT162-01 trial, Visit 1 in this trial is =24 weeks after their last IMP injection, unless the subject is a Cohort 13 transplant subject of the BNT162-01 trial.\\n8.\\tIf they received any other BNT162 vaccine candidate than Comirnaty in the BNT162-01 or BNT162-04 trial or are a Cohort 13 transplant subject, Visit 1 in this trial is =12 weeks after their last IMP injection.\\n9.\\tHave not been diagnosed with SARS-CoV-2 infection in the 12 weeks prior to Day 1 (baseline). Subjects who screen-fail on this criterion may be rescreened.\\n10. Platelets = 125,000 to 550,000/mm3.\\n11.\\tChemistry panel: the following apply: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) are <3.0 times the upper limit of normal, and/or glomerular filtration rate (GFR) is = 40 mL/min/1.73 m2.\\n12.\\tImmunocompromised subjects may be included if their clinical laboratory values are stable in the context of their disease, and if there is no acute deterioration present with the expected need to change their therapy within the 2 weeks after the anticipated trial vaccination.\\n13.\\tWomen of childbearing potential (WOCBP) must test negative in a urine beta-human chorionic gonadotropin (\\u00df-HCG) test at Visits 0 and 1. Women that are post-menopausal or permanently sterilized will be considered as not having reproductive potential.\\n14.\\tWOCBP must agree to practice a highly effective form of contraception during the trial, starting at screening and continuously until Visit 5 (Day 50). \\n15.\\tWOCBP must confirm that they practiced one highly effective form of contraception for the 14 d prior to screening.\\n16.\\tWOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the trial, starting after Visit 0 and continuously until Visit 5 (Day 50).\\n17.\\tMen who are sexually active with a WOCBP and have not had a vasectomy must agree to use a highly effective form of contraception with their female partner of childbearing potential during the trial, starting after Visit 0 and continuously until Visit 5 (Day 50).\\n18.\\tMen must be willing to refrain from sperm donation, starting after Visit 0 and continuously until Visit 5 (Day 50).\\n\\n\\nAre the trial subjects under 18? no\\nNumber of subjects fo\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1.\\tHave received any SARS-CoV-2 vaccine outside of the BNT162-01 or BNT162-04 trials.\\n2.\\tHave a known allergy, hypersensitivity, or intolerance to the planned IMP including any excipients of the IMP.\\n3.\\tHave a current febrile illness (body temperature =38.0\\u00b0C) or other acute illness within 48 h prior to Day 1/IMP injection in this trial. Subjects who screen-fail on this criterion may be rescreened.\\n4.\\tHave received a live or live attenuated vaccine within 30 d prior to Day 1/IMP injection, or any other vaccination within 14 d prior to Day 1/IMP injection. Subjects who screen-fail on this criterion may be rescreened.\\n5.\\tHave an ongoing AE assessed as related to any BNT162-01 or BNT162-04 trial vaccine.\\n\\n\", \"study_population\": \"\", \"study_target_sample_size\": 549, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: Timepoints are given in the description. See also section 9.4.2 of the study protocol.;Primary end point(s): For all Group A and Group B subjects:\\n\\tThe proportion of subjects in each treatment group with at least one SAE or the proportion of AESIs occurring up to 26 weeks after the first IMP injection.\\nFor Group A and a selected subset of Group B subjects:\\n\\tThe frequency of solicited local reactions (pain, tenderness, erythema/redness, induration/swelling) at the injection site recorded up to 7 d after each IMP injection.\\n\\tThe frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue/tiredness, fever, chills, nausea, new or worsened muscle pain, new or worsening joint pain) recorded up to 7 d after each IMP injection.\\nFor Group A subjects only:\\n\\tThe proportion of subjects with at least one unsolicited TEAE or at least one AE related to IMP occurring up to 28 d after IMP injection in each treatment group.;Secondary Objective: To describe changes in SARS-CoV-2 neutralizing antibody titers from baseline to reference and SARS-CoV-2 SA variant (B.1.351);Main Objective: To determine the safety and tolerability of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 in BNT162-01 trial subjects, or two boosting doses of Comirnaty in BNT162-04 trial subjects.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: no\\nRandomised: yes\\nOpen: yes\\nSingle blind: no\\nDouble blind: no\\nParallel group: no\\nCross over: no\\nOther: no\\nIf controlled, specify comparator, Other Medicinial Product: no\\nPlacebo: no\\nOther: no\\nNumber of treatment arms in the trial: 2\\n\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: BNT162b2s01\\nPharmaceutical Form: Concentrate for solution for injection\\n\\nTrade Name: COMIRNATY\\nProduct Name: COMIRNATY (COVID-19 mRNA vaccine (nucleoside-modified)\\nPharmaceutical Form: Concentrate for dispersion for injection\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"EUCTR2021-003246-20-ES","content":"{\"resource_id\": \"EUCTR2021-003246-20-ES\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003246-20\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Phase 2b study, conducted in few medical centers, patients will be allocated randomly to receive active drug or placebo. The study will evaluate the efficacy and safety of the drug in patients with respiratory failure due to COVID-19.\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"EUCTR2021-003246-20-ES\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Enlivex Therapeutics R&D, Ltd.\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 <br>MedDRA version: 23.0\\nLevel: PT\\nClassification code 10051905\\nTerm: Coronavirus infection\\nSystem Organ Class: 10021881 - Infections and infestations\\n\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n1. Male or female >18 and <85 years of age.\\n2. Laboratory confirmation of SARS-CoV-2 infection by reverse transcription polymerase chain reaction from any diagnostic sampling source.\\n3. Patient hospitalized due to COVID-19 within 7 days prior to enrollment, meeting the criteria for severe or critical COVID-19 \\n4. Patient with mild to moderate ARDS:\\n5. Signed written informed consent by the patient.\\n6. Women and men who are of childbearing potential, willing to use acceptable contraceptive measures during 4 weeks from enrollment.\\nAre the trial subjects under 18? no\\nNumber of subjects for this age range: \\nF.1.2 Adults (18-64 years) yes\\nF.1.2.1 Number of subjects for this age range 62\\nF.1.3 Elderly (>=65 years) yes\\nF.1.3.1 Number of subjects for this age range 90\\n\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n1. Patient on IMV/ECMO.\\n2. Woman who is pregnant or breastfeeding.\\n3. Patient with weight <50 kg or >120 kg or BMI >40 kg/m2.\\n4. Patient with stage 4 or 5 chronic kidney disease or estimated glomerular filtration rate <30 mL/min.\\n5. Patient with an active malignant tumor (diagnosed or on active treatment for the past 6 months).\\n6. Patient who is participating in other concurrent interventional clinical trials or have been treated with any experimental agents within 30 days prior to enrollment.\\n7. Patient who based on their medical history and receipt of therapies that would suggest infection, has suspected serious, active bacterial (including a suspected clinical diagnosis of current active tuberculosis [TB] or, if known, latent TB treated for less than 4 weeks with appropriate anti-TB therapy per institutional guidelines), fungal, or viral (including, but not limited to, active HBV, HCV, or HIV/AIDS) infection.\\n8. Patient with known immunocompromised state or immunosuppressive medications taken for indications other than SARS-CoV-2 as follows: \\na. Prednisone or equivalent to a dose >10 mg/day, methotrexate >15 mg/week, within the last 60 days; cyclophosphamide, cyclosporine A (unless as ophthalmic formulation), leflunomide/teriflunomide (unless as monotherapy), tacrolimus (unless as a topical formulation), everolimus, temsirolimus, or azathioprine, in the last 60 days;\\nb. Methylprednisolone, dexamethasone, cortisone, or betamethasone for more than 7 days within the last 28 days or within 5 half-lives, whichever is longer;\\nc. Chemotherapy in the last 3 months; \\nd. Mycophenolate mofetil or sirolimus for solid organ transplant or bone marrow transplant;\\ne. Thalidomide within the last 72 hours;\\nf. Anti-tumor necrosis factor (TNF) agents, interleukin (IL)-1 receptor antagonists, CTLA-4 fusion proteins, anti-CD20, anti-CD52, anti-IL-2, anti-IL-6R, anti-IL-12/23, anti-B-cell activation factor (BAFF) or integrin inhibitor agents within the last 8 weeks.\\n9. Patient with known New York Heart Association (NYHA) class III and IV heart failure or unstable angina, ventricular arrhythmias, ischemic heart disease, or myocardial infarction within 6 months prior to diagnosis of COVID-19.\\n10. Patient with known active upper gastrointestinal (GI) tract ulceration or hepatic dysfunction including but not limited to biopsy-proven cirrhosis; end-stage cirrhosis (Child Pugh Class C); portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.\\n11. Patient with known idiopathic pulmonary fibrosis.\\n12. Patient with chronic respiratory disease requiring home oxygen therapy on a regular basis for more than 6 hours per day.\\n13. Patient with known chronic obstructive pulmonary disease GOLD 4 (forced expiratory volume in one second <30% predicted).\\n14. Patient with any medical, psychiatric or substance abuse condition, concurrent medical therapies, or abnormal laboratory values that in the opinion of the site Investigator may be of greater safety risk, influence response to study product, or interfere with the study assessments.\\n15. Patient with Glasgow Coma Scale <13 with verbal score <5.\\n16. Patient with hemoglobin <8 g/dL.\\n17. Patient with history of chronic liver disease, evidence of acute cholangitis or cholecystitis. Patients with at least one of the following:\\n\\u2022 Alanine transaminase (ALT) or aspartate transaminase\\n(AST) >10\\u00d7ULN (upper limit of normal)\\n\\u2022 Bilirubin >5\\u00d7\", \"study_population\": \"\", \"study_target_sample_size\": 152, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): A primary composite endpoint will be assessed, as compared to placebo, separately for the two study subpopulations (severely ill and critically ill patients):\\n-\\tTime (days) to improvement, defined as the first day, during the period of 28 days post study treatment administration, when a patient reached the score of 6, 7 or 8 on the 8-point ordinal scale.\\nIf no improvement is reached by Day 28, the patient will be assigned a maximal score of 29.\\n-\\tSupport by invasive mechanical ventilation (IMV)/ECMO. If required during the period of 28 days post study treatment administration, a patient will be assigned the maximal score of 29.\\n-\\tMortality by Day 28 post study treatment administration. Deceased patients will be assigned the maximal score of 29.;Secondary Objective: To assess additional efficacy parameters and the safety of Allocetra-OTS in the treatment of COVID-19 patients;Main Objective: To assess the effect of Allocetra-OTS on ventilation-free survival and recovery in the treatment of COVID-19 patients\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: yes<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>\\nRecruitment status: Authorised\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\nProduct Name: Allocetra-OTS cells in Ringer's Lactate Solution\\nPharmaceutical Form: Solution for infusion\\nINN or Proposed INN: allogeneic peripheral blood mononuclear cells induced to apoptotic state\\nOther descriptive name: Allogeneic peripheral blood mononuclear cells induced to apoptotic state\\nConcentration unit: Other\\nConcentration type: equal\\nConcentration number: 10000000000-\\nPharmaceutical form of the placebo: Solution for infusion\\nRoute of administration of the placebo: Intravenous use\\n\\n\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"ISRCTN10077335","content":"{\"resource_id\": \"ISRCTN10077335\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://isrctn.com/ISRCTN10077335\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"ISRCTN10077335\", \"id_type\": \"ISRCTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 (SARS-CoV-2 infection) and acute respiratory distress syndrome (ARDS) <br>Infections and Infestations\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"19.03.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n                1. Aged 18 or older\\n                2. Critically ill\\n                3. COVID-19 and acute respiratory distress syndrome (ARDS) according to Berlin-Definition\\n                4. No contra-indication to PiCCO-monitoring\\n            \", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: 1. Pregnant\", \"study_population\": \"\", \"study_target_sample_size\": 25, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Extravascular lung water index EVLWI measured using TPTD (PiCCO; Pulsion Medical Systems; Feldkirechen Germany) daily from intubation until extubation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Observational single-centre cohort study; comparison to a recent cohort of non-COVID-19 patients with ARDS (see ISRCTN32938630) (Diagnostic)\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"ISRCTN12394803","content":"{\"resource_id\": \"ISRCTN12394803\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://isrctn.com/ISRCTN12394803\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"DIAMONDS-SEARCH study: Designing new tests that can diagnose the causes of fever, including COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"ISRCTN12394803\", \"id_type\": \"ISRCTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Imperial College London\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"Patients with suspected infection or suspected inflammatory conditions including patients with suspected COVID-19 (SARS-CoV-2 infection) <br>Infections and Infestations\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"27.04.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n                1. A patient of any age who attends or who is admitted at a participating hospital\\n                2. AND who has one or more of the following;\\n                2.1. Fever (=38.0 \\u00b0C) or history of fever in the preceding 24 hours\\n                2.2. Symptoms (including non-specific signs) suggestive of infection\\n                2.3. Symptoms suggestive of inflammation (including exacerbation of pre-existing inflammatory disease), and including non-specific signs/symptoms such as fever, joint pains, muscle pains, headaches, lymphadenopathy/fatigue, abdominal pain, rashes, mucosal inflammation, elevated inflammatory markers, unexplained cytopenias\\n                3. AND EITHER who gives consent for samples to be taken for research\\n                4. OR who retrospectively gives consent, according to a deferred consent model in which consent is obtained after initial sample collection\\n            \", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n                1. Patients who do not give consent\\n                2. RNA sample is not taken\\n            \", \"study_population\": \"\", \"study_target_sample_size\": 5000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"\\n                Gene expression measured using RNA sequencing at presentation in children and adults with different infectious and inflammatory conditions\\n\\n                RNA biomarker signature with a sensitivity of 95% and specificity of 95% based on groups of at least 50 patients in each diagnostic category, which would allow capture of the effect sizes between the different comparator groups of as little as 1.5 fold change.\\n            \", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Observational case-control laboratory study (Other)\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"ISRCTN13539303","content":"{\"resource_id\": \"ISRCTN13539303\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://isrctn.com/ISRCTN13539303\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"An international registry of coronavirus exposure in pregnancy\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"ISRCTN13539303\", \"id_type\": \"ISRCTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Pregistry LLC\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 (SARS-CoV-2 infection) during pregnancy <br>Infections and Infestations <br>COVID-19 (SARS-CoV-2 infection)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Female\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: Adult pregnant women with clinical confirmation of COVID-19 or tested for SARS-CoV-2 at any time during their pregnancy\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: Subjects who do not meet the inclusion criteria\", \"study_population\": \"\", \"study_target_sample_size\": 25000, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"\\n                Measured by maternal self-report using online questionnaire at baseline:\\n                1. Pregnancy outcomes:\\n                1.1. Miscarriage (or spontaneous abortion)\\n                1.2. Elective termination\\n                1.3. Stillbirth\\n                1.4. Preterm delivery\\n                2. Birth outcomes (measured at additional time points up to 90 days):\\n                2.1. Major structural defects\\n                2.2. Neonatal death\\n                2.3. Admission into the Neonatal Intensive Care Unit\\n                2.4. Maternal obstetric complications\\n                2.5. Post-partum health\\n            \", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Prospective observational study (Other)\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"ISRCTN14810048","content":"{\"resource_id\": \"ISRCTN14810048\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"http://isrctn.com/ISRCTN14810048\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"AspCOVID-19 study: fungal infection of the airways in severe COVID-19 pneumonia\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"ISRCTN14810048\", \"id_type\": \"ISRCTN\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Klinikum der Universit\\u00e4t M\\u00fcnchen\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19 (SARS-CoV-2 infection) related pneumonia <br>Infections and Infestations\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"25.03.2020\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: Critically ill patients with severe COVID-19 pneumonia\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n                1. Younger than 18 years old\\n                2. Pregnancy\\n                3. Missed informed consent\\n            \", \"study_population\": \"\", \"study_target_sample_size\": 32, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Pulmonary aspergillosis infection measured using the galactomannan from serum and broncho-alveolar lavage on day 1, 3, 7, 10, 14 and then every three days after ICU admission and intubation/mechanical ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Prospective observational study (Screening)\\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT02735707","content":"{\"resource_id\": \"NCT02735707\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Critical care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Statin\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Ceftaroline\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Levofloxacin\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Ceftriaxone\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Apremilast\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Anti-Bacterial Agents\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Pneumonia\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Intensive care\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"DMX-200\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Respiratory Tract Diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Anti-Infective Agents\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Lung Diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Therapeutic Anticoagulation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Influenza\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Vitamin C\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Amoxicillin-clavulanate\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Piperacillin-tazobactam\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Antibiotics\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Respiratory Tract Infections\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Ivermectin\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Invasive Mechanical Ventilation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Oseltamivir\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Hydrocortisone\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Eritoran\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Convalescent plasma\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Moxifloxacin\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"http://www.remapcap.org\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia\"}], \"resource_descriptions\": [{\"description\": \"Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.\\n\\nPatients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.\\n\\nThis clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:\\n\\nEvaluate multiple treatment strategies, at the same time, in the same patient.\\nReach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached\\nUtilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial\\nNew questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended\\nInteractions between interventions in different domains can be evaluated\\n\\nIt is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.\\n\\nPrevious pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"REMAP-CAP\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT02735707\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1189-1653\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2015-002340-14\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"602525\", \"id_type\": \"Other\", \"id_relation_type\": \"has grant number\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"16/631\", \"id_type\": \"Other\", \"id_relation_type\": \"has grant number\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"APP1101719\", \"id_type\": \"Other\", \"id_relation_type\": \"has grant number\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"158584\", \"id_type\": \"Other\", \"id_relation_type\": \"has grant number\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Lennie Derde\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"UMC Utrecht\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"UMC Utrecht\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Australian and New Zealand Intensive Care Research Centre\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Medical Research Institute of New Zealand\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Unity Health\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Berry Consultants\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Global Coalition for Adaptive Research\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"University of Pittsburgh Medical Center\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Intensive Care National Audit & Research Centre\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"St. Marianna University School of Medicine\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"National Intensive Care Surveillance MORU\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Cameron Green, MSc\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"info@remapcap.org\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Wilma Van Bentum-Puijk, MSc\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"EU.remapcap@umcutrecht.nl\", \"role_phone\": \"+31 (0) 88 755 5555\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains\", \"study_conditions\": [{\"study_conditions\": \"Community-acquired Pneumonia, Influenza, COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"11.04.2016\", \"study_end_date\": \"15.12.2025\", \"study_country\": [\"Hungary\", \"Saudi Arabia\", \"India\", \"Pakistan\", \"Portugal\", \"United Kingdom\", \"Canada\", \"Ireland\", \"Spain\", \"Romania\", \"Colombia\", \"United States\", \"Germany\", \"Croatia\", \"Nepal\", \"Belgium\", \"New Zealand\", \"Netherlands\", \"Australia\", \"Japan\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 322, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 10000, \"study_obtained_sample_size\": 10000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"All-cause mortality\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 90\"}, {\"study_outcome_title\": \"Days alive and not receiving organ support in ICU\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Primary end-point for patients with suspected or proven COVID-19 pandemic infection\", \"study_outcome_time_frame\": \"Day 21\"}, {\"study_outcome_title\": \"ICU Mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 90\"}, {\"study_outcome_title\": \"ICU length of stay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 90\"}, {\"study_outcome_title\": \"Hospital length of stay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 90\"}, {\"study_outcome_title\": \"Ventilator free days\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 28\"}, {\"study_outcome_title\": \"Organ failure free days\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 28\"}, {\"study_outcome_title\": \"All-cause mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Health-related Quality of life assessment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"EQ5D-5L and WHODAS 2.0 (not completed in all regions)\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Proportion of intubated patients who receive a tracheostomy\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 28\"}, {\"study_outcome_title\": \"Destination at time of hospital discharge\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital\", \"study_outcome_time_frame\": \"Free text Day 90\"}, {\"study_outcome_title\": \"Readmission to the index ICU during the index hospitalization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 90\"}, {\"study_outcome_title\": \"World Health Organisation 8-point ordinal scale outcome\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Hospital discharge\"}, {\"study_outcome_title\": \"Occurrence of multi-resistant organism colonisation/infection\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Antibiotic Domain specific outcome\", \"study_outcome_time_frame\": \"Day 90, censored at hospital discharge\"}, {\"study_outcome_title\": \"Occurrence clostridium difficile\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Antibiotic Domain specific outcome\", \"study_outcome_time_frame\": \"Day 90, censored at hospital discharge\"}, {\"study_outcome_title\": \"Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Macrolide Duration Domain specific outcome.\", \"study_outcome_time_frame\": \"Day 90, censored at hospital discharge\"}, {\"study_outcome_title\": \"Change from baseline influenza virus levels in upper and lower respiratory tract specimens\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Antiviral Domain specific outcome. Only required at selected sites.\", \"study_outcome_time_frame\": \"Day 3, up to Day 7\"}, {\"study_outcome_title\": \"Confirmed deep vein thrombosis\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and hospital discharge\"}, {\"study_outcome_title\": \"Confirmed pulmonary embolism\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and hospital discharge\"}, {\"study_outcome_title\": \"Confirmed ischaemic cerebrovascular event\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and hospital discharge\"}, {\"study_outcome_title\": \"Total red blood cell units transfused\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and end of study day 15\"}, {\"study_outcome_title\": \"Confirmed acute myocardial infarction\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and hospital discharge\"}, {\"study_outcome_title\": \"Peak troponin\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and end of study day 15\"}, {\"study_outcome_title\": \"Major bleeding event\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and end of study day 15\"}, {\"study_outcome_title\": \"Other confirmed thrombotic event, including mesenteric ischaemia and limb ischaemia\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.\", \"study_outcome_time_frame\": \"Between randomisation and hospital discharge\"}, {\"study_outcome_title\": \"Acute kidney injury (KDIGO stage >= 2 acute kidney injury)\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for ACE2 RAS Domain\", \"study_outcome_time_frame\": \"Between randomisation and 7 days\"}, {\"study_outcome_title\": \"Change from baseline to peak creatinine\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for ACE2 RAS Domain\", \"study_outcome_time_frame\": \"Between randomisation and 14 days\"}, {\"study_outcome_title\": \"Angioedema\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for ACE2 RAS Domain\", \"study_outcome_time_frame\": \"Between randomisation and end of study day 12\"}, {\"study_outcome_title\": \"Change from baseline AST, ALT and bilirubin\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Domain-specific outcome for ACE2 RAS Domain\", \"study_outcome_time_frame\": \"Between randomisation and 14 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04292730","content":"{\"resource_id\": \"NCT04292730\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\\u2122) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04292730\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"GS-US-540-5774\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-000842-32\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ISRCTN85762140\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Gilead Sciences\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"15.03.2020\", \"study_end_date\": \"26.06.2020\", \"study_country\": [\"Hong Kong\", \"United States\", \"Singapore\", \"Germany\", \"United Kingdom\", \"Netherlands\", \"Japan\", \"China\", \"Switzerland\", \"Spain\", \"Italy\", \"Sweden\", \"France\", \"Taiwan\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 184, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 1113, \"study_obtained_sample_size\": 1113, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of \\\"1\\\" was used for all days on or after the date of death; score of \\\"7\\\" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.\", \"study_outcome_time_frame\": \"Day 11\"}, {\"study_outcome_title\": \"Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.\", \"study_outcome_time_frame\": \"First dose date up to last dose date (maximum: 10 days) plus 30 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.\", \"study_data_sharing_plan_supporting_information\": [\"Study protocol\"], \"study_data_sharing_plan_time_frame\": \"18 months after study completion\", \"study_data_sharing_plan_access_criteria\": \"A secured external environment with username, password, and RSA code.\", \"study_data_sharing_plan_url\": \"https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy\"}}"}
{"id":"NCT04292899","content":"{\"resource_id\": \"NCT04292899\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\\u2122) in Participants With Severe COVID-19\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04292899\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"GS-US-540-5773\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-000841-15\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ISRCTN15874265\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Gilead Sciences\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"06.03.2020\", \"study_end_date\": \"30.06.2020\", \"study_country\": [\"Hong Kong\", \"United States\", \"Singapore\", \"Germany\", \"United Kingdom\", \"Netherlands\", \"Japan\", \"China\", \"Switzerland\", \"Spain\", \"Italy\", \"Sweden\", \"France\", \"Taiwan\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 183, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 4891, \"study_obtained_sample_size\": 4891, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Clinical status was derived from death, hospital discharge, and the ordinal scale as follows: score of \\\"1\\\" was used for all days on or after the date of death; score of \\\"7\\\" was used for all days on or after discharged alive date; last assessment carried forward for any missing values.The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or ECMO; 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration); 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for the Remdesivir for 10 days group vs the Remdesivir for 5 days group.\", \"study_outcome_time_frame\": \"Day 14\"}, {\"study_outcome_title\": \"Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study treatment start date and no later than 30 days after the permanent discontinuation of the study treatment and/or the AEs that led to premature discontinuation of study treatment.\", \"study_outcome_time_frame\": \"First dose date up to last dose date (maximum: 10 days) plus 30 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.\", \"study_data_sharing_plan_supporting_information\": [\"Study protocol\"], \"study_data_sharing_plan_time_frame\": \"18 months after study completion\", \"study_data_sharing_plan_access_criteria\": \"A secured external environment with username, password, and RSA code.\", \"study_data_sharing_plan_url\": \"https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy\"}}"}
{"id":"NCT04302766","content":"{\"resource_id\": \"NCT04302766\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Remdesivir\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"GS-5734\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734\\u2122)\"}], \"resource_descriptions\": [{\"description\": \"The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV; GS-5734\\u2122) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04302766\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"S-20-01\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"U.S. Army Medical Research and Development Command\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Coronavirus Disease 2019\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [\"Afghanistan\", \"Djibouti\", \"Iraq\", \"United States\", \"Germany\", \"Guam\", \"Japan\", \"Kuwait\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 22, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"DoD-affiliated personnel as defined in DoDI 6200.02, which includes emergency-essential civilian employees and/or contractor personnel accompanying the Armed Forces who are subject to the same health risk as military personnel\\nHave a laboratory-confirmed COVID-19 diagnosis with moderate to severe disease presentation as determined by the principal investigator\\nPatient or legally authorized representative (LAR) provides written informed consent, except as noted in 21 CFR 50.23\\nUnderstands and agrees to comply with planned study procedures\\nAvailable for clinical follow-up for duration of the treatment and follow-up period\\n\\nWoman of childbearing potential must\\n\\nHave a negative pregnancy test within 24 hours before starting treatment\\nAgree not to become pregnant during treatment and for 1 months after receiving remdesivir (Treatment will be a maximum of 10 doses given over a 10-day interval)\\nUse at least 2 reliable forms of effective contraception, including 1 barrier method, during treatment and for 1 month after the treatment period\", \"study_eligibility_exclusion_criteria\": \"ALT/AST \\u2265 5 times the upper limit of normal\\nStage 4 severe kidney disease or requiring dialysis (i.e. eGFR <30)\\nAnticipated transfer to another hospital that is not a study site within 72 hours\\nAllergy to any components of the study medication [GS-5734, sulfobutylether \\u03b2-cyclodextrin sodium (SBECD) and hydrochloric acid and/or sodium hydroxide]\\nConcomitant antiviral therapy (lopinavir/ritonavir [Kaletra])\\nPregnant or nursing\", \"study_population\": \"\", \"study_target_sample_size\": null, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: \\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04321265","content":"{\"resource_id\": \"NCT04321265\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Elderly patients\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"http://vipstudy.org/covip-study/\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients\"}], \"resource_descriptions\": [{\"description\": \"The study started in March 2020 and included until summer 2021 nearly 4000 patients. Several comprehensive analyses were conducted and published. Subsequently, in December 2021 the protocol was slightly changed and recruitment continues in 2022.\\n\\nData are collected regarding: Pre-Admission life conditions with Frailty (Clinical Frailty Scale, CFSF.R.A.I.L Score); vaccination status; ICU-Admission (e.g. SOFA), ICU-Treatment, Survival (30 day and 3 months).\\n\\nData are collected electronically through an e-CRF and with baseline documentation of the ICU. The database is located in Denmark, at the Department of Epidemiology, University of Aarhus. Each ICU will only have access through the database of their own patients, and patient ID is not registered (Names, birth-date or social security numbers) so it is in that sense anonymous.\\n\\nThe goal is to recruit at up to 400 ICUs that will continuously collect data. The COVIP Study had two different previous recruitment periods. Period 1 (march to May 2020) finished representing the first wave of the pandemic in most countries. The second recruitment period has been defined being from September 1st to December 31st 2020 representing the second wave in most countries. Recruitment in 2021 also continued until the summer without allocating a specific recruitment period. However, the third recruitment period opened January 1st 2022 and is still ongoing.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVIP\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04321265\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"20-004\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Heinrich-Heine University, Duesseldorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Christian Jung, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"contact@vipstudy.org\", \"role_phone\": \"+2118118800\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Raphael Bruno, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"covip@med.uni-duesseldorf.de\", \"role_phone\": \"+2118118800\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Elderly Patients\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Critical Illness\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Survival\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Old Age\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"19.03.2020\", \"study_end_date\": \"31.03.2023\", \"study_country\": [\"Denmark\", \"Germany\", \"Norway\", \"France\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 7, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 70, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Age > 70 years\\nICU-Admission\\nInfection with SARS-CoV-2\", \"study_eligibility_exclusion_criteria\": \"1. Age <70 years\", \"study_population\": \"Patient with Infection with SARS-CoV-2\", \"study_target_sample_size\": 1500, \"study_obtained_sample_size\": 1500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Survival\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"up to 30 days\"}, {\"study_outcome_title\": \"Frailty\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Frailty will be measured by using the Clinical frailty scale (CFS) a global clinical measure of fitness and frailty in elderly people (1=very fit to 9= terminally ill)\", \"study_outcome_time_frame\": \"pre-admission\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: \\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04323761","content":"{\"resource_id\": \"NCT04323761\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04323761\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"GS-US-540-5821\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-001453-49\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Gilead Sciences\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV2 Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [\"Hungary\", \"Slovakia\", \"France\", \"Portugal\", \"Cyprus\", \"United Kingdom\", \"Estonia\", \"Canada\", \"Ireland\", \"Lithuania\", \"Spain\", \"Romania\", \"Slovenia\", \"United States\", \"Denmark\", \"Germany\", \"Poland\", \"Greece\", \"Switzerland\", \"Italy\", \"Israel\", \"Belgium\", \"Austria\", \"Netherlands\", \"Iceland\", \"Australia\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 272, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants \\u2265 18 years of age), or willing and able to provide assent (participants \\u2265 12 and < 18 years of age, where locally and nationally approved) prior to performing study procedures. For participants \\u2265 12 and < 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures.\\nAge \\u2265 18 years or aged \\u2265 12 and < 18 years of age weighing \\u2265 40 kg (where permitted according to local law and approved nationally and by the relevant institutional review board (IRB) or independent ethics committee (IEC))\\nHospitalized with confirmed SARS-CoV2 by polymerase chain reaction (PCR) or known contact of confirmed case with syndrome consistent with coronavirus disease (COVID-19) with PCR pending\\nOxygen saturation (SpO2) \\u2264 94% on room air or requiring supplemental oxygen at baseline\\nAlanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) by local laboratory measure and/or ALT < 3 x ULN and bilirubin < 2 x ULN\\nFemales of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception\\nLactating females must agree to discontinue nursing before the study drug is administered and while they are participating in the study\", \"study_eligibility_exclusion_criteria\": \"Evidence of multiorgan failure including but not limited to coagulopathy (significant thrombocytopenia), hepatic failure (elevated bilirubin) or renal failure (low urine output or estimated glomerular filtration rate (eGFR) < 30 mL/min), or significant cardiomyopathy (low cardiac output)\\nUse of more than 1 pressor for septic shock (note that use of 1 pressor at low/medium doses for inotropic support due to the use of sedation and paralytics while on the ventilator is allowed)\\nRenal failure (eGRF < 30 mL/min using the Cockcroft-Gault formula for participants \\u2265 18 years of age and Schwartz Formula for participants < 18 years of age) or dialysis or continuous Veno-Venous Hemofiltration)\\nEligible for enrollment in a randomized clinical trial studying remdesivir for treatment of SARS-CoV2 at the medical facility where the participant is admitted\\nKnown hypersensitivity to the study drug, the metabolites, or formulation excipient\\nRequiring venous arterial (V-A) extracorporeal membrane oxygen (ECMO) (venous venous (V-V) ECMO is not an exclusion criteria)\", \"study_population\": \"\", \"study_target_sample_size\": null, \"study_obtained_sample_size\": null, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: \\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04324190","content":"{\"resource_id\": \"NCT04324190\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"anxiety\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"mental health\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"depression\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"psychosocial stress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"guided\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"somatic symptom disorder\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"online support\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic\"}], \"resource_descriptions\": [{\"description\": \"The overall aim of this randomised trial with observational component is to estimate the effects of a guided digital online support program to increase mental health and reduce psychosocial stress in the context of the COVID-19 pandemic. More specifically, the main hypothesis is to estimate whether the improvement in mental health is stronger during the first two weeks of applying the online support program as compared to a two weeks waiting condition (with provision of WHO information on 'coping with stress during the 2019-nCoV' outbreak only). In addition to the randomised control group (second arm: waiting condition, followed by online support program), the study comprises as third arm a non-randomised comparator condition, consisting of subjects not intending to participate in the online support program. Furthermore, our aim is to estimate changes in the outcomes along taking part in the program.\\n\\nAdditional research questions are:\\n\\nto compare the intervention effects across modules and chapters of the online support program, including between module comparison with an unspecific, control (comparator) module: \\\"general information on the corona virus\\\" and its unspecific chapters;\\nto estimate the effects of selected modules on additional outcomes (e.g. physical activity, and schooling related factors);\\nto describe the magnitude and course of psychosocial stress, mental health and related factors in the context of the COVID-19 pandemic;\\nto estimate and predict which subjects profit most from specific parts of the program.\\n\\nFollow-up assessment shall include estimating whether the program prevents the development of detrimental mental health conditions, e.g. depression, anxiety, etc.\\n\\nIn order to make first study results available as early as possible, we intend to conduct quick complete analyses (primary outcome and relevant parts of secondary/other outcomes): These analyses will be conducted with data including subjects from the first 4 weeks of recruitment, given that a sample size of at least 300 for the online support program arm and a sample size of at least 300 for the waiting condition is reached; or if not yet reached after 4 weeks of recruitment, as soon as a sample size of at least 300 for the online support program arm and a sample size of at least 300 for the waiting condition is reached. However, we intend to continue recruiting beyond this point in time and sample size (until the COVID-19 pandemic situation has come to an end, i.e., vaccination is broadly available), to allow further, also more detailed analyses at a later point in time, resulting in more precise estimates.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"DISPOSE\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04324190\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"IPUB_2020_01\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor-Investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Gunther Meinlschmidt\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"International Psychoanalytic University Berlin\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Gunther Meinlschmidt\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Selfapy GmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Gunther Meinlschmidt, Prof. Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"gunther.meinlschmidt@ipu-berlin.de\", \"role_phone\": \"+49 30 300117\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Randomized controlled trial with a waiting comparator condition (provision of WHO recommendations, comparable to treatment as usual, TAU), consisting of a two weeks waiting period during which general WHO recommendations how to handle stress in the context of the COVID-19 pandemic will be provided. All subjects in the waiting condition will undergo the intervention following the waiting period. Main assessments will be conducted before the waiting period, before beginning of the intervention, two weeks after beginning of the intervention (+2 weeks), +4 weeks, +12 weeks, and follow ups at +6 months and +12 months.\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Psychosocial Stress\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Mental Health\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"08.04.2020\", \"study_end_date\": \"15.12.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 600, \"study_obtained_sample_size\": 600, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The SF-36 is a widely used patient-reported outcome assessment tool to measure health-related quality of life and has high acceptability. The SF-36 is a standardised questionnaire with good psychometric properties.\", \"study_outcome_time_frame\": \"Change from T1 (baseline before online support - day 1) to T2 (T1 + 2 weeks) in arm 1, versus change from T0 (baseline before waiting) to T1 (baseline before online support) in arm 2\"}, {\"study_outcome_title\": \"Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"mental health related quality of life\", \"study_outcome_time_frame\": \"T2 (T1+2 weeks) (arm 2 only), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Chronic stress items (9 items)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessing chronic stress (Petrowski et al., 2019)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Generalized Anxiety Disorder Scale (GAD-7)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessing anxiety symptoms (L\\u00f6we et al., 2008)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Patient Health Questionnaire (PHQ8)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessing depressive symptoms (Kroenke et al., 2001)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Somatic Symptom Disorder (SSD-12)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessing depressive symptoms (Toussaint et al., 2019)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Somatic Symptom Scale (SSS-8)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessing somatic symptoms (Gierk et al., 2015)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Allgemeine Selbstwirksamkeit Kurzskala (ASKU)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"competence expectations to deal with difficulties and obstacles in daily life (Beierlein et al., 2014)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T2 (T1+2 weeks), T3 (T1+4 weeks), T4 (T1+12 weeks), follow ups: T1+ 6 months, T1+12 months\"}, {\"study_outcome_title\": \"Screening Tool for Psychological Distress (STOP-D) - selected items\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"stress, anxiety, depression, social support - single item assessments to be applied repeatedly along the online support intervention (Young, Ignaszewski, Fofonoff, Kaan; 2007), including stress of children and anticipation\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after each module of the online intervention\"}, {\"study_outcome_title\": \"Physical activity\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Vigorous, moderate, and walking activity (minutes/day)\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after sports and physical activity module; at baseline: before COVID-19 pandemic\"}, {\"study_outcome_title\": \"Home-schooling\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Questions related to home-schooling related stress & learning\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after sports and physical activity module; at baseline: before COVID-19 pandemic\"}, {\"study_outcome_title\": \"Information related to COVID-19 and SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Questions related to COVID-19 and SARS-CoV-2 symptoms, disease, and testing, anxiety, stressors\", \"study_outcome_time_frame\": \"baseline before waiting (T0, arm 2 only); baseline before online support (day 1, T1), T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months; before & after the sports and physical activity module of the online intervention\"}, {\"study_outcome_title\": \"Unintended effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Unintended effects of online support program\", \"study_outcome_time_frame\": \"only after undergoing online support program: T1+2 weeks, T1+4 weeks, T1+12 weeks, follow ups: T1+ 6 months, T1+12 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04331106","content":"{\"resource_id\": \"NCT04331106\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Corona\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Corona-Virus\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Anxiety\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Public Health\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Health\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Mental Disorders\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Mental Health\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany\"}], \"resource_descriptions\": [{\"description\": \"The COVID-19 pandemic is currently one of the greatest challenges for numerous countries - also for Germany. In addition to its somatic and economic consequences, the psychological dimension of the Coronavirus pandemic is discussed increasingly and is visible in public life - e.g. in the \\\"pandemic-caused experience of threat\\\", \\\"loss of control\\\" and \\\"panic\\\" of multiple people. The study examines the phenomenon of this \\\"corona-related anxiety\\\" in terms of epidemiological, clinical and psychosocial characteristics. It is investigated how \\\"corona anxiety\\\" affects people who already have an anxiety disorder or other mental illnesses as well as formerly mentally healthy people. It is also examined how media reporting and personal consequences of COVID-19 are connected with corona-related anxiety and if there is a need for therapeutic support regarding corona-related anxiety.\\n\\nTo answer these questions a longitudinal online survey targeting the general population in Germany is carried out. The survey takes place all three weeks as long as the pandemic lasts and ends with one follow-up one year later.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CORA\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04331106\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"EA1/071/20\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Antonia Bendau\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Charite University, Berlin, Germany\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Charite University, Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Antonia Bendau, M.Sc.Psych.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"antonia.bendau@charite.de\", \"role_phone\": \"+4930450517274\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Andreas Str\\u00f6hle, Prof.Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"andreas.stroehle@charite.de\", \"role_phone\": \"+4930450517217\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Anxiety Related to the COVID-19 Pandemic\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"27.03.2020\", \"study_end_date\": \"15.04.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"informed consent was given\\nage \\u2265 18\\nable to complete the questionnaire in German\\ncountry of residence: Germany\", \"study_eligibility_exclusion_criteria\": \"if at least one of the inclusion criteria is not met\", \"study_population\": \"General population in Germany\", \"study_target_sample_size\": 7500, \"study_obtained_sample_size\": 7500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Characteristics of COVID-19-related anxiety\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.\", \"study_outcome_time_frame\": \"1 day\"}, {\"study_outcome_title\": \"COVID-19-related anxiety symptoms\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.\", \"study_outcome_time_frame\": \"1 day\"}, {\"study_outcome_title\": \"Self-efficacy and coping with COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Self-efficacy and coping with the COVID-19 pandemic are measured with 13 self created items. Values ranging from 1 to 6; higher scores indicate a better outcome (except inverted items).\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"Consequences of COVID-19 in the last three weeks.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Personal consequences of the COVID-19 pandemic in the last three weeks are collected with five self-created items.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"General Illness Attitude\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"General illness attitudes are measured with 3 subscales (Worry about illness; Thanatophobia; Bodily preoccupations) of the German version of the Illness Attitude Scales (IAS) by Hiller & Rief (2004). 9 Items; values ranging from 1 to 5, higher scores indicate a worse outcome.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"Media reporting\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Frequency, effects and formats of consumed media related to COVID-19 are measured with 5 self created items.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"Ultra-brief screening scale for anxiety and depression\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To screen for general anxiety and depressive symptoms the German version of the Patient Health Questionnaire-4 (PHQ-4) by L\\u00f6we (2015) is used. 4 items; values ranging from 0 to 3, higher scores indicate a worse outcome.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"Change in characteristics of COVID-19-related anxiety\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To investigate specific fears regarding the COVID-19 pandemic 9 self created items are used. Values ranging from 1 to 6, higher scores indicate a worse outcome.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}, {\"study_outcome_title\": \"Change in COVID-19-related anxiety symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Modified German version of the DSM-5 Severity-Measure-For-Specific-Phobia-Adult-Scale by Beesdo-Baum et al. (2014). 10 items, values ranging from 1 to 5, higher scores indicate a worse outcome. The Scale was adapted to anxiety symptoms related to COVID-19.\", \"study_outcome_time_frame\": \"baseline (1 day) + after 3 weeks + after 6 weeks + after 9 weeks + after 6 months + after 7 months + after 9 months + after 12 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04335136","content":"{\"resource_id\": \"NCT04335136\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"APN01-COVID-19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04335136\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"APN01-01-COVID19\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Apeiron Biologics\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"30.04.2020\", \"study_end_date\": \"26.12.2020\", \"study_country\": [\"Denmark\", \"Germany\", \"United Kingdom\", \"Austria\", \"Russian Federation\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 22, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 80, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Hospitalized male or female\\nDiagnosed to be COVID-19 POSITIV\\nSigned Inform Consent Form\", \"study_eligibility_exclusion_criteria\": \"Any patient whose clinical condition is deteriorating rapidly\\nKnown history of positive Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody\\nHistory of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation\\nPregnant females as determined by positive serum or urine hCG test prior to dosing\\nLung transplantation\\nPre-existing renal failure, i.e. requiring renal replacement therapy with hemodialysis or peritoneal dialysis\\nThere are other uncontrolled co-morbidities that increase the risks associated with the study drug administration, that are assessed by the medical expert team as unsuitable\\nPatient in clinical trials for COVID-19 within 30 days before ICF\\nImmunocompromised patients (chemotherapy, HIV, organ transplants, stem cell transplants)\", \"study_population\": \"\", \"study_target_sample_size\": 185, \"study_obtained_sample_size\": 185, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"All Cause-death or Invasive Mechanical Ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary endpoint was a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Lactate Dehydrogenase (LDH) Level\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Log transformed levels of LDH at Day 5 as a surrogate marker for organ damage (powered secondary endpoint).\", \"study_outcome_time_frame\": \"Day 5\"}, {\"study_outcome_title\": \"Mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"28-day mortality (all cause-death).\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Ventilator-free Days (VFD)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"VFD up to 28 days or hospital discharge. VFD and mechanical-VFD (mVFD) were calculated as time in the study minus duration of ventilation and were set to zero if the duration of ventilation exceeded the time in the study.\\n\\nThree analysis approaches were used: 1) Death not censored: (m)VFD was set to zero for patients who died. 2) Death censored: patients who died before or on Day 28 were censored at the day before death. 3) Alive patients analyzed: only patients who were alive at Day 28, hospital discharge, or early termination were included in the analysis.\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Time to Death\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Time to death (all causes).\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Number of Responders, Defined as \\u22652 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):\\n\\nUninfected, no viral deoxyribonucleic acid (DNA) detected = 0;\\n\\nAsymptomatic, viral DNA detected = 1;\\n\\nSymptomatic, independent = 2;\\n\\nSymptomatic, assistance needed = 3;\\n\\nHospitalized, no oxygen therapy = 4;\\n\\nHospitalized, oxygen by mask or nasal prongs = 5;\\n\\nHospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;\\n\\nIntubation and mechanical ventilation, partial pressure of oxygen (pO2)/fraction of inspired oxygen (FiO2)\\u2265 150 or oxygen saturation (SpO2)/FiO2\\u2265200 = 7;\\n\\nMechanical ventilation, pO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors = 8;\\n\\nMechanical ventilation, pO2/FiO2 < 150 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = 9;\\n\\nDead = 10.\\n\\nA decrease in the score reflects an improvement.\", \"study_outcome_time_frame\": \"Day 7, Day 10, Day 14, Day 28\"}, {\"study_outcome_title\": \"Time to Hospital Discharge\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The number of days from randomization to discharge from hospital was calculated (Kaplan-Meier analysis).\\n\\nPatients without hospitalization or without documented hospital discharge who completed the study or were early terminated before Day 28 were censored at the date of study completion or discontinuation, respectively.\\n\\nPatients who died before Day 28 were censored at the date of death even if early terminated before.\", \"study_outcome_time_frame\": \"Up to 28 days\"}, {\"study_outcome_title\": \"Viral Ribonucleic Acid (RNA).\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Viral RNA was assessed in blood samples using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and projected to RNA copies per mL.\", \"study_outcome_time_frame\": \"Day 1, Day 3, Day 5, Day 7, Day 14, and Day 28/End of study (EOS)\"}, {\"study_outcome_title\": \"Time to a 2-point Decrease in WHO's 11-Point Score System\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The time from randomization to an at least 2-point decrease in the WHO scale was calculated. The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):\\n\\nUninfected, no viral DNA detected = 0;\\n\\nAsymptomatic, viral DNA detected = 1;\\n\\nSymptomatic, independent = 2;\\n\\nSymptomatic, assistance needed = 3;\\n\\nHospitalized, no oxygen therapy = 4;\\n\\nHospitalized, oxygen by mask or nasal prongs = 5;\\n\\nHospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;\\n\\nIntubation and mechanical ventilation, pO2/FiO2 \\u2265 150 or SpO2/FiO2\\u2265200 = 7;\\n\\nMechanical ventilation, pO2/FiO2 < 150 (SpO2/FiO2 < 200) or vasopressors = 8;\\n\\nMechanical ventilation, pO2/FiO2 < 150 and vasopressors, dialysis, or ECMO = 9;\\n\\nDead = 10.\\n\\nA decrease in the score reflects an improvement in disease status.\", \"study_outcome_time_frame\": \"Up to 28 days.\"}, {\"study_outcome_title\": \"Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The number of patients receiving mechanical ventilation and supplemental oxygen was evaluated.\", \"study_outcome_time_frame\": \"Up to 28 days\"}, {\"study_outcome_title\": \"Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Time from randomization to first use of invasive mechanical ventilation was calculated (Kaplan-Meier analysis).\\n\\nPatients without documented invasive mechanical ventilation who completed the study, were early terminated or discharged from hospital before Day 28 were censored at the date of study completion, discontinuation or discharge from hospital, respectively.\", \"study_outcome_time_frame\": \"Up to 28 days\"}, {\"study_outcome_title\": \"PaO2/FiO2 Value\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The ratio in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) was assessed by analysis of patient's blood gas.\", \"study_outcome_time_frame\": \"Day 1, Day 7, Day 10, Day 14, and Day 28\"}, {\"study_outcome_title\": \"Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The mSOFA score predicts intensive care unit mortality using clinical and laboratory variables. 5 organ systems (respiratory SpO2/FiO2; liver; cardiovascular/hypotension; Central nervous System/Glasgow Coma Score; renal/creatinine), all, except for liver, scored on a 0 to 4 scale (liver: 2-point scale: 0 or 3) according to specified criteria indicating severity, with the total score ranging from 0 to a maximum score of 19. A higher score reflects a worse disease state.\", \"study_outcome_time_frame\": \"Day -1 (Screening), Day 7, Day 10, Day 14, Day 28/End of study\"}, {\"study_outcome_title\": \"Lymphocyte Count\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Lymphocytes were assessed in blood samples from the patients.\", \"study_outcome_time_frame\": \"Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study\"}, {\"study_outcome_title\": \"C-reactive Protein Levels\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"C-reactive protein was assessed in blood samples from the patients.\", \"study_outcome_time_frame\": \"Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study\"}, {\"study_outcome_title\": \"D-Dimer\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"D-Dimer was assessed in blood samples from the patients.\", \"study_outcome_time_frame\": \"Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study\"}, {\"study_outcome_title\": \"Log-transformed Levels of LDH\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Log transformed levels of LDH in blood were assessed as a surrogate marker for organ damage.\", \"study_outcome_time_frame\": \"Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04335188","content":"{\"resource_id\": \"NCT04335188\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04335188\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COVID-19 Registry\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"IHF GmbH - Institut f\\u00fcr Herzinfarktforschung\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Ministerium f\\u00fcr Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Anselm Gitt, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"gitta@klilu.de\", \"role_phone\": \"+49 621 5032944\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Sebastian Diebold, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"diebold@ihf.de\", \"role_phone\": \"+4962159577214\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"06.04.2020\", \"study_end_date\": \"31.07.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"In-patients fulfilling the following criteria:\\n\\nSARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study\", \"study_eligibility_exclusion_criteria\": \"No explicit medical exclusion criteria are stated to avoid selection bias.\", \"study_population\": \"About 110 hospitals in Rhineland-Palatinate (Germany) treating patients with SARS-CoV-2 infection.\\n\\nAll stationary treated patients with SARS-CoV-2 infection will be included.\\n\\nPreferably all hospitals in Rhineland-Palatinate, Germany, treating patients with SARS-CoV-2 infection.\\n\\nConsecutive enrolment of all patients fulfilling the patient selection criteria to avoid selection bias.\", \"study_target_sample_size\": 4000, \"study_obtained_sample_size\": 4000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Chest x-ray\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"presence of infiltrates\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Chest CT\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"presence of infiltrates\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Supportive care - ICU\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with ICU treatment required\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Supportive care - oxygen therapy\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with oxygen therapy required\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Supportive care - ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with ventilation required\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Medication\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with medication changes\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Therapeutic strategies\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with ECMO required\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Lab parameters\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with significant changes in lab parameters\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Intra-hospital complications\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"number of patients with complications during hospital stay\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}, {\"study_outcome_title\": \"Vital status at discharge\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"vital status at discharge: alive, dead\", \"study_outcome_time_frame\": \"throughout study completion, in average 1.5 years\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04341285","content":"{\"resource_id\": \"NCT04341285\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)\"}], \"resource_descriptions\": [{\"description\": \"The severe form of COVID-19 infection is characterized and marked by severe pneumonia and the Acute Respiratory Distress Syndrome (ARDS). ARDS is characterized by the loss of pulmonary tissue compliance and severe hypoxia. The central pathophysiologic changes of COVID-19+ ARDS are dysregulated inflammation within the alveolar space and altered permeability of the alveolar-capillary barrier. The public health impact of this COVID-19+ ARDS is considerable with a large number of ARDS cases that need to be treated currently on German Intensive Care Units. To date, the associated mortality ranges between 30 to 50%. In the ongoing COVID-19 crisis cases of ARDS will still increase and pose a significant challenge to the German Medical System. Despite the emerging understanding of COVID-19+ ARDS, treatment only remains to be symptomatic using mechanical ventilation, prone positioning and in severe cases of hypoxia extracorporal membrane oxygenation (ECMO). Current evidence generated by clinical trials demonstrates that patients with ARDS should be referred to a specialized center to receive expert treatment. The use of ECMO might have a beneficial effect on overall patient outcome, yet this has not been proven by clinical trials and to date ECMO is recommended as measure of last resort in the current ARDS treatment guidelines. The timing of ECMO placement to relieve hypoxia is an important question for the treating clinician but is not well studied to date. This might also have impact on the long-term functional outcome of patients. In addition, evidence about the role of ECMO in the outcome of COVID-19+ patients might have significant impact on the referral of patients to a specialized center and is important for the treating physician. Therefore, the investigators want to pursue the questions whether early ECMO placement is superior than the placement of ECMO as a rescue measure, and whether this could result in improved overall outcome of patients with COVID-19+ ARDS.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ECMO-VID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04341285\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ECMO-VID\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Hospital Tuebingen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"University Hospital Freiburg\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"RWTH Aachen University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"University Hospital Muenster\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.\\n\\nDuration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: 90days or until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers\", \"study_conditions\": [{\"study_conditions\": \"ARDS, Human\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Terminated: Recruitment, data collection, data and quality management halted prematurely and will not resume\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"At the planning stage\", \"study_status_halted_reason\": \"study protocol was changed to include non-COVID patients and registered under a different ID\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.08.2020\", \"study_end_date\": \"01.05.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"COVID-19positive(+) ARDS as defined according to the Berlin Definition\\nratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/ FiO2) \\u2264100\\nBilateral opacities consistent with pulmonary edema on frontal chest radiograph\\nrequirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation\\nno clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mmHg.\\n\\u2264 7 days from the initiation of mechanical ventilation at the time of randomization. - Patients must be enrolled within 96 hours of onset of ARDS -\", \"study_eligibility_exclusion_criteria\": \"COVID-19negative(-) ARDS\\nAge less than 18 years\\nMore than 7 days since initiation of mechanical ventilation\\nmore than 96 hours since meeting ARDS criteria\\npatient, surrogate or physician not committed to full intensive care support.\\npregnancy\", \"study_population\": \"\", \"study_target_sample_size\": 0, \"study_obtained_sample_size\": 0, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"28 day all cause mortality\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"survival in 28-day follow-up period (28 day all cause mortality)\", \"study_outcome_time_frame\": \"28 Days\"}, {\"study_outcome_title\": \"90 day all cause mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"90 day all cause mortality\", \"study_outcome_time_frame\": \"90 days\"}, {\"study_outcome_title\": \"Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days\", \"study_outcome_time_frame\": \"day 1-14, 28 and 90\"}, {\"study_outcome_title\": \"duration of mechanical ventilation support\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"duration of mechanical ventilation support\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Ventilator Associated Pneumonia\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of patients with Ventilator Associated Pneumonia\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Bleeding complications\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"number of blood transfusion units\", \"study_outcome_time_frame\": \"28 das\"}, {\"study_outcome_title\": \"Acute Renal Failure\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Days on real replacement therapy\", \"study_outcome_time_frame\": \"28 days\"}, {\"study_outcome_title\": \"Discharge Location\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Discharge to (home, skilled nursing facility, rehabilitation)\", \"study_outcome_time_frame\": \"90 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04344171","content":"{\"resource_id\": \"NCT04344171\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"ventilation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ECMO\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antiviral therapy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Sars-Cov-2\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"https://www.covid-db.com\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"CovidDB: The Covid-19 Inpatient Database\"}], \"resource_descriptions\": [{\"description\": \"The exponentially increasing number of SARS-CoV-2 infected people, despite the influence of the currently existing non-medical measures, is generating a rapidly increasing number of inpatients, some of whom need artificial ventilation. The average focus is on the extent to which the hospitals' capacities will be sufficient to adequately treat all patients. Regardless of this, it can be expected that even if the non-medical measures are successful, the number of inpatients treated will remain high in the course of the pandemic. With regard to the distribution of infection, it can be expected that clinics with a wide range of expertise will have to treat a large number of Covid-19 patients.\\n\\nSo far, however, there is little to no experience in treating patients. In addition to epidemiological data, only case descriptions and some Chinese studies mostly from Wuhan based on fewer patients are available. In view of the rapidly spreading pandemic, preprints are increasingly being used. What has been missing so far is a uniform, structured recording of the courses of Covid-19 inpatients handled by many clinics, which goes beyond the epidemiological events in terms of depth of detail. With this documentation of real processes, the basis for a large number of studies and the associated better understanding of the disease process could be created.\\n\\nThe current dynamics make it imperative that the clinics, even those who have not received the most up-to-date scientific knowledge, cannot wait for the results of studies, but rather need concrete help in the treatment of patients. Efficient assistance within the framework of a close exchange between the treatment units is only possible with a multicentre, uniform documentation environment.\\n\\nThe aim of the project is to better understand the Covid-19 inpatient course of the disease and to quickly identify the positive experiences in the treatment in order to update guidelines for the treatment and use of medication.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04344171\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CovidDB\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"ClarData\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Julia Ferencz, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"j.ferencz@clardata.com\", \"role_phone\": \"+4917687607223\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Sebastian Dieng\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"s.dieng@clardata.com\", \"role_phone\": \"+4915140212025\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"30.03.2020\", \"study_end_date\": \"30.06.2023\", \"study_country\": [\"Germany\", \"Romania\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 9, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Covid-19 inpatients\", \"study_eligibility_exclusion_criteria\": \"assumed Covid-19 patient\", \"study_population\": \"The study is focused on all Covid-19 inpatients which are treated in the recruited hospitals.\", \"study_target_sample_size\": 5000, \"study_obtained_sample_size\": 5000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Outcome comparison between different antiviral therapies\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Different antivirals and their combinations will be tested and the outcome (cured/deceased) will be assessed\", \"study_outcome_time_frame\": \"through study completion, an average of 1 year\"}, {\"study_outcome_title\": \"Outcome comparisons between ventilation types\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Different ventilation types will be tested and the outcome (cured/deceased) will be assessed\", \"study_outcome_time_frame\": \"through study completion, an average of 1 year\"}, {\"study_outcome_title\": \"Identification of risk factors\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Clinical and laboratory risk factors will be recorded and the outcome (cured/deceased) will be assessed\", \"study_outcome_time_frame\": \"through study completion, an average of 1 year\"}, {\"study_outcome_title\": \"Number of days in hospital vs. clinical classification\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Correlation between number of days in hospital and worst clinical classification will be calculated\", \"study_outcome_time_frame\": \"through study completion, an average of 1 year\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04345510","content":"{\"resource_id\": \"NCT04345510\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Testing for COVID-19 Infection in Asymptomatic Persons\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04345510\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COVID-19-1.0-DKFZ\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"German Cancer Research Center\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19 Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"20.04.2020\", \"study_end_date\": \"30.09.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"DKFZ employee\", \"study_eligibility_exclusion_criteria\": \"Non DKFZ employee\", \"study_population\": \"DKFZ employees\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"COVID-19 infection\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"6 weeks\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04352634","content":"{\"resource_id\": \"NCT04352634\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"healthcare professionals\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"pandemic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"mental health\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"The Impact of the Covid-19 Pandemic on the Mental Health of Workers in Health Services: The Covid-19 HEalth caRe wOrkErS (HEROES) Study\"}], \"resource_descriptions\": [{\"description\": \"Since December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population. Based on the literature to date, Covid-19 is significantly larger than previous pandemics in terms of the number of affected people worldwide, its spread across countries, its impact on healthcare systems and the severity of measures that have been taken by governments. Immediate consequences are palpable in the health care system. Many healthcare workers are overwhelmed by the increased workload; the lack of supplies and materials to provide appropriate treatment; the lack of clinical guidelines on prioritization and triage; and the increased feelings of isolation and loneliness. Previous research indicates that these negative effects can last over time and lead to the development of serious mental health problems such as post-traumatic stress disorder.\\n\\nRecent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress). Also, it is necessary to take into account the nature and the extent of the health response (e.g., deployment, increased workload) in order to advance our understanding of these complex phenomenon and to inform policy and develop the kind of supports that this population deems useful.\\n\\nThe COVID-19 HEalth caRe wOrkErS (HEROES) study is a large, bottom-up, South-North initiative aimed to evaluate the impact of the COVID-19 pandemic on the mental health of health care workers (HCWs). HEROES encompasses a wide variety of academic institutions in 19 LMICs and 8 HICs, in partnership with the Pan American Health Organization (PAHO) and with support from the World Health Organization (WHO). The HEROES study is led by Dr. Rub\\u00e9n Alvarado at University of Chile, and Dr. Ezra Susser and Franco Mascayano at Columbia U Mailman School of Public Health.\\n\\nParticipants will complete an online questionnaire, which will be completely self-administered. It will take approximately 12 minutes and includes sociodemographic data, questions on work activity, training, fears and concerns related to Covid-19, as well as the GHQ-12 and a series of questions on other mental health issues (e.g., suicide, acute stress), resilience and psycho/social factors (e.g., formal and informal support).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"HEROES\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04352634\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"HEROES Covid-19\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Rub\\u00e9n Alvarado\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"University of Chile\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Chile\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Columbia University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Rub\\u00e9n Alvarado, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"ralvarado@med.uchile.cl\", \"role_phone\": \"+56 2 2978 6967\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Mental Health Disorder\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Stress Disorder\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Anxiety\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Depression\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"26.04.2020\", \"study_end_date\": \"31.12.2021\", \"study_country\": [\"Argentina\", \"Bolivia\", \"Turkey\", \"Saudi Arabia\", \"Costa Rica\", \"Nigeria\", \"Venezuela\", \"Puerto Rico\", \"Spain\", \"United States\", \"Germany\", \"Armenia\", \"Chile\", \"Italy\", \"Tunisia\", \"Guatemala\", \"Mexico\", \"Netherlands\", \"Australia\", \"Lebanon\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 22, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Legal age\\nCurrently working on a health service that provides care to COVID-19 patients\\nGive informed consent\", \"study_eligibility_exclusion_criteria\": \"Inability to use electronic devices (required to complete the survey)\", \"study_population\": \"This study will include workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)\", \"study_target_sample_size\": 2000, \"study_obtained_sample_size\": 2000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Anxiety and depressive symptoms\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Experiences, fears and concerns about the Covid-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on experiences, fears, and concerns about Covid-19\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Experiences, fears and concerns about the Covid-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on experiences, fears, and concerns about Covid-19\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Experiences, fears and concerns about the Covid-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on experiences, fears, and concerns about Covid-19\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Experiences, fears and concerns about the Covid-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on experiences, fears, and concerns about Covid-19\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Training and resource prioritization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on Covid-19 training and resource prioritization\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Training and resource prioritization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on Covid-19 training and resource prioritization\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Training and resource prioritization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on Covid-19 training and resource prioritization\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Training and resource prioritization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on Covid-19 training and resource prioritization\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Suicide ideation (presence)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Suicide ideation (presence)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Suicide ideation (presence)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Suicide ideation (presence)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Suicide ideation (frequency)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Suicide ideation (frequency)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Suicide ideation (frequency)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Suicide ideation (frequency)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Acute stress symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Acute stress symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Acute stress symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Acute stress symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Psycho/social support and network\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Psycho/social support and network\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Psycho/social support and network\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Psycho/social support and network\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Resilience\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Resilience\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Resilience\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Resilience\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.\", \"study_outcome_time_frame\": \"12 months\"}, {\"study_outcome_title\": \"Anxiety and depressive symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Anxiety and depressive symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Anxiety and depressive symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries\", \"study_outcome_time_frame\": \"6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04368312","content":"{\"resource_id\": \"NCT04368312\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"psychological distress\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"quality of life\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Psychological Impairment Due to Covid-19 in Hospital Staff\"}], \"resource_descriptions\": [{\"description\": \"Hospital staff and emergency personell are confronted with severe and life-threatening situations, therefore this group is considered to be at risk for impaired psychological health. A pandemic such as the Covid-19 endemic is suggested to severely impair the psychological state of this profession, amongst others Quality of life, anxiety, depression and other parameters. Therefore, it is crucial to assess the impact of impairment due to this global threat on the psychological health of health care providers. We therefore designed this study to evaluate baseline psychological characteristics and to re-assess those values in an interval of 60 days.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04368312\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"TEMP553914-BO\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Hospital, Essen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Psychological Distress\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Quality of Life\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"06.05.2020\", \"study_end_date\": \"30.12.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Hospital staff (doctors and nurses)\", \"study_eligibility_exclusion_criteria\": \"None\", \"study_population\": \"Inclusion of all persons which can be attributed to hospital stuff, those include doctors and nurses (male/female)\", \"study_target_sample_size\": 100, \"study_obtained_sample_size\": 100, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"PCL5 Questionnaire\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Validated 20-items questionnaire for PTSD\", \"study_outcome_time_frame\": \"14 days\"}, {\"study_outcome_title\": \"BSI - Brief symptom inventory\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The Brief Symptom Inventory (BSI) is a 53-item screener for mental health problems with 9 subscales.\", \"study_outcome_time_frame\": \"14 days\"}, {\"study_outcome_title\": \"PHQD\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Instrument for psychological diagnostics, able to test the severity of mental disorders and the success of their treatment\", \"study_outcome_time_frame\": \"14 days\"}, {\"study_outcome_title\": \"WHO - QoL BREF\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Qol Questionnaire, assessed QoL with respect to the individual's perceptions in the context of culture and value systems.\", \"study_outcome_time_frame\": \"14 days\"}, {\"study_outcome_title\": \"STAXI\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The State-Trait Anger Expression Inventory is used to measure the expressions & control of anger\", \"study_outcome_time_frame\": \"14 days\"}, {\"study_outcome_title\": \"AUDIT questionnaire\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The AUDIT questionnaire is designed to help in the self assessment of alcohol consumption\", \"study_outcome_time_frame\": \"14 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04370119","content":"{\"resource_id\": \"NCT04370119\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"epidemiology\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antibody formation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"immunity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Serology\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers\"}], \"resource_descriptions\": [{\"description\": \"This study aims to collect information on staff working at the Greifswald University hospital.\\n\\nOver a 5 year period, a maximum of 6 study visits per participant are planned. At each visit, nasal/throat swabs (for PCR testing) and/or blood samples (to assess immunological responses, e.g. for SARS-CoV-2 antibody testing) will be collected. This will help to gain a better understanding of viral load and immunological responses, e.g. antibody development and their effects over time.\\n\\nAt study visit 2 - 6, participants will also be asked to fill in a questionnaire (asking for SARS-CoV-2 risk factors, perceived risk, impact of the pandemic on their quality of life, their interest in getting a SARS-CoV-2 vaccine/their SARS-CoV-2 vaccination status and vaccination side effects).\\n\\nThe remaining blood samples will be stored in a repository for future research.\\n\\nThe study is part of a modular SARS-CoV-2-research programme of the University Medicine Greifswald.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SeCo\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04370119\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"BB 068/20\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Medicine Greifswald\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Friedrich Loefler Institute for Animal Health\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"EUROIMMUN AG\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention ongoing\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"27.04.2020\", \"study_end_date\": \"15.05.2025\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \">= 18 years of age\\nWilling and able to complete a written consent form\\nWilling to have blood samples stored for future research\\nHealthcare worker employed at Greifswald University Hospital\", \"study_eligibility_exclusion_criteria\": \"< 18 years of age\\nDecline to participate\", \"study_population\": \"Health Care Worker\", \"study_target_sample_size\": 1092, \"study_obtained_sample_size\": 1092, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Number of people with detectable SARS-CoV-2 nucleic acid\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 PCR\", \"study_outcome_time_frame\": \"First study visit (baseline)\"}, {\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"First study visit (baseline)\"}, {\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"3 years\"}, {\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"4 years\"}, {\"study_outcome_title\": \"Number of people with detectable antibodies to SARS-CoV-2\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Anti-SARS-CoV-2 S protein IgG ELISA/ Anti-SARS-CoV-2 NCP IgG ELISA\", \"study_outcome_time_frame\": \"5 years\"}, {\"study_outcome_title\": \"Number of people with detectable SARS-CoV-2 nucleic acid\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"SARS-CoV-2 PCR\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Number of people with detectable SARS-CoV-2 nucleic acid\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"SARS-CoV-2 PCR\", \"study_outcome_time_frame\": \"3 years\"}, {\"study_outcome_title\": \"Number of people with detectable SARS-CoV-2 nucleic acid\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"SARS-CoV-2 PCR\", \"study_outcome_time_frame\": \"4 years\"}, {\"study_outcome_title\": \"Number of people with detectable SARS-CoV-2 nucleic acid\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"SARS-CoV-2 PCR\", \"study_outcome_time_frame\": \"5 years\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, impact of the pandemic on quality of life, vaccination interest/vaccination status, vaccination side effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"As assessed by a questionnaire\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, impact of the pandemic on quality of life, vaccination interest/vaccination status, vaccination side effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"As assessed by a questionnaire\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, impact of the pandemic on quality of life, vaccination interest/vaccination status, vaccination side effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"As assessed by a questionnaire\", \"study_outcome_time_frame\": \"3 years\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, impact of the pandemic on quality of life, vaccination interest/vaccination status, vaccination side effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"As assessed by a questionnaire\", \"study_outcome_time_frame\": \"4 years\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, impact of the pandemic on quality of life, vaccination interest/vaccination status, vaccination side effects\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"As assessed by a questionnaire\", \"study_outcome_time_frame\": \"5 years\"}, {\"study_outcome_title\": \"Serological changes after SARS-CoV-2 vaccination\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Serological changes after SARS-CoV-2 vaccination, cohort 3 only\", \"study_outcome_time_frame\": \"7 days to 6 months after vaccination\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"Serum, nasal/throat swabs\"}}}"}
{"id":"NCT04379271","content":"{\"resource_id\": \"NCT04379271\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19\"}], \"resource_descriptions\": [{\"description\": \"The trial consists of a Phase 2 proof-of-concept phase (Part 1) with the option to extend enrollment (without interruption) to Phase 3 (Expansion Phase, Part 2).\\n\\nThis trial is a multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to evaluate the safety and efficacy of IMU-838 as addition to investigator's choice of SoC treatment in patients with COVID-19. Eligible patients will be centrally randomized 1:1 to twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC) or placebo (+ SoC). Randomization will be stratified by age (< or >=65 years) and antiviral therapy (no antivirals, Hydroxychloroquine and Chloroquine, all other antivirals).\\n\\nAdaptive sequential trial design and overall trial design\\n\\nThe trial uses an adaptive sequential design. An IDMC will review unblinded data and provide the Sponsor with recommendations regarding modifications of sample size and trial conduct.\\n\\nA 1st interim analysis (IA1) will be performed after approximately 200 patients have completed the trial (either as scheduled or prematurely), while enrollment continues. If no activity of IMU 838 is observed by the IDMC in this IA, further patient enrollment will be stopped, and a final analysis of Part 1 will be performed (FA1). It is expected that the final analysis of Part 1 will include approximately 230 patients. If the IA1 results indicate activity of IMU-838 in COVID-19, the trial may be extended to Part 2 with a revised sample size derived by the IDMC based on IA1 results and with possible other trial adjustments. If the trial is extended into Part 2, a 2nd IA (IA2) is planned after approximately two-thirds of patients (based on the overall global sample size [Part 1 and Part 2 combined]) have been enrolled to potentially adjust sample size and other trial features if needed. The final analysis of the trial (FA2) will then be done after all patients have completed Part 2.\\n\\nIn addition, an early interim safety analysis will be performed and evaluated by the IDMC after 30 patients have been enrolled to assess unblinded safety data. Further safety analyses can be initiated at any time by the IDMC or Sponsor when new safety signals are identified within this or other trials of IMU-838.\\n\\nScreening\\n\\nPatients can be screened for a maximum of 2 days (from Day -2 to Day 0) and eligible patients will be randomized on Day 0 and treated with IMP + SoC for 14 days. It is encouraged to screen potential participants immediately at the day of hospitalization (including informed consent, assessment of inclusion/exclusion criteria, screening laboratory tests all done locally, assessment of clinical and blood gas criteria) and randomize patients on the same day (Day 0). To assess eligibility criteria, existing local laboratory values obtained within 48 hours of randomization can also be used, except for testing of positive status of SARS-CoV-2 infection where a 4-day window is allowed.\\n\\nIMP administration should start as quickly as possible after randomization and first IMP intended to be given in the evening of the screening day (Day 0).\\n\\nBlinded Treatment period (Day 0 to Day 13) and Day 14 (end-of-treatment)\\n\\nThe first dose of IMP (2 tablets) should always be given on Day 0 (allowed range for first dose: 12:00 noon on Day 0 to 02:00 a.m.). All further IMP doses are 1 tablet each in the morning and evening. Information about the status and patient care are continuously obtained and documented once or twice daily.\\n\\nAfter the last IMP dose in the evening of Day 13, the end-of-treatment assessments will be done on Day 14. Blood sampling for IMU-838 trough values must be performed in the morning around the time the morning dose was usually taken by the respective patient. Patients may then continue to receive SoC without any further restrictions on concomitant medications as during the 14-day BT period .\\n\\nDay 28 Visit (EoS)\\n\\nThe patient should return for the final trial visit on Day 28 (EoS). If IMP is prematurely discontinued for any reason, the EoS visit should always be conducted on Day 28 and no earlier EoS should be performed. If patients withdraw from IMP prematurely, they should be encouraged to allow the EoS visit as part of the follow-up. If the patient dies during the trial, the investigator should indicate that this visit was not performed. However, even if no EoS visit was performed, information about patient status should be reported on the EoS page in the case report form. If the patient refuses any EoS visit or the patient is lost to follow-up, it is permissive in this trial that the investigator contacts the patient, the family of the patient or the referring physician by phone or email to obtain status of life information, or is able to search in registers or publicly available information for such status of life information.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04379271\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"P2-IMU-838-COV\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Immunic AG\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"FGK Clinical Research GmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: double-blind, placebo-controlled, randomized, parallel-group trial\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"11.06.2020\", \"study_end_date\": \"23.02.2021\", \"study_country\": [\"Germany\", \"Bulgaria\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 4, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Male or female patients at least 18 years old (may be extended to include also children 12 years or older after the 1st interim analysis)\\n\\nAdmitted to the hospital or other medical in-patient treatment facility for treatment of COVID-19 The hospitalization needs to be for medical reasons (treatment of COVID-19 disease) and cannot be for social reasons or due to housing insecurity.\\n\\nFor US sites only: If the investigator would commonly hospitalize the patient but for healthcare resource reasons decides to treat the patient in a specially designed out-patient setting, then such patients are also allowed to enter the trial (please note that in this case the patient would be counted as clinical status category 3). The investigator then must assure that the patient has at least a twice daily assessment by qualified trial personnel and all laboratory assessments can be adequately performed as per protocol. The Sponsor reserves the right to discontinue this option via administrative letter if such assurances cannot be met by any site.\\n\\nSARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) test in a nasopharyngeal, oropharyngeal or respiratory sample at \\u22644 days before randomization\\n\\nModerate COVID-19 disease defined as fulfilling clinical status category 3 or 4 on the WHO 9-point ordinal scale [21]:\\n\\nCategory 3: Hospitalized (see note above for US only), virus-positive, no oxygen therapy with the following conditions:\\nThe hospitalization needs to be for medical reasons (treatment of COVID-19 disease) and cannot be for social reasons or due to housing insecurity\\nCategory 4: Hospitalized, virus-positive, oxygen by mask or nasal prongs (excluding high-flow oxygen therapy) with the following conditions:\\nPeripheral capillary oxyhemoglobin saturation (SpO2) >92% at maximum of 6 liters oxygen flow per minute\\nStable respiratory rate \\u226430 breaths/min at maximum of 6 liters oxygen flow per minute\\nPresence of at least 1 symptom characteristic for COVID-19 disease i.e., fever, cough or respiratory distress\\nWillingness and ability to comply with the protocol\\nWritten informed consent given prior to any trial-related procedure\\n\\nFor women of childbearing potential: Application of a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly) together with a barrier method between trial consent and 30 days after the last intake of the IMP.\\n\\nHighly effective forms of birth control are those with a failure rate less than 1% per year and include:\\n\\noral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraceptives associated with inhibition of ovulation\\noral, injectable, or implantable progestogen-only hormonal contraceptives associated with inhibition of ovulation\\nintrauterine device or intrauterine hormone-releasing system\\nbilateral tubal occlusion\\nvasectomized partner (i.e., the patient's male partner underwent effective surgical sterilization before the female patient entered the clinical trial and is the sole sexual partner of the female patient during the clinical trial)\\nsexual abstinence (acceptable only if it is the patient's usual form of birth control/lifestyle choice; periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are no acceptable methods of contraception)\\n\\nBarrier methods of contraception include:\\n\\nCondom\\nOcclusive cap (diaphragm or cervical/vault caps) with spermicidal gel/film/cream/suppository\\n\\nMale patients must agree not to father a child or to donate sperm starting at Screening, throughout the clinical trial and for 30 days after the last intake of the IMP. Male patients must also\\n\\nabstain from sexual intercourse with a female partner (acceptable only if it is the patient's usual form of birth control/lifestyle choice), or\\nuse adequate barrier contraception during treatment with the IMP and until at least 30 days after the last intake of the IMP, and\\nif they have a female partner of childbearing potential, the partner should use a highly effective contraceptive method as outlined in inclusion criterion 8\\nif they have a pregnant partner, they must use condoms while taking the IMP to avoid exposure of the fetus to the IMP\", \"study_eligibility_exclusion_criteria\": \"Underlying disease-related exclusion criteria\\n\\nInvolvement in the trial is not in the patient's best interest according to the investigator's decision, including the presence of any condition that would, in the assessment of the investigator, not allow the protocol to be followed safely Note: The investigator should particularly consider exclusion of patients at increased risk for serious or fatal AEs in case of worsening of the pulmonary perfusion. This includes, but is not limited to, pre-existing pulmonary hypertension, severe chronic respiratory disease, severely increased risk for thromboembolic complications and moderate to severe left ventricular ejection fraction (LVEF) dysfunction. In addition, other known risk factors of highest risk of mortality in COVID-19 patients should be considered.\\nPresence of respiratory failure, shock, and/or combined failure of other organs that requires ICU monitoring in the near foreseeable future\\nCritical patients whose expected survival time <48-72 hours\\n\\nPresence of the following laboratory values at screening:\\n\\nWhite blood cell count (WBC) <1.0 x 109/L\\nPlatelet count <100,000/mm\\u00b3 (<100 x 109/L)\\nTotal bilirubin>2 x ULN\\nAlanine aminotransferase (ALT) or gamma glutamyl transferase (GGT) >5 x ULN\\nParticipation in any other interventional clinical trial\\nHospitalization primarily for other reasons than COVID-19 (including primarily for concomitant conditions during ongoing SARS-CoV-2 infection)\\nAnticipated transport to a different hospital or institution, in particular when such transport is anticipated for pending ECMO or RRT treatment\\nClinical suspicion of a bacterial superinfection at Screening IMP-related exclusion criteria\\nPatients who cannot take drugs orally\\nAllergic or hypersensitive to the IMP or any of the ingredients\\n\\nUse of the following concomitant medications is prohibited from Screening to end of treatment with IMP in this trial (up to Day 14) if not indicated otherwise in this protocol:\\n\\nConcurrent use of any mycophenolate mofetil or of methotrexate exceeding 17.5 mg weekly\\nAny medication known to significantly increase urinary elimination of uric acid, in particular lesinurad (Zurampic\\u2122) as well as uricosuric drugs such as probenecid\\nCurrent treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafenib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib\\nAny drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogs\\nUse of rosuvastatin at daily doses higher than 10 mg\\nArbidol and Colchicine\\nAny use of other DHODH inhibitors, including teriflunomide (Aubagio\\u2122) or leflunomide (Arava\\u2122)\\nChloroquine and Hydroxychloroquine during the entire trial unless taken for indicated use before entering the trial\\nUse of any investigational product within 8 weeks or 5x the respective half-life before the date of informed consent, whichever is longer, and throughout the duration of the trial General exclusion criteria\\nPatients who have a \\\"do not intubate\\\" or \\\"do not resuscitate\\\" order (unless the patient waives in writing this order and will allow intubation for the duration of the trial period)\\nPatients with end-stage liver disease (Child Pugh C score)\\nHistory or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4) Note: NYHA class 3: Cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.\\nLegal incapacity, limited legal capacity, or any other condition that makes the patient unable to provide consent for the trial\\nPregnant or breastfeeding\\nAn employee of an investigator or Sponsor or an immediate relative of an investigator or Sponsor\\nPatients institutionalized due to judicial order\", \"study_population\": \"\", \"study_target_sample_size\": 223, \"study_obtained_sample_size\": 223, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Proportion of patients without any need* for INV until end-of-study (EoS)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Clinical\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Duration of ICU treatment until EoS\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Key Secondary\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"28-day all-cause mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Key Secondary\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Time to clinical improvement\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy: defined as the time from first dose of investigational medicinal product (IMP) to an improvement of at least 2 points on the WHO 9 category ordinal scale , or live discharge from hospital without oxygen supplementation, whichever comes first\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Duration of hospitalization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy: Duration of hospitalization (for US sites only: or treatment in special outpatient setting in lieu of hospitalization due to resource restraints)\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients both for all patients and surviving patients free of renal-replacement therapy (RRT)* until EoS\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients both for all patients and surviving patients free from extracorporeal membrane oxygenation (ECMO)* until EoS\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients free of INV until Days 6 and 14*\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients free of RRT until Days 6 and 14*\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Day 0 to Days 6 and 14\"}, {\"study_outcome_title\": \"Proportion of patients free ECMO until Days 6 and 14*\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Day 0 to Days 6 and 14\"}, {\"study_outcome_title\": \"Proportion of patients with improvement of at least 2 points (from randomization) on the 9-category WHO ordinal scale1 on Days 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"on Days 6, 14, and 28\"}, {\"study_outcome_title\": \"Proportion of patients with auxiliary oxygen therapy (including all types of oxygen therapy) on Days 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"on Days 6, 14, and 28\"}, {\"study_outcome_title\": \"Proportion of patients with clinical recovery: Axillary temperature \\u226436.6 \\u2103, or oral temperature \\u226437.2 \\u2103, or rectal or tympanic temperature \\u226437.8 \\u2103;\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients with clinical recovery: Respiratory frequency \\u226424 times/min without oxygen inhalation; and\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients with clinical recovery: Oxygen saturation \\u226598% without oxygen inhalation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Proportion of patients with clinical improvement, defined as the time from first dose of IMP to an improvement of at least 2 points on the WHO 9 category ordinal scale, or live discharge from hospital without oxygen supplementation, whichever comes first\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Clinical patient status on the 9-category WHO ordinal scale1 on Days 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"on Days 6, 14, and 28\"}, {\"study_outcome_title\": \"Duration of INV\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28 )\"}, {\"study_outcome_title\": \"Duration of ECMO\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Duration of RRT\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Duration of auxiliary oxygen therapy (including all types of oxygen therapy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Duration of hospitalization for survivors\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"The rate of ICU* admission on Days 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"on Days 6, 14, and 28\"}, {\"study_outcome_title\": \"Hospital-free days\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time from IMP treatment initiation to death\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time to first prescription of INV\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time to first prescription of RRT\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time to first prescription of ECMO\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time to first prescription of INV, RRT, and ECMO\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Time to ICU admission\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Cumulative dose of vasoactive therapies and days with vasoactive therapies (daily until Day 14)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Day 0 to day 14\"}, {\"study_outcome_title\": \"Time to clinical recovery\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Efficacy\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Pharmacokinetics\", \"study_outcome_time_frame\": \"on Days 0, 1, 2, 3, 6, 14, and 28\"}, {\"study_outcome_title\": \"Correlation of trough levels (quartiles) to selected clinical outcomes (Clinical improvement accoding to WHO criteria)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Pharmacokinetics\", \"study_outcome_time_frame\": \"on Days 0, 1, 2, 3, 6, 14, and 28\"}, {\"study_outcome_title\": \"Adverse events (AEs) and serious AEs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Vital signs: height\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety Height in centimeters will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.\", \"study_outcome_time_frame\": \"only at Screening\"}, {\"study_outcome_title\": \"Vital signs: weight\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety Weight in kilograms will be recorded without shoes. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Vital signs: body temperature (\\u00baC)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety Body temperature can be measured axillary, oral, rectal or tympanic, but should be always measured by the same method for a patient. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Vital signs: pulse rates,\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety Pulse must be measured with the patient in a seated position (if possible), after at least 5 minutes at rest. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Vital signs: systolic and diastolic blood pressures\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety Blood pressure (systolic and diastolic) must be measured with the patient in a seated position (if possible), after at least 5 minutes at rest. Changes in vital signs judged by the investigator as clinically significant will be reported as an AE.\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Clinical laboratory parameters: blood chemistry\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Clinical laboratory parameters: hematology\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Clinical laboratory parameters: urinalysis\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"12-lead electrocardiogram: heart rate\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Day 0 to Day 6 and Day 28\"}, {\"study_outcome_title\": \"12-lead electrocardiogram: PQ-interval\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Day 0 to Day 6 and Day 28\"}, {\"study_outcome_title\": \"12-lead electrocardiogram: QRS-interval\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Day 0 to Day 6 and Day 28\"}, {\"study_outcome_title\": \"12-lead electrocardiogram: QT interval\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Day 0 to Day 6 and Day 28\"}, {\"study_outcome_title\": \"12-lead electrocardiogram: the heart rate-corrected QTc interval (according to Bazett's formula)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Day 0 to Day 6 and Day 28\"}, {\"study_outcome_title\": \"Temperature\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Safety\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"D-dimer\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Lactate dehydrogenase (LDH)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"C-reactive protein\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Troponin I\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Procalcitonin\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Correlation of disease markers to selected clinical outcomes (Clinical improvement accoding to WHO criteria)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Disease markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Decrease of SARS-CoV-2 viral load\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Virologic markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Severe Acute Respiratory Syndrome Coronavirus Virus (SARS-CoV-2) mean viral load - log10 copies in spontaneous sputum and nasopharyngeal swab samples: Time course of SARS-CoV-2 viral load\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Virologic markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Qualitative virologic clearance in spontaneous sputum and nasopharyngeal swab samples (= 2 consecutive negative SARS-CoV-2 reverse transcriptase polymerase chain reaction tests at least 24 hours apart)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Virologic markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Rate of conversion to a negative SARS-CoV-2 (qualitative) test on Days 6, 14 and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Virologic markers\", \"study_outcome_time_frame\": \"on Days 6, 14 and 28\"}, {\"study_outcome_title\": \"Time to conversion to a negative SARS-CoV-2 (qualitative) test\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Virologic markers\", \"study_outcome_time_frame\": \"Throughout the Study (Day 0 to Day 28)\"}, {\"study_outcome_title\": \"Interleukin (IL)-17\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Biomarkers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and Day 28\"}, {\"study_outcome_title\": \"Interleukin (IL)-1\\u00df\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Biomarkers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and Day 28\"}, {\"study_outcome_title\": \"Interleukin (IL)-6\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Biomarkers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and 28\"}, {\"study_outcome_title\": \"interferon gamma (IFN\\u03b3)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Biomarkers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and 28\"}, {\"study_outcome_title\": \"tumor necrosis factor alpha\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Biomarkers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and 28\"}, {\"study_outcome_title\": \"Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: \\u2022 Time to appearance of IgA and/or IgG antibodies\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Serologic markers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and 28\"}, {\"study_outcome_title\": \"Immunoglobulin (Ig)A and IgG antibodies against SARS-CoV-2: \\u2022 Proportion of patients with IgA and/or IgG antibodies on Days 6, 14, and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Serologic markers\", \"study_outcome_time_frame\": \"Day 0, 6, 14 and 28\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04381273","content":"{\"resource_id\": \"NCT04381273\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Oral Health and Psychosocial Factors During the Covid-19 Pandemic\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04381273\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"S-303/2020\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Dr. Antonio Ciardo\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Heidelberg University\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Heidelberg University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Periodontal Diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"15.05.2020\", \"study_end_date\": \"08.08.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\u226518 years old\\nResidence in Germany\\nUnderstanding of study participation and consent\", \"study_eligibility_exclusion_criteria\": \"<18 years old\\nResidence outside of Germany\", \"study_population\": \"The largest possible number of people should be given the opportunity to participate in this questionnaire considered the eligibility criteria.\", \"study_target_sample_size\": 1178, \"study_obtained_sample_size\": 1178, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"How do people assess their oral health-related quality of life in times of the Covid-19 pandemic?\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.\", \"study_outcome_time_frame\": \"08.05.2020-31.07.2020\"}, {\"study_outcome_title\": \"Does the periodontitis risk have an influence on the severety of the Covid-19 disease and its' treatment?\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.\", \"study_outcome_time_frame\": \"08.05.2020-31.07.2020\"}, {\"study_outcome_title\": \"Do psychosocial stress factors in times of the Covid-19 pandemic have an impact on their oral health related quality of life?\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.\", \"study_outcome_time_frame\": \"08.05.2020-31.07.2020\"}, {\"study_outcome_title\": \"Have people changed their oral hygiene practices in times of the Covid-19 pandemic?\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The survey consists of validated and unvalidated items giving the opportunity to assess periodontitis risk, psychosocial stress, anxiety, depression and oral health related quality of life as well as questions focusing on experiences of the covid-19 pandemic.\", \"study_outcome_time_frame\": \"08.05.2020-31.07.2020\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Cross-sectional\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04383678","content":"{\"resource_id\": \"NCT04383678\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Multicenter European Study\"}], \"resource_descriptions\": [{\"description\": \"We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04383678\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COVID-19 ECMO\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Fausto Biancari\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Helsinki University Central Hospital\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Helsinki University Central Hospital\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Extracorporeal Membrane Oxygenation Complication\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Acute Respiratory Distress Syndrome\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.03.2020\", \"study_end_date\": \"01.04.2021\", \"study_country\": [\"Finland\", \"Germany\", \"United Kingdom\", \"Italy\", \"Sweden\", \"France\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 11, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"PCR-confirmed or suspected COVID-19 infection with ARDS who require any ECMO therapy\", \"study_eligibility_exclusion_criteria\": \"None\", \"study_population\": \"Patients with PCR-confirmed or suspected COVID-19 infection with ARDS who require veno-venous or veno-arterial ECMO therapy\", \"study_target_sample_size\": 132, \"study_obtained_sample_size\": 132, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"In-hospital mortality\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"All-cause mortality\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Death on ECMO\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Death during ECMO therapy\", \"study_outcome_time_frame\": \"During the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Stroke\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Stroke was defined as any focal or global neurological syndrome caused by ischemia and/or hemorrhage not resolving within 24 hours.\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Blood stream infection\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Blood stream infection detected on blood cultures\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Lung complications requiring surgical treatment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Pneuthorax, pneumonia and/or abscess requiring surgical treatment\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Blood transfusion\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Transfusion of red blood cells\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Acute kidney injury\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Acute renal failure according to the Kidney Disease: Improving Global Outcomes classification (KDIGO) criteria\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Duration of mechanical ventilation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Duration of mechanical ventilation\", \"study_outcome_time_frame\": \"During index hospital stay follow-up until 1 year after ECMO initiation\"}, {\"study_outcome_title\": \"Deep vein thrombosis\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Thrombosis of lower limb deep venous system\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Pulmonary embolism\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Pulmonary embolism\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Length of intensive care unit stay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Length of stay in the intensive care unit\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Length of hospital stay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Length of hospital stay\", \"study_outcome_time_frame\": \"Immediately after the intervention/procedure/surgery\"}, {\"study_outcome_title\": \"Death after hospital discharge\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"All-cause death\", \"study_outcome_time_frame\": \"Up to 6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Retrospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04385147","content":"{\"resource_id\": \"NCT04385147\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Cholangitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Obstructive Jaundice\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Endoscopic retrograde cholangiopancreatography\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Endoscopy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Pancreas Cancer\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"esophagogastroduodenoscopy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Endoscopic ultrasound\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study\"}], \"resource_descriptions\": [{\"description\": \"In this study, investigators aim to explore the status of advanced endoscopy (endoscopic retrograde cholangiopancreatography and endoscopic ultrasound on a global level) in different endoscopy units all over the world, to report the characteristics of patients presented to these units and their procedure details.\\n\\nevaluate the validity of different GI societies recommendations applied in different GI endoscopy units on the prevention of SARS-CoV-2 nosocomial transmission and the overall impact of this recommendations on the service provided by each GI unit.\\n\\nTarget audience:\\n\\n- Physicians performing advanced gastrointestinal endoscopies in different countries.\\n\\nObjectives:\\n\\nPrimary objective:\\n\\n1- To explore the status of advanced endoscopy (endoscopic retrograde cholangiopancreatography and endoscopic ultrasound on a global level) in different endoscopy units all over the world, to report the characteristics of patients presented to these units and their procedure details.\\n\\nSecondary objectives:\\n\\nEffect of COVID-19 precautions on procedure time, procedure success, complications and patient outcomes\\nEffect of COVID-19 on working time and staff number\\n\\nProcess:\\n\\nA questionnaire containing advanced endoscopy procedure details in different countries will be distributed via emails. Responses will be collected in an online platform and data will be analyzed to reveal the effect of SARS-CoV-2 pandemic on different aspects of advanced endoscopy practice in the studied countries.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04385147\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Global-Endo-COVID\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Mohamed Alboraie\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Al-Azhar University\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Al-Azhar University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Helwan University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"National Liver Institute, Egypt\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Cholangitis, Secondary Biliary\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Cholangiocarcinoma\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Obstructive Jaundice\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Pancreas Cancer\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"18.05.2020\", \"study_end_date\": \"05.07.2020\", \"study_country\": [\"Egypt\", \"United States\", \"Singapore\", \"Germany\", \"Peru\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 5, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients referred for ERCP or EUS during the study period\", \"study_eligibility_exclusion_criteria\": \"Patients refusing to participate in the study\", \"study_population\": \"All patients with digestive disorders referred for ERCP or EUS during the study period in the participating centers\", \"study_target_sample_size\": 670, \"study_obtained_sample_size\": 670, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Age, gender, nationality\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Investigators will report the baseline demographic data (age, gender, nationality) of all patients.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Indication for procedure, status of SARS-CoV-2 infection\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Complete blood count and liver functions tests\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"procedure related complications\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Investigators will report the procedure related complications.\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Effect of COVID-19 precautions on procedure time\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Investigators will report wether the precautions lead to increase timing of the procedure\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Effect of COVID-19 precautions on staff number\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Investigators will report wether the precautions affected staff number (increased or decreased)\", \"study_outcome_time_frame\": \"3 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"Investigators may share data after first publication\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04393038","content":"{\"resource_id\": \"NCT04393038\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"ABX464\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged \\u2265 65 and Patients Aged \\u226518 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.\"}], \"resource_descriptions\": [{\"description\": \"This phase 2/3 study will evaluate the efficacy and safety of ABX464 50mg QD (oral capsule), on treating inflammation and preventing acute respiratory failure in patients infected with SARS-CoV-2.\\n\\nEligible patients will be randomized according to a 2:1 ratio into 2 treatment cohorts as follows:\\n\\nStandard of Care + Placebo cohort: 344 patients\\nStandard of Care + ABX464 50mg QD: 690 patients\\n\\nStudy design:\\n\\nThe study will consist of 2 periods:\\n\\nTreatment phase: randomized patients will be treated for 28 days\\nSafety follow-up phase of 14 days after which the End of Study visit (EOS) will be performed.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"Mir-Age\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04393038\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ABX464-401\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Abivax S.A.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Phase 2/3, randomized, double blind, placebo-controlled study\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.07.2020\", \"study_end_date\": \"16.04.2021\", \"study_country\": [\"Brazil\", \"Germany\", \"Belgium\", \"United Kingdom\", \"Mexico\", \"Spain\", \"Italy\", \"France\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 30, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Adult (\\u2265 18 years old) men or women, hospitalized or not hospitalized, diagnosed for SARS-CoV-2 infection by PCR, with at least one associated risk factor. Considered risk factors are:\\n\\nAge \\u2265 65 years\\nObesity defined as BMI \\u2265 30\\nRecent history of uncontrolled High Blood Pressure (SBP > 150 mm Hg DBP >100 mm Hg) according to investigator\\nTreated diabetes (type I or II)\\nHistory of ischemic cardiovascular disease\\nSymptomatic patients at enrollment. Symptoms are defined as fever (body temperature \\u2265 37.8 C oral/tympanic, or \\u2265 38.2 C rectal) for more than 24 hours associated either with headache, sore throat, dry cough, fatigue, chest pain or choking sensation (with no associated respiratory distress), myalgia, anosmia or ageusia.\\nPatients with pulse oximetry arterial saturation \\u2265 92 % on room air at enrolment.\\n\\nPatients with the following hematological and biochemical laboratory parameters obtained within 7 days prior to Day 0:\\n\\nHemoglobin above 9.0 g / dL\\nAbsolute Neutrophil Count \\u2265 1000 / mm3\\nPlatelets \\u2265 100 000 mm3;\\nCreatinine clearance \\u2265 50 mL / min by the Cockcroft Gault formula\\nTotal serum bilirubin < 2 x ULN\\nAlkaline phosphatase < 2 x ULN, AST (SGOT) and ALT (SGPT) < 3 x ULN;\", \"study_eligibility_exclusion_criteria\": \"Patients with moderate or severe acute respiratory failure or requiring noninvasive ventilation or oxygen or with SpO2 < 92% or tachypnea (respiratory rate \\u2265 30 breaths/min).\\nPatients treated with immunosuppressors and/or immunomodulators.\\nEngrafted patients (organ and/or hematopoietic stem cells).\\nPatients with uncontrolled auto-immune disease.\\nPatients with known or suspected active (i.e. not controlled) bacterial, viral (excluding COVID-19) or fungal infections.\\nPatients with preexisting, severe and not controlled organ failure.\\nHistory or active malignancy requiring chemotherapy or radiation therapy (excluding 2 years disease free survivor patients).\\nPregnant or breast-feeding women.\\nIllicit drug or alcohol abuse or dependence that may compromise the patient's safety or adherence to the study protocol.\\nUse of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer.\\nHypersensitivity to ABX464 and/or its excipients.\\nAny condition, which in the opinion of the investigator, could compromise the patient's safety or adherence to the study protocol.\", \"study_population\": \"\", \"study_target_sample_size\": 509, \"study_obtained_sample_size\": 509, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"at the end of the 28-day treatment period\"}, {\"study_outcome_title\": \"Rate of patients hospitalized\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28-day treatment period\"}, {\"study_outcome_title\": \"Percentage of patients reporting each severity rating on a 7-point ordinal scale\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"7-point ordinal scale is defined as Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death\", \"study_outcome_time_frame\": \"28-day treatment period\"}, {\"study_outcome_title\": \"Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"at each study visit during the 28-day treatment period\"}, {\"study_outcome_title\": \"Rate of patients requiring oxygen supplementation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28-day treatment period\"}, {\"study_outcome_title\": \"Time to hospitalization\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28-day treatment period\"}, {\"study_outcome_title\": \"Time to assisted ventilation and oxygen supplementation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28-day treatment period\"}, {\"study_outcome_title\": \"Change from baseline in microRNA-124 levels\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"at each study visit during the 28-day treatment period\"}, {\"study_outcome_title\": \"Change from baseline in CRP, Troponin I & T and D-dimer\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"at each study visit during the 28-day treatment period\"}, {\"study_outcome_title\": \"SARS-CoV-2 viral load\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Nasopharyngeal sample and/or in blood\", \"study_outcome_time_frame\": \"at each study visit during the 28-day treatment period\"}, {\"study_outcome_title\": \"Number and rates of participants with Treatment Emergent Adverse Event\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28-day treatment period\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04408339","content":"{\"resource_id\": \"NCT04408339\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19 Disease in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care in the Hamburg Metropolitan Area Including Prospective Biobanking\"}], \"resource_descriptions\": [{\"description\": \"Based on patients, who are treated in the University Cancer Center Hamburg (UCCH) and its contracted partner network, which comprises all cancer treating departments at the University Medical Center of Hamburg-Eppendorf (UKE), as well as 19 office-based oncologists and 20 surrounding hospitals, recruitment for the study will be done as follows:\\n\\n(i) as a cancer patient during regular aftercare appointments who reports a current or past COVID-19 infection.\\n\\n(ii) as an acute COVID-19 patient who reports a prevalent cancer diagnosis\\n\\nData will be collected as available from routine clinical care and includes demographic and biometric data, medical history, baseline data at inclusion as well as inpatient and intensive care unit admissions. Upon consent, patients will provide peripheral blood samples at time of inclusion and after 6 month. Recruitment is limited to a one-year period (April 2020 - April 2021).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVIDHELP\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04408339\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"PV7313\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4tsklinikum Hamburg-Eppendorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"University of Schleswig-Holstein, Campus L\\u00fcbeck\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Universit\\u00e4tsklinikum Schleswig-Holstein, Campus Kiel\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Katja Weisel, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"k.weisel@uke.de\", \"role_phone\": \"+49407410\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Niklas Boerschel, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"n.boerschel@uke.de\", \"role_phone\": \"+49407410\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Cancer\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"15.04.2020\", \"study_end_date\": \"14.04.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"Our study population consists of patients, who are treated in the University Cancer Center Hamburg (UCCH) and its contracted partner network, who are either cancer patients reporting a current or past COVID-19 infection, or acute COVID-19 patients who report a prevalent cancer diagnosis.\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Rate of hospitalization\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Duration of hospitalization\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in days from date of admission to definitive discharge\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Rate of admission to intensive care unit\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Length of stay in intensive care unit\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in days from date of admission to intensive care unit to the date of discharge\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Need of mechanical ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Duration of mechanical ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in days from the date of intubation to the stop date of mechanical ventilation\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Disease-specific mortality rate\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"COVID-19 associated mortality rate\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Rate of patients, whose oncologic treatment had to be modified due to COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured in percentage. Modification is defined as cancellation, postponement or dose-adjustment of treatment.\", \"study_outcome_time_frame\": \"2 years\"}, {\"study_outcome_title\": \"Cellular and humoral immune response to COVID-19 infection\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Analysis of blood samples at time of diagnosis and after 6 month\", \"study_outcome_time_frame\": \"6 month\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"Aggregated data will be shared\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": 1, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"Peripheral Blood\"}}}"}
{"id":"NCT04446338","content":"{\"resource_id\": \"NCT04446338\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Seroprevalence\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Immune Status: Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Sample of the Eye Department (University Eye Hospital and Research Institute T\\u00fcbingen)\"}], \"resource_descriptions\": [{\"description\": \"In the current pandemic, the assessment of actual COVID-19 infections plays an important role in the assessment of the risk and progress of the epidemic. Shortly, more and more rapid tests will be available, the aim of which is to be able to obtain a good overview of the immune status of corresponding samples in a timely manner.\\n\\nEmployees in the health sector are faced with additional challenges, not only due to the tightened hygiene regulations. The concern about infecting other people and/or exposing oneself to a relevant health risk is of great importance. A moderate to high transmission risk can be assumed for ophthalmology. In view of older patients and sometimes unavoidable proximity, targeted and reliable diagnostics can offer the potential to reduce the risk potential for the current situation by determining antibodies.\\n\\nA rapid diagnosis is not yet available outside of clinical studies, especially since deficits in specificity (contact with other coronaviruses) are to be expected. Studies on the serological reaction are not yet available for longer observation periods, but it can be assumed that positive direct detection of IgG (Anti Sars-CV-2-ELISA; Euroimmun) is available at the latest 3 weeks after the onset of symptoms. Without larger and representative analyses, it is currently unclear whether seroconversion is associated with permanent immunity or a lack of it leads to a possible susceptibility to reinfection. A combined test procedure is therefore to be offered to employees within the framework of a random sample.\\n\\nThe query of anamnestic parameters allows the assignment to different groups (CC: past COVID infection, PC: possible infection, N: asymptomatic). The primary goal of the planned study is to provide a first preliminary evaluation of the tests used in the current context.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CovidImmunEye\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04446338\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"292/2020BO2\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Hospital Tuebingen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Institute of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Focke Ziemssen, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"focke.ziemssen@med.uni-tuebingen.de\", \"role_phone\": \"+49 7071 29 88088\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Tarek Bayyoud, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"tarek.bayyoud@med.uni-tuebingen.de\", \"role_phone\": \"+49 7071 29 88088\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"History of Covid-19, Seroprevalence\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"13.05.2020\", \"study_end_date\": \"15.08.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Employees of the health facility described\\nvoluntary request for testing\", \"study_eligibility_exclusion_criteria\": \"- None\", \"study_population\": \"Employee of the Department of Ophthalmology (at a university institution)\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": 300, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Seroprevalence\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Rate of anti-SARS-CoV-2 Antibodies\", \"study_outcome_time_frame\": \"through study completion, maximum of one year\"}, {\"study_outcome_title\": \"Agreement of the test results and questionnaire\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Kappa statistics\", \"study_outcome_time_frame\": \"through study completion, maximum of one year\"}, {\"study_outcome_title\": \"Positive predictive / negative values of the tests applied\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"through study completion, maximum of one year\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"Blood\"}}}"}
{"id":"NCT04451902","content":"{\"resource_id\": \"NCT04451902\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"skin\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19 and Rare Skin Diseases. European Observational Study (Data Research) During an Epidemic\"}], \"resource_descriptions\": [{\"description\": \"Medical and demographic data will be collected from the medical records of patients. The data required will be specified in Appendix 1 (collection form). Patients will be identified by their initials (first letter of their surname and first name); The study will last for one year to cover the COVID-19 epidemic in France (which includes the areas of mainland France and its overseas departments and territories) and in Europe, via the ERN-Skin European Network.\\n\\nThe frequency of severe forms of COVID-19 will be calculated with a bilateral 95% confidence interval using, as a numerator, the number of patients with a severe form of COVID-19 and, as a denominator, the number of patients with a COVID-19 diagnosis confirmed by PCR, chest scan, serological assay or by suggestive clinical signs during the medical consultation. A severe form of COVID is defined as a case requiring hospitalisation in an intensive care unit, requiring resuscitation, or resulting in death.\\n\\nAnalysis of the impact of COVID-19 infection on rare skin diseases: complications, potential comorbidity factors, impact on the management of chronic conditions (change in treatment) and the experience of patients.\\n\\nThe results of the analysis may be compared with those obtained for other groups of diseases. Gaining a better understanding of high-risk situations, as well as any aggravation or protective factors, should enable us to issue recommendations adapted to this kind of disease but that may also be useful for the general population. This type of study may also provide \\\"reassurance\\\" to patients with rare diseases who have many questions during this period of epidemic and heightened concern.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04451902\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COVID19-RareSkin\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Imagine Institute\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"R\\u00e9becca GENE\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"rebecca.gene@aphp.fr\", \"role_phone\": \"0144492582\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Anna GAROFANO\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"anna.garofano@aphp.fr\", \"role_phone\": \"0144494443\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Rare Diseases\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"30.06.2020\", \"study_end_date\": \"31.12.2022\", \"study_country\": [\"Germany\", \"France\", \"Lithuania\", \"Italy\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 13, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patient with a rare skin disease,\\nPatient of any age (paediatric or adult),\\nPatient with suspected COVID-19 infection (remote consultation, face-to-face consultation, general practitioner, hospital physician),\\nPatient in contact with a subject infected with the COVID-19 virus,\\nAsymptomatic patient for COVID-19 viral infection but with a positive serology,\\nStudy information given to the patient and/or to their legal representative,\\nPatient who has been informed and has agreed to this data collection process.\", \"study_eligibility_exclusion_criteria\": \"Patients not suffering from a rare skin disease,\\nPatient and/or their legal representative who object to their participation in the study at the presentation of the information leaflet,\\nAdult patient unable to understand the implications and constraints of the study,\\nProtected adult subject to guardianship or safeguarding measures.\", \"study_population\": \"This is a European observational cohort study (research data) involving multiple centres whose main objective is to determine the impact of a COVID-19 virus infection in a cohort of patients with rare skin diseases and particularly if these rare diseases and their treatments are risk factors of infection severity. The cohort of patients with rare skin diseases is monitored by the European Reference Network (ERN-Skin) and FIMARAD network centres. This is a public health impact study.\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": 80, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Analysis of the impact of COVID-19 infection on rare skin diseases: complications\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Frequency of hospitalisations related to suspected and confirmed cases of Covid-19 infection and consequences\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Analysis of the impact of COVID-19 infection on rare skin diseases: potential comorbidity factors\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Frequency of hospitalisations related to suspected and confirmed cases of Covid-19 infection and analysis of associated factors: age, gender, pathology, comorbidities, medications\", \"study_outcome_time_frame\": \"Baseline\"}, {\"study_outcome_title\": \"Analysis of the impact of COVID-19 infection on rare skin diseases: impact on the management of chronic conditions (change in treatment)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Frequency of confirmed and suspected unconfirmed Covid-19 infections; description of clinical signs and signs of an impact on the chronic disease; description of possible therapeutic changes due to the Covid-19 infections\", \"study_outcome_time_frame\": \"Baseline\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Other\"], \"study_target_follow-up_duration\": 1, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04527497","content":"{\"resource_id\": \"NCT04527497\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Clinical Course and Treatment of COVID-19 Inpatients in Hospital\"}], \"resource_descriptions\": [{\"description\": \"The aim of this study is to describe the course of disease and the treatment of patients suffering from COVID-19 who are hospitalized and treated as inpatients:\\n\\nAre there common features (previous illnesses, medication, age, BMI, etc.), which may influence the course of disease?\\nAre there therapeutic procedures that have a positive or negative impact on the course of the disease or the length of stay in the intensive care unit/ the duration of ventilation (early/late intubation, CPAP, NIV, ECMO)?\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04527497\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"WI_20-1294\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Wissenschaftliches Institut Bethanien e.V\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Marcel Treml, Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"institut@klinik-bethanien.de\", \"role_phone\": \"+49212636661\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Anja Pietzke-Calcagnile, Dr.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"institut@klinik-bethanien.de\", \"role_phone\": \"+49212636663\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.08.2020\", \"study_end_date\": \"31.08.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"positive COVID-19 test result\\nAge > 18 years\", \"study_eligibility_exclusion_criteria\": \"Age < 18 years\\nnegative COVID-19 test result\\nlack of agreement\\nAny medical, psychological or other condition, that restricts the ability of the person to be informed and to give the consent for voluntary participation in this trial\", \"study_population\": \"All patients who are inpatients at Bethanien Hospital and have a proven COVID-19 infection and who agree to participate in the study during the period from 01.08.2020 - 30.05.2021.\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": 50, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"convalescence/death\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"has patient died or has patient recovered\", \"study_outcome_time_frame\": \"through study completion, an average of 2 months\"}, {\"study_outcome_title\": \"length of stay in the intensive care unit\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"length of stay in the intensive care unit\", \"study_outcome_time_frame\": \"through study completion, an average of 2 months\"}, {\"study_outcome_title\": \"length of stay in hospital\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"length of stay in hospital\", \"study_outcome_time_frame\": \"through study completion, an average of 2 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: \\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04537949","content":"{\"resource_id\": \"NCT04537949\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Coronavirus infection\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"RNA Vaccine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Coronavirus\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Virus Diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Vaccine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Protection against COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Coronavirus Disease 2019\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults\"}], \"resource_descriptions\": [{\"description\": \"This study was a multi-site, Phase I/II, open-label, dose-escalation study. The study included the first in human dose and dose ranging groups in healthy younger participants (aged 18 to 55 years [yrs]) and older participants (aged 56 to 85 yrs). The conducted Part A followed a dose escalation design. Discretionary dose de-escalation and refinement was also planned. Study participants with the first-in-human [FIH] immunization and any subsequent dose escalation cohorts were immunized using a sentinel dosing/subject staggering. For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with doses lower than previously tested, participants were dosed using a subject staggering process. Cohorts in older participants were optional and dependent on acceptability of dosing in younger participants. Part A consisted of a treatment phase (screening to Visit 7) and a follow-up phase (Visits 8 to 10).\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04537949\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"BNT162-04\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-003267-26\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"U1111-1254-4840\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"BioNTech SE\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Protection Against COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"09.09.2020\", \"study_end_date\": \"07.02.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 85, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Have given informed consent by signing the informed consent form (ICF) before initiation of any trial-specific procedures.\\nThey must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow good practices to reduce their chances of being infected or spreading COVID-19), and other requirements of the trial.\\nThey must be able to understand and follow trial-related instructions.\\nFor younger adult cohorts, volunteers must be aged 18 to 55 years, have a body mass index over 19 kg/m^2 and under 30 kg/m^2 (i.e., be neither underweight nor obese), and weigh at least 50 kg at Visit 0.\\n\\nOR For older adult cohorts, volunteers must be aged 56 to 85 years, have a body mass index over 19 kg/m^2 and under 30 kg/m^2 (i.e., be neither underweight nor obese), and weigh at least 50 kg at Visit 0.\\n\\nThey must be healthy, in the clinical judgment of the investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests (blood chemistry, hematology, and urine chemistry) at Visit 0.\\nWomen of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are postmenopausal or permanently sterilized will be considered as not having reproductive potential.\\nWOCBP must agree to practice a highly effective form of contraception during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization. WOCBP must agree to require their male partners to use condoms during sexual contact (unless male partners are sterilized or infertile).\\nWOCBP must confirm that they practiced at least one highly effective form of contraception for the 14 days prior to Visit 0.\\nWOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.\\nMen who are sexually active with a WOCBP and have not had a vasectomy must agree to practice a highly effective form of contraception with their female partner of childbearing potential during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.\\nMen must be willing to refrain from sperm donation, starting after Visit 0 and continuously until 60 days after receiving the last immunization.\\nThey must have confirmation of their health insurance coverage prior to Visit 0.\\nThey must agree to not be vaccinated during the trial, starting after Visit 0 and continuously until 28 days after receiving the last immunization.\", \"study_eligibility_exclusion_criteria\": \"Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the first immunization. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\\nAre breastfeeding on the day of Visit 0 or who plan to breastfeed during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.\\nHave a known allergy, hypersensitivity, or intolerance to the planned investigational medicinal product (IMP) including any excipients of the IMP.\\nHad any medical condition or any major surgery (e.g., requiring general anesthesia) within the past 5 years which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\\nHave any surgery planned during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.\\nHad any chronic use (more than 21 continuous days) of any systemic medications, including immunosuppressants or other immune-modifying drugs, within the 6 months prior to Visit 0 unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise subject safety.\\nReceived any vaccination within the 28 days prior to Visit 0.\\nHad administration of any immunoglobulins and/or any blood products within the 3 months prior to Visit 0.\\nHad administration of another IMP including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Visit 0.\\nHave a known history or a positive test of any of human immunodeficiency virus (HIV) 1 or 2, Hepatitis B, or Hepatitis C, within the 30 days prior to Visit 0.\\nHave a positive polymerase chain reaction (PCR)-based test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the 30 days prior to Visit 1.\\nHave a positive drugs of abuse (for amphetamines, benzodiazepines, barbiturates, cocaine, cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and tricyclic antidepressants) result at Visit 0 or Visit 1.\\nHave a positive breath alcohol test at Visit 0 or Visit 1.\\nPreviously participated in an investigational trial involving lipid nanoparticles.\\nAre subject to exclusion periods from other investigational trials or simultaneous participation in another clinical trial.\\nHave any affiliation with the trial site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the trial site).\\nHave a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\\nHave a history of hypersensitivity or serious reactions to previous vaccinations.\\nHave a history of Guillain-Barr\\u00e9 Syndrome within 6 weeks following a previous vaccination.\\nHave a history of narcolepsy.\\nHave history of alcohol abuse or drug addiction within 1 year before Visit 0.\\nHave a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Visit 0.\\nHave any abnormality or permanent body art (e.g., tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site.\\nHave had any blood loss >450 mL, e.g., due to donation of blood or blood products or injury, within the 7 days prior to Visit 0 or plan to donate blood during the trial, starting after Visit 0 and continuously until at least 7 days after receiving the last immunization.\\nSymptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.\\nHave had contact with persons diagnosed with COVID-19 or who tested positive for SARS-CoV-2 by any diagnostic test within the 30 days prior to Visit 1.\\nAre soldiers, subjects in detention, contract research organization (CRO) or sponsor staff or their family members.\\nRegular receipt of inhaled/nebulized corticosteroids.\\n\\nHave a condition known to put them at high risk for severe COVID-19, including those with any of the following risk factors:\\n\\nCancer\\nCOPD (chronic obstructive pulmonary disease)\\nImmunocompromised state (weakened immune system) from solid organ transplant\\nObesity (BMI of 30 or higher)\\nSerious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies\\nSickle cell disease\\nDiabetes mellitus\\nHypertension\\nAsthma\\nChronic liver disease\\nKnown Stage 3 or worse chronic kidney disease (glomerular filtration rate <60 mL/min/1.73 m^2)\\nAnticipating the need for immunosuppressive treatment within the next 6 months\\nResident in a long-term facility\\nCurrent vaping or smoking (occasional smoking is acceptable)\\nHistory of chronic smoking within the prior year\", \"study_population\": \"\", \"study_target_sample_size\": 96, \"study_obtained_sample_size\": 96, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry \\\"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\\\". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries.\", \"study_outcome_time_frame\": \"From Day 1 to Day 8 for Prime Immunization and from Day 22 to Day 29 for Boost Immunization\"}, {\"study_outcome_title\": \"Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry \\\"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\\\". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries.\", \"study_outcome_time_frame\": \"From Day 1 to Day 8 for Prime Immunization and from Day 22 to Day 29 for Boost Immunization\"}, {\"study_outcome_title\": \"The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Prime Immunization up to Boost Immunization or 28 Days After Prime Immunization\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Treatment emergent adverse events (TEAEs) were analyzed by age group, dose level, and for each IMP dose. The number and percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade >=3 TEAE) using the Safety Set.\", \"study_outcome_time_frame\": \"28 days following first IMP dose or up to second IMP dose (whichever was first)\"}, {\"study_outcome_title\": \"The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring up to 28 Days After Boost Immunization or After Prime Immunization (if no Boost Immunization)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Treatment emergent adverse events (TEAEs) were analyzed by age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade >=3 TEAE) using the Safety Set.\", \"study_outcome_time_frame\": \"28 days following second IMP dose or first IMP dose (if no second IMP dose as given)\"}, {\"study_outcome_title\": \"Functional Antibody Responses\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 7 and 21 days after primary immunization and at 7, 14, 21, 28 days after boost immunization.\", \"study_outcome_time_frame\": \"up to 50 days following first IMP dose\"}, {\"study_outcome_title\": \"Fold Increase in Functional Antibody Titers\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 7 and 21 days after primary immunization and at 7, 14, 21, and 28 days after the boost immunization.\", \"study_outcome_time_frame\": \"up to 50 days following first IMP dose\"}, {\"study_outcome_title\": \"Number of Subjects With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 7 and 21 days after primary immunization and at 7, 14, 21, and 28 days after the boost immunization.\", \"study_outcome_time_frame\": \"up to 50 days following first IMP dose\"}, {\"study_outcome_title\": \"Functional Antibody Responses\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 63, 162, 365 days after boost immunization.\", \"study_outcome_time_frame\": \"From 51 to up to 365 days following first IMP dose\"}, {\"study_outcome_title\": \"Fold Increase in Functional Antibody Titers\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 63, 162, 365 days after boost immunization.\", \"study_outcome_time_frame\": \"From 51 to up to 365 days following first IMP dose\"}, {\"study_outcome_title\": \"Number of Subjects With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"At 63, 162, 365 days after boost immunization.\", \"study_outcome_time_frame\": \"From 51 to up to 365 days following first IMP dose\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04556318","content":"{\"resource_id\": \"NCT04556318\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04556318\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"HC-N-H-2004\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"B. Braun Melsungen AG\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"23.09.2020\", \"study_end_date\": \"11.06.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"SARS-CoV-2-Polymerase chain reaction (PCR) test result is available\\nSigns or symptoms of any respiratory system infection or Signs or symptoms indicating SARS-CoV-2 infection or Radiological findings suggesting viral lung infection\\nBreath test (Study intervention) must be performed within a 2 day time period after latest SARS-CoV-2 PCR\", \"study_eligibility_exclusion_criteria\": \"History of SARS-CoV-2 outside the current respiratory episode (known from medical history)\\nParticipation in another clinical study prior to breath analysis which could influence the result of the breath analysis\", \"study_population\": \"Patients with signs or symptoms of any respiratory system infection or signs or symptoms indicating SARS-CoV-2 infection or radiological findings suggesting viral lung infection\", \"study_target_sample_size\": 396, \"study_obtained_sample_size\": 396, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"SARS-CoV-2 related volatile organic compounds (VOC)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"1 hour after breath gas sampling\"}, {\"study_outcome_title\": \"To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 and diagnostic findings\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Within 3 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04568551","content":"{\"resource_id\": \"NCT04568551\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor - CAASPtrial\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CAASP\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04568551\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"UKGEB001\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Marcus Riemer, MD\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Martin-Luther-Universit\\u00e4t Halle-Wittenberg\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Martin-Luther-Universit\\u00e4t Halle-Wittenberg\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Anxiety State\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"30.10.2020\", \"study_end_date\": \"31.07.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Female\"], \"study_eligibility_inclusion_criteria\": \"consenting ability\", \"study_eligibility_exclusion_criteria\": \"language barrier\\nuncompleted questionary\", \"study_population\": \"pregnant women between 33 until 37 weeks of Gestations with planned Labor in University Hospital of Halle or St.Elisabeth and St.Barbara Hospital Halle, Germany\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": 300, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"anxiety for anomalies during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for anomalies in pandemics\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"anxiety for stillbirths during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for stillbirths in pandemics\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"anxiety for preterm labour during COVID-19-pandemic and before (percentage difference in agreement to the items of the questionnaire)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measurement of self-reported anxiety by a questionnaire and State-Trait Anxiety Inventory (STAI) and comparison with different empiric studies of anxiety for preterm labour in pandemics\", \"study_outcome_time_frame\": \"6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04569877","content":"{\"resource_id\": \"NCT04569877\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"GM-CSF\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ARDS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)\"}], \"resource_descriptions\": [{\"description\": \"COVID-19 pneumonia is induced by the newly emerging pandemic Severe acute respiratory Syndrome (SARS) coronavirus 2 and results in progression to the acute respiratory distress syndrome (ARDS). Apart from protective ventilation, fluid restriction, prone positioning and extracorporeal membrane oxygenation (ECMO), no specific therapeutic options exist to treat this devastating disease with a mortality rate of up to 50%. The growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) is widely recognized to promote differentiation and mobilization of different myeloid leukocyte subsets including neutrophils, tissue macrophages/dendritic cells or their circulating precursors. GM-CSF was found to be crucial for alveolar epithelial repair following hyperoxic and inflammatory lung injury.The aim of the current trial is to prevent progression to ARDS in COVID-19 pneumonia patients by preemptive GM-CSF Inhalation.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"GI-COVID\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04569877\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"KKS-279\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-001654-21\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Giessen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Severe Acute Respiratory Syndrome (SARS) Pneumonia\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 Pneumonia\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention ongoing\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"24.09.2020\", \"study_end_date\": \"30.12.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 9, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Signed informed consent form by the patient according to local regulations\\nMan or non-pregnant woman\\nAge \\u226518 years\\nWillingness of patients with reproductive potential to use highly effective contraceptive methods by practicing abstinence or by using at least two methods of birth control from the date of consent to the end of the study. If abstinence could not be practiced, a combination of hormonal contraceptive (oral, injectable, or implants) and a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used *.\\nLab-confirmed COVID-19 pneumonia where pneumonia is diagnosed by radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR clinical assessment (evidence of rales/crackles on exam) AND pulse oximeter oxygen saturation \\u2264 94% at room air in patients that do not have chronic hypoxia; or less than their baseline oxygenation in patients that suffer from chronic hypoxia\\nNegative serum pregnancy test in women of childbearing potentia\", \"study_eligibility_exclusion_criteria\": \"Pregnancy or breast feeding\\nAutoimmune thrombocytopenia, myelodysplastic syndromes with > 20% marrow blast cells\\nHistory or presence of hypersensitivity or idiosyncratic reaction to molgramostim (e.g. Leucomax\\u00ae) or to related compounds (e.g. Leukine\\u00ae)\\nPatient not able to use nebulizer device as well as immediately foreseeable mechanical ventilation of the patient\\nSimultaneous participation in another clinical trial with an experimental treatment\", \"study_population\": \"\", \"study_target_sample_size\": 63, \"study_obtained_sample_size\": 63, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Mechanical ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Need for mechanical ventilation within 15 days after randomization\", \"study_outcome_time_frame\": \"During 15 days\"}, {\"study_outcome_title\": \"Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale):\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Not hospitalized, no limitations on activities\\nNot hospitalized, limitation on activities;\\nHospitalized, not requiring supplemental oxygen;\\nHospitalized, requiring supplemental oxygen;\\nHospitalized, on non-invasive ventilation or high flow oxygen devices;\\nHospitalized, on invasive mechanical ventilation or ECMO;\\nDeath.\", \"study_outcome_time_frame\": \"At day 15 and day 29\"}, {\"study_outcome_title\": \"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] will be measured at day 0 (day before first dose), day 1-9, and day 15\", \"study_outcome_time_frame\": \"At day 0 (day before first dose), day 1-9, and day 15\"}, {\"study_outcome_title\": \"Oxygen supply\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Need for oxygen supply (l/min) to reach peripheral oxygen saturation of 98%\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 (24 hours/48 hours post dose) and day 15\"}, {\"study_outcome_title\": \"Clinical parameter: temperature\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Clinical parameter (4 times daily): temperature (\\u00b0C degree)\", \"study_outcome_time_frame\": \"Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Clinical parameter: blood pressure\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Clinical parameter (4 times daily): blood pressure (mmHg)\", \"study_outcome_time_frame\": \"Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Clinical parameter: heart beat\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Clinical parameter (4 times daily): hear beat (beats per minute)\", \"study_outcome_time_frame\": \"Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Clinical parameter: respiratory rate\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Clinical parameter (4 times daily): respiratory rate (breaths per minute)\", \"study_outcome_time_frame\": \"Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Presence of Severe acute respiratory syndrome coronavirus 2 nucleic acid by PCR test in swabs or tracheal aspirates/bronchoalveolar lavage\", \"study_outcome_time_frame\": \"Max. 48 hours before day 0 and at day 8-9\"}, {\"study_outcome_title\": \"Laboratory: C-reactive protein test\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"C-reactive protein test measures the amount of C-reactive protein in blood (mg/L)\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Laboratory: ferritin\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Ferritin test measures the amount of ferritin in the blood (ng/ml)\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Laboratory: Interleukin-6\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Interleukin-6 test (IL-6) measures the amount of IL-6 in the blood (pg/ml)\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Laboratory: procalcitonin\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Procalcitonin (PCT) test measures the amount of PCT in the blood in (\\u03bcg/l)\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Bacterial pneumonia\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Occurrence of secondary bacterial pneumonia\", \"study_outcome_time_frame\": \"At day 0, day 1-7, day 8-9 and day 15\"}, {\"study_outcome_title\": \"Vaso-active drugs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Days on vaso-active drugs in a 29-day period\", \"study_outcome_time_frame\": \"At day 29\"}, {\"study_outcome_title\": \"Mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"All-cause mortality\", \"study_outcome_time_frame\": \"At day 29\"}, {\"study_outcome_title\": \"GM-CSF\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"GM-CSF levels in serum\", \"study_outcome_time_frame\": \"At day 0 and day 1-7\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Study protocol will be provided after publication\", \"study_data_sharing_plan_supporting_information\": [\"Study protocol\"], \"study_data_sharing_plan_time_frame\": \"3 Months after publication\", \"study_data_sharing_plan_access_criteria\": \"Central server\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04575597","content":"{\"resource_id\": \"NCT04575597\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04575597\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"4482-002\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"MK-4482-002\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"PHRR201209-003186\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"jRCT2031210148\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-003368-24\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Merck Sharp & Dohme LLC\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Coronavirus Disease (COVID-19)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"19.10.2020\", \"study_end_date\": \"05.05.2022\", \"study_country\": [\"Argentina\", \"France\", \"United Kingdom\", \"South Africa\", \"Canada\", \"Russian Federation\", \"Spain\", \"Philippines\", \"Taiwan\", \"Ukraine\", \"Colombia\", \"United States\", \"Germany\", \"Chile\", \"Poland\", \"Italy\", \"Guatemala\", \"Egypt\", \"Israel\", \"Brazil\", \"Mexico\", \"Japan\", \"Sweden\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 173, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Has documentation of laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection \\u22645 days prior to the day of randomization. PCR is the preferred method; however with evolving approaches to laboratory confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral ribonucleic acid (RNA) or protein are allowed if authorized for use in the country. Serological tests that detect host antibodies generated in response to recent or prior infection are not allowed.\\nHad initial onset of signs/symptoms attributable to COVID-19 for \\u22645 days prior to the day of randomization and at least 1 of the following sign/symptom attributable to COVID-19 on the day of randomization.\\nHas mild or moderate COVID-19.\\nHas at least 1 characteristic or underlying medical condition associated with an increased risk of severe illness from COVID-19.\\nMales agree to the following during the intervention period and for at least 4 days after the last dose of study intervention: Either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception.\\nFemales are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP); or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for at least 4 days after the last dose of study intervention; a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention.\", \"study_eligibility_exclusion_criteria\": \"Is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization.\\nIs on dialysis or has reduced estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2 by the Modification of Diet in Renal Disease (MDRD) equation.\\nHas any of the following conditions: human immunodeficiency virus (HIV) with a recent viral load >50 copies/mL (regardless of CD4 count) or an AIDS-defining illness in the past 6 months, participants with HIV may only be enrolled if on a stable antiretroviral therapy regimen; a neutrophilic granulocyte absolute count <500/mm^3.\\nHas a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3X upper limit of normal at screening.\\nHas a platelet count <100,000/\\u03bcL or received a platelet transfusion in the 5 days prior to randomization.\\nIs taking or is anticipated to require any prohibited therapies.\\nIs unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.\\nHas hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.\\nHas any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.\", \"study_population\": \"\", \"study_target_sample_size\": 1734, \"study_obtained_sample_size\": 1734, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Percentage of participants who are hospitalized and/or die\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Hospitalization (all cause) is \\u226524 hours of acute care in a hospital or similar acute care facility. Death is due to any cause.\", \"study_outcome_time_frame\": \"Up to 29 days\"}, {\"study_outcome_title\": \"Percentage of participants with an adverse event (AE)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.\", \"study_outcome_time_frame\": \"Up to ~7 months\"}, {\"study_outcome_title\": \"Percentage of participants who discontinued study intervention due to an AE\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.\", \"study_outcome_time_frame\": \"Up to 6 days\"}, {\"study_outcome_title\": \"Time to sustained resolution or improvement of each targeted COVID-19 sign/symptom\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement of each sign/symptom will be assessed.\", \"study_outcome_time_frame\": \"Up to 29 days\"}, {\"study_outcome_title\": \"Time to progression of each targeted COVID-19 sign/symptom\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The number of days from randomization to the first day on or before study Day 29 for each targeted self-reported sign/symptom will be assessed.\", \"study_outcome_time_frame\": \"Up to 29 days\"}, {\"study_outcome_title\": \"WHO 11-point outcomes score on a scale\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 to 10 with higher score indicating clinical progression.\", \"study_outcome_time_frame\": \"Up to 29 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"http://engagezone.msd.com/ds_documentation.php\"}}"}
{"id":"NCT04581148","content":"{\"resource_id\": \"NCT04581148\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-Cov2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Pediatrics\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Determination of SARS-CoV2 Antibody Prevalence in Pediatric Patients\"}], \"resource_descriptions\": [{\"description\": \"Since the beginning of the year, the entire world has been concerned with a novel virus called SARS-CoV2. After the first case descriptions in Wuhan, there has been a rapid increase in the number of cases in Germany as well. In the case of a disease with the virus, the patients affected can suffer from a slight infection of the upper respiratory tract to severe lung failure and death. Since the beginning of the pandemic, an increasing number of complications such as thromboses, kidney failure and neurological damage have also been described. Interestingly, to date, children are usually less severely affected than adults, but the actual infection rates are probably similar to those of adults5 , although the actual prevalence in children is difficult to quantify and has so far been localized. The actual extent of the disease in children has also been little researched to date, and the same applies to pregnant women and their newborns.\\n\\nIn order to be able to understand the course of infection as well as possible and to protect the population, comprehensive testing is necessary. However, this poses great challenges for local health authorities. In addition, intensive research into possible therapy strategies and new vaccines is necessary. Here, however, the number of clinical trials in children is far behind. For adult patients, symptomatic therapies such as immunosuppressive drugs (dexamethasone) and controversially discussed antiviral drugs (e.g. ritonavir) are currently available. The medium-term goal, the establishment of a vaccine, seems to be within reach, but an exact date is not foreseeable.\\n\\nIn the future, in addition to the detection of the active virus by molecular diagnostic tests, the quantitative serological detection of antibodies will also be important in order to be able to make epidemiological statements about herd immunization or vaccination. An interim analysis of the SeBlueCo study showed a proportion of just 1.3% seropositive individuals among blood donors. Similar studies have already been registered and partially conducted throughout Germany. Some studies are also investigating pediatric patients, as both the routes of infection and the way the immune system deals with the virus are probably different from those in adults. Furthermore, the time course of antibody concentrations after infection with SARS-CoV2 and thus the duration of a safe immunity is much discussed. In this study, the investigators want to quantify the prevalence of SARS-Cov2 antibodies in children and adolescents during the pandemic, in order to describe the extent of antibody formation depending on various factors.\\n\\nAt the Children and Youth Clinic Erlangen, at least one blood sample will be taken from all inpatients and most of the patients treated as outpatients. At least one EDTA and one lithium heparin and often also one serum tube is taken. Due to the in-house laboratory, the analysis is designed for very small blood volumes. Therefore there is almost always some residual blood left in the blood tubes, which is then stored for about 7 days and only then discarded (reserve sample). For the study now planned, these residual blood samples from paediatric patients of the paediatric and adolescent clinic will serve as a basis for the analysis. The timing is such that 6, 12, 18 and 24 months after the outbreak of the pandemic in Germany, a SARS-Cov2 antibody prevalence of the local area will be determined. This will allow to investigate the local infection situation as well as the influence of a possibly available vaccination on the extent of immunization in the future.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SARS-CoV2_KIDS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04581148\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"405_20 Bc\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Erlangen-N\\u00fcrnberg Medical School\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Adrian Regensburger, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"adrian.regensburger@uk-erlangen.de\", \"role_phone\": \"+91318533118\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Antje Neubert, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"+91318533118\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS-Cov2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.10.2020\", \"study_end_date\": \"30.06.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 18, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"residual blood sample\", \"study_eligibility_exclusion_criteria\": \"insufficient blood in the residual blood sample\", \"study_population\": \"All patients who were treated in the respective month (M6, M12, M15, M18, M24) in the Department of Children and Adolescent Medicine as outpatients, inpatients or semi-inpatients.\", \"study_target_sample_size\": 7000, \"study_obtained_sample_size\": 7000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Prevalence of antibodies against SARS-CoV-2 at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Prevalence of antibodies against SARS-CoV-2 at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_time_frame\": \"Single assessment per patient in \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\"}, {\"study_outcome_title\": \"Quantitative antibodies against SARS-CoV-2 at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Quantitative antibodies against SARS-CoV-2 at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_time_frame\": \"Single assessment per patient in \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\"}, {\"study_outcome_title\": \"Rate of SARS-CoV-2 antibodies in comparison between month M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Rate of SARS-CoV-2 antibodies in comparison between month M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\", \"study_outcome_time_frame\": \"Single assessment per patient in \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\"}, {\"study_outcome_title\": \"Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Stratification of the antibodies against SARS-Cov-2 with patient characteristics (age, gender, clinical history) at timepoint \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\", \"study_outcome_time_frame\": \"Single assessment per patient in \\\"M6, M12, M15, M19, M21, M22, M23, M24, M25 and M26\\\"\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04619407","content":"{\"resource_id\": \"NCT04619407\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"epidemiology\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"antibody formation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"serology\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Screening for SARS-CoV-2-Infections in Teachers, Childcare Educators, Pupils and Preschoolers in the State of Mecklenburg-Vorpommern\"}], \"resource_descriptions\": [{\"description\": \"Detailed Description:\\n\\nThis study aims to collect information on teachers and childcare educators as well as on pupils and preschoolers in the State of Mecklenburg-Vorpommern\\n\\nOver a 5 month period, 5 study visits per participant are planned. At each visit, nasal/throat swabs (for PCR testing) will be collected and participants will be asked to fill in a questionnaire (asking for SARS-CoV-2 risk factors, perceived risk, and impact of the pandemic on their quality of life). In adults, additional blood samples (for SARS-CoV-2 antibody testing) will be collected at the first and the last study visit. This will help to gain a better understanding of viral load and antibody development over time.\\n\\nThe remaining blood samples will be stored in a repository for future research.\\n\\nThe study is part of a modular SARS-CoV-2-research programme of the University Medicine Greifswald.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COKITS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04619407\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"BB 179/20\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Medicine Greifswald\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Ministry of Education, Science and Culture of the State of Mecklenburg-Vorpommern\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Ministry of Social Affairs, Integration and Equality of the State of Mecklenburg-Vorpommern\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"State Office for Health and Social Affairs of the State of Mecklenburg-Vorpommern\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"04.11.2020\", \"study_end_date\": \"26.03.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 3, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 67, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"Teachers and childcare educators as well as pupils and preschoolers\", \"study_target_sample_size\": 142, \"study_obtained_sample_size\": 142, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"5 months\"}, {\"study_outcome_title\": \"Seroprevalence of SARS-CoV-2 antibodies\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)\", \"study_outcome_time_frame\": \"At study inclusion\"}, {\"study_outcome_title\": \"Seroprevalence of SARS-CoV-2 antibodies\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)\", \"study_outcome_time_frame\": \"5 months\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"At study inclusion\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"1 month\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"2 months\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"4 months\"}, {\"study_outcome_title\": \"SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"As assessed by a monthly questionnaire\", \"study_outcome_time_frame\": \"5 months\"}, {\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"At study inclusion\"}, {\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"1 month\"}, {\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"2 months\"}, {\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"3 months\"}, {\"study_outcome_title\": \"Share of participants with SARS-CoV-2 detectable in PCR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)\", \"study_outcome_time_frame\": \"4 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"serum, nasal/throat swabs\"}}}"}
{"id":"NCT04649931","content":"{\"resource_id\": \"NCT04649931\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Study to Evaluate Whether Differences in Exhaled Breath Can be Identified Using Ion Mobility Spectrometry (IMS) in Subjects Tested Positive for SARS-CoV-2 Infection and Subjects Tested Negative\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04649931\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"HC-N-H-2006\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"B. Braun Melsungen AG\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"CeGaT GmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS (Severe Acute Respiratory Syndrome)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"14.12.2020\", \"study_end_date\": \"25.04.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"PCR (= Polymerase Chain Reaction) testing for SARS CoV-2 will be/has been performed in a timely manner of sampling exhaled breath or PCR test for SARS-CoV-2 was performed within 96 hours, but preferably within 48 hours before sampling exhaled breath and PCR test result is already available\\nSubject must be able to comply with study-specific procedures, e.g.is able to comply with breathing commands\", \"study_eligibility_exclusion_criteria\": \"Previous (history) SARS-CoV-2 infection, independent of the current episode\\nParticipation in a therapeutic study prior to breath analysis which could influence the result of the breath analysis\", \"study_population\": \"Adult patients with suspected or diagnosed SARS-CoV-2 infection.\", \"study_target_sample_size\": 450, \"study_obtained_sample_size\": 450, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"SARS-CoV-2 related volatile organic compounds (VOC)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"1 hour after breath gas sampling\"}, {\"study_outcome_title\": \"To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 (Corona Virus Disease 2019)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"within 1 hour\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04674189","content":"{\"resource_id\": \"NCT04674189\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Vaccine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Immunogenicity\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Safety\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04674189\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CV-NCOV-005\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"CureVac AG\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"German Federal Ministry of Education and Research\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Coronavirus\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Severe Acute Respiratory Syndrome\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"23.12.2020\", \"study_end_date\": \"08.06.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Male or female participants 18 years of age or older.\\nHealth care workers (HCWs), employees or students in clinical training.\\nProvide written informed consent prior to initiation of any trial procedures.\\nExpected compliance with protocol procedures and availability for clinical follow-up through the last planned visit.\\nFemales of non-childbearing potential defined as follows: surgically sterile (history of bilateral tubal ligation/occlusion, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as amenorrhea for \\u226512 consecutive months prior to screening [Day 1] without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the investigator to confirm postmenopausal status.\\nFemales of childbearing potential: negative urine pregnancy test (human chorionic gonadotropin within 24 hours prior to each trial vaccination on Day 1 and Day 29.\\n\\nFemales of childbearing potential must use highly effective methods of birth control from 2 weeks before the first administration of the trial vaccine until 3 months following the last administration. The following methods of birth control are considered highly effective when used consistently and correctly:\\n\\nCombined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal);\\nProgestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable);\\nIntrauterine devices (IUDs);\\nIntrauterine hormone-releasing systems (IUSs);\\nBilateral tubal ligation;\\nVasectomized partner;\\nSexual abstinence (periodic abstinence [e.g., calendar, ovulation, symptothermal and post-ovulation methods] and withdrawal are not acceptable).\", \"study_eligibility_exclusion_criteria\": \"History of virologically confirmed SARS-CoV-2 infection or SARS-CoV-2 positive serology.\\nFor females: pregnancy or lactation.\\nUse of any investigational or non-registered product (vaccine or drug) within 28 days preceding the administration of the first trial vaccine or planned use during the trial.\\nReceipt of licensed vaccines within 28 days (for live vaccines) or 14 days (for inactivated vaccines) prior to the administration of trial vaccine.\\nPrior administration of any investigational SARS-CoV-2 vaccine or other coronavirus (SARS-CoV, MERS-CoV) vaccine or planned use during the trial.\\nAny treatment with immunosuppressants or other immune-modifying drugs (including but not limited to corticosteroids, biologicals and methotrexate) for > 14 days total within 6 months preceding the administration of trial vaccine or planned use during the trial. For corticosteroid use, this means prednisone or equivalent, 0.5 mg/kg/day for 14 days or more. The use of inhaled, topical, or localized injections of corticosteroids (e.g., for joint pain/inflammation) is permitted.\\nAny medically diagnosed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination including known infection with human immunodeficiency virus (HIV), current diagnosis of or treatment for cancer including leukemia, lymphoma, Hodgkin disease, multiple myeloma or generalized malignancy; chronic renal failure or nephrotic syndrome; and receipt of an organ or bone marrow transplant.\\nActive or chronic disease of, or currently on treatment for, hepatitis B virus (HBV) or hepatitis C virus (HCV).\\nHistory of angioedema (hereditary or idiopathic), or a history of any anaphylactic reaction.\\nHistory of Potential immune-mediated disease (pIMD).\\nHistory of allergy to any component of CVnCoV vaccine.\\nAdministration of immunoglobulins or any blood products within 3 months prior to the administration of trial vaccine, or planned receipt during the trial.\\nParticipants with a significant acute or chronic medical or psychiatric illness that, in the opinion of the investigator, precludes trial participation (e.g., may increase the risk of trial participation, render the participant unable to meet the requirements of the trial, or may interfere with the participant's trial evaluations). These include severe and/or un-controlled cardiovascular disease, gastrointestinal disease, liver disease, renal disease, respiratory disease, endocrine disorder, and neurological and psychiatric illnesses.\\nParticipants with impaired coagulation or any bleeding disorder in whom an intramuscular (IM) injection or a blood draw is contraindicated. However, those with controlled and stable cases can be included in the trial.\\nForeseeable non-compliance with protocol as judged by the Investigator.\", \"study_population\": \"\", \"study_target_sample_size\": 2351, \"study_obtained_sample_size\": 2351, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Number of Participants with Medically-attended Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 211\"}, {\"study_outcome_title\": \"Intensity of Medically-attended Adverse Events per Investigator's Assessment\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 211\"}, {\"study_outcome_title\": \"Number of Participants with Medically-attended Adverse Events Considered Related to Trial Vaccine\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 211\"}, {\"study_outcome_title\": \"Number of Participants with One or More Serious Adverse Events (SAEs)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Intensity of Serious Adverse Events (SAEs) per Investigator's Assessment\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with One or More Adverse Events of Special Interest (AESIs)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Intensity of Adverse Events of Special Interest (AESIs) per Investigator's Assessment\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with One or More Serious Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with Death due to a Serious Adverse Event (SAE)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with Adverse Events (AEs) Leading to Vaccine Withdrawal or Study Discontinuation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 29 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants with Solicited Local Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Duration of Solicited Local Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Number of Participants with Solicited Systemic Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Duration of Solicited Systemic Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"7 days after vaccination\"}, {\"study_outcome_title\": \"Number of Participants with Unsolicited Adverse Events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28 days after vaccination\"}, {\"study_outcome_title\": \"Intensity of Unsolicited Adverse Events per the Investigator's Assessment\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28 days after vaccination\"}, {\"study_outcome_title\": \"Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"28 days after vaccination\"}, {\"study_outcome_title\": \"Individual SARS-CoV-2 Spike (S) Protein-Specific Antibody Levels in Serum\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured using Enzyme-Linked Immunosorbent Assay (ELISA).\", \"study_outcome_time_frame\": \"Days 1, 29 and 43\"}, {\"study_outcome_title\": \"Number of Participants Seroconverting for SARS-CoV-2 Spike (S) Protein Antibodies\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured using Enzyme-Linked Immunosorbent Assay (ELISA). Seroconversion is defined as detectable SARS-CoV-2 RBD of S protein antibodies in the serum of participants who tested seronegative on prior to vaccination on Day 1.\", \"study_outcome_time_frame\": \"Days 1, 29 and 43\"}, {\"study_outcome_title\": \"Number of Participants that Contract COVID-19 of Any Severity\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 1 to Day 393\"}, {\"study_outcome_title\": \"Number of Participants that Contract Mild, Moderate, Severe and Moderate to Severe COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 1 to Day 393\"}, {\"study_outcome_title\": \"Burden of Disease (BoD) Score Based on First Episodes of Virologically-confirmed Cases of COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Day 1 to Day 393\"}, {\"study_outcome_title\": \"Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured by a virus neutralizing assay in a subset of participants.\", \"study_outcome_time_frame\": \"Days 1, 29 and 43\"}, {\"study_outcome_title\": \"Number of Participants Seroconverting to SARS-CoV-2\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured by a virus neutralizing assay in a subset of participants.\", \"study_outcome_time_frame\": \"Days 1, 29 and 43\"}, {\"study_outcome_title\": \"Individual Serum Antibodies to Spike (S) Protein of SARS-CoV-2\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured by a virus neutralizing assay in a subset of participants.\", \"study_outcome_time_frame\": \"Day 43\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04680858","content":"{\"resource_id\": \"NCT04680858\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"endoscopic procedure\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"team communication\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"endoscopy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Impact of Digital Enhanced Telecommunication for Team Communication in Endoscopic Procedures During COVID-19 Pandemic\"}], \"resource_descriptions\": [{\"description\": \"Optimal communication is crucial for team work in high class endoscopy. Team work is highly challenged by the COVID-19 pandemic. Necessary protective equipment as FFP-mask and face shields impair communication significantly. Digital enhanced approaches to maintain team communication during endoscopic procedures are mandatory not only in actual circumstances.\\n\\nMaterials and methods:A prospective, two-armed interventional study will be performed at an endoscopy unit at a tertiary center. 200 endoscopic examinations (EGD, colonoscopy, EUS, ERCP) were randomly assigned (1:1) to a group that was performed with DECT equipped endoscopy team or with standard communication. All examinations were performed under protective equipment. Primary outcome was rate of communication associated adverse events. Secondary outcomes included team subjectively perceived comfort with DECT enhanced communication during endoscopic work, duration of examinations, SAE.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"EndoCom\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04680858\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"122020\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Thomas Seufferlein\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"University of Ulm\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Ulm\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Two-armed study\", \"study_conditions\": [{\"study_conditions\": \"Endoscopy\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Communication\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"Yes\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.07.2020\", \"study_end_date\": \"15.02.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 68, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Member of staff of the endoscopic team (Doctor, nurse)\", \"study_eligibility_exclusion_criteria\": \"Deafness\\nsignificantly impaired hearing\", \"study_population\": \"\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Communication associated adverse events\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Adverse events arising from impaired communication by COVID-19 protection equipment\", \"study_outcome_time_frame\": \"From start to stop of endoscopic procedure\"}, {\"study_outcome_title\": \"Severe adverse events\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Severe adverse evatent, not arising from from impaired communication by COVID-19 protection equipment\", \"study_outcome_time_frame\": \"From start to stop of endoscopic procedure\"}, {\"study_outcome_title\": \"Subjective Comfort of DECT communication\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Subjectiveley perceived level of comfort using DECT communication during endoscopic procedures rated by numeric rating scale (1-6)\", \"study_outcome_time_frame\": \"From start to stop of endoscopic procedure\"}, {\"study_outcome_title\": \"Endoscopic time\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Duration of performed endoscopic procedures\", \"study_outcome_time_frame\": \"From start to stop of endoscopic procedure\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04681430","content":"{\"resource_id\": \"NCT04681430\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"TMPRSS2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"camostat mesilate\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Covid-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"reconvalescent plasma\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals\"}], \"resource_descriptions\": [{\"description\": \"The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This trial focusses on SARS-CoV-2 positive patients with pre-existing risk factors for a moderate or severe COVID-19 disease course. This study is a 4-arm, multicenter, randomized, partly double-blind, controlled trial to evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe COVID-19. Camostat mesylate acts as an inhibitor of the host cell serine protease TMPRSS2 and prevents the virus from entering the cell. Convalescent plasma (CP) represents another antiviral strategy in terms of passive immunization. The working hypothesis to be tested in the RES-Q HR study is that the early use of convalescent plasma (CP) or camostat mesylate (Foipan\\u00ae) reduces the likelihood of disease progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"RES-Q-HR\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04681430\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"RES-Q-HR\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-004695-18\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Heinrich-Heine University, Duesseldorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"The Federal Ministry of Health, Germany (Bundesministerium f\\u00fcr Gesundheit, BMG)\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: The study is a multicenter trial that will be conducted in approx. 10 - 15 centers in Germany.\\n\\nAt each center, patients will be randomized into four groups: two treatment groups and two control groups. The randomization rate in this study is two to one (2:1) in favor to therapy, i.e.\\n\\nincluded patients have twice the chance to receive interventional therapy than placebo / SoC.\", \"study_conditions\": [{\"study_conditions\": \"Corona Virus Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2 Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2 PCR Test Positive\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV-2 Acute Respiratory Disease\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"08.01.2021\", \"study_end_date\": \"29.10.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 6, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Individuals (female, male, diverse) \\u2265 18 years with SARS-CoV-2 infection, confirmed by PCR before study enrollment\\nSARS-CoV-2 positive PCR \\u2264 3 days old (date of NP swab)\\nPresence of \\u2265 1 SARS-CoV-2 typical symptom (fever, cough, shortness of breath, sore throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms, exanthema) and symptom duration <= 3 days.\\nAbility to provide written informed consent\\n\\nPresence of at least one of the following criteria:\\n\\nPatients > 75 years\\nPatients > 65 years with at least one other risk factor (BMI >35 kg/m2, coronary artery disease, chronic kidney disease (CKD) with glomerular filtration rate (GFR) <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease)\\nPatients with a BMI >35 kg/m2 with at least one other risk factor (CAD, CKD with GFR <60 ml/min but >= 30 ml/min, diabetes mellitus, active tumor disease)\\nPatients with a BMI >40 kg/m2\\nPatients with chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis\", \"study_eligibility_exclusion_criteria\": \"Age <18 years\\nUnable to give informed consent\\nPregnant women or breast-feeding mothers\\nPrevious transfusion reaction or other contraindication to a plasma transfusion\\nKnown hypersensitivity to camostat mesylate and/or severe pancreatitis\\nVolume stress due to CP administration would be intolerable\\nKnown IgA deficiency\\nLife expectancy < 6 months\\nDuration SARS-CoV-2 typical symptoms > 3 days\\nSARS-CoV-2 PCR detection older than 3 days\\nSARS-CoV-2 associated clinical condition >= WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria).\\nPreviously or currently hospitalized due to SARS-CoV-2\\nPrevious antiviral therapy for SARS-CoV-2\\nalanine aminotransferase (ALT) or aspartate transferase (AST) > 5 times upper limit of normal (ULN) at screening\\nLiver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial)\\nChronic kidney disease with GFR < 30 ml/min\\nConcurrent or planned anticancer treatment during trial period\\nAccommodation in an institution due to legal orders (\\u00a740(4) AMG).\\nAny psycho-social condition hampering compliance with the study protocol.\\nEvidence of current drug or alcohol abuse.\\nUse of other investigational treatment within 5 half-lives of enrollment is prohibited\\nPrevious use of convalescent plasma for COVID-19\\nConcomitant proven influenza A infection\\nPatients with organ or bone marrow transplant in the three months prior to Screening Visit\", \"study_population\": \"\", \"study_target_sample_size\": 22, \"study_obtained_sample_size\": 22, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"WHO ordinal Covid-19 scale up to day 28\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale \\u2265 4b up to and including day 28\", \"study_outcome_time_frame\": \"up to and including day 28\"}, {\"study_outcome_title\": \"Cumulative number WHO categories 4b-8\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 4b-8\", \"study_outcome_time_frame\": \"day 8, day 14, day 56 and day 90\"}, {\"study_outcome_title\": \"Cumulative number WHO categories 3-4a\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 3-4a\", \"study_outcome_time_frame\": \"day 8, day 14, day 28, day 56 and day 90\"}, {\"study_outcome_title\": \"Not hospitalized\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Cumulative number of participants not hospitalized at day 90\", \"study_outcome_time_frame\": \"at day 90\"}, {\"study_outcome_title\": \"All-cause mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"All-cause mortality at day 90\", \"study_outcome_time_frame\": \"at day 90\"}, {\"study_outcome_title\": \"Reinfection\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of patient with SARS-CoV-2 reinfection up to day 90\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"Secondary sclerosing cholangitis (SSC)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of patient with secondary sclerosis cholangitis at day 90\", \"study_outcome_time_frame\": \"at day 90\"}, {\"study_outcome_title\": \"chronic pulmonary disease as sequelae from COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of patient with COVID-19 associated chronic pulmonary disease\", \"study_outcome_time_frame\": \"at day 90\"}, {\"study_outcome_title\": \"patients with remdesivir treatment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The proportion of patients with remdesivir therapy\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"COVID-19 WHO status of patients at start of remdesivir treatment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The clinical status on the WHO COVID-19 ordinal scale of at the start of remdesivir treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"patients with dexamethasone treatment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The proportion of patients on dexamethasone therapy\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"COVID-19 WHO status of patients at start of dexamethasone treatment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The clinical status on the WHO COVID-19 ordinal scale of at the start of dexamethasone treatment\\n\\nWHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"resolution of COVID-19 symptoms\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Time to resolution of COVID-19 related symptoms (e.g. fever)\", \"study_outcome_time_frame\": \"until day of resolution up to day 90\"}, {\"study_outcome_title\": \"negative SARS-CoV-2-PCR test\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Time to first negative SARS-CoV-2-PCR (polymerase chain reaction)\", \"study_outcome_time_frame\": \"until day of first negative test up to day 90\"}, {\"study_outcome_title\": \"Oxygen therapy\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Duration of oxygen therapy (in days)\", \"study_outcome_time_frame\": \"number of days with oxygen therapy up to day 90\"}, {\"study_outcome_title\": \"COVID-19 pneumonia\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Frequency of occurrence of COVID-19 pneumonia\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"Percentage of participants requiring mechanical ventilation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Percentage of participants in each group with need for mechanical ventilation\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"Number of ventilation days per participant up to day 90\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of ventilation days per participant up to day 90\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"hospital stay and intensive care\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Duration of hospital stay (in days), duration in intensive care/intermediate care (IMC) (in days)\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"Mortality\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"All-cause mortality at day 28\", \"study_outcome_time_frame\": \"at day 28\"}, {\"study_outcome_title\": \"SAEs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Cumulative incidence of Serious Adverse Events (SAE) per group within 90 days follow up\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"Grade 3/4 AEs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Cumulative incidence of grade 3/4 Adverse Events (AE) per group\", \"study_outcome_time_frame\": \"up to day 90\"}, {\"study_outcome_title\": \"SARS-CoV-2 antibody IgA concentrations\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 antibody concentrations (IgA in g/l) in serum on day 8, day 14, day 90\", \"study_outcome_time_frame\": \"on day 8, day 14, day 90\"}, {\"study_outcome_title\": \"SARS-CoV-2 antibody IgG concentrations\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 antibody concentrations (IgG in g/l) in serum on day 8, day 14, day 90\", \"study_outcome_time_frame\": \"on day 8, day 14, day 90\"}, {\"study_outcome_title\": \"SARS-CoV-2 neutralizing antibody titers\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 neutralizing antibody titers in serum on day 8, day 14, day 90\", \"study_outcome_time_frame\": \"on day 8, day 14, day 90\"}, {\"study_outcome_title\": \"Plasma treatment screening failures\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of screening failures due to the lack of a suitable plasma preparation\", \"study_outcome_time_frame\": \"up to day 8 (End of treatment)\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04732949","content":"{\"resource_id\": \"NCT04732949\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Interferon beta\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Coronavirus disease-2019 (COVID-19)\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Eligible patients with SARS-CoV-2 infection confirmed by a positive virus test and who are hospitalised due to COVID-19 and require oxygen therapy, will be randomised in a 1:1 ratio to receive SNG001 two syringes or placebo two syringes. SNG001 or placebo will be administered via the Ultra nebuliser. Patients will receive a dose of SNG001 or placebo once a day for 14 days and will be followed up for up to 90 days after the first dose of study medication. Study data will be collected from patients daily, as per the study schedule.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"SPRINTER\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04732949\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"SG018\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-004743-83\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Synairgen Research Ltd.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Severe Acute Respiratory Syndrome Coronavirus 2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"12.01.2021\", \"study_end_date\": \"10.02.2022\", \"study_country\": [\"Argentina\", \"Romania\", \"Portugal\", \"Israel\", \"Brazil\", \"Colombia\", \"United States\", \"Germany\", \"Belgium\", \"United Kingdom\", \"Mexico\", \"Netherlands\", \"Serbia\", \"Spain\", \"India\", \"Italy\", \"France\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 112, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Admitted to hospital due to the severity of their COVID-19\\nPositive virus test for SARS-CoV-2 using a validated molecular assay or antigen assay. Patients who had a positive virus test for SARS-CoV-2 prior to hospitalisation will be randomised no later than 48 hours after hospital admission. If the virus test is performed more than 96 hours prior to hospitalisation, the test will have to be repeated in the hospital prior to randomisation. Only patients whose repeated virus test is positive will be randomised, no later than 48 hours after confirmation of SARS-CoV-2 infection. Patients who had their first positive virus test for SARS-CoV-2 after hospitalisation will be randomised no later than 48 hours after confirmation of SARS-CoV-2 infection\\nRequire oxygen therapy via nasal prongs or mask (WHO OSCI score of 4)\\nProvided informed consent\\nFemale patients must be \\u22651 year post-menopausal, surgically sterile, or using a protocol defined highly effective method of contraception\\nWomen of child bearing potential should have been stable on their chosen method of birth control for a minimum of 3 months before entering the trial and should continue with birth control for 1 month after the last dose of inhaled interferon-\\u03b2 (IFN-\\u03b21a)/matching placebo. In addition to the highly effective method of contraception (except for the practice of total sexual abstinence), a condom (in United Kingdom with spermicides) should be used by the male partner for sexual intercourse from randomisation (Visit 2) and for 1 month after the last dose of inhaled IFN-\\u03b21a/matching placebo to prevent pregnancy\\nWomen not of childbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomisation without an alternative medical cause. The following age specific requirements apply: women <50 years old will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and if follicle stimulating hormone (FSH) levels are in the postmenopausal range; women \\u226550 years old will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment. If, in the setting of the pandemic, the use of an acceptable birth control method is not possible, the decision to enrol a woman of childbearing potential should be based on the benefit-risk for the patient, which should be discussed with the patient at the time of the informed consent.\", \"study_eligibility_exclusion_criteria\": \"Evidence of ongoing SARS-CoV-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay\\nNon-invasive ventilation continuous positive airway pressure/bilevel positive airway pressure (CPAP/BiPAP) or high-flow nasal oxygen therapy (WHO OSCI score of 5)\\nEndotracheal intubation and invasive mechanical ventilation (WHO OSCI score of \\u22656) or admission to intensive care\\nPrevious SARS-CoV-2 infection confirmed by a validated molecular assay or validated antigen assay\\nAny condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation\\nParticipation in previous clinical trials of SNG001\\nCurrent or previous participation in another clinical trial where the patient has received a dose of an Investigational Medicinal Product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study\\nInability to use a nebuliser with a mouthpiece\\nInability to comply with the requirements for storage conditions of study medication in the home setting\\nHistory of hypersensitivity to natural or recombinant IFN-\\u03b2 or to any of the excipients in the drug preparation\\nFemales who are breast-feeding, lactating, pregnant or intending to become pregnant.\", \"study_population\": \"\", \"study_target_sample_size\": 623, \"study_obtained_sample_size\": 623, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Time to hospital discharge\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"To evaluate the time to hospital discharge in patients with moderate COVID-19 after administration of SNG001 compared to placebo. Here, hospital discharge can be considered when World Health Organization (WHO) Ordinal Scale for Clinical Improvement (OSCI) score of 2 (limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}, {\"study_outcome_title\": \"Time to recovery\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"To evaluate recovery in patients with moderate COVID-19 after administration of SNG001 compared to placebo by time to recovery. Here, recovery is defined as the WHO OSCI score of 1 (no limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}, {\"study_outcome_title\": \"Progression to severe disease or death\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to severe disease or death. Progression to severe disease or death is defined by the WHO OSCI score of 5 (non-invasive ventilation or high-flow oxygen) or above within 35 days of first dose. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death. This is a key secondary endpoint.\", \"study_outcome_time_frame\": \"Day 1 until Day 35 or randomisation date if the patient is not dosed\"}, {\"study_outcome_title\": \"Progression to intubation or death\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing progression to intubation or death. Here, progression to intubation or death defined by the WHO OSCI score of 6 (intubation and mechanical ventilation) or above within 35 days of first dose. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death. This is a key secondary endpoint.\", \"study_outcome_time_frame\": \"Day 1 until Day 35 or randomisation date if the patient is not dosed\"}, {\"study_outcome_title\": \"Death within 35 days of first dose\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Death within 35 days of first dose, defined by the WHO OSCI score of 8 (death). This is a key secondary endpoint.\", \"study_outcome_time_frame\": \"Day 1 until Day 35 or randomisation date if the patient is not dosed\"}, {\"study_outcome_title\": \"Recovery as analysed at Days 7, 14, 21 and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing recovery. Recovery is defined as the WHO OSCI score of 1 (no limitation of activities) or below, with no rebound at subsequent assessments. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.\", \"study_outcome_time_frame\": \"Days 7, 14, 21 and 28\"}, {\"study_outcome_title\": \"Hospital discharge by days 7, 14, 21 and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing hospital discharge on given days.\", \"study_outcome_time_frame\": \"Days 7, 14, 21 and 28\"}, {\"study_outcome_title\": \"Number of patients with improvement based on entire WHO OSCI score by days 7, 14, 21 and 28\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing improvement across the entire WHO OSCI. Improvement in clinical status is based on the 9-point OSCI score. The score ranges from 0 to 8, where lower score of 0 represents no clinical or virological evidence of infection and higher score of 8 represents death.Higher scores indicated worse outcome.\", \"study_outcome_time_frame\": \"Days 7, 14, 21 and 28\"}, {\"study_outcome_title\": \"Change in total score according to the breathlessness, cough and sputum scale (BCSS) and disaggregated breathlessness and cough scores\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared with placebo in patients with moderate COVID-19 by assessing changes in daily breathlessness, cough and sputum scores on a scale of 0 (no symptoms) up to 4 (severe symptoms)\", \"study_outcome_time_frame\": \"Day 1 until Day 28 and then on Day 60 and Day 90\"}, {\"study_outcome_title\": \"Changes in National Early Warning Score (NEWS2) during the hospitalisation period\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing changes in NEWS2 during hospitalisation period. The NEWS2 is a tool which is used in detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes. Six physiological parameters such as: respiration rate, oxygen saturation, any supplementary oxygen, temperature, systolic blood pressure, heart rate, and alert, voice, pain, and unresponsive form the basis of the scoring system.\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}, {\"study_outcome_title\": \"Number of patients with presence of COVID-19 symptoms based on daily assessment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of COVID-19 symptoms. The presence of COVID-19 symptoms will be assessed. Individual symptoms related to COVID-19/SARS-CoV-2 infection such as fever, breathlessness, and fatigue will be assessed.\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}, {\"study_outcome_title\": \"Number of patients with limitations of usual activities based on daily assessment\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by daily assessment of limitation of usual activities. The patients with limitations of usual activities will be patients who are unable to do usual activities (work, study, housework, family or leisure activities).\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}, {\"study_outcome_title\": \"Quality of life measured using EuroQol 5-dimension 5-level (EQ-5D-5L)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by using EQ-5D-5L. The EQ-5D-5L provides a simple descriptive profile and a single index value for health status. The EQ-5D-5L self-rated questionnaire includes a visual analogue scale, which records the respondent's self-rated health status on a graduated (0-100) scale, with higher scores for higher health-related quality of life. It also includes the EQ-5D-5L descriptive system, which comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. Here, 100 means the best health and 0 means the worst health. The mobility, self-care and usual activities dimensions of the questionnaire will be assessed daily from Day 1 to Day 35.\", \"study_outcome_time_frame\": \"Day 0, Day 7, Day 15, Day 28, Day 60 and Day 90; Day 1 until Day 35 (mobility, self care and usual activities dimension)\"}, {\"study_outcome_title\": \"Number of patients with long-COVID-19 symptoms based on General Anxiety Disorder 7 Questionnaire (GAD-7)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To evaluate the efficacy of SNG001 compared to placebo in patients with moderate COVID-19 by assessing long-COVID-19 symptoms. Assessment of long-COVID-19 symptoms based on GAD-7. Scoring will be done based on how often patients have been bothered by the problems as: feeling nervous, anxious or on edge; not being able to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it's hard to sit still; becoming easily annoyed or irritable, and feeling afraid at if something awful might happen. The scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.\", \"study_outcome_time_frame\": \"Day 15, Day 28, Day 60 and Day 90\"}, {\"study_outcome_title\": \"Number of patients with long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessment of long-COVID-19 symptoms based on FACIT Fatigue Scale (Version 4). The FACIT Fatigue Scale (Version 4) will include statements for patients such as: I feel fatigued; I feel weak all over; I feel listless (\\\"washed out\\\"); I feel tired; I have trouble starting things because I am tired; I have trouble finishing things because I am tired; I have energy; I am able to do my usual activities; I need to sleep during the day; I am too tired to eat; I need help doing my usual activities; and I am frustrated by being too tired to do the things I want to do. Based on responses on above statements, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates very much bothered every day by any of the above problems. Higher scores indicated worse outcome.\", \"study_outcome_time_frame\": \"Day 15, Day 28, Day 60 and Day 90\"}, {\"study_outcome_title\": \"Number of patients with long-COVID-19 symptoms based on Patient Health Questionnaire-9 (PHQ-9)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessment of long-COVID-19 symptoms based on PHQ-9. Patient health questionnaire included: little interest or pleasure in doing things; feeling down, depressed, or hopeless; trouble falling asleep or staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself - or that you are a failure of have let yourself or your family down; trouble concentrating on things, such as reading the newspaper or watching television; moving or speaking so slowly that other people could have noticed or so fidgety or restless that you have been moving a lot more than usual; and thoughts that you would be better off dead; or thoughts of hurting yourself in some way. Based on responses on questionnaire, scoring will be done and scores ranges from 0 to 4, where 0 represents not at all bothered by any of the above problems and 4 indicates nearly bothered every day by any of the above problems. Higher scores indicated worse outcome.\", \"study_outcome_time_frame\": \"Day 15, Day 28, Day 60 and Day 90\"}, {\"study_outcome_title\": \"Number of patients with long-COVID-19 symptoms based on Brief Pain Inventory (Short Form)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Assessment of long-COVID-19 symptoms based on brief pain inventory form. Form include questionnaires as: did patient had pain other than everyday kinds of pain on assessment day; body part where patient feels pain; rate patient's pain: at worst, at least in the last 24 hours, at average, and at right now, by giving scores from 0 to 10, where 0 indicates no pain and 10 represents pain as bad as one can imagine; treatments or medications receiving for pain by patients; rate how much relief have pain treatments have provided from 0% to 100%, where 0% represents no relief and 100% indicates complete relief; assessment of interference of pain in following patients activity: general activity; mood; walking ability; normal work; relations with other people; sleep; enjoyment of life, and assessment will be done by scoring and scores ranges from 0 to 10, where 0 represents pain does not interfere and 10 indicates pain completely interferes in above activity.\", \"study_outcome_time_frame\": \"Day 15, Day 28, Day 60 and Day 90\"}, {\"study_outcome_title\": \"Number of patients with adverse events (AEs) and serious adverse events (SAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To assess the general safety and tolerability of SNG001 compared to placebo when administered to patients with moderate COVID-19 by assessing number of patients with AEs.\", \"study_outcome_time_frame\": \"Day 1 until Day 28\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04741412","content":"{\"resource_id\": \"NCT04741412\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"SARS-CoV-2 Infections in Children and Adolescents: Course of COVID-19, Immune Responses, Complications and Long-term Consequences in Entire Households With Members Younger Than 18 Years\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"PEDCOVID-19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04741412\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"212_20 B\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Prof. Dr. Holm Schneider\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"University Hospital Erlangen\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Hospital Erlangen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Hypohidrotic Ectodermal Dysplasia\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"03.06.2020\", \"study_end_date\": \"31.05.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"household with one or more members registered as patient(s) in the University Hospital Erlangen\\nat least one person <18 years of age\\nat least one household member who has or had a SARS-CoV-2 infection confirmed by a positive PCR test, detection of specific antibodies against this virus, or by development of COVID-19 symptoms after being in close contact with a person known to be infected with SARS-CoV-2\\ninformed consent\", \"study_eligibility_exclusion_criteria\": \"missing informed consent of one or more household members\\nlanguage barriers to communication that would prevent informed consent\", \"study_population\": \"households with children and/or adolescents and at least one member who has or had a SARS-CoV-2 infection\", \"study_target_sample_size\": 231, \"study_obtained_sample_size\": 231, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"age-dependence of SARS-CoV-2 infection\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"registry of household members with and without symptoms of COVID-19 (entire households)\", \"study_outcome_time_frame\": \"3 months from the point in time at which the first household member shows symptoms of COVID-19\"}, {\"study_outcome_title\": \"percentage of household members infected by SARS-CoV-2\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The infection rate is determined on the basis of specific PCR tests and detectibility of antibodies against SARS-CoV-2.\", \"study_outcome_time_frame\": \"3 months from the point in time at which the first household member shows symptoms of COVID-19\"}, {\"study_outcome_title\": \"duration of primary COVID-19 symptoms\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The possible association between the length of time with symptoms of COVID-19 and specific immune responses, in particular the development of virus-neutralizing antibodies, is studied.\", \"study_outcome_time_frame\": \"2 months from the onset of COVID-19 symptoms\"}, {\"study_outcome_title\": \"frequency of late-onset cardiovascular complications\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Patient-reported known and yet unknown long-term consequences of COVID-19 are registered and investigated further (questionnaire, specific data confirmed by clinical examination).\", \"study_outcome_time_frame\": \"2-12 months from the onset of COVID-19 symptoms\"}, {\"study_outcome_title\": \"frequency of postviral fatigue\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Patient-reported symptoms of fatigue are registered (questionnaire).\", \"study_outcome_time_frame\": \"2-12 months from the onset of COVID-19 symptoms\"}, {\"study_outcome_title\": \"frequency of noticeable temporary hair loss after COVID-19\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Patient-reported extent of hair loss is registered (questionnaire).\", \"study_outcome_time_frame\": \"2-12 months from the onset of COVID-19 symptoms\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"serum, peripheral blood mononuclear cells\"}}}"}
{"id":"NCT04743947","content":"{\"resource_id\": \"NCT04743947\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"kidney transplantation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vaccination\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"dialysis\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Observational Study on the Effects of SARS-CoV-2 Vaccination in Dialysis and Kidney Transplant Patients\"}], \"resource_descriptions\": [{\"description\": \"Patients on dialysis and kidney transplant patients infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) have an increased risk to develop a more severe course of disease or die from COVID-19 (coronavirus disease 2019). SARS-CoV-2 vaccination can increase protection against COVID-19. Kidney transplant patients and patients requiring dialysis suffer from an acquired immune deficiency. Due to the dysfunctional immune response, the general vaccine response in dialysis patients and kidney transplant patients is in many cases insufficient.\\n\\nUntil now, the vaccination response in dialysis patients and kidney-transplanted patients is unpredictable. Verification of vaccine response can provide important information on how to treat and protect these patients from a COVID-19. Therefore, there is a medical need to monitor vaccine protection after SARS-CoV-2 vaccination in clinical practice. In this observational study, data of the SARS-CoV-2 vaccination response collected in clinical routine will be analyzed from these patients. Based on this observational study, the investigators aim to get first evidence whether and to what extent vaccination against COVID-19 causes a vaccine response in immunocompromised patients with kidney disease.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04743947\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-1237\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"PD Dr. med. Johannes Stegbauer\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Heinrich-Heine University, Duesseldorf\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Heinrich-Heine University, Duesseldorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Johannes Stegbauer, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"johannes.stegbauer@med.uni-duesseldorf.de\", \"role_phone\": \"+492118117502\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Claudia Schmidt, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"claudia.schmidt@med.uni-duesseldorf.de\", \"role_phone\": \"+492118108074\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Chronic Kidney Disease Stage 5 on Dialysis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Chronic Kidney Disease Stage 5 With Transplant\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Vaccine Response Impaired\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"21.12.2020\", \"study_end_date\": \"31.12.2025\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 5, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"receiving dialysis (hemodialysis or peritoneal dialysis)\\ncapable of giving consent\\nage 18 or older\", \"study_eligibility_exclusion_criteria\": \"- non-capable of giving consent\", \"study_population\": \"Patients who are treated in a nephrology in- or out-patient clinic and how are willing to get a SARS-CoV-2 vaccination.\", \"study_target_sample_size\": 400, \"study_obtained_sample_size\": 400, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"SARS-CoV-2- antibody- titer\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SARS-CoV-2- antibody- titer after vaccine\", \"study_outcome_time_frame\": \"2 years\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04753242","content":"{\"resource_id\": \"NCT04753242\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"COVID-19 related psychosocial burden in patients, relatives and staff\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals - an International Online Survey of Psychosomatic, Psychiatric and Psychological Consultation and Liaison (C&L) Services\"}], \"resource_descriptions\": [{\"description\": \"Background:\\n\\nThe COVID-19 pandemic raised new challenges in supporting patients, relatives and staff for psychosomatic, psychiatric and psychological C&L services in general hospitals worldwide. It is intended to build upon the experience gained so far in order to be well prepared for the future.\\n\\nObjectives:\\n\\nThe aims of this international online survey are\\n\\nTo summarize the efforts made in psychosocial care in the context of the COVID-19 pandemic.\\nTo assess the experiences made with the established services so far.\\nTo assess the need for networking, cooperation and support.\\nImprovement of psychosocial care in acute hospitals in the context of pandemics.\\n\\nStudy Design:\\n\\nThis health services research project will be carried out as an observational study in the form of an international cross-sectional online survey.\\n\\nThere will be one survey time point. Study reporting will follow the STROBE Statement (Strengthening the Reporting of Observational Studies in Epidemiology).\\n\\nEthic approval:\\n\\nIn all participating countries the respective ethics committees were informed about the survey and it was checked with them, how far and what kind of country-specific vote of an ethics committee was necessary. Written statements, declarations or votes were obtained from all participating countries.\\n\\nSetting:\\n\\nThe heads of all psychosomatic, psychiatric and psychological C&L services in acute care hospitals across all participating countries are contacted and asked to participate. Contact is made via the respective national professional societies and relevant working and interest groups.\\n\\nParticipants This study is an international online survey with psychosomatic, psychiatric and psychological C&L services from 14 European countries (Austria, Belgium, Finland, Germany, France, Greece, Ireland, Italy, Norway, Poland, Portugal, Spain, Switzerland, United Kingdom) as well as parts of Canada (Quebec and Ontario region) and Iran participating.\\n\\nCountry specific regions:\\n\\nThe national coordinators of the participating country provided lists of specific regions for their respective country following the NUTS logic (Nomenclature of Territorial Units for Statistics; https://en.wikipedia.org/wiki/Nomenclature_of_Territorial_Units_for_Statistics), preferably a NUTS level that leads to 5 - 20 NUTS for each country.\\n\\nOnline survey questionnaire:\\n\\nSelf-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding characterization of the participating C&L services, involvement of the respective hospitals in the physical care of COVID-19 patients, structures / organization of psychosocial care for COVID-19 patients in the participating hospitals, specific psychosocial support for patients, relatives and staff established in the participating hospital in the context of COVID-19, communication - How the different target groups were informed about the COVID-19 related psychosocial support services and offers, burden of the COVID-19 pandemic on the psychosocial C&L teams, needs and wishes for the future.\\n\\nThe study questionnaire was translated by a professional company from German into English, French and Italian. Language harmonization and cultural adaptation followed a modified committee-based approach informed by the European Social Survey (ESS) Round 9 Translation Guidelines. Participants are free to choose the language version to be worked on.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04753242\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Req-2020-00861; th21Schaefert\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Hospital, Basel, Switzerland\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 Related Psychosocial Burden\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"08.12.2020\", \"study_end_date\": \"03.10.2021\", \"study_country\": [\"Norway\", \"Portugal\", \"Finland\", \"Germany\", \"Belgium\", \"United Kingdom\", \"Austria\", \"Poland\", \"Canada\", \"Ireland\", \"Greece\", \"Switzerland\", \"Spain\", \"Italy\", \"France\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 22, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"heads of all psychosomatic, psychiatric and psychological C&L services in acute care hospitals across all participating countries\", \"study_eligibility_exclusion_criteria\": \"None\", \"study_population\": \"The heads of all psychosomatic, psychiatric and psychological C&L services in acute care hospitals across all participating countries will be contacted and asked to participate. Contact will be made via the respective national professional societies and relevant working and interest groups\", \"study_target_sample_size\": 230, \"study_obtained_sample_size\": 230, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Structural and process quality of COVID-19 related psychosocial C&L services\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Data basis for improving quality of COVID-19 related psychosocial C&L services:\\n\\ncharacterization of participating C&L services\\ninvolvement of respective hospitals in the physical care of COVID-19 patients\\nstructures/ organization of psychosocial care for COVID-19 patients in participating hospitals\\n\\nspecific psychosocial support established in participating hospitals in context of COVID-19 for\\n\\npatients\\nrelatives\\nstaff\\ncommunication strategies - How the different target groups were informed about COVID-19 related psychosocial support services and offers\\nburden of COVID-19 pandemic on psychosocial C&L teams\\n\\nneeds and wishes of the participating psychosocial C&L services\\n\\nfor support or exchange of experience regarding psychosocial care in the COVID 19 context\\nfor changes / improvements considered essential for the future with regard to psychosocial care services in the participating hospitals in the COVID-19 context\", \"study_outcome_time_frame\": \"6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Cross-sectional\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04771585","content":"{\"resource_id\": \"NCT04771585\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Aerosols\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Face mask\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Exhaled particles\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Quantification of Exhaled Particles to Identify Airborne Transmission Risks of SARS-Co-V-2\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"QUELLE\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04771585\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"20-14 QUELLE\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Fraunhofer-Institute of Toxicology and Experimental Medicine\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: In part A of the study, aerosol emission of subjects will be characterized. From this population, the 10 highest-emitting subjects will enter part B of the study to investigate the effect of face masks on aerosol emission down to the submicron range.\", \"study_conditions\": [{\"study_conditions\": \"Healthy\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"29.03.2021\", \"study_end_date\": \"20.08.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 80, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Able and willing to give written informed consent.\\nHealthy male and female subjects, aged 18-80 years.\\nBody mass index between 18 and 35 kg/m2.\\nFEV1 \\u2265 80% predicted.\", \"study_eligibility_exclusion_criteria\": \"Any clinically relevant abnormal findings in physical examination or lung function at screening visit, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study.\\nRisk of non-compliance with study procedures.\\nSuspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.\\nHistory of an acute respiratory infection with symptoms such as cough, rhinitis, sore throat, hoarseness or fever, within four weeks prior to the informed consent visit. In case of acute respiratory infection during study participation, the visit may be rescheduled within the allowed time window. Subjects must be asymptomatic for at least 3 days. Re-screening is allowed should the time window be exceeded.\\nHistory of lung disease including but not confined to COPD, asthma or pulmonary fibrosis.\\nHistory of latex allergy.\", \"study_population\": \"\", \"study_target_sample_size\": 30, \"study_obtained_sample_size\": 30, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"To compare the emitted small particle fraction between various respiratory activities.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Change of particle number per time unit between tidal breathing and various respiratory activities.\", \"study_outcome_time_frame\": \"Day 1, Day 2 to 14\"}, {\"study_outcome_title\": \"To assess the influence of different face masks on the emitted small particle fraction of various respiratory activities.\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Change of particle number per time unit between tidal breathing and selected respiratory activities for community masks, surgical masks, FFP2 and FFP3 respirators in high-emitting subjects.\", \"study_outcome_time_frame\": \"After completion of Study part A (approximately 3 months)\"}, {\"study_outcome_title\": \"To assess the emitted particle size distribution of various respiratory activities.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Compare changes of emitted particle size spectrum as quantity per size range during tidal breathing and selected respiratory activities.\", \"study_outcome_time_frame\": \"Day 1, Day 2 to 14\"}, {\"study_outcome_title\": \"To assess the reproducibility of exhaled particle quantification.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Compare results for particle number per time unit and particle size spectrum from visit 1 and 2.\", \"study_outcome_time_frame\": \"Day 2 to 14\"}, {\"study_outcome_title\": \"To assess the influence of different face masks on the emitted particle size distribution of various respiratory activities.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Compare changes of emitted particle size spectrum as quantity per size range during tidal breathing and selected respiratory activities for community masks, surgical masks, FFP2 and FFP3 respirators in high-emitting subjects.\", \"study_outcome_time_frame\": \"After completion of Study part A (approximately 3 months)\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04779346","content":"{\"resource_id\": \"NCT04779346\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting: Prevalence and Serological Immunity in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf\"}], \"resource_descriptions\": [{\"description\": \"In this prospective observational study all cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE) will be included in the study upon consent.\\n\\nData will be collected as follows:\\n\\n(i) Serological antibody screening at study inclusion and every 3 months (ia) In case of vaccination monthly screening for 3 months (ii) Routine clinical data: demographic and biometric data, medical history, common laboratory parameters (iii) Patient questionnaire: assessment of past COVID-19 infection, past COVID-19 specific symptoms, social environment, vaccination\\n\\nRecruitment is limited to a one-year period (December 2020 - December 2021)\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVIDOUT\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04779346\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-10275-BO-ff\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4tsklinikum Hamburg-Eppendorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Marianne Sinn, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"ma.sinn@uke.de\", \"role_phone\": \"+49407410\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Martin Sch\\u00f6nlein, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"m.schoenlein@uke.de\", \"role_phone\": \"+49407410\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Cancer\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Immunity\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"21.12.2020\", \"study_end_date\": \"31.12.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Known diagnosis of cancer\\nActive disease or (in case of cure) last systemic therapy <12 months\\nSigned informed consent\", \"study_eligibility_exclusion_criteria\": \"Refusal of participation\", \"study_population\": \"The study population consists of cancer patients who are regularly treated in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf (UKE)\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Rate of SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"Up to 1 year\"}, {\"study_outcome_title\": \"Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"Up to 1 year\"}, {\"study_outcome_title\": \"Rate of unknown prior COVID19 disease in SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Rate of cancer entities in SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Rate of therapy modalities in SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Subgroup analysis of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dependency of rate on cancer entity, therapy modality, age, sex and immune status [Measured in percentage]\", \"study_outcome_time_frame\": \"Up to 1 year\"}, {\"study_outcome_title\": \"Rate of re-infection in SARS-CoV-2 antibody positive patients\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Measured in percentage\", \"study_outcome_time_frame\": \"1 year\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"Aggregated data will be shared\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04797091","content":"{\"resource_id\": \"NCT04797091\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Kidney in Coronavirus Disease 2019 Registry\"}], \"resource_descriptions\": [{\"description\": \"The SARS-CoV-2 virus is a virus newly identified in January 2020 in Wuhan, China, which belongs to the group of coronaviruses and causes COVID-19. Due to the rapid spread worldwide, high morbidity and virulence the of causing SARS-CoV-2 , the WHO defined COVID-19 as a health emergency of international importance in February 2020. Due to the rapid spread of the new virus, a comprehensive understanding of the transmission, the course of the disease, the diagnosis and the therapeutic regimen is of the utmost importance. Initial case reports indicate that human-to-human transmission takes place through droplet infection. In contrast to previously known infections from the group of coronaviruses, the SARS-CoV-2 virus has a high ability to infect with already mild symptoms resulting in frequent outbreak situation of worldwide importance. Furthermore, high viral loads are found in the upper respiratory tract of infected people leading to the high virulence of causing SARS-CoV-2. The clinical manifestation of the COVID-19 disease cannot be fully described in the short time. However, symptoms of SARS-CoV-2 virus infection are described with mild symptoms like fever, muscle pain, and dry cough as well as severe complications like virus pneumonia, Acute Respiratory Distress Syndrome (ARDS) and death. Interestingly older and chronically ill patients in particular have a severe course of COVID-19 with intensive care treatment and high mortality. At present, there is no specific therapy available for COVID-19. Treatment approaches are primarily supportive with admission of patients to the intensive care unit (ICU), mechanical ventilation, extracorporeal membrane oxygenation (ECMO) and maintenance of fluid and electrolyte balance. Patients with severe renal insufficiency and fluid retention, pulmonary edema or hyperkalemia may require dialysis. First insights in patients suffering from acute kidney injury (AKI) during COVID-19 indicate severe course with high mortality. First case reports do not describe a beneficial effect of antiviral therapy. The locally varying spread of SARS CoV-2 infection requires a better understanding of clinical course of COVID-19 in order to be able to establish future treatment approaches. Investigators have to attach great importance to high-risk cohorts like patients suffering from chronic renal disease with many comorbidities or patients after kidney transplantation under immunosuppressive drug treatment. Although COVID-19 has been studied for only a few month it is known that especially these patients develop a severe clinical course. Due to increasingly frequent outbreak situations and globally chances in species distributions, local, as well as worldwide surveillances in epidemiology and species distribution are urgently needed. As the clinical course of COVID-19 disease is dependent on the causing viral pathogen and the full picture of clinical manifestation is not yet understand further studies with regard to the disease course are mandatory.\\n\\nAdditionally, the examination of attributable mortality and costs of COVID-19 will need to be studied on a multinational basis and therefore Kidney in COVID-19 Registry will particularly use a matched case control design.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"KidneyCOVID19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04797091\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Kidney in COVID-19\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Volker Burst\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"University of Cologne\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Cologne\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Felix K\\u00f6hler, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"felix.koehler@uk-koeln.de\", \"role_phone\": \"+4922147897222\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Victor Suarez, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"victor.suarez@uk-koeln.de\", \"role_phone\": \"+4922147897222\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Case-control\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Corona Virus Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV 2\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"20.04.2020\", \"study_end_date\": \"31.08.2026\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Virology evidence of SARS-CoV-2-infection\\nPathological evidence of SARS-CoV-2-infection\", \"study_eligibility_exclusion_criteria\": \"Occurrence of ARDS (acute respiratory distress syndrome) without evidence of SARS-CoV-2 infection\\nAcute kidney injury without evidence of SARS-CoV-2 infection\", \"study_population\": \"Particularly, controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital).\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Determination of the global incidence of SARS-CoV-2 infections\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Determination of the global incidence of SARS-CoV-2 infections and the resulting effects on kidney function as well as monitoring of global and local developments over time.\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of the incidence of acute kidney damage in the context of SARS-CoV2 infections\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Identification of risk groups and risk factors\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Identification of risk groups and risk factors by examining SARS-CoV-2 infections in patients with chronic kidney disease and kidney transplantation\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Documentation of mortality rates due to SARS-CoV-2 infections\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Documentation of mortality rates in % in comparison to case controls enrolled in the same hospital\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"Documentation of additional costs due to SARS-CoV-2 infections\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Documentation of additional costs in euros in comparison to case controls enrolled in the same hospital\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"To assess increasing costs associated with SARS-CoV-2-infections\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To assess increasing costs associated with SARS-CoV-2-infections\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"To analyze the effect of SARS-CoV-2-infections on the kidney by means of eGFR\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To analyze the effect of SARS-CoV-2 infections on kidney function as determined by estimated Glomerular Filtration Rate (eGFR) after SARS-CoV-2 infection\", \"study_outcome_time_frame\": \"6 months\"}, {\"study_outcome_title\": \"To analyze the effect of SARS-CoV-2-infections on the kidney by means of maximum creatinine\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"To analyze the effect of SARS-CoV-2 infections on kidney function as determined by maximum creatinine after SARS-CoV-2 infection\", \"study_outcome_time_frame\": \"6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Retrospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04799873","content":"{\"resource_id\": \"NCT04799873\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin\"}], \"resource_descriptions\": [{\"description\": \"The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CORSAAR-AAT\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04799873\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CORSAAR-AAT-001\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Robert Bals\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4t des Saarlandes\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4t des Saarlandes\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"08.04.2020\", \"study_end_date\": \"01.12.2020\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 110, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Infection with SARS-COV2\\nAge over 18 years\", \"study_eligibility_exclusion_criteria\": \"Unability to consent\\nInvasive ventilation\", \"study_population\": \"All COVID-19 patients without need for invasive ventilation\", \"study_target_sample_size\": 10, \"study_obtained_sample_size\": 10, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Clinical course\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Disease course such as death, need for ICU treatment, ventilatory support or deterioration are monitored\", \"study_outcome_time_frame\": \"3 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"Serum, RNA, DNA, EDTA plasma\"}}}"}
{"id":"NCT04822701","content":"{\"resource_id\": \"NCT04822701\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://clinicaltrials.gov/show/NCT04822701\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04822701\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Boehringer Ingelheim\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Other\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"\\n\\n        Inclusion criteria phase II and III:\\n\\n\\n\\n          -  = 18 years old, males and females\\n\\n\\n\\n          -  Signed and dated written informed consent in accordance with International Council on\\n\\n             Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to\\n\\n             admission to the trial\\n\\n\\n\\n          -  Documentation of laboratory-confirmed Severe acute respiratory syndrome coronavirus 2\\n\\n             (SARS-CoV-2) infection, as determined by a molecular test (antigen or nucleic acid)\\n\\n             from any respiratory tract specimen (nasopharyngeal (NP) or nasal swab or saliva)\\n\\n             collected no more than 72 hours prior to start of treatment\\n\\n\\n\\n          -  Patients experienced mild to moderate Coronavirus Disease 2019 (COVID-19)-related\\n\\n             symptoms or measured fever for no more than 5 days prior to start of treatment where\\n\\n             symptoms are defined by fever, feeling feverish, fatigue, cough, shortness of breath\\n\\n             at rest or during activity, sore throat, body pain or muscle pain/ aches, chills,\\n\\n             headache, nasal obstruction or congestion, loss of smell or taste, nausea, diarrhea,\\n\\n             vomiting, or dysgeusia\\n\\n\\n\\n          -  One or more of the following signs/symptoms present on day of start of treatment:\\n\\n             fever, feeling feverish, fatigue, cough, shortness of breath at rest or during\\n\\n             activity, sore throat, body pain or muscle pain/ aches, chills, headache, nasal\\n\\n             obstruction or congestion, loss of smell or taste, nausea, diarrhea, vomiting, or\\n\\n             dysgeusia\\n\\n\\n\\n          -  Women of childbearing potential (WOCBP) and men able to father a child must be ready\\n\\n             and able to use highly effective methods of birth control per ICH M3 (R2) that result\\n\\n             in a low failure rate of less than 1% per year when used consistently and correctly\\n\\n\\n\\n        Exclusion criteria phase II and III:\\n\\n\\n\\n          -  Body weight of less than 40 kg\\n\\n\\n\\n          -  Severe or critical COVID-19 including at least one of\\n\\n\\n\\n               -  Oxygen saturation (SpO2) = 93 % on room air or on their usual level of oxygen\\n\\n                  supplementation in case of chronic oxygen use\\n\\n\\n\\n               -  Ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to\\n\\n                  fractional inspired oxygen (FiO2) < 300 (in case arterial blood sample was taken)\\n\\n\\n\\n               -  History of hospitalization for COVID-19\\n\\n\\n\\n               -  Current or imminent need for hospitalization or immediate medical attention in\\n\\n                  the clinical opinion of the site investigator. Does not include patients\\n\\n                  hospitalized for isolation only\\n\\n\\n\\n          -  Receipt of intravenous immunoglobulin within 12 weeks prior to Visit 2\\n\\n\\n\\n          -  Receipt of COVID-19 convalescent plasma treatment at any time prior to Visit 2\\n\\n\\n\\n          -  Receipt of any SARS-CoV-2 monoclonal antibody treatment at any time prior to Visit 2\\n\\n\\n\\n          -  Receipt of SARS-CoV-2 vaccine at any time prior to Visit 2\\n\\n\\n\\n          -  Receipt of an investigational product for COVID-19 within 5 half-lives prior to Visit\\n\\n             2\\n\\n\\n\\n          -  Receipt of systemic steroids (e.g. prednisone, dexamethasone) within 4 weeks prior to\\n\\n             Visit 2 unless used for chronic condition Further exclusion criteria apply.\\n\\n\\n\\n        Exclusion criterion phase III only:\\n\\n\\n\\n        - Previous enrolment in this trial. Patients participating in Phase II are not eligible for\\n\\n        Phase III. Re-screening is allowed once, for repeat of Quantitative Reverse Transcription\\n\\n        Polymerase chain reaction (RT-qPCR) or antigen SARS-CoV-2 test, if required. The test\\n\\n        method used for initial screening (RT-qPCR or antigen) should be used for re-screening.\\n\\n      \", \"study_eligibility_exclusion_criteria\": \"\", \"study_population\": \"\", \"study_target_sample_size\": 5, \"study_obtained_sample_size\": null, \"study_age_min_examined\": 18.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Phase III: Hospitalization or death from any cause by Day 29;Phase II: Time-weighted change from baseline in viral shedding over 8 days in site collected nasopharyngeal (NP) swabs by Quantitative Reverse Transcription Polymerase chain reaction (RT-qPCR), defined as a change from baseline in log10 viral load\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). \\nRecruitment status: Not recruiting\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2-phase-3\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"Drug: Placebo inhaled;Drug: Placebo intravenous;Drug: BI 767551 inhaled;Drug: BI 767551 intravenous\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
{"id":"NCT04826770","content":"{\"resource_id\": \"NCT04826770\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"immune response\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vaccine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"immunokinetics\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"vaccination\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Blood Donations From Healthy Probands for the Study of the Adaptive Immune Response to COVID-19 Vaccination (AICOVI)\"}], \"resource_descriptions\": [{\"description\": \"AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at elucidating the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers at the Greifswald University hospital.\\n\\nParticipants were recruited before their intended vaccination. Participants received the basic immunization with either two i. m. doses of BNT162b2 (Comirnaty\\u00ae, tozinameran (INN), BioNTech/Pfizer) with a time interval of 21 days or two i. m. dose of AZD 1222 (Vaxzevria\\u00ae, Covishield\\u00ae, ChadOx1 nCoV-19, Oxford University/Astra-Zeneca) with a time interval of 12 weeks (homologous vaccination), or one i. m. dose of AZD 1222 as the first vaccination and one i. m. dose of BNT162b2 or mRNA-1273 (Spikevax\\u00ae, elasomeran (INN), Moderna) as the second vaccination with a time interval of at least 4 weeks (heterologous vaccination). Approximately 6 months later, participants received a booster vaccination with BNT162b2.\\n\\nWithin the study, volunteers donate peripheral blood by venipuncture on each day of vaccination as well as 7 and 14 days after each vaccination. EDTA plasma and peripheral mononuclear cells (PBMCs) are prepared and stored at -20 \\u00b0C.\\n\\nVolunteers are also asked to complete a standardized questionnaire on each day of blood sampling. Questionnaires collect data about physical characteristics, COVID-19 vaccination, previous SARS-CoV-2 infection as well as current infections, medication, immune relevant diseases and side effects of the vaccination.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"AICOVI\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04826770\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"BB 001/21f\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University Medicine Greifswald\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"SARS-CoV-2 Vaccination\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention ongoing\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"06.01.2021\", \"study_end_date\": \"31.12.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Planned participation in COVID-19 vaccination\\nCompletion of the 18th year of life\\nverbal and written consent given\", \"study_eligibility_exclusion_criteria\": \"current infectious diseases\\nunderweight (BMI<18,5)\\nblood coagulation disorders, anemia or similar diseases\\nknown congenital or acquired immunodeficiencies\\n\\nInclusion criteria for control/validation group of TRP participants:\\n\\ninformed written consent\", \"study_population\": \"Employees at the University Medicine Greifswald, Germany, who plan to be vaccinated against COVID-19\", \"study_target_sample_size\": 70, \"study_obtained_sample_size\": 70, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production and cumulative antibody titer on the day of the 1st vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted on the day of the 1st vaccination.\", \"study_outcome_time_frame\": \"1 day\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 7 days after the 1st vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 7 days after the 1st vaccination.\", \"study_outcome_time_frame\": \"7 days after the 1st vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 14 days after the 1st vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 14 days after the 1st vaccination.\", \"study_outcome_time_frame\": \"14 days after the 1st vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production on the day of the 2nd vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted on the day of the 2nd vaccination.\", \"study_outcome_time_frame\": \"day of the 2nd vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 7 days after the 2nd vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 7 days after the 2nd vaccination.\", \"study_outcome_time_frame\": \"7 days after the 2nd vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 14 days after the 2nd vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 14 days after the 2nd vaccination.\", \"study_outcome_time_frame\": \"14 days after the 2nd vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production and cumulative antibody titer on the day of the booster vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts.\\n\\nFor this purpose PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted on the day of the booster vaccination.\", \"study_outcome_time_frame\": \"1 day\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 7 days after the booster vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 7 days after the booster vaccination.\", \"study_outcome_time_frame\": \"7 days after the booster vaccination\"}, {\"study_outcome_title\": \"mean current anti-SARS-CoV-2 antibody production 14 days after the booster vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Serum antibody titers represent a cumulative measure of any preceded or recent immune responses. The current antibody production can be quantified using MENSA (medium enriched for newly synthesized antibodies), an approach that measures antibodies released from recently stimulated circulating antibody-secreting plasmablasts. For this purpose, PBMCs are collected from the subject's whole blood sample, washed to remove serum antibodies, and then cultured for 7 days. Antibodies released ex vivo from the antibody-secreting plasmablasts can now be detected in the culture supernatant. These newly synthesized antibodies are a measure of the instantaneous antibody response.\\n\\nSampling is conducted 14 days after the booster vaccination.\", \"study_outcome_time_frame\": \"14 days after the booster vaccination\"}, {\"study_outcome_title\": \"plasma antibody levels against SARS-CoV-2\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Anti-SARS-CoV-2 antibodies are quantified using ELISA and/or xMAP(R) technology.\", \"study_outcome_time_frame\": \"On each day of vaccination as well as 7 and 14 days after each vaccination\"}, {\"study_outcome_title\": \"immune cell phenotyping (B cells, T cells)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"flow cytometry-based analyses\", \"study_outcome_time_frame\": \"On each day of vaccination as well as 7 and 14 days after each vaccination\"}, {\"study_outcome_title\": \"Characterization of antibody proteomics profile changes after vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The antibody profile in plasma is assessed using mass spectrometry.\", \"study_outcome_time_frame\": \"On each day of vaccination as well as 7 and 14 days after each vaccination\"}, {\"study_outcome_title\": \"Characterization of the cytokine profile elicited after vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The cytokine profile elicited after vaccination is assessed using a multiplex immunoassay.\", \"study_outcome_time_frame\": \"On each day of vaccination as well as 7 and 14 days after each vaccination\"}, {\"study_outcome_title\": \"Measurement of neutralizating antibodies after vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Neutralizing antibodies are measured by neutralization tests.\", \"study_outcome_time_frame\": \"On each day of vaccination as well as 7 and 14 days after each vaccination\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"EDTA plasma, peripheral blood mononuclear cells\"}}}"}
{"id":"NCT04834869","content":"{\"resource_id\": \"NCT04834869\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Vaccines\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Safety\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Side Effects\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVID-19 Vaccines Safety Tracking: Global Consortium Study\"}], \"resource_descriptions\": [{\"description\": \"Introduction:\\n\\nCOVID-19 vaccines are the foremost asset to overcome the ongoing pandemic; therefore, mass vaccination has become a high priority for the world's governments. While vaccination strategies need to be accelerated to minimise daily fatalities and relieve the pandemic's economic burdens, vaccine hesitancy (VH) remains a serious challenge for these efforts. VH refers to \\\"delay in acceptance or refusal of vaccines despite availability of vaccine services\\\",; and it is an emerging public health challenge nourished by misinformation related to vaccines effectiveness and safety. Aversion to vaccines' potential side effects is the most frequent cause of VH among population groups. Therefore, a recent systematic review revealed that raising public awareness of vaccines' effectiveness and side effects is vital for improving vaccine uptake.\\n\\nPublic health systems globally experience a novel and unique challenge due to the variety of vaccines manufacturers and the high levels of public awareness about those manufacturers and their marketing strategies. This unprecedented situation is predicted to create what we can refer to as \\\"vaccine selectivity, \\\" increasing the pressure on our weakened health systems and economies and increasing vaccine hesitancy levels. Independent (non-sponsored) studies with rigorous methods can perfectly lead the pharmacovigilance efforts of COVID-19 vaccines globally. Given their independent nature and transparent design, these studies can play a key role in suppressing vaccine hesitancy levels by enhancing public confidence in vaccines.\\n\\nDesign\\n\\nThis project comprises two phases; a) a cross-sectional survey for the short-term side effects of COVID-19 vaccines; b) a prospective cohort study for the long-term safety of COVID-19 vaccines.\\n\\nPhase A:\\n\\nA validated self-administered questionnaire will be developed and delivered online to the target population groups (HCW, OA & ST). The questionnaire will be inquiring about the short-term side effects that emerged within 30 days following the vaccine shot (either the first or the second dose). The side effects will be classified as local or systemic, and their onset, duration, and intensity will be self-assessed and self-reported by the respondents. This phase is proposed to take place until December 31st, 2021.\\n\\nPhase B:\\n\\nA validated self-administered questionnaire will be developed and delivered online to the volunteers who participated in Phase A and expressed their interest to report their long-term side effects. In this phase, the vaccine effectiveness and side effects will be evaluated after booster doses. Phase B will take place for five consecutive years starting from 2022.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04834869\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CoVaST\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Masaryk University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Miloslav Klugar, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"klugar@med.muni.cz\", \"role_phone\": \"+420549495676\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Abanoub Riad, DDS\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"abanoub.riad@med.muni.cz\", \"role_phone\": \"+420549496572\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Adverse Reaction to Vaccine\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID19 Vaccine\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.04.2021\", \"study_end_date\": \"31.12.2026\", \"study_country\": [\"Ethiopia\", \"Portugal\", \"Slovenia\", \"United States\", \"Germany\", \"Estonia\", \"Croatia\", \"Mexico\", \"Canada\", \"Ghana\", \"Poland\", \"Russian Federation\", \"Serbia\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 14, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"HCW, OA and ST who received COVID-19 vaccine.\\nParticipating subjects should be at least 18-year-old and able to give their informed consent independently.\", \"study_eligibility_exclusion_criteria\": \"Non HCW, OA and ST who received the COVID-19.\", \"study_population\": \"In Phase A, a pragmatic approach will track each target group according to the governmental plan; in most countries, it went from HCW to OA to ST. The sample of Phase B will be pre-identified based on the outcome of Phase A. If \\u2265 25% of HCW, 10% of OA and 10% of ST of Phase A showed their interest to join Phase B, no additional recruitment will be required. If < 25% of HCW, 10% of OA and 10% of ST of Phase A showed their interest in Phase B, additional recruitment will be carried out targeting healthcare workers who will receive booster doses. In case of the emergence of special side effects after booster doses, additional recruitment of healthcare workers will be required.\", \"study_target_sample_size\": 30000, \"study_obtained_sample_size\": 30000, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Local Side Effects\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Dichotomous outcome for the emergence of local side effects (e.g. injection site pain, injection site swelling, and injection site redness)\", \"study_outcome_time_frame\": \"0-30 days after the COVID-19 vaccine shot\"}, {\"study_outcome_title\": \"Systemic Side Effects\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Dichotomous outcome for the emergence of systemic side effects (e.g. fever, chills, headache, fatigue, nausea, diarrhea, etc)\", \"study_outcome_time_frame\": \"0-30 days after the COVID-19 vaccine shot\"}, {\"study_outcome_title\": \"Unrecognized Side Effects\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dichotomous outcome for the emergence of oral and dermatologic side effects (e.g. oral paresthesia, oral ulcers, dysgeusia, skin rash, acne, urticaria, etc)\", \"study_outcome_time_frame\": \"0-30 days after the COVID-19 vaccine shot\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04849598","content":"{\"resource_id\": \"NCT04849598\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"long-term oxygen therapy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post SARS-CoV-2 infection\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"automatic oxygen-titration\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"hypoxemia\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Effects of an Automatic Oxygen Titration vs. Constant Oxygen Flow Rates During Daily Activities in Patients After SARS-CoV-2 Infection\"}], \"resource_descriptions\": [{\"description\": \"Rationale\\n\\nAfter an infection with SARS-CoV-2, some patients still experience hypoxemia even after being discharged from the hospital. Long-term oxygen therapy (LTOT) is then used to increase the patients blood oxygen level and prolong the time spent within the SpO2 target range, decreasing the probability of severe hypoxemia or at least lowering the time spent in this severe hypoxemia and all in all enhance the patient's endurance. A prescription for LTOT is usually given for constant flow rates which might vary during day- and night use.\\n\\nThis study is a randomized, controlled cross-over trial. Its aim is to investigate the effects of an automatic oxygen titration in patients after SARS-CoV-2 infection on the blood oxygen saturation level during activities of daily life (walking). Secondary, the effects of using an automatic titration on endurance, pCO2 blood level as well as heart rate and breathing frequency are compared to using the prescribed constant flow oxygen therapy.\\n\\nDesign:\\n\\nEach patient undergoes a series of shuttle walk tests. After an initial incremental shuttle walk test (ISWT) to determine the patient's maximum walking speed, the patient undergoes 2 endurance shuttle walk tests (ESWTs) at 85% of the maximum walking speed. One of these ESWTs is performed with the prescribed constant oxygen flow, the other with the O2matic automatic oxygen titration in a random order.\\n\\nIn addition to the shuttle walk tests, patient will perform two stair walking tests, again one with the prescribed constant oxygen flow, the other with the O2matic automatic oxygen titration in a random order.\\n\\nFurthermore, patients will be asked to rate their experienced comfort after each ESWT and to name their preferred oxygen titration system.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04849598\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"O2matic_COVID\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Prof. Dr. Andreas Rembert Koczulla\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Sch\\u00f6n Klinik Berchtesgadener Land\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Sch\\u00f6n Klinik Berchtesgadener Land\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Post-COVID19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"13.04.2021\", \"study_end_date\": \"27.08.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"validated COVID19 disease in case history\\nhypoxemia (PO2 < 55 mmHg) under room air conditions (rest or during exercise) or SpO2 <88% during exercise\\nalready established Long-term oxygen therapy or given indication for a Long-term oxygen therapy\", \"study_eligibility_exclusion_criteria\": \"acute infection\\ncardiovascular diseases that limit physical fitness\\northopedic diseases preventing the patient from undergoing the walking tests\", \"study_population\": \"\", \"study_target_sample_size\": 15, \"study_obtained_sample_size\": 15, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Change of oxygen saturation during the endurance shuttle walk Tests\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SpO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor\\u00ae (Sentec, Therwil, Switzerland)\", \"study_outcome_time_frame\": \"Day 2, 3\"}, {\"study_outcome_title\": \"Change of transcutaneous pCO2 during ESWTs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"tc pCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor\\u00ae (Sentec, Therwil, Switzerland)\", \"study_outcome_time_frame\": \"Day 2, 3\"}, {\"study_outcome_title\": \"Change of heart rate during ESWTs and stair walking tests\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Heart rate measured by continuous transcutaneous recording via Sentec-Digital Monitor\\u00ae (Sentec, Therwil, Switzerland)\", \"study_outcome_time_frame\": \"Day 2, 3, 4\"}, {\"study_outcome_title\": \"Change of respiratory rate during ESWTs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Respiratory rate measured by ApneaLink Air\\u2122\", \"study_outcome_time_frame\": \"Day 2, 3\"}, {\"study_outcome_title\": \"Change of time to desaturation (SpO2 \\u2264 90%) and to severe desaturation (SpO2 \\u2264 85%) during ESWTs and Stair Walking Tests\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SpO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor\\u00ae (Sentec, Therwil, Switzerland) and O2matic Device.\", \"study_outcome_time_frame\": \"Day 2, 3, 4\"}, {\"study_outcome_title\": \"Change of Endurance time (s)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Change of Walking Duration during the ESWT and Stair Walking Tests\", \"study_outcome_time_frame\": \"Day 2, 3, 4\"}, {\"study_outcome_title\": \"Change of capillary partial pressure of CO2 (pCO2) during endurance shuttle walk tests\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"pCO2 measured by capillary blood gases taken before and after the ESWT\", \"study_outcome_time_frame\": \"Day 2, 3\"}, {\"study_outcome_title\": \"Change of capillary partial pressure of O2 (pO2) during endurance shuttle walk tests\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"pO2 measured by capillary blood gases taken before and after the ESWT\", \"study_outcome_time_frame\": \"Day 2,3\"}, {\"study_outcome_title\": \"Patients preference due to oxygen delivery system\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Patients will be asked to rate their experienced comfort after each ESWT\", \"study_outcome_time_frame\": \"Day 3\"}, {\"study_outcome_title\": \"Change of number of stairs\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Change of the number of stairs the patient was able to climb during Stair Walking Tests\", \"study_outcome_time_frame\": \"Day 4\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04869358","content":"{\"resource_id\": \"NCT04869358\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2 mRNA vaccine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"MS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Relapsing Multiple Sclerosis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"immune response\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"adult\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"RMS\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Ofatumumab\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS)\"}], \"resource_descriptions\": [{\"description\": \"This is a two cohort, multicenter, open-label, prospective study of 40 (optionally up to 60) patients with relapsing multiple sclerosis (RMS) planning to undergo a SARS-CoV-2 mRNA vaccination (initial vaccinations or booster vaccines) as part of clinical routine. The maximal duration of the study for an individual patient is 22 months.\\n\\nThe first cohort will be RMS patients receiving SARS-CoV-2 mRNA vaccine (initial vaccinations or booster vaccines) as part of clinical routine prior to starting ofatumumab treatment.\\nThe second cohort will be participants receiving SARS-CoV-2 mRNA vaccine (initial vaccinations or booster vaccines) as part of clinical routine while already stable on ofatumumab treatment for at least 4 weeks (since first dose).\\n\\nDevelopment of SARS-CoV-2 specific T-cells and functional anti-SARS-CoV-2 antibodies will be investigated for up to 18 months after the participants' vaccination.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"KYRIOS\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04869358\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COMB157GDE01\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Novartis Pharmaceuticals\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Novartis Pharmaceuticals\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"novartis.email@novartis.com\", \"role_phone\": \"+41613241111\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Novartis Pharmaceuticals\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Multiple Sclerosis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"27.05.2021\", \"study_end_date\": \"30.07.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 8, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 100, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Relapsing Multiple Sclerosis (RMS) diagnosis\\neligible for ofatumumab treatment\\nwilling and eligible to receive SARS-CoV-2 mRNA vaccine\", \"study_eligibility_exclusion_criteria\": \"known prior or current COVID-19 infection\\nprevious treatment with BTK inhibitor or anti-CD20 therapy other than ofatumumab\\n\\nOther protocol-defined inclusion/exclusion criteria may apply\", \"study_population\": \"\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": 40, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Percentage of RMS patients having established SARS-CoV-2-specific T cells after receiving a modRNA vaccine\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Detection of SARS-CoV-2 specific T-cells measured at the central laboratory e.g. by enzyme-linked immunosorbent spot (ELIspot) assay from peripheral blood mononuclear cells\", \"study_outcome_time_frame\": \"at 1 month after second dose of vaccine or booster vaccine\"}, {\"study_outcome_title\": \"Percentage of participants achieving seroconversion\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 neutralizing antibodies measured at the central laboratory\", \"study_outcome_time_frame\": \"at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine\"}, {\"study_outcome_title\": \"Percentage of participants maintaining SARS-CoV-2 specific T-cells\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Maintenance of SARS-CoV-2 specific T-cells over time measured at the central laboratory e.g. by enzyme-linked immunosorbent spot (ELIspot) assay from peripheral blood mononuclear cells\", \"study_outcome_time_frame\": \"at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine\"}, {\"study_outcome_title\": \"Immunophenotyping of peripheral blood mononuclear cells\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Phenotypic description of the cellular immune response performed at the central laboratory by FACS analysis\", \"study_outcome_time_frame\": \"at baseline, 1 week, 1 , 6, 12 and 18 months after second dose of vaccine or 1,6 and 12 months after booster vaccine\"}, {\"study_outcome_title\": \"Number of treatment emergent adverse events, serious adverse events and COVID-19 infections\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Untoward medical occurrences (including abnormal laboratory tests, vital signs and other safety assessments) will be captured as adverse events including COVID-19 infections\", \"study_outcome_time_frame\": \"Up to 18 months after second dose of vaccine or 12 months after booster vaccine\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\\n\\nThis trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04898062","content":"{\"resource_id\": \"NCT04898062\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"CRP-apheresis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19\"}], \"resource_descriptions\": [{\"description\": \"The prognostic value of C-reactive protein (CRP) in assessing disease progression in COVID-19 is well known: The steeper the CRP rise in the days after infection and the higher the CRP concentration at hospitalization, the worse the prognosis. It is believed that CRP concentration not only reflects tissue damage but also causally contributes to the severity of the damage that occurs. CRP apheresis effectively limits CRP rise, which may lead to improved prognosis. CRP apheresis is a therapeutic hemapheresis procedure that selectively removes C-reactive protein from the patient's plasma. Other causal therapies for immediate selective reduction of CRP in the acute phase of disease are not currently available.\\n\\nIn the planned 'CAPMYKCO' study, CRP-apheresis in addition to current standard COVID-19 therapy is expected to mitigate the severity of disease progression, particularly with regard to tissue injury in the lungs, the heart and/or the kidneys and their respective clinical consequences.\\n\\nCRP-apheresis treatment in COVID-19 patients should reduce the necessity and duration of non-invasive / invasive ventilation compared to the control group.\\n\\nThe influence of CRP-apheresis on the course of the COVID-19 disease will also be demonstrated by evaluating different organ biomarkers and the duration of intensive medical treatment.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CAPMYKCO\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04898062\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"21-10018-BO\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Pentracor GmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Matthias Thielmann, Prof.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"matthias.thielmann@uk-essen.de\", \"role_phone\": \"+49201 723 84908\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Wolfgang Ristau\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"wolfgang.ristau@uk-essen.de\", \"role_phone\": \"+494201 723 84927\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"05.05.2021\", \"study_end_date\": \"31.03.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 4, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Confirmed SARS CoV-2 infection (PCR-test)\\nOxygen therapy (maximum 'high-flow' therapy)\\nCRP plasma concentration \\u2265 50 mg/l and/or\\nCRP increase \\u2265 15 mg/l within 24 h after admission.\\nCompleted informed consent and written informed consent.\\nLegal capacity\", \"study_eligibility_exclusion_criteria\": \"Age < 18 years\\nPregnancy / lactation period\\nInvasive, mechanical ventilation\\nExtracorporeal membrane oxygenation (ECMO)\\nParticipation in other interventional trials\\nExtracorporeal membrane oxygenation (ECMO) support\\nParticipation in other interventional trials\", \"study_population\": \"\", \"study_target_sample_size\": 50, \"study_obtained_sample_size\": 50, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Necessity and duration of non-invasive/ invasive ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"In the intervention group, a reduced necessity and duration of non-invasive/ invasive ventilation is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Length of intensive care unit stay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a shorter intensive care unit stay is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Necessity of endotracheal intubation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduced necessity of endotracheal intubation is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Reduction of lung injury\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduced lung injury as reflected by peripheral oxygen saturation, oxygen supplementation, Horovitz index, lung injury score is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Reduction of myocardial damage\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduced myocardial damage as reflected by hs troponin, creatin kinase, creatin kinase MB fraction is expected.\", \"study_outcome_time_frame\": \"up to 10 days\"}, {\"study_outcome_title\": \"Reduction of kidney damage\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduced kidney damage as reflected by creatinine, glomerular filtration rate, onset of dialysis, CKD stadium is expected.\", \"study_outcome_time_frame\": \"up to 10 days\"}, {\"study_outcome_title\": \"Improvement in general immune status\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, an improved general immune status as reflected by CRP, fibrinogen, leukocytes, thrombocytes and lactate dehydrogenase is expected.\", \"study_outcome_time_frame\": \"up to 10 days\"}, {\"study_outcome_title\": \"Cardiovascular, respiratory and renal SOFA score\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, improvements in cardiovascular, respiratory and renal SOFA scores are expected.\\n\\n*(Vincent JL: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. In:Intensive Care Med 1996:22;707-10.)\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Respiratory events\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduction of respiratory events (pulmonary embolism) is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Myocardial events\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduction of cardial events (cardiac arrhythmias, myocardial infarction, cardiopulmonary resuscitation, low cardiac output syndrome (LCOS), operation, percutaneous coronary intervention (PCI), angina pectoris) is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Renal events\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, a reduction of renal events (onset of dialysis requirement, deterioration of renal function (CKD increase) is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}, {\"study_outcome_title\": \"Safety of CRF apheresis\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"In the intervention group, the absence of serious incidents is expected.\", \"study_outcome_time_frame\": \"through study completion, an average of 14 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT04908722","content":"{\"resource_id\": \"NCT04908722\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04908722\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CR108960\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2020-005801-14\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"VAC31518COV3003\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Janssen Vaccines & Prevention B.V.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Study Contact\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"Participate-In-This-Study@its.jnj.com\", \"role_phone\": \"844-434-4210\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19 Prevention\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"18.06.2021\", \"study_end_date\": \"28.12.2023\", \"study_country\": [\"Brazil\", \"United States\", \"Germany\", \"Poland\", \"South Africa\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 55, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 55, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study\\nParticipant must be healthy, in the investigator's clinical judgment, as confirmed by medical history, physical examination, and vital signs performed at screening. Participant may have underlying illnesses, as long as the symptoms and signs are medically controlled and not considered to be comorbidities related to an increased risk of severe Coronavirus disease 2019 (COVID-19), except for smoking, which is allowed. If on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participant will be included on the basis of physical examination, medical history, and vital signs\\nAll female participants of childbearing potential must: a) have a negative highly sensitive urine pregnancy test at screening; b) have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration\\nParticipant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine\\nParticipant must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study\", \"study_eligibility_exclusion_criteria\": \"Participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (>=) 38.0 degree Celsius (C) (100.4 degree Fahrenheit [F]) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor\\nParticipant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)\\nParticipant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of the first or subsequent study vaccinations; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of the first or subsequent study vaccinations\\nParticipant received an investigational drug (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational immunoglobulin (Ig) or monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study\\nParticipant previously received a coronavirus vaccine\", \"study_population\": \"\", \"study_target_sample_size\": 1590, \"study_obtained_sample_size\": 1590, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Main Study: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Concentration Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.\", \"study_outcome_time_frame\": \"28 days after first vaccination (Day 29)\"}, {\"study_outcome_title\": \"Main Study: ELISA Geometric Mean Concentrations (GMCs) 28 Days After First Vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Non-inferiority (NI) will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.\", \"study_outcome_time_frame\": \"28 days after first vaccination (Day 29)\"}, {\"study_outcome_title\": \"Main Study: SARS-CoV-2 S Protein Binding Antibodies Concentration Measured by ELISA 14 Days After Second Vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.\", \"study_outcome_time_frame\": \"14 days after second vaccination (Day 71)\"}, {\"study_outcome_title\": \"Main Study: ELISA GMCs 14 Days After Second Vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"NI will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.\", \"study_outcome_time_frame\": \"14 days after second vaccination (Day 71)\"}, {\"study_outcome_title\": \"Main and Sub Study: Serological Response to Vaccination to SARS-COV-2 S Protein as Measured by ELISA\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Serological response to vaccination to SARS-COV-2 S protein as measured by ELISA will be reported.\", \"study_outcome_time_frame\": \"Up to 60 weeks\"}, {\"study_outcome_title\": \"Main and Sub Study: SARS-CoV-2 S Protein Binding Antibody GMCs as Measured by ELISA or Equivalent Assay\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SARS-CoV-2 S protein binding antibody GMCs as measured by ELISA or equivalent assay will be reported.\", \"study_outcome_time_frame\": \"Up to 60 weeks\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Solicited local AEs include injection site pain/tenderness, erythema and swelling at the study vaccine injection site and the extent (largest diameter) of any erythema and swelling (using the ruler supplied) will be noted in the participant diary after 7 days after each vaccination.\", \"study_outcome_time_frame\": \"7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Solicited systemic AEs (include body temperature, fatigue, headache, nausea, myalgia) will be noted in the participant diary after 7 days of each vaccination.\", \"study_outcome_time_frame\": \"7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.\", \"study_outcome_time_frame\": \"28 days after first vaccination on Day 1 (up to Day 29); 28 days after second vaccination on Day 57 (up to Day 85)\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Serious Adverse Events (SAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.\", \"study_outcome_time_frame\": \"Up to 60 weeks\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Adverse Events of Special Interest (AESIs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of participants with AESIs will be reported. Thrombosis with thrombocytopenia syndrome is considered to be an AESI.\", \"study_outcome_time_frame\": \"Up to 60 weeks\"}, {\"study_outcome_title\": \"Main and Sub Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.\", \"study_outcome_time_frame\": \"6 months after second vaccination (up to 32 weeks)\"}, {\"study_outcome_title\": \"Main Study: Number of Participants with AEs Leading to Study Discontinuation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Number of participants with AEs leading to study discontinuation will be reported.\", \"study_outcome_time_frame\": \"Up to 60 weeks\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"https://www.janssen.com/clinical-trials/transparency\"}}"}
{"id":"NCT04927403","content":"{\"resource_id\": \"NCT04927403\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"irritable bowel syndrome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"integrative medicine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"fibromyalgia syndrome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Crohn's disease\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"pain patients\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"oncological diseases\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"irritable bowel disease\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"complementary medicine\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"day clinic\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post Covid syndrome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"naturopathy\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"rheumatism\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"ulcerative colitis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"chronic pain syndrome\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Prospective Observational Study in the Context of an Internal Medicine Clinic for Naturopathy and Integrative Medicine\"}], \"resource_descriptions\": [{\"description\": \"This prospective uncontrolled observational study will include a minimum of 600 patients over six months. In the evaluation of the day clinic, the goal is at least 300 (up to approx. 600) patients. Primary outcome is general quality of life (SF-12). Secondary outcomes are anxiety and depression (HADS), well-being/flourishing (Flourishing), stress perception (PSS-10), and disease activity and disease-specific quality of life. In chronic gastroenterological patients, a distinction is made between patients suffering from irritable bowel syndrome (IBS-SSS + IBS-QOL), ulcerative colitis modifed MAYO Score + IBDQ) and Crohn's disease (HBI+ IBDQ). MAYO score: The partial MAYO score is used in this study. This contains only the non-invasive components of the full MAYO score, endoscopic findings are not considered. For chronic rheumatologic/pain patients, a distinction is made between pain patients in general (PDI), rheumatism (DAS-28, RAID), and fibromyalgia syndrome (Fibromyalgia Symptom Questionnaire, PHQ-15, PHQ-4, FIQ). The German Pain Questionnaire/ Severity Grading according to von Korff is applied to each of the three diseases. In addition, sociodemographics (age, gender, educational level, employment status, family situation), previous course of the disease, previous experience with/application of complementary medicine and naturopathic procedures, expectations of complementary medicine and naturopathic procedures used in the clinic, assessment and satisfaction with inpatient therapy program and planned and realized application of learned procedures are considered. In the case of post-covid disease, the Brief Pain Inventory (BPI) and the EQ-5D-5L are evaluated in addition to the modified baseline questionnaire, which is based on socio-demographic data, Covid-19 history. The survey of patients takes place at admission, discharge and after 6 months.\\n\\nSub-Study \\\"Intestinal barrier dysfunction\\\" - Gastroenterological patients who undergo routine gastroscopy and/or colonoscopy with confocal laser endomicroscopy (cLE) and tissue biopsies at the beginning of their inpatient stay are explicitly examined for the presence of a barrier disorder. Patient groups: Crohn's disease (MC), ulcerative colitis (CU), irritable bowel syndrome (IBS). With this sub-study, the barrier disorder (primary or secondary) detected in the context of routine care and the corresponding therapies are to be observed in the course. At timepoints week 0 and after the end therapy (week 12-24) following parameters were assessed: the serum marker I-FABP and tissue samples for immunohistochemistry and gene expression analyzes.\\n\\nIn the day clinic program also patients with oncological diseases (questionnaires: QLQ-C30 and FBK-R23) will be asked. In some day clinic groups a group discussion of about 45-60 minutes is to take place at the end of the treatment. Participants of the respective course who agree to take part in the group discussion, will be asked to make additional comments on the attended programme by means of standardised questionnaires.\\n\\nSome participants (20) are also asked to take part in an individual telephone interview 6 months after completion of the programme. In this interview, the course of the patient's illness and the effects of participation in the day clinic on the illness and the patient's lifestyle in the past months are to be determined in more detail. A special focus is on the independent continuation of health-promoting measures after the end of the day clinic participation and the evaluation of supporting factors and obstacles in the implementation of the learned contents and techniques of the programme. The patients are selected on the basis of socio-demographic and clinical characteristics with the aim of obtaining a sample that is as heterogeneous as possible. The survey of patients takes place at the beginning of the day clinic, at the end of the programme (week 10 or 11) and after 6 months after the treatment.\\n\\nThe German Pain Questionnaire/ Severity Grading according to von Korff is applied to each of the three diseases. In addition, sociodemographics (age, gender, educational level, employment status, family situation), previous course of the disease, previous experience with/application of complementary medicine and naturopathic procedures, expectations of complementary medicine and naturopathic procedures used in the clinic, assessment and satisfaction with inpatient therapy program and planned and realized application of learned procedures are considered.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"InteChron\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04927403\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"20068\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Jost Langhorst\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Universit\\u00e4t Duisburg-Essen\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4t Duisburg-Essen\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Sozialstiftung Bamberg\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Jost Langhorst, Prof.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"jost.langhorst@sozialstiftung-bamberg.de\", \"role_phone\": \"0049951-503-11251\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Christine Uecker\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"christine.uecker@sozialstiftung-bamberg.de\", \"role_phone\": \"0049951-503-16932\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Chronic Disease\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"04.01.2021\", \"study_end_date\": \"31.12.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Patients at least 18 years of age\\nsigned declaration of consent\", \"study_eligibility_exclusion_criteria\": \"Patients who have not reached the age of 18.\\nExpected life expectancy < 6 months (oncology patients).\", \"study_population\": \"All patients who are admitted to the Clinic for Integrative Medicine and Naturopathy for inpatient treatment and belong to the following patient groups can participate:\\n\\nchronic gastroenterological patients: irritable bowel syndrome, ulcerative colitis, Crohn's disease chronic pain patients: rheumatism, fibromyalgia syndrome, chronic pain syndrome post Covid syndrome patients: post Covid syndromes oncological patients: all kinds of oncological diseases (only day clinic treatment)\", \"study_target_sample_size\": 600, \"study_obtained_sample_size\": 600, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Generic quality of life\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SF-12, Short Form 36 Health Survey Questionnaire\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Generic quality of life\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SF-12, Short Form 36 Health Survey Questionnaire\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"Generic quality of life\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SF-12, Short Form 36 Health Survey Questionnaire\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"anxiety and depression\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"anxiety and depression\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"anxiety and depression\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Hospital Anxiety and Depression Scale (HADS), 14 items (7 each for depressive symptoms or symptoms of anxiety). The two summated scores of the summated scales HADS-A and HADS-D range between 0 and 21. high scores indicate depressivness and anxiety\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"sex\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"identification of the gender\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"age\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"age in years\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"job\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"identification of the current job (questionnaire)\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Educational level\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"identification of the educational level (questionnaire)\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Expectation of the treatment (questionnaire)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"patient's expectations regarding treatment\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Use of complementary medicine/natural remedies (questionnaire)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"medication and naturopathic approaches\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Course of the disease (questionnaire)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"diagnosis, treatment methods, medication\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"wellbeing/flourishing\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Flourishing Scale (FS-D), total value of the scale vary between 8 (minimum) and 56 (maximum). A high value corresponds to a person with many psychological resources and strengths\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"wellbeing/flourishing\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Flourishing Scale (FS-D), total value of the scale vary between 8 (minimum) and 56 (maximum). A high value corresponds to a person with many psychological resources and strengths\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"wellbeing/flourishing\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Flourishing Scale (FS-D), total value of the scale vary between 8 (minimum) and 56 (maximum). A high value corresponds to a person with many psychological resources and strengths\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Perceived stress\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (=never) to 5 (=very often), high stress is assumed from a total score of 20 points\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Perceived stress\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (=never) to 5 (=very often), high stress is assumed from a total score of 20 points\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"Perceived stress\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Perceived Stress Scale (PSS), Rating on a five-step scale from 1 (=never) to 5 (=very often), high stress is assumed from a total score of 20 points\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"IBS-SSS: To assess or evaluate the severity of the disease; the questionnaire includes 5 dimensions assessed with a visual analog scale (VAS): Severity of abdominal pain, frequency of abdominal pain, severity of abdominal distension, dissatisfaction with bowel habits, and impairment of quality of life.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"IBS-SSS: To assess or evaluate the severity of the disease; the questionnaire includes 5 dimensions assessed with a visual analog scale (VAS): Severity of abdominal pain, frequency of abdominal pain, severity of abdominal distension, dissatisfaction with bowel habits, and impairment of quality of life.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"IBS-SSS: To assess or evaluate the severity of the disease; the questionnaire includes 5 dimensions assessed with a visual analog scale (VAS): Severity of abdominal pain, frequency of abdominal pain, severity of abdominal distension, dissatisfaction with bowel habits, and impairment of quality of life.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Irritable Bowel Syndrome Quality of Life (IBS-QOL) ; these are 34 items that reflect the impact of IBS on everyday life (0-100 points).\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Irritable Bowel Syndrome Quality of Life (IBS-QOL) ; these are 34 items that reflect the impact of IBS on everyday life (0-100 points).\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (irritable bowel syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Irritable Bowel Syndrome Quality of Life (IBS-QOL) ; these are 34 items that reflect the impact of IBS on everyday life (0-100 points).\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"Partial Mayo Score, disease activity (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Partial Mayo Scoring Index consists of a few questions for the patient to answer, and one question for the physician to answer. The numerical results provide a score that represents an estimate of ulcerative colitis disease severity.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"Partial Mayo Score, disease activity (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Partial Mayo Scoring Index consists of a few questions for the patient to answer, and one question for the physician to answer. The numerical results provide a score that represents an estimate of ulcerative colitis disease severity.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"Partial Mayo Score, disease activity (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Partial Mayo Scoring Index consists of a few questions for the patient to answer, and one question for the physician to answer. The numerical results provide a score that represents an estimate of ulcerative colitis disease severity.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (ulcerative colitis)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Harvey-Bradshaw Index - HBI is used to assess the degree of illness in individuals with Crohn's disease. The highest possible sum is 30 points and indicates a severe course of disease. A lower sum than 5 points indicates a clinical remission.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Harvey-Bradshaw Index - HBI is used to assess the degree of illness in individuals with Crohn's disease. The highest possible sum is 30 points and indicates a severe course of disease. A lower sum than 5 points indicates a clinical remission.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Harvey-Bradshaw Index - HBI is used to assess the degree of illness in individuals with Crohn's disease. The highest possible sum is 30 points and indicates a severe course of disease. A lower sum than 5 points indicates a clinical remission.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (Crohn's disease)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Inflammatory Bowel Disease Questionnaire (IBD-Q), Recording on 7-point Likert scale, high values mean good, low values a reduced quality of life (1=worst score, 7=best score)\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Pain Disability Index (PDI) was developed specifically for patients with pain. The German-language translation (Dillmann et al., 1994), which is consistent with the original in terms of content and form, consists of seven items that assess the impact of pain on individual domains of life: family and domestic obligations, leisure activities, social activities, occupation, sexual life, self-care, and activities essential to life. For each area, the patient is asked to indicate on an eleven-point scale the extent to which he or she is impaired here by his or her pain.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Pain Disability Index (PDI) was developed specifically for patients with pain. The German-language translation (Dillmann et al., 1994), which is consistent with the original in terms of content and form, consists of seven items that assess the impact of pain on individual domains of life: family and domestic obligations, leisure activities, social activities, occupation, sexual life, self-care, and activities essential to life. For each area, the patient is asked to indicate on an eleven-point scale the extent to which he or she is impaired here by his or her pain.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (pain patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Pain Disability Index (PDI) was developed specifically for patients with pain. The German-language translation (Dillmann et al., 1994), which is consistent with the original in terms of content and form, consists of seven items that assess the impact of pain on individual domains of life: family and domestic obligations, leisure activities, social activities, occupation, sexual life, self-care, and activities essential to life. For each area, the patient is asked to indicate on an eleven-point scale the extent to which he or she is impaired here by his or her pain.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The DAS (Disease Activity Score) is a scoring system developed by the European League of Rheumatism (EULAR). With the DAS28, the disease activity of rheumatoid arthritis is recorded on the basis of 28 defined joints (finger, hand, large joints) and a score between 0 and 10 is determined.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The DAS (Disease Activity Score) is a scoring system developed by the European League of Rheumatism (EULAR). With the DAS28, the disease activity of rheumatoid arthritis is recorded on the basis of 28 defined joints (finger, hand, large joints) and a score between 0 and 10 is determined.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The DAS (Disease Activity Score) is a scoring system developed by the European League of Rheumatism (EULAR). With the DAS28, the disease activity of rheumatoid arthritis is recorded on the basis of 28 defined joints (finger, hand, large joints) and a score between 0 and 10 is determined.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Rheumatoid Arthritis Impact of Disease (RAID): Rheumatoid Arthritis Symptom Burden Questionnaire. The current questionnaire contains numeric scales from 0 to 10 for the assessment of pain, sleep, fatigue/exhaustion, impaired functioning, psychological well-being, situational awareness, and physical well-being.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Rheumatoid Arthritis Impact of Disease (RAID): Rheumatoid Arthritis Symptom Burden Questionnaire. The current questionnaire contains numeric scales from 0 to 10 for the assessment of pain, sleep, fatigue/exhaustion, impaired functioning, psychological well-being, situational awareness, and physical well-being.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Rheumatoid Arthritis Impact of Disease (RAID): Rheumatoid Arthritis Symptom Burden Questionnaire. The current questionnaire contains numeric scales from 0 to 10 for the assessment of pain, sleep, fatigue/exhaustion, impaired functioning, psychological well-being, situational awareness, and physical well-being.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity and diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity and diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity and diseasespecific quality of life (rheumatism)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Schmerzfragebogen/ Schweregraduierung nach von Korff -The intensity of the pain is determined with the help of the severity grading according to von Korff. On an 11-step rating scale (0 = no pain to 10 = strongest pain imaginable), the current, average and greatest pain intensity in the past 4 weeks is recorded. In addition, the extent of pain-related, subjectively experienced impairment is recorded for the areas of everyday life, leisure activities and ability to work.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Fibromyalgia Symptom Questionnaire (FSQ) captures the severity of key fibromyalgia syndrome symptoms and the presence of various pain points over time in four sections.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"disease activity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Fibromyalgia Symptom Questionnaire (FSQ) captures the severity of key fibromyalgia syndrome symptoms and the presence of various pain points over time in four sections.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"disease activity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Fibromyalgia Symptom Questionnaire (FSQ) captures the severity of key fibromyalgia syndrome symptoms and the presence of various pain points over time in four sections.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"symptom severity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Patient Health Questionnaire 15 (PHQ-15) consists of 15 items in the area of somatoform and depressive disorders. The PHQ-15 is scored by forming a sum score across all items. Symptom severity is assessed by the total score: minimal, mild, moderate, or severe.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"symptom severity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Patient Health Questionnaire 15 (PHQ-15) consists of 15 items in the area of somatoform and depressive disorders. The PHQ-15 is scored by forming a sum score across all items. Symptom severity is assessed by the total score: minimal, mild, moderate, or severe.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"symptom severity (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Patient Health Questionnaire 15 (PHQ-15) consists of 15 items in the area of somatoform and depressive disorders. The PHQ-15 is scored by forming a sum score across all items. Symptom severity is assessed by the total score: minimal, mild, moderate, or severe.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"symptom severity - depression and anxiety (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"PHQ-4 captures the dimensions of depression and anxiety with 4 items; patients are asked to indicate how often certain complaints (e.g., little happiness, dejection, anxiety) occurred over the course of the past two weeks\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"symptom severity - depression and anxiety (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"PHQ-4 captures the dimensions of depression and anxiety with 4 items; patients are asked to indicate how often certain complaints (e.g., little happiness, dejection, anxiety) occurred over the course of the past two weeks\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"symptom severity - depression and anxiety (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"PHQ-4 captures the dimensions of depression and anxiety with 4 items; patients are asked to indicate how often certain complaints (e.g., little happiness, dejection, anxiety) occurred over the course of the past two weeks\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Fibromyalgia Impact Questionnaire (FIQ) is an instrument that quantifies the general impact of fibromyalgia syndrome in many dimensions. For example, it assesses functional ability, pain levels, fatigue, and sleep disturbances in patients affected by FMS. The FIQ is presented on a scale of 0-100, with a lower number indicating better health. It is a sensitive tool for therapy evaluation in fibromyalgia.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"diseasespecific quality of life (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Fibromyalgia Impact Questionnaire (FIQ) is an instrument that quantifies the general impact of fibromyalgia syndrome in many dimensions. For example, it assesses functional ability, pain levels, fatigue, and sleep disturbances in patients affected by FMS. The FIQ is presented on a scale of 0-100, with a lower number indicating better health. It is a sensitive tool for therapy evaluation in fibromyalgia.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (fibromyalgia syndrome)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The Fibromyalgia Impact Questionnaire (FIQ) is an instrument that quantifies the general impact of fibromyalgia syndrome in many dimensions. For example, it assesses functional ability, pain levels, fatigue, and sleep disturbances in patients affected by FMS. The FIQ is presented on a scale of 0-100, with a lower number indicating better health. It is a sensitive tool for therapy evaluation in fibromyalgia.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"EQ-5D-5L Five dimensions of quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. This questionnaire assesses the state of health (mobility, self-care, general activities, pain/physical discomfort and anxiety/dejection) as well as general health status on a VAS of 0-100. The questionnaire assesses is used for Post-Covid-Patients.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"EQ-5D-5L Five dimensions of quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. This questionnaire assesses the state of health (mobility, self-care, general activities, pain/physical discomfort and anxiety/dejection) as well as general health status on a VAS of 0-100. The questionnaire assesses is used for Post-Covid-Patients.\", \"study_outcome_time_frame\": \"week 2 (inpatient), week 10/11 (day clinic)\"}, {\"study_outcome_title\": \"EQ-5D-5L Five dimensions of quality of life\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"This questionnaire assesses the state of health (mobility, self-care, general activities, pain/physical discomfort and anxiety/dejection) as well as general health status on a VAS of 0-100. The questionnaire assesses is used for Post-Covid-Patients.\", \"study_outcome_time_frame\": \"week 24 (inpatient), week 34/35 (day clinic)\"}, {\"study_outcome_title\": \"Pain and impairment (post-covid)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Brief pain inventory (BPI). It is used for Post-Covid-Patients. This questionnaire asks about pain and impairments in everyday life that occur due to these\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Pain and impairment (post-covid)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Brief pain inventory (BPI). It is used for Post-Covid-Patients. This questionnaire asks about pain and impairments in everyday life that occur due to these.\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Pain and impairment (post-covid)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Dt. Brief pain inventory (BPI). It is used for Post-Covid-Patients. This questionnaire asks about pain and impairments in everyday life that occur due to these\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Lactoferrin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of lactoferrin in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Lactoferrin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of lactoferrin in the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Lactoferrin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of lactoferrin in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Calprotectin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of calprotectin in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Calprotectin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of calprotectinin the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Calprotectin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of calprotectin in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"PMN-Elastase (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of PMN-Elastase in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"PMN-Elastase (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of PMN-Elastasethe in the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"PMN-Elastase (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of PMN-Elastasethe in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Humanes Beta-Defensin (hBD-2) (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Humanes Beta-Defensin (hBD-2) in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Humanes Beta-Defensin (hBD-2) (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Humanes Beta-Defensin (hBD-2) in the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Humanes Beta-Defensin (hBD-2) (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Humanes Beta-Defensin (hBD-2) in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Zonulin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of zonulin in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Zonulin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of zonulin in the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Zonulin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of zonulin in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay)\"}, {\"study_outcome_title\": \"Alpha-Antitrypsin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Alpha-Antitrypsin in the stool\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"Alpha-Antitrypsin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Alpha-Antitrypsin in the stool\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"Alpha-Antitrypsin (chronic gastroenterological)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of Alpha-Antitrypsin in the stool\", \"study_outcome_time_frame\": \"week 24 (inpatient stay - follow-up)\"}, {\"study_outcome_title\": \"CRP (C-reactive protein)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of CRP in the blood\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"CRP (C-reactive protein)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of CRP in the blood\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"BKS (blood cell sedimentation rate)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of BKS in the blood\", \"study_outcome_time_frame\": \"week 0 (inpatient stay)\"}, {\"study_outcome_title\": \"BKS (blood cell sedimentation rate)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of BKS in the blood\", \"study_outcome_time_frame\": \"week 2 (inpatient stay)\"}, {\"study_outcome_title\": \"I-FABP (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"intestinal fatty-acid binding protein (blood)\", \"study_outcome_time_frame\": \"inpatient stay (baseline)\"}, {\"study_outcome_title\": \"I-FABP (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"intestinal fatty-acid binding protein (blood)\", \"study_outcome_time_frame\": \"inpatient stay (up to 24 weeks)\"}, {\"study_outcome_title\": \"IgG (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"immunoglobuline-G (blood)\", \"study_outcome_time_frame\": \"inpatient stay (baseline)\"}, {\"study_outcome_title\": \"IgG (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"immunoglobuline-G (blood)\", \"study_outcome_time_frame\": \"inpatient stay (up to 24 weeks)\"}, {\"study_outcome_title\": \"IgE (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"immunoglobuline-E (blood)\", \"study_outcome_time_frame\": \"inpatient stay (baseline)\"}, {\"study_outcome_title\": \"IgE (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"immunoglobuline-E (blood)\", \"study_outcome_time_frame\": \"inpatient stay (up to 24 weeks)\"}, {\"study_outcome_title\": \"tissue samples (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Immunochemistry and gene expression analysis\", \"study_outcome_time_frame\": \"inpatient stay (baseline)\"}, {\"study_outcome_title\": \"tissue samples (chronic gastroenterological - substudy)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Immunochemistry and gene expression analysis\", \"study_outcome_time_frame\": \"inpatient stay (up to 24 weeks)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"QLQ-C30: The EORTC QLQ-C30 questionnaire contains 30 questions and assesses the quality of life of oncological patients multidimensionally via 10 subscales. There are a number of additional modules for the disease-specific assessment of oncology patients.\", \"study_outcome_time_frame\": \"week 0 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"QLQ-C30: The EORTC QLQ-C30 questionnaire contains 30 questions and assesses the quality of life of oncological patients multidimensionally via 10 subscales. There are a number of additional modules for the disease-specific assessment of oncology patients.\", \"study_outcome_time_frame\": \"week 11 (day clinic)\"}, {\"study_outcome_title\": \"diseasespecific quality of life (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"QLQ-C30: The EORTC QLQ-C30 questionnaire contains 30 questions and assesses the quality of life of oncological patients multidimensionally via 10 subscales. There are a number of additional modules for the disease-specific assessment of oncology patients.\", \"study_outcome_time_frame\": \"week 36 (day clinic)\"}, {\"study_outcome_title\": \"psychological burden (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"FBK-R23: Questionnaire on the Burden of Cancer Patients, 23 items on psychological, somatic and social burden.\", \"study_outcome_time_frame\": \"week 0\"}, {\"study_outcome_title\": \"psychological burden (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"FBK-R23: Questionnaire on the Burden of Cancer Patients, 23 items on psychological, somatic and social burden.\", \"study_outcome_time_frame\": \"week 11 (day clinic)\"}, {\"study_outcome_title\": \"psychological burden (oncological patients)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"FBK-R23: Questionnaire on the Burden of Cancer Patients, 23 items on psychological, somatic and social burden.\", \"study_outcome_time_frame\": \"week 36 (day clinic)\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT04930016","content":"{\"resource_id\": \"NCT04930016\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"survivorship\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"colorectal cancer\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"health services research\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"complex intervention\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"quality of life\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Quality of Life and Survival of Patients With Colorectal Cancer 5 Years After Surgery and Their Aftercare Situation During the COVID-19 Pandemic - Long-term Follow-up of the Randomized Trial DIQOL\"}], \"resource_descriptions\": [{\"description\": \"In a complex intervention a clinical pathway with quality of life (QoL) diagnosis and tailored therapy had been developed for patients with colorectal cancer and its effectiveness was evaluated in a randomized trial (RCT DIQOL, NCT02321813, Klinkhammer-Schalke et al, 2020). In the RCT DIQOL a total of 220 patients were randomised (1:1) into two groups: a care pathway, including QoL-profiles consisting of 13 QoL scales plus specific therapeutic recommendations forwarded to the patient's doctor (intervention) or standard postoperative care (control). QoL was measured (EORTC QLQ-C30, QLQ-CR29) in all patients after surgery and during aftercare (3, 6, 12, 18 months postoperatively). A need for QoL therapy was defined as a score <50 points on at least one QoL scale. It was demonstrated that the proportion of patients with a need for QoL therapy was significantly lower in intervention group patients at 12 months after surgery (primary endpoint).\\n\\nUntil now, it is unclear whether there are also long-term benefits of QoL diagnosis and therapy. Therefore, the aim of this observational, cross-sectional follow-up study of the RCT DIQOL is to investigate long-term effects of the intervention on present QoL (EORTC QLQ-C30, QLQ-CR29), overall survival, and recurrence-free survival more than 5 years after surgery by comparing former intervention and control group patients. Moreover, participants will be asked for their experiences during aftercare in relation of the COVID-19 pandemic and for their recollection of their illness and therapy. Data are collected via questionnaire.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"DIQOLFollow-up\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT04930016\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"DIQOL_Follow-up_2021\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Prof. Dr. Monika Klinkhammer-Schalke\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Tumor Center Regensburg\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Tumor Center Regensburg\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Quality of Life\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Colorectal Cancer\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Colorectal Neoplasms\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Survivorship\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"14.04.2021\", \"study_end_date\": \"07.10.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"former participants of the RCT DIQOL with a primary diagnosis of colorectal cancer between 01/2014 and 10/2015 who did not refuse to participate during the RCT\\ninformed consent\", \"study_eligibility_exclusion_criteria\": \"- none -\", \"study_population\": \"Former participants of the RCT DIQOL with a primary diagnosis of colorectal cancer between 01/2014 and 10/2015 who had been surgically treated in one of four participating certified centers for colorectal cancer (Krankenhaus Barmherzige Br\\u00fcder Regensburg, Germany; Caritas-Krankenhaus St. Josef Regensburg, Germany; Klinikum Neumarkt, Germany; Klinikum St. Elisabeth Straubing, Germany). Originally, 220 patients were included in the RCT DIQOL. Of the 220 participants who were included in the RCT 12 patients refused participation during the trial so that the final sample for the follow-up study encompasses 208 patients. The questionnaire is mailed to survivors of this cohort. Overall survival and recurrence-free surival will be analzyed in all 208 former study participants.\", \"study_target_sample_size\": 208, \"study_obtained_sample_size\": 208, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"need for QoL therapy of colorectal cancer survivors\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"proportion of patients in both groups with a need for QoL therapy (<50 points in at least one dimension) more than 5 years after surgery\", \"study_outcome_time_frame\": \">5 years after surgery for colorectal cancer\"}, {\"study_outcome_title\": \"specific need for QoL therapy of colorectal cancers survivors in specific QoL dimensions\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"rates of patients with a need for QoL therapy in each single dimension of the QoL-profile more than 5 years after surgery\", \"study_outcome_time_frame\": \">5 years after surgery for colorectal cancer\"}, {\"study_outcome_title\": \"overall survival\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"survival after surgery for colorectal cancer\", \"study_outcome_time_frame\": \"surgery for colorectal cancer (01/2014-10/2015) up to 10/2021\"}, {\"study_outcome_title\": \"recurrence-free survival\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"recurrence-free survival after surgery for colorectal cancer\", \"study_outcome_time_frame\": \"surgery for colorectal cancer (01/2014-10/2015) up to 10/2021\"}, {\"study_outcome_title\": \"aftercare of colorectal cancer survivors during the COVID-19 pandemic\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"self-created questionnaire with quantitative questions asking whether and how the COVID-19 pandemic affected \\u00b4aftercare\", \"study_outcome_time_frame\": \">5 years after surgery for colorectal cancer\"}, {\"study_outcome_title\": \"colorectal cancer survivors' recollections of their illness an therapy\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"self-created questionnaire with three qualitative questions asking for worst experiences during the colorectal cancer episode, positive aspects of the illness, and any advice survivors would give to newly diagnosed patients\", \"study_outcome_time_frame\": \">5 years after surgery for colorectal cancer\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Anonymized IPD that underlie the results in a publication are planned to be made available upon request of scientists.\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"6 months after date of publication until 60 months after date of publication\", \"study_data_sharing_plan_access_criteria\": \"Data will be made available to other scientists upon request for nonprofit research. The contact address is monika.klinkhammer-schalke@ur.de. Scientists are required to send their predefined statistical analysis plan. Together with the scientific review board of the Tumor Center Regensburg a decision will be made based on the quality and usefulness of planned statistical analysis. In case of a positive decision the scientist is required to sign a contract for data usage before receiving anonymized IPD.\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Cross-sectional\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT05000255","content":"{\"resource_id\": \"NCT05000255\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Loneliness, Depression, Anxiety, Post-COVID, COVID-19, Psych\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Coping With Covid-19: Loneliness, Self-Efficacy, Social Support and Depression and Anxiety in Patients in Medical Rehabilitation. A Field Study in Geriatrics and Physical Medicine\"}], \"resource_descriptions\": [{\"description\": \"Background: Increased depressive symptoms and anxiety symptoms have been observed in about 23% of all post-COVID patients, also called post-COVID depression (Huang et al., 2021). However, what a) promotes post-COVID depression after the disease and whether it is b) even post-Covid specific has not yet been conclusively understood and will be investigated in this proposed research. The theoretical basis of the proposed work is Cacioppo, Peplau, and Perlman's theory of loneliness, Bandura's self-efficacy theory, and Schwarzer's HAPA model.\\n\\nObjectives: The aim of the study is to investigate possible predictors and factors that may be associated with the development and maintenance of mental and physical health constrains including depression and anxiety symptomatology as well as loneliness in hospitalized post-COVID patients and non-COVID patients in Germany. Furthermore, it will be investigated whether psychological interventions have an effect on anxiety and depression symptomatology, on loneliness values, self-efficacy and perceived social support values. Specifically, the research aim is to examine the relationships between loneliness, self-efficacy, and social support and to address the question of what factors increase the risk of post covid depression/anxiety, and to test the buffering effect of physical and social activities. For this purpose, a correlational study and an experimental group comparison will be applied, in which two interventions will be performed on post-COVID patients and non-COVID patients. These two data collections will serve as the basis for a later longitudinal study, which is still in the planning stage, as follow-up questions still need to be elaborated. Methods: Around 300 patients should be included in the study. The correlation study at the first measurement point also includes a regression analysis (moderated mediation analysis). Furthermore, an experimental group comparison is performed. For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft f\\u00fcr Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of COVID-19 patients (DGP, 2020). The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. In this experiment, the psychological interventions will be applied to both groups of patients (non-Covid/Covid patients). The interventions start approximately two days after data collection at T0. The second measurement time point (T1) is scheduled at the time of patient discharge after the interventions have been implemented. Only patients who scored 8 or higher on the Hospital Anxiety and Depression Scale (HADS) at admission will participate in the interventions. Patients will be asked to complete the questionnaire again six months after discharge to include a third measurement point and to conduct the aforementioned longitudinal study. Patients who refuse to participate in one of the interventions but nevertheless agree to complete the questionnaires at the measurement time points are treated according to the standards of the complex treatment in early rehabilitation in which a twice psychological contact and screening by means of HADS is obligatory. They form a third group. The following instruments will be used: Items from the UCLA Loneliness Scale (Russel, 1980, German version), the Hospital Anxiety and Depression Scale (Snaith & Zigmond, 2010), Perceived Social Support Questionnaire (F-SozU K-6, Fydrich et al., 2009); SWE - General Self-Efficacy Expectancy Scale (Schwarzer et al., 1999); various self-efficacy instruments, such as staging and Activities Against Loneliness (Lippke, 2007, adapted from Godin & Shepard, 1985). It is expected that self-efficacy and social support play a role as mediator variables and moderator variables and that the symptomatology of depression and anxiety improves after an intervention in COVID and non-COVID patients alike. The findings of this research will contribute to a better understanding of the experience and behavior of patients with and without an infection with COVID-19 in early rehabilitation and identify opportunities for psychological intervention.\\n\\nThe ethics committee of Jacobs University Bremen, where Prof. Dr. Lippke supervises the PhD project, has already approved the research project. Therefore, the project is already in the recruitment phase in order to be able to use data from the third wave from the first quarter of 2021, as this is a special situation in the pandemic and the data would not be reproducible in this way.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05000255\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"HeliosRC\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor-Investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Annette Reichardt, MD\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Helios Research Center\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Annette Reichardt, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Jacobs University Bremen gGmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Annika Roskoschinski, MSc\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"Annika.Roskoschinski@helios-gesundheit.de\", \"role_phone\": \"+49 30 9401-14837\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Annette Reichardt, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"annette.reichardt@helios-gesundheit.de\", \"role_phone\": \"+49 30 9401-14852\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: an experimental group comparison is performed. For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft f\\u00fcr Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of COVID-19 patients (DGP, 2020). The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. In this experiment, the psychological interventions will be applied to both groups of patients (non-Covid/post-Covid patients). . Patients who refuse to participate in one of the interventions but nevertheless agree to complete the questionnaires at the measurement time points are treated according to the standards of the complex treatment in early rehabilitation\", \"study_conditions\": [{\"study_conditions\": \"Loneliness\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Depression, Anxiety\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Self Efficacy\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Social Support\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Covid19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Psychology\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"18.01.2021\", \"study_end_date\": \"30.09.2025\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"patients aged 18 years to no upper limit\\npatients were diagnosed with COVID-19\\nNon-COVID patients with the need to participate in early rehab\", \"study_eligibility_exclusion_criteria\": \"a too high language barrier or dyslexia\\npatients with intellectual and cognitive impairment (like primary psychiatric illness, e.g., schizophrenia or dementia, if admitted by means of medical history by a physician or if the score achieved in the cognitive screening by means of the mini-mental-state-examination (MMSE) is 23 or below 23 and no improvement of the cognitive performance is to be expected, e.g. because of an incipient dementia)\", \"study_population\": \"\", \"study_target_sample_size\": 300, \"study_obtained_sample_size\": 300, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Measurement with the UCLA Loneliness Scale\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Improvement in scores for loneliness: Psychological interventions are expected to improve feelings of loneliness and to decrease loneliness scores.\\n\\nThe following questionnaire/scale will be used for measurement at the 1st measurement time point and 2nd measurement time point 14 days later for comparison:\\n\\n- UCLA Loneliness Scale, German version, short form, 3 Items The lower the scores on the UCLA Loneliness Scale, the better. There is no cut-off Score.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurement with the Hospital Anxiety and Depression Scale (HADS)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Improvement in scores for anxiety, and depression: Psychological interventions are expected to improve depression symptomatology and anxiety scores.\\n\\nThe following questionnaire/scale will be used for measurement at the 1st measurement time point and 2nd measurement time point 14 days later for comparison:\\n\\n- HADS - Hospital Anxiety and Depression Scale (HADS-D, German adaptation, 7 items Anxiety, 7 items Depression) A score of 8 or more indicates elevated levels of anxiety and depression. Scores below 8 are targeted by psychological interventions.The cut-off for anxiety and depression is 8 or more.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurements with the General Self-Efficacy Expectancy Scale (GSE)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Improvement in scores for self-efficacy: Psychological interventions are expected to increase self-efficacy scores.\\n\\nThe following questionnaire/scale will be used for measurement at the first measurement time point and 2nd measurement time point 14 days later:\\n\\n- General Self-Efficacy Expectancy Scale (GSE), German Version, by Schwarzer, R.\\n\\nThe higher the values for the above scales, the better. There is no cut-off score.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurements of Stage-specific Self-Efficacy, German Version, by Lippke, S.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Improvement of Stage-specific Self-Efficacy:\\n\\nPsychological interventions are expected to improve Stage-specific Self-Efficacy.\\n\\nThe following questionnaire/scale will be used for measurement at the 1st measurement time point and 2nd measurement time point 14 days later:\\n\\n- Stage-specific Self-Efficacy, by Lippke, 1 Item, German Version There is no cut-off value.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurements of Activities against loneliness, German Version, by Lippke, S.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Improvement of Activities against loneliness:\\n\\nPsychological interventions are expected to improve or motivate activities against loneliness.\\n\\nThe following questionnaire/scale will be used for measurement at the 1st measurement time point and 2nd measurement time point 14 days later:\\n\\n- Activities against loneliness, by Lippke, 13 Items, German Version The higher the value for the above scale, the better. There is no cut-off value.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurements of Perceived Social Support, (F-SozU K-6), German Short Version, by Fydrich\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Improvement in scores for social support:\\n\\nPsychological interventions are expected to increase scores of subjectively perceived social support.\\n\\nThe following questionnaire/scale will be used for measurement at the 1st measurement time point and 2nd measurement time point 14 days later:\\n\\n- Perceived Social Support Questionnaire (F-SozU K-6), German Version, by Fydrich (6 Items) The higher the values for the above scales, the better. there is no cut-off value.\", \"study_outcome_time_frame\": \"approx. 14 days\"}, {\"study_outcome_title\": \"Measurement of loneliness before the COVID-19 pandemic and during the COVID-19 pandemic with prescribed measures (social constraints).\", \"study_outcome_type\": \"Other\", \"study_outcome_description\": \"Improving feelings of loneliness during the COVID-19 pandemic.\\n\\nScale: Feelings of loneliness before and during the pandemic, von Lippke, 2020.\\n2 items are used\\n\\nThere is no cut-off value. The lower the scores for loneliness before and during the pandemic, the better.\", \"study_outcome_time_frame\": \"approx. 14 days\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT05012306","content":"{\"resource_id\": \"NCT05012306\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis\"}], \"resource_descriptions\": [{\"description\": \"This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive information on SARS-CoV-2 seroprevalence changes over time and the subsequent clinical impact on pwCF. The study will be conducted at participating CF centres over a 3-year period. Study participants will include paediatric and adult pwCF. For the United Kingdom (UK) section of the study, UK investigators in the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) will be invited to participate. Participating investigators can enrol all eligible pwCF over a 12-month period. Participants are then followed up for 24 months. Participants will donate blood samples at their routine clinic visits. Blood samples will be collected at Day 0 (baseline), at Months 6, 12, 18 and 24 (to coincide with routine clinical reviews). Additional blood samples will be taken opportunistically every time the participant visits the clinic for blood draws. These blood samples could be related to, routine care, annual review visits, pulmonary exacerbations (PEx), CF complications or when initiating new treatments (e.g. CFTR modulators).\\n\\nSerum from blood samples will be shipped to a central laboratory (Queen's University Belfast) for standardized measurement of SARS-CoV-2 antibodies.\\n\\nAlongside the blood samples the investigator will also collect clinical data from the patient's health records and will input this data into the case report form (CRF). Clinical data will be collected in conjunction with routine care visits, according to local clinical practice. Investigators will collect data elements from information routinely recorded in the patients' medical records. Data will be collected at baseline, month 6, 12, 18 and 24 as per the study schedule, and at additional blood sampling timepoints as previously explained above. Data collection will include routine data available from CF clinic follow-ups including background demographic information, CF medical history, medications, exacerbation information, sputum microbiology and clinical and lung function parameters. Information on SARS-CoV-2 infection history and vaccine receipt will also be collected.\\n\\nThe maximum follow-up duration of participation in the study for each patient will be 24 months. This study duration (24-month follow-up) is justified as it provides sufficient time to observe changes in antibody prevalence over the course of the COVID-19 pandemic as well as sufficient time to determine long term clinical outcomes for pwCF who are SARS-CoV-2 seropositive. Furthermore, the investigators anticipate the 2-year study follow-up period will provide sufficient time to observe the impact of vaccination on antibody levels given that a number of vaccines are now commercially available.\\n\\nThe investigators will compare the level of antibody responses between natural COVID-19 infection and vaccination in pwCF and how this varies over time. This will be achieved by analyzing seroprevalence and antibody levels according to natural infection and vaccination status and according to time of sample post infection or post vaccination, if known.\\n\\nOptional Study sample collection:\\n\\nFor participants who consent, a second blood sample will also be drawn into Ethylenediamine tetraacetic acid (EDTA) tubes (plasma). Consent to this optional study sample would allow this sample and any remaining serum (following antibody testing) to be stored for future analysis and allow further research to be carried out on related studies to COVID-19 and CF.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"CAR-CF\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05012306\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"V1.0_01-MAR-2021\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4tsklinikum K\\u00f6ln\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Silke van Koningsbruggen-Rietschel, MD, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"Silke.vanKoningsbruggen@uk-koeln.de\", \"role_phone\": \"+49-221-478-4492\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Meike Meyer, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"Meike.Meyer@uk-koeln.de\", \"role_phone\": \"+49-221-478-42128\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Cystic Fibrosis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"28.05.2021\", \"study_end_date\": \"15.05.2024\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 8, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": null, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity will be eligible to participate in the study. The study population is expected to be representative of the general CF population.\", \"study_eligibility_exclusion_criteria\": \"There are no specific exclusion criteria other than refusal to give informed consent, or contraindication to venepuncture.\", \"study_population\": \"Participants already enrolled in a clinical trial are eligible for enrolment in this study. Inclusion in CAR-CF should not preclude enrolment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"To evaluate SARS-CoV-2 seroprevalence\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"To evaluate SARS-CoV-2 seroprevalence in a cohort of people with cystic fibrosis, followed longitudinally over a 3-year period (comprising a 1-year enrollment period and a 2-year follow-up). [ Time Frame: 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) ] To examine the associations between SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in a cohort of people with cystic fibrosis\", \"study_outcome_time_frame\": \"3-year period (comprising a 1-year enrollment period and a 2-year follow-up)\"}, {\"study_outcome_title\": \"Storage of samples for future analysis\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Storage of samples for future analysis on the impact of COVID-19 immune response in people with cystic fibrosis\", \"study_outcome_time_frame\": \"anticipated 5-10 years\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"blood serum\"}}}"}
{"id":"NCT05059080","content":"{\"resource_id\": \"NCT05059080\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Long-COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Observational\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"SARS-CoV-2\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Mild to Moderate COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Coronavirus Disease 2019\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"A Multicenter, Observational, 6-Month Follow-up Study of Patients With COVID-19 Previously Enrolled in a RO7496998 (AT-527) Study\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"MEADOWSPRING\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05059080\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"CV43140\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2021-000627-12\", \"id_type\": \"EudraCT\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Hoffmann-La Roche\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Atea Pharmaceuticals, Inc.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Long COVID\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"15.06.2021\", \"study_end_date\": \"16.03.2022\", \"study_country\": [\"Argentina\", \"Romania\", \"Portugal\", \"Ukraine\", \"Brazil\", \"Denmark\", \"Germany\", \"Belgium\", \"Turkey\", \"Mexico\", \"Switzerland\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 45, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 12, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Participant was diagnosed with COVID-19 and enrolled in a Phase III RO7496998 (AT-527) COVID-19 study\", \"study_eligibility_exclusion_criteria\": \"Participation in an interventional study at the time of enrollment or plans to enroll in an interventional study during this study.\\nAny serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study\", \"study_population\": \"Participants enrolled in a RO7496998 (AT-527) study.\", \"study_target_sample_size\": 73, \"study_obtained_sample_size\": 73, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"COVID-19 Symptoms Assessment through the COVID-19 Symptom Diary (Items 1-14)\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"COVID-19 symptoms will be evaluated using the COVID-19 Symptom Diary (items 1-14). The severity of each COVID-19 symptom will be recorded on a Likert scale (i.e none/mild/moderate/severe).\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Dyspnea Symptoms Assessment through the Patient Reported Outcomes Measurement Information System (PROMIS) - Dyspnea Questionnaire\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The PROMIS-Dyspnea Questionnaire will be used to evaluate the impact of Dyspnea on specific activities. The severity of impact on each activity will be recorded on a Likert scale with a recall period over the last 7 days (i.e no shortness of breath, mild/moderate/severe shortness of breath or not applicable)\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Respiratory Symptoms Assessment through the St. George's Respiratory Questionnaire (SGRQ)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"The SGRQ is a 50-item respiratory-specific health-related quality of life instrument that measures health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks.\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Proportion of Participants with COVID-19 Related Medically-Attended Visits\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"COVID-19-related medically-attended visits are defined as hospitalization, ER visit, urgent care visit, physician's office visit, or telemedicine visit with the primary reason for the visit being COVID-19 or COVID-19-related symptoms.\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Proportion of Participants with Death Attributable to Progression of COVID-19\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Proportion of Participants Re-Infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Proportion of Participants with any Post-Treatment Infection\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Frequency of COVID-19 Related Complications\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Examples of COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis and cardiac failure.\", \"study_outcome_time_frame\": \"Up to 6 months\"}, {\"study_outcome_title\": \"Proportion of Participants with Adverse Events (AEs) and Serious AEs (SAEs)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Event severity will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE v5.0)\", \"study_outcome_time_frame\": \"Up to 6 months\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT05074017","content":"{\"resource_id\": \"NCT05074017\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://doi.org/10.4324/9780203771587\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"COVAG Study - Covid-19 Antigen Study\"}], \"resource_descriptions\": [{\"description\": \"Background:\\n\\nCoronavirus disease 2019 (COVID-19) has quickly spread worldwide from Wuhan (China) since December 2019. Reliable diagnostic technologies are pivotal to the fight against COVID-19. While real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based testing of respiratory specimens remains the gold standard for COVID- 19 diagnostics, several commercial assays for antibodies against (SARS-CoV-2) have emerged during the previous months (Stocking et al., 2020).\\n\\nMeasuring the presence or absence of viral proteins (antigens), antigen tests may provide results diagnosing an active SARS-CoV-2 infection much faster than RT-PCR or equivalent tests. It has been argued that antigen tests may have a lower sensitivity than RT-PCR or equivalent RNA-based tests, and as a result they are much more likely to give false-negative results in individuals with lower amounts of virus. This may possibly make them unreliable in individuals with an asymptomatic course of the disease, in individuals in the first days of infection, and later than 5-7 days after onset of symptoms (SYNLAB press release, 22.09.2020).\\n\\nObjective:\\n\\nThe objective of this non-interventional study is to demonstrate that rapid antigen tests for SARS-CoV-2 (Abbott and Roche) provide fast results and perform equally well than RT-PCR, at least in symptomatic patients with high viral loads.\\n\\nStudy Design:\\n\\nThe study will be performed in at the Corona Test Center Stuttgart Cannstatter Wasen operated by Dr. med. Hans-J\\u00f6rg Wertenauer, Stuttgart, in close collaboration with the SYNLAB MVZ Leinfelden-Echterdingen GmbH. Approximately 2000 patients will be enrolled at after having signed the Informed Consent Form (ICF). Upon a scheduled study duration of eight weeks, the investigators will be able to collect the required 2000 samples (50 patients per day).\\n\\nOne study visit is planned for data and blood collection (15,5 ml), antigen tests, RT-PCR, serological tests, basic laboratory tests to be communicated to participants, and ancillary blood tests (incriminated to be related to COVID-19 like inflammatory markers, and micronutrients and vitamins). These will be performed at the at the SYNLAB MVZ Leinfelden GmbH. Aliquots of the materials collected will be stored -20 degrees for control measurements and ancillary tests, maximally for one year after the last patient was enrolled into the study.\\n\\nRationale:\\n\\nIn the past weeks, there has been much discussion about rapid antigen tests for SARS- CoV-2. The most recent generation of these tests, available from several different suppliers, are expected to perform well in patients with high viral loads. This is usually the case approximately 3-10 days after infection with the virus, when the person is contagious, and may be asymptomatic or in the first days of symptoms.\\n\\nIt is therefore hoped that rapid antigen tests can support diagnosis of COVID-19 in people who have the first symptoms. In the USA, some tests have received authorization for diagnostic testing in symptomatic individuals, within 5-7 days from the onset of symptoms (3).\\n\\nRisks and benefits:\\n\\nThree nasopharyngeal swabs and one blood sample will be obtained from each of the participants. Antigen tests, RT-PCR and serological and ancillary laboratory tests are performed in this study.\\n\\nRisks from nasopharyngeal swabs: The biggest risk is discomfort. Rarely - 1 in thousands - the person receiving the swab passes out from being super sensitive or gets a mild nosebleed.\\n\\nRisks from blood draw: The risks of venipuncture include being the most common reaction. Significant complications (defined as cellulitis, phlebitis, diaphoresis, hypotension, near syncope, syncope) are observed in Minor bruising at the site where the blood is taken and hematoma (12 % approximately), with minor bruising approximately 3.5% of patients. The most frequent single significant complication is hypotension at a frequency occurred of approximately 2.6%. Syncope is seen in less than 1% of patients. Other serious local reactions such as cellulitis or phlebitis are very rare (Galena HJ, J. Fam. Pract. 1992 May;34(5):582-4). Blood sampling is therefore conducted in each of the study sites under the surveillance of a board licensed physician.\\n\\nBenefits to public health: Point of care antigen testing is an integral component of the current national testing strategy serving for preventing of the spread of COVID 19 https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/C oronavirus/Nationale_Teststrategie_kurz_041220.pdf There is, however, significant uncertainty as to the reliability of antigen testing in comparison to the gold standard of testing, rt-PCR. To the authors \\u0301 knowledge a prospective, sufficiently sizeable and challengeable evaluation of antigen testing under practice conditions has not been completed so far. The current study is intended to close this gap. Its results are urgently required and will have immediate impact on current recommendations for using antigen testing. In particular, it will demonstrate weaknesses and strengths of antigen testing and will allow to outweigh potential technical limitations of antigen testing compared to rt-PCR against the advantage of short-term availability of test results.\\n\\nFurther, the thorough recording of the clinical health status and the basic laboratory analysis performed in this study, it will be able to get further insights into clinical predictors for the susceptibility for COVID 19.\\n\\nBenefits to the individual. Participants will benefit in two ways. Other than with rt-PCR, they will obtain the results of the antigen testing at once and on-site. In addition, offering two antigen tests simultaneously, the results of the point-of-care testing will be even more reliable than the result of a single test. Further, the participants are offered a free of charge basic laboratory health check including the following actionable health markers: basic blood cell count, C-reactive protein, HbA1c, cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, gamma-glutamyl-transferase, creatinine along with formula-derived creatinine, vitamin D.\\n\\nThe investigators conclude that benefits of this study to the healthcare system which is faced with the life-threatening and to the individual study participants clearly outweigh the minor and manageable risks.\\n\\nPopulation:\\n\\nThe investigators will include approximately 2000 consecutive male and female patients aged 18 years or above attending the Corona Test Center Stuttgart Cannstadter Wasen, in whom RT- PCR testing for SARS-CoV-2 is medically indicated or requested.\\n\\n6.1 Inclusion Criteria:\\n\\nSubjects eligible for inclusion in this study must meet the following criteria:\\n\\nSigned informed consent must be obtained prior to study participation. The patient must be capable of understanding the nature, significance and implication of the trial.\\nAge 18 years or more\\n\\n6.2 Exclusion criteria:\\n\\nLack of informed consent\\nInability to understand the nature, significance and implication of the trial.\\nSevere clinical conditions requiring emergency hospitalization\\nChildren and adolescents under the age of 18 years\\n\\n7. Informed consent procedures Eligible subjects may only be included in the study after providing IRB/IEC-approved informed consent. Informed consent must be obtained before performing any study- specific procedures (Appendix 2).\\n\\n8. Assessment schedule and assessments:\\n\\nInformed Consent Form, Collection of demographic data and X relevant Medical History SARS-CoV-2 Rapid Antigen Test (Roche), PANBIO Covid-19 Ag Rapid Test (Abbott), RT-PCR Serological test (blood sample, 15,5 ml) Ancillary testing 8.1 Demographics, Medical history, sampling: Patient demographic data and other characteristic data to be collected on all patients include sex, age, weight, height, relevant medical history, vital signs and symptoms characteristic of COVID-19 including precise time specifications for onset of symptoms.\\n\\nNo information about medication will be collected. Three independent nasopharyngeal swabs will be obtained following standard procedures To avoid any bias due to the sequence of taking the nasopharyngeal swabs, the investigators will randomly allocate the patients to three sampling groups Group 1: RT-PCR - Antigen Test Roche - Antigen Test Abbott Group 2: Antigen Test Roche - Antigen Test Abbott - RT-PCR Group 3: Antigen Test Abbott - RT-PCR - Antigen Test Roche\\n\\nThe assignment of patients to each of these groups will be clearly specified on the case record forms. There will be two forms for each patient:\\n\\nForm 1: Routine analysis request sheet as used by the collection point for patient identification which will be labelled with a bar code carrying the study number of a patient Form 2: Study specific form containing a copy of the bar code with the study number, initials of the patient and the year of birth.\\n\\n8.2 SARS-CoV-2 Rapid Antigen Test (Roche): The SARS-CoV-2 Rapid Antigen Test is a rapid point of care chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.\\n\\n8.3 PANBIO Covid-19 Ag Rapid Test (Abbott): Panbio COVID-19 Ag Rapid Test Device is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 antigen (Ag) in human nasopharyngeal swab specimens.\\n\\n8.4 RT-PCR: RT-PCR evaluates the presence or absence of the SARS-CoV-2 genome in samples from nasopharyngeal and oropharyngeal swabs and will be conducted according to the protocols established at the SYNLAB MVZ Leinfelden GmbH.\\n\\n8.5 Serological and ancillary testing: Blood samples (10 ml heparin plasma and 5.5 ml EDTA plasma) will be collected to detect the presence of antibodies (specific immune response) against SARS-CoV-2 antigenic proteins (e.g. Roche, Abbott). Specifically, all participants will be offered to receive the results for the following analytes in acknowledgment of their participation in the study: blood cell count, C-reactive protein, HbA1c, cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, gamma-glutamyl-transferase, creatinine along with formula-derived creatinine, vitamin D. Backup samples will be collected to determine ancillary parameters like inflammatory markers, and micronutrients and vitamins.\\n\\n9. Observation Period:\\n\\nNIS schedule:\\n\\nStart of the patient recruitment: February 1, 2021 End of the observation period: March 31, 2021 Final report: May 31, 2021\\n\\n10.Data analysis and statistical methods: A database of the pseudonymized data and results will be generated. The investigators hypothesize that each of the antigen tests has a sensitivity and specificity of 1.0 in relation to RT-PCR which will be considered as the reference test. A p value of less than 0.05 will be required to consider each of the two rapid tests equivalent to RT-PCR.\\n\\nWith the aid of power calculations for chi-square tests for two degrees of freedom, required type I error probability equal to 0.05, required (1-type II error probability)equal to 0.8 and required effect size equal to 0.1 (small effect size in the sense of (4)) the investigators obtain a number of at least N=964 observations for consecutive testing of incoming patients in order to fulfill our requirements on significance and power to answer the first research question. Because of the expected number of around 10% positive out of 1000 cases, the assumption of a chi-square distribution is permissible.\\n\\nThe investigators will also address the question whether different pre-test probabilities will affect the sensitivity of the of the antigen tests. The investigators expect two major indication groups with different pre-test probabilities contributing approximately 90 percent of the rt-PCR positive samples: a) participants admitted for rt-PCR testing by a physician b) participants seeking for rt-PCR testing upon recommendation my health care authorities/contact persons. A total of approximately 200 rt-PCR samples will be required to detect a statistically significant difference between these two groups at a type 1 error of 0.05 and a statistical power of 0.80. To answer this second question, the investigators will extend the study to 2000 participants.\\n\\n11. Ethics: The study protocol will be submitted to the Ethics Committee the Medical Faculty Mannheim, University of Heidelberg and the study will not begin until written permission is obtained. The study will be conducted in accordance with German law, EU Clinical Trial regulations and the Declaration of Helsinki on the ethical principles of clinical research.\\n\\n11.1 Patient information and Informed Consent: The objective, nature and extent of the document must be explained in writing to every patient before he or she is included in the study (Appedix 1). The patient must not be included unless he or she has given written consent (Appendix 2). Patients will have the right to refuse to participate or to withdraw from the study for any reason and at any stage without affecting the quality or accessibility of their health care.\\n\\n11.2 Data protection: The patient data collected for the study will be recorded in a pseudonymised form (Appendix 4), with a patient number that cannot be attributed to the identity of the patient. In the event of the study results being published, the personal data may only be used if the patient's anonymity is upheld. The patient's data is guaranteed to be always absolutely protected.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"COVAG\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05074017\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"COVAG study protocol 2.0\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Christoph Wertenauer\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Synlab Holding Deutschland GmbH\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Synlab Holding Deutschland GmbH\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Other\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS-CoV2 Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"SARS (Disease)\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.02.2021\", \"study_end_date\": \"31.03.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Signed informed consent must be obtained prior to study participation. The patient must be capable of understanding the nature, significance and implication of the trial.\\nAge 18 years or more\", \"study_eligibility_exclusion_criteria\": \"Lack of informed consent\\nInability to understand the nature, significance and implication of the trial.\\nSevere clinical conditions requiring emergency hospitalization\\nChildren and adolescents under the age of 18 years\", \"study_population\": \"We will include approximately 2000 consecutive male and female patients aged 18 years or above attending the Corona Test Center Stuttgart Cannstadter Wasen, in whom RT- PCR testing for SARS-CoV-2 is medically indicated or requested.\", \"study_target_sample_size\": 2222, \"study_obtained_sample_size\": 2222, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Sensitivity of the rapid antigen tests\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"31.03.2021\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Yes, there is a plan to make data available.\", \"study_data_sharing_plan_description\": \"Data will be made available to researchers upon request and formal agreement formal agreement to make sure that rules of good scientific practice are obeyed and that credit is given to the people who have been in charge of the design and the organization of the study. Interested researchers are invited to address their request or proposal to Prof. Dr. med. Winfried M\\u00e4rz (Winfried.Maerz@synlab.com).\\n\\nFinally, the authors confirm that they accessed and validated these data and that all other researchers can access the data in the same manner the authors did.\", \"study_data_sharing_plan_supporting_information\": [\"Study protocol\"], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"https://www.synlab.de/fileadmin/pdf/news/covag-covid-antigentest-studienprotokoll-synlab-english.pdf\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Other\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT05077267","content":"{\"resource_id\": \"NCT05077267\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects\"}], \"resource_descriptions\": [{\"description\": \"For this Phase 2 trial ABNCoV2-01, in a run in phase 6 adults (comprising of 3 subjects in each Group 1 and 2) will be vaccinated at 1 clinical trial site in a consecutive manner, with an at least 48 hours interval between the first and second subject of each group, then the second and third subject dosed on consecutive days, before opening up to full enrolment of the trial. Safety assessments will be based on solicited and unsolicited AE data (first week after vaccination) evaluated by an independent Data Monitoring Committee (DMC). After a positive DMC recommendation, enrolment to the rest of Group 1 and 2 of the trial will commence. Group 3 subjects will be enrolled after completion of Group 2 enrollment.\\n\\nThis phase 2 trial will evaluate a homologous prime-boost regimen with 100 \\u00b5g ABNCoV2 in initially seronegative adult subjects (Group 1), as determined by a qualitative test for SARS-CoV-2 antibodies, compared to a single boost vaccination with 100 \\u00b5g (Group 2) and 50 \\u00b5g (Group 3) ABNCoV2 in initially seropositive subjects, as defined by a positive qualitative test for SARS-CoV-2 antibodies and either a history of SARS-CoV-2 vaccination or previous COVID-19 disease (Group 2 and 3) at least 90 days prior to planned trial vaccination.\\n\\nDue to the timing of the addition of Group 3, enrollment into Group 2 will be completed prior to enrolling subjects into Group 3. Therefore, no randomization will be required for the seropositive subjects.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05077267\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ABNCoV2-01\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Bavarian Nordic\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19 Disease\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (III): Recruitment completed, but data collection ongoing\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention ongoing\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"19.08.2021\", \"study_end_date\": \"01.02.2024\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Multicentric\", \"study_centers_number\": 2, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Seronegative (Group 1): negative qualitative test for SARS-CoV-2 antibodies at SCR.\\n\\nSeropositive (Group 2 and Group 3): Previous COVID-19 disease or previously completed vaccination regimen with an authorized SARS-CoV-2 vaccine at least 90 days before planned trial vaccination and a positive qualitative test for SARS-CoV-2 antibodies at SCR. \\\"Authorized\\\" SARS-CoV-2 vaccine refers to authorization status at SCR, i.e., subjects can be eligible if the subject previously received investigational vaccines that have since been authorized for emergency use or granted full market licensure. Receipt of a single dose of an authorized COVID-19 vaccine regimen in subjects with a previous diagnosis of COVID-19 or a mix/match series of 2 doses of any authorized COVID-19 vaccine will be considered as a completed vaccination.\\n\\nGeneral good health, without acute medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator.\\nBody mass index (BMI) \\u226518.5 and <40.\\nFemale subjects of childbearing potential (WOCBP) must agree to the use of an effective method of birth control from at least 30 days prior to administration of the vaccine until 30 days after the vaccination. Male subjects who are sexually active with a WOCBP must agree to the use of an effective method of birth control from the day of administration of the vaccine until 30 days after the vaccination.\\nNegative human immunodeficiency virus antibody test (anti HIV), negative hepatitis B surface antigen (HBsAG) and negative antibody to hepatitis C virus (HCV).\", \"study_eligibility_exclusion_criteria\": \"\\u2022 Group 1 only: History of COVID-19 infection or previous vaccination with a licensed or candidate SARS-CoV-2 vaccine, or positive qualitative test for SARS-CoV-2 antibodies at SCR.\\n\\nGroups 2 and 3 only: History of COVID-19 infection and subsequent receipt of more than one licensed or candidate SARS-CoV-2 vaccine.\\n\\nPositive test for SARS-CoV-2 infection at SCR.\\nPregnant or breastfeeding women.\\nSubject has an acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses.\\nHistory of or active autoimmune disease. History of Guillain-Barr\\u00e9 syndrome or Reye's syndrome. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.\\nKnown or suspected impairment of immunologic functions including, but not limited to, known immunodeficiency syndrome.\\nHistory of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to SCR that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.\\nLaboratory parameters (such as complete blood count, serum biochemistry including aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphokinase [AP], bilirubin, or creatinine values), pulse rate, blood pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically relevant by the investigator.\\nClinically significant mental disorder not adequately controlled by medical treatment.\\nActive or recent history (within 6 months before SCR) of chronic alcohol abuse, intravenous drug abuse, or nasal drug abuse.\\nHistory of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\\nHistory of anaphylaxis or severe allergic reaction to any vaccine.\\nHaving received any vaccinations or planned vaccinations with a live vaccine within 30 days prior to or after trial vaccination.\\nHaving received any vaccinations or planned vaccinations with an inactivated vaccine within 14 days prior to or after trial vaccination.\\nRecent blood donation (including platelets, plasma and red blood cells) within 4 weeks prior to SCR, or planned blood donations during the active trial phase.\\nChronic systemic administration (defined as more than 14 days of >5 mg prednisone [or equivalent]/day), or any other immune-modifying drugs during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. The use of topical, inhaled, ophthalmic and nasal glucocorticoids is allowed.\\nPost organ transplant subjects, whether or not receiving chronic immunosuppressive therapy.\\nAdministration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. Receipt of packed red blood cells given for an emergency indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells given in emergency during an elective surgery).\\nUse of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the administration of trial vaccine, or planned administration of such a drug or vaccine throughout the trial.\", \"study_population\": \"\", \"study_target_sample_size\": 197, \"study_obtained_sample_size\": 197, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"SARS-CoV-2 neutralizing antibody titers\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"SARS-CoV-2 neutralizing antibody titers\", \"study_outcome_time_frame\": \"2 weeks after the last vaccination, i.e., after the second vaccination in initially seronegative subjects and after the single boost vaccination in initially seropositive subjects.\"}, {\"study_outcome_title\": \"Subjects reporting any SAEs or AESIs assessed as related to trial vaccine.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Subjects reporting any SAEs or AESIs assessed as related to trial vaccine.\", \"study_outcome_time_frame\": \"Within 8 days after vaccination\"}, {\"study_outcome_title\": \"Subjects reporting any Grade 3 or higher AEs assessed as related to trial vaccine.\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Subjects reporting any Grade 3 or higher AEs assessed as related to trial vaccine.\", \"study_outcome_time_frame\": \"8 days after vaccination\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT05175859","content":"{\"resource_id\": \"NCT05175859\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"How Timing of Tracheostomy in COVID-19 Patients Changed and Its Impact on Mortality\"}], \"resource_descriptions\": [{\"description\": \"\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05175859\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Tracheostomy in COVID-19\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Armin N. Flinspach\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Goethe University\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Goethe University\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Tracheostomy\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Completed: Recruitment, data collection, and data quality management completed normally\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"Intervention completed\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.04.2020\", \"study_end_date\": \"25.12.2021\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 80, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"- Severe COVID-19 infection requiring endotracheal intubation and prolonged invasive ventilation as part of the treatment of severe to moderate acute respiratory distress syndrome.\", \"study_eligibility_exclusion_criteria\": \"COVID-19 disease, without the need for endotracheal ventilation.\\nCOVID-19 disease with need for endotracheal intubation with anticipated short-term invasive ventilation.\", \"study_population\": \"Patients with underlying sheer COVID-19 disease and need for endotracheal airway management. Who required a tracheostomy due to the prolonged ventilation and ventilatory weaning required.\", \"study_target_sample_size\": 117, \"study_obtained_sample_size\": 117, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Mortality\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Deaths in the course of treatment\", \"study_outcome_time_frame\": \"During intensive care treatment (Usually within 8 weeks)\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Retrospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT05191381","content":"{\"resource_id\": \"NCT05191381\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"Hypercytokinemia\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Mesenchymal stem cells\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"COVID-19\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Tissue reconstitution\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Sepsis\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Immune modulation\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Exosomes\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Critical illness\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19\"}], \"resource_descriptions\": [{\"description\": \"Critically ill patients with COVID-19 may develop lung failure and require extracorporal oxygenation due to hyperinflammation and progressive lung fibrosis. The anti-inflammatory and immune modulatory function of mesenchymal stem cells will be investigated by whole blood stimulation experiments using stem cell derived exosomes. Exosome preparations have been characterized by miRNA and protein expression patterns and suggest their tissue regenerative capacity.\\n\\nThe hypothesis of the present study is that mesenchymal stem cell derived exosomes attenuate inflammation and support anti-fibrotic pathways.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"IMECOV19\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05191381\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"Lung fibrosis in COVID19\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Manfred Weiss\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"University of Ulm\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"University of Ulm\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Manfred Weiss, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"manfred.weiss@uniklinik-ulm.de\", \"role_phone\": \"+49(0)731500\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Marion Schneider, PhD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"marion.schneider@uni-ulm.de\", \"role_phone\": \"+49(0)731500\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Critical Illness\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Hypercytokinemia\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Lung Fibrosis\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"22.12.2021\", \"study_end_date\": \"31.12.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 90, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Critically ill COVID-19 patients with lung dysfunction\\nCOVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)\\nBody weight > 50 kg\\nInformed consent\", \"study_eligibility_exclusion_criteria\": \"Pregnant or breast feeding women\", \"study_population\": \"Critically ill COVID-19 patients, COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)\", \"study_target_sample_size\": 40, \"study_obtained_sample_size\": 40, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"Cytokine profile in supernatants\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Quantification of pro- and anti-inflammatory biomarkers after 24 hours of whole blood culture\", \"study_outcome_time_frame\": \"24 hours, 1 year\"}, {\"study_outcome_title\": \"Immune phenotyping\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Immune phenotypes related to type I interferon signaling\", \"study_outcome_time_frame\": \"1 year\"}, {\"study_outcome_title\": \"Genetic predisposition to hyperinflammation\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Determination of functional single nucleotide polymorphisms of inflammatory genes and receptors\", \"study_outcome_time_frame\": \"1 year\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"4 ml of heparin- and 2 ml of EDTA-anti-coagulated blood\"}}}"}
{"id":"NCT05289154","content":"{\"resource_id\": \"NCT05289154\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"post COVID-19, sequelae, chronic fatigue\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Self- Applied Acupressure and Online Qigong for Patients Suffering From Chronic Fatigue After Corona Virus Infection 19 (COVID-19) - a Randomized Controlled Mixed-methods Study.\"}], \"resource_descriptions\": [{\"description\": \"Prospective two-arm (parallel groups) randomised controlled confirmatory intervention study with mixed methods approach in 2x 100 patients (n=200).\\n\\nIntervention: self-applied acupressure and online Qigong course over 8 weeks and follow up at week 16.\\n\\nGroup 1: Acupressure + Qigong: Massage of the points daily for 3 minutes per point with the finger or an acupuncture pen (some points can be massaged bilaterally, therefore total approx. 20 min). In addition, twice a week an online guided Qigong course with a duration of 30-45 min. The patients should practise Qigong at least 3 times a week (including the course date). In addition, all patients will receive the guidebook literature for the treatment of complaints after SARS-CoV2 infection.\\n\\nGroup 2: Patients will receive advice literature on the treatment of chronic fatigue after SARS-CoV2 infection. After the end of this study the patients of this group will receive written information and video material regarding the acupressure and Qigong exercises.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ACUQiG\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05289154\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"ACUQiG\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Benno Brinkhaus\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Charite University, Berlin, Germany\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Charite University, Berlin, Germany\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Karl and Veronica Carstens Foundation\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Joanna Dietzel, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"joanna.dietzel@charite.de\", \"role_phone\": \"+49 30 450 529 002\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Miriam Ortiz, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"miriam.ortiz@charite.de\", \"role_phone\": \"+49 30 450 529 002\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"\", \"study_type\": \"\", \"study_type_description\": \"Description of study type: Prospective, randomised controlled, confirmatory intervention study with mixed methods approach\", \"study_conditions\": [{\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"At the planning stage\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.05.2022\", \"study_end_date\": \"01.10.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": 60, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"diagnosis of chronic fatigue (after SARS-CoV2 infection)\\nwith at least 3 of 7 criteria at time of study inclusion: sleeping disorder, headaches, joint pain/muscle pain, anxiety/depression, memory impairment/ concentration problems, anosmia, exercise intolerance.\\nacute SARS-CoV2 infection at least 12 weeks ago\\nage 18-60 years\\nvisual analogue scale (0-100 mm) physical resilience of maximum 60 mm\\nSF-36 physical function of maximum 65\\ntechnically equipped to participate in the online intervention and willing to follow the study procedure, acupressure and Qigong to perform the exercise series at home\\nwritten informed consent available.\", \"study_eligibility_exclusion_criteria\": \"fatigue already present before the SARS-CoV2 infection\\nother underlying diseases leading to symptoms of chronic fatigue, such as major depression, oncological diseases, multiple sclerosis, fibromyalgia and drug abuse\\nother serious underlying diseases, such as severe pulmonary, cardiac, psychiatric or infectious diseases, which could interfere with study participation or affect the results\\nongoing opioid therapy or opioid therapy in the week prior to study entry\\nchronic use of cannabinoids before or during the study.\\nstart of psychotherapy or interruption of ongoing therapy during study participation\\nfemale participants: pregnancy or breastfeeding\\nparticipation in another clinical intervention study during study participation\\nongoing pension procedure or planned claiming of a pension procedure due to disability\\nplanned inpatient rehabilitation measures during study participation due to PostCOVID-19 -\", \"study_population\": \"\", \"study_target_sample_size\": 200, \"study_obtained_sample_size\": 200, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"SF-36 Physical Function subscale\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Primary study objective is to assess the changes in the mean score of the SF-36 Physical Function subscale between the two study arms assessing the degree of fatigue.\", \"study_outcome_time_frame\": \"week 8\"}, {\"study_outcome_title\": \"EQ5D (EuroQoL 5 domains)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"disease specific QoL\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"SF36 PFS (Short Form 36 physical function subscale)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"changes in the mean score of the SF-36 Physical Function subscale- assessing the degree of fatigue\", \"study_outcome_time_frame\": \"week 16\"}, {\"study_outcome_title\": \"Chalder Fatigue-Scale\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Fatigue severity\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"VAS physical resilience (visual analogue scale)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"visual analogue scale for subjective physical resilience\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"PHQ9 (Patient Health Questionnaire 9)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"Patient Health Questionnaire assessing depression\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"VAS pain (visual analogue scale)\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"visual analogue scale for subjective pain\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"hand grip strength\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"hand grip strength\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"Spirometry\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"forced expiratory volume\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"autonomic dysfunction orthostasis test\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"heart rate and blood pressure analysis in orthostasis\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"d2- test\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"test for concentration- ability to focus\", \"study_outcome_time_frame\": \"week 8 and 16\"}, {\"study_outcome_title\": \"qualitative substudy\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"interviews regarding experience of illness and therapy\", \"study_outcome_time_frame\": \"week 8 and 16\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\"}}"}
{"id":"NCT05303012","content":"{\"resource_id\": \"NCT05303012\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"International, Prospective Multicentre Study to Record the Mental and Physical Effects of the COVID-19 Pandemic on Two Obese Patient Cohorts Pre- and Post-bariatric Surgery (COBESITY-Study)\"}], \"resource_descriptions\": [{\"description\": \"The COVID-19 pandemic, first reported in November 2019, has led to a global health systems emergency. The number of confirmed COVID-19-associated deaths, according to WHO, is higher in countries with high obesity prevalence. However, whether obesity is an independent risk factor of the severity of COVID-19 remains unclear.\\n\\nObesity represents one of the major health problems worldwide and the COVID-19 pandemic is expected to further increase obesity prevalence rates. Initial research indicates that the pandemic has also led to an increased incidence and/or worsening of depression and eating disorders. Additional weight gain due to the COVID-19 pandemic may be suspected to increase the prevalence of psychological comorbidities in patients before weight-reducing surgery compared to patients who have already undergone weight-reducing surgery.\\n\\nTherefore, the main aim of this international study is to gain a better understanding of the mental and physical effects of the coronavirus pandemic on obese patients before and after a weight-reducing surgery and use this to develop approaches for solutions. This study also aims to investigate the country-specific differences (Germany vs England) as well as the differences in the mental effects experienced by overweight patients who have or have not been infected with COVID-19.\\n\\nTo achieve these aims, obese patients aged 18 years and older, before and after weight-reducing surgery, will be recruited from the bariatric surgery clinic at King's College Hospital, NHS Trust Foundation as well as from the Medical University Hospital Hamburg-Eppendorf, Germany. Participants will be asked to complete a questionnaire about their health, socio-economic status, and the effects of the COVID-19 pandemic on their physical and mental health. The questionnaire will take 15 minutes to complete and can be done at home or during the patient's appointment at the bariatric surgery clinic to minimise unnecessary travel.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05303012\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"2021-100673\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Universit\\u00e4tsklinikum Hamburg-Eppendorf\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"King's College Hospital NHS Trust\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Other\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Pia Roser, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"p.roser@uke.de\", \"role_phone\": \"+494074100\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"COVID-19 Pandemic\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Overweight and Obesity\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"01.12.2021\", \"study_end_date\": \"01.12.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Overweight and obese patient cohort\\n\\nAge: 18 years and older\\nBMI \\u2265 25kg/m\\u00b2\\n\\nOverweight and obese patient cohort with bariatric surgery\\n\\nAge: 18 years and older\\nBMI \\u2265 25kg/m\\u00b2\\nStatus post sleeve or gastric bypass surgery\", \"study_eligibility_exclusion_criteria\": \"Age under 18 years\\nCognitive, mental and/or linguistic limitations to complete the questionnaire independently\\nSevere somatic illnesses, such as tumour diseases\\nPregnancy or breastfeeding\\nAcute need for treatment due to comorbid mental disorders\", \"study_population\": \"Overweight and obese patients with or without bariatric surgery\", \"study_target_sample_size\": 500, \"study_obtained_sample_size\": 500, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"PHQ-4\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Impact of the COVID-19 pandemic on mental health (measured by PHQ-4, PSS-10, and EDEQ scores) as well as on physical health (measured by \\u0394 BMI (kg/m^2) before and after the onset of the pandemic) in two obese patient cohorts pre- and post- bariatric surgery.\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"PSS-10\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Impact of the COVID-19 pandemic on mental health (measured by PHQ-4, PSS-10, and EDEQ scores) as well as on physical health (measured by \\u0394 BMI (kg/m^2) before and after the onset of the pandemic) in two obese patient cohorts pre- and post- bariatric surgery.\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"EDEQ-score\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Impact of the COVID-19 pandemic on mental health (measured by PHQ-4, PSS-10, and EDEQ scores) as well as on physical health (measured by \\u0394 BMI (kg/m^2) before and after the onset of the pandemic) in two obese patient cohorts pre- and post- bariatric surgery.\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"BMI\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"Impact of the COVID-19 pandemic on mental health (measured by PHQ-4, PSS-10, and EDEQ scores) as well as on physical health (measured by \\u0394 BMI (kg/m^2) before and after the onset of the pandemic) in two obese patient cohorts pre- and post- bariatric surgery.\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"Country-specific differences of the physical and psychological impact of the COVID-19 pandemic\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"Differences in psychological impact in obese patients pre- and post-bariatric surgery\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}, {\"study_outcome_title\": \"Differences in psychological impact between obese patients with and without COVID-19 infection\", \"study_outcome_type\": \"Secondary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"Before the COVID-19 pandemic vs. since the COVID-19 pandemic\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"NCT05313048","content":"{\"resource_id\": \"NCT05313048\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"The APSantiCo Observational Study - Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination\"}], \"resource_descriptions\": [{\"description\": \"Prospective observational study to evaluate a possible change in antiphospholipid antibody profiles after coronavirus disease 2019 (COVID-19) infection or vaccination.\\n\\nPatients with antiphospholipid syndrome (APS) with thromboembolic complications recorded using the retrospective database of the APSANTICO registry (ClinicalTrials.gov Identifier: NCT05195372) will serve as a baseline for a prospective observational study to investigate the extent to which COVID 19 infection and/or COVID 19 vaccination alters APS antibody profiles.\\n\\nCurrent literature suggests that patients who have been or are infected with COVID-19 are at higher risk of thrombosis. This increased risk is due to, among other things, damaged endothelium, slower blood flow and observed hypercoagulability of the blood.\\n\\nIt has also been described that COVID-19 patients may have a higher prevalence of lupus anticoagulant. Based on these assumptions, one of the aims of the prospective observational study is to determine whether and to what extent COVID-19 infection affects the antibody profile of APS patients.\\n\\nIn addition, atypical thrombosis with thrombocytopenia has been repeatedly reported recently as a rare side effect after COVID-19 vaccination with two recombinant adenoviral vectors encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca and Ad26.COV2.S, Johnson&Johnson).\\n\\nThe extent to which thrombosis could also occur after messenger RNA (mRNA) vaccines has not yet been clearly proven.\\n\\nFurthermore, it is unclear whether COVID-19 infections and/or vaccinations can possibly influence the expression and level of antiphospholipid antibody titres. Therefore, another aim of the prospective observational study is to compare the antiphospholipid antibody results available from the retrospective registry before COVID-19 vaccination or COVID-19 infection with the antibody results after COVID-19 infection and/or vaccination. For this purpose, the patients who were recorded in the retrospective register are contacted by post with an information letter and then called in by telephone to the investigators coagulation centre for a follow-up examination after the COVID-19 vaccinations have been carried out and/or after COVID-19 infection. Then, during this examination, a blood sample is taken to monitor the course of the antiphospholipid antibodies. In addition, patients are offered a test of COVID-19 nucleocapsid antibodies and COVID-19 spike antibodies free of charge to check the success of the vaccination. This is of particular interest as some of these patients are taking immunosuppressive drugs due to an underlying autoimmune disease, which could weaken the immune response.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"APSantiCo\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05313048\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"APSantiCo-Study\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Principal investigator\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Prof. Dr. med. E. Lindhoff-Last\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Prof. Dr.\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"Cardioangiologisches Centrum Bethanien\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Cardioangiologisches Centrum Bethanien\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Edelgard Lindhoff-Last, Prof. MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"e.lindhoff-last@ccb.de\", \"role_phone\": \"0049699450280\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Barbara Zydek, MD\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"b.zydek@ccb.de\", \"role_phone\": \"0049-699450280\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Cohort\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Antiphospholipid Syndrome\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 Infection\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19 Vaccination\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"15.03.2022\", \"study_end_date\": \"31.03.2023\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"Minimum age of 18 years\\nConfirmed antiphospholipid syndrome with thromboembolic clinical manifestations (venous thromboembolism, pulmonary embolism, thrombophlebitis etc.)\\nPatients with APS antibody risk profile (single/double/triple positivity)\\nWritten consent for participation in the prospective APSantiCo observational study\", \"study_eligibility_exclusion_criteria\": \"APS with isolated pregnancy complications\\nNo anticoagulation medication\\nInadequately diagnosed APS\\nNon-compliance on the part of the patient\", \"study_population\": \"Patients with antiphospholipid syndrome with thromboembolic clinical manifestations (venous thromboembolism, pulmonary embolism, thrombophlebitis etc.) or Patients with APS antibody risk profile (single/double/triple positivity)\", \"study_target_sample_size\": 80, \"study_obtained_sample_size\": 80, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"change in APS antibody status after surviving COVID-19 infection and/or receiving COVID-19 vaccination\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"The main observational variable is the change in APS antibody status in patients with antiphospholipid syndrome after surviving COVID-19 infection and/or receiving COVID-19 vaccination.\", \"study_outcome_time_frame\": \"2015-2022\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: No\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"No, there is no plan to make data available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Prospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"frozen citrated plasma samples\"}}}"}
{"id":"NCT05441657","content":"{\"resource_id\": \"NCT05441657\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [{\"resource_keywords_label\": \"EIT\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"long-COVID\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"post-acute COVID-19 syndrome\", \"resource_keywords_label_code\": \"\"}, {\"resource_keywords_label\": \"Electric impedance tomographie\", \"resource_keywords_label_code\": \"\"}], \"resource_language\": [], \"resource_web_page\": \"\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ClinicalTrials.gov\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"Visualisation of Changes in Regional Ventilation in Dyspnoeic Postacute COVID-19 Patients: A Case-control Study Using Electrical Impedance Tomography (EIT)\"}], \"resource_descriptions\": [{\"description\": \"When treating patients with dyspnoea, conventional diagnostic tools (computed tomography, spirometry, body plethysmography) often fail to detect pathological changes, making it difficult for the treating physician to choose an appropriate therapeutic approach. Therefore, it would be desirable to have an examination method that reveals the pulmonary changes in postacute Corona-Virus-Disease-2019 (COVID-19) syndrome patients that remain hidden from other diagnostic procedures.\\n\\nElectrical impedance tomography (EIT) is a non-invasive and radiation-free imaging technique that can show the regional ventilation of the lungs almost \\\"in real-time\\\" based on the changes in the electrical impedance of the thorax during inspiration and expiration. This method is based on the observation that the electrical conductivities of biological tissues vary considerably depending on their nature and functional state. Clinical questions in which the inhomogeneity of lung ventilation is to be analysed (e.g., under- or overinflation of individual lung areas, lung collapse, etc.) can be investigated particularly well with EIT since intrathoracic impedance changes correlate strongly with changes in regional lung ventilation.\\n\\nUp to now, EIT has mainly been used as a monitoring method in intensive care medicine to adapt ventilation settings and other therapeutic measures to the individual needs of patients. In this field, the method has proven useful for obtaining an overview of the distribution of a respiratory volume in a transverse EIT slice, comparing different lung regions, identifying inhomogeneities and assessing regional ventilation during spontaneous breathing.\\n\\nThe aim of this case-control study is to use EIT data obtained during routine examinations of post-COVID patients to analyse whether EIT is suitable as a radiation-free, non-invasive imaging technique for assessing regional ventilation of the lung in spontaneously breathing post-COVID patients and whether additional evidence of regional ventilation disorders in these patients can be found by determining lung ventilation using EIT. As there are no reference data from spontaneously breathing lung-healthy patients so far, a reference group will be generated whose EIT data will be compared with those of post-COVID patients.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"ViReVentPoCov\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"NCT05441657\", \"id_type\": \"NCT(ClinicalTrials.gov)\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}, {\"id_identifier\": \"KIM-IV-EIT-04\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"-\", \"role_name_personal_family_name\": \"-\", \"role_name_personal_title\": \"Other\", \"role_name_identifiers\": [], \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_organisational\": \"Jena University Hospital\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Jan-Christoph Lewejohann, Dr.med.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"jan-christoph.lewejohann@med.uni-jena.de\", \"role_phone\": \"+49 3641 9322013\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}, {\"role_name_organisational\": \"Philipp Reuken, Dr.med.\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Organisational\", \"role_email\": \"philipp.reuken@med.uni-jena.de\", \"role_phone\": \"+49 3641 9324504\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\"}], \"study_design\": {\"study_primary_design\": \"Non-interventional\", \"study_type\": \"Case-control\", \"study_type_description\": \"Description of study type: \", \"study_conditions\": [{\"study_conditions\": \"Ventilatory Defect\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"COVID-19\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Post-acute COVID-19 Syndrome\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Electric Impedance Tomography\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Ongoing (I): Recruitment ongoing, but data collection not yet started\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"\", \"study_start_date\": \"21.05.2022\", \"study_end_date\": \"30.10.2022\", \"study_country\": [\"Germany\"], \"study_region\": \"\", \"study_centers\": \"Monocentric\", \"study_centers_number\": 1, \"study_subject\": \"Person\", \"study_sampling\": \"Non-probability\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": 18, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": null, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Male\", \"Female\", \"Diverse\"], \"study_eligibility_inclusion_criteria\": \"for control group: no lung diseases, no allergic symptoms, non-smokers, over 18 years old\\nfor patients with postacute COVID-19 syndrome: over 18 years, dyspnoeic symptoms\", \"study_eligibility_exclusion_criteria\": \"heart pacemaker\\nepilepsy\\nBMI over 50\", \"study_population\": \"20 dyspnoeic patients with postacute COVID-19 syndrome who present themselves at the outpatient clinic of the University hospital in Jena were examined. 20 lunghealthy volunteers who are studying medicine or are working in the hospital were asked to be examined.\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": 20, \"study_age_min_examined\": null, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": null, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"pathogenic changes in regional lung ventilation\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"pathogenic changes in regional lung ventilation considered\", \"study_outcome_time_frame\": \"until July 2022\"}], \"study_design_comment\": \"Are healthy volunteers permitted to participate in the clinical study?: Accepts Healthy Volunteers\\nIs eligibility based on gender (not on sex)?: \\nAdditional information about gender eligibility criteria: \", \"study_data_sharing_plan_generally\": \"\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"non_interventional_study_design\": {\"study_time_perspective\": [\"Retrospective\"], \"study_target_follow-up_duration\": null, \"study_biospecimen_retention\": [], \"study_biospecomen_description\": \"\"}}}"}
{"id":"PER-055-20","content":"{\"resource_id\": \"PER-055-20\", \"resource_type\": \"Study\", \"resource_type_general\": \"Other\", \"resource_keywords\": [], \"resource_language\": [], \"resource_web_page\": \"https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=055-20\", \"resource_version\": \"\", \"resource_format\": \"\", \"resource_use_rights_label\": \"Not applicable\", \"resource_use_rights_description\": \"\", \"provenance\": {\"data_source\": \"Automatically uploaded: ICTRP\"}, \"resource_titles\": [{\"title_language\": \"EN (English)\", \"title\": \"STUDY OF EFFICACY AND SAFETY OF DFV890 IN PATIENTS WITH COVID-19 PNEUMONIA\"}], \"resource_descriptions\": [{\"description\": \"Summary is not provided.\", \"description_language\": \"EN (English)\"}], \"resource_acronyms\": [{\"acronym\": \"\", \"acronym_language\": \"EN (English)\"}], \"ids\": [{\"id_identifier\": \"PER-055-20\", \"id_type\": \"Other\", \"id_relation_type\": \"has alternate ID\", \"id_date\": \"\", \"id_resource_type_general\": \"Other\"}], \"roles\": [{\"role_type\": \"Sponsor (primary)\", \"role_name_type\": \"Organisational\", \"role_name_organisational\": \"Novartis Pharma AG.,\", \"role_email\": \"\", \"role_phone\": \"\", \"role_affiliation_name\": \"\", \"role_affiliation_address\": \"\", \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": []}, {\"role_name_identifiers\": [], \"role_affiliation_web_page\": \"\", \"role_affiliation_identifiers\": [], \"role_type\": \"Contact person\", \"role_name_type\": \"Personal\", \"role_name_personal_given_name\": \"Jacqueline\", \"role_name_personal_family_name\": \"Giron\", \"role_name_personal_title\": \"Other\", \"role_email\": \"jacqueline.giron@novartis.com\", \"role_phone\": \"986730921\", \"role_affiliation_name\": \"NOVARTIS BIOSCIENCES PERU S.A.      \", \"role_affiliation_address\": \"Jr. Juan de Arona 151, Oficinas 601-602\"}], \"study_design\": {\"study_primary_design\": \"Interventional\", \"study_type\": \"Unknown\", \"study_type_description\": \"\", \"study_conditions\": [{\"study_conditions\": \"_x000D_\\n\\t\\t\\t\\t-B342 Coronavirus infection, unspecified site_x000D_\\n\\t\\t\\t <br>Coronavirus infection, unspecified site\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"B342\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}, {\"study_conditions\": \"Coronavirus infection, unspecified site\", \"study_conditions_classification\": \"Free text\", \"study_conditions_classification_code\": \"\"}], \"study_ethics_commitee_approval\": \"\", \"study_status\": \"Other\", \"study_status_enrolling_by_invitation\": \"\", \"study_status_when_intervention\": \"\", \"study_status_halted_stage\": \"\", \"study_status_halted_reason\": \"\", \"study_recruitment_status_register\": \"Recruiting\", \"study_start_date\": \"\", \"study_end_date\": \"\", \"study_country\": [], \"study_region\": \"\", \"study_centers\": \"\", \"study_centers_number\": null, \"study_subject\": \"Unknown\", \"study_sampling\": \"\", \"study_data_source\": [], \"study_data_source_description\": \"\", \"study_eligibility_age_min\": -1.0, \"study_eligibility_age_min_description\": \"\", \"study_eligibility_age_max\": -1.0, \"study_eligibility_age_max_description\": \"\", \"study_eligibility_gender\": [\"Not applicable\"], \"study_eligibility_inclusion_criteria\": \"Inclusion criteria: \\n\\n\\t\\t\\t\\t\\u2022\\tMale and female patients aged 18-80 years inclusive at screening\\n\\n\\t\\t\\t\\t\\u2022\\tClinically diagnosed with the SARS-CoV-2 virus by polymerase chain reaction (PCR) or by other approved diagnostic methodology within 7 days prior to randomization\\n\\n\\t\\t\\t\\t\\u2022\\tHospitalized with COVID-19-induced pneumonia evidenced by chest X-ray, computed tomography scan (CT scan) or magnetic resonance scan (MR scan), taken within 5 days prior to randomization (within 24 hours in patients in the Netherlands)\\n\\n\\t\\t\\t\\t\\u2022\\tImpaired respiratory function, defined as peripheral oxygen saturation (SpO2) &#8804;93% on room air or partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) <300 millimeter of mercury (mmHg) at screening. For cities located at altitudes greater than 2500 m above sea level, these will be substituted with SpO2 <90% and PaO2/FiO2 <250 mmHg.\\n\\n\\t\\t\\t\\t\\u2022\\tAPACHE II score of &#8805;10 at  screening\\n\\n\\t\\t\\t\\t\\u2022\\tC-reactive protein (CRP) &#8805;20 mg/L and/or ferritin level &#8805;600 &#956;g/L at screening\\n\\n\\t\\t\\t\\t\\u2022\\tBody mass index of &#8805;18 to <40kg/m2 at screening\\n\\n\\t\\t\\t\", \"study_eligibility_exclusion_criteria\": \"Exclusion criteria: \\n\\n\\t\\t\\t\\t\\u2022\\tSuspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral, or other infection (besides SARS-CoV-2)\\n\\n\\t\\t\\t\\t\\u2022\\tIn the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment\\n\\n\\t\\t\\t\\t\\u2022\\tIntubated prior to randomization\\n\\n\\t\\t\\t\\t\\u2022\\tSuspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral, or other infection (besides SARS-CoV-2)\\n\\n\\t\\t\\t\\t\\u2022\\tIn the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment\\n\\n\\t\\t\\t\\t\\u2022\\tIntubated prior to randomization\\n\\n\\t\\t\\t\\t\\u2022\\tPrevious treatment with anti-rejection and immunomodulatory drugs within the past 2 weeks, or within the past 30 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies or prohibited drugs (see Section 6.2.1.2), with the exception of hydroxychloroquine, chloroquine or corticosteroids:\\n\\n\\t\\t\\t\\t\\u2022\\tFor  COVID-19 infection, ongoing corticosteroid treatment is permitted at doses as per local SoC\\n\\n\\t\\t\\t\\t\\u2022\\tFor non-COVID-19 disorders, ongoing corticosteroid treatment is permitted at doses up to and including prednisolone 10 mg daily (or equivalent).  (see Section 6.2.1)\\n\\n\\t\\t\\t\\t\\u2022\\tIn patients in the Netherlands only, the use of hydroxychloroquine and/or chloroquine in the past 2 weeks are exclusionary.\\n\\n\\t\\t\\t\\t\\u2022\\tSerum alanine transaminase (ALT) or aspartate transaminase (AST) >5 times upper limit of normal detected within 24 hours at screening or at baseline (according to local laboratory reference ranges) or other evidence if severe hepatic impairment (Child-Pugh Class C, see Appendix 4)\\n\\n\\t\\t\\t\\t\\u2022\\tAbsolute peripheral blood neutrophil count of &#8804;1000/mm3\\n\\n\\t\\t\\t\\t\\u2022\\tEstimated GFR (eGFR) &#8804;30 mL/min/1.73m2 (based on CKD-EPI formula)\\n\\n\\t\\t\\t\\t\\u2022\\tPatients currently being treated with drugs known to be strong or moderate inducers of isoenzyme CYP2C9 and/or strong inhibitors of  CYP2C9 and/or strong inducers of cytochrome P450, family 3, subfamily A (CYP3A) (see list of prohibited drugs: Section 6.2.1.2) and the treatment cannot be discontinued or switched to a different medication prior to starting study treatment\\n\\n\\t\\t\\t\\t\\u2022\\tPatients with innate or acquired immunodeficiencies\\n\\n\\t\\t\\t\\t\\u2022\\tPatients who have undergone solid organ or stem cell transplantation\\n\\n\\t\\t\\t\", \"study_population\": \"\", \"study_target_sample_size\": 20, \"study_obtained_sample_size\": null, \"study_age_min_examined\": -1.0, \"study_age_min_examined_description\": \"\", \"study_age_max_examined\": -1.0, \"study_age_max_examined_description\": \"\", \"study_hypothesis\": \"\", \"study_outcomes\": [{\"study_outcome_title\": \"\\n\\t\\t\\t\\tOutcome name:clinical and in-hospital outcomes, and laboratory values, including serum CRP, a key biomarker of inflammasome inhibition and safety during and after the 14-day treatment period.\\n\\t\\t\\t\\tMeasure:the APACHE II score (range 0 to 71) on day 15 or on day of discharge (whichever is earlier) with worst case imputation for death as this disease severity score provides a comprehensive structured assessment of the clinical, physiological and laboratory parameters that have been routinely employed by physicians in the current situation to access the overall clinical status of COVID-19 patients with pneumonia and respiratory failure\\n\\t\\t\\t\\tTimepoints:day 15 or on day of discharge\\n\\t\\t\\t\", \"study_outcome_type\": \"Primary\", \"study_outcome_description\": \"\", \"study_outcome_time_frame\": \"\"}], \"study_design_comment\": \"Additional information about study design: <br>\\t\\t\\t\\tScreening / Baseline visit (Day -1 to 1): lasts up to a maximum of 24 hours and comprises a screening / baseline assessment<br>\\t\\t\\t\\tTreatment period (Day 1-15): Participants in the investigational treatment arm will receive DFV890 50 mg b.i.d. orally or via a nasogastric feeding tube administered for a total of 14 days (28 doses) in addition to SoC.<br>\\t\\t\\t\\tThe End of Treatment (EOT) visit will take place on Day 15. If participants are discharged from the hospital prior to Day 15, assessments on the day of discharge should be performed according to the schedule listed under Day 15.<br>\\t\\t\\t\\tFollow-up (Day 16-29): After completion of the 14 day- treatment period, participants will be observed until Day 29 or discharged from hospital, whichever is sooner.<br>\\t\\t\\t\\t30-day safety follow-up assessment (Day 45): A follow-up visit for safety will be conducted by telephone<br>\\t\\t\\t\", \"study_data_sharing_plan_generally\": \"Undecided, it is not yet known if data will be made available.\", \"study_data_sharing_plan_description\": \"\", \"study_data_sharing_plan_supporting_information\": [], \"study_data_sharing_plan_time_frame\": \"\", \"study_data_sharing_plan_access_criteria\": \"\", \"study_data_sharing_plan_url\": \"\", \"interventional_study_design\": {\"study_primary_purpose\": \"\", \"study_phase\": \"Phase-2\", \"study_masking\": null, \"study_masking_roles\": [], \"study_masking_description\": \"\", \"study_allocation\": \"\", \"study_off_label_use\": \"\", \"interventional_study_design_arms\": [], \"interventional_study_design_interventions\": [{\"study_intervention_name\": \"\", \"study_intervention_type\": \"\", \"study_intervention_description\": \"\\n\\t\\t\\t\\tGroup name:DFV890 50 mg b.i.d. + standar of care Type of group;1 N\\u00c2\\u00b0 of participants:5 Intervention(s) description:\\u00e2\\u20ac\\u00a2\\tDFV890 50 mg will be administered orally twice per day approximately 12 hours apart (morning and evening).\\n\\t\\t\\t\\t\\u00e2\\u20ac\\u00a2\\tFor participants unable to ingest tablets, study drug can be administered through a nasogastric tube (8 French or greater) as follows:\\n\\t\\t\\t\\t\\u00e2\\u20ac\\u00a2\\tSuspend both tablets in approximately 40 mL of water with stirring for approximately 3 minutes\\n\\t\\t\\t\\t\\u00e2\\u20ac\\u00a2\\tThe suspension can then be administered through a nasogastric tube using an appropriate syringe. This needs to take place within a maximum of 6 hours of the tablets being dispersed\\n\\t\\t\\t\\t\\u00e2\\u20ac\\u00a2\\tDuration of treatment is 14 days.\\n\\t\\t\\t\\tGroup name:Standar of Care Type of group;2 N\\u00c2\\u00b0 of participants:4 Intervention(s) description:The treatment is assigned considering the evaluation perfomed by the physician up to 14 days.\\n\\t\\t\\t\", \"study_intervention_arm_group_label\": \"\"}]}}}"}
